<SEC-DOCUMENT>0001804220-21-000033.txt : 20211104
<SEC-HEADER>0001804220-21-000033.hdr.sgml : 20211104
<ACCEPTANCE-DATETIME>20211104071948
ACCESSION NUMBER:		0001804220-21-000033
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211104
DATE AS OF CHANGE:		20211104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REGENERON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000872589
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133444607
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19034
		FILM NUMBER:		211377993

	BUSINESS ADDRESS:	
		STREET 1:		777 OLD SAW MILL RIVER ROAD
		CITY:			TARRYTOWN
		STATE:			NY
		ZIP:			10591
		BUSINESS PHONE:		9148477000

	MAIL ADDRESS:	
		STREET 1:		777 OLD SAW MILL RIVER ROAD
		CITY:			TARRYTOWN
		STATE:			NY
		ZIP:			10591

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REGENERON PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>regn-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:08b52028-35ad-4384-abb4-ffa84b7c541b,g:79516084-017d-4f01-b220-9a6b8eb4ad51,d:ae35796f039b495ba4b10877e85a1c6f--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:regn="http://www.regeneron.com/20210930" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2021" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>regn-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80L2ZyYWc6MWZlMmM0MzRjYjA1NDkxMTk1NjkzZjFiZGRiZGM4ZjAvdGFibGU6YzdhNWY5ZTUxZTczNGYzOWE2MDQzMDEyYjc5YzRmMzgvdGFibGVyYW5nZTpjN2E1ZjllNTFlNzM0ZjM5YTYwNDMwMTJiNzljNGYzOF80LTEtMS0xLTA_bf307d66-ef8b-43f5-942c-ca7965b67db4">0000872589</ix:nonNumeric><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80L2ZyYWc6MWZlMmM0MzRjYjA1NDkxMTk1NjkzZjFiZGRiZGM4ZjAvdGFibGU6YzdhNWY5ZTUxZTczNGYzOWE2MDQzMDEyYjc5YzRmMzgvdGFibGVyYW5nZTpjN2E1ZjllNTFlNzM0ZjM5YTYwNDMwMTJiNzljNGYzOF81LTEtMS0xLTA_7c2e1649-1a0a-45cc-9739-0bec29012009">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80L2ZyYWc6MWZlMmM0MzRjYjA1NDkxMTk1NjkzZjFiZGRiZGM4ZjAvdGFibGU6YzdhNWY5ZTUxZTczNGYzOWE2MDQzMDEyYjc5YzRmMzgvdGFibGVyYW5nZTpjN2E1ZjllNTFlNzM0ZjM5YTYwNDMwMTJiNzljNGYzOF85LTEtMS0xLTA_b5c7f3bb-f8fc-4028-a472-b4b26956cee5">2021</ix:nonNumeric><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80L2ZyYWc6MWZlMmM0MzRjYjA1NDkxMTk1NjkzZjFiZGRiZGM4ZjAvdGFibGU6YzdhNWY5ZTUxZTczNGYzOWE2MDQzMDEyYjc5YzRmMzgvdGFibGVyYW5nZTpjN2E1ZjllNTFlNzM0ZjM5YTYwNDMwMTJiNzljNGYzOF8xMC0xLTEtMS0w_cb9fa15a-1e75-4b6e-95a6-3a5e53ff8bad">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80L2ZyYWc6MWZlMmM0MzRjYjA1NDkxMTk1NjkzZjFiZGRiZGM4ZjAvdGFibGU6YzdhNWY5ZTUxZTczNGYzOWE2MDQzMDEyYjc5YzRmMzgvdGFibGVyYW5nZTpjN2E1ZjllNTFlNzM0ZjM5YTYwNDMwMTJiNzljNGYzOF8xMS0xLTEtMS0w_7a49f6eb-415d-424f-b5f7-97bec046f818">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="regn-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="icc16664525144692bafad224736d7dbc_I20211022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida653b0f9e874bc6a9d652fb00e0d46b_I20211022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e0582c9be764ded815021b5841e304e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia1f2d0c6a01e40a1a132025d16ef17ca_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65b94c6346a4410db40c1e51f2964b9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i010ed964f154499ca13c88bdf3995dd6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e6fff47dfed4a8890d58fd118bc6b39_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i701b6278270643ea9ea3e4f71bac2244_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93da59ad5160490cb75eb85818530df4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if39174df528047a1a58851162c8756dc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1d6c2cf98ab48708f23e1c442baff3a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb855af148d44803bf5a5a397f72a4a6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81ec7f922ada451f954d39c3398269f2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2011ff92b7314bba86afeec4eeaf8b4d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38c63575c6ef4f41b900486402535348_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id10cdd0c27b642138616b7b32f4d6ee8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebab4f2f32234aa480f0f8082f54bd53_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b8d7bccc16342b88d4e13958c1c3e11_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibabe614a09ed4deaa4de04435940de78_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i770f931b2ede4bdeb5ef82d0dd8a554d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cb541cbbbef4d78a54cbec6a7e81726_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76c0001967fc483996710f1c2b1392ce_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i463b28633c04475b8ede195911dcb3ce_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3239cd5923f34e0ca9e9ec38de051f2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i035ed65f313f47239e1ba7a980f112a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i563d0a3bfa17497bbaf9ccff6e61e331_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0904b48c5834d8382585d98978efa6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ba799e31f25451293026f6a5a092606_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb59f0839edb41abb0134a8358db4753_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c94e3f729d1401291b50c0edf45498a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i224a9ebaa95b46c587b2caf10b449995_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45a7c7a2a79f45b599510ec6d98f5234_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i771bf5f554d244a29f26c5501f4293f3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie140c8b387dc4645b81c9879149a8e9d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49df9a95773d49e6967753fb9f9de580_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i970227f3acea4503918b252309b84460_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcd2927b7554444faad537d5a6d30eb9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99065775605c4e47ab2780914630a4e5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95d0fd1cd63743f18bd2b4ef498d61b6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2b9d9e8e8d94aafb8cf016d634bce00_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1db85b4dd6a74732adc71927ecf1a4b4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i485a4b467eae4806b0b1ebd35f44e2c2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d895db990f24cf3a08e7953476d96f7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90967a0a2559464e89e7ac0cf8e2bdbc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if027b47fcff24b09bc17374a79225282_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdc7f3436f2d4c15be968a3a0446d58b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01a22b1457534e58971e7c3840ce8a74_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aca85854a7e44a4967c9de4200b7275_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4692004524e482c94791bc9cdad2f45_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5ee4bf1abbe4e4aa728bc791fd9e4be_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58536bd9f96a400195ebcbf3b27c73ef_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idca5a9d3669d4ad4abd5502c841c9b83_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8637e07a17044e3bc80d1b3f1ac3709_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c2c8b599684423e810cce4bc7569486_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81bba3e7b3f14597be97fbb190f9dbff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic22073ba422e4cd19578e069ff93a548_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1af4b6d98674144aede03c90b76ecde_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa09e4ef649b446d8a986b009222a48c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea16b9252afa422babee5f32af655235_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f7ae795859466f9949d77297734d41_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5ea589759884ae08a57e4895180d768_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4a9df31fbd2432eb37434ec52ac6097_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i241d3af3190948bebbe76ddd7a69650a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc06747141a8415abdc99e415fd10ec4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73dec6c7995c456c9140fce39007c0e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0bf589234254d1fa1a8439438ed348f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b0eaf7cc1b34bc3a8ce4fceda06456c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f1bbe31c49144b58bd31a8fdaaa287b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i843aefe7a57e49a4b8057f411d68d2d6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfb0c989543b47b4b84dfc63cacdb340_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8be30bd45174fe1a757f0b806ef45ff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3a84e5477f34a4fa157fc0ff96532f9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d9fc7c849641a29c4015bb2c26ff95_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia85c03a3ab92450c8de1356f1f1c58d3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f1758a625d84d929d4de5bf11529687_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98313781c6ec4d6b8b48f6da3becd23f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51f918e0a47440ff9a42a36261a6d16d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76b230224ec74a4ebd37c4fa613a51f6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6c4ef5941f242a783b93fdf18b331b7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93db50d47f1b4831b473f4caa658d588_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1448dfba64a24ca98ed5cca7a68f936c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8e249a62ffd40df9c9149d8b996539c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3282a3bb766e427c92f46bd8d3cc7e59_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57cb86b034e44ad089ebc3504d4d0411_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82a2982cdc3744dfab46a0e3a207a741_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90f143b898064fb1a010fcdce8a28b66_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5505226ac8da4156a58673a2fec740bd_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fef85b8750b47bbb313ad7db28ce663_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaedf97f07c304e0eb9b3fff6304ec0c1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb44990ceb62481894ef4f3997282c75_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae6682412d744b10a6d5e33564d0af56_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63120c4477c04522a145f1c834f52464_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88e0d4f0e2bb4a66bbb456ea665d882d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib41afa111c3149648c0cc3bac7c5b435_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9c7d2da9c9f4d09a60482a44e3c8ca7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72a6a418d67447f6bf91301e4805ad9b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia83d2540d3bf4a078040cd71ec1f972b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4de7c52f2b7a4fe89360820891e3f073_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic71c7174d5cc448398e06391a7827688_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic16fc6f626e146c18705d2b1e22411bc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0102174142414cbd89010684f4e14032_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7e951f6bc2b47f9a0f83bbc19cfee0b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d580d7d41ab4c779d21e7ecf46f3208_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e5ba528b04c4762aa61bced9949c785_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782ae2009f954090860e6e0bb4a7039f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i960a6b708491473d9570c3942b7eef6c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09b0b1c1c2a94afb988a7c59c235eee7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5335858050745058b22cc99a0b825d8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eb34b902a3d4092a2e3d84fafaf8db3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12dab876c382416aaa473774a2318a69_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a1e78634a724621bc14ad6838cb7aaa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0b4d6b8672847c38f0dba0dde9118a6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i993e0c30b54544e0a4d7a1785fe7f5ec_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide588defaf434359bba81a3f3acff2b8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfb6acb24daa4045bfab3c8c4d9acd34_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id715132664af44b4a97c8f5b2eef6789_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfdef107afb54ad899df3e57fa9ccb8f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ce220d2cde34bf583732793c841cc94_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf31cf4bebfa40e5868081cbe1915ba4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedfb0cf9c4594b929abde62607752ef2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia50d948a15194872b1d382957ed144d6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b848f38b8a54f65bd9393c17a2aaed0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if965233833744f19a7d0aba74b97b8d6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9771830c61ff46c0ab9a5252ea2be0af_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4030650199fe4f198ed816c8ab79a91a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ebaa7f4723242569b7922152e81345e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19d89574821b49b9bdfa6137bd82652d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if04488d631ba4e129b9e0f0fb3558a31_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64fcfb6110c74cbe816d03379fae5d1d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80f2e762be11477183ef6c02dba52897_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39c987382ee344fca75a3010f34022b5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3f29614787e4465a5554d3f160fa259_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib58a328c7a1044db991b18bc06aec4ca_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04e74fae60044b55bf008643f8ce273e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f629c0363834da2a784610d8a5403af_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id628995c65e443418912b4df46bdf6a1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bab1de7a18e431086c872b4f16dbf84_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="id1b54518517447e2976804aef2938a70_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c91a96c8ea541df9b383e31edb76cdb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f3623e111f49f58059e4a3c761728b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5418f4d22034df899d1576e95d98e46_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i785a29c3adcc4a36be31fef32659e71d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e92e56fe7a44e5a31ddecd1964e64a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie051ae25fb44472e83a56290575ab26c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i486929221d2f42f5919727d4483f7090_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if50c4763f6dc43428e8360ca23d39d0d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:USGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5546196bf9d43679e3e52ddbffdfc7e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:USGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifded74cc07f44048a2c104e76b70e48e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58ac074fe6864f70ba50e4e7c6e81c9b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86244a8c59904b46967de22d14ea53dd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a1190ae8ab3474b9e2213bc83518d76_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0fffea9317f417ba61a67279b657180_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12aa7e5e1d7b416bb27fbac0ea8d1e88_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeab61feac444da7a016dd64df872cd9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i563d16d0ea8f4b1ea8c10c797482d489_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad7689d0635c4905af67a87b5aaa5f3a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aa5f2b1cbb14dbf9d951201819f5db2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb5b96ecbed1428ab26d61c8aa6e8b67_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i554ab772b5d0462a803c80fd10072849_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d920ab6a62942aab7073efd72dacef2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94b188b561e248948e1916e16ec1f0f3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f4316365c63469e84bbdb4402df49fa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a9b2764717433a815608cd7e18b125_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i791e6e6420e54c049daf6dd49164145f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic370d9cb5fd24bf799cbdf2177dacd50_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e36a0ccdeb14ec984f4085858cbc3ee_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if02ac5fb5d2f4310931908004cbf9aa0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1800f040ae0e4df991d07fe38d222324_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9efebbfd0f048c990bcc09d5b26f8c5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4f2a3dc80794091ae61e4de88cdbc43_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide6a2ab36d5d4e759f8c6fe1ecff6f01_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41696d03ccef49c2bf26d35317b03caa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica632ffb58b44d6194988501bb54fc73_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3081e3ffc7954b088fc9cb4152e95c85_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bbc219c44fc46859865214fb8165394_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i546b0b3a556d452f8e64404ed081302b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacfc81b93d7b4b4f8c6d7d4593e9dace_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c484984a09a4caaa0b9d6543ec482d5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i419f91c33865447b9e9338dab3f66b55_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6fc47b747054dab86fa5a363336c85e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i449513f8039f41138f8e72756af57c6d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb63ff75d0aa4f96af3798e301bd5bf6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e787fec51894471bcabbf60f6051058_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a756b10359641988b7f46edddeec13a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53cb49561acd4537ba93ba5db20eb4f0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b548827d54647c9ad6d75a0d12bb79f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icea40f4714334f43b2a0bc4763fd6bb4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ddacad667a94b23ac241aa7301b853a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5df0acd0f02348d3ba5d9669e15f2adb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib604dcd13e224121adb3a5c3b372b125_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6f1c8c4538460cb2956cf9359d3cae_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16ef0dd09ff34bd9832c510c5fcb9394_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3caafefa1d954278ad93efec805163b1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27a6f9b6cec64cddae7a84326e0b5ffe_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7383412bc7ac4797bad32eb100cb0abb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08ef15ce810b475c803431262514e1e9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f689f71f8a240b2a33290b4e3bfa31b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65d333ff83094f148e490ee53841f02f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad6e8d74360c4e38b0f7e558981f7f7f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a5801eab8e4442a8423dca2e534dad1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a8ed766d24e4af78c21550a7b7302a3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7432bde3ff84eafbcfb0af4b10fa31f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78fb2bfa7e774e23970aa2139ee245db_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75cfc29b08e54dbcb23f41eeb66d7d5e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44705b78f91d457fb2bee63fb813ff55_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9483a9e8f5b474ea373471543f0536b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf63d465ccd3423187f9af7e8b4bc7e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i182dd47bcec04ee292243a30a58dea41_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:PraluentCrossLicenseAndCommercializationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i814fd946f5074904942acc5d9194d0fb_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:PraluentCrossLicenseAndCommercializationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ca366da43e409298cf61eea017813d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9bfe175438f49a9be01e98bcc545764_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebfd12dc45514f458d53a2791ef44ec9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i509963cbbe784be8973a31df2b9a8963_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia985bae849b44c219201a836f385ce29_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1ba982dde844a9c82475e880a5f75f0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i955142d326434513a46962fe495e0fa1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaee3d49fec54b8a9e5fd65ae301bee3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i402f7f4cd8f04e6497716ec2e663706b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e46aceade444644b9dd70d4cecbf25b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if94b654450124728b790785f2b2cde12_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4e41d48528d49caae8c91f124239822_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2bf015dbfa7438092254a9cd1ea14ed_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf88f57a03b140b780d64166b452794e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ae6fd17f82a4bb6bdbe987bc274fbb2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5353a1ff784f4cf18d143c0765148747_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i073ce9da231842b3b7cd60b5bf3ca507_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i381b143df0d94c9a86aa2eeae5839128_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11dfc2547ca74cfc84608cbde114c10d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc5f19126e9840eb9029c6f52c25185b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa62c40f54c54ca1ad0abe0e53b2a453_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d7420067c744c329c85c868130a6ded_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a1d208f0eb4428db5488e7d8ed9b2f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6533a61e5ab4ad3a159b912aa4b022e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3fe6a3db0be4a5184a1b7acc80f29d7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86b44f35ec1c46cabb41e44d2197b227_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id21ae34bc9b64b5796aa956e68521d55_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i784465fd68bc485f93061c14f0464626_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20d13d4e4a7241f7b1b59f2578dfa67c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d0836ec7e74c33926c74712109896c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice301c2478284e1590cd4fe592b2d490_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic802850933a14320a118ce1085b1dbcc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64f2394a4ea74ae88bf23a677f4f957f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="dose"><xbrli:measure>regn:dose</xbrli:measure></xbrli:unit><xbrli:context id="ie940f37df2c049fd89c26eaeab0debe8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f04700578124cab99fe2de9a5db10bc_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i859fc8964b6340f8bf9073e37098a30a_D20220131-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27c9ab022abc478d8f79666d02a78330_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fcf5bf64c5f4e23b07547fddb4834c1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idae7c39276e247b99aa741d38663bd97_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie439420bfacb4ac3a711d43c21ed2b7a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7481e994a8ef47a4bc764250f091d6be_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id222f9b1cb5248d9bc897bf0e1e74fad_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i820df2abc71243a09f1e9d12e9631bf0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic40440c4c14b457ebef02ad35de7b6ee_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a7ab84ea29f4779b5a42b782dc5859e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70d249e67e354239b79dd039bbf41c79_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe25403ae1ba406b8be348b085927476_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:IntelliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i171b9fb71e894402b6278e0d6cf6ed66_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:IntelliaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i767fc2b3c91d49368bb428e956e1c15f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a52920e795646119a53ceb1ce382a02_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89f5b96bc5434e47892bfa9a96bc713f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2fe8e8115b14acaab1a1d5efd01ab92_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e9ea9623abe41a1afbf09779e3252b2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a9416d782bf46e3aac5cafdd70af82a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia467795663df48f8839e66b5689ec354_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb41ac995da4481eb5a2ee2048fd8b8e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i305115a444d14bd096edfc2b3a5fe574_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79da790fd94b4499bae26a25903f21e4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2b88f865b474f1fb605c319670ea555_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib08523f726914db6b88055d68a3804a8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f29c06129fa4ad385d3c25e70264511_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if160a4c1aa8a4e9ca18c15065b56268a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd87398154424f32abe288424051e254_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ebccad4b04e45f2973de4acc552e081_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd175f5bfcff4131b4291c7e886d11d0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3171b6f1e42044f6ad1521433ca23a16_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18110cf9fe854c0eac1362e59d0b3203_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f73b339b3634a3ab3b8e05805434ee9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60fa6e193603436099beee74e654012a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7188015c6d354b4aa4b026149b2f2dad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b306c67e2eb415eae154eec63a64166_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i709e307512f84f2d89f62a447afdbb84_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if15ed14fd37044feb3727eba888a012a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fedc6825bfd4a59a2bd6c1543230955_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i169c45bce7e14e0ebf7c4d8391c33a67_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92f4b800c8ac4853bc03e53e4b78405e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51ee79229d4e4ebfb388e4a3ad90b0a5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5f7030e51844bd39ff0f0a3b3ef5fb4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63130650b22f42fea4fa33623b9ba1bd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30e4687b375546d1af527e2a3df23ab3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i497ca48ecca04ba48c5d7ada2d2bbdc4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i318a17e861d840c98b3031789019aaea_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72abcc35bfe04c718a639cb1f6b996a4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f153fe081624b709016b5dcb2453c32_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9382f8343a0540b4a048b778c440d26b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c0224b00f9c4667827991e766d2f703_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i879b9c7c242c4ed5aad14987370b0a55_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26e6516b07ee48baac59da55f9ab9360_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8496a4fdf8714163a39d2735849938ce_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bf2a5edcb4f4d9d9c943737ce0824f6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fc9503772ed4063887ac7fa4b9d589f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0719e563f1ad45fe8cae8d7518999c47_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c4b945e334d45e8ae01e61b5260ebdc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bfd8f8a61bc4f3d99eaaf7d514b4d90_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i928f7d720b6248cd934975804e4ee21a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1011bfe7b3f241bdae36c2c04bdef602_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1ec84991e2545a8b15f060aad624a82_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i073bb6c4ef1d4dfd94ffa5d20de5a81b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideeb185943494d1d8c34874a74b6f176_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i718180e7a06c47d79ec5283f5004e756_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd8180afebff478b9f8bc963fa0e19d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee6b453205d44a0aa0e06f339c4344f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b0fb7a5bf6b4426b9c1f868210548d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf5e87dcd3a64a1da4267f0373377c04_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia20d85573fb143dd87f197ce54b7e399_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13a0befca2744f1e8f5c062d988ff10f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9263ef91fcc44315917f2dfc964e2ce2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2e7690d25b64054b80e2f57e6dc1292_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia21a946152114cde8edfdd4190cf231b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i371d5635a65d48f0b357645d217ce740_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6463b9ea289444d4a8a0c350da774f0e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7beed26d4e7440baf4167a9e144bd8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9ccf4d0492c49158f8907609cacb785_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6361d9ec906c4de9bb2da4f5e1bb347a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i880c4f56f4bf49eaa68316dd64419c31_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04298c88b3394119bf9d1c4903dba435_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c66fdf4db544d99a6ab7cc74a9bba46_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b9114a5c0054c229df4345b7d59365a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebd67af6e4c44ae197f75086c30ed696_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d2aae955be14f268249627181155c1c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6ae2cc961e14f028a26aaf88a03941b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2b125c56e464e7d83e39ceed25911e1_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:BridgeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id293bfb3eddd4aff80d65cf0394b1943_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f0cbd4933e54839aa58d6992050314c_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0dfa4b658804eb3a16f8cee0ca8be17_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i534da4670c274a81ae3524fbdfe06604_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i650510a2eb214adc84a48e8722d60ddf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i518fc4089b494e66895c51aae0a95ae4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1490f50984443fa9fc09db8661cd762_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9fe51ad3f5d44d7b51f9c7d2bb1636b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07fe2aef96e54e809240ec9fba24d72c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaefeb3e5dbc2406c9e11d7dbcba3ee98_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e98493124404aad8a8c0e1cb049d5ec_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgram2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ca3ec3e33eb4ab29ddc909bd33e67d0_D20201231-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgram2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-31</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieef2a875d0184972869268bd64fb3df7_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramJanuary2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69ddf6100ec6432d8b2d4ac0d6998971_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramJanuary2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31a864c8cc3a49e086a3fde76b1e1695_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:LibtayoDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bfec289c7074f5282b731594a9587a9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:DupilumabREGN3500EligibleInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied92924a0c784856bbf8ed8a35ac7f57_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:LibtayoDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec719ff1e7724d85bfffb28a5eac401e_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d93ce0ffcda4c05912416ab54808098_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5148f71a87a04e13ac8076f503a1425e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i222bcb21c9a4477ab7dc7af26e32e7ee_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>regn:claim</xbrli:measure></xbrli:unit><xbrli:context id="i2e4f524ab89b4891b4ccfbd3555e3a26_I20190225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">regn:Amgenv.s.RegeneronMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A165PatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i870177ce53f7404e98979e8f07c9609f_I20190225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">regn:Amgenv.s.RegeneronMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A741PatentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae9a73d5ea4745d09d9bbb09f273f524_D20170728-20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A487PatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-28</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34e55477ad8e4cfebda758de4b6f0516_I20190214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A487PatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="request"><xbrli:measure>regn:request</xbrli:measure></xbrli:unit><xbrli:context id="i4c1e030c474b48ada51944d7eb45dbb7_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EYLEAAfliberceptInjectionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A226PatentAnd992PatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4b960d3dff6442ba38d7de8747b8883_D20200716-20200716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A631PatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-16</xbrli:startDate><xbrli:endDate>2020-07-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iae35796f039b495ba4b10877e85a1c6f_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGV4dHJlZ2lvbjo2NGRjNGYxZDUzODE0YWY4YTBiZTAwNzZhNTEyODdkMF80MTk_0345316c-d122-4b5b-aa92-96efe7c18255">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Mark One)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6M2UwYzg4ZWNkOTUwNDI2YjgwZjgwNTdhZGEzZjBjYmEvdGFibGVyYW5nZTozZTBjODhlY2Q5NTA0MjZiODBmODA1N2FkYTNmMGNiYV8xLTAtMS0xLTA_6c9b9340-12de-42af-b9eb-e02a3c1e231a">&#9746;</ix:nonNumeric></span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6M2UwYzg4ZWNkOTUwNDI2YjgwZjgwNTdhZGEzZjBjYmEvdGFibGVyYW5nZTozZTBjODhlY2Q5NTA0MjZiODBmODA1N2FkYTNmMGNiYV8yLTEtMS0xLTAvdGV4dHJlZ2lvbjo0MDJlMTdhYTg1NGY0MWZiYmE4OTU1NDA2OGE1ZTNmZV8zNQ_01f85dc9-93fd-4bac-9d5f-fe2584788ea3">September 30, 2021</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">OR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6M2UwYzg4ZWNkOTUwNDI2YjgwZjgwNTdhZGEzZjBjYmEvdGFibGVyYW5nZTozZTBjODhlY2Q5NTA0MjZiODBmODA1N2FkYTNmMGNiYV80LTAtMS0xLTA_da45c916-7ed0-4540-9be8-058a0610c178">&#9744;</ix:nonNumeric></span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the transition period from __________ to __________</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.578%"><tr><td style="width:1.0%"></td><td style="width:29.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commission File Number: <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6NzNhOGZiNjE3ZGFkNDA3MTkyOWVmMzgxOGI0YzlkNjMvdGFibGVyYW5nZTo3M2E4ZmI2MTdkYWQ0MDcxOTI5ZWYzODE4YjRjOWQ2M18wLTEtMS0xLTAvdGV4dHJlZ2lvbjozNTFkNTE0OGNjNjI0OGE1YmNlZjA3YjBmNTE2NWFhM18yOQ_958cac48-d2f3-4b89-bc4d-035082ad3c11">0-19034</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGV4dHJlZ2lvbjo2NGRjNGYxZDUzODE0YWY4YTBiZTAwNzZhNTEyODdkMF80MjA_3fd13ddd-2a4e-4d51-9466-2f59e919da8a">REGENERON PHARMACEUTICALS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YzdkN2Q5YzQyMjYyNGRkNWFhZDE3Y2IwYmI3NjhiMWYvdGFibGVyYW5nZTpjN2Q3ZDljNDIyNjI0ZGQ1YWFkMTdjYjBiYjc2OGIxZl8wLTAtMS0xLTA_dd6e8bdd-e6c1-4c08-b1c3-83b8bf29e281">New York</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YzdkN2Q5YzQyMjYyNGRkNWFhZDE3Y2IwYmI3NjhiMWYvdGFibGVyYW5nZTpjN2Q3ZDljNDIyNjI0ZGQ1YWFkMTdjYjBiYjc2OGIxZl8wLTItMS0xLTA_2c544dc2-c036-42fd-a647-73adfe217811">13-3444607</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.479%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YjMzYWYwYjBhYjIzNDI4NzljNjA3OTQwODY4MjNiNDMvdGFibGVyYW5nZTpiMzNhZjBiMGFiMjM0Mjg3OWM2MDc5NDA4NjgyM2I0M18wLTAtMS0xLTAvdGV4dHJlZ2lvbjozM2IwOTAxMTA3YjQ0OTA0YTUzMjJiODNjOThhMmYwNF80_52d92c12-852b-49f6-87b6-cbdc201c0bb1">777 Old Saw Mill River Road</ix:nonNumeric>, <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YjMzYWYwYjBhYjIzNDI4NzljNjA3OTQwODY4MjNiNDMvdGFibGVyYW5nZTpiMzNhZjBiMGFiMjM0Mjg3OWM2MDc5NDA4NjgyM2I0M18wLTAtMS0xLTAvdGV4dHJlZ2lvbjozM2IwOTAxMTA3YjQ0OTA0YTUzMjJiODNjOThhMmYwNF85_de43b59c-89cb-4712-8b2b-778750be6c08">Tarrytown</ix:nonNumeric>, <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YjMzYWYwYjBhYjIzNDI4NzljNjA3OTQwODY4MjNiNDMvdGFibGVyYW5nZTpiMzNhZjBiMGFiMjM0Mjg3OWM2MDc5NDA4NjgyM2I0M18wLTAtMS0xLTAvdGV4dHJlZ2lvbjozM2IwOTAxMTA3YjQ0OTA0YTUzMjJiODNjOThhMmYwNF8xNA_e802ac28-db52-4b05-a824-d962ea4c1201">New York</ix:nonNumeric> <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YjMzYWYwYjBhYjIzNDI4NzljNjA3OTQwODY4MjNiNDMvdGFibGVyYW5nZTpiMzNhZjBiMGFiMjM0Mjg3OWM2MDc5NDA4NjgyM2I0M18wLTAtMS0xLTAvdGV4dHJlZ2lvbjozM2IwOTAxMTA3YjQ0OTA0YTUzMjJiODNjOThhMmYwNF8xOA_798de8b7-7496-4a89-a87b-21a61bdadd09">10591-6707</ix:nonNumeric></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGV4dHJlZ2lvbjo2NGRjNGYxZDUzODE0YWY4YTBiZTAwNzZhNTEyODdkMF80MjE_7b465ca5-a4db-4eac-b6aa-4dc8c375391e">914</ix:nonNumeric>) <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGV4dHJlZ2lvbjo2NGRjNGYxZDUzODE0YWY4YTBiZTAwNzZhNTEyODdkMF80MjI_3ad88680-fd70-4a62-8207-781aa3aa9c73">847-7000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.619%"><tr><td style="width:1.0%"></td><td style="width:41.314%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.315%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6NGRiZWMxZmNlYmFjNGJiZGI1MDBiYTFiODEwOTUxOGIvdGFibGVyYW5nZTo0ZGJlYzFmY2ViYWM0YmJkYjUwMGJhMWI4MTA5NTE4Yl8xLTAtMS0xLTA_9f1e2efc-c80b-43bf-8069-8314cb3a5e7e">Common Stock - par value $.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6NGRiZWMxZmNlYmFjNGJiZGI1MDBiYTFiODEwOTUxOGIvdGFibGVyYW5nZTo0ZGJlYzFmY2ViYWM0YmJkYjUwMGJhMWI4MTA5NTE4Yl8xLTEtMS0xLTA_7794ec0c-c788-4bb2-9b33-4d20f0760590">REGN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6NGRiZWMxZmNlYmFjNGJiZGI1MDBiYTFiODEwOTUxOGIvdGFibGVyYW5nZTo0ZGJlYzFmY2ViYWM0YmJkYjUwMGJhMWI4MTA5NTE4Yl8xLTItMS0xLTA_a7d06297-6220-41bb-a1ef-34fb96bae345">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:87.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YjBkMzljYzIyYTgwNGRkM2IzNjk0ZWRmM2NiNWNlODIvdGFibGVyYW5nZTpiMGQzOWNjMjJhODA0ZGQzYjM2OTRlZGYzY2I1Y2U4Ml8wLTEtMS0xLTA_87c4ab76-5bd4-4e05-89bb-a63a67ca6444">Yes</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YjBkMzljYzIyYTgwNGRkM2IzNjk0ZWRmM2NiNWNlODIvdGFibGVyYW5nZTpiMGQzOWNjMjJhODA0ZGQzYjM2OTRlZGYzY2I1Y2U4Ml8yLTEtMS0xLTA_e8ab895c-9d55-4d62-895f-8abd0ef0de19">Yes</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:13.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6MTkyNmNkZDVhNzllNGVhNzk2MTk4MWMzM2MyYWI5ODQvdGFibGVyYW5nZToxOTI2Y2RkNWE3OWU0ZWE3OTYxOTgxYzMzYzJhYjk4NF8wLTAtMS0xLTA_5dd6a895-9543-428a-9305-21f6ddd11705">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6MTkyNmNkZDVhNzllNGVhNzk2MTk4MWMzM2MyYWI5ODQvdGFibGVyYW5nZToxOTI2Y2RkNWE3OWU0ZWE3OTYxOTgxYzMzYzJhYjk4NF8wLTEwLTEtMS0w_2d2063c1-d394-49b3-a383-25e6e3218f3a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6MTkyNmNkZDVhNzllNGVhNzk2MTk4MWMzM2MyYWI5ODQvdGFibGVyYW5nZToxOTI2Y2RkNWE3OWU0ZWE3OTYxOTgxYzMzYzJhYjk4NF8wLTEzLTEtMS0w_de59b02a-23c6-4361-9f9c-17a6f6ebbfee">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:86.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YjdmYWYxYzg1OGNjNGJjNjg2ZTkwMDdmYjUxMTM2YmEvdGFibGVyYW5nZTpiN2ZhZjFjODU4Y2M0YmM2ODZlOTAwN2ZiNTExMzZiYV8yLTQtMS0xLTA_ccdea811-6aff-4f13-872b-3119cd71a553">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of each of the registrant's classes of common stock as of October&#160;22, 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.526%"><tr><td style="width:1.0%"></td><td style="width:47.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.002%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class of Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of Shares</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class A Stock, $.001 par value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc16664525144692bafad224736d7dbc_I20211022" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6NDcxNzBhYWJlOTUxNGY5NmFmNDZjOTI1NmM1NWNhYWIvdGFibGVyYW5nZTo0NzE3MGFhYmU5NTE0Zjk2YWY0NmM5MjU2YzU1Y2FhYl8xLTItMS0xLTA_2594461f-9116-4a55-a6a1-a17306e63a0c">1,823,283</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock, $.001 par value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida653b0f9e874bc6a9d652fb00e0d46b_I20211022" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6NDcxNzBhYWJlOTUxNGY5NmFmNDZjOTI1NmM1NWNhYWIvdGFibGVyYW5nZTo0NzE3MGFhYmU5NTE0Zjk2YWY0NmM5MjU2YzU1Y2FhYl8yLTItMS0xLTA_1058ae08-5c39-4dc2-9aa6-d0220c8968a3">105,719,735</ix:nonFraction></span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.789%"><tr><td style="width:1.0%"></td><td style="width:9.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page Numbers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_10">PART I</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_13">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_13">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_13">2</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_16">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_16"> 30, 2021 and December 31, 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_16">2</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_19">Condensed Consolidated Statements of Operations and Comprehensive Income for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_19">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_19"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_19">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_19"> 30, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_19">3</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_22">Condensed Consolidated Statements of Stockholders' Equity for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_22">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_22"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_22">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_22"> 30, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_22">4</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_25">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_25">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_25"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_25"> 30, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_25">6</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_28">7</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_67">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_67">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_67">25</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_94">Item 3. </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_94">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_94">51</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_97">Item 4.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_97">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_97">52</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_100">PART II</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_100">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_103">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_103">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_103">52</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_106">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_106">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_106">52</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_109">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_109">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_109">87</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_112">Item 6.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_112">Exhibits</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_112">87</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_115">SIGNATURE PAGE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_115">88</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">"ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">"Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">" (in the United States), "Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">" (in the United States), "REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Regeneron</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "Regeneron Genetics Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Veloci-Bi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociGene</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociHum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociMab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociMouse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociSuite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VelociT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">," and "ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">" are trademarks of Regeneron Pharmaceuticals, Inc. Trademarks and trade names of other companies appearing in this report are, to the knowledge of Regeneron Pharmaceuticals, Inc., the property of their respective owners. This report refers to products of Regeneron Pharmaceuticals, Inc., its collaborators, and other parties. Consult the product label in each territory for specific information about such products. </span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="iae35796f039b495ba4b10877e85a1c6f_13"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="iae35796f039b495ba4b10877e85a1c6f_16"></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions, except share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNC0xLTEtMS0w_ecd08079-ee47-4a13-8a2c-3d761c3b4069">3,432.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNC0zLTEtMS0w_bc136d06-2515-47de-b2d5-fb92e4050b26">2,193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNS0xLTEtMS0w_05f3017e-e4d9-411d-bd34-deede09583da">2,355.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNS0zLTEtMS0w_e6e91b04-ba5f-4b07-a608-fac5d14b3c0a">1,393.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNi0xLTEtMS0w_c07fbd01-33ee-464e-aac6-ea28ef622bd3">5,452.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNi0zLTEtMS0w_4e082629-7cf6-4a54-9c7e-db431620a6d3">4,114.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNy0xLTEtMS0w_3bcedecf-1222-4c3e-aa45-f47db3345f7a">2,053.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNy0zLTEtMS0w_f9bcf2d6-64b0-45aa-8a7f-fc46ea28553c">1,916.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfOC0xLTEtMS0w_26c02cf5-3fe1-44e0-b8c2-dd6e16218c16">482.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfOC0zLTEtMS0w_3bc2be9d-5ed7-4ecc-8563-e870b5383f1c">160.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfOS0xLTEtMS0w_288f53ec-9ad1-428a-baf2-8af174d53f9a">13,775.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfOS0zLTEtMS0w_e2914ded-f3b0-462f-8f57-72bf21be778b">9,779.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTEtMS0xLTEtMA_f94ee12c-80c9-44fe-a4a5-e8b1dbc8186b">5,631.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTEtMy0xLTEtMA_722bd005-111c-4657-9390-44a0b1a0f8a9">3,135.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTItMS0xLTEtMA_a2d5ffc9-9832-4be7-8683-a1d170c339c0">3,395.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTItMy0xLTEtMA_390a8586-3fe2-428d-a99f-aeef8409b7ea">3,221.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTMtMS0xLTEtMA_c0775bef-f419-43f9-8a2d-cd922761919a">723.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTMtMy0xLTEtMA_f4cee08d-140e-49e0-a780-9733d384e9c4">858.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTQtMS0xLTEtMA_fd6710aa-c87e-44f2-9514-e651e44e7486">145.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTQtMy0xLTEtMA_c02baafe-4503-44d3-ab46-4ff075d101f0">168.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTUtMS0xLTEtMA_bff4d707-5052-4686-9b92-11d94a242eac">23,671.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTUtMy0xLTEtMA_5e0faf64-80c3-4ea0-82d6-161eda33e4c3">17,163.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTktMS0xLTEtMA_9c8b8c05-1a61-4841-9774-88c065980b5d">427.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTktMy0xLTEtMA_500f1265-4c59-4617-bd34-4808550b4717">475.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjAtMS0xLTEtMA_7b932754-9cc8-4c21-89ee-25a1b2ad0907">2,061.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjAtMy0xLTEtMA_54202786-662c-409b-ad38-587d6a5aff8e">1,644.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjEtMS0xLTEtMA_6e3e5ab4-c09d-4bcf-b67f-6b80ac706f60">719.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjEtMy0xLTEtMA_512e95ae-b499-42ee-a723-baff3957883c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjItMS0xLTEtMA_97e045ba-d0d3-49d4-9836-aa6a8ceac2f2">507.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjItMy0xLTEtMA_9c6a5465-8d13-40c9-ac52-7e8ea3f46983">577.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjMtMS0xLTEtMA_1b98d309-331b-4f96-accd-aa7c170334d1">3,714.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjMtMy0xLTEtMA_073c3be9-c2eb-44b8-9985-8d3ef9ad0f64">2,697.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjUtMS0xLTEtMA_9f669d3a-a387-4395-ae96-5524464faa1e">1,979.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjUtMy0xLTEtMA_42e0001c-5350-40e0-8588-412dcdf1fd79">1,978.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjYtMS0xLTEtMA_2b53bee8-0f64-431b-8af1-37f9d461db8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjYtMy0xLTEtMA_ab29349d-5ca0-456a-8c05-a74ba65d641a">717.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjctMS0xLTEtMA_188c9e2f-dbf4-4280-9fc4-e04707c73783">56.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjctMy0xLTEtMA_dc70d8e0-2d41-4504-ab24-5f35b8f4457c">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjgtMS0xLTEtMA_b353b92e-d71c-4788-9d09-e019af7f4bc1">662.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjgtMy0xLTEtMA_539d0cd0-366c-4469-b40c-f6d0527dea69">687.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjktMS0xLTEtMA_3f33389d-cd03-4341-b8fb-aecdce0a1e5b">6,413.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjktMy0xLTEtMA_7b0bf68a-4729-4fd7-ad97-697fcbefc147">6,138.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3XzIy_0dedf0b4-1ea2-45c1-91fa-e2187973fb66"><ix:nonFraction unitRef="usdPerShare" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3XzIy_10cd1e29-ae02-4002-a331-0e4e43158211">.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3XzM2_6b8368c8-fd22-4d56-859e-031af8d9c8e8"><ix:nonFraction unitRef="shares" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3XzM2_8d6baee4-7284-4f66-bd65-e9cc5d37cc10">30,000,000</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3Xzgz_3086c1d6-aaf0-4655-b827-cee536916a01"><ix:nonFraction unitRef="shares" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3Xzgz_747a9d4b-23b2-44bc-9c0e-9a4b1b14e532"><ix:nonFraction unitRef="shares" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3Xzgz_992a3cdd-8451-49da-81d9-c027f13b4a40"><ix:nonFraction unitRef="shares" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3Xzgz_a3a78400-247a-406e-b383-19e2b98dcfa0">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>ne</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMS0xLTEtMA_abb7ffdd-aae5-48a1-9b87-b0cdd72c6f41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMy0xLTEtMA_1cb2125b-7b10-4d60-ba86-f127a358f7e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A Stock, convertible, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia1f2d0c6a01e40a1a132025d16ef17ca_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzMy_2fc72c31-5ec3-4335-9683-7e53b64cd788"><ix:nonFraction unitRef="usdPerShare" contextRef="i65b94c6346a4410db40c1e51f2964b9d_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzMy_b6ec77ca-e923-4860-bdaa-c294d9694c09">.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i65b94c6346a4410db40c1e51f2964b9d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzQ2_e1cb586b-db2e-43e5-b553-c8a575dde886"><ix:nonFraction unitRef="shares" contextRef="ia1f2d0c6a01e40a1a132025d16ef17ca_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzQ2_f26c104d-747c-4a5c-bf2d-db0894431415">40,000,000</ix:nonFraction></ix:nonFraction> shares authorized; shares issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="i65b94c6346a4410db40c1e51f2964b9d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzEwMA_1f9aa019-ab02-48ea-a68b-8715623b6493"><ix:nonFraction unitRef="shares" contextRef="ia1f2d0c6a01e40a1a132025d16ef17ca_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzEwMA_9979bfbe-750d-4e87-9bd5-66e652684c74"><ix:nonFraction unitRef="shares" contextRef="i65b94c6346a4410db40c1e51f2964b9d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzEwMA_c40fd984-59d4-4dbc-b262-6bd5c45e32d3"><ix:nonFraction unitRef="shares" contextRef="ia1f2d0c6a01e40a1a132025d16ef17ca_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzEwMA_e0222bfa-fef4-425c-9a75-ebdab8417ba9">1,848,970</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> in 2021 and 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f2d0c6a01e40a1a132025d16ef17ca_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMS0xLTEtMA_797c6efb-4e73-4e3b-a293-5a469cd6acec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65b94c6346a4410db40c1e51f2964b9d_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMy0xLTEtMA_aa70a882-9f99-4c4b-b38a-09e9ef96b509">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i010ed964f154499ca13c88bdf3995dd6_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjFiYzI1OWYzYTZhYTQ4N2Q5ZmE1NWQzMWVmZTY4ZDVmXzE4_96b40aee-1f34-4eec-89a3-72bfa43b4304"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e6fff47dfed4a8890d58fd118bc6b39_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjFiYzI1OWYzYTZhYTQ4N2Q5ZmE1NWQzMWVmZTY4ZDVmXzE4_a84154d7-83cd-4e09-ad05-4f9261c8eb9f">.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i1e6fff47dfed4a8890d58fd118bc6b39_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjFiYzI1OWYzYTZhYTQ4N2Q5ZmE1NWQzMWVmZTY4ZDVmXzMy_47bf5932-b45d-4fe4-994a-9f75caec087b"><ix:nonFraction unitRef="shares" contextRef="i010ed964f154499ca13c88bdf3995dd6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjFiYzI1OWYzYTZhYTQ4N2Q5ZmE1NWQzMWVmZTY4ZDVmXzMy_91ffb6d6-0d42-4fa6-928e-324b507efae2">320,000,000</ix:nonFraction></ix:nonFraction> shares authorized; shares issued - <ix:nonFraction unitRef="shares" contextRef="i010ed964f154499ca13c88bdf3995dd6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjFiYzI1OWYzYTZhYTQ4N2Q5ZmE1NWQzMWVmZTY4ZDVmXzcw_a209e28c-07f9-46fb-a643-09dcb6a370aa">124,608,241</ix:nonFraction> in 2021 and <ix:nonFraction unitRef="shares" contextRef="i1e6fff47dfed4a8890d58fd118bc6b39_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjFiYzI1OWYzYTZhYTQ4N2Q5ZmE1NWQzMWVmZTY4ZDVmXzg1_c89434a3-27bf-460b-88d1-d49cdd2386eb">121,533,460</ix:nonFraction> in 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i010ed964f154499ca13c88bdf3995dd6_I20210930" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMS0xLTEtMA_5d28fac9-53b5-4f87-b69a-ec4fc0a6587a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6fff47dfed4a8890d58fd118bc6b39_I20201231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMy0xLTEtMA_d4756339-1e8d-4bfe-aa00-1b94084f9921">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzUtMS0xLTEtMA_2a8e34d9-fdde-4b1a-8cb8-f66e0b6a226c">7,919.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzUtMy0xLTEtMA_fe3db2ca-4fb6-4c65-a28d-aafce75ed795">6,716.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzYtMS0xLTEtMA_c97001f6-df76-4da1-8c1e-549b83c6e46d">16,739.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzYtMy0xLTEtMA_ddd6f3fb-03b7-4ea5-8597-c3e3cc016903">10,893.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzctMS0xLTEtMA_d06b97e7-810a-462c-8537-46274a43ffbc">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzctMy0xLTEtMA_1551ef4e-e515-4233-a8a7-1c697947b9c7">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Stock, at cost; <ix:nonFraction unitRef="shares" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjYyZTk4MTE5Y2EzMTQ4M2I4M2Y2ZjI1ZDNiOTlhZDEwXzI5_46e2810b-2824-43e0-92ac-61c0babcd2be">17,930,390</ix:nonFraction> shares in 2021 and <ix:nonFraction unitRef="shares" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjYyZTk4MTE5Y2EzMTQ4M2I4M2Y2ZjI1ZDNiOTlhZDEwXzUx_6cfc6193-0f57-48da-9486-202976b1f364">16,431,520</ix:nonFraction> shares in 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzgtMS0xLTEtMA_6c94a006-4a91-4772-8c2d-0861a43a7644">7,410.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzgtMy0xLTEtMA_0f1a159f-7bc2-4c4b-b356-61d8c98cdcb0">6,613.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzktMS0xLTEtMA_c1fd5752-c1e8-499b-a9d1-1f36986100ad">17,258.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzktMy0xLTEtMA_eba8c10d-f77b-4211-a1c9-52e0865c1048">11,025.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNDAtMS0xLTEtMA_6810afd8-a818-48b6-b39f-5181d8103689">23,671.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNDAtMy0xLTEtMA_a15c4699-e4a0-4986-b23c-de52baf109df">17,163.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 13.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions, except per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i701b6278270643ea9ea3e4f71bac2244_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNC0yLTEtMS0w_483723dc-d484-497c-97fc-3faa0e0fbbcc">2,279.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93da59ad5160490cb75eb85818530df4_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNC00LTEtMS0w_86dc1e09-eef6-4177-bd5e-a2e4edd88e45">1,482.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if39174df528047a1a58851162c8756dc_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNC02LTEtMS0w_4a29e826-e223-402e-b67d-6161941a5ddd">8,142.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d6c2cf98ab48708f23e1c442baff3a_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNC04LTEtMS0w_ea51742a-072d-4e4f-a62f-411884c18580">3,945.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb855af148d44803bf5a5a397f72a4a6_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNS0yLTEtMS0w_9af838f8-fa15-4df7-bef6-5dd59324bd69">1,073.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ec7f922ada451f954d39c3398269f2_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNS00LTEtMS0w_c891afac-655e-4839-b4d6-c9bdd515e5cd">653.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011ff92b7314bba86afeec4eeaf8b4d_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNS02LTEtMS0w_b913205e-222b-4287-af03-cc13d8c4fc6b">2,783.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38c63575c6ef4f41b900486402535348_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNS04LTEtMS0w_63dd2068-fccc-4106-bf55-2d777d453156">1,694.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id10cdd0c27b642138616b7b32f4d6ee8_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNi0yLTEtMS0w_54e3e424-a6ad-415a-b65d-b3e0dc7be999">99.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebab4f2f32234aa480f0f8082f54bd53_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNi00LTEtMS0w_f83a0d0e-8386-483a-9eea-9139146c77c9">158.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b8d7bccc16342b88d4e13958c1c3e11_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNi02LTEtMS0w_3474e13e-0fcb-4316-ac7b-8f83a58cf471">195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibabe614a09ed4deaa4de04435940de78_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNi04LTEtMS0w_eb6b5c7c-45c7-414d-9e69-09f38b9acacf">433.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNy0yLTEtMS0w_ce3596b1-3013-4fc4-83ed-3307035b2276">3,452.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNy00LTEtMS0w_1033f19b-2e7e-479f-b0e6-11cd65f434ae">2,294.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNy02LTEtMS0w_3fa21cd5-e8f8-4375-8820-e80a6da64c2e">11,120.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNy04LTEtMS0w_786b41d5-099a-458b-9d51-e49461513536">6,074.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTAtMi0xLTEtMA_0484c5b0-dcc5-4c50-b9bd-2a192bbf8070">665.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTAtNC0xLTEtMA_3d0aef58-ffcb-43a7-abfb-b8aa2889d80c">684.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTAtNi0xLTEtMA_cb748c11-a62a-4cdf-a945-729ace53a682">2,122.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTAtOC0xLTEtMA_4489dfb9-3745-4bbc-b049-103468afd2c4">1,990.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTEtMi0xLTEtMA_9d3084a0-51d0-4211-8f09-c476cf3ed7b4">445.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTEtNC0xLTEtMA_514b1957-dad7-49af-8387-6156087f954e">326.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTEtNi0xLTEtMA_23358009-6527-4e70-a231-e6ae707af583">1,265.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTEtOC0xLTEtMA_3790640f-3d62-48ab-adfd-673b9e03cc3b">1,042.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i701b6278270643ea9ea3e4f71bac2244_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTItMi0xLTEtMA_8c55f518-f6f4-45b4-bdc5-1ef709b2cc2a">238.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93da59ad5160490cb75eb85818530df4_D20200701-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTItNC0xLTEtMA_4355eca1-974e-4f18-8080-1918b1ad8b51">131.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if39174df528047a1a58851162c8756dc_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTItNi0xLTEtMA_84b0c011-3a8f-42b5-9cf1-4a819a0926a2">961.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d6c2cf98ab48708f23e1c442baff3a_D20200101-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTItOC0xLTEtMA_9089452f-6366-4db4-912c-e511f481ef4b">312.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration and contract manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770f931b2ede4bdeb5ef82d0dd8a554d_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTMtMi0xLTEtMA_98f5a367-9db7-4364-9144-8c6db9a29ca9">214.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cb541cbbbef4d78a54cbec6a7e81726_D20200701-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTMtNC0xLTEtMA_2e6f9dea-bbe5-494e-ad8e-db860e9f05fc">143.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76c0001967fc483996710f1c2b1392ce_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTMtNi0xLTEtMA_88cbf489-0662-4987-9d04-f2874564284c">493.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i463b28633c04475b8ede195911dcb3ce_D20200101-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTMtOC0xLTEtMA_6e1e945f-985c-4fe8-94ee-72ce2d284fbe">454.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expense (income), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTQtMi0xLTEtMA_f0232eb5-58d1-472f-bb30-738025b7cbc1">42.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTQtNC0xLTEtMA_ecef97cc-454b-4b03-beff-9e2605dee0ee">44.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTQtNi0xLTEtMA_8bdbefa2-fa9c-4615-bafe-b96462daa0c9">29.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTQtOC0xLTEtMA_9d13a289-7d12-419d-9c05-2006000e5341">135.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTUtMi0xLTEtMA_89e8fb1f-f9c8-458c-b19c-0245087729f4">1,605.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTUtNC0xLTEtMA_1c38c7d2-9fd4-43b2-a106-589a99da9543">1,240.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTUtNi0xLTEtMA_4ef4330a-54a5-4163-b82f-2f71d01762e5">4,812.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTUtOC0xLTEtMA_fc418b2e-f7fc-499e-a5fd-13367e8c88f4">3,664.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTctMi0xLTEtMA_eddc1998-ee8b-4d9e-8209-84d71a904579">1,847.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTctNC0xLTEtMA_9d9ef7ab-a1d8-405e-a29d-b15291ff1f46">1,053.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTctNi0xLTEtMA_05d5bc3c-f5bb-45bf-a121-600301409e05">6,307.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTctOC0xLTEtMA_c12e108b-3d97-4daa-a12d-471794c7a27c">2,409.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjAtMi0xLTEtMA_1e41e0a5-9a54-40af-a93f-8c5c9931fd67">16.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjAtNC0xLTEtMA_f2d30e84-e89a-4af8-a14d-0297447d865c">28.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjAtNi0xLTEtMA_08ad9d83-e46d-4157-a67d-71ceb824171c">558.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjAtOC0xLTEtMA_322a42a1-0110-4f7c-974f-9beea2b1c4b4">218.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjEtMi0xLTEtMA_6cf690b3-0b54-4642-b930-a4012f745e79">14.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjEtNC0xLTEtMA_d27bb08c-f8a5-49c7-b054-7cae03e8ecdd">26.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjEtNi0xLTEtMA_4b63ad0c-1d99-4fda-a50e-52507735fb6e">43.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjEtOC0xLTEtMA_2fa25ed3-956b-4d73-b799-1a2829ce1998">42.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjItMi0xLTEtMA_15128cfb-d7a8-4f17-a80d-8368e5fd9608">30.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjItNC0xLTEtMA_fca2e55f-640c-47cf-bdb4-41041c3549b1">54.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjItNi0xLTEtMA_edc14b53-42d4-4501-85bf-0d776f2e9059">515.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjItOC0xLTEtMA_624dcdd2-2a1e-45d7-8ed3-28168d49f8a1">176.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjQtMi0xLTEtMA_091c893e-5e6c-4597-87cd-c643f411fd93">1,816.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjQtNC0xLTEtMA_fd10730c-0804-4881-a13b-a118c37dedc9">998.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjQtNi0xLTEtMA_4e33d7d8-1c2e-4b97-96f7-672ea6d1a92c">6,822.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjQtOC0xLTEtMA_958dc159-80cb-4733-9e4f-041245b01cbf">2,585.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjYtMi0xLTEtMA_8da1377a-9898-46a1-bcf4-02bb1f805229">184.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjYtNC0xLTEtMA_b748cb12-4ccd-45b4-a632-8c899c4b97ea">156.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjYtNi0xLTEtMA_03edd9e4-9d14-41e7-b41e-730921d977cd">976.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjYtOC0xLTEtMA_42e003e5-de5b-4799-bbab-cf3e1b038409">221.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjgtMi0xLTEtMA_c3d33da7-5980-4e0e-9d9e-0d06f223ee5e">1,632.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjgtNC0xLTEtMA_9736ea86-8f84-4538-81ff-322a0e89821c">842.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjgtNi0xLTEtMA_92f5e1a8-e56a-4b80-b901-a7b3f3f04ea1">5,846.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjgtOC0xLTEtMA_8dfa1d41-d419-40ae-997a-933f281a460e">2,364.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzAtMi0xLTEtMA_13a07884-1051-41ee-8d3d-71985de07e64">15.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzAtNC0xLTEtMA_af93f0fe-1ebb-4860-992a-47849241ce65">7.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzAtNi0xLTEtMA_becfe970-1755-41e2-8547-97ec7849bb0c">55.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzAtOC0xLTEtMA_78d0936e-10e3-4ddc-a0ae-bff606c307d3">21.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzEtMi0xLTEtMA_7d39cf31-d071-4cd2-aa87-069318d1aaf3">14.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzEtNC0xLTEtMA_a9ac5cda-5c5b-4fa3-a96c-0c87ad5f0e99">7.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzEtNi0xLTEtMA_a99ef49d-6403-4bcd-8917-3633615f60c3">52.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzEtOC0xLTEtMA_8cf9c909-d68f-48ee-86bb-611b8844566c">20.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzMtMi0xLTEtMA_24541e57-7939-4df3-a023-18a82320d638">106.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzMtNC0xLTEtMA_6caebecf-56ef-47fb-84bf-6f7c1a9ba544">105.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzMtNi0xLTEtMA_ba1f5c8d-0974-46d3-bb42-dfbaea80c1e2">105.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzMtOC0xLTEtMA_5a62a876-c5f1-44b4-b194-3c510a113f27">108.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzQtMi0xLTEtMA_2226ecbc-ac78-4ee2-9daf-74e4d9406156">113.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzQtNC0xLTEtMA_f9244828-e332-48b1-92c4-99621c8d3383">113.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzQtNi0xLTEtMA_1fbe7fde-f5de-462a-9636-41cea2b1e474">111.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzQtOC0xLTEtMA_f2ed91c8-adeb-4718-8b45-9955e5f5f096">116.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Comprehensive Income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzctMi0xLTEtMA_3ba9e1dc-9124-4289-a8a0-09ab48efe403">1,632.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzctNC0xLTEtMA_0af8566b-f9cd-477d-aa8b-2fd014d35d2f">842.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzctNi0xLTEtMA_f09ae306-1a7f-4635-9646-5473fdbeec72">5,846.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzctOC0xLTEtMA_b125c730-85d3-4c4b-9bbf-c001ea8c80a7">2,364.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzktMi0xLTEtMA_f974501c-076a-4e56-b7b4-ce30ae8cecfe">6.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzktNC0xLTEtMA_a41dfb2e-16fe-436a-a2c4-cbf31c114a4f">4.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzktNi0xLTEtMA_22526bf8-e403-4251-b721-523b11a83398">20.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzktOC0xLTEtMA_14e0a4b2-a797-4db6-af68-f3a7610ec508">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDAtMi0xLTEtMA_3c260641-c4f2-44f3-bd37-697d198373e9">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDAtNC0xLTEtMA_d0d420da-c81d-42ef-be08-31f53a246d68">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDAtNi0xLTEtMA_159ff9e0-a289-45bb-8a8a-5c6f398c3f30">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDAtOC0xLTEtMA_6dafbde0-6dc0-469b-8269-4a8ba214056a">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDEtMi0xLTEtMA_917c587b-76c1-4791-b233-1fc4dadea317">1,626.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDEtNC0xLTEtMA_dcfe6347-d0f5-4662-8176-0dc6512edf11">837.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDEtNi0xLTEtMA_2c35c084-dd67-471d-8cd9-a2c4a54d52bf">5,826.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDEtOC0xLTEtMA_04fe43a4-8c17-4995-ad14-0a0734d8a183">2,373.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.414%"><tr><td style="width:1.0%"></td><td style="width:33.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.824%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.849%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Class A Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3239cd5923f34e0ca9e9ec38de051f2e_I20201231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi0yLTEtMS0w_d8795d60-8de2-4665-a6ea-201a52bca272">1.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3239cd5923f34e0ca9e9ec38de051f2e_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi00LTEtMS0w_b6d3da83-1b51-4f8f-b848-37ea22e1cda6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i035ed65f313f47239e1ba7a980f112a4_I20201231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi02LTEtMS0w_c80a9572-c806-479c-b6f7-96ec51481c03">121.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035ed65f313f47239e1ba7a980f112a4_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi04LTEtMS0w_9b9c2367-1c9b-4d4e-b7b2-d44a4b1bde84">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i563d0a3bfa17497bbaf9ccff6e61e331_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi0xMC0xLTEtMA_7d0c806b-030c-4037-8e05-b053ae16b0b5">6,716.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0904b48c5834d8382585d98978efa6b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi0xMi0xLTEtMA_be0e055f-cb9d-41ca-86a9-91f218a7c7c5">10,893.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ba799e31f25451293026f6a5a092606_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi0xNC0xLTEtMA_8c13d20c-5068-4755-87e0-742e7aa1e253">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icb59f0839edb41abb0134a8358db4753_I20201231" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi0xNi0xLTEtMA_f7abec87-a47f-470f-9057-404dbac77d8d">16.4</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb59f0839edb41abb0134a8358db4753_I20201231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi0xOC0xLTEtMA_35018d3d-3151-40e3-936b-c3c3b44c3dea">6,613.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi0yMC0xLTEtMA_acf2eae2-7635-48ce-9686-d841294283df">11,025.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c94e3f729d1401291b50c0edf45498a_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMy02LTEtMS0w_9446363e-4159-467e-9e32-9d1a9da712bb">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i224a9ebaa95b46c587b2caf10b449995_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMy0xMC0xLTEtMA_5179e6c6-04f2-4b2d-87f2-4ece1178d794">93.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMy0yMC0xLTEtMA_cd17e4aa-ae76-4030-ade9-84cfd01fc659">93.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3c94e3f729d1401291b50c0edf45498a_D20210101-20210331" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNC02LTEtMS0w_ca2aac3f-78b1-48d3-be01-fdb5f0525daf">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i224a9ebaa95b46c587b2caf10b449995_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNC0xMC0xLTEtMA_5e5b82ff-fde8-421d-883b-e3b7f313d41c">66.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNC0yMC0xLTEtMA_837dcce0-71c6-42b2-8158-75fbfe991c52">66.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i224a9ebaa95b46c587b2caf10b449995_D20210101-20210331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNS0xMC0xLTEtMA_8fa15896-68b7-41bb-a063-91f75d4ba515">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45a7c7a2a79f45b599510ec6d98f5234_D20210101-20210331" decimals="-5" format="ixt:fixed-zero" name="regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNS0xNi0xLTEtMA_b33914c0-ff34-435f-bf0d-2fbb6819dc30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45a7c7a2a79f45b599510ec6d98f5234_D20210101-20210331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNS0xOC0xLTEtMA_27ecd922-416a-4cff-92f8-5167f550b3b3">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNS0yMC0xLTEtMA_d8b11809-a556-4bad-841c-a364d995d32b">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i45a7c7a2a79f45b599510ec6d98f5234_D20210101-20210331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNi0xNi0xLTEtMA_be72f82e-ebf9-4c86-a90c-89eaec281248">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45a7c7a2a79f45b599510ec6d98f5234_D20210101-20210331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNi0xOC0xLTEtMA_402e7a0b-6f49-4b76-b2f0-fa356ca0d5fd">323.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNi0yMC0xLTEtMA_63b1bd5e-4bfc-4d2c-9408-75592c451db5">323.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i224a9ebaa95b46c587b2caf10b449995_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNy0xMC0xLTEtMA_cf6a3772-be74-4e12-8f3a-2c88e5f48e57">135.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNy0yMC0xLTEtMA_a0270a38-1747-406a-86bd-a397074d874e">135.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771bf5f554d244a29f26c5501f4293f3_D20210101-20210331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfOC0xMi0xLTEtMA_88f9dc0f-8a66-4df5-b00e-ba792f27dd19">1,115.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfOC0yMC0xLTEtMA_4468c4f4-3fd5-4325-815b-82761d41f4f9">1,115.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie140c8b387dc4645b81c9879149a8e9d_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfOS0xNC0xLTEtMA_6c45c514-4686-4fa3-9966-41779d7c6dc3">13.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfOS0yMC0xLTEtMA_68714259-5952-4aa5-859f-84d6e5f3d86f">13.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49df9a95773d49e6967753fb9f9de580_I20210331" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtMi0xLTEtMA_ea167919-25f0-417e-8371-744d32c0b7b0">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49df9a95773d49e6967753fb9f9de580_I20210331" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtNC0xLTEtMA_7b086973-b54c-48c7-976c-397f1c7d867d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i970227f3acea4503918b252309b84460_I20210331" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtNi0xLTEtMA_6036af60-2f49-4742-8c50-15b271e4c47d">121.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i970227f3acea4503918b252309b84460_I20210331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtOC0xLTEtMA_5317edee-6bae-4960-b593-2db37345fad0">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd2927b7554444faad537d5a6d30eb9_I20210331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtMTAtMS0xLTA_418ae38a-38be-4af7-ab59-ceb05b9030cd">6,887.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99065775605c4e47ab2780914630a4e5_I20210331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtMTItMS0xLTA_3efdf689-78b7-412c-9e2b-6c9287c69d94">12,008.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d0fd1cd63743f18bd2b4ef498d61b6_I20210331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtMTQtMS0xLTA_b32b6e63-16c2-4259-ba77-15a4ea6f8473">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie2b9d9e8e8d94aafb8cf016d634bce00_I20210331" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtMTYtMS0xLTA_69e3cdcc-80c3-4717-b550-a86c3cf14027">17.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2b9d9e8e8d94aafb8cf016d634bce00_I20210331" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtMTgtMS0xLTA_570b7d16-4760-48ea-9585-8c1741194d6f">6,935.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1db85b4dd6a74732adc71927ecf1a4b4_I20210331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtMjAtMS0xLTA_584ebe28-d8ad-4f4c-9588-f8c13387bcc7">11,977.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i485a4b467eae4806b0b1ebd35f44e2c2_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTEtNi0xLTEtMA_d965f191-9fcb-40b2-a0f5-dda60a53800b">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d895db990f24cf3a08e7953476d96f7_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTEtMTAtMS0xLTA_ae6a50bf-e41a-45fc-81ff-7c3040f3213b">216.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTEtMjAtMS0xLTA_f967078c-2b99-4261-b045-01bc9ee2b78b">216.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i485a4b467eae4806b0b1ebd35f44e2c2_D20210401-20210630" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTItNi0xLTEtMA_16b65c99-c4cc-473b-a98b-93a2c9e2973b">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d895db990f24cf3a08e7953476d96f7_D20210401-20210630" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTItMTAtMS0xLTA_e05198bc-f089-4075-9fa1-b23a877d3208">26.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTItMjAtMS0xLTA_5fe1a718-b1e8-4f24-a1c2-d5afa8656f19">26.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d895db990f24cf3a08e7953476d96f7_D20210401-20210630" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTMtMTAtMS0xLTA_ab56c031-2d02-4846-a327-02cb00012116">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90967a0a2559464e89e7ac0cf8e2bdbc_D20210401-20210630" decimals="-5" format="ixt:fixed-zero" name="regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTMtMTYtMS0xLTA_22d5d454-494f-43a5-a751-7685be91e28c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90967a0a2559464e89e7ac0cf8e2bdbc_D20210401-20210630" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTMtMTgtMS0xLTA_0363b95f-dffd-4d4e-a634-30ca6dfc7cb4">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTMtMjAtMS0xLTA_5ca7349a-18ff-4339-bf26-b6c8834deec0">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i90967a0a2559464e89e7ac0cf8e2bdbc_D20210401-20210630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTQtMTYtMS0xLTA_e66eb3c3-51ec-46d2-8de5-4b3baba1b374">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90967a0a2559464e89e7ac0cf8e2bdbc_D20210401-20210630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTQtMTgtMS0xLTA_5abfc4bb-3d19-445b-8ff3-f0c8b2d1931e">288.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTQtMjAtMS0xLTA_635d8036-bec0-4d2f-8cbf-885e88672b1a">288.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d895db990f24cf3a08e7953476d96f7_D20210401-20210630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTUtMTAtMS0xLTA_9fb4c035-c2a8-4646-8874-be0d6dd18ddb">135.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTUtMjAtMS0xLTA_11eb92e0-bc99-41b0-a860-e2e5ac270494">135.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if027b47fcff24b09bc17374a79225282_D20210401-20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTYtMTItMS0xLTA_50cfbbf9-28c5-487b-a5cc-2feb71f74ecd">3,098.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTYtMjAtMS0xLTA_40a5b591-ace7-4e94-ba51-df3ebd9dfca6">3,098.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdc7f3436f2d4c15be968a3a0446d58b_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTctMTQtMS0xLTA_79d666a1-06c1-40fa-9260-a5a507484640">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTctMjAtMS0xLTA_13cd8406-ccda-41f8-b7d4-bcf14b79c789">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01a22b1457534e58971e7c3840ce8a74_I20210630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtMi0xLTEtMA_949cb7ed-0a62-4c90-9df8-5f5dc5166100">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01a22b1457534e58971e7c3840ce8a74_I20210630" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtNC0xLTEtMA_ca123bb2-a5f4-4736-bbec-abc8b9c05483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9aca85854a7e44a4967c9de4200b7275_I20210630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtNi0xLTEtMA_8fe417bf-6f09-431e-b344-ec99119f2d1e">122.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aca85854a7e44a4967c9de4200b7275_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtOC0xLTEtMA_ceca3e50-3667-4083-a46d-9ddc37836e51">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4692004524e482c94791bc9cdad2f45_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtMTAtMS0xLTA_0432077a-81a4-43c1-847c-3ecd318b3e18">7,225.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ee4bf1abbe4e4aa728bc791fd9e4be_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtMTItMS0xLTA_925efdf1-ac77-401d-8c5c-894bbfd7ea7d">15,107.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58536bd9f96a400195ebcbf3b27c73ef_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtMTQtMS0xLTA_7d851aa3-213f-457c-ae40-e3ba756e7ce1">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idca5a9d3669d4ad4abd5502c841c9b83_I20210630" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtMTYtMS0xLTA_ea778630-b596-48bc-8260-de115c77cc67">17.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idca5a9d3669d4ad4abd5502c841c9b83_I20210630" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtMTgtMS0xLTA_79d5476b-4bd2-4d7e-bee2-0ac8443983c0">7,221.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8637e07a17044e3bc80d1b3f1ac3709_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtMjAtMS0xLTA_b81c58a7-9f03-4212-837c-6b7e530243df">15,127.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c2c8b599684423e810cce4bc7569486_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTktNi0xLTEtNDY_5cbd3028-3ba6-4500-8c52-308aac874e0a">2.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81bba3e7b3f14597be97fbb190f9dbff_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTktMTAtMS0xLTQ2_b41663f8-b9f5-4f9c-b428-c1ff0fb09d08">816.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTktMjAtMS0xLTQ2_3d7955a5-68e6-4065-aa1e-16f041c6e789">816.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3c2c8b599684423e810cce4bc7569486_D20210701-20210930" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjAtNi0xLTEtNDY_11a51f81-1ad3-4d1a-a3b9-251cc809f91e">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81bba3e7b3f14597be97fbb190f9dbff_D20210701-20210930" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjAtMTAtMS0xLTQ2_914b7dc1-2269-4488-8dd1-e45083627710">269.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjAtMjAtMS0xLTQ2_55c9af24-c7d5-4295-b0bc-91ec2eb7abac">269.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81bba3e7b3f14597be97fbb190f9dbff_D20210701-20210930" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjEtMTAtMS0xLTQ2_981e77cb-5bbc-4458-9eb3-bbc37a1050d0">10.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic22073ba422e4cd19578e069ff93a548_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjEtMTYtMS0xLTQ2_4a8ff7f5-1903-47be-b040-8e3f681b4b80">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22073ba422e4cd19578e069ff93a548_D20210701-20210930" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjEtMTgtMS0xLTQ2_bd94fee3-bfb6-44ac-b75f-88b3760c62d1">1.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjEtMjAtMS0xLTQ2_d1c7b380-a5ce-49db-a7cb-dfb88034acb5">12.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic22073ba422e4cd19578e069ff93a548_D20210701-20210930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjItMTYtMS0xLTQ2_4c5fbad6-765f-4d1a-a1e2-9a8cec5e8180">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic22073ba422e4cd19578e069ff93a548_D20210701-20210930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjItMTgtMS0xLTQ2_0ad5fb76-ad3f-4025-853b-e8319fd1e543">190.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjItMjAtMS0xLTQ2_c0e46caf-5d05-47f6-bbad-1f5d7e2ee7f2">190.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81bba3e7b3f14597be97fbb190f9dbff_D20210701-20210930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMTAtMS0xLTQ2_cf883df3-39c7-4cd9-89a2-5f51e75de631">136.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMjAtMS0xLTQ2_7a8b13dc-24b3-4941-87f2-074f45501f3f">136.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1af4b6d98674144aede03c90b76ecde_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjQtMTItMS0xLTQ2_5d7da682-7336-4bd1-888a-54cdf9680c57">1,632.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjQtMjAtMS0xLTQ2_806894ba-715d-4a2a-8e8e-231eb13fabc0">1,632.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa09e4ef649b446d8a986b009222a48c_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjUtMTQtMS0xLTQ2_a6289105-3ef3-4538-a65a-dbdec0ebc88c">6.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjUtMjAtMS0xLTQ2_b9455959-2ebf-485b-a329-08bd407844ec">6.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea16b9252afa422babee5f32af655235_I20210930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMi0xLTEtNDY_e506f8d9-793f-4368-946e-c635d7c260c6">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea16b9252afa422babee5f32af655235_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtNC0xLTEtNDY_f246cbbd-df6f-481b-82c2-1a7ec3d2f76b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31f7ae795859466f9949d77297734d41_I20210930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtNi0xLTEtNDY_465f991c-ac61-47f5-99d2-77630d15b82a">124.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31f7ae795859466f9949d77297734d41_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtOC0xLTEtNDY_702af6f1-7c3e-4400-9685-3cd7d64be57a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5ea589759884ae08a57e4895180d768_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTAtMS0xLTQ2_ac3f868d-e263-4749-abed-f69b46892c5a">7,919.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a9df31fbd2432eb37434ec52ac6097_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTItMS0xLTQ2_24a1e1ba-dab3-4bbb-95f5-73a0486b5d33">16,739.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i241d3af3190948bebbe76ddd7a69650a_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTQtMS0xLTQ2_a3af4aa1-6beb-4d19-b353-5a5fc07503f4">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idc06747141a8415abdc99e415fd10ec4_I20210930" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTYtMS0xLTQ2_bae0bf94-c9fc-4c61-87b0-8dae447d30d4">17.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc06747141a8415abdc99e415fd10ec4_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTgtMS0xLTQ2_aff98bd1-8c1b-4396-b993-47b00c5a1886">7,410.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMjAtMS0xLTQ2_2fcb54c3-0b4a-4f39-9185-507152fc8fac">17,258.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.414%"><tr><td style="width:1.0%"></td><td style="width:33.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.824%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="63" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td></tr><tr style="height:26pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Class A Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73dec6c7995c456c9140fce39007c0e9_I20191231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMi0xLTEtMA_156eaa0f-c17c-4e42-bf2a-61afe6038751">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73dec6c7995c456c9140fce39007c0e9_I20191231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtNC0xLTEtMA_f60bccb4-f1c4-4f1d-bca9-9fd6c146b9da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0bf589234254d1fa1a8439438ed348f_I20191231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtNi0xLTEtMA_42d4e466-00ed-44b8-955c-336446f6d381">113.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0bf589234254d1fa1a8439438ed348f_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtOC0xLTEtMA_62472175-bcd5-400d-a947-3512a58cbbb2">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b0eaf7cc1b34bc3a8ce4fceda06456c_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMTAtMS0xLTA_9dfe231b-b3ef-4931-8d06-19387254efa5">4,428.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f1bbe31c49144b58bd31a8fdaaa287b_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMTItMS0xLTA_ec30a13d-ef5d-4f76-8152-7a508cfff7ee">7,379.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i843aefe7a57e49a4b8057f411d68d2d6_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMTQtMS0xLTA_0111ce08-4228-4042-8f21-1581d70a5acf">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idfb0c989543b47b4b84dfc63cacdb340_I20191231" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMTYtMS0xLTA_b36ba0dd-724e-4ae0-ba91-370abd46c938">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfb0c989543b47b4b84dfc63cacdb340_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMTgtMS0xLTA_8e78af2b-eb98-4b0f-b62b-7d9857260479">739.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8be30bd45174fe1a757f0b806ef45ff_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMjAtMS0xLTA_ff55b39b-253b-4d2b-84ba-628602da39ee">11,089.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3a84e5477f34a4fa157fc0ff96532f9_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjQtNi0xLTEtMA_a8eebcca-f1be-4e5d-891b-5092704aa128">3.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d9fc7c849641a29c4015bb2c26ff95_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjQtMTAtMS0xLTA_a7a2412a-05b5-4cbd-a658-0ecf1ae37a35">817.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjQtMjAtMS0xLTA_5b1d82cc-9821-4ecb-a1ee-f325d5fa4a9f">817.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib3a84e5477f34a4fa157fc0ff96532f9_D20200101-20200331" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjUtNi0xLTEtMA_0208e1bc-6706-4a99-802a-683420308ed8">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67d9fc7c849641a29c4015bb2c26ff95_D20200101-20200331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjUtMTAtMS0xLTA_aeab10b6-1c1f-4395-83a5-0ae31bdcec31">155.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjUtMjAtMS0xLTA_c4849b85-4944-4bf3-a1f3-5f02a8c6dd58">155.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d9fc7c849641a29c4015bb2c26ff95_D20200101-20200331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTAtMS0xLTA_43acf98e-1f28-4092-b796-b24609363427">12.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia85c03a3ab92450c8de1356f1f1c58d3_D20200101-20200331" decimals="-5" format="ixt:fixed-zero" name="regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTYtMS0xLTA_3a8bf02a-f18a-429d-ac99-72821e0dadab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia85c03a3ab92450c8de1356f1f1c58d3_D20200101-20200331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTgtMS0xLTA_23a03bed-0561-48dc-85d3-74ad09f9f651">2.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMjAtMS0xLTA_1d6bcd67-1cde-47e1-9ce9-bc7dfc962d53">14.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia85c03a3ab92450c8de1356f1f1c58d3_D20200101-20200331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjctMTYtMS0xLTA_d175d875-0c53-494b-be7f-aee6723ed209">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia85c03a3ab92450c8de1356f1f1c58d3_D20200101-20200331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjctMTgtMS0xLTA_d25a75e9-327b-45f7-9d84-aee0feb98798">336.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjctMjAtMS0xLTA_d15a4ee1-de98-4996-a94d-843dc73d8b80">336.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d9fc7c849641a29c4015bb2c26ff95_D20200101-20200331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjgtMTAtMS0xLTA_85ecbd4d-5951-450a-bb27-934da4fe52a1">108.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjgtMjAtMS0xLTA_9dcaa235-b047-49e6-b4ad-fbd8b5a8c859">108.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f1758a625d84d929d4de5bf11529687_D20200101-20200331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjktMTItMS0xLTA_29e7bea5-66a2-47a2-8e76-7f38c9b51074">624.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjktMjAtMS0xLTA_59a96e26-b974-4049-87e5-1c1a2e41db96">624.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98313781c6ec4d6b8b48f6da3becd23f_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzAtMTQtMS0xLTA_ed439df6-a9c4-4477-9d65-37dbb10aea3a">30.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzAtMjAtMS0xLTA_7b0aab53-3640-4d57-bcea-8af87ce3b79e">30.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51f918e0a47440ff9a42a36261a6d16d_I20200331" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtMi0xLTEtMA_34cc98cf-72de-4f72-8235-2add14bc05b1">1.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f918e0a47440ff9a42a36261a6d16d_I20200331" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtNC0xLTEtMA_aceaadc5-1e30-47b2-aa6a-551040f3e7d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i76b230224ec74a4ebd37c4fa613a51f6_I20200331" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtNi0xLTEtMA_8ef775f7-ee4a-4788-a1b9-8aaba1158da0">116.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76b230224ec74a4ebd37c4fa613a51f6_I20200331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtOC0xLTEtMA_f38bfa48-a511-4672-8a2d-73ab7e5afa11">0.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6c4ef5941f242a783b93fdf18b331b7_I20200331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtMTAtMS0xLTA_58bd9794-a6c0-45ff-863d-47bf4859d163">5,211.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93db50d47f1b4831b473f4caa658d588_I20200331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtMTItMS0xLTA_55bb3fad-e621-407a-8c6a-1e597c23ba3f">8,004.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1448dfba64a24ca98ed5cca7a68f936c_I20200331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtMTQtMS0xLTA_87251474-59af-4282-853f-6ba56f43d9b2">9.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if8e249a62ffd40df9c9149d8b996539c_I20200331" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtMTYtMS0xLTA_c4586c56-2cd6-4998-ac85-04c3e1b0a8c5">5.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e249a62ffd40df9c9149d8b996539c_I20200331" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtMTgtMS0xLTA_e21746e2-5076-41fe-8177-88fb5279ecd5">1,073.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3282a3bb766e427c92f46bd8d3cc7e59_I20200331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtMjAtMS0xLTA_4953e1a9-e74d-4f60-a7e5-ec4ba654dc7e">12,133.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57cb86b034e44ad089ebc3504d4d0411_D20200401-20200630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzItNi0xLTEtMA_ac070394-f4a2-41e4-b33a-e0bc0ccc6e00">4.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a2982cdc3744dfab46a0e3a207a741_D20200401-20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzItMTAtMS0xLTA_362679c3-9255-4f57-b8f7-29ef8396dde6">1,355.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzItMjAtMS0xLTA_95acbe7c-01c2-494b-85a4-eb9c69e9fc21">1,355.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i57cb86b034e44ad089ebc3504d4d0411_D20200401-20200630" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzMtNi0xLTEtMA_e6379d0d-37ed-4456-af92-b7c35de9943a">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82a2982cdc3744dfab46a0e3a207a741_D20200401-20200630" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzMtMTAtMS0xLTA_457389a0-eab1-4c02-85e8-b1ed4860e7c2">416.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzMtMjAtMS0xLTA_68455b32-c091-45dd-9c7f-f7d771357f8a">416.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a2982cdc3744dfab46a0e3a207a741_D20200401-20200630" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzQtMTAtMS0xLTA_233b2d27-21e3-4a25-b4fc-d3052011c8b7">7.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90f143b898064fb1a010fcdce8a28b66_D20200401-20200630" decimals="-5" format="ixt:fixed-zero" name="regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzQtMTYtMS0xLTA_31857e56-009f-4778-845a-7a517d4cfa54">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90f143b898064fb1a010fcdce8a28b66_D20200401-20200630" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzQtMTgtMS0xLTA_b1d9baa5-dfd9-446c-80e9-adff0950f34b">2.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzQtMjAtMS0xLTA_ad4639c0-ca95-4373-a5a4-379bb3f5fa06">10.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i90f143b898064fb1a010fcdce8a28b66_D20200401-20200630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzUtMTYtMS0xLTA_4e7312eb-d560-423b-a055-d824ca425b37">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90f143b898064fb1a010fcdce8a28b66_D20200401-20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzUtMTgtMS0xLTA_daa06afd-05a9-46af-9b6c-81750010b2ab">5,071.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzUtMjAtMS0xLTA_05b5dc87-574d-4aa0-a926-5c1428b4959e">5,071.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a2982cdc3744dfab46a0e3a207a741_D20200401-20200630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzYtMTAtMS0xLTA_9908b1f8-c1ca-44cd-9a51-6db05bc51bc7">105.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzYtMjAtMS0xLTA_d861b412-e59a-46ef-a9ef-e9873eb32033">105.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5505226ac8da4156a58673a2fec740bd_D20200401-20200630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzctMTItMS0xLTA_71c1fed6-b24a-45a0-b23f-721730b4f388">897.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzctMjAtMS0xLTA_de2d934d-5c3b-4cf7-8bb1-2924fdf79732">897.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fef85b8750b47bbb313ad7db28ce663_D20200401-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzgtMTQtMS0xLTA_fe7db3bb-32f3-409e-a48d-9aa674422494">44.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzgtMjAtMS0xLTA_986749bd-4b7f-4516-b4ca-b2786fa209d9">44.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaedf97f07c304e0eb9b3fff6304ec0c1_I20200630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktMi0xLTEtMA_b3348cb0-9273-43f7-8ca1-bbe39cd73c8d">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaedf97f07c304e0eb9b3fff6304ec0c1_I20200630" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktNC0xLTEtMA_19a0a13a-ea52-47f2-bc15-6adc847efae3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb44990ceb62481894ef4f3997282c75_I20200630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktNi0xLTEtMA_802808f1-eb2c-4606-bf7d-c2bcf26772db">119.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb44990ceb62481894ef4f3997282c75_I20200630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktOC0xLTEtMA_219b8d04-7482-46ef-9eb7-59849aa0d85b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6682412d744b10a6d5e33564d0af56_I20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktMTAtMS0xLTA_9ba67f70-09d0-4c53-8fa3-0afa72382f2d">6,263.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63120c4477c04522a145f1c834f52464_I20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktMTItMS0xLTA_bdc80d8d-a58b-46ca-bf54-408cbb280818">8,901.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88e0d4f0e2bb4a66bbb456ea665d882d_I20200630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktMTQtMS0xLTA_b8783d16-241e-4628-bbba-e84f9c93d538">35.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib41afa111c3149648c0cc3bac7c5b435_I20200630" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktMTYtMS0xLTA_a44767d4-c281-42e0-8ac7-a817a445055c">15.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib41afa111c3149648c0cc3bac7c5b435_I20200630" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktMTgtMS0xLTA_74c5f920-5ea8-45c5-9e9f-385bc8c426cd">6,142.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9c7d2da9c9f4d09a60482a44e3c8ca7_I20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktMjAtMS0xLTA_70ec7c8a-a07c-4d0c-ab20-a4db8653764f">9,057.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Common Stock for equity awards granted under long-term incentive plans</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72a6a418d67447f6bf91301e4805ad9b_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNDgtNi0xLTEtNjE_39dc3968-bbd2-405c-964e-0804e74cf2c5">0.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d2540d3bf4a078040cd71ec1f972b_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNDgtMTAtMS0xLTYx_b9bdc080-fcb1-4efb-ac6b-b04cf74a32ea">297.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNDgtMjAtMS0xLTYx_84985772-1303-441a-b2b3-067a19e5e58c">297.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i72a6a418d67447f6bf91301e4805ad9b_D20200701-20200930" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNDktNi0xLTEtNjE_217b6c53-6c4f-4c15-9b3f-07cb67ebbbbe">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83d2540d3bf4a078040cd71ec1f972b_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNDktMTAtMS0xLTYx_e49827ec-478d-4817-9fc6-88ef8eef6991">80.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNDktMjAtMS0xLTYx_c20691c7-bbe6-4adb-b92e-9573c08447f9">80.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance/distribution of Common Stock for 401(k) Savings Plan</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d2540d3bf4a078040cd71ec1f972b_D20200701-20200930" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTAtMTAtMS0xLTYx_365bc35f-b2e6-4f68-9de1-68d211cb9710">8.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4de7c52f2b7a4fe89360820891e3f073_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTAtMTYtMS0xLTYx_ad5fae71-4da1-4cc0-a67f-f67ebeabbfaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de7c52f2b7a4fe89360820891e3f073_D20200701-20200930" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTAtMTgtMS0xLTYx_6601ae1b-a497-4149-af6f-57c99b85b707">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTAtMjAtMS0xLTYx_4b2b8579-51ef-4716-8804-a7293d52f508">9.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4de7c52f2b7a4fe89360820891e3f073_D20200701-20200930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTEtMTYtMS0xLTYx_88024743-cb87-4d71-9712-d5343bab0821">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4de7c52f2b7a4fe89360820891e3f073_D20200701-20200930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTEtMTgtMS0xLTYx_fdb5d63f-3ce7-4ca0-8a28-fd64c4400d94">100.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTEtMjAtMS0xLTYx_c7162b25-c05a-4e46-8e9b-72a413db4dec">100.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation charges</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d2540d3bf4a078040cd71ec1f972b_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTItMTAtMS0xLTYx_e65e6173-d11f-4b9a-af04-7747646c1fdd">104.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTItMjAtMS0xLTYx_5d0c13f4-60e3-4e23-b3bb-5aa1f732c5ee">104.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic71c7174d5cc448398e06391a7827688_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTMtMTItMS0xLTYx_b979f23b-736e-4f47-8e44-6016fd2cc7a5">842.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTMtMjAtMS0xLTYx_9792e61a-6364-4e87-89f2-a24ce8e953ea">842.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic16fc6f626e146c18705d2b1e22411bc_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTQtMTQtMS0xLTYx_d6f575b2-0946-4fad-a9ca-ccce9b61f72c">4.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTQtMjAtMS0xLTYx_654159e4-fe9d-42cd-b347-175247b5b590">4.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0102174142414cbd89010684f4e14032_I20200930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtMi0xLTEtNjE_32b17897-2e4e-4b0c-8865-d4063f872784">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0102174142414cbd89010684f4e14032_I20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtNC0xLTEtNjE_a250d88e-d6b0-47ca-9d93-2c72f2f0153e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7e951f6bc2b47f9a0f83bbc19cfee0b_I20200930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtNi0xLTEtNjE_22bafdcc-7ff4-479d-94a7-fca506c15dc5">120.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7e951f6bc2b47f9a0f83bbc19cfee0b_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtOC0xLTEtNjE_3687158b-069a-4e8c-8740-8d37cb3453fe">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d580d7d41ab4c779d21e7ecf46f3208_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtMTAtMS0xLTYx_25c9f4b7-473e-4ea4-b759-1c85d5aa15ae">6,592.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e5ba528b04c4762aa61bced9949c785_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtMTItMS0xLTYx_b6aaeaf9-c253-421a-bd01-432910ab4655">9,743.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782ae2009f954090860e6e0bb4a7039f_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtMTQtMS0xLTYx_8368852e-7736-4e00-a144-da1dea47a9df">30.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i960a6b708491473d9570c3942b7eef6c_I20200930" decimals="-5" sign="-" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtMTYtMS0xLTYx_0d4b2844-168d-4e60-853a-6b901487eb4e">15.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i960a6b708491473d9570c3942b7eef6c_I20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtMTgtMS0xLTYx_2a05ff78-9360-48df-909d-3b91f6797737">6,242.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b0b1c1c2a94afb988a7c59c235eee7_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtMjAtMS0xLTYx_8e197b7b-a008-432f-b52c-1283069496b3">10,125.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="63" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:71.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMy0yLTEtMS0w_fc487412-161b-4c25-888b-1a5babdb19a0">5,846.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMy00LTEtMS0w_148d4856-7902-4d9b-84fc-2c8cf101e6cc">2,364.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfNS0yLTEtMS0w_84effa95-4b2e-4bb5-b603-b996cf79334f">211.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfNS00LTEtMS0w_a485711f-334a-44f8-af25-e986925a4b0c">174.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfNi0yLTEtMS0w_4a112fa4-3022-4044-87b3-3d861dd517bd">413.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfNi00LTEtMS0w_0511251f-3560-4ac4-b3c3-2e8e5500724c">310.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains on marketable and other securities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:MarketableSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfNy0yLTEtMS0w_483f6db1-5a34-421c-9d88-530a3728f85e">524.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:MarketableSecuritiesGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfNy00LTEtMS0w_28441eff-9b2d-4879-b87b-749a0849d16c">162.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash items, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfOC0yLTEtMS0w_c577ed94-bb0a-4b16-a383-6f3960046239">264.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfOC00LTEtMS0w_b58e4d5d-31cc-4aac-82c2-c233f6ec1088">51.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfOS0yLTEtMS0w_52c75df6-41bc-42e4-a09a-5a001de17cda">58.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfOS00LTEtMS0w_97b8ab14-9e99-431b-83ef-e55a919ce5cf">117.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTEtMi0xLTEtMA_442469a4-4c07-4069-b95a-2b5b2c6e0c36">1,342.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTEtNC0xLTEtMA_0a71af61-1292-496e-91f2-30b689aea898">1,275.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTItMi0xLTEtMA_f27148c1-01ec-45e7-9654-81d441941867">330.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTItNC0xLTEtMA_77947bb5-c4cb-4661-a1f4-4f7d8aa7918a">402.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) decrease in prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTMtMi0xLTEtMA_b50a5920-db39-4f4f-9b13-16b8649fe85a">316.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTMtNC0xLTEtMA_3675459e-b3bb-4a3a-87a7-49f057466e0c">16.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTQtMi0xLTEtMA_b15bf385-b2b9-4223-88b9-251987fcfac3">71.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTQtNC0xLTEtMA_42482feb-3d83-45f0-906f-b460ca8d07c7">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in accounts payable, accrued expenses, and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTUtMi0xLTEtMA_619ecddb-84b9-4d92-a68e-7fcd65193b51">500.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTUtNC0xLTEtMA_ac58c741-e7c6-4f09-81c1-ea3f81b940f7">80.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTYtMi0xLTEtMA_7cf59cd6-fc07-48cc-83a1-063f4111569b">1,137.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTYtNC0xLTEtMA_80753f23-8e80-4433-910a-8bbcea711002">976.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTctMi0xLTEtMA_e5cfb75d-9e74-4d15-ab2c-6c52f9238351">4,708.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTctNC0xLTEtMA_ee411231-04cf-4942-acc3-3cdb3d50e2f4">1,387.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable and other securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjAtMi0xLTEtMA_0ef0f54f-307e-4dec-b661-dd5a505164a1">4,872.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjAtNC0xLTEtMA_37438e9b-25f7-43f7-8da2-658166709142">2,642.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales or maturities of marketable and other securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjEtMi0xLTEtMA_8ba644ea-bf9c-4667-be9a-337dbd339a8e">1,897.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjEtNC0xLTEtMA_91973c36-061f-49f3-894b-92fd54a77714">3,330.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjItMi0xLTEtMA_49df4e0f-d245-4d6e-8aab-35f174bc848f">397.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjItNC0xLTEtMA_9cf2571b-1136-410a-b869-1faed5f4c9b4">453.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjMtMi0xLTEtMA_27b3f9df-0e64-478f-af8e-80caa2edbdd8">3,372.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjMtNC0xLTEtMA_ab56bb63-4c2e-411a-8c88-b3671d5df5ef">234.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjctMi0xLTEtMA_2c87238e-2543-4a63-b2bf-6fa9a82fbbea">1,129.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjctNC0xLTEtMA_32018ded-a4b9-4b0f-ab4e-8f08dbf4a2bc">2,471.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments in connection with Common Stock tendered for employee tax obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjgtMi0xLTEtMA_9edc5fae-49b7-4969-9997-8a46d44ba979">450.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjgtNC0xLTEtMA_2955421d-1d4c-45ec-b568-12b1889023e8">652.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjktMi0xLTEtMA_e5808003-6339-49cb-943e-543a0d85f00e">778.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjktNC0xLTEtMA_6e81fb7b-d16c-4341-b592-daea45fd44b0">5,465.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzItMi0xLTEtNDAwNzg_940eef4c-f0b5-4722-a3b9-169ef20a0c23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzItNC0xLTEtNDAwNzg_38a17305-fca0-404f-b8b9-2eb2c740e2d9">1,981.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from bridge loan facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzMtMi0xLTEtNDAwNzg_31431eaa-c38a-46e3-a391-9c01d985b305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzMtNC0xLTEtNDAwNzg_2bd5dc67-284e-40cd-9277-b4ced57ea258">1,500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of bridge loan facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzQtMi0xLTEtNDAwNzg_e944f0e4-cbbc-46e5-8850-581dc0c6ddd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzQtNC0xLTEtNDAwNzg_ef110a35-b94c-4b86-a860-22a2e402d208">1,500.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzAtMi0xLTEtMA_b2b7fa9a-3baf-4fe2-a10e-ce823bd3eca7">99.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzAtNC0xLTEtMA_fae5ecf7-50c0-4b23-88ed-55f06ff29729">1,665.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzItMi0xLTEtMA_d7172aaa-230d-46ae-97db-1031d6649fe1">1,237.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzItNC0xLTEtMA_b084493c-bfd1-4cfa-9b35-b7b82ed3c794">43.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzQtMi0xLTEtMA_543014c9-c909-4338-b34f-39b8a7363b63">2,207.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8be30bd45174fe1a757f0b806ef45ff_I20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzQtNC0xLTEtMA_2a0c1a58-95f7-4076-b69a-dd589254fbc9">1,630.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzYtMi0xLTEtMA_317c7112-9632-4753-90ba-6125a50da959">3,444.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b0b1c1c2a94afb988a7c59c235eee7_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzYtNC0xLTEtMA_ec98a9dc-5324-43cf-8ed6-ba641788a4c5">1,586.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="15" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The accompanying notes are an integral part of the financial statements.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_28"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div></div><div><span><br/></span></div><div id="iae35796f039b495ba4b10877e85a1c6f_31"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zMS9mcmFnOjVlMDNiNWJmOTI3MTQxMWJiY2I2ZjZjNzFkYWZlNzY0L3RleHRyZWdpb246NWUwM2I1YmY5MjcxNDExYmJjYjZmNmM3MWRhZmU3NjRfMTQzNw_20b74fff-af0b-48e0-9a0c-a8575f3bca78" continuedAt="i194b138d53534b79bf0bf635ad3ed195" escape="true">Interim Financial Statements</ix:nonNumeric></span></div><ix:continuation id="i194b138d53534b79bf0bf635ad3ed195"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zMS9mcmFnOjVlMDNiNWJmOTI3MTQxMWJiY2I2ZjZjNzFkYWZlNzY0L3RleHRyZWdpb246NWUwM2I1YmY5MjcxNDExYmJjYjZmNmM3MWRhZmU3NjRfMTQ0Mg_59746d96-b2ef-4260-9142-d8c88d5bda33" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December&#160;31, 2020 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_34"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RleHRyZWdpb246ZWM5Yzc5YjUxNzUyNGIwZDk1MmI5YzI4N2YxNmNhMTdfNDkw_473e2caf-e85d-4e4b-9cb2-611a2d1de956" continuedAt="i49cc9ead3cfb4914b7ccdebb4b5db143" escape="true">Product Sales</ix:nonNumeric></span></div><ix:continuation id="i49cc9ead3cfb4914b7ccdebb4b5db143"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RleHRyZWdpb246ZWM5Yzc5YjUxNzUyNGIwZDk1MmI5YzI4N2YxNmNhMTdfNDkx_0a716247-3186-4d05-811b-cfd8a23394e0" continuedAt="idd8f3e0ab2284a28916fa3af161ad293" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.309%"><tr><td style="width:1.0%"></td><td style="width:46.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Net Product Sales in the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5335858050745058b22cc99a0b825d8_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMi0yLTEtMS0w_78137a7e-86e4-4b16-b14d-278d3780ddea">1,473.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb34b902a3d4092a2e3d84fafaf8db3_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMi00LTEtMS0w_d792442b-4d5b-4b77-a881-b4a180d0c513">1,318.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12dab876c382416aaa473774a2318a69_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMi02LTEtMS0w_e6d5c31e-51bf-4d73-b56b-8e6c03ebb5e5">4,245.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1e78634a724621bc14ad6838cb7aaa_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMi04LTEtMS0w_c9a8bd2f-5c88-48a0-a53d-5091c56d667d">3,604.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0b4d6b8672847c38f0dba0dde9118a6_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMy0yLTEtMS0w_f15e991b-d245-499b-9b91-98f68e921109">78.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i993e0c30b54544e0a4d7a1785fe7f5ec_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMy00LTEtMS0w_d4b85bfe-8728-4597-a634-cfad181bc6f2">71.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide588defaf434359bba81a3f3acff2b8_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMy02LTEtMS0w_9beafec4-7186-46fd-bdd1-f5ab6e947711">225.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfb6acb24daa4045bfab3c8c4d9acd34_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMy04LTEtMS0w_90f9003d-2ccd-44e8-9aee-085d8c1b8651">196.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id715132664af44b4a97c8f5b2eef6789_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNC0yLTEtMS0w_1a12762e-3671-48f0-b471-6ec8da2d2b6e">44.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdef107afb54ad899df3e57fa9ccb8f_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNC00LTEtMS0w_dd219c7b-1472-465b-85c5-3d72a5a6ab27">48.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce220d2cde34bf583732793c841cc94_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNC02LTEtMS0w_29efe50e-478f-4a2d-a937-e4c798a6432a">130.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf31cf4bebfa40e5868081cbe1915ba4_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNC04LTEtMS0w_b1f54381-1914-4d04-826e-cf96b57fc524">95.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfb0cf9c4594b929abde62607752ef2_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNS0yLTEtMS0w_e6c8a3d5-3d70-4739-80c0-8dc1c5a991d5">676.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia50d948a15194872b1d382957ed144d6_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNS00LTEtMS0w_0372addf-9468-41f4-84e1-3caa9c71c34f">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b848f38b8a54f65bd9393c17a2aaed0_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNS02LTEtMS0w_598d731c-8403-481c-84f2-38f22d288801">3,530.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if965233833744f19a7d0aba74b97b8d6_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNS04LTEtMS0w_2461a87a-ddb0-4ff5-baa3-69ea407766b0">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9771830c61ff46c0ab9a5252ea2be0af_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNi0yLTEtMS0w_c0815aed-4c82-48fc-915b-2b61bbe80756">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4030650199fe4f198ed816c8ab79a91a_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNi00LTEtMS0w_bfd97b95-8ab2-4605-9e13-6b9edb927a73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ebaa7f4723242569b7922152e81345e_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNi02LTEtMS0w_4c66e2df-5494-4b26-842c-0e0a0e7a8d05">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19d89574821b49b9bdfa6137bd82652d_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNi04LTEtMS0w_31ccf744-d030-46b6-addd-d1050cb5f683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if04488d631ba4e129b9e0f0fb3558a31_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNy0yLTEtMS0w_c3eb510f-d2a7-4d97-908f-9dcc565a405b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64fcfb6110c74cbe816d03379fae5d1d_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNy00LTEtMS0w_9776fa68-ce8b-4468-ab91-fe09d70a9be9">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f2e762be11477183ef6c02dba52897_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNy02LTEtMS0w_0d523121-c36f-45d6-abc9-c458b4129c20">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39c987382ee344fca75a3010f34022b5_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNy04LTEtMS0w_515284f9-06fa-4f8a-a04b-b92888ceb1c0">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3f29614787e4465a5554d3f160fa259_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfOC0yLTEtMS0w_beb5a98e-0855-48a8-907b-42e8fe375465">2,279.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib58a328c7a1044db991b18bc06aec4ca_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfOC00LTEtMS0w_7d52dfd8-f310-44a8-96fb-7d9f0d15d5bf">1,482.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e74fae60044b55bf008643f8ce273e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfOC02LTEtMS0w_9875ab96-0f8e-4e0c-b372-b55514b0f341">8,142.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f629c0363834da2a784610d8a5403af_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfOC04LTEtMS0w_0184fb13-6502-485c-94e8-bcad15ded116">3,945.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Previously, Sanofi recorded net product sales of Praluent in the United States. See Note 3 for further details.</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="id628995c65e443418912b4df46bdf6a1_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RleHRyZWdpb246ZWM5Yzc5YjUxNzUyNGIwZDk1MmI5YzI4N2YxNmNhMTdfMTAx_b07cc301-138d-49ff-8939-51b1f024dc81">4.086</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i8bab1de7a18e431086c872b4f16dbf84_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RleHRyZWdpb246ZWM5Yzc5YjUxNzUyNGIwZDk1MmI5YzI4N2YxNmNhMTdfMTA4_00933aa3-6875-46a1-9a95-76f10d2196cd">3.112</ix:nonFraction>&#160;billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for the three and nine months ended September&#160;30, 2021 and 2020. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RleHRyZWdpb246ZWM5Yzc5YjUxNzUyNGIwZDk1MmI5YzI4N2YxNmNhMTdfNDg3_78e1a541-7dd1-4efe-bc1b-edff1ad9ae7f" continuedAt="i2382627a73a545bcb4604970e2e16d21" escape="true">Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><ix:continuation id="i2382627a73a545bcb4604970e2e16d21"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"></td><td style="width:45.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Besse Medical, a subsidiary of AmerisourceBergen Corporation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1b54518517447e2976804aef2938a70_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMi0yLTEtMS0w_eba38be7-aec1-480d-930f-6f98f11d13ad">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c91a96c8ea541df9b383e31edb76cdb_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMi00LTEtMS0w_9ded6364-3139-47a3-84d1-9926575a9409">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9f3623e111f49f58059e4a3c761728b_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMi02LTEtMS0w_af5e7c2b-71a2-4a16-b51d-560cc882ff6c">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5418f4d22034df899d1576e95d98e46_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMi04LTEtMS0w_34ea94d1-ff11-4e74-a541-623e360dee8a">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i785a29c3adcc4a36be31fef32659e71d_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMy0yLTEtMS0w_4bcee2ad-9b19-4563-a2f5-166de98acc40">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3e92e56fe7a44e5a31ddecd1964e64a_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMy00LTEtMS0w_8f024ef1-1092-4f4a-b8ed-1aa2117760b3">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie051ae25fb44472e83a56290575ab26c_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMy02LTEtMS0w_ca64163c-3847-44eb-be60-be51da0af148">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i486929221d2f42f5919727d4483f7090_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMy04LTEtMS0w_2623d03c-bc55-4d5d-9fd5-7302f1c79dbb">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government (see Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if50c4763f6dc43428e8360ca23d39d0d_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfNC0yLTEtMS0w_dae11dca-1ad9-43e0-8d43-800b1c14cdfc">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5546196bf9d43679e3e52ddbffdfc7e_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfNC02LTEtMS0w_c2872fbb-53f0-43b9-8630-f8c094d0bb45">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Sales to the U.S. Government represented less than 10% of total gross product revenue during the period.</span></div></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_37"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTE1MzE_1a1e578d-5a09-4c11-8c11-636900a60f4d" continuedAt="i7025118e4e4b424cae4a2cffba0d6fd4" escape="true">Collaboration, License, and Other Agreements</ix:nonNumeric></span></div><ix:continuation id="i7025118e4e4b424cae4a2cffba0d6fd4" continuedAt="iac60aa699fdd4b7d9bf3ee916709d3d0"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a. Sanofi </span></div><ix:continuation id="idd8f3e0ab2284a28916fa3af161ad293" continuedAt="i6c2c11ab525b4e87a90b579e26ea10aa"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.118%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifded74cc07f44048a2c104e76b70e48e_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMy00LTEtMS0w_486f0c5d-9e80-454b-a4fa-a02403ccdd9b">387.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ac074fe6864f70ba50e4e7c6e81c9b_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMy02LTEtMS0w_e05615ee-7b3a-4762-ac52-b711bf8fc8d6">212.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86244a8c59904b46967de22d14ea53dd_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMy04LTEtMS0w_384c00e3-ff7c-48a1-9422-7b281c6fd50d">975.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1190ae8ab3474b9e2213bc83518d76_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMy0xMC0xLTEtMA_d7bc0223-fb1e-4ad6-93f0-b58681ec0d57">555.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestone earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0fffea9317f417ba61a67279b657180_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC00LTEtMS0yNTI_829ab6f0-331a-4840-a93e-e1a3e886e174">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12aa7e5e1d7b416bb27fbac0ea8d1e88_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC02LTEtMS0yNTI_1265a6ef-b843-41e1-96db-ed3e03c4c1b0">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeab61feac444da7a016dd64df872cd9_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC04LTEtMS0yNTI_22460544-a30d-4bab-8ded-d61895782517">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i563d16d0ea8f4b1ea8c10c797482d489_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC0xMC0xLTEtMjUy_f5e68efc-94e4-4706-aeff-967469de908b">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad7689d0635c4905af67a87b5aaa5f3a_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC00LTEtMS0w_546d7f8c-dbd4-4fd9-a093-35b6a689e0f6">144.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aa5f2b1cbb14dbf9d951201819f5db2_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC02LTEtMS0w_f871b6bf-d907-4629-940e-c532305e1c9c">94.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5b96ecbed1428ab26d61c8aa6e8b67_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC04LTEtMS0w_3fd3d904-1858-4031-b8d2-4495489e5d0a">361.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ab772b5d0462a803c80fd10072849_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC0xMC0xLTEtMA_b2616010-124e-42aa-9e74-ae563537849d">275.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d920ab6a62942aab7073efd72dacef2_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNS00LTEtMS0w_d606209f-d60e-455c-b70c-d07259fdf03a">45.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94b188b561e248948e1916e16ec1f0f3_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNS02LTEtMS0w_28a055ab-12c1-4bb5-95e1-350a6d60bb54">45.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f4316365c63469e84bbdb4402df49fa_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNS04LTEtMS0w_ec0d102f-2b7e-4af2-a182-ab19d41d68e9">122.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a9b2764717433a815608cd7e18b125_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNS0xMC0xLTEtMA_03c39598-6665-4034-80d5-40d5a4bb7161">174.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i791e6e6420e54c049daf6dd49164145f_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNi00LTEtMS0w_6c39f23d-a6bd-4876-99ed-d156bc8b6fa4">10.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic370d9cb5fd24bf799cbdf2177dacd50_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNi02LTEtMS0w_5c259783-7063-4939-9bd7-2790d00f6de4">17.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e36a0ccdeb14ec984f4085858cbc3ee_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNi04LTEtMS0w_aebeebae-eb2e-4b06-96ab-1e806315c023">32.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if02ac5fb5d2f4310931908004cbf9aa0_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNi0xMC0xLTEtMA_2b4d8f19-ae30-466d-9980-9376595166d1">59.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1800f040ae0e4df991d07fe38d222324_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNy00LTEtMS0w_7e77d240-9dd7-4203-9d60-20e75cd8dfa0">79.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9efebbfd0f048c990bcc09d5b26f8c5_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNy02LTEtMS0w_edc88260-e0cc-4987-984d-62a844c073e3">83.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4f2a3dc80794091ae61e4de88cdbc43_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNy04LTEtMS0w_51fed96a-7ace-439d-beb1-fd6d9ed097be">216.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6a2ab36d5d4e759f8c6fe1ecff6f01_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNy0xMC0xLTEtMA_cda90c81-0685-48ab-ac04-28b9b5e280b0">260.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of losses in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41696d03ccef49c2bf26d35317b03caa_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTAtNC0xLTEtMA_ee2e40ba-1d88-43c6-8d16-789b4eb7f91a">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica632ffb58b44d6194988501bb54fc73_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTAtNi0xLTEtMA_f306c402-5ae0-4122-a5ce-2042ed18c7b6">4.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3081e3ffc7954b088fc9cb4152e95c85_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTAtOC0xLTEtMA_016f9ec8-a69e-4c6d-a58e-808b65fd1a9a">12.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bbc219c44fc46859865214fb8165394_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTAtMTAtMS0xLTA_db41855e-2116-4174-bf03-f421c14048fa">17.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546b0b3a556d452f8e64404ed081302b_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTEtNC0xLTEtMA_ae501424-670a-4d37-b253-1e33b71e1819">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacfc81b93d7b4b4f8c6d7d4593e9dace_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTEtNi0xLTEtMA_4fe77cea-32dc-44f2-afc9-bf9c34d6cf62">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c484984a09a4caaa0b9d6543ec482d5_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTEtOC0xLTEtMA_016b85ed-d136-467f-b675-4e136896ee88">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i419f91c33865447b9e9338dab3f66b55_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTEtMTAtMS0xLTA_9690ef0a-0d70-4324-a96e-50257c43a808">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6fc47b747054dab86fa5a363336c85e_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTItNC0xLTEtMA_22985a48-7737-4339-be92-67d15948b689">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449513f8039f41138f8e72756af57c6d_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTItNi0xLTEtMA_e9bd6e07-02bf-4ced-a113-aa7c091df327">49.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb63ff75d0aa4f96af3798e301bd5bf6_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTItOC0xLTEtMA_13533d36-f2f6-4e01-b110-e8cb163dc328">66.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e787fec51894471bcabbf60f6051058_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTItMTAtMS0xLTA_236409ee-afd2-4b22-83ca-21539fbabc12">136.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a756b10359641988b7f46edddeec13a_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTMtNC0xLTEtMA_c0af4ecf-1705-4ec5-b011-b977a50ad9d3">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53cb49561acd4537ba93ba5db20eb4f0_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTMtNi0xLTEtMA_58081bf3-2a65-42a2-814e-53996bfb302c">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b548827d54647c9ad6d75a0d12bb79f_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTMtOC0xLTEtMA_f8c741f9-2053-49cd-ac38-4f0a5d5bdcd1">62.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea40f4714334f43b2a0bc4763fd6bb4_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTMtMTAtMS0xLTA_20be7d3d-6179-4f57-a3cb-8a993f2c2fca">39.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi commercial expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ddacad667a94b23ac241aa7301b853a_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTQtNC0xLTEtMA_3fb35e63-949f-4a81-8884-eb183fc59303">9.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5df0acd0f02348d3ba5d9669e15f2adb_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTQtNi0xLTEtMA_e74568ae-d21e-40d8-95ee-a0d9c71291db">6.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib604dcd13e224121adb3a5c3b372b125_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTQtOC0xLTEtMA_b03575c0-66c9-4ae6-89dc-f4ecb8fafe81">28.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f6f1c8c4538460cb2956cf9359d3cae_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTQtMTAtMS0xLTA_b8a59a24-e065-49d1-a068-3f920f7477ab">15.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16ef0dd09ff34bd9832c510c5fcb9394_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTUtNC0xLTEtMA_3c8187cc-7faa-40b5-9348-55081f81c2d3">34.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3caafefa1d954278ad93efec805163b1_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTUtNi0xLTEtMA_3caf5d7c-1216-4d5b-a856-8a1d2b67de85">31.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27a6f9b6cec64cddae7a84326e0b5ffe_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTUtOC0xLTEtMA_236e1b65-978a-438d-90fa-d7b2e2b4cce1">99.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7383412bc7ac4797bad32eb100cb0abb_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTUtMTAtMS0xLTA_c7161a3d-9c20-4a70-9a32-5736fd3f0d05">86.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08ef15ce810b475c803431262514e1e9_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTYtNC0xLTEtMA_5c819c9b-cfe9-45bf-87b1-fe443eb0edde">47.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f689f71f8a240b2a33290b4e3bfa31b_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTYtNi0xLTEtMA_34efef30-f95a-43ca-a132-646970559b47">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65d333ff83094f148e490ee53841f02f_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTYtOC0xLTEtMA_f988f3e7-9e90-4546-9574-8c6c5d862bd1">4.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad6e8d74360c4e38b0f7e558981f7f7f_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTYtMTAtMS0xLTA_090e3e51-5527-4499-ba9b-1e2fa1d3699c">57.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the "Antibody Collaboration"), which currently consists of Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (dupilumab), Kevzara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sarilumab), and itepekimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Antibody License and Collaboration Agreement ("LCA"), Sanofi is generally responsible for funding <ix:nonFraction unitRef="number" contextRef="i4a5801eab8e4442a8423dca2e534dad1_D20210101-20210930" decimals="2" name="regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNTgz_3fb0ae5b-8ec8-4929-8e1b-3f7bd5ca488b">80</ix:nonFraction>%&#8211;<ix:nonFraction unitRef="number" contextRef="i5a8ed766d24e4af78c21550a7b7302a3_D20210101-20210930" decimals="2" name="regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNTg2_40721e6f-0f2b-4764-a779-2da9b795606c">100</ix:nonFraction>% of agreed-upon development costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi leads commercialization activities for products under the Antibody Collaboration, subject to the Company's right to co-commercialize such products. In addition to profit and loss sharing, the Company is entitled to receive sales milestone payments from Sanofi. In the third quarter of 2020, the Company earned, and recognized as revenue, the first $<ix:nonFraction unitRef="usd" contextRef="if7432bde3ff84eafbcfb0af4b10fa31f_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTY0OTI2NzQ1NDIwMA_5382393f-8380-4794-9c4b-a8fa7deca112">50.0</ix:nonFraction>&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $<ix:nonFraction unitRef="usd" contextRef="i78fb2bfa7e774e23970aa2139ee245db_D20200101-20200930" decimals="-8" format="ixt:num-dot-decimal" name="regn:LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTY0OTI2NzQ1NDI2Nw_76843a6e-2875-4030-90b9-d79e16b7a685">1.0</ix:nonFraction>&#160;billion on a rolling <ix:nonNumeric contextRef="i78fb2bfa7e774e23970aa2139ee245db_D20200101-20200930" format="ixt-sec:durwordsen" name="regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNDM5ODA0NjUyNDA5NQ_7b03e6dc-647b-4774-b530-d1d44c804b6e">twelve-month</ix:nonNumeric> basis. In the third quarter of 2021, the Company earned, and recognized as revenue, the second $<ix:nonFraction unitRef="usd" contextRef="i75cfc29b08e54dbcb23f41eeb66d7d5e_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTY0OTI2NzQ1NDU3Ng_32763bed-4fc8-449c-b134-19040d74951f">50.0</ix:nonFraction>&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $<ix:nonFraction unitRef="usd" contextRef="i44705b78f91d457fb2bee63fb813ff55_D20210101-20210930" decimals="-8" format="ixt:num-dot-decimal" name="regn:LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTY0OTI2NzQ1NDYwNA_eda93b35-dbb4-45b4-ab81-4022d84c307f">1.5</ix:nonFraction>&#160;billion on a rolling <ix:nonNumeric contextRef="i44705b78f91d457fb2bee63fb813ff55_D20210101-20210930" format="ixt-sec:durwordsen" name="regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNDM5ODA0NjUyNDA4Mg_601a3bfa-7185-439c-adca-fe4b63a3a3af">twelve-month</ix:nonNumeric> basis. We are entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i44705b78f91d457fb2bee63fb813ff55_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="regn:RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTY0OTI2NzQ1NDIzMA_2b652e0c-e6e7-4851-ac28-3454f5d72aff">150.0</ix:nonFraction>&#160;million in additional sales milestone payments from Sanofi.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><ix:continuation id="iac60aa699fdd4b7d9bf3ee916709d3d0" continuedAt="ied06065e6de34c1c863d1553d8368a35"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTE1MzM_a322bbad-e34c-435b-8a0e-180c784f9be4" continuedAt="i22dddc1e1ca34446b8a52b348b96378f" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.502%"><tr><td style="width:1.0%"></td><td style="width:49.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.489%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9483a9e8f5b474ea373471543f0536b_I20210930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFkZWI3ZTQzOGQ2NDQyMGFiZmJmNzNmNjQzYzM2OGM4L3RhYmxlcmFuZ2U6YWRlYjdlNDM4ZDY0NDIwYWJmYmY3M2Y2NDNjMzY4YzhfMi0yLTEtMS0w_43851c5f-d996-4937-a2ef-1cbd6c30f5b2">536.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf63d465ccd3423187f9af7e8b4bc7e1_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFkZWI3ZTQzOGQ2NDQyMGFiZmJmNzNmNjQzYzM2OGM4L3RhYmxlcmFuZ2U6YWRlYjdlNDM4ZDY0NDIwYWJmYmY3M2Y2NDNjMzY4YzhfMi00LTEtMS0w_aefa6a0f-734a-4231-b939-32a491bc1b49">407.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9483a9e8f5b474ea373471543f0536b_I20210930" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFkZWI3ZTQzOGQ2NDQyMGFiZmJmNzNmNjQzYzM2OGM4L3RhYmxlcmFuZ2U6YWRlYjdlNDM4ZDY0NDIwYWJmYmY3M2Y2NDNjMzY4YzhfMy0yLTEtMS0w_67851fd5-b3c3-4657-9a31-c5747e3e1bbb">431.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf63d465ccd3423187f9af7e8b4bc7e1_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFkZWI3ZTQzOGQ2NDQyMGFiZmJmNzNmNjQzYzM2OGM4L3RhYmxlcmFuZ2U6YWRlYjdlNDM4ZDY0NDIwYWJmYmY3M2Y2NDNjMzY4YzhfMy00LTEtMS0w_24175dfb-2f68-4cd2-af5f-665691dad5a9">347.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company and Sanofi entered into an amendment to the LCA in connection with, among other things, the removal of Praluent from the LCA such that (i) effective April 1, 2020, the LCA no longer governs the development, manufacture, or commercialization of Praluent and (ii) the quarterly period ended March 31, 2020 was the last quarter for which Sanofi and the Company shared profits and losses for Praluent under the LCA. The parties also entered into a Praluent Cross License &amp; Commercialization Agreement (the "Praluent Agreement") pursuant to which, effective April 1, 2020, the Company, at its sole cost, became solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, became solely responsible for the development and commercialization of Praluent outside of the United States. Under the Praluent Agreement, Sanofi will pay the Company a <ix:nonFraction unitRef="number" contextRef="i182dd47bcec04ee292243a30a58dea41_D20200401-20200401" decimals="2" name="regn:RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTk0MQ_9a4fab45-1a4e-4173-a728-fc4078a707b1">5</ix:nonFraction>% royalty on Sanofi&#8217;s net product sales of Praluent outside the United States until March 31, 2032. The Company will not owe Sanofi royalties on the Company&#8217;s net product sales of Praluent in the United States. Although each party will be responsible for manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for a certain transitional period, the Company will continue to supply drug substance to Sanofi and Sanofi will continue to supply finished product to Regeneron. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third-party royalty payments resulting from certain patent litigation proceedings against up to <ix:nonFraction unitRef="number" contextRef="i814fd946f5074904942acc5d9194d0fb_D20200401-20200401" decimals="2" name="regn:PercentageOfRoyaltyPaymentThatCanBeOffset" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMzA2Mw_29616a49-8652-4d20-9686-8d19fa6ced71">50</ix:nonFraction>% of any Praluent royalty payment owed to Regeneron). The parties will each bear <ix:nonFraction unitRef="number" contextRef="i182dd47bcec04ee292243a30a58dea41_D20200401-20200401" decimals="2" name="regn:LossContingencyPercentageOfDamagesResponsibleFor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMzE0NQ_8f5f175d-813a-4a9e-bddc-ff676249d99c">50</ix:nonFraction>% of any damages arising out of Praluent sales or other activities prior to April 1, 2020. See Note 12 for discussion of legal proceedings related to Praluent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a collaboration with Sanofi to research, develop, and commercialize antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective December 31, 2018, the Company and Sanofi entered into an Amended and Restated Immuno-oncology Discovery and Development Agreement ("Amended IO Discovery Agreement"), which narrowed the scope of the existing discovery and development activities conducted by the Company under the 2015 IO Discovery Agreement to developing therapeutic bispecific antibodies targeting (i) BCMA and CD3 (the "BCMAxCD3 Program") and (ii) MUC16 and CD3 (the "MUC16xCD3 Program") through clinical proof-of-concept. During the first quarter of 2021, Sanofi did not exercise its options to license rights to these product candidates; as a result, we retain the exclusive right to develop and commercialize such product candidates and Sanofi will receive a royalty on sales (if any). In addition, the Company has no further obligations to develop drug product candidates under the Amended IO Discovery Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Immuno-oncology License and Collaboration Agreement, the parties are co-developing and co-commercializing Libtayo (cemiplimab). The parties share equally, on an ongoing basis, agreed-upon development and commercialization expenses for Libtayo. The Company has principal control over the development of Libtayo and leads commercialization activities in the United States (see Note 2 for related product sales information), while Sanofi leads commercialization activities outside of the United States. The parties share equally in profits and losses in connection with the commercialization of Libtayo.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021, we updated our estimate of the total research and development costs expected to be incurred (which resulted in a change to the estimate of the stage of completion) in connection with the IO Collaboration, and, as a result, recorded a cumulative catch-up adjustment of $<ix:nonFraction unitRef="usd" contextRef="i89ca366da43e409298cf61eea017813d_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTY0OTI2NzQ1ODI5Ng_fdc04352-2a1d-4228-9ed3-5bd6a2f26b9e">66.9</ix:nonFraction>&#160;million as a reduction to other operating income.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><ix:continuation id="ied06065e6de34c1c863d1553d8368a35" continuedAt="if621aad58a3241678ddc3f72ffb785ce"><ix:continuation id="i22dddc1e1ca34446b8a52b348b96378f" continuedAt="i317fc5bd2d0e4f3781b8906c2844c750"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.941%"><tr><td style="width:1.0%"></td><td style="width:49.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.314%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9bfe175438f49a9be01e98bcc545764_I20210930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjkyZTNhOGQxMDFjMTRmMTQ5NzgzYmMxZTExMTkzZTg4L3RhYmxlcmFuZ2U6OTJlM2E4ZDEwMWMxNGYxNDk3ODNiYzFlMTExOTNlODhfMi0yLTEtMS0w_3fb5cafd-ce14-4ce5-9025-83d8b15d8b74">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebfd12dc45514f458d53a2791ef44ec9_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjkyZTNhOGQxMDFjMTRmMTQ5NzgzYmMxZTExMTkzZTg4L3RhYmxlcmFuZ2U6OTJlM2E4ZDEwMWMxNGYxNDk3ODNiYzFlMTExOTNlODhfMi00LTEtMS0w_9e074112-a7eb-4f84-9505-bb96bd250c14">6.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9bfe175438f49a9be01e98bcc545764_I20210930" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjkyZTNhOGQxMDFjMTRmMTQ5NzgzYmMxZTExMTkzZTg4L3RhYmxlcmFuZ2U6OTJlM2E4ZDEwMWMxNGYxNDk3ODNiYzFlMTExOTNlODhfMy0yLTEtMS0w_f950cce6-ba75-4232-a325-0b02f469678c">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfd12dc45514f458d53a2791ef44ec9_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjkyZTNhOGQxMDFjMTRmMTQ5NzgzYmMxZTExMTkzZTg4L3RhYmxlcmFuZ2U6OTJlM2E4ZDEwMWMxNGYxNDk3ODNiYzFlMTExOTNlODhfMy00LTEtMS0w_5ee74d92-773c-4308-8d76-f1c8f6ed3e16">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9bfe175438f49a9be01e98bcc545764_I20210930" decimals="-5" name="us-gaap:OtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjkyZTNhOGQxMDFjMTRmMTQ5NzgzYmMxZTExMTkzZTg4L3RhYmxlcmFuZ2U6OTJlM2E4ZDEwMWMxNGYxNDk3ODNiYzFlMTExOTNlODhfNC0yLTEtMS0w_e04574fb-c675-4657-93de-b913b961a8e8">286.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfd12dc45514f458d53a2791ef44ec9_I20201231" decimals="-5" name="us-gaap:OtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjkyZTNhOGQxMDFjMTRmMTQ5NzgzYmMxZTExMTkzZTg4L3RhYmxlcmFuZ2U6OTJlM2E4ZDEwMWMxNGYxNDk3ODNiYzFlMTExOTNlODhfNC00LTEtMS0w_37ee6d38-4e1e-4646-881f-713650b66560">280.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities include up-front payments received from Sanofi for which recognition has been deferred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the estimated consideration under the IO Collaboration related to the Company's obligation that was unsatisfied (or partially unsatisfied) as of September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ie9bfe175438f49a9be01e98bcc545764_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNTUwOQ_b043b584-0343-4f32-8202-444b241e62bf">591.4</ix:nonFraction>&#160;million. This amount is expected to be recognized over the remaining period in which the Company is obligated to satisfy its obligation in connection with performing development activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">b. Bayer </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license and collaboration agreement with Bayer for the global development and commercialization of EYLEA outside the United States. All agreed upon EYLEA development expenses incurred by the Company and Bayer are shared equally. Bayer markets EYLEA outside the United States, where, for countries other than Japan, the companies share equally in profits and losses from sales of EYLEA. In Japan, the Company is currently entitled to receive a tiered percentage of between <ix:nonFraction unitRef="number" contextRef="i509963cbbe784be8973a31df2b9a8963_D20210101-20210930" decimals="3" name="regn:RevenueBasedOnPercentageOfAnnualSalesInJapan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNjIwMg_0a1e6d39-6449-4acb-a2b2-d441ec00b8db">33.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia985bae849b44c219201a836f385ce29_D20210101-20210930" decimals="3" name="regn:RevenueBasedOnPercentageOfAnnualSalesInJapan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNjIwOQ_c0ecaffe-d1f1-4bae-b655-52d05de0fec3">40.0</ix:nonFraction>% of EYLEA net product sales through 2021, and thereafter, the companies will share equally in profits and losses from sales of EYLEA. </span></div><ix:continuation id="i6c2c11ab525b4e87a90b579e26ea10aa" continuedAt="ie93cfe24fddc48cf9034c1feb6710576"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our Bayer EYLEA collaboration are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.286%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's net profit in connection with commercialization of EYLEA outside the United States</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1ba982dde844a9c82475e880a5f75f0_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMi00LTEtMS0w_3f88ae2d-7f3a-4500-b8d4-35b4d8111618">351.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955142d326434513a46962fe495e0fa1_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMi02LTEtMS0w_7852dd04-5a38-47a2-99d6-cec76d60478a">287.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaee3d49fec54b8a9e5fd65ae301bee3_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMi04LTEtMS0w_0e78034b-b509-461d-b69b-2a51ff2dec89">995.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402f7f4cd8f04e6497716ec2e663706b_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMi0xMC0xLTEtMA_61bca3bb-1a9e-478d-b369-9f3f69f41f8f">772.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e46aceade444644b9dd70d4cecbf25b_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMy00LTEtMS0w_4808ca9c-bcb6-4c28-86fe-88f40eabfee4">14.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if94b654450124728b790785f2b2cde12_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMy02LTEtMS0w_a911ff58-c41b-423d-b3dd-d906dd98383c">12.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4e41d48528d49caae8c91f124239822_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMy04LTEtMS0w_bfe8a144-e796-457b-a71c-ea6c88b31359">41.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2bf015dbfa7438092254a9cd1ea14ed_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMy0xMC0xLTEtMA_6ad5dccd-ebfa-47fc-989f-03cb465aeb3d">52.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf88f57a03b140b780d64166b452794e_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNC00LTEtMS0w_3d4082fe-b70c-4158-a926-daa20e18aae1">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="padding-left:15.75pt;text-indent:-9pt"><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae6fd17f82a4bb6bdbe987bc274fbb2_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNC02LTEtMS0w_fa7ccf25-bafe-4021-aa85-c35846ec1991">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5353a1ff784f4cf18d143c0765148747_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNC04LTEtMS0w_d39000b5-dacd-47ba-8bfd-9a1b35909aff">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i073ce9da231842b3b7cd60b5bf3ca507_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNC0xMC0xLTEtMA_2e28e33f-790d-4cb2-889d-9645ba205fa5">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Bayer research and development expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i381b143df0d94c9a86aa2eeae5839128_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNS00LTEtMS0w_56365848-131c-41df-bafd-1eadf3f24ee2">8.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11dfc2547ca74cfc84608cbde114c10d_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNS02LTEtMS0w_e3da19c6-120b-43e4-a88f-46aec5d90799">12.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc5f19126e9840eb9029c6f52c25185b_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNS04LTEtMS0w_9073ec92-4764-43a4-b8a1-3c3b0fabaf8c">31.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa62c40f54c54ca1ad0abe0e53b2a453_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNS0xMC0xLTEtMA_1b46d63b-0fb9-4ac9-834d-6c5e1e0f89e3">26.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:continuation id="i317fc5bd2d0e4f3781b8906c2844c750" continuedAt="i84cee3b1af1a469c8eb8a0ba5bb10036"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with our Bayer EYLEA collaboration:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"><tr><td style="width:1.0%"></td><td style="width:49.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d7420067c744c329c85c868130a6ded_I20210930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmM3MzhhOTFhY2Q5MzQ4MjA4MmQwZTMxNGEzMmIwMWQ3L3RhYmxlcmFuZ2U6YzczOGE5MWFjZDkzNDgyMDgyZDBlMzE0YTMyYjAxZDdfMi0yLTEtMS0w_e41d8b79-5d10-4b96-9b3c-26aa765aed87">374.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1d208f0eb4428db5488e7d8ed9b2f0_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmM3MzhhOTFhY2Q5MzQ4MjA4MmQwZTMxNGEzMmIwMWQ3L3RhYmxlcmFuZ2U6YzczOGE5MWFjZDkzNDgyMDgyZDBlMzE0YTMyYjAxZDdfMi00LTEtMS0w_eb607fb3-f003-4bb0-b386-2671d05b735e">336.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d7420067c744c329c85c868130a6ded_I20210930" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmM3MzhhOTFhY2Q5MzQ4MjA4MmQwZTMxNGEzMmIwMWQ3L3RhYmxlcmFuZ2U6YzczOGE5MWFjZDkzNDgyMDgyZDBlMzE0YTMyYjAxZDdfMy0yLTEtMS0w_2446c26f-e2ba-4bb8-909b-6a58a4db3655">115.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1d208f0eb4428db5488e7d8ed9b2f0_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmM3MzhhOTFhY2Q5MzQ4MjA4MmQwZTMxNGEzMmIwMWQ3L3RhYmxlcmFuZ2U6YzczOGE5MWFjZDkzNDgyMDgyZDBlMzE0YTMyYjAxZDdfMy00LTEtMS0w_16da0a6e-5e07-4680-b3b4-24b40d5dd2d1">99.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><ix:continuation id="if621aad58a3241678ddc3f72ffb785ce" continuedAt="i73907646d2244b74a885ef54c058c5e5"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">c. Teva</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Teva are parties to a collaboration agreement (the "Teva Collaboration Agreement") to develop and commercialize fasinumab globally, excluding certain Asian countries that are subject to our collaboration agreement with Mitsubishi Tanabe Pharma Corporation. The Company leads global development activities, and the parties share development costs equally, on an ongoing basis, under a global development plan.</span></div><ix:continuation id="ie93cfe24fddc48cf9034c1feb6710576" continuedAt="iffb32478df394f00b1b9cd326a19ab7b"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our collaboration with Teva are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.286%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6533a61e5ab4ad3a159b912aa4b022e_D20210701-20210930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMi00LTEtMS0w_bda3f296-8cdb-4edc-a795-21389dcb475d">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3fe6a3db0be4a5184a1b7acc80f29d7_D20200701-20200930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMi02LTEtMS0w_3a9aebcd-d5a7-4980-bdb3-92fa13dc20a6">25.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b44f35ec1c46cabb41e44d2197b227_D20210101-20210930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMi04LTEtMS0w_c9540a61-057e-4440-9f96-5750a9318038">36.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id21ae34bc9b64b5796aa956e68521d55_D20200101-20200930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMi0xMC0xLTEtMA_c3df6a00-ebb6-4dee-b3de-f9e2e7c6b3d1">82.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front and development milestone payments received</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784465fd68bc485f93061c14f0464626_D20210701-20210930" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMy00LTEtMS0w_813e2a46-6e9d-4035-83e2-ffdf17955697">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d13d4e4a7241f7b1b59f2578dfa67c_D20200701-20200930" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMy02LTEtMS0w_6ecc8737-ea3c-4b3e-aded-0ef68c5f6df4">17.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7d0836ec7e74c33926c74712109896c_D20210101-20210930" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMy04LTEtMS0w_a6abbf42-b61f-4f37-a18e-abb65832aae0">22.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice301c2478284e1590cd4fe592b2d490_D20200101-20200930" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMy0xMC0xLTEtMA_d870eb85-6b13-4687-8db2-0f2e09157231">54.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:continuation id="i84cee3b1af1a469c8eb8a0ba5bb10036" continuedAt="ida67f5ce10ce453785e94758d02c121f"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Teva Collaboration Agreement:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"><tr><td style="width:1.0%"></td><td style="width:49.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic802850933a14320a118ce1085b1dbcc_I20210930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFjOWNiOTI1ZjA4ODQxZDk4NjVkMTI3ZjRkNmMwZWQzL3RhYmxlcmFuZ2U6YWM5Y2I5MjVmMDg4NDFkOTg2NWQxMjdmNGQ2YzBlZDNfMi0yLTEtMS0w_16a663ac-e872-4fa3-a954-2abb20d662d2">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f2394a4ea74ae88bf23a677f4f957f_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFjOWNiOTI1ZjA4ODQxZDk4NjVkMTI3ZjRkNmMwZWQzL3RhYmxlcmFuZ2U6YWM5Y2I5MjVmMDg4NDFkOTg2NWQxMjdmNGQ2YzBlZDNfMi00LTEtMS0w_8cd3128c-c296-4903-9e27-e4a98a704ea4">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic802850933a14320a118ce1085b1dbcc_I20210930" decimals="-5" name="us-gaap:OtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFjOWNiOTI1ZjA4ODQxZDk4NjVkMTI3ZjRkNmMwZWQzL3RhYmxlcmFuZ2U6YWM5Y2I5MjVmMDg4NDFkOTg2NWQxMjdmNGQ2YzBlZDNfMy0yLTEtMS0w_ed9dc6bb-39d2-4ed3-8a6b-2892a44726aa">43.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64f2394a4ea74ae88bf23a677f4f957f_I20201231" decimals="-5" name="us-gaap:OtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFjOWNiOTI1ZjA4ODQxZDk4NjVkMTI3ZjRkNmMwZWQzL3RhYmxlcmFuZ2U6YWM5Y2I5MjVmMDg4NDFkOTg2NWQxMjdmNGQ2YzBlZDNfMy00LTEtMS0w_6ab38d33-ad1e-4e96-9643-2c3c301e8aac">66.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities include up-front and development milestone payments received from Teva for which recognition has been deferred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the estimated consideration under the Teva Collaboration Agreement related to the Company's obligation that was unsatisfied (or partially unsatisfied) as of September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ic802850933a14320a118ce1085b1dbcc_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNzUzNw_63895566-2557-407b-86c1-10c017950699">96.7</ix:nonFraction>&#160;million. This amount is expected to be recognized over the remaining period in which the Company is obligated to satisfy its obligation in connection with performing development activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">d. U.S. Government </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">REGEN-COV (casirivimab and imdevimab)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, we announced an expansion of our Other Transaction Agreement with the Biomedical Advanced Research Development Authority ("BARDA"), pursuant to which the U.S. Department of Health and Human Services ("HHS") was obligated to fund certain of our costs incurred for research and development activities related to COVID-19 treatments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we entered into an agreement with entities acting at the direction of BARDA and the U.S. Department of Defense to manufacture and deliver filled and finished drug product of REGEN-COV to the U.S. government. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced an agreement with an entity acting on behalf of the U.S. Department of Defense and HHS to manufacture and deliver additional filled and finished drug product of REGEN-COV to the U.S. government. Pursuant to the agreement, the U.S. government was obligated to purchase the <ix:nonFraction unitRef="dose" contextRef="ie940f37df2c049fd89c26eaeab0debe8_D20210101-20210630" decimals="INF" format="ixt:num-dot-decimal" name="regn:CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNDM5ODA0NjUyNzM2NA_2e0d947c-0b04-4ea1-ab5d-ef0279f2f572">1.25</ix:nonFraction>&#160;million doses of drug product that we delivered by June 30, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has completed its final deliveries of drug product under the agreements described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company announced an amendment to its January 2021 agreement to supply the U.S. government with an additional <ix:nonFraction unitRef="dose" contextRef="i7f04700578124cab99fe2de9a5db10bc_D20210901-20210930" decimals="INF" format="ixt:num-dot-decimal" name="regn:CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNDM5ODA0NjUyMzI0OA_39f9d660-7d18-4a54-8a31-8c28b85dcb34">1.4</ix:nonFraction>&#160;million doses of REGEN-COV. Pursuant to the agreement, the U.S. government is obligated to purchase all filled and finished doses of such additional drug product delivered by January 31, 2022, resulting in payments to the Company of up to $<ix:nonFraction unitRef="usd" contextRef="i859fc8964b6340f8bf9073e37098a30a_D20220131-20220131" decimals="-6" format="ixt:num-dot-decimal" name="regn:MaximumTransactionAgreementPayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTQyOTM2NTExNzQ1MTM_77220b72-a330-402e-96b5-daa33b87300a">2.940</ix:nonFraction>&#160;billion in the aggregate. Additionally, Roche will supply a portion of the doses to Regeneron to fulfill our agreement with the U.S. government (see "Roche" below for further details regarding our collaboration agreement with Roche).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 for REGEN-COV net product sales recognized in connection with these agreements. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><ix:continuation id="i73907646d2244b74a885ef54c058c5e5"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">e. Roche</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, we entered into a collaboration agreement (the "Roche Collaboration Agreement") with Roche to develop, manufacture, and distribute the casirivimab and imdevimab antibody cocktail (known as REGEN-COV in the United States and Ronapreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in other countries). We lead global development activities for casirivimab and imdevimab, and the parties jointly fund certain ongoing studies, as well as any mutually agreed additional new global studies to evaluate further the potential of casirivimab and imdevimab in treating or preventing COVID-19. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the agreement, each party is obligated to dedicate a certain amount of manufacturing capacity to casirivimab and imdevimab each year. We distribute the product in the United States and Roche distributes the product outside of the United States. The parties share gross profits from worldwide sales based on a pre-specified formula, depending on the amount of manufactured product supplied by each party to the market. Each quarter, a single payment is due from one party to the other to true-up the global gross profits between the parties. If Regeneron is to receive a true-up payment from Roche, such amount will be recorded to Collaboration revenue. If Regeneron is to make a true-up payment to Roche, such amount will be recorded to Cost of goods sold.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><ix:continuation id="iffb32478df394f00b1b9cd326a19ab7b"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts recognized in our Statements of Operations in connection with the Roche Collaboration Agreement are as follows:</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.411%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit true-up payment owed from Roche in connection with sales of casirivimab and imdevimab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27c9ab022abc478d8f79666d02a78330_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMi00LTEtMS0w_6456e61c-00fc-4152-9664-ffacdc323feb">127.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcf5bf64c5f4e23b07547fddb4834c1_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMi02LTEtMS0w_111c06e0-34c1-4274-ba18-33f9391463c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idae7c39276e247b99aa741d38663bd97_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMi04LTEtMS0w_13730cb0-ff3b-4925-8086-4664d16f410f">361.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie439420bfacb4ac3a711d43c21ed2b7a_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMi0xMC0xLTEtMA_e6b91bd4-b446-4559-b4ed-a996915f5f53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7481e994a8ef47a4bc764250f091d6be_D20210701-20210930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMy00LTEtMS0w_a1ed9509-1246-47fa-8e65-f4f4111a5a64">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id222f9b1cb5248d9bc897bf0e1e74fad_D20200701-20200930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMy02LTEtMS0w_8dddc900-9160-4e9c-a8c1-b3c5e71896c3">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820df2abc71243a09f1e9d12e9631bf0_D20210101-20210930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMy04LTEtMS0w_dd72e9f9-83ca-4edb-88e6-48abc6571406">138.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic40440c4c14b457ebef02ad35de7b6ee_D20200101-20200930" decimals="-5" name="regn:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMy0xMC0xLTEtMA_1f2b082b-50d5-493a-8cdf-23c53e2f3135">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:continuation id="ida67f5ce10ce453785e94758d02c121f"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Roche Collaboration Agreement:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"><tr><td style="width:1.0%"></td><td style="width:49.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7ab84ea29f4779b5a42b782dc5859e_I20210930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmY4Y2ZiZGJhMjQ4MDQwOWU4NzhjYmY2NWJkNThiMTI0L3RhYmxlcmFuZ2U6ZjhjZmJkYmEyNDgwNDA5ZTg3OGNiZjY1YmQ1OGIxMjRfMi0yLTEtMS0w_71e9542b-9290-4648-a0d7-dc3d066a1fb2">305.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d249e67e354239b79dd039bbf41c79_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmY4Y2ZiZGJhMjQ4MDQwOWU4NzhjYmY2NWJkNThiMTI0L3RhYmxlcmFuZ2U6ZjhjZmJkYmEyNDgwNDA5ZTg3OGNiZjY1YmQ1OGIxMjRfMi00LTEtMS0w_e594eeba-2e83-45a6-af56-0bc9a685a00a">77.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">f. Intellia</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2016, we entered into a license and collaboration agreement with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapeutic development. The parties collaborate to conduct research for the discovery, development, and commercialization of new therapies, in addition to the research and technology development of the CRISPR/Cas9 platform.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, we expanded our existing collaboration with Intellia to provide us with rights to develop products for additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CRISPR/Cas9-based therapeutic targets and for the parties to jointly develop potential products for the treatment of hemophilia A and B. In addition, we also received non-exclusive rights to independently develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> gene edited products. In connection with the agreement, we made a $<ix:nonFraction unitRef="usd" contextRef="ibe25403ae1ba406b8be348b085927476_D20200401-20200630" decimals="-5" format="ixt:num-dot-decimal" name="regn:CollaborativeArrangementUpfrontPaymentMade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTEyMTU_98745076-7424-46c3-b674-6d1a597aab78">70.0</ix:nonFraction>&#160;million up-front payment and purchased shares of Intellia common stock for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i171b9fb71e894402b6278e0d6cf6ed66_I20200531" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedAtCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTEzMTk_5928dcca-0a49-4f89-aba9-380f9f0ed603">30.0</ix:nonFraction>&#160;million. The up-front payment and the amount paid in excess of the fair market value of the shares purchased, or $<ix:nonFraction unitRef="usd" contextRef="ibe25403ae1ba406b8be348b085927476_D20200401-20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTE0Mjc_8e40b1be-3f33-4253-9216-51ba2040cc2c">15.0</ix:nonFraction>&#160;million, were recorded to Research and development expense during the three months ended June 30, 2020.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_40"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RleHRyZWdpb246MjJjMDkyM2QwMjA1NGFiNWEyMGU4ZjZmZDIzZDNiZTlfNzU4_4aadcd1f-b17c-40a9-8173-e49f01bbf624" continuedAt="i296feb93d99f44e98f24165727a54c80" escape="true">Net Income Per Share </ix:nonNumeric></span></div><ix:continuation id="i296feb93d99f44e98f24165727a54c80"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing net income by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net income per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. Diluted net income per share includes the potential dilutive effect of other securities as if such securities were converted or exercised during the period, when the effect is dilutive. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RleHRyZWdpb246MjJjMDkyM2QwMjA1NGFiNWEyMGU4ZjZmZDIzZDNiZTlfNzUx_dc871e95-f843-4c58-b6b3-3aeb3ca9b964" continuedAt="i6b3e2457aaaf44b0930ae5c5ea4ac24c" escape="true">The calculations of basic and diluted net income per share are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><ix:continuation id="i6b3e2457aaaf44b0930ae5c5ea4ac24c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"></td><td style="width:48.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMi0yLTEtMS0w_ee022e32-6bc1-4cf4-8f63-5f3df5121b91">1,632.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMi00LTEtMS0w_9736ea86-8f84-4538-81ff-322a0e89821c">842.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMi02LTEtMS0w_fc487412-161b-4c25-888b-1a5babdb19a0">5,846.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMi04LTEtMS0w_148d4856-7902-4d9b-84fc-2c8cf101e6cc">2,364.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNC0yLTEtMS0w_dac0c0c9-04dc-4291-a564-15ef45b678df">106.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNC00LTEtMS0w_6caebecf-56ef-47fb-84bf-6f7c1a9ba544">105.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNC02LTEtMS0w_ba1f5c8d-0974-46d3-bb42-dfbaea80c1e2">105.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNC04LTEtMS0w_5a62a876-c5f1-44b4-b194-3c510a113f27">108.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i767fc2b3c91d49368bb428e956e1c15f_D20210701-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNi0yLTEtMS0w_cd2e5f27-6880-4056-9463-4f1620a0eeb1">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a52920e795646119a53ceb1ce382a02_D20200701-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNi00LTEtMS0w_5e882070-4d22-4753-bfc3-f0cd27343731">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89f5b96bc5434e47892bfa9a96bc713f_D20210101-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNi02LTEtMS0w_9a96f4d8-a9d7-4ecc-a588-a93efc9a2bbe">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia2fe8e8115b14acaab1a1d5efd01ab92_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNi04LTEtMS0w_ccf2f519-ac71-4c47-a5f6-c9546497debd">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e9ea9623abe41a1afbf09779e3252b2_D20210701-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNy0yLTEtMS0w_4fe9121b-2b9e-4f68-bfb3-6f6db2c83cff">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a9416d782bf46e3aac5cafdd70af82a_D20200701-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNy00LTEtMS0w_d516228a-6455-41b7-b518-ace57724d7b0">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia467795663df48f8839e66b5689ec354_D20210101-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNy02LTEtMS0w_80c6f120-92d3-4f7a-a192-c5a6568368a5">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb41ac995da4481eb5a2ee2048fd8b8e_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNy04LTEtMS0w_d1f463a0-7ab3-4e10-a025-1feb48eaa46d">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfOC0yLTEtMS0w_9825a7dc-7ef5-42f6-bdb7-445ed93f1d5c">113.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfOC00LTEtMS0w_ae149d99-c628-4410-a14b-cf585dd45061">113.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfOC02LTEtMS0w_bf2613bd-ce3e-4386-b419-10fe6d0003ab">111.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfOC04LTEtMS0w_5cecb20d-c04c-4361-9abc-bcc49cc53485">116.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTAtMi0xLTEtMA_13a07884-1051-41ee-8d3d-71985de07e64">15.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTAtNC0xLTEtMA_af93f0fe-1ebb-4860-992a-47849241ce65">7.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTAtNi0xLTEtMA_becfe970-1755-41e2-8547-97ec7849bb0c">55.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTAtOC0xLTEtMA_78d0936e-10e3-4ddc-a0ae-bff606c307d3">21.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTEtMi0xLTEtMA_7d39cf31-d071-4cd2-aa87-069318d1aaf3">14.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTEtNC0xLTEtMA_a9ac5cda-5c5b-4fa3-a96c-0c87ad5f0e99">7.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTEtNi0xLTEtMA_a99ef49d-6403-4bcd-8917-3633615f60c3">52.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTEtOC0xLTEtMA_8cf9c909-d68f-48ee-86bb-611b8844566c">20.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RleHRyZWdpb246MjJjMDkyM2QwMjA1NGFiNWEyMGU4ZjZmZDIzZDNiZTlfNzU5_0b688c29-9242-4e7f-aeb0-d3918ea52543" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.181%"><tr><td style="width:1.0%"></td><td style="width:36.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.257%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Shares in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i305115a444d14bd096edfc2b3a5fe574_D20210701-20210930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOjk2YTU0YWMzNTJjMTQ1YzRiNGE5ZTUyYTIxZmRhZjEwL3RhYmxlcmFuZ2U6OTZhNTRhYzM1MmMxNDVjNGI0YTllNTJhMjFmZGFmMTBfMi0yLTEtMS0w_12bf92ce-c168-4314-badc-614d5c105641">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79da790fd94b4499bae26a25903f21e4_D20200701-20200930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOjk2YTU0YWMzNTJjMTQ1YzRiNGE5ZTUyYTIxZmRhZjEwL3RhYmxlcmFuZ2U6OTZhNTRhYzM1MmMxNDVjNGI0YTllNTJhMjFmZGFmMTBfMi00LTEtMS0w_71f03417-19bd-4037-b022-91278bf50eff">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2b88f865b474f1fb605c319670ea555_D20210101-20210930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOjk2YTU0YWMzNTJjMTQ1YzRiNGE5ZTUyYTIxZmRhZjEwL3RhYmxlcmFuZ2U6OTZhNTRhYzM1MmMxNDVjNGI0YTllNTJhMjFmZGFmMTBfMi02LTEtMS0w_2f8367f0-9fbf-434a-8a09-189a2e5b5b65">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib08523f726914db6b88055d68a3804a8_D20200101-20200930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOjk2YTU0YWMzNTJjMTQ1YzRiNGE5ZTUyYTIxZmRhZjEwL3RhYmxlcmFuZ2U6OTZhNTRhYzM1MmMxNDVjNGI0YTllNTJhMjFmZGFmMTBfMi04LTEtMS0w_c780f83a-a036-4b85-97cb-b8f928fab304">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_43"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfMTQxNw_a969ea90-3706-440d-9c64-deb3f8313ed3" continuedAt="iae0c67ed09db47d29195df653a0d3276" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="iae0c67ed09db47d29195df653a0d3276" continuedAt="ibddeb2a9914343c3afc9cb09296eab43"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities as of September&#160;30, 2021 and December&#160;31, 2020 consist of both available-for-sale debt securities of investment grade issuers (see below and Note 6) as well as equity securities of publicly traded companies (see Note 6).</span></div><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfMTQxMw_9de7cdff-2ac5-4a03-8d2d-f72b2d466c5a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's investments in available-for-sale debt securities: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:46.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMi0yLTEtMS0w_3d9e7593-0f54-4f63-b694-86ee263e7234">5,911.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMi00LTEtMS0w_1951087a-2235-4a5b-af1a-24bcfe65dd24">19.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMi02LTEtMS0w_e661f47b-30f8-475c-abfe-0613a0e6b990">6.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMi04LTEtMS0w_606e33d7-b54d-4e84-a1e2-f734c55e5380">5,924.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMy0yLTEtMS0w_89a73ff6-5756-4951-8298-515e10ce7ebd">101.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMy00LTEtMS0w_bd872d97-1b8a-43d3-9fa3-19ea0e02b986">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMy02LTEtMS0w_30b8fd02-03b3-4a66-9913-e54e30629d70">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMy04LTEtMS0w_4609fcde-1fac-44aa-8eed-deb5c6d5e201">101.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd87398154424f32abe288424051e254_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNC0yLTEtMS0w_4f5bb37d-871f-4fa7-8f99-ac1aed8c2983">64.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd87398154424f32abe288424051e254_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNC00LTEtMS0w_6064247d-9551-4b34-845d-c0ebbdfa122c">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd87398154424f32abe288424051e254_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNC02LTEtMS0w_bffc957c-676c-4207-b5c5-693f88bc8655">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd87398154424f32abe288424051e254_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNC04LTEtMS0w_53c28d9f-5665-4e08-9c94-e181931bc746">65.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ebccad4b04e45f2973de4acc552e081_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNS0yLTEtMS0w_bfbec6e2-ed18-4217-972b-6bb702d9d452">272.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ebccad4b04e45f2973de4acc552e081_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNS00LTEtMS0w_0e41dfd5-0e6a-4914-87bd-e28dfbc5cd83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ebccad4b04e45f2973de4acc552e081_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNS02LTEtMS0w_1e718b9b-7d74-42bc-bf38-1e3c33b4ce55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ebccad4b04e45f2973de4acc552e081_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNS04LTEtMS0w_bd292402-7a2f-4a03-adbe-b74d84f9353d">272.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd175f5bfcff4131b4291c7e886d11d0_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNi0yLTEtMS0w_05524db7-3856-406c-a5b6-f5f1c43c8201">231.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd175f5bfcff4131b4291c7e886d11d0_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNi00LTEtMS0w_24099615-a7a2-461a-aa62-79f973e66d78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd175f5bfcff4131b4291c7e886d11d0_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNi02LTEtMS0w_00bb4265-79a7-4e4d-a2e6-70f12b54b10d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd175f5bfcff4131b4291c7e886d11d0_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNi04LTEtMS0w_19cebd2b-b21c-4078-bd6f-3b25ae534e8e">231.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3171b6f1e42044f6ad1521433ca23a16_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy0yLTEtMS0zNzkzNw_7c75b5be-94bf-49f9-8f2b-7df5a73775a1">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3171b6f1e42044f6ad1521433ca23a16_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy00LTEtMS0zNzkzNw_283c572c-d0ac-44a7-82cd-54dee95be1d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3171b6f1e42044f6ad1521433ca23a16_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy02LTEtMS0zNzkzNw_565f209b-a1f8-4b72-94d2-d2db241e87c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3171b6f1e42044f6ad1521433ca23a16_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy04LTEtMS0zNzkzNw_ead020d5-644b-4c3d-9fc1-b0c40f0f1531">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy0yLTEtMS0w_ddd8cd65-94b8-4e62-8096-3d4db304d35a">6,600.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy00LTEtMS0w_27a946ab-c01d-4f2b-a7ba-0b7c2c90f43c">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy02LTEtMS0w_29e2c3f1-3261-48e6-82c9-032b413affec">7.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy04LTEtMS0w_da2cc468-2c4a-4f2c-b14d-f59b974e0441">6,614.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTAtMi0xLTEtMA_8bb45931-8d58-425a-92de-72631d48886b">3,053.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTAtNC0xLTEtMA_b94fd1dc-8e51-4685-b82b-d703a891c19a">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTAtNi0xLTEtMA_064ce3e3-bf04-4405-83b4-0b3cefb38824">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTAtOC0xLTEtMA_fa6f3244-febe-4271-889e-37c5f06ad277">3,090.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18110cf9fe854c0eac1362e59d0b3203_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTEtMi0xLTEtMA_708a6c64-e096-4e4e-8002-d62ad164372c">127.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18110cf9fe854c0eac1362e59d0b3203_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTEtNC0xLTEtMA_54388907-00ff-493a-bf49-5c067dcd348d">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18110cf9fe854c0eac1362e59d0b3203_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTEtNi0xLTEtMA_fbbc2fe7-e088-4640-8211-833aa97a7cea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18110cf9fe854c0eac1362e59d0b3203_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTEtOC0xLTEtMA_fbe09896-20c7-46ed-9870-b808e0270a3d">128.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f73b339b3634a3ab3b8e05805434ee9_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTItMi0xLTEtMA_fddebe87-2948-43e9-bdfd-40158d65bc85">65.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f73b339b3634a3ab3b8e05805434ee9_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTItNC0xLTEtMA_bc8ce8ab-d125-4d37-8ce6-96bd3022894c">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f73b339b3634a3ab3b8e05805434ee9_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTItNi0xLTEtMA_84dc1b46-3f96-4c76-8c38-09ac78e89e9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f73b339b3634a3ab3b8e05805434ee9_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTItOC0xLTEtMA_6eb1ee6c-d75c-4aeb-9232-9859876709bd">66.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60fa6e193603436099beee74e654012a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTMtMi0xLTEtMA_c81a9288-2e1b-4e84-a29a-006abfcbee9d">276.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60fa6e193603436099beee74e654012a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTMtNC0xLTEtMA_482ff03c-67e2-4bc7-8888-8c13e013a774">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60fa6e193603436099beee74e654012a_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTMtNi0xLTEtMA_91e4a949-dbbe-49f0-824f-f32bc038d6d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60fa6e193603436099beee74e654012a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTMtOC0xLTEtMA_d45451e9-0ce1-4009-915d-052c86dac716">276.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7188015c6d354b4aa4b026149b2f2dad_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTQtMi0xLTEtMA_cefa0f47-378a-4837-ae5b-4775218cdc2b">127.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7188015c6d354b4aa4b026149b2f2dad_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTQtNC0xLTEtMA_65f13e4b-2145-49de-b2e3-0607c30a23d8">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7188015c6d354b4aa4b026149b2f2dad_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTQtNi0xLTEtMA_b6224197-5106-43eb-81e2-f702d4d9d5ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7188015c6d354b4aa4b026149b2f2dad_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTQtOC0xLTEtMA_8a04dc56-21b1-4493-9a51-24a041c6afb0">127.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTUtMi0xLTEtMA_df4dc8d1-72a6-43ec-a98c-79f6f67684f5">3,649.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTUtNC0xLTEtMA_415f2c24-e012-4905-b6b9-d3fba657d1ef">40.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTUtNi0xLTEtMA_1c1a2601-7093-4144-bf24-17b935d9ee5f">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTUtOC0xLTEtMA_f9c933d2-e2cf-4b54-8cdb-d95fa12e78c3">3,689.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its investments in available-for-sale debt securities based on their contractual maturity dates. The available-for-sale debt securities listed as of September&#160;30, 2021 mature at various dates through September 2026. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfMTQyNw_5b4cfee8-1a0e-43de-96db-28bb8720a375" continuedAt="i71030682965a4ded801dcf0672758100" escape="true">The fair values of available-for-sale debt securities by contractual maturity consist of the following:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><ix:continuation id="i71030682965a4ded801dcf0672758100"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.473%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOmUxNTYzMjM1ZGM2ODQ5ZGY4YWRhMWE1YzExNTlmMzRhL3RhYmxlcmFuZ2U6ZTE1NjMyMzVkYzY4NDlkZjhhZGExYTVjMTE1OWYzNGFfMi0yLTEtMS0w_61e85cf7-e633-425a-be99-52f63fcad3a9">2,355.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOmUxNTYzMjM1ZGM2ODQ5ZGY4YWRhMWE1YzExNTlmMzRhL3RhYmxlcmFuZ2U6ZTE1NjMyMzVkYzY4NDlkZjhhZGExYTVjMTE1OWYzNGFfMi00LTEtMS0w_93852da1-c128-4931-92f9-dfd405ac9914">1,393.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOmUxNTYzMjM1ZGM2ODQ5ZGY4YWRhMWE1YzExNTlmMzRhL3RhYmxlcmFuZ2U6ZTE1NjMyMzVkYzY4NDlkZjhhZGExYTVjMTE1OWYzNGFfMy0yLTEtMS0w_41989b29-55b5-4208-8d7e-4beda76490e2">4,259.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOmUxNTYzMjM1ZGM2ODQ5ZGY4YWRhMWE1YzExNTlmMzRhL3RhYmxlcmFuZ2U6ZTE1NjMyMzVkYzY4NDlkZjhhZGExYTVjMTE1OWYzNGFfMy00LTEtMS0w_22f4f9be-f177-4268-a257-8314c7afb8f9">2,295.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOmUxNTYzMjM1ZGM2ODQ5ZGY4YWRhMWE1YzExNTlmMzRhL3RhYmxlcmFuZ2U6ZTE1NjMyMzVkYzY4NDlkZjhhZGExYTVjMTE1OWYzNGFfNC0yLTEtMS0w_4983c557-1d13-4b69-b02d-98707c612b05">6,614.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOmUxNTYzMjM1ZGM2ODQ5ZGY4YWRhMWE1YzExNTlmMzRhL3RhYmxlcmFuZ2U6ZTE1NjMyMzVkYzY4NDlkZjhhZGExYTVjMTE1OWYzNGFfNC00LTEtMS0w_a3c364e4-b186-426c-84ed-2b265520d558">3,689.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfMTQxNg_63f5ea12-9f9e-43c0-a7ae-93164f8d9172" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the fair value of the Company's available-for-sale debt securities&#160;that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMi0xLTEtMS0w_f67a70fc-bbd2-421f-bb9d-a03a788e799e">2,905.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMi0zLTEtMS0w_0457140b-6914-48aa-9988-c6ad98d6dae3">6.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMi01LTEtMS0w_f013c802-1085-4e5c-9d5b-0eea53a609a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMi03LTEtMS0w_93a601c0-5469-4092-8062-425df7e06fca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMi05LTEtMS0w_32d0d53c-c748-4af9-9db8-aeb929c04f37">2,905.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMi0xMS0xLTEtMA_75d911ac-75f5-453f-a0ba-7626e7bcbec4">6.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMy0xLTEtMS0w_0eae5ca2-2bb1-4a9c-8808-8988fa154826">27.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMy0zLTEtMS0w_8fade018-75a9-4123-8264-9768ec609d5b">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMy01LTEtMS0w_f5241ad4-5d87-42b7-93e6-a05368c9a654">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMy03LTEtMS0w_6b9870f5-8a4c-4cc1-a630-510029c513b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMy05LTEtMS0w_3ba09187-6090-424d-bf3c-2711b81c28f3">27.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMy0xMS0xLTEtMA_cc47d59f-6361-476e-a5f9-7d8a819a2a5c">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfNS0xLTEtMS0w_3c37786a-4598-4e5a-ae52-b7472822df76">2,932.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfNS0zLTEtMS0w_7c090539-d631-4873-9c71-d599e7aed55c">7.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfNS01LTEtMS0w_fcf4fe30-eeae-47ba-8d2b-5988d0c22aa3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfNS03LTEtMS0w_1d3d0d82-02c4-4f44-a85e-9748a94cc459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfNS05LTEtMS0w_44d4ee71-6dc1-409c-a7ae-b620666e88a3">2,932.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfNS0xMS0xLTEtMA_f723679d-636f-4e8f-a59f-7ef0f192f319">7.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfOC0xLTEtMS0w_8f2cf720-a98b-462b-889f-6c491f4a8cd0">364.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfOC0zLTEtMS0w_604a5bc3-d762-4702-95c4-c46f2a9c46d0">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfOC01LTEtMS0w_93112726-e60f-4600-8088-86cebcd9ad24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfOC03LTEtMS0w_5ea4b1e3-eb96-4796-872e-6c4ec19a2d6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfOC05LTEtMS0w_487cc68d-fe1b-4cfc-a644-d8ecce741c06">364.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfOC0xMS0xLTEtMA_30cd14d4-d6e6-4369-bcad-27ccb3c067d6">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2021, realized gains and losses on sales of marketable securities were <ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfNDM5ODA0NjUxNjAzNQ_3e1a05a8-60d1-4ab1-a396-c560b7151349"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfNDM5ODA0NjUxNjAzNQ_bef04b9f-32d1-48d6-9992-75c587058ee9">no</ix:nonFraction></ix:nonFraction>t material. For the three months ended September&#160;30, 2020, realized gains and losses on sales of marketable securities were <ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfNDM5ODA0NjUxNjA0Mw_4504f061-6a81-4d13-97f0-76bea0b8abfd">no</ix:nonFraction>t material. Realized gains were $<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="regn:MarketableSecuritiesRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfMTA0NDUzNjA0Njg0ODA_9b161100-215b-4a92-8396-67d8b1f427bd">28.5</ix:nonFraction> million and realized losses were <ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="regn:MarketableSecuritiesRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfMTA0NDUzNjA0Njg1MTA_0064bdd8-7d1c-4c2c-98fd-efced827e140">no</ix:nonFraction>t material for the nine months ended September&#160;30, 2020.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibddeb2a9914343c3afc9cb09296eab43">With respect to marketable securities, for the three and nine months ended September&#160;30, 2021 and 2020, amounts reclassified from Accumulated other comprehensive income into Other (expense) income, net were related to realized gains and losses on sales of available-for-sale debt securities.</ix:continuation></span></div><div id="iae35796f039b495ba4b10877e85a1c6f_46"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfMTQ5Mg_73bbdb0c-acc6-4fd2-9f44-fc315208d0dd" continuedAt="i8870b4dd8f504fdf8f1ad6aeb3ae4156" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i8870b4dd8f504fdf8f1ad6aeb3ae4156"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfMTQ5Mw_34329de7-982e-4663-ac5e-b5c92ff56478" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Significant other unobservable inputs</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:48.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b306c67e2eb415eae154eec63a64166_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMy0xLTEtMS0w_c7c2e6a3-7c30-4233-a7de-bbc6a109dc68">5,924.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i709e307512f84f2d89f62a447afdbb84_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMy0zLTEtMS0w_750343f0-62e5-44cf-8973-7fde22df8bc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15ed14fd37044feb3727eba888a012a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMy01LTEtMS0w_e1b9985f-e933-41cf-a60d-9144748e2358">5,924.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fedc6825bfd4a59a2bd6c1543230955_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNC0xLTEtMS0w_dcaf7738-44eb-4fa7-b936-1c387f0888eb">101.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169c45bce7e14e0ebf7c4d8391c33a67_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNC0zLTEtMS0w_930c114f-39f6-4836-a28b-e6b634985bf8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92f4b800c8ac4853bc03e53e4b78405e_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNC01LTEtMS0w_fd0e0ab0-216e-47b4-95d4-9e24f3ea751f">101.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51ee79229d4e4ebfb388e4a3ad90b0a5_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNS0xLTEtMS0w_3bd58e8d-f779-458a-a2f2-342e8784b856">65.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5f7030e51844bd39ff0f0a3b3ef5fb4_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNS0zLTEtMS0w_293b8709-c6e7-46c7-88e7-60f620ff50b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63130650b22f42fea4fa33623b9ba1bd_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNS01LTEtMS0w_2ca67344-037b-4321-9da9-d81ad307f10d">65.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e4687b375546d1af527e2a3df23ab3_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNi0xLTEtMS0w_66256dac-bf9d-4145-ab1d-2e646d29bc00">272.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i497ca48ecca04ba48c5d7ada2d2bbdc4_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNi0zLTEtMS0w_b0f23959-38da-4365-a7e5-dbc282e86a6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a17e861d840c98b3031789019aaea_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNi01LTEtMS0w_ce608f32-53eb-4b04-8b47-d34233433225">272.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72abcc35bfe04c718a639cb1f6b996a4_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNy0xLTEtMS0w_612b27e0-30bd-4f90-a9a9-40a16a402267">231.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f153fe081624b709016b5dcb2453c32_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNy0zLTEtMS0w_111a6f9a-b740-49f8-9d45-0c8567a01dd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9382f8343a0540b4a048b778c440d26b_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNy01LTEtMS0w_8758324a-7d16-414e-9616-ab6be0f014c0">231.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c0224b00f9c4667827991e766d2f703_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOC0xLTEtMS0zODAzMw_9bc5e4b3-d9a8-4612-866d-68d4ef6566a2">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879b9c7c242c4ed5aad14987370b0a55_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOC0zLTEtMS0zODAzMw_b837d9a2-32e2-4df8-8404-01cbd0227cfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26e6516b07ee48baac59da55f9ab9360_I20210930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOC01LTEtMS0zODAzMw_15ac050c-57ad-46cb-8a31-bcddd27059b9">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8496a4fdf8714163a39d2735849938ce_I20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOC0xLTEtMS0w_2293f4f4-988a-4e18-ae95-adcb33412856">35.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf2a5edcb4f4d9d9c943737ce0824f6_I20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOC0zLTEtMS0w_5f67400e-c2b7-4ac1-a548-02c7d3c660cc">35.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc9503772ed4063887ac7fa4b9d589f_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOC01LTEtMS0w_18e1b42f-f73e-45a2-b7aa-4de5602282d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0719e563f1ad45fe8cae8d7518999c47_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOS0xLTEtMS0w_fdf45471-d499-4bcd-8177-335fa3f6fbb5">1,335.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c4b945e334d45e8ae01e61b5260ebdc_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOS0zLTEtMS0w_8058cbb2-7504-4b1b-b3a1-45d514a3abfb">1,335.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bfd8f8a61bc4f3d99eaaf7d514b4d90_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOS01LTEtMS0w_9950e3eb-a0c7-4416-b8d8-3e215039fed2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i928f7d720b6248cd934975804e4ee21a_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTAtMS0xLTEtMA_43b4f7b3-f688-486a-ba91-5ae345333120">7,986.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1011bfe7b3f241bdae36c2c04bdef602_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTAtMy0xLTEtMA_2cda7737-59f0-4460-a127-c21b8077e991">1,371.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ec84991e2545a8b15f060aad624a82_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTAtNS0xLTEtMA_7497cb70-11a4-4722-9ca0-d7a568a91410">6,614.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i073bb6c4ef1d4dfd94ffa5d20de5a81b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTQtMS0xLTEtMA_ab471f84-12b3-46ea-b7ef-205a111e561f">3,090.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeb185943494d1d8c34874a74b6f176_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTQtMy0xLTEtMA_0d6949dc-aa49-4f1a-8967-7d13cd36c639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i718180e7a06c47d79ec5283f5004e756_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTQtNS0xLTEtMA_0c6358e1-3ef2-494f-afd4-637df9d31665">3,090.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd8180afebff478b9f8bc963fa0e19d7_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTUtMS0xLTEtMA_07e538f1-d6b2-44b6-88b1-bfaf65d50283">128.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee6b453205d44a0aa0e06f339c4344f5_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTUtMy0xLTEtMA_c4299816-dafa-478c-bafe-047c8e085e9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b0fb7a5bf6b4426b9c1f868210548d6_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTUtNS0xLTEtMA_b9fed11d-6133-4e19-9699-c4a692905168">128.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf5e87dcd3a64a1da4267f0373377c04_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTYtMS0xLTEtMA_8d749662-71e0-48e5-a7de-94dc9b2e4d60">66.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia20d85573fb143dd87f197ce54b7e399_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTYtMy0xLTEtMA_cbeb6413-fa84-4e4c-ae51-456be4b40469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a0befca2744f1e8f5c062d988ff10f_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTYtNS0xLTEtMA_fc7468d2-2442-4a43-b806-c600dc4560d0">66.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9263ef91fcc44315917f2dfc964e2ce2_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTctMS0xLTEtMA_81a30fc8-ec2d-458d-a8b8-9a4de87a9c7a">276.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e7690d25b64054b80e2f57e6dc1292_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTctMy0xLTEtMA_641e2023-99a0-4e1d-9b71-d3e69dfd3e0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia21a946152114cde8edfdd4190cf231b_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTctNS0xLTEtMA_307fde85-99d0-498e-aa9a-39fbf4e7d338">276.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i371d5635a65d48f0b357645d217ce740_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTgtMS0xLTEtMA_e7df2085-bc8d-4e59-b788-201bf7102c54">127.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6463b9ea289444d4a8a0c350da774f0e_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTgtMy0xLTEtMA_59d40a91-51d9-4a4e-8f88-ff81fffd3cc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7beed26d4e7440baf4167a9e144bd8a_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTgtNS0xLTEtMA_241c530f-70e7-408a-9cff-95abb8cabe01">127.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9ccf4d0492c49158f8907609cacb785_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTktMS0xLTEtMA_270f56dd-eb57-4661-9bfd-383a76d09a20">48.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6361d9ec906c4de9bb2da4f5e1bb347a_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTktMy0xLTEtMA_4a095bb5-0c62-4617-95af-22ea58619e47">48.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i880c4f56f4bf49eaa68316dd64419c31_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTktNS0xLTEtMA_8946b547-d9de-4852-9880-87a4aa4dc0c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04298c88b3394119bf9d1c4903dba435_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMjAtMS0xLTEtMA_5af9a5da-fa59-4e26-b105-d65850016485">791.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c66fdf4db544d99a6ab7cc74a9bba46_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMjAtMy0xLTEtMA_0bbfa8b1-2628-46d5-95a9-51920f499cd1">791.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b9114a5c0054c229df4345b7d59365a_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMjAtNS0xLTEtMA_740e8e56-344e-4020-90f7-4efcb8e518dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd67af6e4c44ae197f75086c30ed696_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMjEtMS0xLTEtMA_d9975d21-4964-4219-8cc3-0e4afad1bf4e">4,528.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2aae955be14f268249627181155c1c_I20201231" decimals="-5" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMjEtMy0xLTEtMA_8635ee4a-cb0b-4a4c-b550-ef2ce2aee57c">839.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ae2cc961e14f028a26aaf88a03941b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMjEtNS0xLTEtMA_67f6ed89-fcc1-4c62-b132-a056130dcbf5">3,689.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held certain restricted equity securities as of September&#160;30, 2021 which are subject to transfer restrictions that expire at various dates through 2024. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021, we recorded $<ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfODY0_e684aaab-52db-45f5-9b7d-038d889f502b">29.1</ix:nonFraction> million of net unrealized losses and $<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfODcx_1e6b4f0c-7cb4-4084-9ce2-40f28cea0846">523.8</ix:nonFraction> million of net unrealized gains, respectively, on equity securities in Other (expense) income, net. During the three and nine months ended September&#160;30, 2020, we recorded $<ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfOTk1_6bc6ddbf-a2a0-476a-99f3-f2cda98dd53b">37.5</ix:nonFraction>&#160;million of net unrealized losses and $<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfMTAwMg_4df463d7-7c89-4de7-9d79-45dad11c9b14">133.8</ix:nonFraction>&#160;million of net unrealized gains, respectively, on equity securities in Other (expense) income, net. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the investments summarized in the table above,&#160;as of September&#160;30, 2021 and December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfMTE2OA_98384d76-1237-4b45-b183-1c8b1d4fa473">40.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfMTE3NQ_b509c9de-f015-4eda-87af-345ec56094d6">59.2</ix:nonFraction>&#160;million, respectively, in equity investments that do not have a readily determinable fair value. These investments are recorded within Other noncurrent assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term debt (see Note 8), which was determined based on Level 2 inputs, was estimated to be $<ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfMTQ0Nw_37b515b1-bd84-4148-9b9d-ca5bbc5650e1">1.891</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfMTQ1NA_706c7d41-cf58-4d75-89d7-5ca933040d20">1.958</ix:nonFraction> billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_49"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RleHRyZWdpb246NGM3NWI3ZThlMDU3NDM3MGIyYmM3YWUzNGI2YzdlMGVfNDM2_9ce11c02-6109-4160-b85f-d56580db6b3e" continuedAt="i5005729ce7304226a8cd86beedf158b4" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i5005729ce7304226a8cd86beedf158b4"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RleHRyZWdpb246NGM3NWI3ZThlMDU3NDM3MGIyYmM3YWUzNGI2YzdlMGVfNDQw_7405e377-8ecb-43bd-b307-e18fb65ad955" escape="true"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"><tr><td style="width:1.0%"></td><td style="width:47.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfMi0xLTEtMS0w_41f7f000-190e-40ac-9609-6612199d25df">646.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfMi0zLTEtMS0w_ca09a1b4-51f6-42d6-8af4-50670727b75f">459.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfMy0xLTEtMS0w_808ce70c-abdc-4469-8770-eee5b89b7992">843.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfMy0zLTEtMS0w_6c917620-83f1-4097-8b0b-b519e3f5ff1c">904.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfNC0xLTEtMS0w_8093df63-d1ea-4d5b-b3c3-94fd713a127f">60.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfNC0zLTEtMS0w_ad3e08d5-8bd4-4da8-bd86-25f7b45134e8">121.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:OtherInventoryNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfNS0xLTEtMS0w_b341f6ef-1ad6-4292-a61d-187c36684f23">503.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" name="us-gaap:OtherInventoryNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfNS0zLTEtMS0w_57399d98-19df-4c86-8994-32f5998bc15c">430.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfNi0xLTEtMS0w_58609aa5-a7a7-4764-983b-e1a6a7221726">2,053.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0582c9be764ded815021b5841e304e_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfNi0zLTEtMS0w_ab9d9f3a-cd9e-41f8-b310-74386f42da06">1,916.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred costs represent the costs of product manufactured and shipped to the Company's collaborators for which recognition of revenue has been deferred. For the three and nine months ended September&#160;30, 2021, Cost of goods sold included inventory write-offs and reserves totaling $<ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RleHRyZWdpb246NGM3NWI3ZThlMDU3NDM3MGIyYmM3YWUzNGI2YzdlMGVfMzI0_2db9baca-8d6e-40d9-b107-fa31caea91b8">38.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RleHRyZWdpb246NGM3NWI3ZThlMDU3NDM3MGIyYmM3YWUzNGI2YzdlMGVfMzMx_47c78166-d787-4f01-b21a-4c89368fbd37">188.0</ix:nonFraction> million, respectively. For the three and nine months ended September 30, 2020, Cost of goods sold included inventory write-offs and reserves totaling $<ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RleHRyZWdpb246NGM3NWI3ZThlMDU3NDM3MGIyYmM3YWUzNGI2YzdlMGVfMTY0OTI2NzQ0MjM4NA_7fef15c3-1103-408e-9ca1-ba68e4dfc867">11.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RleHRyZWdpb246NGM3NWI3ZThlMDU3NDM3MGIyYmM3YWUzNGI2YzdlMGVfMTY0OTI2NzQ0MjM2OQ_add0fcc6-2805-4128-a898-58ca9011e829">23.6</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div id="iae35796f039b495ba4b10877e85a1c6f_52"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RleHRyZWdpb246NjEzZGUxOTZkMWM0NDI2ZWJmOTk0NDk4MDkzMTliNTlfMTM1OA_12622ccd-0a5f-411c-aed9-e439238f051d" continuedAt="i09e8c1f82c6a4ee7bcd111279ee68a83" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i09e8c1f82c6a4ee7bcd111279ee68a83"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bridge Loan Facility</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 10, in the second quarter of 2020, we purchased shares of our Common Stock from Sanofi in connection with Sanofi's secondary offering of our Common Stock held by Sanofi. This purchase was partially funded with proceeds from loans under a $<ix:nonFraction unitRef="usd" contextRef="ic2b125c56e464e7d83e39ceed25911e1_I20200531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RleHRyZWdpb246NjEzZGUxOTZkMWM0NDI2ZWJmOTk0NDk4MDkzMTliNTlfMzEw_87a3d041-88bf-4d62-a587-caeb33e36049">1.5</ix:nonFraction>&#160;billion senior unsecured bridge loan facility (the "Bridge Facility") which was entered into in May 2020. The loans under the Bridge Facility bore interest at a variable interest rate based on either the London Interbank Offered Rate or the alternate base rate, plus an applicable margin that varied with our debt rating and total leverage ratio. The Bridge Facility was repaid in full during the third quarter of 2020 following the closing of the issuance and sale of the Company's senior notes (as described below).</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we issued and sold $<ix:nonFraction unitRef="usd" contextRef="id293bfb3eddd4aff80d65cf0394b1943_I20200831" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RleHRyZWdpb246NjEzZGUxOTZkMWM0NDI2ZWJmOTk0NDk4MDkzMTliNTlfOTQ4_0918820b-d5d5-4cb3-a03d-a6c69355e31f">1.250</ix:nonFraction>&#160;billion aggregate principal amount of senior unsecured notes due 2030 and $<ix:nonFraction unitRef="usd" contextRef="i8f0cbd4933e54839aa58d6992050314c_I20200831" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RleHRyZWdpb246NjEzZGUxOTZkMWM0NDI2ZWJmOTk0NDk4MDkzMTliNTlfMTAxNw_7431cffc-8351-41d3-b963-e9b5c20ef323">750</ix:nonFraction> million aggregate principal amount of senior unsecured notes due 2050. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RleHRyZWdpb246NjEzZGUxOTZkMWM0NDI2ZWJmOTk0NDk4MDkzMTliNTlfMTM1OQ_05017cd9-8f31-4bc9-94b6-2d9e880006a3" continuedAt="i2d43d4f315fc41399ca4c8c42d17d060" escape="true">Long-term debt in connection with our senior unsecured notes (collectively, the "Notes"), net of underwriting discounts and offering expenses, consists of the following:</ix:nonNumeric></span></div><div style="margin-bottom:1pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center"><ix:continuation id="i2d43d4f315fc41399ca4c8c42d17d060"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"></td><td style="width:61.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.013%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if0dfa4b658804eb3a16f8cee0ca8be17_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfMi0wLTEtMS0wL3RleHRyZWdpb246N2FiMmRmMjMxY2NmNGY1NDhmZGEzMGJkYzQyZmQxOGVfNA_e7420dd0-8243-4f2e-a2cd-974943a14a60">1.750</ix:nonFraction>% Senior Notes due September 2030</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dfa4b658804eb3a16f8cee0ca8be17_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfMi0xLTEtMS0w_b099e945-8b88-4484-823e-c1f59c99038c">1,239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i534da4670c274a81ae3524fbdfe06604_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfMi0zLTEtMS0w_0bf244dd-1d65-4bdc-9ebe-de12e4aa5d75">1,238.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i650510a2eb214adc84a48e8722d60ddf_I20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfMy0wLTEtMS0wL3RleHRyZWdpb246MjNmZTc5YTA0NTdmNGU1MzljNWMzZmNlMWMyNzUzNTFfNA_43c091d4-6d3c-4598-b930-9f60b2f671b6">2.800</ix:nonFraction>% Senior Notes due September 2050</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i650510a2eb214adc84a48e8722d60ddf_I20210930" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfMy0xLTEtMS0w_edff9a4b-9dc8-4cb4-a4d3-ed4d0f2d6f6a">740.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i518fc4089b494e66895c51aae0a95ae4_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfMy0zLTEtMS0w_d66eb84e-77d3-4bba-ae48-9dde5c301a68">739.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1490f50984443fa9fc09db8661cd762_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfNC0xLTEtMS0w_b2016fbd-1d66-4df1-b325-e5d058a20b3a">1,979.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9fe51ad3f5d44d7b51f9c7d2bb1636b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfNC0zLTEtMS0w_50aecaed-691a-4aad-8d97-c51e8d06f007">1,978.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to the Notes for the three and nine months ended September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i07fe2aef96e54e809240ec9fba24d72c_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RleHRyZWdpb246NjEzZGUxOTZkMWM0NDI2ZWJmOTk0NDk4MDkzMTliNTlfMTMzNQ_0f6abe11-24a2-4b38-be73-57485d014cf8">11.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iaefeb3e5dbc2406c9e11d7dbcba3ee98_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RleHRyZWdpb246NjEzZGUxOTZkMWM0NDI2ZWJmOTk0NDk4MDkzMTliNTlfMTM0Mg_821130a2-e334-4b90-897f-579719395d3b">33.3</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div id="iae35796f039b495ba4b10877e85a1c6f_55"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81NS9mcmFnOmY1ZTliMWY5Y2EyNDQzMDg5MWRiN2ViYTE0OWZiMDdkL3RleHRyZWdpb246ZjVlOWIxZjljYTI0NDMwODkxZGI3ZWJhMTQ5ZmIwN2RfMTQxMQ_caee9877-466e-47a5-92ec-e26ce668735f" continuedAt="ib5cf963fd85142e49e51e8c467899764" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib5cf963fd85142e49e51e8c467899764">The Company is subject to U.S. federal, state, and foreign income taxes. The Company's effective tax rate was <ix:nonFraction unitRef="number" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81NS9mcmFnOmY1ZTliMWY5Y2EyNDQzMDg5MWRiN2ViYTE0OWZiMDdkL3RleHRyZWdpb246ZjVlOWIxZjljYTI0NDMwODkxZGI3ZWJhMTQ5ZmIwN2RfMTMx_ae8be8b9-c9da-4a8e-bd2b-0954791e6a81">10.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81NS9mcmFnOmY1ZTliMWY5Y2EyNDQzMDg5MWRiN2ViYTE0OWZiMDdkL3RleHRyZWdpb246ZjVlOWIxZjljYTI0NDMwODkxZGI3ZWJhMTQ5ZmIwN2RfMTM4_026bd87c-72a1-46b3-85c3-d9c4aa75e409">15.6</ix:nonFraction>% for the three months ended September&#160;30, 2021 and 2020, respectively, and <ix:nonFraction unitRef="number" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81NS9mcmFnOmY1ZTliMWY5Y2EyNDQzMDg5MWRiN2ViYTE0OWZiMDdkL3RleHRyZWdpb246ZjVlOWIxZjljYTI0NDMwODkxZGI3ZWJhMTQ5ZmIwN2RfMTk3_fcdf2a42-6545-46ac-b2ab-0d861ee4a0e7">14.3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81NS9mcmFnOmY1ZTliMWY5Y2EyNDQzMDg5MWRiN2ViYTE0OWZiMDdkL3RleHRyZWdpb246ZjVlOWIxZjljYTI0NDMwODkxZGI3ZWJhMTQ5ZmIwN2RfMjA0_3c3845fb-074e-4eae-b3f5-8963276e95b1">8.6</ix:nonFraction>% for the nine months ended September&#160;30, 2021 and 2020, respectively. The Company's effective tax rate for the three and nine months ended September&#160;30, 2021 was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation, income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate, the foreign-derived intangible income deduction, and federal tax credits for research activities. In addition, the effective tax rate for the nine months ended September 30, 2021 was positively impacted by the reversal of liabilities related to uncertain tax positions. During the nine months ended September&#160;30, 2021, we reduced the amount of liabilities for uncertain tax positions related to the Company&#8217;s federal income tax returns for 2015 and 2016, as these audits are effectively settled. The Company's federal income tax returns for 2017 and 2018 are currently under audit by the Internal Revenue Service ("IRS"). The Company's effective tax rate for the three and nine months ended September&#160;30, 2020 was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation, and, to a lesser extent, income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate and federal tax credits for research activities.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_58"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMzY1OQ_28679b50-0f34-40e2-ba2b-52091fb56d94" continuedAt="ia08c601496da4a2ca4229ec5ebc217b3" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="ia08c601496da4a2ca4229ec5ebc217b3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, our board of directors authorized a share repurchase program to repurchase up to&#160;$<ix:nonFraction unitRef="usd" contextRef="i4e98493124404aad8a8c0e1cb049d5ec_I20191130" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMTU1_b757faec-38d7-4538-9a00-ed0b56713d03">1.0</ix:nonFraction> billion&#160;of our Common Stock. The share repurchase program permitted the Company to effect repurchases through a variety of methods, including open-market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in compliance with Rule 10b-18 of the Exchange Act. As of December&#160;31, 2020, the Company had repurchased the entire $<ix:nonFraction unitRef="usd" contextRef="i8ca3ec3e33eb4ab29ddc909bd33e67d0_D20201231-20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfNjIw_2f2d104a-df4f-4841-851d-cd1ee5f129af">1.0</ix:nonFraction> billion it was authorized to repurchase under the program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, our board of directors authorized an additional share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="ieef2a875d0184972869268bd64fb3df7_I20210131" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfNzc2_45cc7fe6-39f9-4a4a-9e34-219996c5be9a">1.5</ix:nonFraction>&#160;billion of our Common Stock. The share repurchase program was approved under terms substantially similar to the November 2019 share repurchase program described above. Repurchases may be made from time to time at management&#8217;s discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. The program has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases in the future. As of September&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i69ddf6100ec6432d8b2d4ac0d6998971_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMTY0OTI2NzQ0NTQ5MA_004148e8-b63c-4fbd-90a0-93501a55b6f4">697.3</ix:nonFraction>&#160;million remained available for share repurchases under the program. </span></div><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMzY1NQ_ab4bee26-d94c-4c1d-aec1-7e97bb12bd35" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the shares of our Common Stock we repurchased under the programs during the three and nine months ended September&#160;30, 2021 and 2020 and the cost of the shares received, which were recorded as Treasury Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"><tr><td style="width:1.0%"></td><td style="width:44.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMi0xLTEtMS0w_e0e1341b-9ff1-4098-9664-1767a603fc04">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMi0zLTEtMS0w_9bf49aa8-69f8-441e-828f-be6c32ba4ae4">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMi01LTEtMS0w_22d9ba1e-62a1-4f2f-b25c-f56907d5f64a">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMi03LTEtMS0w_944c0186-5e63-48b0-9319-75ba8edfb9fe">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares received </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMy0xLTEtMS0w_f66f1063-0751-4b1b-ad41-218177a7f15a">190.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMy0zLTEtMS0w_15a42d99-b761-43d9-9bf7-f551a3941f52">100.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMy01LTEtMS0w_6ff7ecec-733b-412b-895a-bf0022701a51">802.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMy03LTEtMS0w_b629f993-2d57-48a8-a134-41c8c1062309">373.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi Funding of Certain Development Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company and Sanofi entered into a letter agreement (the "Letter Agreement") in connection with, among other matters, the allocation of additional funds to certain activities relating to dupilumab and itepekimab (collectively, the "Dupilumab/Itepekimab Eligible Investments"). Pursuant to the Letter Agreement, we agreed to allow Sanofi to satisfy its funding obligations with respect to Dupilumab/Itepekimab Eligible Investments, as well as Libtayo development costs, for quarterly periods ending on September 30, 2020 by selling our Common Stock owned by Sanofi. During the nine months ended September&#160;30, 2020, Sanofi elected to sell, and we elected to purchase (by issuing a credit towards the amount owed by Sanofi), <ix:nonFraction unitRef="shares" contextRef="i31a864c8cc3a49e086a3fde76b1e1695_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMjQwMA_be3e16d9-30ce-4bbe-b0e4-aeac3d48b383">77,677</ix:nonFraction> shares of our Common Stock to satisfy Sanofi's funding obligation related to Libtayo development costs, and we recorded the cost of the shares received, or $<ix:nonFraction unitRef="usd" contextRef="i31a864c8cc3a49e086a3fde76b1e1695_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMjU4MA_f4323459-a99f-45ab-83e2-ab92cf5f2986">41.7</ix:nonFraction>&#160;million, as Treasury Stock. During the nine months ended September&#160;30, 2020, Sanofi elected to sell, and we elected to purchase (in cash), <ix:nonFraction unitRef="shares" contextRef="i5bfec289c7074f5282b731594a9587a9_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMjcyOA_ef58e0d2-d031-45f6-a26c-a5e72fdf2a7a">171,471</ix:nonFraction> shares of our Common Stock in connection with Sanofi's funding obligation for Dupilumab/Itepekimab Eligible Investments, and we recorded the cost of the shares received, or $<ix:nonFraction unitRef="usd" contextRef="i5bfec289c7074f5282b731594a9587a9_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMjkyMg_99833c6e-901f-40d5-964a-ac0588d81731">93.3</ix:nonFraction>&#160;million, as Treasury Stock. During the three months ended September&#160;30, 2020, there were <ix:nonFraction unitRef="shares" contextRef="ied92924a0c784856bbf8ed8a35ac7f57_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMTY0OTI2NzQ0NTQ5OA_c36718ac-72ce-4fec-9eea-7e904675dfb1">no</ix:nonFraction> shares of our Common Stock purchased from Sanofi to satisfy Sanofi's funding obligations related to Libtayo development costs and/or Dupilumab/Itepekimab Eligible Investments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Stock Purchased from Sanofi</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, a secondary offering of <ix:nonFraction unitRef="shares" contextRef="iec719ff1e7724d85bfffb28a5eac401e_D20200501-20200531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMzAzNQ_a6304a51-bb8e-48cd-9329-b5fbc13de2b0">13,014,646</ix:nonFraction> shares of our Common Stock (the "Secondary Offering") held by Sanofi was completed. In connection with the Secondary Offering, we also purchased <ix:nonFraction unitRef="shares" contextRef="iec719ff1e7724d85bfffb28a5eac401e_D20200501-20200531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMzE4Mw_c5d1e3c0-00f6-403b-948b-f0c1784d6338">9,806,805</ix:nonFraction> shares directly from Sanofi for an aggregate purchase amount of $<ix:nonFraction unitRef="usd" contextRef="iec719ff1e7724d85bfffb28a5eac401e_D20200501-20200531" decimals="-8" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMzI1MA_1165631f-89b1-426e-9ede-329e5c63c693">5.0</ix:nonFraction>&#160;billion (the "Stock Purchase"). As a result of the Secondary Offering and the Stock Purchase, Sanofi disposed of all of its shares of our Common Stock, other than <ix:nonFraction unitRef="shares" contextRef="i0d93ce0ffcda4c05912416ab54808098_I20200531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMzQwOA_0f597936-2a4d-4991-a386-ef0f53d7e366">400,000</ix:nonFraction> shares that it retained as of the closing of the Secondary Offering and the Stock Purchase (a portion of which Sanofi used for the funding of certain Libtayo development costs and/or Dupilumab/Itepekimab Eligible Investments as described above).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_61"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RleHRyZWdpb246MmZlMGI3ZGNiNGE1NGRjN2FiY2EzZWIzMWQ2MWQ1MDBfODA3_36476b45-32d7-4ed5-bfbd-37f38688e31d" continuedAt="ifa1164eccc434d069b8afe88dbc940b7" escape="true">Statement of Cash Flows</ix:nonNumeric></span></div><ix:continuation id="ifa1164eccc434d069b8afe88dbc940b7"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RleHRyZWdpb246MmZlMGI3ZGNiNGE1NGRjN2FiY2EzZWIzMWQ2MWQ1MDBfNzk5_ff6b9ce5-5f68-492c-a4e7-551e138df304" escape="true"><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RleHRyZWdpb246MmZlMGI3ZGNiNGE1NGRjN2FiY2EzZWIzMWQ2MWQ1MDBfODAw_522a1cab-7475-476a-b513-2f56c4c7b0b2" escape="true"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"></td><td style="width:58.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.172%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjI1ZTgzZDA4OTEzMTRmYTg4NDY2NjNmOTY0OWYzMTIxL3RhYmxlcmFuZ2U6MjVlODNkMDg5MTMxNGZhODg0NjY2M2Y5NjQ5ZjMxMjFfMi0yLTEtMS0w_ecd08079-ee47-4a13-8a2c-3d761c3b4069">3,432.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b0b1c1c2a94afb988a7c59c235eee7_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjI1ZTgzZDA4OTEzMTRmYTg4NDY2NjNmOTY0OWYzMTIxL3RhYmxlcmFuZ2U6MjVlODNkMDg5MTMxNGZhODg0NjY2M2Y5NjQ5ZjMxMjFfMi00LTEtMS0w_c58f5259-2891-4335-bf4a-798a46d646c3">1,573.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjI1ZTgzZDA4OTEzMTRmYTg4NDY2NjNmOTY0OWYzMTIxL3RhYmxlcmFuZ2U6MjVlODNkMDg5MTMxNGZhODg0NjY2M2Y5NjQ5ZjMxMjFfMy0yLTEtMS0w_3d432eb3-242b-4f1d-a1e9-175236fd51b6">12.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b0b1c1c2a94afb988a7c59c235eee7_I20200930" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjI1ZTgzZDA4OTEzMTRmYTg4NDY2NjNmOTY0OWYzMTIxL3RhYmxlcmFuZ2U6MjVlODNkMDg5MTMxNGZhODg0NjY2M2Y5NjQ5ZjMxMjFfMy00LTEtMS0w_b28fc7e3-d3cb-42c7-ac88-e2912615b7b1">13.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjI1ZTgzZDA4OTEzMTRmYTg4NDY2NjNmOTY0OWYzMTIxL3RhYmxlcmFuZ2U6MjVlODNkMDg5MTMxNGZhODg0NjY2M2Y5NjQ5ZjMxMjFfNC0yLTEtMS0w_34c6c890-aa58-4a27-ad7e-37a9fc9e2db6">3,444.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b0b1c1c2a94afb988a7c59c235eee7_I20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjI1ZTgzZDA4OTEzMTRmYTg4NDY2NjNmOTY0OWYzMTIxL3RhYmxlcmFuZ2U6MjVlODNkMDg5MTMxNGZhODg0NjY2M2Y5NjQ5ZjMxMjFfNC00LTEtMS0w_757e0697-0388-4531-a40d-0d6bc09f22fe">1,586.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of amounts held by financial institutions pursuant to contractual arrangements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental disclosure of non-cash investing and financing activities</span></div><ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RleHRyZWdpb246MmZlMGI3ZGNiNGE1NGRjN2FiY2EzZWIzMWQ2MWQ1MDBfODAx_4efea0a0-e40d-4b50-a0fd-1ba531079a60" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts were included in accounts payable, accrued expenses, and other liabilities:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:26.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjNkOWQwYWYyMTA4ODRmYTRhNGZiZTlhYzM1ZjA4YWZhL3RhYmxlcmFuZ2U6M2Q5ZDBhZjIxMDg4NGZhNGE0ZmJlOWFjMzVmMDhhZmFfMi0xLTEtMS0w_b131ca33-0235-4808-8068-74ddf40fd9f1">70.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5148f71a87a04e13ac8076f503a1425e_D20200101-20201231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjNkOWQwYWYyMTA4ODRmYTRhNGZiZTlhYzM1ZjA4YWZhL3RhYmxlcmFuZ2U6M2Q5ZDBhZjIxMDg4NGZhNGE0ZmJlOWFjMzVmMDhhZmFfMi0zLTEtMS0w_776cf5c6-f438-434a-a2f8-7aa8f4337b64">83.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjNkOWQwYWYyMTA4ODRmYTRhNGZiZTlhYzM1ZjA4YWZhL3RhYmxlcmFuZ2U6M2Q5ZDBhZjIxMDg4NGZhNGE0ZmJlOWFjMzVmMDhhZmFfMi01LTEtMS0w_ea85c977-caa2-4e8f-97f0-57aa68e8d6c5">100.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i222bcb21c9a4477ab7dc7af26e32e7ee_D20190101-20191231" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjNkOWQwYWYyMTA4ODRmYTRhNGZiZTlhYzM1ZjA4YWZhL3RhYmxlcmFuZ2U6M2Q5ZDBhZjIxMDg4NGZhNGE0ZmJlOWFjMzVmMDhhZmFfMi03LTEtMS0w_953d4293-b4d1-4276-91f4-ec7c03d11ce0">133.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iae35796f039b495ba4b10877e85a1c6f_64"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfMzUxMzI_4c027689-82fd-4689-b2d2-75b06e10532f" continuedAt="i82c5d87a29b7474f802deb9b5b6ba204" escape="true">Legal Matters</ix:nonNumeric></span></div><ix:continuation id="i82c5d87a29b7474f802deb9b5b6ba204" continuedAt="ia875f8508c7a4b30afccbcde3e274a3b"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to legal proceedings in the course of the Company's business. <ix:nonNumeric contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930" name="us-gaap:LegalCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfMzUxMjk_7d4ef2e1-ad07-448f-9fe0-e30046cc082c" escape="true">Costs associated with the Company's involvement in legal proceedings are expensed as incurred.</ix:nonNumeric> The outcome of any such proceedings, regardless of the merits, is inherently uncertain. The Company recognizes accruals for loss contingencies associated with such proceedings when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. As of September&#160;30, 2021 and December&#160;31, 2020, the Company's accruals for loss contingencies were not material. If the Company were unable to prevail in any such proceedings, its consolidated financial position, results of operations, and future cash flows may be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Praluent (alirocumab) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in greater detail below, the Company is currently a party to patent infringement actions initiated by Amgen Inc. (and/or its affiliated entities) against the Company and/or Sanofi (and/or the Company's and Sanofi's respective affiliated entities) in a number of jurisdictions relating to Praluent. See Note 3 for a description of the Company's and Sanofi's arrangement regarding the costs resulting from or associated with such actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Amgen asserted claims of U.S. Patent Nos. 8,829,165 (the "'165 Patent") and 8,859,741 (the "'741 Patent"), and sought a permanent injunction to prevent the Company and the Sanofi defendants from commercial manufacturing, using, offering to sell, or selling within the United States (as well as importing into the United States) (collectively, "Commercializing") Praluent. Amgen also sought a judgment of patent infringement of the asserted patents, monetary damages (together with interest), costs and expenses of the lawsuits, and attorneys' fees. As described in greater detail under "Second Jury Trial and Appeal" below, on February 11, 2021, the Federal Circuit (as defined below) affirmed the lower court's decision that certain of Amgen's asserted patent claims are invalid based on lack of enablement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Jury Trial and Appeal.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first jury trial in this litigation (the "First Trial") was held in the United States District Court for the District of Delaware (the "District Court") from March 8 to March 16, 2016. During the course of the First Trial, the District Court ruled as a matter of law in favor of Amgen that the asserted patent claims were not obvious, and in favor of the Company and the Sanofi defendants that there was no willful infringement of the asserted patent claims by the Company or the Sanofi defendants. On March 16, 2016, the jury returned a verdict in favor of Amgen in the First Trial, finding that the asserted claims of the '165 and '741 Patents were not invalid based on either a lack of written description or a lack of enablement. On October 5, 2017, the United States Court of Appeals for the Federal Circuit (the "Federal Circuit") reversed in part the District Court's decision and remanded for a new trial on the issues of written description and enablement. In addition, it affirmed the District Court's ruling that Amgen's patents were not obvious.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><ix:continuation id="ia875f8508c7a4b30afccbcde3e274a3b" continuedAt="i4eab7f4ea9dc4ed2b45f0b3a8c93db96"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Jury Trial and Appeal.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2019, the District Court held oral argument in the remanded proceedings on the Company and the Sanofi defendants' motion for judgment on the pleadings regarding Amgen's willful infringement claim. On January 18, 2019, the District Court entered an order (i) denying the Company and the Sanofi defendants' motion for summary judgment on validity, (ii) denying Amgen's motion for partial summary judgment on estoppel, and (iii) granting the Company and the Sanofi defendants' cross-motion for summary judgment on estoppel. On February 8, 2019, the District Court granted the Company and the Sanofi defendants' motion for judgment on the pleadings, thereby dismissing Amgen's claim of willful infringement. The second jury trial in this litigation (the "Second Trial") was held before the District Court in February 2019 to determine the validity of Amgen's asserted patent claims. On February 25, 2019, the jury returned a verdict in the Second Trial generally in favor of Amgen, finding that <ix:nonFraction unitRef="claim" contextRef="i2e4f524ab89b4891b4ccfbd3555e3a26_I20190225" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfNDI0MA_0ae9c262-07fe-4b56-b7e4-102d23bd059c">two</ix:nonFraction> claims of the '165 Patent and <ix:nonFraction unitRef="claim" contextRef="i870177ce53f7404e98979e8f07c9609f_I20190225" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfNDI3Mw_646b4a82-893c-47f1-be94-129edfb0a88a">one</ix:nonFraction> claim of the '741 Patent were not invalid. The jury also found that <ix:nonFraction unitRef="claim" contextRef="i2e4f524ab89b4891b4ccfbd3555e3a26_I20190225" decimals="INF" format="ixt-sec:numwordsen" name="regn:LossContingencyClaimsInvalidNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfNDM0NA_a4f30906-51a0-423e-b4f8-cd09aa7d7d9a">two</ix:nonFraction> claims of the '165 Patent were invalid for lack of adequate written description while rejecting the lack of enablement challenges to those two claims. On August 28, 2019, the District Court ruled as a matter of law that Amgen's asserted patent claims are invalid based on lack of enablement. The District Court also conditionally denied the Company and the Sanofi defendants' motion for a new trial. On October 23, 2019, Amgen filed a notice of appeal of the District Court's decision with the Federal Circuit. An oral hearing before the Federal Circuit was held on December 9, 2020. On February 11, 2021, the Federal Circuit affirmed the District Court's decision that certain of Amgen's asserted patent claims are invalid based on lack of enablement. On April 14, 2021, Amgen filed a petition for a rehearing en banc, which was denied on June 21, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Injunctive Relief Proceedings.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2019, Amgen filed a renewed motion for a permanent injunction to prohibit the Company and the Sanofi defendants from Commercializing Praluent in the United States (a "Permanent Injunction"), and an oral hearing on this motion was held in June 2019. Previously, the Federal Circuit stayed and then vacated a Permanent Injunction granted by the District Court in connection with the First Trial. On August 28, 2019, the District Court dismissed as moot Amgen's renewed motion for a Permanent Injunction. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Europe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen has asserted European Patent No. 2,215,124 (the "'124 Patent"), which pertains to PCSK9 monoclonal antibodies, in the countries in Europe discussed below. In October 2020, the '124 Patent claims directed to compositions of matter and medical use relevant to Praluent were ruled invalid based on a lack of inventive step by the Technical Board of Appeal (the "TBA") of the European Patent Office (the "EPO"). This decision impacted each of the infringement proceedings based on the '124 Patent discussed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen filed lawsuits in Germany, the United Kingdom, and France in July 2016, July 2016, and September 2016,  respectively, against the Company and certain of Sanofi's affiliated entities for infringement of the relevant designation of the '124 Patent in each such jurisdiction; and these lawsuits were dismissed in November 2020, September 2021, and June 2021, respectively. The dismissal in Germany followed an earlier finding of infringement and granting of an injunction, both of which were subsequently overturned. In December 2019, Amgen also filed lawsuits in the Netherlands, Italy, and Spain for infringement of the relevant designation of the '124 Patent in each such jurisdiction; the Company was not named as a defendant in any of these actions, and each of these lawsuits was dismissed in February 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Japan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously reported, on March 31, 2020, Amgen filed a lawsuit in the Tokyo District Court against Sanofi K.K. seeking damages incurred by Amgen as a result of the earlier finding of infringement of Amgen's Japanese Patent Nos. 5,906,333 and 5,705,288 by the Tokyo District Court Civil Division. The Company has not been named as a defendant in this damages action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Dupixent (dupilumab) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2017, the Company, Sanofi-Aventis U.S. LLC, and Genzyme Corporation initiated an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review ("IPR") in the United States Patent and Trademark Office ("USPTO") seeking a declaration of invalidity of U.S. Patent No. 8,679,487 (the "'487 Patent") owned by Immunex Corporation relating to antibodies that bind the human interleukin-4 receptor and subsequently filed <ix:nonFraction unitRef="claim" contextRef="iae9a73d5ea4745d09d9bbb09f273f524_D20170728-20170731" decimals="INF" format="ixt-sec:numwordsen" name="regn:GainContingencyInterPartesReviewFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfMTMwMTU_1c6b753a-8ca7-430d-9b86-0a5e4d9aadc7">two</ix:nonFraction> additional IPR petitions in the USPTO seeking declarations of invalidity of the '487 Patent based on different grounds (the "Additional IPR Petitions"). The Patent Trial and Appeal Board ("PTAB") of the USPTO issued a final written decision on the Additional IPR Petitions on February 14, 2019, invalidating all <ix:nonFraction unitRef="claim" contextRef="i34e55477ad8e4cfebda758de4b6f0516_I20190214" decimals="INF" name="regn:GainContingencyClaimsInvalidatedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfMTM3NzA_d6b53929-5945-4c00-ab32-2ad1ea7f4ef6">17</ix:nonFraction> claims of the '487 Patent as obvious. This decision was subsequently affirmed by the Federal Circuit and Immunex's petition for writ of certiorari was denied by the United States Supreme Court. The '487 Patent expired in May 2020 following Immunex's filing of a terminal disclaimer with the USPTO.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2017, Immunex Corporation filed a lawsuit against the Company, Sanofi, Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Aventisub LLC in the United States District Court for the Central District of California seeking a judgment of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><ix:continuation id="i4eab7f4ea9dc4ed2b45f0b3a8c93db96" continuedAt="i2bee54542aa64db59f7cf1111cc8c88b"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent infringement of the '487 Patent and a declaratory judgment of infringement of the '487 Patent, in each case by the Company's and the other defendants' Commercializing of Dupixent; monetary damages (together with interest); an order of willful infringement of the '487 Patent, which would allow the court in its discretion to award damages up to three times the amount assessed; costs and expenses of the lawsuit; and attorneys' fees. The court subsequently granted a joint stipulation by the parties to stay the litigation pending resolution of the appeals of the PTAB's final written decisions on the Additional IPR Petitions discussed above; and, on August 3, 2021, granted a motion to dismiss the lawsuit, dismissing all of Immunex's claims with prejudice. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Europe</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2016, Sanofi initiated a revocation proceeding in the United Kingdom to invalidate the U.K. counterpart of European Patent No. 2,292,665 (the "'665 Patent"), another patent owned by Immunex relating to antibodies that bind the human interleukin-4 receptor. At the joint request of the parties to the revocation proceeding, the U.K. Patents Court ordered on January 30, 2017 that the revocation action be stayed pending the final determination of the currently pending EPO opposition proceedings initiated by the Company and Sanofi in relation to the '665 Patent. The oral hearing before the EPO on the oppositions occurred on November 20, 2017, at which the claims of the '665 Patent were found invalid and the patent was revoked. A final written decision of revocation of the '665 Patent was issued by the EPO on January 4, 2018. Immunex filed a notice of appeal of the EPO's decision on January 31, 2018, and an oral hearing before the TBA has been scheduled for March 2022. On September 20, 2017 and September 21, 2017, respectively, the Company and Sanofi initiated opposition proceedings in the EPO against Immunex's European Patent No. 2,990,420 (the "'420 Patent"), a divisional patent of the '665 Patent (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a patent that shares the same priority date, disclosure, and patent term of the parent '665 Patent but contains claims to a different invention). The oral hearing before the EPO on the oppositions occurred on February 14&#8211;15, 2019, at which the '420 Patent was revoked in its entirety. Immunex filed a notice of appeal of the EPO's decision on May 31, 2019, and an oral hearing before the TBA has been scheduled for March 2022. The original patent term of the Immunex patents expired in May 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to EYLEA (aflibercept) Injection</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2021, Chengdu Kanghong Pharmaceutical Group Co., Ltd. ("Chengdu Kanghong") filed an IPR petition in the USPTO against the Company' s U.S. Patent No. 10,464,992 (the "'992 Patent") and a post-grant review ("PGR") petition against the Company's U.S. Patent No. 10,828,345 (the "'345 Patent") seeking declarations of invalidity of the '992 Patent and '345 Patent. On June 23, 2021, Chengdu Kanghong filed motions to dismiss each of these petitions and terminate the respective proceedings, which were granted by the USPTO on June 25, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2020, anonymous parties filed <ix:nonFraction unitRef="request" contextRef="i4c1e030c474b48ada51944d7eb45dbb7_I20200211" decimals="INF" format="ixt-sec:numwordsen" name="regn:LossContingencyExParteReexaminationFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfMTg4Njg_84405472-4ae9-481a-b32e-f27fd38e3033">two</ix:nonFraction> requests for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reexamination of the Company's U.S. Patent No. 10,406,226 and the '992 Patent, and the USPTO has granted both requests to initiate reexamination proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, Mylan Pharmaceuticals Inc. filed IPR petitions in the USPTO against the Company's U.S. Patent Nos. 9,254,338 (the "'338 Patent") and 9,669,069 (the "'069 Patent") seeking declarations of invalidity of the '338 Patent and the '069 Patent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2021, Celltrion, Inc. filed a PGR petition in the USPTO against the Company's U.S. Patent No. 10,857,231 (the "'231 Patent") seeking a declaration of invalidity of the '231 Patent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26 and October 27, 2021, anonymous parties initiated opposition proceedings in the EPO against the Company's European Patent No. 2,944,306 (the "'306 Patent") seeking revocation of the '306 Patent in its entirety. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to EYLEA (aflibercept) Injection Pre-filled Syringe</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, "Novartis") filed a complaint with the U.S. International Trade Commission (the "ITC") pursuant to Section 337 of the Tariff Act of 1930 requesting that the ITC institute an investigation relating to the importation into the United States and/or sale within the United States after importation of EYLEA pre-filled syringes ("PFS") and/or components thereof which allegedly infringe Novartis&#8217;s U.S. Patent No. 9,220,631 (the "'631 Patent"). Novartis also requested a permanent limited exclusion order forbidding entry into the United States of EYLEA PFS or components thereof; a permanent cease-and-desist order from the importation, sale, offer for sale, advertising, packaging, or solicitation of any sale by the Company of EYLEA PFS or components thereof; and a bond should the Company continue to import EYLEA PFS (if found to infringe) during, if applicable, any 60-day Presidential review period (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the period when the President of the United States (or his designee) can disapprove any ITC decision to issue an exclusion order or cease-and-desist order). The ITC instituted the investigation on July 22, 2020 and a trial was scheduled for April 19&#8211;23, 2021. On March 26, 2021, the staff attorney appointed by the ITC's Office of Unfair Import Investigations ("OUII")&#8212;an independent government party to the case representing the public interest&#8212;</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><ix:continuation id="i2bee54542aa64db59f7cf1111cc8c88b" continuedAt="i218e6cbf010e49da95460f17dc679e3d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined that the '631 Patent is invalid on several grounds. On April 8, 2021, Novartis moved to terminate the ITC investigation in its entirety based on its withdrawal of the complaint; and, on May 3, 2021, the ITC terminated the investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, Novartis also filed a patent infringement lawsuit (as amended on August 2, 2021) in the U.S. District Court for the Northern District of New York asserting claims of the '631 Patent and seeking preliminary and permanent injunctions to prevent the Company from continuing to infringe the '631 Patent. Novartis also seeks a judgment of patent infringement of the '631 Patent, monetary damages (together with interest), an order of willful infringement of the '631 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuits, and attorneys' fees. On July 30, 2020, the court granted the Company's motion to stay these proceedings until a determination in the ITC proceedings discussed above, including any appeals therefrom, becomes final. On June 11, 2021, the court, at the request of Novartis, lifted the stay.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, the Company initiated <ix:nonFraction unitRef="claim" contextRef="ib4b960d3dff6442ba38d7de8747b8883_D20200716-20200716" decimals="INF" format="ixt-sec:numwordsen" name="regn:GainContingencyInterPartesReviewFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfMjIxNjg_5910e297-28e3-4def-b648-3eefa669426c">two</ix:nonFraction> IPR petitions in the USPTO seeking a declaration of invalidity of the '631 Patent on two separate grounds. On January 15, 2021, the USPTO declined to institute an IPR proceeding on procedural grounds in light of the pending ITC investigation discussed above; the other IPR petition has been withdrawn. Following Novartis's motion to terminate the ITC investigation discussed above, on April 16, 2021 the Company filed a new IPR petition seeking a declaration of invalidity of the '631 Patent based on the same grounds that were the basis for the OUII staff attorney's determination discussed above. On October 26, 2021, the USPTO issued a decision instituting the IPR proceeding.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, the Company filed an antitrust lawsuit against Novartis and Vetter Pharma International Gmbh ("Vetter") in the United States District Court for the Southern District of New York seeking a declaration that the '631 Patent is unenforceable and a judgment that the defendants' conduct violates Sections 1 and 2 of the Sherman Antitrust Act of 1890, as amended (the "Sherman Antitrust Act"). The Company is also seeking injunctive relief and treble damages. On September 4, 2020, Novartis filed, and Vetter moved to join, a motion to dismiss the complaint, to transfer the lawsuit to the Northern District of New York, or to stay the suit; and on October 19, 2020, Novartis filed, and Vetter moved to join, a second motion to dismiss the complaint on different grounds. On January 25, 2021, the Company filed an amended complaint seeking a judgment that Novartis's conduct violates Section 2 of the Sherman Antitrust Act based on additional grounds, as well as a judgment of tortious interference with contract. On February 22, 2021, Novartis filed, and Vetter moved to join, a motion to dismiss the amended complaint. On September 21, 2021, the court granted Novartis and Vetter's motion to transfer this lawsuit to the Northern District of New York. As a result, this lawsuit was transferred to the same judge that had been assigned to the patent infringement lawsuit discussed above.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Related to "Most Favored Nation" Interim Final Rule</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2020, the Company filed a lawsuit in the United States District Court for the Southern District of New York against the U.S. Department of Health and Human Services, the Secretary of HHS, the Centers for Medicare &amp; Medicaid Services ("CMS"), and the Administrator of CMS seeking declaratory and injunctive relief related to the interim final rule with comment period entitled "Most Favored Nation (MFN) Model" issued on November 20, 2020 by HHS, acting through CMS. On the same day, the Company filed a motion for a preliminary injunction and temporary restraining order, seeking to prevent implementation of the MFN Rule. On December 22, 2020, the court heard oral argument on the Company's motion for a preliminary injunction and temporary restraining order. On December 31, 2020, the court granted the Company's motion and issued a preliminary injunction. On February 2, 2021, the government stated to the court that the Solicitor General had determined not to appeal the preliminary injunction. On February 10, 2021, the court entered a 90-day stay of the litigation and subsequently extended the stay, with the most recent 30-day extension granted on October 11, 2021. On August 6, 2021, CMS issued a Notice of Proposed Rulemaking that proposes to rescind the MFN Rule.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to fasinumab</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 21, 2020, the Company and Teva Pharmaceutical Industries Limited ("Teva") filed a lawsuit against Rinat Neurosciences Corp. ("Rinat"), a wholly owned subsidiary of Pfizer Inc., in the English High Court of Justice in London, seeking invalidation and revocation of Rinat's European Patent No. 2,270,048 (the "'048 Patent"), European Patent No. 1,871,416 (the "'416 Patent"), and European Patent No. 2,305,711 (the "'711 Patent"), each of which pertains to the use of NGF monoclonal antibodies to treat certain symptoms in patients suffering from osteoarthritis. On July 21, 2020, Rinat filed its defense and counterclaim seeking a declaration of infringement of the '048 Patent by fasinumab. The counterclaim also seeks a permanent injunction, damages, an accounting of profits, and costs and interest. On December 15, 2020, Rinat filed an amended defense and counterclaim seeking a declaration of infringement of the '711 Patent by fasinumab. On May 5, 2021, the court stayed this litigation on terms mutually agreed by the parties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The '048 Patent is subject to opposition proceedings in the EPO, which were initiated by the Company on August 10, 2016 and two other opponents on August 11, 2016. On January 3, 2018, the Opposition Division of the EPO issued a preliminary, non-binding opinion regarding the validity of the '048 Patent, indicating that it considered the granted patent to be invalid. An oral </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><ix:continuation id="i218e6cbf010e49da95460f17dc679e3d" continuedAt="i419c1669033146eabf6c44fb94fb8dca"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hearing on the oppositions against the '048 Patent was held on November 29&#8211;30, 2018, at which the Opposition Division upheld the validity of the '048 Patent's claims in amended form. The Company filed a notice of appeal to the TBA of the EPO on March 7, 2019. On October 21, 2020, Teva filed a notice of intervention with the TBA to take part in the appeal proceedings as an intervener. An oral hearing before the TBA has been scheduled for April 5&#8211;6, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The '711 Patent is also subject to opposition proceedings in the EPO, which were initiated by the Company on May 1, 2018. On January 31, 2019, the Opposition Division of the EPO issued a preliminary, non-binding opinion regarding the validity of the '711 Patent, indicating that it considered the granted patent to be invalid. An oral hearing on the opposition against the '711 Patent was held on December 3, 2019, at which the Opposition Division upheld the validity of the '711 Patent's claims in amended form. The Company filed a notice of appeal to the TBA on December 20, 2019. On January 29, 2021, Teva filed a notice of intervention with the TBA to take part in the appeal proceedings as an intervener. An oral hearing before the TBA was held on July 29, 2021, at which the '711 Patent was revoked in its entirety. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to REGEN-COV (casirivimab and imdevimab)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2020, Allele Biotechnology and Pharmaceuticals, Inc. ("Allele") filed a lawsuit (as amended on April 8, 2021) against the Company in the United States District Court for the Southern District of New York, asserting infringement of U.S. Patent No. 10,221,221 (the "'221 Patent").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allele seeks a judgment of patent infringement of the '221 Patent, an award of monetary damages (together with interest), an order of willful infringement of the '221 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuit, and attorneys' fees. On July 16, 2021, the Company filed a motion to dismiss the complaint.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating to its support of 501(c)(3) organizations that provide financial assistance to patients; documents concerning its provision of financial assistance to patients with respect to products sold or developed by Regeneron (including EYLEA, Praluent, ARCALYST, and ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); and certain other related documents and communications. On June 24, 2020, the U.S. Attorney's Office for the District of Massachusetts filed a civil complaint in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. On August 24, 2020, the Company filed a motion to dismiss the complaint in its entirety. On December 4, 2020, the court denied the motion to dismiss.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company and Regeneron Healthcare Solutions, Inc., a wholly-owned subsidiary of the Company, each received a civil investigative demand ("CID") from the U.S. Department of Justice pursuant to the federal False Claims Act relating to remuneration paid to physicians in the form of consulting fees, advisory boards, speaker fees, and payment or reimbursement for travel and entertainment allegedly in violation of the federal Anti-Kickback Statute. The CIDs relate to EYLEA, Praluent, Dupixent, ZALTRAP, ARCALYST, and Kevzara and cover the period from January 2015 to the present. On June 3, 2021, the United States District Court for the Central District of California unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint filed against the Company, Regeneron Healthcare Solutions, Inc., and Sanofi-Aventis U.S. LLC by two </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plaintiffs (known as relators) purportedly on behalf the United States and various states (the "State Plaintiffs"), asserting causes of action under the federal False Claims Act and state law. Also on June 3, 2021, the United States and the State Plaintiffs notified the court of their decision to decline to intervene in the case. On October 29, 2021, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plaintiffs filed an amended complaint in this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company received a CID from the U.S. Department of Justice pursuant to the federal False Claims Act. The CID states that the investigation concerns allegations that the Company (i) violated the False Claims Act by paying kickbacks to distributors and ophthalmology practices to induce purchase of EYLEA, including through discounts, rebates, credit card fees, free units of EYLEA, and inventory management systems; and (ii) inflated reimbursement rates for EYLEA by excluding applicable discounts, rebates, and benefits from the average sales price reported to CMS. The CID covers the period from January 2011 through June 2021. The Company is cooperating with this investigation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Initiated by UnitedHealthcare</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2020, UnitedHealthcare Insurance Company and United Healthcare Services, Inc. (collectively, "UHC") filed a lawsuit against the Company in the United States District Court for the Southern District of New York alleging UHC has been damaged by the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. UHC alleges causes of action under state law and the federal Racketeer Influenced and Corrupt Organizations Act (the "RICO Act") and seeks monetary damages and equitable relief. On March 1, 2021, the Company filed a motion to dismiss the complaint in its entirety. On March 25, 2021, UHC filed an amended complaint; and, on April 22, 2021, the Company filed a motion to dismiss this amended complaint in its entirety. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><ix:continuation id="i419c1669033146eabf6c44fb94fb8dca"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Proceedings Initiated by Humana</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 22, 2021, Humana Inc. ("Humana") filed a lawsuit against the Company in the United States District Court for the Southern District of New York alleging Humana has been damaged by the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. Humana alleges causes of action under state law and the RICO Act and seeks monetary damages and equitable relief. On September 27, 2021, the Company filed a motion to dismiss the complaint in its entirety.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Demand</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or about September 30, 2020, the Company's board of directors received a demand letter from a purported shareholder of the Company. The demand alleges that Regeneron and its shareholders have been damaged by the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The demand letter requests that the Company's board of directors investigate alleged breaches of fiduciary duty by its officers and directors and other alleged violations of law and corporate governance practices and procedures; bring legal action against the persons responsible for causing the alleged damages; and implement and maintain an effective system of internal controls, compliance mechanisms, and corporate governance practices and procedures. The Company's board of directors, working with outside counsel, investigated and evaluated the allegations in the demand letter and has concluded that pursuing the claims alleged in the demand would not be in the Company's best interests at this time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Shareholder Derivative Complaint</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, an alleged shareholder filed a shareholder derivative complaint in the New York Supreme Court, naming the current and certain former members of the Company's board of directors and certain current and former executive officers of the Company as defendants and Regeneron as a nominal defendant. The complaint asserts that the individual defendants breached their fiduciary duties in relation to the allegations in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The complaint seeks an award of damages allegedly sustained by the Company; an order requiring Regeneron to take all necessary actions to reform and improve its corporate governance and internal procedures; disgorgement from the individual defendants of all profits and benefits obtained by them resulting from their sales of Regeneron stock; and costs and disbursements of the action, including attorneys' fees. On July 28, 2021, the defendants filed a notice of removal, removing the case from the New York Supreme Court to the U.S. District Court for the Southern District of New York. On September 24, 2021, the individual defendants moved to dismiss the complaint in its entirety. Also on September 24, 2021, the plaintiff filed a motion to remand the case to the New York Supreme Court.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="iae35796f039b495ba4b10877e85a1c6f_70"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, "Regeneron," "Company," "we," "us," and "our"), and actual events or results may differ materially from these forward-looking statements.&#160;Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.&#160;These statements concern, and these risks and uncertainties include, among others, the impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regeneron's business and its employees, collaborators, and suppliers and other third parties on which Regeneron relies, Regeneron's and its collaborators&#8217; ability to continue to conduct research and clinical programs, Regeneron's ability to manage its supply chain, net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron&#8217;s Products"), and the global economy; the nature, timing, and possible success and therapeutic applications of Regeneron's Products and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates") and research and clinical programs now underway or planned, including without limitation EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;(aflibercept) Injection, Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;(dupilumab) Injection, Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(cemiplimab) Injection, Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;(alirocumab) Injection, Kevzara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;(sarilumab) Injection, Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (evinacumab), Inmazeb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(atoltivimab, maftivimab, and odesivimab-ebgn), REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (casirivimab and imdevimab), fasinumab, garetosmab, pozelimab, odronextamab, itepekimab, REGN5458, REGN5713-5714-5715, REGN1908-1909, Regeneron's other oncology programs (including its costimulatory bispecific portfolio), Regeneron's and its collaborators' earlier-stage programs, and the use of human genetics in Regeneron's research programs; the likelihood and timing of achieving any of our anticipated development milestones referenced in this report; safety issues resulting from the administration of Regeneron's Products and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; the likelihood, timing, and scope of possible regulatory approval and commercial launch of our late-stage product candidates and new indications for Regeneron's Products, including without limitation those listed above; the extent to which the results from the research and development programs conducted by us and/or our collaborators may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates; uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties on the commercial success of Regeneron's Products and Regeneron's Product Candidates; our ability to manufacture and manage supply chains for multiple products and product candidates; the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the availability and extent of reimbursement of Regeneron&#8217;s Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; unanticipated expenses; the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including our agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), as well as Regeneron's agreement with Roche relating to the casirivimab and imdevimab antibody cocktail (known as REGEN-COV in the United States and Ronapreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in other countries) and its REGEN-COV supply agreement with the U.S. government, to be cancelled or terminated; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA, Dupixent, Praluent, and REGEN-COV described further in Note 12 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 12 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.&#160;These statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any such statements.&#160;In evaluating such statements, shareholders and potential investors should specifically consider the various factors identified under Part II, Item 1A. "Risk Factors," which could cause actual events and results to differ </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">materially from those indicated by such forward-looking statements. We do not undertake any obligation to update (publicly or otherwise) any forward-looking statement, whether as a result of new information, future events, or otherwise.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Our commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our core business strategy is to maintain a strong foundation in basic scientific research and discovery-enabling technologies, and to build on that foundation with our clinical development, manufacturing, and commercial capabilities. Our objective is to continue to be an integrated, multi-product biotechnology company that provides patients and medical professionals with important options for preventing and treating human diseases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected financial information is summarized as follows:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.099%"><tr><td style="width:1.0%"></td><td style="width:43.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,120.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,074.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,846.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this report, references to our products encompass products marketed or otherwise commercialized by us and/or our collaborators or licensees and references to our product candidates encompass product candidates in development by us and/or our collaborators or licensees (in the case of collaborated or licensed products or product candidates under the terms of the applicable collaboration or license agreements), unless otherwise stated or required by the context.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products that have received marketing approval are summarized in the table below.</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:28.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disease Area</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EU</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Japan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA (aflibercept) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neovascular age-related macular degeneration ("wet AMD")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetic macular edema ("DME")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Macular edema following retinal vein occlusion ("RVO"), which includes macular edema following central retinal vein occlusion ("CRVO") and macular edema following branch retinal vein occlusion ("BRVO")</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Myopic choroidal neovascularization ("mCNV")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diabetic retinopathy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neovascular glaucoma ("NVG")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent (dupilumab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis (in adults and adolescents)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Atopic dermatitis (in pediatrics 6&#8211;11 years of age)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asthma (in adults and adolescents)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asthma (in pediatrics 6&#8211;11 years of age)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic rhinosinusitis with nasal polyposis ("CRSwNP")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:28.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.337%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disease Area</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Japan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo (cemiplimab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or locally advanced first-line non-small cell lung cancer ("NSCLC")</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or locally advanced basal cell carcinoma ("BCC")</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or locally advanced cutaneous squamous cell carcinoma ("CSCC")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent (alirocumab) Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LDL-lowering in heterozygous familial hypercholesterolemia ("HeFH") or clinical atherosclerotic cardiovascular disease ("ASCVD")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiovascular risk reduction in patients with established cardiovascular disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Homozygous familial hypercholesterolemia ("HoFH")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevzara (sarilumab) Solution for Subcutaneous Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis ("RA")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza (evinacumab) Injection</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HoFH (in adults and adolescents)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Infection caused by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zaire ebolavirus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (rilonacept) Injection for Subcutaneous Use</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cryopyrin-associated periodic syndromes ("CAPS"), including familial cold auto-inflammatory syndrome ("FCAS") and Muckle-Wells syndrome ("MWS") (in adults and adolescents)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deficiency of interleukin-1 receptor antagonist ("DIRA") (in adults and pediatrics)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recurrent pericarditis (in adults and adolescents)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ziv-aflibercept) Injection for Intravenous Infusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic colorectal cancer ("mCRC")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Webdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Note 1: Refer to "Net Product Sales of Regeneron-Discovered Products" section below for information regarding whether net product sales for a particular product are recorded by us or others.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Note 2: Product is approved for use in adults, unless otherwise noted, in the disease area described above</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In collaboration with Bayer outside the United States</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Sanofi</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Pursuant to a 2020 agreement, the Company is solely responsible for the development and commercialization of Praluent in the United States, and Sanofi is solely responsible for the development and commercialization of Praluent outside of the United States (and Sanofi pays us a royalty on net product sales of Praluent outside the United States).</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Rest of world. Checkmark in this column indicates that the product has received marketing approval in at least one country outside of the United States, European Union ("EU"), or Japan.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Known as REGEN-COV in the United States and Ronapreve in other countries</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pursuant to a 2017 license agreement with Kiniksa Pharmaceuticals, Ltd., we granted Kiniksa the right to develop and commercialize certain new indications for ARCALYST. In March 2021, Kiniksa received marketing approval for its first new indication of ARCALYST in the United States; consequently we granted U.S. commercial rights to ARCALYST for all previously approved indications and Kiniksa pays us a share of ARCALYST profits. Refer to "Collaboration, License, and Other Agreements - Kiniksa" section below for further details.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Sanofi is solely responsible for the development and commercialization of ZALTRAP, and Sanofi pays us a percentage of aggregate net product sales of ZALTRAP.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">REGEN-COV - Emergency and Temporary Use Authorizations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the antibody cocktail casirivimab and imdevimab administered together, known as REGEN-COV in the United States, received Emergency Use Authorization ("EUA") from the U.S. Food and Drug Administration ("FDA") for the treatment of mild to moderate COVID-19 in adults, as well as in pediatric patients at least 12 years of age and weighing at least 40 kg, who have received positive results of direct SARS-CoV-2 viral testing and are at high risk for progressing to severe COVID-19 and/or hospitalization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the FDA updated the EUA for REGEN-COV, lowering the dose to 1,200 mg (which is half the dose originally authorized) and allowing for subcutaneous injections as an alternative when intravenous ("IV") infusion is not feasible and would lead to a delay in treatment. In July 2021, the FDA also expanded the EUA to include post-exposure prophylaxis in people at high risk for progression to severe COVID-19, who are not fully vaccinated or are not expected to mount an adequate response to vaccination, and who have been exposed to a SARS-CoV-2 infected individual or are at high risk of exposure to an infected individual because of infection occurring in the same institutional setting (such as in nursing homes or prisons). For people who are not expected to mount an adequate immune response to vaccination, REGEN-COV can also now be administered monthly for the duration of ongoing exposure to SARS-CoV-2.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EUA is temporary and does not replace a formal Biologics License Application ("BLA") submission review and approval process. This use is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use, unless terminated or revoked sooner. See information regarding ongoing clinical trials of REGEN-COV in the "Programs in Clinical Development" section below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Outside the United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP") issued a positive opinion, recommending that the casirivimab and imdevimab antibody cocktail be used to treat COVID-19 patients who do not require supplemental oxygen and are at high risk of progressing to severe COVID-19. The CHMP's positive opinion can be used by EU member states when making decisions on the possible use of the antibody cocktail at a national level prior to a market authorization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the United Kingdom's ("UK") Medicines and Healthcare products Regulatory Agency ("MHRA") granted Conditional Marketing Authorization for the casirivimab and imdevimab antibody cocktail in England, Scotland, and Wales to prevent and treat acute COVID-19 infection. In addition, the MHRA authorized emergency supply of the antibody cocktail to prevent and treat acute COVID-19 infection in Northern Ireland.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergency or temporary pandemic use authorizations are also currently in place in certain other countries outside the United States, including within the European Union, India, Switzerland, and Canada.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Sales of Regeneron-Discovered Products</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Total Sales)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,473.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,098.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(h)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevzara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(h)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Total Sales)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,904.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,706.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,364.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,424.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,872.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,530.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(h)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevzara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 5.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(h)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="45" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Regeneron records net product sales of EYLEA in the United States. Bayer records net product sales of EYLEA outside the United States. The Company records its share of profits/losses in connection with sales of EYLEA outside the United States.</span></div></td></tr><tr><td colspan="45" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Sanofi records global net product sales of Dupixent, Kevzara, and ZALTRAP. The Company records its share of profits/losses in connection with global sales of Dupixent and Kevzara, and Sanofi pays the Company a percentage of net sales of ZALTRAP.</span></div></td></tr><tr><td colspan="45" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Regeneron records net product sales of Libtayo in the United States and Sanofi records net product sales of Libtayo outside the United States. The parties equally share profits/losses in connection with global sales of Libtayo. </span></div></td></tr><tr><td colspan="45" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective April 1, 2020, Regeneron records net product sales of Praluent in the United States. Also effective April 1, 2020, Sanofi records net product sales of Praluent outside the United States and pays the Company a royalty on such sales. Previously, Sanofi recorded global net product sales of Praluent and the Company recorded its share of profits/losses in connection with such sales. Refer to "Collaboration, License, and Other Agreements - Sanofi" section below for further details.</span></div></td></tr><tr><td colspan="45" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Regeneron records net product sales of REGEN-COV in connection with its agreements with the U.S. government. Roche records net product sales of the antibody cocktail outside the United States and the parties share gross profits from global sales. Refer to "Agreements Related to COVID-19" below for further details. </span></div></td></tr><tr><td colspan="45" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Regeneron records net product sales of Evkeeza in the United States</span></div></td></tr><tr><td colspan="45" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States and pays us a share of ARCALYST profits, if any. Prior to April 1, 2021, Regeneron recorded net product sales of ARCALYST in the United States. Refer to "Products" section above and "Collaboration, License, and Other Agreements - Kiniksa" section below for further details.</span></div></td></tr><tr><td colspan="45" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Percentage not meaningful</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Programs in Clinical Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product candidates in clinical development, which are being developed by us and/or our collaborators, are summarized in the table below. We believe that our ability to develop product candidates is enhanced by the application of our&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelociSuite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;technology platforms. We continue to invest in the development of enabling technologies to assist in our efforts to identify, develop, manufacture, and commercialize new product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous uncertainties associated with drug development, including uncertainties related to safety and efficacy data from each phase of drug development (including any post-approval studies), uncertainties related to the enrollment and performance of clinical trials, changes in regulatory requirements, changes to drug pricing and reimbursement regulations and requirements, and changes in the competitive landscape affecting a product candidate. The planning, execution, and results of our clinical programs are significant factors that can affect our operating and financial results.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators conduct clinical trials in multiple countries across the world. The COVID-19 pandemic and the restrictions adopted around the globe to reduce the spread of the disease have impacted and may continue to impact our clinical development programs. We continue to evaluate the impact of the COVID-19 pandemic on an individual trial basis and oversee trial management while also working to ensure patient safety and provide sufficient supply of product candidates for the studies.&#160;The ultimate impact (including possible delays in recruiting and/or obtaining data) resulting from the COVID-19 pandemic will depend, among other factors, on the extent of the pandemic in the areas with study sites and patient populations. It is possible that the COVID-19 pandemic may cause clinical disruptions beyond those we have described. In addition, there may be delays in the timing of regulatory review and other projected milestones discussed in the table below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Part II, Item 1A. "Risk Factors" for a description of these and other risks and uncertainties that may affect our clinical programs, including those related to the COVID-19 pandemic.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ophthalmology</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EYLEA (aflibercept)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;High-dose formulation in wet AMD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Retinopathy of prematurity ("ROP")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;High-dose formulation in wet AMD</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;High-dose formulation in DME</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;ROP (Japan)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initial results from National Institutes of Health ("NIH")-sponsored Protocol W trial in non-proliferative diabetic retinopathy ("NPDR") were announced; data confirmed results from Company-sponsored PANORAMA trial and demonstrated reduced risk of developing vision-threatening complications with every-16-weeks dosing regimen</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Completed enrollment in Phase 3 study for ROP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Completed enrollment in Phase 3 studies for high-dose formulation in wet AMD and DME</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported that Phase 2 trial of high-dose formulation in wet AMD met its primary safety and efficacy endpoints</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit supplemental BLA ("sBLA") for every-16-weeks dosing regimen in patients with NPDR (first half 2022)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report results from Phase 3 studies for high-dose formulation in wet AMD and DME (second half 2022)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology &amp; Inflammation</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dupixent (dupilumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL-4R alpha subunit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Peanut allergy<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Grass allergy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Atopic dermatitis in pediatrics (6 months&#8211;5 years of age) (Phase 2/3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Eosinophilic esophagitis ("EoE")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in adults</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, adolescents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, and pediatrics</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Asthma in pediatrics (6&#8211;11 years of age) (EU)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;EoE in adults and adolescents (U.S.)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported that Phase 3 trial for atopic dermatitis in pediatrics (6 months&#8211;5 years of age) met its primary and key secondary endpoints</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiated Phase 3 study in hand and foot atopic dermatitis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit sBLA (Q4 2021) and Marketing Authorization Application ("MAA") (first half 2022) for atopic dermatitis in pediatric patients (6 months&#8211;5 years of age)</span></div></td></tr><tr style="height:38pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dupixent (dupilumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Chronic obstructive pulmonary disease ("COPD")</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Bullous pemphigoid (Phase 2/3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Chronic spontaneous urticaria ("CSU")</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Prurigo nodularis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Allergic bronchopulmonary aspergillosis ("ABPA")</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Chronic inducible urticaria</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Chronic rhinosinusitis without nasal polyposis </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Allergic fungal rhinosinusitis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by FDA for asthma in pediatrics (6&#8211;11 years of age)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported that Phase 3 trial in CSU met its primary and key secondary endpoints</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported that Phase 3 trial in prurigo nodularis met its primary and key secondary endpoints</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported that Part B of the Phase 3 trial in adults and adolescents with EoE met its co-primary endpoints</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by FDA for 200 mg auto-injector </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported that Phase 2 trial of Dupixent in combination with Aimmune Therapeutics' AR101, an oral immunotherapy, in pediatric patients with peanut allergy met its primary and key secondary endpoint</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;European Commission ("EC") decision on regulatory submission for asthma in pediatrics (6&#8211;11 years of age) (first half 2022)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Complete rolling sBLA submission for EoE in adults and adolescents (first half 2022)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report results from Phase 2 study in peanut allergy (first half 2022)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report results from additional Phase 3 CSU study (first half 2022)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report results from additional Phase 3 prurigo nodularis study (first half 2022)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kevzara (sarilumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL-6R</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Polyarticular-course juvenile idiopathic arthritis ("pcJIA")<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Systemic juvenile idiopathic arthritis ("sJIA")</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Itepekimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN3500)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL-33</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;COPD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN1908-1909</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Multi-antibody therapy to Fel d 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Cat allergy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported that Phase 2 study in cat allergic patients with mild asthma met its primary and key secondary endpoints</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5713-5714-5715</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Multi-antibody therapy to Bet  v 1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Birch allergy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initial Phase 3 study in birch allergic patients with allergic rhinoconjunctivitis met its primary endpoint </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN6490</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL-36R</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Palmo-plantar pustulosis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solid Organ Oncology</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Libtayo (cemiplimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(g)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to PD-1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Metastatic or locally advanced CSCC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Neoadjuvant CSCC</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Second-line cervical cancer, ISA101b combination</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;First-line NSCLC, chemotherapy combination</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Second-line cervical cancer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Adjuvant CSCC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Second-line cervical cancer (U.S.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by FDA and EC for first-line NSCLC, monotherapy<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by FDA and EC for BCC<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported Phase 3 chemotherapy combination trial in NSCLC met its overall survival primary endpoint; trial stopped early based on Independent Data Monitoring Committee ("IDMC") recommendation<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported positive results from Phase 3 trial in cervical cancer, demonstrating an overall survival benefit; trial stopped early based on IDMC recommendation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;FDA decision on sBLA for cervical cancer (target action date of January 30, 2022)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit MAA for cervical cancer (Q4 2021)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit sBLA (Q4 2021) and MAA (Q1 2022) for NSCLC, chemotherapy combination</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN4018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting MUC16 and CD3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Platinum-resistant ovarian cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report results from Phase 1 study in platinum-resistant ovarian cancer (2022)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5668</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting MUC16 and CD28</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Ovarian cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5678</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting PSMA and CD28</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Prostate cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report results from Phase 1 study in prostate cancer (2022)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5093</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting two distinct MET epitopes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;MET-altered advanced NSCLC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5093-M114</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody-drug conjugate targeting two distinct MET epitopes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;MET overexpressing advanced cancer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fianlimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN3767)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to LAG-3 </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Solid tumors and advanced hematologic malignancies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Presented positive data from Phase 1 trial in combination with Libtayo in advanced melanoma at American Society of Clinical Oncology Annual Meeting</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate Phase 3 study in first-line metastatic melanoma (2022)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN6569</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to GITR</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Solid tumors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN7075</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting EGFR and CD28</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Solid tumors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hematology</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Odronextamab (REGN1979)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting CD20 and CD3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Certain B-cell malignancies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;B-cell non-Hodgkin lymphoma ("B-NHL") (potentially pivotal study)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Resumed enrollment of patients with follicular lymphoma ("FL") and diffuse large B-cell lymphoma ("DLBCL") following protocol amendments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate Phase 3 program (2022)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5458</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting BCMA and CD3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Multiple myeloma (potentially pivotal study)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Expand into earlier lines of multiple myeloma therapy (first half 2022)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5459</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bispecific antibody targeting BCMA and CD3</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Multiple myeloma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:81pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pozelimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN3918)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to C5; studied as monotherapy and in combination with cemdisiran</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;CD55-deficient protein-losing enteropathy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, monotherapy (potentially pivotal study)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Paroxysmal nocturnal hemoglobinuria ("PNH"), cemdisiran combination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(n)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Myasthenia gravis, cemdisiran combination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(n)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit BLA for CD55-deficient protein-losing enteropathy, monotherapy (first half 2022) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Initiate Phase 3 study in PNH, cemdisiran combination (2022)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cemdisiran</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(n)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">siRNA therapeutic targeting C5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Immunoglobulin A nephropathy</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN7257</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to IL2Rg</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Aplastic anemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NTLA-2001</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(m)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">TTR gene knockout using CRISPR/Cas9</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Hereditary transthyretin amyloidosis with polyneuropathy </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">("ATTRv-PN")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported positive interim data from Phase 1 trial in ATTRv-PN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN9933</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to Factor XI</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Thrombosis<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Medicine</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGEN-COV (casirivimab and imdevimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)(k)(l)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Multi-antibody therapy to SARS-CoV-2 virus</span></div><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;COVID-19 multi-dose safety study</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;COVID-19 dose-ranging virology study in non-hospitalized patients</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;COVID-19 treatment in non-hospitalized patients </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;COVID-19 treatment in hospitalized patients </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;COVID-19 prevention</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;COVID-19 prevention in immunocompromised patients</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;COVID-19 treatment and prevention (U.S. and EU)<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;EUA amendment to add COVID-19  treatment for hospitalized patients and pre-exposure prophylaxis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported that Phase 3 trials in non-hospitalized COVID-19 patients met primary and key secondary endpoints</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> published positive results from Phase 3 trial in non-hospitalized COVID-19 patients</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;NIH COVID-19 Treatment Guidelines updated to strongly recommend REGEN-COV be used in non-hospitalized COVID-19 patients at high risk of clinical progression</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;FDA decision on BLA (target action date of April 13, 2022) and EC decision on regulatory submission (Q4 2021) for COVID-19 treatment of non-hospitalized patients and prevention <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Submit BLA (Q4 2021) and MAA (Q1 2022) for COVID-19 treatment in hospitalized patients</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGEN-COV (casirivimab and imdevimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)(k)(l)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(continued)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported that Phase 3 trial in hospitalized COVID-19 patients met its primary endpoint<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported that all tested doses in Phase 2 dose-ranging study in non-hospitalized patients met its primary endpoint<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;FDA updated EUA, lowering dose to 1,200 mg, allowing for subcutaneous injections in certain circumstances, and to include post-exposure prophylaxis<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by Ministry of Health, Labour and Welfare ("MHLW") for COVID-19 treatment in Japan<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Reported that Phase 3 prevention trial in uninfected household contacts of SARS-CoV-2 infected individuals met its primary and key secondary endpoints<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Positive results reported from Phase 3 RECOVERY trial in hospitalized patients</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Praluent (alirocumab)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to PCSK9</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;HeFH in pediatrics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by FDA for HoFH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:83pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regulatory Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Events to Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Select Upcoming Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fasinumab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(j)(f) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN475)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to NGF</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Osteoarthritis pain of the knee or hip</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Report additional longer-term safety results from Phase 3 studies in osteoarthritis pain of the knee or hip (Q4 2021)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Continue discussions with regulatory authorities and determine next steps for the program (Q4 2021)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(evinacumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to ANGPTL3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Acute pancreatitis prevention</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Approved by FDA and EC for HoFH<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Completed Phase 2 study in severe hypertriglyceridemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Garetosmab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(REGN2477)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Antibody to Activin A</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Fibrodysplasia ossificans progressiva </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">("FOP")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(d)(e) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(potentially pivotal study)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Further review trial data and determine next steps for the program (2022)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN4461</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Agonist antibody to leptin receptor ("LEPR")</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Generalized lipodystrophy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGN5381</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Agonist antibody to NPR1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Heart failure</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALN-HSD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(n)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">RNAi therapeutic targeting HSD17B13</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8211;Nonalcoholic steatohepatitis<br/>("NASH")</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.893%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Note: For purposes of the table above, a program is classified in Phase 1, 2, or 3 clinical development after recruitment for the corresponding study or studies has commenced.</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In collaboration with Sanofi</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In collaboration with Bayer outside of the United States</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> FDA granted orphan drug designation</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDA granted Breakthrough Therapy designation</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> FDA granted Fast Track designation</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Sanofi did not opt-in to or elected not to continue to co-develop the product candidate. Under the terms of our agreement, Sanofi is entitled to receive royalties on any future sales of the product candidate.</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Studied as monotherapy and in combination with other antibodies and treatments</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Information in this column relates to U.S., EU, and Japan regulatory submissions only</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As described in the section preceding the table above and Part II, Item 1A. "Risk Factors," development timelines may be further subject to change as a result of the impact of the COVID-19 pandemic.</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(j) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In collaboration with Teva and Mitsubishi Tanabe Pharma</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain trials conducted with the National Institute of Allergy and Infectious Diseases ("NIAID"), part of the NIH</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(l)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Roche </span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(m)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Intellia</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(n)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> In collaboration with Alnylam</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate profits and to generate positive cash flow from operations over the next several years depends significantly on the continued success in commercializing EYLEA and Dupixent. We expect to continue to incur substantial expenses related to our research and development activities, a portion of which we expect to be reimbursed by our collaborators. Also, our research and development activities outside our collaborations, the costs of which are not reimbursed, are expected to expand and require additional resources. We also expect to incur substantial costs related to the commercialization of our marketed products. Our financial results may fluctuate from quarter to quarter and will depend on, among other factors, the net sales of our products; the scope and progress of our research and development efforts; the timing of certain expenses; the continuation of our collaborations, in particular with Sanofi and Bayer, including our share of collaboration profits or losses from sales of commercialized products and the amount of reimbursement of our research and development expenses that we receive from collaborators; and the amount of income tax expense we incur, which is partly dependent on the profits or losses we earn in each of the countries in which we operate. We cannot predict whether or when new products or new indications for marketed products will receive regulatory approval or, if any such approval is received, whether we will be able to successfully commercialize such product(s) and whether or when they may become profitable.</span></div><div id="iae35796f039b495ba4b10877e85a1c6f_79"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Information - Clinical Development Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">REGEN-COV (casirivimab and imdevimab)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Treatment Study - Non-Hospitalized Patients</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IDMC for the REGEN-COV Phase 3 trial in non-hospitalized patients with COVID-19 found clear clinical efficacy for reducing the rate of hospitalization and death with both the 1,200 mg and 2,400 mg doses of REGEN-COV compared to placebo, and recommended stopping enrollment in the placebo group.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we announced positive top-line results from the Phase 3 trial in non-hospitalized COVID-19 patients. The trial met its primary endpoint, showing that REGEN-COV reduced the risk of hospitalization or death by 70% (1,200 mg dose IV) and 71% (2,400 mg dose IV) compared to placebo. The trial also met key secondary endpoints, including the ability to reduce symptom duration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company also announced that all tested doses (IV: 2,400 mg, 1,200 mg, 600 mg and 300 mg; subcutaneous injections: 1,200 mg and 600 mg) in the Phase 2 dose-ranging trial in non-hospitalized COVID-19 patients met the primary endpoint.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company announced positive data from the Phase 3 treatment trial in recently infected asymptomatic COVID-19 patients. The trial was being jointly run with the NIAID and met all primary and key secondary endpoints. The trial demonstrated that the 1,200 mg subcutaneous injection of REGEN-COV reduced the risk of progressing to symptomatic COVID-19 by 31% (primary endpoint), and by 76% after the third day.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Treatment Study - Hospitalized Patients</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, positive results were reported from the Phase 3 UK-based RECOVERY trial in hospitalized patients with severe COVID-19. The trial found that adding REGEN-COV to usual care reduced the risk of death by 20% in patients who had not mounted a natural antibody response on their own against SARS-CoV-2, compared to usual care alone. We have shared these data with regulatory authorities and requested that the EUA be expanded to include COVID-19 treatment for appropriate hospitalized patients. We were subsequently notified by the sponsor of the RECOVERY trial of a Good Clinical Practices ("GCPs") inspection of the trial by the UK MHRA, which found certain deviations from GCP compliance. The MHRA report stated that it found no evidence that the identified issues had impacted the overall data integrity to such an extent that the data would be unreliable based on those findings. However, it noted that certain aspects of data quality could not be fully assured and requested that certain corrective and preventative actions be taken; the sponsor of the trial has been in discussions with the MHRA and is responding to these findings. We have shared this information with the FDA.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Phase 2/3 portion of the treatment study in hospitalized patients being run by the Company, REGEN-COV met the primary virologic endpoint, showing that REGEN-COV reduced viral load in these hospitalized patients, but did not achieve statistical significance in the pre-specified primary clinical endpoint: reduction in mechanical ventilation or death from day 6 to day 29 in patients with high viral load at baseline. However, four out of five secondary clinical endpoints of the study were nominally significant including an endpoint preferred by the FDA: reduction in mechanical ventilation or death from day 1 to day 29 in all patients who were SARS-CoV-2 PCR-positive at baseline. The relative risk reduction with REGEN-COV versus placebo ranged from approximately 24% to 47% on these various clinical endpoints. In addition, an approximately 36% reduction in all-cause mortality was seen from day 1 to day 29, supporting the results of the RECOVERY trial.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company announced that a Phase 3 trial in patients hospitalized with COVID-19 met its primary endpoint. The trial showed that REGEN-COV significantly reduced viral load within 7 days of treatment in patients who entered the trial without having mounted their own antibody response (seronegative) and required low-flow or no supplemental oxygen. Patients who received REGEN-COV in this trial experienced a 36% reduced risk of death within 29 days of receiving treatment, and in patients who were seronegative when they entered the trial the risk of death was reduced by 56%. The FDA is currently reviewing the Company's request to expand the EUA to include treatment in hospital settings. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Prevention Study</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we announced positive results from the Phase 3 COVID-19 prevention trial in household contacts of SARS-CoV-2 infected individuals. The trial, which was jointly run with the NIAID, part of the NIH, met its primary and key secondary endpoints, showing that REGEN-COV 1,200 mg subcutaneous injection reduced the risk of symptomatic infections by 81% in those who were not infected.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, we also initiated a Phase 2 trial in high-risk children aged 12 years and under to assess the safety and tolerability of REGEN-COV.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreements Related to COVID-19</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Government </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company announced an expansion of its Other Transaction Agreement with the Biomedical Advanced Research Development Authority ("BARDA"), pursuant to which the U.S. Department of Health and Human Services ("HHS") was obligated to fund certain of our costs incurred for research and development activities related to COVID-19 treatments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company announced a $466 million agreement with entities acting at the direction of BARDA and the U.S. Department of Defense to manufacture and deliver filled and finished drug product of REGEN-COV to the U.S. government. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced an agreement with an entity acting on behalf of the U.S. Department of Defense and HHS to manufacture and deliver additional filled and finished drug product of REGEN-COV to the U.S. government. Pursuant to the agreement, the U.S. government was obligated to purchase all filled and finished doses of drug product delivered by June 30, 2021, up to 1.25 million doses, at the lowest treatment dose authorized or approved by the FDA for the indication authorized under the EUA, resulting in payments to the Company of $2.625 billion (as described under "Products - REGEN-COV - Emergency and Temporary Use Authorizations" above). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has completed its final deliveries of drug product under the agreements described above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company announced an amendment to its January 2021 agreement to supply the U.S. government with an additional 1.4&#160;million doses of REGEN-COV. Pursuant to the agreement, the U.S. government is obligated to purchase all filled and finished doses of such additional drug product delivered by January 31, 2022, resulting in payments to the Company of up to $2.940&#160;billion in the aggregate. A number of factors may impact the quantity and timing of filled and finished drug product supply, including manufacturing considerations. Additionally, Roche will supply a portion of the doses to Regeneron to fulfill our agreement with the U.S. government (see "Roche" below for further details regarding our collaboration agreement with Roche).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Results of Operations - Revenues" below for REGEN-COV net product sales recognized in connection with these agreements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Roche</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into a collaboration agreement with Roche to develop, manufacture, and distribute the casirivimab and imdevimab antibody cocktail. We lead global development activities for casirivimab and imdevimab, and the parties jointly fund certain on-going studies, as well as any mutually agreed additional new global studies to evaluate further the potential of casirivimab and imdevimab in treating or preventing COVID-19. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the agreement, each party is obligated to dedicate a certain amount of manufacturing capacity to casirivimab and imdevimab each year. We distribute the product in the United States and Roche distributes the product outside of the United States. The parties share gross profits from worldwide sales based on a pre-specified formula, depending on the amount of manufactured product supplied by each party to the market. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration, License, and Other Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are collaborating with Sanofi on the global development and commercialization of Dupixent, Kevzara, and itepekimab (the "Antibody Collaboration"). See discussion below for updates related to the development and commercialization of Praluent effective April 1, 2020. Under the terms of the Antibody License and Collaboration Agreement (the "LCA"), Sanofi is generally responsible for funding 80%&#8211;100% of agreed-upon development costs. We are obligated to reimburse Sanofi for 30%&#8211;50% of worldwide development expenses that were funded by Sanofi based on our share of collaboration profits from commercialization of collaboration products. However, we are only required to apply 10% of our share of the profits from the Antibody Collaboration in any calendar quarter to reimburse Sanofi for these development costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration agreement, Sanofi records product sales for commercialized products, and Regeneron has the right to co-commercialize such products on a country-by-country basis. We co-commercialize Dupixent in the United States and in certain countries outside the United States. We supply certain commercial bulk product to Sanofi. We and Sanofi equally share profits and losses from sales within the United States. We and Sanofi share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (us) and ending at 55% (Sanofi)/45% (us), and share losses outside the United States at 55% (Sanofi)/45% (us). In addition to profit and loss sharing, we are entitled to receive sales milestone payments from Sanofi. In the third quarter of 2020, the Company earned the first $50.0&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.0&#160;billion on a rolling twelve-month basis. In the third quarter of 2021, the Company earned the second $50.0&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.5&#160;billion on a rolling twelve-month basis. We are entitled to receive up to an aggregate of $150.0&#160;million in additional sales milestone payments from Sanofi.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company and Sanofi entered into an amendment to the LCA in connection with, among other things, the removal of Praluent from the LCA such that (i) effective April 1, 2020, the LCA no longer governs the development, manufacture, or commercialization of Praluent and (ii) the quarterly period ended March 31, 2020 was the last quarter for which Sanofi and the Company shared profits and losses for Praluent under the LCA. The parties also entered into a Praluent Cross License &amp; Commercialization Agreement (the "Praluent Agreement") pursuant to which, effective April 1, 2020, the Company, at its sole cost, became solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, is solely responsible for the development and commercialization of Praluent outside of the United States. Under the Praluent Agreement, Sanofi will pay the Company a 5% royalty on Sanofi&#8217;s net product sales of Praluent outside the United States until March 31, 2032. The Company will not owe Sanofi royalties on the Company&#8217;s net product sales of Praluent in the United States. Although each party will be responsible for manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for a certain transitional period, the Company will continue to supply drug substance to Sanofi and Sanofi will continue to supply finished product to Regeneron. With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third-party royalty payments resulting from certain patent litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron). The parties will each bear 50% of any damages arising out of Praluent sales or other activities prior to April 1, 2020. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are collaborating with Sanofi on the development and commercialization of antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective December 31, 2018, the Company and Sanofi entered into an Amended and Restated Immuno-oncology Discovery and Development Agreement (the "Amended IO Discovery Agreement"), which narrowed the scope of the existing discovery and development activities conducted by the Company ("IO Development Activities") under the original 2015 Immuno-oncology Discovery and Development Agreement (the "2015 IO Discovery Agreement") to developing therapeutic bispecific antibodies targeting (i) BCMA and CD3 (the "BCMAxCD3 Program") and (ii) MUC16 and CD3 (the "MUC16xCD3 Program") through clinical proof-of-concept. The Amended IO Discovery Agreement provided for, among other things, Sanofi's prepayment for certain IO Development Activities regarding the BCMAxCD3 Program and the MUC16xCD3 Program. Under the terms of the Amended IO Discovery Agreement, the Company was required to conduct development activities with respect to (i) the BCMAxCD3 Program through the earlier of clinical proof-of-concept or the expenditure of $70.0 million (the "BCMAxCD3 Program Costs Cap") and (ii) the MUC16xCD3 Program through the earlier of clinical proof-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of-concept or the expenditure of $50.0 million (the "MUC16xCD3 Program Costs Cap"). We are obligated to reimburse Sanofi for half of the development costs they funded that are attributable to clinical development of antibody product candidates under the Amended IO Discovery Agreement from our share of profits from commercialized IO Collaboration products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to the BCMAxCD3 Program and the MUC16xCD3 Program, when the applicable Program Costs Cap was reached, Sanofi had the option to license rights to the product candidate and other antibodies targeting the same targets for, with regard to BCMAxCD3, immuno-oncology indications, and with regard to MUC16xCD3, all indications, pursuant to the Immuno-oncology License and Collaboration Agreement (the "IO License and Collaboration Agreement"), as amended. During the first quarter of 2021, Sanofi did not exercise its options to license rights to these product candidates; as a result, we retain the exclusive right to develop and commercialize such product candidates and Sanofi will receive a royalty on sales (if any).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the IO License and Collaboration Agreement, the parties are co-developing and co-commercializing Libtayo. We have principal control over the development of Libtayo, and the parties share equally, on an ongoing basis, development and commercialization expenses for Libtayo. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to Libtayo, we lead commercialization activities in the United States, while Sanofi leads commercialization activities outside of the United States and the parties equally share profits from worldwide sales. Sanofi has exercised its option to co-commercialize Libtayo in the United States. We will be entitled to a milestone payment of $375.0 million in the event that global sales of Libtayo equal or exceed $2.0 billion in any consecutive twelve-month period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EYLEA outside the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Bayer are parties to a license and collaboration agreement for the global development and commercialization outside the United States of EYLEA. Under the agreement, we and Bayer collaborate on, and share the costs of, the development of EYLEA. Bayer markets EYLEA outside the United States, where, for countries other than Japan, the companies share equally in profits and losses from sales of EYLEA. In Japan, we are entitled to receive a tiered percentage of between 33.5% and 40.0% of EYLEA net sales through 2021, and thereafter, the companies will share equally in profits and losses from the sales of EYLEA. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to reimburse Bayer for 50% of the development costs that it has incurred under the agreement from our share of the collaboration profits (including payments to us based on sales in Japan). The reimbursement payment in any quarter will equal 5% of the then outstanding repayment obligation, but never more than our share of the collaboration profits in the quarter unless we elect to reimburse Bayer at a faster rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the United States, we retain exclusive commercialization rights to EYLEA and are entitled to all profits from such sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teva</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fasinumab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Teva are parties to a collaboration agreement to develop and commercialize fasinumab globally, excluding certain Asian countries that are subject to our collaboration agreement with Mitsubishi Tanabe Pharma Corporation ("MTPC"). In connection with the agreement, Teva made a $250.0 million non-refundable up-front payment. We lead global development activities, and the parties share equally, on an ongoing basis, development costs under a global development plan. As of September&#160;30, 2021, we had earned an aggregate of $120.0 million of development milestones from Teva and we are entitled to receive up to an aggregate of $340.0 million in additional development milestones and up to an aggregate of $1.890 billion in contingent payments upon achievement of specified annual net sales amounts. We are responsible for the manufacture and supply of fasinumab globally.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the United States, we will lead commercialization activities, and the parties will share equally in any profits or losses in connection with commercialization of fasinumab. In the territory outside of the United States, Teva will lead commercialization activities and we will supply product to Teva at a tiered purchase price, which is calculated as a percentage of net sales of the product (subject to adjustment in certain circumstances).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alnylam</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we and Alnylam Pharmaceuticals, Inc. entered into a collaboration to discover RNA interference ("RNAi")  therapeutics for NASH and potentially other related diseases, as well as to research, co-develop and commercialize any therapeutic product candidates that emerge from these discovery efforts (including ALN-HSD, which is currently in Phase 1 clinical development). ALN-HSD is being co-developed with Alnylam with terms generally consistent with the form of a Co-Commercialization Collaboration Agreement in connection with the 2019 collaboration agreement as described below. Alnylam </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is conducting the Phase 1 clinical trial for ALN-HSD and Regeneron will be responsible for all other development as the lead party. The parties share equally, on an ongoing basis, development expenses for ALN-HSD.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we and Alnylam entered into a global, strategic collaboration to discover, develop, and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic disease targets expressed in the eye and central nervous system ("CNS"), in addition to a select number of targets expressed in the liver. Under the terms of the agreement, we made an up-front payment of $400.0&#160;million to Alnylam. For each program, we will provide Alnylam with a specified amount of funding at program initiation and at lead candidate designation, and Alnylam is eligible to receive up to an aggregate of $200.0 million in clinical proof-of-principle milestones for eye and CNS programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during 2019, the parties entered into a Co-Commercialization Collaboration Agreement for a silencing RNA ("siRNA") therapeutic targeting the C5 component of the human complement pathway being developed by Alnylam, with Alnylam as the lead party, and a License Agreement for a combination product consisting of cemdisiran and pozelimab, with us as the licensee. Under the C5 siRNA Co-Commercialization Collaboration agreement, the parties share costs equally and will split profits (if commercialized); and under the License Agreement, the licensee is responsible for its own costs and expenses. The C5 siRNA License Agreement contains a flat low double-digit royalty payable to Alnylam on our potential future net sales of the combination product only subject to customary reductions, as well as up to $325.0 million in commercial milestones.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellia</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2016, we entered into a license and collaboration agreement with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapeutic development. NTLA-2001, which is in clinical development, is subject to a co-development and co-commercialization arrangement pursuant to which Intellia will lead development and commercialization activities and the parties share an agreed-upon percentage of development expenses and profits (if commercialized)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, we expanded our existing collaboration with Intellia Therapeutics, Inc. to provide us with rights to develop products for additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CRISPR/Cas9-based therapeutic targets and for the companies to jointly develop potential products for the treatment of hemophilia A and B, with Regeneron leading development and commercialization activities. In addition, we also received non-exclusive rights to independently develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> gene edited products. In connection with the May 2020 agreement, we made a $70.0 million up-front payment and purchased shares of Intellia common stock for an aggregate purchase price of $30.0 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BARDA</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We and BARDA are parties to agreements pursuant to which HHS provided certain funding to develop, test, and manufacture a treatment for Ebola virus infection. In July 2020, HHS exercised its option under an existing agreement to provide up to $344.6&#160;million of additional funding for the manufacture and supply of Inmazeb. We expect to deliver a pre-specified number of Inmazeb treatment doses over the course of approximately six years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See "Agreements Related to COVID-19 - U.S. Government"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">section above for information related to our COVID-19 agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Kiniksa</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described under "Products" above, pursuant to a 2017 license agreement, we granted Kiniksa the right to develop and commercialize certain new indications for ARCALYST. During the first quarter of 2021, Kiniksa received marketing approval in the United States for a new indication of ARCALYST, recurrent pericarditis, and, as a result, we received a $20.0 million milestone payment from Kiniksa. The quarterly period ended March 31, 2021 was the last quarter for which the Company recorded net product sales of ARCALYST.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this approval, Kiniksa is solely responsible for the U.S. development and commercialization of ARCALYST in all approved indications, and Regeneron will continue to supply clinical and commercial product to Kiniksa. Kiniksa will pay Regeneron 50% of its profits from sales of ARCALYST and the parties will not share in any losses incurred by Kiniksa in connection with commercialization of ARCALYST.</span></div><div id="iae35796f039b495ba4b10877e85a1c6f_82"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in the State of New York in 1988 and publicly listed in 1991. Our principal executive offices are located at 777 Old Saw Mill River Road, Tarrytown, New York 10591, and our telephone number at that address is (914) 847-7000. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available free of charge on or through our Internet website (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.regeneron.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and, if applicable, amendments to those reports filed or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission ("SEC"). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors and other interested parties should note that we use our media and investor relations website (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://newsroom.regeneron.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and our social media channels to publish important information about Regeneron, including information that may be deemed material to investors. We encourage investors and other interested parties to review the information we may publish through our media and investor relations website and the social media channels listed on our media and investor relations website, in addition to our SEC filings, press releases, conference calls, and webcasts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained on our websites and social media channels is not included as a part of, or incorporated by reference into, this report.</span></div><div id="iae35796f039b495ba4b10877e85a1c6f_85"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Three and Nine Months Ended September&#160;30, 2021 and 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.880%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,120.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,074.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,812.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,307.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,409.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,822.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,585.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,846.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:31.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales in the United States:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,473.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:9pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,530.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:9pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:9pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,294.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,120.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,074.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,045.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Net product sales of Praluent in the United States were recorded by Sanofi prior to April 1, 2020.</span></div></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Sales</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales of EYLEA in the United States increased for the three and nine months ended September&#160;30, 2021, compared to the same periods in 2020, primarily due to higher sales volume (including the adverse impact of the COVID-19 pandemic on U.S. EYLEA demand during the three months ended June 30, 2020), partly offset by an increase in sales-related deductions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Refer to "Collaboration, License, and Other Agreements - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" section above for further details. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three and nine months ended September&#160;30, 2021 and 2020, net product sales of REGEN-COV were recorded in connection with our agreements with the U.S. government. Refer to "Agreements Related to COVID-19 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">U.S. Government</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">" section above for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Sanofi Collaboration Revenue</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"></td><td style="width:47.851%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestone earned</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Antibody</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,386.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of losses in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Immuno-oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Sanofi collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Corresponding costs incurred by us in connection with such production is recorded within Cost of collaboration and contract manufacturing</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Antibody</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi provides us with an estimate of our share of the profits or losses from commercialization of antibodies for the most recent fiscal quarter; these estimates are reconciled to actual results in the subsequent fiscal quarter, and our portion of the profits or losses is adjusted accordingly, as necessary. During the three and nine months ended September&#160;30, 2021, the increase in our share of profits in connection with commercialization of antibodies, compared to the same periods of 2020, was driven by higher Dupixent profits. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron's share of profits in connection with the commercialization of Dupixent, Praluent (through March 31, 2020), and Kevzara is summarized below: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:52.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent, Praluent, and Kevzara net product sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,658.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,151.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of collaboration profits  </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of development expenses incurred by Sanofi in accordance with Regeneron's payment obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105.0)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.5)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555.6</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of collaboration profits as a percentage of Dupixent, Praluent, and Kevzara net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Global net product sales of Dupixent and Kevzara are recorded by Sanofi. The quarter ended March 31, 2020 was the last quarter for which Sanofi and the Company shared profits and losses in connection with Sanofi's global net sales and the related commercialization of Praluent (see further details below); therefore, the quarter ended March 31, 2020 was the last quarter for which net product sales of Praluent were included in the table above.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above under "Collaboration, License, and Other Agreements - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sanofi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States. Under the new agreement, Sanofi is solely responsible for the development and commercialization of Praluent outside of the United States, and pays the Company a 5% royalty on Sanofi&#8217;s net product sales of Praluent outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021 and 2020, the Company earned $50.0&#160;million sales-based milestones from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.5&#160;billion and $1.0&#160;billion, respectively, on a rolling twelve-month basis. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bayer Collaboration Revenue</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:52.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's net profit in connection with commercialization of EYLEA outside the United States</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Bayer collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Corresponding costs incurred by us in connection with such production is recorded within Cost of collaboration and contract manufacturing</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron's net profit in connection with commercialization of EYLEA outside the United States is summarized below: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:52.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA net product sales outside the United States </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of collaboration profit from sales outside the United States</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.4)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's net profit in connection with commercialization of EYLEA outside the United States</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772.6</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's net profit as a percentage of EYLEA net product sales outside the United States</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37%</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bayer records net product sales of EYLEA outside the United States. Bayer provides us with an estimate of our share of the profit, including the percentage of sales in Japan that we earned, from commercialization of EYLEA outside the United States for the most recent fiscal quarter; these estimates are reconciled to actual results in the subsequent fiscal quarter, and our portion of the profit is adjusted accordingly, as necessary.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Roche Collaboration Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above under "Agreements Related to COVID-19 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", Roche distributes and records net product sales of the casirivimab and imdevimab antibody cocktail outside the United States, and the parties share gross profits from worldwide sales, depending on the amount of manufactured product supplied by each party to the market. Each quarter, a single payment is due from one party to the other to true-up the global gross profits between the parties. If Regeneron is to receive a true-up payment from Roche, such amount will be recorded to Collaboration revenue. If Regeneron is to make a true-up payment to Roche, such amount will be recorded to Cost of goods sold.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2021, true-up payments owed from Roche in connection with this agreement were $127.1 million and $361.8 million, respectively. Roche provides us with an estimate of its gross profits for the most recent fiscal quarter; these estimates are reconciled to actual results in the subsequent fiscal quarter, and the true-up of global gross profits is adjusted accordingly, as necessary.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue decreased during the three and nine months ended September&#160;30, 2021, compared to the same periods of 2020, primarily due to lower amounts recognized in connection with our agreement with BARDA related to funding of certain development activities for COVID-19 antibodies, and, to a lesser extent, Inmazeb. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.267%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except headcount data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,122.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,990.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration and contract manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expense (income), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,812.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average headcount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Includes costs incurred as well as cost reimbursements from collaborators who are not deemed to be our customers</span></div></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Cost of goods sold primarily includes costs in connection with producing commercial supplies for products that are sold by Regeneron in the United States (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">i.e.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> for which we record net product sales), any royalties we are obligated to pay on such sales, and amounts we are obligated to pay to Sanofi for its share of Libtayo U.S. gross profits.</span></div></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Cost of collaboration and contract manufacturing includes costs we incur in connection with producing commercial drug supplies for collaborators and others.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses included a total of $136.9 million and $101.2 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $413.3 million and $310.5 million for the nine months ended September&#160;30, 2021 and 2020, respectively, of non-cash compensation expense related to equity awards granted under our long-term incentive plans. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our estimates of direct research and development expenses by clinical development program and other significant categories of research and development expenses. Direct research and development expenses are comprised primarily of costs paid to third parties for clinical and product development activities, including costs related to preclinical research activities, clinical trials, and the portion of research and development expenses incurred by our collaborators that we are obligated to reimburse. Indirect research and development expenses have not been allocated directly to each program, and primarily consist of costs to compensate personnel, overhead and infrastructure costs to maintain our facilities, and other costs related to activities that benefit multiple projects. Clinical manufacturing costs primarily consist of costs to manufacture bulk drug product for clinical development purposes as well as related external drug filling, packaging, and labeling costs. Clinical manufacturing costs also includes pre-launch commercial supplies which did not meet the criteria to be capitalized as inventory. The table below also includes reimbursements of research and development expenses by collaborators, as when we are entitled to reimbursement of all or a portion of such expenses that we incur under a collaboration, we record those reimbursable amounts in the period in which such costs are incurred.</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo (cemiplimab)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dupixent (dupilumab)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fasinumab</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up-front payments related to license and collaboration agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other product candidates in clinical development and other research programs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect research and development expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab supplies and other research and development costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy and other operating costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total indirect research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical manufacturing costs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses by collaborators</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(411.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,122.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,990.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Certain prior year amounts have been reclassified to conform to the current year's presentation</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the nine months ended September 30, 2020 included the $70.0 million up-front payment and the amount paid in excess of the fair value of the shares purchased, or $15.0 million, in connection with our collaboration agreement with Intellia (see "Collaboration and License Agreements - Intellia" above). Direct research and development expenses in 2020 also include costs incurred in connection with Kevzara for the treatment of COVID-19 patients (included within "Other product candidates in clinical development and other research programs" in the table above).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement of research and development expenses by collaborators included reimbursements from Roche related to REGEN-COV of $10.5&#160;million and $138.3&#160;million for the three and nine months ended September&#160;30, 2021, respectively, and $9.5&#160;million for both the three and nine months ended September&#160;30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses included non-cash compensation expense of $73.1 million and $55.9 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $213.7 million and $169.5 million for the nine months ended September&#160;30, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous uncertainties associated with drug development, including uncertainties related to safety and efficacy data from each phase of drug development, uncertainties related to the enrollment and performance of clinical trials, changes in regulatory requirements, changes in the competitive landscape affecting a product candidate, and other risks and uncertainties described in Part II, Item 1A. "Risk Factors" (including those relating to the disruptions caused by the COVID-19 pandemic). There is also variability in the duration and costs necessary to develop a pharmaceutical product, potential opportunities and/or uncertainties related to future indications to be studied, and the estimated cost and scope of the projects. The lengthy process of seeking FDA and other applicable approvals, and subsequent compliance with applicable statutes and regulations, require the expenditure of substantial resources. Any failure by us to obtain, or delay in obtaining, regulatory approvals could materially adversely affect our business. We are unable to reasonably estimate if our product candidates in clinical development will generate material product revenues and net cash inflows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General, and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses increased for the three and nine months ended September&#160;30, 2021, compared to the same periods in 2020, primarily due to higher headcount-related costs and an increase in commercialization-related expenses for EYLEA, including direct-to-consumer advertising. In addition, the nine months ended September 30, 2021 included increased commercialization-related expenses for Libtayo and costs associated with educational campaigns related to COVID-19. Selling, general, and administrative expenses also included non-cash compensation expense of $48.7 million and $35.9 million for the three months ended September&#160;30, 2021 and 2020, respectively, and $149.1 million and $114.4 million for the nine months ended September&#160;30, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold increased for the three and nine months ended September 30, 2021, compared to the same periods in 2020, primarily due to the recognition of manufacturing costs in connection with product sales of REGEN-COV. In addition, Cost of goods sold included inventory write-offs and reserves totaling $38.7 million and $188.0 million for the three and nine months ended September&#160;30, 2021, respectively (primarily related to REGEN-COV for the nine months ended September 30, 2021). Inventory write-offs and reserves were $11.8&#160;million and $23.6&#160;million for the three and nine months ended September&#160;30, 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Collaboration and Contract Manufacturing</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of collaboration and contract manufacturing increased for the three and nine months ended September&#160;30, 2021, compared to the same periods in 2020, primarily due to the recognition of manufacturing costs associated with higher sales of Dupixent. The increase for the nine months ended September&#160;30, 2021 was partly offset by the recognition of process validation costs during 2020 in connection with manufacturing Inmazeb under our BARDA agreement; such costs did not recur during 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Expense (Income)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expense (income), net, includes recognition of a portion of amounts previously deferred in connection with up-front and development milestone payments, as applicable, received in connection with Sanofi IO, Teva, and MTPC collaborative arrangements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021, we updated our estimate of the total research and development costs expected to be incurred (which resulted in a change to the estimate of the stage of completion) in connection with the Sanofi IO Collaboration, and, as a result, recorded a cumulative catch-up adjustment of $66.9&#160;million as a reduction to other operating income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net, for the nine months ended September 30, 2021, compared to the same period in 2020, was primarily impacted by the recognition of higher unrealized gains on equity securities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:46.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.193%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.193%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.193%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except effective tax rate)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for the three and nine months ended September&#160;30, 2021 was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation, income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate, the foreign-derived intangible income deduction, and federal tax credits for research activities. In addition, the effective tax rate for the nine months ended September 30, 2021 was positively impacted by the reversal of liabilities related to uncertain tax positions. Our effective tax rate for the three and nine months ended&#160;September&#160;30, 2020&#160;was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation, and, to a lesser extent, income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate and federal tax credits for research activities.</span></div><div id="iae35796f039b495ba4b10877e85a1c6f_88"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.853%"><tr><td style="width:1.0%"></td><td style="width:44.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,432.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - current </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,355.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,631.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,135.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,418.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,722.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,696.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,775.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,779.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,996.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,714.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,060.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,081.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we also had borrowing availability of $750.0 million under a revolving credit facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash for the Nine Months Ended September&#160;30, 2021 and 2020</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.818%"><tr><td style="width:1.0%"></td><td style="width:48.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.083%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.083%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,708.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,321.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows (used in) provided by investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,372.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,606.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,665.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of marketable securities during the nine months ended September 30, 2020 included proceeds in connection with funding our stock repurchase from Sanofi (as described below). Capital expenditures during the nine months ended September&#160;30, 2021 included costs associated with the expansion of our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, including construction of a fill/finish facility and related equipment. We expect to incur capital expenditures of $545 million to $575 million for the full year of 2021 primarily in connection with the continued expansion of our manufacturing facilities, including the fill/finish facility. Capital expenditures expected to be incurred during the remainder of 2021 also include costs related to plans to expand our research, preclinical manufacturing, and support facilities at our Tarrytown, New York campus. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuances of Common Stock, in connection with exercises of employee stock options, were&#160;$1.130 billion during the nine months ended September&#160;30, 2021, compared to&#160;$2.471 billion&#160;during the nine months ended September&#160;30, 2020. For additional information related to cash flows from financing activities, see "Share Repurchase Program", "Secondary Offering and Purchase of Regeneron Common Stock Held by Sanofi", and "Issuance of Senior Notes" sections below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, our board of directors authorized a share repurchase program to repurchase up to&#160;$1.0 billion&#160;of our Common Stock. As of December 31, 2020, the Company had repurchased the entire $1.0 billion of its Common Stock that it was authorized to repurchase under this program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, our board of directors authorized an additional share repurchase program to repurchase up to $1.5&#160;billion of our Common Stock. The share repurchase program was approved under terms substantially similar to the November 2019 share repurchase program. Repurchases may be made from time to time at management&#8217;s discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. The program has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases in the future. We plan to finance the share repurchase program with available cash.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2021, we repurchased&#160;1,567,555 shares of our Common Stock under the January 2021 program and recorded the cost of the shares received, or&#160;$802.7 million, as Treasury Stock. As of September&#160;30, 2021, $697.3 million remained available for share repurchases under the program. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Secondary Offering and Purchase of Regeneron Common Stock Held by Sanofi</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, a secondary offering of 13,014,646 shares of our Common Stock (the "Secondary Offering") held by Sanofi was completed. In connection with the Secondary Offering, we also purchased 9,806,805 shares of our Common Stock directly from Sanofi for an aggregate purchase amount of $5.0&#160;billion (the "Stock Purchase"). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded the Stock Purchase with a combination of cash on hand, proceeds from the sale of marketable securities, and proceeds from loans under a $1.5&#160;billion senior unsecured bridge loan facility (the "Bridge Facility") which was entered into in May 2020. The Bridge Facility was repaid in August 2020 following the issuance and sale of the Company's senior unsecured notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of Senior Notes</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we issued and sold $1.250&#160;billion aggregate principal amount of senior unsecured notes due 2030 (the "2030 Notes") and $750&#160;million aggregate principal amount of senior unsecured notes due 2050 (the "2050 Notes" and, together with the 2030 Notes, the "Notes"). Net proceeds from the issuance and sale of the Notes (after deducting underwriting discounts and offering expenses) were used in part to repay in full the Bridge Facility described above, including accrued interest and related fees and expenses in connection therewith.</span></div><div id="iae35796f039b495ba4b10877e85a1c6f_91"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our critical accounting policies and use of estimates are presented in Part II, Item&#160;7. "Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020 (filed February 8, 2021).&#160;There have been no material changes to our critical accounting policies and use of estimates during the nine months ended September&#160;30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Impact of Recently Issued Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the future adoption of recently issued accounting standards is not expected to have a material impact on the Company's financial position or results of operations.</span></div><div id="iae35796f039b495ba4b10877e85a1c6f_94"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks, and the way we manage them, are summarized in Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020 (filed February 8, 2021). There have been no material changes to our market risks or to our management of such risks as of September&#160;30, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.  CONTROLS AND PROCEDURES </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this report. Based on this evaluation, our principal executive officer and principal financial officer each concluded that, as of the end of such period, our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported on a timely basis, and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September&#160;30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="iae35796f039b495ba4b10877e85a1c6f_100"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="iae35796f039b495ba4b10877e85a1c6f_103"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.  LEGAL PROCEEDINGS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item is incorporated herein by reference to the information set forth in Note 12 to our Condensed Consolidated Financial Statements included in this report.</span></div><div id="iae35796f039b495ba4b10877e85a1c6f_106"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in an environment that involves a number of significant risks and uncertainties. We caution you to read the following risk factors, which have affected, and/or in the future could affect, our business, prospects, operating results, and financial condition. The risks described below include forward-looking statements, and actual events and our actual results may differ materially from these forward-looking statements. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may also impair our business, prospects, operating results, and financial condition. Furthermore, additional risks and uncertainties are described under other captions in this report and should also be considered by our investors. For purposes of this section (as well as this report in general), references to our products encompass products marketed or otherwise commercialized by us and/or our collaborators or licensees and references to our product candidates encompass product candidates in development by us and/or our collaborators or licensees  (in the case of collaborated or licensed products or product candidates under the terms of the applicable collaboration or license agreements), unless otherwise stated or required by the context. In this section, we first provide a summary of the more significant risks and uncertainties we face and then provide a full set of risk factors and discuss them in greater detail. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Summary of Risk Factors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As noted above, we are subject to a number of risks that if realized could materially harm our business, prospects, operating results, and financial condition. Some of the more significant risks and uncertainties we face include those summarized below. The summary below is not exhaustive and is qualified by reference to the full set of risk factors set forth in this "Risk Factors" section. Please carefully consider all of the information in this Form 10-Q, including the full set of risks set forth in this "Risk Factors" section, and in our other filings with the SEC before making an investment decision regarding Regeneron.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business may be further adversely affected by the effects of the COVID-19 pandemic, including those impacting our manufacturing and supply chain operations, research and development efforts, commercial operations and sales force, administrative personnel, third-party service providers, and business partners and customers, as well as the demand for our marketed products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks related to the development, manufacturing, and commercialization of REGEN-COV.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization Risks </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on the success of EYLEA and Dupixent. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sales of our products are dependent on the availability and extent of reimbursement from third-party payors, including private payors and government programs such as Medicare and Medicaid, which could change due to various factors such as drug price control measures that have been or may be introduced in the United States by various federal and state authorities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The commercial success of our products is subject to significant competition from products or product candidates that may be superior to, or more cost effective than, our products or product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our collaborators on which we rely to commercialize some of our marketed products may be unable to continue to successfully commercialize or co-commercialize our products, both in the United States and abroad.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                     </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory and Development Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development and obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Serious complications or side effects in connection with the use or development of our products or product candidates could cause our regulatory approvals to be revoked or limited or lead to delay or discontinuation of development of our product candidates or new indications for our marketed products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to formulate or manufacture our product candidates in a way that is suitable for clinical or commercial use, which would delay or prevent continued development of such candidates and/or receipt of regulatory approval or commercial sale.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of our products are intended to be used in combination with drug-delivery devices, which may result in additional regulatory, commercialization, and other risks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property and Market Exclusivity Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to protect the confidentiality of our trade secrets, and our patents or other means of defending our intellectual property may be insufficient to protect our proprietary rights.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patents or proprietary rights of others may restrict our development, manufacturing, and/or commercialization efforts and subject us to patent litigation and other proceedings that could find us liable for damages.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss or limitation of patent rights, and regulatory pathways for biosimilar competition, could reduce the duration of market exclusivity for our products, including EYLEA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We rely on limited internal and contracted manufacturing and supply chain capacity, which could adversely affect our ability to commercialize our products and to advance our clinical pipeline. As we increase our production in response to higher product demand or in anticipation of a potential regulatory approval, our current manufacturing capacity will likely not be sufficient, and our dependence on our collaborators and/or contract manufacturers may increase, to produce adequate quantities of drug material for both commercial and clinical purposes.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanding our manufacturing capacity and establishing fill/finish capabilities will be costly and we may be unsuccessful in doing so in a timely manner, which could delay or prevent the launch and successful commercialization of our products approved for marketing and could jeopardize our clinical development programs.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to manufacture products may be impaired if any of our or our collaborators&#8217; manufacturing activities, or the activities of other third parties involved in our manufacture and supply chain, are found to infringe patents of others.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If sales of our marketed products do not meet the levels currently expected, or if the launch of any of our product candidates is delayed or unsuccessful, we may face costs related to excess inventory or unused capacity at our manufacturing facilities and at the facilities of third parties or our collaborators.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party service or supply failures, failures at our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, or failures at the facilities of any other party participating in the supply chain, would adversely affect our ability to supply our products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our or our collaborators&#8217; failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Regulatory and Litigation Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business activities have been, and may in the future be, challenged under federal or state healthcare laws, which may subject us to civil or criminal proceedings, investigations, or penalties.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions, and fines.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face risks from the improper conduct of our employees, agents, contractors, or collaborators, including those relating to potential non-compliance with relevant laws and regulations such as the Foreign Corrupt Practices Act and the U.K. Bribery Act.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations are subject to environmental, health, and safety laws and regulations, including those governing the use of hazardous materials.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in laws and regulations affecting the healthcare industry could adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tax liabilities and risks associated with our operations outside of the United States could adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face potential liability related to the personal information we collect from individuals, data brokers, or research institutions or obtain from clinical trials sponsored by us or our collaborators.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our collaborations with Sanofi or Bayer are terminated or breached, our ability to develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, would be materially harmed.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our collaborators and service providers may fail to perform adequately in their efforts to support the development, manufacture, and commercialization of our drug candidates and current and future products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Risks Factors &#8211; Risks Related to Employees, Information Technology, Financial Results and Liquidity, and Our Common Stock</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is dependent on our key personnel and will be harmed if we cannot recruit and retain leaders in our research, development, manufacturing, and commercial organizations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant disruptions of information technology systems or breaches of data security could adversely affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need additional funding in the future, which may not be available to us, and which may force us to delay, reduce, or eliminate our product development programs or commercialization efforts.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our indebtedness could adversely impact our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price is extremely volatile.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our existing shareholders may be able to exert significant influence over matters requiring shareholder approval and over our management.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*       *       *</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be further adversely affected by the effects of the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, a novel strain of coronavirus, SARS-CoV-2, causing a disease referred to as COVID-19, was reported to have surfaced in Wuhan, China. It has since spread around the world, including the United States; and, in March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. This pandemic has adversely affected or has the potential to adversely affect, among other things, the economic and financial markets and labor resources of the countries in which we operate; our manufacturing and supply chain operations, research and development efforts, commercial operations and sales force, administrative personnel, third-party service providers, and business partners and customers; and the demand for our marketed products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic has resulted in travel and other restrictions to reduce the spread of the disease, including governmental orders across the globe, which, among other things, direct individuals to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, maintain social distancing, order cessation of non-essential travel, and require proof of vaccination and/or negative COVID-19 test results. Though some of these restrictions have eased, the continuation or recurrence of these restrictions remains uncertain and will depend on many factors, including any future spikes in COVID-19 cases and the continued availability and efficacy of vaccines and treatments. It is expected that the pandemic will continue to ebb and flow, with different jurisdictions having higher levels of infections than others over the course of the pandemic. In addition, new variants of the SARS-CoV-2 virus have emerged, have been shown to be present in many geographies, and appear to spread more easily and quickly than other variants. As a result, shelter-in-place and social distancing orders, government-imposed quarantines, and work-from-home policies (which we previously implemented for a significant portion of our employees) may continue to varying degrees for the duration of the COVID-19 pandemic and may further negatively impact productivity, disrupt our business, and delay our clinical programs and development timelines beyond the delays we have already experienced and disclosed; the magnitude of these developments will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Such restrictions and limitations may also further negatively impact our access to regulatory authorities (which are affected, among other things, by applicable travel restrictions and may be delayed in responding to inquiries, reviewing filings, and conducting inspections); our ability to perform regularly scheduled quality checks and maintenance; and our ability to obtain services from third-party specialty vendors and other providers or to access their expertise as fully and timely as needed. The COVID-19 pandemic may also result in the loss of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">some of our key personnel, either temporarily or permanently. We and our employees may also be subject to government vaccine mandates, such as President Biden's recent Executive Order entitled "Executive Order on Ensuring Adequate COVID Safety Protocols for Federal Contractors" applicable to certain federal contractors (which we expect to become effective for us on December 8, 2021). Any such requirement may have a negative impact on our ability to retain employees or hire new employees and could adversely impact our business. In addition, our sales and marketing efforts were previously negatively impacted and may be further negatively impacted by postponement or cancellation of face-to-face meetings and restrictions on access by non-essential personnel to hospitals or clinics to the extent such measures slow down adoption or further commercialization of our marketed products. The demand for our marketed products may also be adversely impacted by the restrictions and limitations adopted in response to the COVID-19 pandemic, particularly to the extent they affect the patients' ability or willingness to start or continue treatment with our marketed products. Any of the foregoing factors may result in lower net product sales of our marketed products. For example, net product sales of EYLEA in the United States decreased for the three months ended June 30, 2020, compared to the same period in 2019, due in part to the impact of the COVID-19 pandemic. See Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Results of Operations" for a discussion of our net product sales. Demand for some or all of our marketed products may be further reduced if shelter-in-place, social distancing, or similar orders remain in effect or are re-implemented and, as a result, some of our inventory may become obsolete and may need to be written off, impacting our operating results. These and similar, and perhaps more severe, disruptions in our operations may materially adversely impact our business, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quarantines, shelter-in-place, social distancing, and similar government orders (or the perception that such orders, shutdowns, or other restrictions on the conduct of business operations could occur) related to COVID-19 previously impacted, and may impact in the future, personnel at our research and manufacturing facilities, our suppliers, and other third parties on which we rely, as well as the availability or cost of materials produced by or purchased from such parties, resulting in supply chain strains or disruptions that may become material. While some materials and services may be obtained from more than one supplier or provider, port closures and other restrictions resulting from the COVID-19 pandemic (including any government restrictions or limitations, such as those that may be imposed under the Defense Production Act) could materially disrupt our supply chain or limit our ability to obtain sufficient materials or services (including fill/finish services) required for the development and manufacturing of our products and product candidates as well as our research efforts. If microbial, viral (including COVID-19), or other contaminations are discovered in our products, product candidates, the materials used for their production, or in our facilities, or in the facilities of our collaborators, third-party contract manufacturers, or other providers or suppliers, the affected facilities may need to be closed or may otherwise be affected for an extended period of time, or the contamination may result in other delays or disruptions in our direct or indirect supply chain. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, infections and deaths related to COVID-19 previously disrupted and may in the future disrupt the United States' healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources away from, or materially delay, FDA review and potential approval of our product candidates and new indications for our marketed products. In addition, some of our clinical trials were previously and may in the future be affected by the COVID-19 pandemic. This impact could result in further delays in site initiation and patient enrollment due to prioritization of hospital resources toward the COVID-19 pandemic, patients' inability to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, and restrictions on trial initiations imposed by hospitals and other trial sites as a result of the COVID-19 pandemic. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, was previously and may in the future be delayed or disrupted. We continue to evaluate the adverse impact of the COVID-19 pandemic on an individual trial basis. Any such disruptions may further negatively impact the progress of our clinical trials, including the readouts of trial results, the timing of regulatory review, and any anticipated program milestones. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, it previously caused significant disruption of global financial markets and could cause more economic disruption in the future, making it more difficult for us to access capital if needed. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our Common Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic continues to rapidly evolve. The ultimate impact of this pandemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems, or the global economy as a whole. These effects could have a material impact on our operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the COVID-19 pandemic adversely affects our business, prospects, operating results, or financial condition, it may also have the effect of heightening many of the other risks described in this "Risk Factors" section.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We face risks related to the development, manufacturing, and commercialization of REGEN-COV.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the recent global outbreak of COVID-19, we developed and are manufacturing and commercializing, in collaboration with Roche, REGEN-COV (known as Ronapreve in other countries outside the United States), a novel investigational antibody cocktail treatment designed to prevent and treat infection from the SARS-CoV-2 virus that received an </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EUA from the FDA in November 2020. There can be no assurance with respect to how long the EUA will remain in effect, whether the EUA will be further expanded (such as to include the treatment of hospitalized COVID-19 patients) based on new clinical trial results or otherwise, and whether the EUA will be revoked by the FDA based on its determination that the underlying health emergency no longer exists or warrants such authorization or other reasons (including if REGEN-COV is found to be less effective or not effective against new variants of the SARS-CoV-2 virus). In addition, there are multiple ongoing clinical trials (as discussed in Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations &#8211; Programs in Clinical Development") evaluating the safety and efficacy of the antibody cocktail and there is no assurance of favorable results from any ongoing or future clinical trials, the timing of their completion, or the FDA's or other regulatory authorities' favorable determinations based on data from any such clinical trial. It is also possible that the FDA and certain other regulatory authorities may not grant the antibody cocktail full marketing approval for the treatment of COVID-19, or that any such marketing approvals, if granted, may have significant limitations on its use. Further, other parties may be successful in developing a more efficacious, more easily administered, more cost-effective, or otherwise superior treatment for COVID-19; and utilization of REGEN-COV has been and may in the future be adversely impacted by other factors, such as the rollout of vaccines providing acquired immunity against COVID-19 and the distribution model for REGEN-COV or other treatments for COVID-19. Any of these factors may negatively impact the uptake or commercialization of REGEN-COV, and such impact may be material. The intense public interest, including speculation by the media, in the development and commercialization of REGEN-COV has caused or contributed to significant volatility in our stock price, which may continue as data and other information from the ongoing and any future clinical trials evaluating REGEN-COV and third-party product candidates for the treatment or prevention of COVID-19 as well as any other regulatory actions become public.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also face risks related to our significant investment in the development, supply, allocation, distribution, pricing, and commercialization of REGEN-COV. Given the severity and urgency of the COVID-19 pandemic, we have committed significant capital and resources to fund and supply clinical trials and to accelerate and scale up the production of REGEN-COV, which involves a complex manufacturing process that is both resource- and time-sensitive. We expect our investment in the development and manufacture of REGEN-COV to continue through 2021 and potentially beyond, although the magnitude of our investment will be subject to clinical data results, the duration of the COVID-19 pandemic, and other factors, including regulatory outcomes. If we are unable to maintain the EUA or obtain regulatory approvals, or if we make a strategic decision to discontinue development of REGEN-COV or are otherwise not successful in the commercialization of REGEN-COV, we may be unable to recoup our significant expenses incurred to date and/or in the future related to the development and production of REGEN-COV. While we previously recognized significant net product sales and collaboration revenue in connection with sales of REGEN-COV and expect to recognize additional significant net product sales under the September 2021 amended supply agreement with the U.S. government, the degree to which future sales of REGEN-COV will continue to impact our results of operations is highly uncertain.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our internal and contracted manufacturing capacity may not be sufficient to cover the demand for REGEN-COV. While we have entered into a collaboration agreement with Roche to develop, manufacture, and distribute REGEN-COV, we cannot be certain that our current manufacturing and distribution capacity for REGEN-COV and the increased manufacturing and distribution capacity through our collaboration with Roche will be sufficient. In addition, we rely entirely on third parties for filling and finishing services for REGEN-COV. Our third-party fill/finish providers may not have sufficient capacity or may otherwise not be able to provide such services on a timely basis in the quantities requested (such as because they devote their capacity to other drugs or vaccines against COVID-19), which we previously experienced. The ability of our third-party providers to deliver such services to us may further be adversely impacted by the imposition of government restrictions or limitations (including those that may be imposed under the Defense Production Act). If we are unable to timely enter into alternative arrangements, or if such alternative arrangements are not available on satisfactory terms or at all, we may experience delays in the development, manufacturing, and distribution of REGEN-COV.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We and Roche also face challenges related to the allocation of existing and future supply of REGEN-COV, particularly with respect to geographic distribution. As supplies of REGEN-COV are expected to remain constrained, it is possible that the U.S. government may limit or restrict our and/or Roche's ability to distribute and commercialize REGEN-COV outside of the United States. In addition, as a result of the emergency situations in many countries, there is a heightened risk that REGEN-COV may be subject to adverse governmental actions in certain countries. The U.S. government may exercise or assert certain rights with respect to our inventions, products, or product candidates. For example, under the Defense Production Act, the U.S. government may, among other things, require domestic industries to provide essential goods and services needed for the national defense, such as drug material or other supplies needed to treat COVID-19 patients, which could require us to allocate manufacturing capacity in a way that impacts our regular operations. In addition, our agreements with the U.S. government contain provisions granting the U.S. government certain rights relating to products, product candidates, and related inventions (as applicable) covered by those agreements. For example, our July 2020 agreement with the U.S. government to manufacture and deliver REGEN-COV to the U.S. government gives the U.S. government, among other rights, the right to require us to grant a non-exclusive license to applicable inventions to a third party if such action is deemed necessary to alleviate certain health or safety needs. This right may be triggered if we, for example, do not manufacture or supply sufficient product to address such needs. If </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the U.S. government exercises or asserts any such rights or imposes these or similar measures with respect to our products, product candidates, or related inventions (including REGEN-COV), it may adversely impact our business and results of operations. Foreign governments (including the government of Ireland, where we have manufacturing facilities) may have similar rights or attempt to assert any such rights. Further, we have observed and are likely to continue to face significant public attention and scrutiny over the complex decisions made regarding the REGEN-COV development program, including any allocation, distribution, or pricing decisions with respect to REGEN-COV. If we are unable to successfully manage these risks, we could face significant reputational harm, which could, among other adverse consequences, negatively affect our stock price.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on the success of EYLEA and Dupixent.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EYLEA net sales represent a substantial portion of our revenues and this concentration of our net sales in a single product makes us substantially dependent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on that product. For the nine months ended September&#160;30, 2021 and 2020, EYLEA net sales in the United States represented 38% and 59% of our total revenues, respectively, with EYLEA net sales as a percentage of our total revenues for the nine months ended September 30, 2021 being significantly lower due to the net product sales of REGEN-COV we recorded in that period in connection with deliveries of drug product under our agreements with the U.S. government. If we were to experience difficulty with the commercialization of EYLEA in the United States or if Bayer were to experience any difficulty with the commercialization of EYLEA outside the United States (including as a result of the COVID-19 pandemic discussed above), or if we and Bayer are unable to maintain current marketing approvals of EYLEA, we may experience a reduction in revenue and may not be able to sustain profitability, and our business, prospects, operating results, and financial condition would be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are dependent on our share of profits from the commercialization of Dupixent under our Antibody Collaboration with Sanofi. If we or Sanofi were to experience any difficulty with the commercialization of Dupixent or if we or Sanofi are unable to maintain current marketing approvals of Dupixent, we may experience a reduction in revenue and our business, prospects, operating results, and financial condition would be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our collaborators are unable to continue to successfully commercialize our products, our business, prospects, operating results, and financial condition will be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the degree of commercial success of our marketed products will continue to depend on many factors, including the following (as applicable):</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on our business and the demand for our marketed products, as well as its continued impact on, among other things, our employees, collaborators, suppliers, and other third parties on which we rely, our ability to continue to manage our supply chain, and the global economy (as further discussed above under "Risks Related to the COVID-19 Pandemic - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business may be further adversely affected by the effects of the COVID-19 pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"); </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectiveness of the commercial strategy in and outside the United States for the marketing of our products, including pricing strategy;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficient coverage of, and reimbursement for, our marketed products by third-party payors, including Medicare and Medicaid in the United States and other government and private payors in the United States and foreign jurisdictions, as well as U.S. and foreign payor restrictions on eligible patient populations and the reimbursement process (including drug price control measures that have been or may be introduced in the United States by various federal and state authorities);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and our collaborators' ability to maintain sales of our marketed products in the face of competitive products and to differentiate our marketed products from competitive products, including as applicable product candidates currently in clinical development; and, in the case of EYLEA, the existing and potential new competition for EYLEA (discussed further under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The commercial success of our products and product candidates is subject to significant competition - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed Products" below) and the willingness of retinal specialists and patients to start or continue treatment with EYLEA or to switch from another product to EYLEA;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of existing and new health care laws and regulations currently being considered or implemented in the United States, including price reporting and other disclosure requirements of such laws and regulations and the potential impact of such requirements on physician prescribing practices and payor coverage;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">serious complications or side effects in connection with the use of our marketed products, as discussed under "Risks Related to Maintaining Approval of Our Marketed Products and the Development and Obtaining Approval of Our Product Candidates and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Serious complications or side effects in connection with the use of our products and in clinical trials for our product candidates and new indications for our marketed products could cause our regulatory approvals to be revoked or limited or lead to delay or discontinuation </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of development of our product candidates or new indications for our marketed products, which could severely harm our business, prospects, operating results, and financial condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining and successfully monitoring commercial manufacturing arrangements for our marketed products with third parties who perform fill/finish or other steps in the manufacture of such products to ensure that they meet our standards and those of regulatory authorities, including the FDA, which extensively regulate and monitor pharmaceutical manufacturing facilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to meet the demand for commercial supplies of our marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of the pending proceedings relating to EYLEA, Dupixent, Praluent, and REGEN-COV (described further in Note 12 to our Condensed Consolidated Financial Statements included in this report), as well as other risks relating to our marketed products and product candidates associated with intellectual property of other parties and pending or future litigation relating thereto (as discussed under "Risks Related to Intellectual Property and Market Exclusivity" below);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the outcome of the pending government proceedings and investigations and other matters described in Note 12 to our Condensed Consolidated Financial Statements included in this report (including the civil complaint filed against us on June 24, 2020 in the U.S. District Court for the District of Massachusetts by the U.S. Attorney's Office for the District of Massachusetts); and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of post-approval studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and studies of other products that could implicate an entire class of products or are perceived to do so.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More detailed information about the risks related to the commercialization of our marketed products is provided in the risk factors below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators are subject to significant ongoing regulatory obligations and oversight with respect to the products we or our collaborators commercialize. If we or our collaborators fail to maintain regulatory compliance for any of such products, the applicable marketing approval may be withdrawn, which would materially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators are subject to significant ongoing regulatory obligations and oversight with respect to the products we or they commercialize for the products' currently approved indications in the United States, EU, and other countries where such products are approved. If we or our collaborators fail to maintain regulatory compliance or satisfy other obligations for such products' currently approved indications (including because the product does not meet the relevant endpoints of any required post-approval studies (such as those required under an accelerated approval by the FDA or other similar type of approval), or for any of the reasons discussed below under "Risks Related to Maintaining Approval of Our Marketed Products and the Development and Obtaining Approval of Our Product Candidates and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), the applicable marketing approval may be withdrawn, which would materially harm our business, prospects, operating results, and financial condition. Failure to comply may also subject us to sanctions, product recalls, or withdrawals of previously approved marketing applications. See also "Risks Related to Manufacturing and Supply - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of our marketed products are dependent on the availability and extent of reimbursement from third-party payors, and changes to such reimbursement may materially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our marketed products in the United States are dependent, in large part, on the availability and extent of reimbursement from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies ("PBMs"), and government programs such as Medicare and Medicaid. Sales of our marketed products in other countries are dependent, in large part, on similar reimbursement mechanisms and programs in those countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future revenues and profitability will be adversely affected in a material manner if such third-party payors do not adequately defray or reimburse the cost of our marketed products to patients. If these entities do not provide coverage and reimbursement with respect to our marketed products or provide an insufficient level of coverage and reimbursement, such products may be too costly for many patients to afford them, and physicians may not prescribe them. Many third-party payors cover only selected drugs, or may prefer selected drugs, making drugs that are not covered or preferred by such payors more expensive for patients. Third-party payors may also require prior authorization for reimbursement, or require failure on another type of treatment before covering a particular drug, particularly with respect to higher-priced drugs. As our currently marketed products and most of our product candidates are biologics, bringing them to market may cost more than bringing traditional, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">small-molecule drugs to market due to the complexity associated with the research, development, production, supply, and regulatory review of such products. Given cost sensitivities in many health care systems (which will likely be exacerbated as a result of the COVID-19 pandemic), our currently marketed products and product candidates are likely to be subject to continued pricing pressures, which may have an adverse impact on our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in order for private insurance and governmental payors (such as Medicare and Medicaid in the United States) to reimburse the cost of our marketed products, we must maintain, among other things, our FDA registration and our National Drug Code, formulary approval by PBMs, and recognition by insurance companies and the Centers for Medicare &amp; Medicaid Services (the "CMS"). There is no certainty that we will be able to obtain or maintain the applicable requirements for reimbursement (including relevant formulary coverage, as discussed further below) of our current and future marketed products, which may have a material adverse effect on our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other third-party payors (including PBMs) are challenging the prices charged for healthcare products and increasingly limiting, and attempting to limit, both coverage and level of reimbursement for prescription drugs, such as by requiring outcomes-based or other pay-for-performance pricing arrangements. They are also imposing restrictions on eligible patient populations and the reimbursement process, including by means of required prior authorizations and utilization management criteria, such as step therapy (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requiring the use of less costly medications before more costly medications are approved for coverage). Some states are also considering legislation that would control the prices and reimbursement of prescription drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any prescription drug for which supplemental rebates are not being paid. It is likely that federal and state legislatures and health agencies will continue to focus on additional health care reform measures in the future that will impose additional constraints on prices and reimbursements for our marketed products; this trend may be further accelerated as a result of the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation and policies (in addition to those already in effect) designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the out-of-pocket cost of prescription drugs, and reform government program reimbursement methodologies for drugs. President Biden and various members of his administration and the current U.S. Congress have indicated that lowering drug prices continues to be a legislative and political priority, as evidenced, for example, by the "Executive Order on Promoting Competition in the American Economy" issued by President Biden in July 2021. Proposals aimed at drug pricing introduced at the federal level include measures that would index the price of certain drugs (including those covered by Medicare Part B, such as EYLEA) using international or domestic reference pricing mechanisms, allow the government to negotiate prescription drug prices for Medicare and potentially other third-party payors, and permit the importation of drugs from other countries into the United States at lower prices. At the state level, legislatures are becoming increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and price and marketing cost disclosure and transparency measures. In some cases, these measures are designed to encourage importation from other countries and bulk purchasing. A reduction in the availability or extent of reimbursement from U.S. government programs (including as a result of the proposals, initiatives, and developments described above) could have a material adverse effect on the sales of EYLEA or our other marketed products. Economic pressure on state budgets may also have a similar impact. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, PBMs often develop formularies to reduce their cost for medications. The breadth of the products covered by formularies varies considerably from one PBM to another. Failure to be included in such formularies or to achieve favorable formulary status may negatively impact the utilization and market share of our marketed products. If our marketed products are not included within an adequate number of formularies, adequate reimbursement levels are not provided, the eligible insured patient population for our products is limited, or a key payor refuses to provide reimbursement for our products in a particular jurisdiction altogether, this could have a material adverse effect on our and our collaborators' ability to commercialize the applicable product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain foreign countries, pricing, coverage, and level of reimbursement of prescription drugs are subject to governmental control, and we and our collaborators may be unable to obtain coverage, pricing, and/or reimbursement on terms that are favorable to us or necessary for us or our collaborators to successfully commercialize our marketed products in those countries. In some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country, and may take into account the clinical effectiveness, cost, and service impact of existing, new, and emerging drugs and treatments. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company placing the medicinal product on the market. Our results of operations may suffer if we or our collaborators are unable to market our products in foreign countries or if coverage and reimbursement for our marketed products in foreign countries is limited or delayed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial success of our products and product candidates is subject to significant competition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketed Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is substantial competition in the biotechnology and pharmaceutical industries from biotechnology, pharmaceutical, and chemical companies. Many of our competitors have substantially greater research, preclinical and clinical product development and manufacturing capabilities, as well as financial, marketing, and human resources, than we do. Our smaller competitors may also enhance their competitive position if they acquire or discover patentable inventions, form collaborative arrangements, or merge with larger pharmaceutical or biotechnology companies. There is significant actual and potential future competition for each of our marketed products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EYLEA faces significant competition in the marketplace. For example, EYLEA competes in one or more of its approved indications with other VEGF inhibitors, including Novartis and Genentech/Roche's Lucentis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ranibizumab), Novartis' Beovu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brolucizumab), and Genentech/Roche's Susvimo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ranibizumab ocular implant), as well as Samsung Bioepis Co., Ltd. and Biogen Inc.'s biosimilar referencing Lucentis. Ophthalmologists are also using off-label, third-party repackaged versions of Genentech/Roche's approved VEGF antagonist, bevacizumab, for the treatment of certain of EYLEA's indications, and we are aware of another company developing an ophthalmic formulation of such product. In DME and RVO, EYLEA also competes with intravitreal implants of corticosteroids. We are also aware of a number of companies working on the development of product candidates and extended delivery devices for the potential treatment of one or more of EYLEA's indications, including those that act by blocking VEGF and VEGF receptors (including therapies designed to extend the treatment interval) and/or other targets (such as Ang2). In addition, we are aware of several companies developing biosimilar versions of EYLEA and other approved anti-VEGF treatments, including other biosimilar versions of Lucentis under regulatory review or in late-stage clinical development. Other potentially competitive products in development include products for use in combination with EYLEA and/or other anti-VEGF treatments, small-molecule tyrosine kinase inhibitors, gene therapies, and other eye-drop formulations, devices, and oral therapies. There also is a risk that third parties repackage ZALTRAP for off-label use and sale for the treatment of diseases of the eye, even though ZALTRAP has not been manufactured and formulated for use in intravitreal injections. We are aware of claims by third parties, including those based on published clinical data, alleging that ZALTRAP may be safely administered to the eye.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for Dupixent's current and potential future indications is also increasingly competitive. In atopic dermatitis, there are several topical ointments or agents either approved or in development. There are also systemic JAK inhibitors and an antibody against IL-13 approved for atopic dermatitis and others are in development. In addition, a number of companies are developing antibodies against IL-13Ra1, OX40, IL-31R, and/or IL-1alpha. In asthma, competitors to Dupixent include antibodies against the IL-5 ligand or the IL-5 receptor or immunoglobulin E; and some of these antibodies are either approved or in development for indications that also compete or may compete in the future with Dupixent in CRSwNP. There are several other potentially competitive products in development that may compete with Dupixent in asthma, as well as potential future indications, including antibodies against thymic stromal lymphopoietin ("TSLP") or IL-33 ligand or receptor. Dupixent also faces competition from inhaled products in asthma and potential future indications.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Libtayo also faces significant competition. There are several competitors that are marketing and/or developing antibodies against PD-1 and/or PDL-1 (some of which were approved in the relevant indications and commercialized before Libtayo), including Merck's Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab), Bristol-Myers Squibb's Opdivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (nivolumab), Roche's Tecentriq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (atezolizumab), and AstraZeneca's Imfinzi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (durvalumab).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant actual and potential future competition for other products marketed or otherwise commercialized by us and/or our collaborators under our collaboration agreements with them. For example, there are several companies that are marketing and/or developing antibodies or other molecules (such as small interfering RNA molecules, or siRNAs) against PCSK9, ANGPTL3 and IL-6 and/or IL-6R, which currently (or, for product candidates in development, may in the future if approved) compete with Praluent, Evkeeza, and Kevzara, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Candidates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> technology, other antibody generation technologies, and late-stage and earlier-stage clinical candidates face competition from many pharmaceutical and biotechnology companies using various technologies, including antibody generation technologies and other approaches such as RNAi and chimeric antigen receptor T cell (CAR-T cell) technologies. For example, we are aware of other pharmaceutical and biotechnology companies actively engaged in the research and development of antibody-based products against targets that are also the targets of our early- and late-stage product candidates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also aware of other companies developing or marketing small molecules or other treatments that may compete with our antibody-based product candidates in various indications, if such product candidates obtain regulatory approval in those indications. If any of these or other competitors announces a successful clinical study involving a product that may be competitive with one of our product candidates or the grant of marketing approval by a regulatory agency for a competitive product, such developments may have an adverse effect on our business or future prospects. In addition, the first product to reach the market in a therapeutic area is often at a significant competitive advantage relative to later entrants to the market. Accordingly, the relative speed with which we, or our collaborators, can develop our product candidates, complete the clinical trials and approval processes, and, if such product candidates are approved for marketing and sale, supply commercial quantities to the market is expected to continue to be an important competitive factor. Due to the uncertainties associated with developing biopharmaceutical products, we may not be the first to obtain marketing approval for a product against any particular target, which may have a material adverse effect on our business or future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on our collaborations with Bayer and Sanofi for commercializing some of our marketed products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have established our own sales and marketing organization for EYLEA in the United States for its currently approved indications, we have no sales, marketing, commercial, or distribution capabilities for EYLEA outside the United States. Under the terms of our license and collaboration agreement with Bayer (which is terminable by Bayer at any time upon six or twelve months' advance notice, depending on the circumstances giving rise to termination), we rely on Bayer (and, in Japan, Santen pursuant to a Co-Promotion and Distribution Agreement with Bayer's Japanese affiliate, as in effect from time to time) for sales, marketing, and distribution of EYLEA in countries outside the United States.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the terms of our Antibody Collaboration and our IO Collaboration, we and Sanofi co-commercialize Dupixent and Libtayo in the United States. As a result, we rely in part on Sanofi's sales and marketing organization in the United States for these products. If we and Sanofi fail to coordinate our United States sales and marketing efforts effectively, sales of any of such products may be materially affected. Sanofi also maintains other important responsibilities relating to Dupixent in the United States. For example, Sanofi records product sales for Dupixent in the United States and leads negotiations with payors relating to this product. We also rely on Sanofi for sales, marketing, and distribution of Dupixent and Libtayo in countries outside the United States. While we exercised our options under the Antibody Collaboration and the IO Collaboration to co-commercialize Dupixent and Libtayo in certain jurisdictions outside the United States and have commenced this co-commercialization with respect to Dupixent, we will continue to rely in part on Sanofi's sales and marketing organization in such jurisdictions and there can be no assurance that we will be able to successfully conduct such co-commercialization in the expected time frame or at all.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we and our collaborators are unsuccessful in continuing to commercialize the marketed products subject to such collaborations, or if Bayer or Sanofi terminate their respective collaborations with us, our business, prospects, operating results, and financial condition would be materially impaired. We have limited commercial capabilities outside the United States and would have to develop or outsource these capabilities. Therefore, termination of the Bayer collaboration agreement, our Antibody Collaboration, or our IO Collaboration would create substantial new and additional risks to the successful commercialization of the applicable products, particularly outside the United States. For additional information regarding our collaborations with Bayer and Sanofi, see "Risks Related to Our Reliance on Third Parties - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If our collaboration with Bayer for EYLEA is terminated, or Bayer materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to continue to develop EYLEA and commercialize EYLEA outside the United States in the time expected, or at all, would be materially harmed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below and "Risks Related to Our Reliance on Third Parties - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If our Antibody Collaboration or our IO Collaboration with Sanofi is terminated, our business, prospects, operating results, and financial condition, and our ability to develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, would be materially harmed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of our marketed products recorded by us and our collaborators could be reduced by imports from countries where such products may be available at lower prices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales of products we commercialize in the United States and our collaborators' sales of products they commercialize or co-commercialize with us under our collaboration agreements with them in the United States and other countries (which impact our share of any profits or losses from the commercialization of these products under the relevant collaboration agreements and, therefore, our results of operations) may be reduced if the applicable product is imported into those countries from lower priced markets, whether legally or illegally (a practice known as parallel trading or reimportation). Parallel traders (who may repackage or otherwise alter the original product or sell it through alternative channels such as mail order or the Internet) take advantage of the price differentials between markets arising from factors including sales costs, market conditions (such as intermediate trading stages), tax rates, or national regulation of prices. Under our arrangement with Bayer, pricing and reimbursement for EYLEA outside the United States is the responsibility of Bayer. Similarly, under our Antibody Collaboration and IO Collaboration with Sanofi, pricing and reimbursement for the products commercialized or co-commercialized thereunder outside the United States are the responsibility of Sanofi. Prices for our marketed products in jurisdictions outside </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the United States are based on local market economics and competition and are likely to differ from country to country. In the United States, prices for pharmaceuticals are generally higher than in the bordering nations of Canada and Mexico and sales of our marketed products in the United States may be reduced if the applicable product marketed in those bordering nations is imported into the United States. In addition, there are proposals to legalize the import of pharmaceuticals from outside the United States into the United States. If such proposals were implemented, our future revenues derived from sales of our marketed products could be reduced. Parallel-trading practices also are of particular relevance to the EU, where they have been encouraged by the current regulatory framework. These types of imports may exert pressure on the pricing of our marketed products in a particular market or reduce sales recorded by us or our collaborators, thereby adversely affecting our results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unsuccessful in continuing the commercialization of our marketed products or in commercializing our product candidates or new indications for our marketed products, if approved, which would materially and adversely affect our business, profitability, and future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if clinical trials demonstrate the safety and effectiveness of any of our product candidates for a specific disease and the necessary regulatory approvals are obtained, the commercial success of any of our product candidates or new indications for our marketed products will depend upon, among other things, their acceptance by patients, the medical community, and third-party payors and on our and our collaborators' ability to successfully manufacture, market, and distribute those products in substantial commercial quantities or to establish and manage the required infrastructure to do so, including large-scale information technology systems and a large-scale distribution network. Establishing and maintaining sales, marketing, and distribution capabilities are expensive and time-consuming. Even if we obtain regulatory approval for our product candidates or new indications, if they are not successfully commercialized, we will not be able to recover the significant investment we have made in developing such products and our business, prospects, operating results, and financial condition would be severely harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our products may also be adversely affected by guidelines or recommendations to healthcare providers, administrators, payors, and patient communities that result in decreased use of our products. Such guidelines or recommendations may be published not only by governmental agencies, but also professional societies, practice management groups, private foundations, and other interested parties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are delivered either by intravenous infusion or by intravitreal or subcutaneous injections, which are generally less well received by patients than tablet or capsule delivery and this could adversely affect the commercial success of those products if they receive marketing approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent upon a small number of customers for a significant portion of our revenue, and the loss of or significant reduction in sales to these customers would adversely affect our results of operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We sell our marketed products for which we record net product sales in the United States to several distributors and specialty pharmacies, as applicable, which generally sell the product directly to healthcare providers or other pharmacies (as applicable). For the nine months ended September&#160;30, 2021 and 2020, our gross product sales of such products to two customers accounted on a combined basis for 53% and 86% of our total gross product revenue, respectively, and gross product sales of REGEN-COV to the U.S. government accounted for an additional 38% of our gross product revenue in this period in 2021. We expect this significant customer concentration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to continue for the foreseeable future. Our ability to generate and grow sales of these products will depend, in part, on the extent to which our distributors and specialty pharmacies are able to provide adequate distribution of these products to healthcare providers. Although we believe we can find additional distributors, if necessary, our revenue during any period of disruption could suffer and we might incur additional costs. In addition, these customers are responsible for a significant portion of our net trade accounts receivable balances. The loss of any large customer, a significant reduction in sales we make to them, any cancellation of orders they have made with us, or any failure to pay for the products we have shipped to them could adversely affect our results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish commercial capabilities outside the United States for products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely affected.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited commercial capabilities outside the United States and do not currently have a fully established organization for the sales, marketing, and distribution of marketed products outside the United States. We will need to establish commercial capabilities outside the United States for any new product we decide to commercialize or co-commercialize outside the United States. For example, following the exercise of our option under the Antibody Collaboration to co-commercialize Dupixent in certain jurisdictions outside the United States, we have begun establishing commercial capabilities for Dupixent in such jurisdictions. There may be other circumstances in which we need to establish commercial capabilities outside the United States, including because we decide to commercialize a particular product independently; we are unable to find an appropriate </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborator; or our existing collaborator decides not to opt in, decides to opt out, or breaches its obligations to us with respect to a particular product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to commercialize or co-commercialize any products outside the United States, we must build our sales, marketing, distribution, managerial, and other non-technical capabilities in the relevant markets or make arrangements with third parties to perform these services, any of which will likely be expensive and time consuming and could delay product launch or the co-commercialization of a product in one or more markets outside the United States. We cannot be certain that we will be able to successfully develop commercial capabilities outside the United States (including as it relates to Dupixent and Libtayo) within an acceptable time frame, without incurring substantial expenses, or at all. These and other difficulties relating to commercializing our products outside the United States may severely harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Maintaining Approval of Our Marketed Products and the Development and Obtaining Approval of Our Product Candidates and New Indications for Our Marketed Products</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our collaborators do not maintain regulatory approval for our marketed products, and obtain regulatory approval for our product candidates or new indications for our marketed products, we will not be able to market or sell them, which would materially and negatively impact our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot sell or market products without regulatory approval. If we or our collaborators do not maintain regulatory approval for our marketed products, and obtain regulatory approval for our product candidates or new indications of our marketed products (or are materially delayed in doing so), the value of our Company and our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we (which, for purposes of this risk factor, includes our collaborators, unless otherwise stated or required by the context) must obtain and maintain approval from the FDA for each drug we intend to sell. Obtaining FDA approval is typically a lengthy and expensive process, and approval is highly uncertain. We cannot predict with certainty if or when we might submit for regulatory approval for any of our product candidates currently under development. Any approvals we may obtain may not cover all of the clinical indications for which we are seeking approval. Also, an approval might contain significant limitations in the form of narrow indications, warnings, precautions, or contra-indications with respect to conditions of use. Additionally, the FDA may determine that a Risk Evaluation and Mitigation Strategy ("REMS") is necessary to ensure that the benefits of a new product outweigh its risks, and the product can therefore be approved. A REMS may include various elements, ranging from a medication guide or patient package insert to limitations on who may prescribe or dispense the drug, depending on what the FDA considers necessary for the safe use of the drug. The FDA has substantial discretion in the approval process (including with respect to setting specific conditions for submission) and may either refuse to accept an application for substantive review or may form the opinion after review of an application that the application is insufficient to allow approval of a product candidate. If the FDA does not accept our application for review or approve our application, it may require that we conduct additional clinical, preclinical, or manufacturing validation studies and submit the data before it will reconsider our application. Depending on the extent of these or any other studies that might be required, approval of any applications that we submit may be delayed significantly, or we may be required to expend more resources. It is also possible that any such additional studies, if performed and completed, may not be considered sufficient by the FDA to make our applications approvable. If any of these outcomes occur, we may be forced to delay or abandon our applications for approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain instances (such as when we use a biomarker-based test to identify and enroll specific patients in a clinical trial), regulatory approval of a companion diagnostic to our therapeutic product candidate may be required as a condition to regulatory approval of the therapeutic product candidate. We may need to rely on third parties to provide companion diagnostics for use with our product candidates. Such third parties may be unable or unwilling on terms acceptable to us to provide such companion diagnostics or to obtain timely regulatory approval of such companion diagnostics, which could negatively impact regulatory approval of our product candidates or may result in increased development costs or delays.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also require us to conduct additional clinical trials after granting approval of a product. Its ability to do so has been enhanced by the Food and Drug Administration Amendments Act of 2007, pursuant to which the FDA has the explicit authority to require postmarketing studies (also referred to as post-approval or Phase 4 studies), labeling changes based on new safety information, and compliance with FDA-approved risk evaluation and mitigation strategies. Post-approval studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other data about our marketed products (or data about products similar to our marketed products that implicate an entire class of products or are perceived to do so) may result in changes in product labeling, restrictions on use, product withdrawal or recall, loss of approval, or lower sales of our products. Obligations equivalent in scope, but which can vary widely in application, apply in foreign countries.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the FDA policies under the Prescription Drug User Fee Act, the FDA system of review times for new drugs includes standard review and priority review. The FDA's goal for a standard review is to review the application within a 10-month time frame from the time the application is filed by the FDA (filing date), which typically occurs approximately 60 days following submission of the application by the applicant. The FDA has stated the goal to act on 90% of standard new molecular entity ("NME") New Drug Application ("NDA") and original BLA submissions within 10 months of the filing date. A priority review designation is given to drugs that treat a serious condition and offer major advances in treatment, or provide a treatment where no adequate therapy exists, and may also be afforded to a human drug application based on a priority review voucher. The FDA has stated the goal to act on 90% of priority NME NDA and original BLA submissions within six months of the filing date. However, the FDA's review goals are subject to change and the duration of the FDA's review depends on a number of factors, including the number and types of other applications that are submitted to the FDA around the same time period or are pending. Even if any of our applications receives a priority review designation, we may not ultimately be able to obtain approval of our application within a time frame consistent with the FDA's stated review goals or at all, and such designation may not actually lead to a faster development or regulatory review or approval process. Procedures that are equivalent in scope, but which can vary widely in application, apply in foreign countries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA and comparable foreign regulatory authorities enforce GCPs and other regulations and legal requirements through periodic inspections of trial sponsors, clinical research organizations ("CROs"), principal investigators, and trial sites. If we or any of the third parties conducting our clinical studies are determined to have failed to fully comply with GCPs, the study protocol or applicable regulations, the clinical data generated in those studies may be deemed unreliable. For example, as previously disclosed, we were recently notified by the sponsor of a trial evaluating REGEN-COV in hospitalized patients with severe COVID-19 of a GCP inspection of the trial that found certain deviations from GCP compliance. There can be no assurance that the data from this trial will be found acceptable by the FDA or other regulatory authorities or will be sufficient for purposes of our request to expand the EUA for REGEN-COV to include COVID-19 treatment for appropriate hospitalized patients. This and similar instances of non-compliance with GCPs could result in non-approval of our product candidates by the FDA or foreign regulatory authorities such as the EC, or we or the FDA or such other regulatory authorities may decide to conduct additional inspections or require additional clinical studies, which would delay our development programs, require us to incur additional costs, and could substantially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a new drug or biologic product, the FDA and such comparable foreign regulatory authorities require that the facilities at which the product will be manufactured or advanced through the supply chain be in compliance with current Good Manufacturing Practices, or cGMP, requirements and regulations governing the manufacture, shipment, and storage of the product. Additionally, manufacturers of biological products and their facilities are subject to payment of substantial user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and adherence to any commitments made in the applicable BLA. These cGMP requirements and regulations are not prescriptive instructions on how to manufacture products, but rather a series of principles that must be observed during manufacturing; as a result, their implementation may not be clearly delineated and may present a challenging task. Manufacturing product candidates in compliance with these regulatory requirements is complex, time-consuming, and expensive. To be successful, our products must be manufactured in compliance with regulatory requirements, and at competitive costs. If we or any of our third-party manufacturers, product packagers, labelers, or other parties performing steps in the supply chain are unable to maintain regulatory compliance with cGMP, the FDA and comparable foreign regulatory authorities can impose monetary penalties or other civil or criminal sanctions, including, among other things, refusal to approve a pending application for a new drug or biologic product, or revocation of a pre-existing approval. For additional information, see "Risks Related to Manufacturing and Supply - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" Our business, prospects, operating results, and financial condition may be materially harmed as a result of noncompliance with the requirements and regulations described in this paragraph.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to ongoing requirements imposed by the FDA and comparable foreign regulatory authorities governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping, and reporting of safety and other post-marketing information. The holder of an approved BLA or foreign equivalent is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA or foreign equivalent must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Advertising and promotional materials must comply with FDA regulations and those of foreign regulatory authorities and may be subject to other potentially applicable federal and state laws. The applicable regulations in countries outside the U.S. grant similar powers to the competent authorities and impose similar obligations on companies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the standard drug approval process, the FDA has the authority to grant an EUA to allow unapproved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when, based on the totality of scientific evidence, there is evidence of effectiveness of the medical product, and there are no adequate, approved, and available alternatives. For example, REGEN-COV has been authorized for use in certain individuals in the United States based on an EUA from the FDA. However, the FDA may revoke this EUA (or any other EUA we may be granted in the future) if it is determined that the underlying health emergency no longer exists or warrants such authorization; therefore, we cannot predict how long this EUA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(or any other EUA we may be granted in the future) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">will</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> remain in effect. Such revocation could adversely impact our business in a variety of ways, including by having to absorb related manufacturing and overhead costs as well as potential inventory write-offs if regulatory approval is not obtained timely or at all.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the FDA and other regulatory agency regulations in the United States, we are subject to a variety of foreign regulatory requirements governing human clinical trials, manufacturing, marketing and approval of drugs, and commercial sale and distribution of drugs in foreign countries. The foreign regulatory approval process is similarly a lengthy and expensive process, the result of which is highly uncertain, and foreign regulatory requirements include all of the risks associated with FDA approval as well as country specific regulations. We and our collaborators must maintain regulatory compliance for the products we or they commercialize in foreign jurisdictions.&#160;From time to time, we may hold a product's marketing approval in a jurisdiction outside the United States where we may have less experience and where our regulatory capabilities may be more limited.&#160;In addition, actions by a regulatory agency in a country or region with respect to a product candidate may have an impact on the approval process for that product candidate in another country or region. Foreign regulatory authorities often also have the authority to require post-approval studies, such as a post-authorization safety study ("PASS") and/or post-authorization efficacy study ("PAES"), which involve various risks similar to those described above, and may ask for additional data in order to begin a clinical study including phase 3 clinical trials required to submit a MAA in the EU. Whether or not we obtain FDA approval for a product in the United States, we must obtain approval of the product by the comparable regulatory authorities in foreign countries before we can market that product or any other product in those countries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in the European Economic Area ("EEA"), if we do not manage to retain a Qualified Person for Pharmacovigilance ("QPPV"), to maintain a Pharmacovigilance System Master File ("PSMF"), or to comply with other pharmacovigilance obligations, we may be at risk of our clinical trials being closed prematurely, our marketing authorization being suspended, and we may be subject to other enforcement actions by the national competent authorities of the EEA or the EC. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exact requirements concerning pharmacovigilance reporting may differ in the numerous countries in which we conduct clinical trials. Failure to comply with the related pharmacovigilance requirements may result in the premature closure of the clinical trials and other enforcement actions by the relevant regulatory authorities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and clinical studies required for our product candidates and new indications of our marketed products are expensive and time-consuming, and their outcome is highly uncertain. If any such studies are delayed or yield unfavorable results, regulatory approval for our product candidates or new indications of our marketed products may be delayed or become unobtainable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As described above, we must conduct extensive testing of our product candidates and new indications of our marketed products before we can obtain regulatory approval to market and sell them. We need to conduct both preclinical animal testing and human clinical trials. Conducting such studies is a lengthy, time-consuming, and expensive process. These tests and trials may not achieve favorable results for many reasons, including, among others, failure of the product candidate to demonstrate safety or efficacy, the development of serious or life-threatening adverse events (or side effects) caused by or connected with exposure to the product candidate (or prior or concurrent exposure to other products or product candidates), difficulty in enrolling and maintaining subjects in a clinical trial, clinical trial design that may not make it possible to enroll or retain a sufficient number of patients to achieve a statistically significant result or the desired level of statistical significance for the endpoint in question, lack of sufficient supplies of the product candidate or comparator drug, and the failure of clinical investigators, trial monitors, contractors, consultants, or trial subjects to comply with the trial plan, protocol, or applicable regulations related to the FDA's Good Laboratory Practice requirements ("GLPs") or GCPs. A clinical trial may also fail because the dose(s) of the investigational drug included in the trial were either too low or too high to determine the optimal effect of the investigational drug in the disease setting.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to reevaluate any drug candidate that does not test favorably and either conduct new studies, which are expensive and time consuming, or abandon that drug development program. If preclinical testing yields unfavorable results, product candidates may not advance to clinical trials. The failure of clinical trials to demonstrate the safety and effectiveness of our clinical candidates for the desired indication(s) would preclude the successful development of those candidates for such indication(s), in which event our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, some of our products and product candidates (such as Libtayo and Dupixent) are studied in combination with agents and treatments developed by us or our collaborators. There may be additional risks and unforeseen safety issues resulting </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from such combined administration, any of which may materially adversely impact clinical development of these product candidates and our ability to obtain regulatory approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some jurisdictions such as the EU, initiating phase 3 clinical trials and clinical trials in the pediatric population is subject to a requirement to obtain approval or a waiver from the competent authorities of the EU Member States and/or the EMA. If we do not obtain such approval, our ability to conduct clinical trials and obtain marketing authorizations or approvals may be severely impaired and our business may be adversely impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful development of our current and future product candidates is uncertain.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only a small minority of all research and development programs ultimately result in commercially successful drugs. Clinical trials may not demonstrate statistically sufficient effectiveness and safety to obtain the requisite regulatory approvals for these product candidates in these indications. Many companies in the biopharmaceutical industry, including our Company, have suffered significant setbacks in clinical trials, even after promising results have been obtained in earlier trials. In a number of instances, we have terminated the development of product candidates due to a lack of or only modest effectiveness, and clinical trials evaluating our product candidates failed to meet the relevant endpoints. For example, in August 2017, we reported that the Phase 3 study evaluating suptavumab, an antibody to RSV, did not meet its primary endpoint of preventing medically-attended RSV infections in infants; as a result, we discontinued further clinical development of this antibody. Moreover, even if we obtain positive results from preclinical testing or clinical trials, we may not achieve the same success in future trials, or the FDA and analogous foreign regulatory authorities may deem the results insufficient for an approval. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our clinical trials are conducted under the oversight of IDMCs. These independent oversight bodies are made up of external experts who review the progress of ongoing clinical trials, including available safety and efficacy data, and make recommendations concerning a trial's continuation, modification, or termination based on interim, unblinded data. Any of our ongoing clinical trials may be discontinued or amended in response to recommendations made by responsible IDMCs based on their review of such interim trial results. For example, in August 2020, we discontinued actively treating patients with fasinumab (which at such time only involved dosing in an optional second-year extension phase of one trial) following a recommendation from the responsible IDMC that the program be terminated based on available evidence to date. The recommended termination or material modification of any of our ongoing late-stage clinical trials by an IDMC could negatively impact the future development of our product candidate(s), and our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are studying our product candidates in a wide variety of indications in clinical trials. Many of these trials are exploratory studies designed to evaluate the safety profile of these compounds and to identify what diseases and uses, if any, are best suited for these product candidates. These product candidates may not demonstrate the requisite efficacy and/or safety profile to support continued development for some or all of the indications that are being, or are planned to be, studied, which would diminish our clinical "pipeline" and could negatively affect our future prospects and the value of our Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Serious complications or side effects in connection with the use of our products and in clinical trials for our product candidates and new indications for our marketed products could cause our regulatory approvals to be revoked or limited or lead to delay or discontinuation of development of our product candidates or new indications for our marketed products, which could severely harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not the drug candidate being studied caused these conditions. Various illnesses, injuries, and discomforts have been reported from time-to-time during clinical trials of our product candidates and new indications for our marketed products. It is possible that as we test our drug candidates or new indications in larger, longer, and more extensive clinical programs, or as use of these drugs becomes more widespread if they receive regulatory approval, illnesses, injuries, and discomforts that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects are only detectable after investigational drugs are tested in large-scale, Phase 3 clinical trials or, in some cases, after they are made available to patients after approval. If additional clinical experience indicates that any of our product candidates or new indications for our marketed products has many side effects or causes serious or life-threatening side effects, the development of the product candidate may be delayed or fail, or, if the product candidate has received regulatory approval, such approval may be revoked, which would severely harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to EYLEA, there are many potential safety concerns associated with significant blockade of VEGF that may limit our ability to further successfully commercialize EYLEA. These serious and potentially life-threatening risks, based on clinical and preclinical experience of VEGF inhibitors, include bleeding, intestinal perforation, hypertension, proteinuria, congestive heart failure, heart attack, and stroke. Other VEGF blockers have reported side effects that became evident only after large-scale trials or after marketing approval when large numbers of patients were treated. There are risks inherent in the intravitreal </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administration of drugs like aflibercept (such as intraocular inflammation ("IOI"), sterile and culture positive endophthalmitis, corneal decomposition, retinal detachment, and retinal tear), which can cause injury to the eye and other complications. The side effects previously reported for EYLEA include conjunctival hemorrhage, macular degeneration, eye pain, retinal hemorrhage, and vitreous floaters. In addition, commercialization of EYLEA or our other products may be impacted by actions of third parties on which we rely, such as manufacturers of syringes or other devices used in the administration of our products. These and other complications or issues or side effects could harm further development and/or commercialization of EYLEA. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dupixent and Libtayo are being studied in additional indications, as shown in the table under Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Overview - Programs in Clinical Development." There is no guarantee that marketing approval of Dupixent or Libtayo (as applicable) in any of these indications will be successfully obtained. The side effects previously reported for Dupixent include hypersensitivity reactions, conjunctivitis and keratitis, injection-site reactions, eye and eyelid inflammation, cold sores, oropharyngeal pain, eosinophilia, insomnia, toothache, gastritis, joint pain (arthralgia), and facial rash or redness; and the side effects previously reported for Libtayo include certain immune-mediated adverse reactions, such as pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and dermatologic reactions, as well as infusion-related reactions, cellulitis, sepsis, pneumonia, urinary tract infection, fatigue, rash, and diarrhea. These and other complications or side effects could harm further development and/or commercialization of Dupixent and Libtayo (as applicable).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also are risks inherent in subcutaneous injections (which are used for administering most of our antibody-based products and product candidates), such as injection-site reactions (including redness, itching, swelling, pain, and tenderness) and other side effects. These and other complications or side effects could harm further development and/or commercialization of our antibody-based products and product candidates utilizing this method of administration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Many of our product candidates in development are recombinant proteins that could cause an immune response, resulting in the creation of harmful or neutralizing antibodies against the therapeutic protein.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the safety, efficacy, manufacturing, and regulatory hurdles faced by our product candidates, the administration of recombinant proteins frequently causes an immune response, resulting in the creation of antibodies against the therapeutic protein. The antibodies can have no effect or can totally neutralize the effectiveness of the protein, or require that higher doses be used to obtain a therapeutic effect. In some cases, the antibody can cross-react with the patient's own proteins, resulting in an "auto-immune" type disease. Whether antibodies will be created can often not be predicted from preclinical or clinical experiments, and their detection or appearance is often delayed, so neutralizing antibodies may be detected at a later date, in some cases even after pivotal clinical trials have been completed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to formulate or manufacture our product candidates in a way that is suitable for clinical or commercial use, which would delay or prevent continued development of such candidates and/or receipt of regulatory approval or commercial sale, which could materially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to continue to develop suitable product formulations or manufacturing processes to support large-scale clinical testing of our product candidates, including our antibody-based product candidates, we may be unable to supply necessary materials for our clinical trials, which would delay or prevent the development of our product candidates. Similarly, if we are unable, directly or through our collaborators or third parties, to supply sufficient quantities of our products or develop formulations of our product candidates suitable for commercial use, we will be unable to obtain regulatory approval for those product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Many of our products are intended to be used and, if approved, our product candidates may be used in combination with drug-delivery devices, which may result in additional regulatory, commercialization, and other risks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our products are used and some of our products and product candidates may be used, if approved, in combination with a drug-delivery device, including a pre-filled syringe, patch pump, auto-injector, or other delivery system. For example, in the United States and the EU, EYLEA is approved in the 2mg pre-filled syringe. The success of our products and product candidates may depend to a significant extent on the performance of such devices, some of which may be novel or comprised of complex components. Given the increased complexity of the review process when approval of the product and device is sought under a single marketing application and the additional risks resulting from a product candidate's designation as a combination product discussed below, our product candidates used with such drug-delivery devices may be substantially delayed in receiving regulatory approval or may not be approved at all. The FDA review process and criteria for such applications are not well established, which could also lead to delays in the approval process. In addition, some of these drug-delivery devices may be provided by single-source, third-party providers or our collaborators. In any such case, we may be dependent on the sustained cooperation of those third-party providers or collaborators to supply and manufacture the devices; to conduct the studies and prepare related documentation required for approval or clearance by the applicable regulatory agencies; and to continue to meet the applicable regulatory and other requirements to maintain approval or clearance once it has been received. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other parties may allege that our drug-delivery devices infringe patents or other intellectual property rights. For example, we are currently party to patent infringement and other proceedings relating to the EYLEA pre-filled syringe, as described in Note 12 to our Condensed Consolidated Financial Statements. Failure to successfully develop or supply the devices, delays in or failure of the studies conducted by us, our collaborators, or third-party providers, or failure of our Company, our collaborators, or the third-party providers to obtain or maintain regulatory approval or clearance of the devices could result in increased development costs, delays in or failure to obtain regulatory approval, and associated delays in a product or product candidate reaching the market. Loss of regulatory approval or clearance of a device that is used with our product may also result in the removal of our product from the market. Further, failure to successfully develop or supply and manufacture these devices, or to gain or maintain their approval, could adversely affect sales of the related products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, each component of a combination product is subject to the requirements established by the FDA for that type of component, whether a drug, biologic, or device. The determination whether a product is a combination product or two separately regulated products is made by the FDA on a case-by-case basis. Although a single marketing application is generally sufficient for the approval, clearance, or licensure of a combination product, the FDA may determine that separate marketing applications are necessary. In addition, submitting separate marketing applications may be necessary to receive some benefit that accrues only from approval under a particular type of application. This could significantly increase the resources and time required to bring a particular combination product to market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property and Market Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot protect the confidentiality of our trade secrets, or our patents or other means of defending our intellectual property are insufficient to protect our proprietary rights, our business and competitive position will be harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business requires using sensitive and proprietary technology and other information that we protect as trade secrets. We seek to prevent improper disclosure of these trade secrets through confidentiality agreements and other means. If our trade secrets are improperly disclosed, by our current or former employees, our collaborators, or otherwise, it could help our competitors and adversely affect our business. We will be able to protect our proprietary rights only to the extent that our proprietary technologies and other information are covered by valid and enforceable patents or are effectively maintained as trade secrets. The patent position of biotechnology companies, including our Company, involves complex legal and factual questions and, therefore, enforceability cannot be predicted with certainty. Our patents may be challenged, invalidated, held to be unenforceable, or circumvented. Patent applications filed outside the United States may be challenged by other parties, for example, by filing third-party observations that argue against patentability or an opposition. Such opposition proceedings are increasingly common in the EU and are costly to defend. For example, our European Patent No. 2,264,163 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">concerns</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genetically engineered mice capable of producing chimeric antibodies that are part human and part mouse) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is the subject of opposition proceedings in the European Patent Office (the "EPO") (currently pending before its Boards of Appeal). In addition, on October 26 and October 27, 2021, anonymous parties initiated opposition proceedings in the EPO against our European Patent No. 2,944,306 (which concerns pre-filled syringes comprising ophthalmic formulations containing VEGF antagonists such as aflibercept for intravitreal administration), as described in Note 12 to our Condensed Consolidated Financial Statements included in this report. We have pending patent applications in the United States Patent and Trademark Office (the "USPTO"), the EPO, and the patent offices of other foreign jurisdictions, and it is likely that we will need to defend patents from challenges by others from time to time in the future. Certain of our U.S. patents may also be challenged by parties who file a request for post-grant review or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review under the America Invents Act of 2011 or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reexamination. For example, on February 11, 2020, anonymous parties filed two requests for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reexamination of two of our patents - U.S. Patent Nos. 10,406,226 (the "'226 Patent") and 10,464,992 (the "'992 Patent"), and the USPTO has granted both requests to initiate reexamination proceedings. In addition, as described in Note 12 to our Condensed Consolidated Financial Statements, on May 5, 2021, Mylan Pharmaceuticals Inc. filed petitions for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of U.S. Patent Nos. 9,254,338 (the "'338 Patent") and 9,669,069 (the "'069 Patent"); and on September 7, 2021, Celltrion, Inc. filed a petition for post-grant review of U.S. Patent No. 10,857,231 (the "'231 Patent"). The '226 Patent concerns methods for manufacturing VEGF antagonist fusion proteins, including aflibercept; the '992 Patent and the '231 Patent concern formulations and vials containing VEGF antagonist fusion proteins, including aflibercept; and the '338 Patent and the '069 Patent concern methods for treating angiogenic eye disorders by administering VEGF antagonist fusion proteins, including aflibercept. Post-grant proceedings are increasingly common in the United States and are costly to defend. Our patent rights may not provide us with a proprietary position or competitive advantages against competitors. Furthermore, even if the outcome is favorable to us, the enforcement of our intellectual property rights can be extremely expensive and time consuming.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions or our ability to obtain, maintain, and enforce our intellectual property rights. Any such changes could also affect the value of our intellectual property or narrow the scope of our patents. For example, the World Trade Organization ("WTO") is currently considering a proposal formulated in connection with the COVID-19 pandemic for a waiver of certain intellectually property rights under the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights; the ultimate timing and scope of this waiver is unknown and we cannot be certain that our intellectual property rights related to REGEN-COV or any other current or future product or product candidate or technology would not be eliminated, narrowed, or weakened by any such waiver.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also currently hold issued trademark registrations and have trademark applications pending in the United States and other jurisdictions, any of which may be the subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the trademark. As our products mature, our reliance on our&#160;trademarks&#160;to differentiate us from our competitors increases and as a result, if we are unable to prevent third parties from adopting, registering, or using&#160;trademarks that infringe, dilute or otherwise violate our trademark rights, our business could be adversely affected.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be restricted in our development, manufacturing, and/or commercialization activities by patents or other proprietary rights of others, and could be subject to awards of damages if we are found to have infringed such patents or rights.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of others (including those relating to trademarks, copyrights, and trade secrets). Other parties may allege that they own blocking patents to our products in clinical development or even to products that have received regulatory approval and are being or have been commercialized, either because they claim to hold proprietary rights to the composition of a product or the way it is manufactured or the way it is used. Moreover, other parties may allege that they have blocking patents to antibody-based products made using our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VelocImmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology, or any other of our technologies, either because of the way the antibodies are discovered or produced or because of a proprietary composition covering an antibody or the antibody's target.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been in the past, are currently, and may in the future be involved in patent litigation and other proceedings involving patents and other intellectual property. For example, we and/or Sanofi are currently party to patent infringement proceedings initiated by Amgen against us and/or Sanofi relating to Praluent and other intellectual property proceedings relating to Dupixent, as described in Note 12 to our Condensed Consolidated Financial Statements. In addition, we are currently party to patent infringement and other proceedings relating to EYLEA and REGEN-COV, as described in Note 12 to our Condensed Consolidated Financial Statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are aware of patents and pending patent applications owned by others that claim compositions and methods of treatment relating to targets and conditions that we are also pursuing with our products and/or product candidates. Although we do not believe that any of our products or our late-stage antibody-based product candidates infringe any valid claim in these patents or patent applications,</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">these other parties could initiate lawsuits for patent infringement and assert that their patents are valid and cover our products or our late-stage antibody-based product candidates, similar to the patent infringement proceedings referred to above. Further, we are aware of a number of patent applications of others that, if granted with claims as currently drafted, may cover our current or planned activities. It could be determined that our products and/or actions in manufacturing or selling our products or product candidates infringe such patents.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent holders could assert claims against us for damages and seek to prevent us from manufacturing, selling, or developing our products or product candidates, and a court may find that we are infringing validly issued patents of others. In the event that the manufacture, use, or sale of any of our products or product candidates infringes on the patents or violates other proprietary rights of others, we may be prevented from pursuing product development, manufacturing, and commercialization of those drugs and may be required to pay costly damages. In addition, in the event that we assert our patent rights against other parties that we believe are infringing our patent rights, such parties may challenge the validity of our patents and we may become the target of litigation, which may result in an outcome that is unfavorable to us. Any of these adverse developments may materially harm our business, prospects, operating results, and financial condition. In any event, legal disputes are likely to be costly and time consuming to defend.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to obtain licenses to patents when, in our judgment, such licenses are needed or advisable. For example, in August 2018, we and Sanofi entered into a license agreement with Bristol-Myers Squibb, E. R. Squibb &amp; Sons, and Ono Pharmaceutical to obtain a license under certain patents owned and/or exclusively licensed by one or more of these parties that includes the right to develop and sell Libtayo. If any licenses are required, we may not be able to obtain such licenses on commercially reasonable terms, if at all. The failure to obtain any such license could prevent us from developing or commercializing any one or more of our products or product candidates, which could severely harm our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss or limitation of patent rights, and regulatory pathways for biosimilar competition, could reduce the duration of market exclusivity for our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the pharmaceutical and biotechnology industries, the majority of an innovative product's commercial value is usually realized during the period in which it has market exclusivity. In the United States and some other countries, when market exclusivity expires and generic versions of a product are approved and marketed, there usually are very substantial and rapid declines in the product's sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our late-stage product candidates or other clinical candidates are approved for marketing in the United States or elsewhere, market exclusivity for those products will generally be based upon patent rights and/or certain regulatory forms of exclusivity. As described above under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we cannot protect the confidentiality of our trade secrets, or our patents or other means of defending our intellectual property are insufficient to protect our proprietary rights, our business and competitive position will be harmed,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" the scope and enforceability of our patent rights may vary from country to country. The failure to obtain patent and other intellectual property rights, or limitations on the use, or the loss, of such rights could materially harm us. Absent patent protection or regulatory exclusivity for our products, it is possible, both in the United States and elsewhere, that generic, biosimilar, and/or interchangeable versions of those products may be approved and marketed, which would likely result in substantial and rapid reductions in revenues from sales of those products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the federal Patient Protection and Affordable Care Act ("PPACA"), there is an abbreviated path in the United States for regulatory approval of products that are demonstrated to be "biosimilar" or "interchangeable" with an FDA-approved biological product. The PPACA provides a regulatory mechanism that allows for FDA approval of biologic drugs that are similar to innovative drugs on the basis of less extensive data than is required by a full BLA. Under this regulation, an application for approval of a biosimilar may be filed four years after approval of the innovator product. However, qualified innovative biological products receive 12 years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12 years after the innovative biological product was first approved by the FDA. However, the term of regulatory exclusivity may not remain at 12 years in the United States and could be shortened if, for example, the PPACA is amended.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of jurisdictions outside of the United States have also established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier versions of biological products. For example, the EU has had an established regulatory pathway for biosimilars since 2005.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increased likelihood of biosimilar competition has increased the risk of loss of innovators' market exclusivity. It is also not possible to predict changes in United States regulatory law that might reduce biological product regulatory exclusivity. Due to this risk, and uncertainties regarding patent protection, it is not possible to predict the length of market exclusivity for any particular product we currently or may in the future commercialize with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory exclusivity. We are aware of several companies developing biosimilar versions of EYLEA, as discussed further under "Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The commercial success of our products and product candidates is subject to significant competition - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed Products" above. In the United States, the regulatory exclusivity period for EYLEA (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the period during which no biosimilar product can be approved by the FDA) expires on November 18, 2023, with the possibility of an additional six months of regulatory exclusivity (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, until May 18, 2024) if the FDA grants pediatric exclusivity based on our completion of certain studies evaluating EYLEA in pediatric patients with ROP and submission of the data from these studies to the FDA no later than 15 months before the date on which regulatory exclusivity would otherwise expire. The loss of market exclusivity for a product (such as EYLEA) would likely materially and negatively affect revenues from product sales of that product and thus our financial results and condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing and Supply</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on limited internal and contracted manufacturing and supply chain capacity, which could adversely affect our ability to commercialize our marketed products and, if approved, our product candidates and to advance our clinical pipeline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have large-scale manufacturing operations in Rensselaer, New York and Limerick, Ireland. Manufacturing facilities operated by us and by third-party contract manufacturers engaged by us would be inadequate to produce the active pharmaceutical ingredients of our current marketed products and our product candidates in sufficient clinical quantities if our clinical pipeline advances as planned. For example, our internal and contracted manufacturing capacity may not be sufficient to cover the demand for REGEN-COV. In addition to expanding our internal capacity, we intend to continue to rely on our collaborators, and may also rely on contract manufacturers, to produce commercial quantities of drug material needed for commercialization of our products. For example, as described in Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations," in August 2020, we announced a collaboration agreement with Roche to develop, manufacture, and distribute REGEN-COV (known as Ronapreve in other countries outside the United States). We </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cannot be certain that our current manufacturing and distribution capacity for REGEN-COV or the increased manufacturing and distribution capacity through our collaboration with Roche will be sufficient. As we increase our production in anticipation of potential regulatory approval for our product candidates, our current manufacturing capacity will likely not be sufficient, and our dependence on our collaborators and/or contract manufacturers may increase, to produce adequate quantities of drug material for both commercial and clinical purposes. We rely entirely on other parties and our collaborators for filling and finishing services, including with respect to drug-delivery devices (such as a pre-filled syringe, patch pump, auto-injector, or other delivery system). Generally, in order for other parties to perform any step in the manufacturing and supply chain, we must transfer technology to the other party, which can be time consuming and may not be successfully accomplished without considerable cost and expense, or at all. We will have to depend on these other parties to perform effectively on a timely basis and to comply with regulatory requirements. If for any reason they are unable to do so, and as a result we are unable to directly or through other parties manufacture and supply sufficient commercial and clinical quantities of our products on acceptable terms, or if we should encounter delays or other difficulties with our collaborators, contract manufacturers, warehouses, shipping, testing laboratories, or other parties involved in our supply chain which adversely affect the timely manufacture and supply of our products or product candidates, our business, prospects, operating results, and financial condition may be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expanding our manufacturing capacity and establishing fill/finish capabilities will be costly and we may be unsuccessful in doing so in a timely manner, which could delay or prevent the launch and successful commercialization of our marketed products and product candidates or other indications for our marketed products if they are approved for marketing and could jeopardize our current and future clinical development programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our existing manufacturing facilities in Rensselaer, New York and Limerick, Ireland, we may lease, operate, purchase, or construct additional facilities to conduct expanded manufacturing or other related activities in the future. Expanding our manufacturing capacity to supply commercial quantities of the active pharmaceutical ingredients for our marketed products and our product candidates if they are approved for marketing, and to supply clinical drug material to support the continued growth of our clinical programs, will require substantial additional expenditures, time, and various regulatory approvals and permits. This also holds true for establishing fill/finish capabilities in the future, for which we are in the process of constructing fill/finish facilities (refer to Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations &#8211; Liquidity and Capital Resources" for information about expected capital expenditures relating to this and other projects). Further, we will need to hire and train significant numbers of employees and managerial personnel to staff our expanding manufacturing and supply chain operations, as well as any future fill/finish activities. Start-up costs can be large, and scale-up entails significant risks related to process development and manufacturing yields. In addition, we may face difficulties or delays in developing or acquiring the necessary production equipment and technology to manufacture sufficient quantities of our product candidates at reasonable costs and in compliance with applicable regulatory requirements. The FDA and analogous foreign regulatory authorities must determine that our existing and any expanded manufacturing facilities and any future fill/finish activities comply, or continue to comply, with cGMP requirements for both clinical and commercial production and license them, or continue to license them, accordingly, and such facilities must also comply with applicable environmental, safety, and other governmental permitting requirements. We may not successfully expand or establish sufficient manufacturing or any future fill/finish capabilities or manufacture our products economically or in compliance with cGMPs and other regulatory requirements, and we and our collaborators may not be able to build or procure additional capacity in the required timeframe to meet commercial demand for our product candidates if they receive regulatory approval, and to continue to meet the requirements of our clinical programs. This would interfere with our efforts to successfully commercialize our marketed products, and could also delay or require us to discontinue one or more of our clinical development programs. As a result, our business, prospects, operating results, and financial condition could be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to manufacture products may be impaired if any of our or our collaborators' manufacturing activities, or the activities of other third parties involved in our manufacture and supply chain, are found to infringe patents of others.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to continue to manufacture products in our Rensselaer, New York and Limerick, Ireland facilities and at additional facilities (if any) in the future (including our ability to conduct any fill/finish activities in the future), the ability of our collaborators to manufacture products at their facilities, and our ability to utilize other third parties to produce our products, to supply raw materials or other products, or to perform fill/finish services or other steps in our manufacture and supply chain, depends on our and their ability to operate without infringing the patents or other intellectual property rights of others. Other parties may allege that our or our collaborators' manufacturing activities, or the activities of other third parties involved in our manufacture and supply chain (which may be located in jurisdictions outside the United States), infringe patents or other intellectual property rights. For example, we are currently party to patent infringement and other proceedings relating to the EYLEA pre-filled syringe, as described in Note 12 to our Condensed Consolidated Financial Statements. A judicial or regulatory decision in favor of one or more parties making such allegations could directly or indirectly preclude the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">manufacture of our products to which those intellectual property rights apply on a temporary or permanent basis, which could materially harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If sales of our marketed products do not meet the levels currently expected, or if the launch of any of our product candidates is delayed or unsuccessful, we may face costs related to excess inventory or unused capacity at our manufacturing facilities and at the facilities of third parties or our collaborators.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our manufacturing facilities primarily to produce bulk product for commercial supply of our marketed products and clinical and preclinical candidates for ourselves and our collaborations. We also plan to use such facilities to produce bulk product for commercial supply of new indications of our marketed products and new product candidates if they are approved for marketing. If our clinical candidates are discontinued or their clinical development is delayed, if the launch of new indications for our marketed products or new product candidates is delayed or does not occur, or if such products are launched and the launch is unsuccessful or the product is subsequently recalled or marketing approval is rescinded, we may have to absorb one hundred percent of related overhead costs and inefficiencies, as well as similar costs of third-party contract manufacturers performing services for us. In addition, if we or our collaborators experience excess inventory, it may be necessary to write down or write off such excess inventory or incur an impairment charge with respect to the facility where such product is manufactured, which could adversely affect our operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party service or supply failures, or other failures, business interruptions, or other disasters affecting our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, the manufacturing facilities of our collaborators, or the facilities of any other party participating in the supply chain, would adversely affect our ability to supply our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bulk drug materials are currently manufactured at our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, as well as at our collaborators' facilities. We and our collaborators would be unable to manufacture these materials if the relevant facility were to cease production due to regulatory requirements or actions, business interruptions, labor shortages or disputes, contaminations, fire, natural disasters, acts of war or terrorism, or other problems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our products and product candidates are very difficult to manufacture. As our products and most of our product candidates are biologics, they require processing steps that are more difficult than those required for many other chemical pharmaceuticals. Accordingly, multiple steps are needed to control the manufacturing processes. Problems with these manufacturing processes, even minor deviations from the normal process or from the materials used in the manufacturing process (which may not be detectable by us or our collaborators in a timely manner), could lead to product defects or manufacturing failures, resulting in lot failures, product recalls, product liability claims, and insufficient inventory. Also, the complexity of our manufacturing process may make it difficult, time-consuming, and expensive to transfer our technology to our collaborators or contract manufacturers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, certain raw materials or other products necessary for the manufacture and formulation of our marketed products and product candidates, some of which are difficult to source, are provided by single-source unaffiliated third-party suppliers. In addition, we rely on certain third parties or our collaborators to perform filling, finishing, distribution, laboratory testing, and other services related to the manufacture of our marketed products and product candidates, and to supply various raw materials and other products. We would be unable to obtain these raw materials, other products, or services for an indeterminate period of time if any of these third parties were to cease or interrupt production or otherwise fail to supply these materials, products, or services to us for any reason, including due to regulatory requirements or actions (including recalls), adverse financial developments at or affecting the supplier, failure by the supplier to comply with cGMPs, contaminations, business interruptions, or labor shortages or disputes (in each case, including as a result of the COVID-19 pandemic). In any such circumstances, we may not be able to engage a backup or alternative supplier or service provider in a timely manner or at all. This, in turn, could materially and adversely affect our or our collaborators' ability to manufacture or supply marketed products and product candidates, which could materially and adversely affect our business and future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the raw materials required in the manufacture and testing of our products and product candidates may be derived from biological sources, including mammalian tissues, bovine serum, and human serum albumin. There are certain regulatory restrictions on using these biological source materials. If we or our collaborators are required to substitute for these sources to comply with such regulatory requirements, our clinical development or commercial activities may be delayed or interrupted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators and other third-party providers are required to maintain compliance with cGMPs, and are subject to inspections by the FDA or comparable agencies in other jurisdictions to confirm such compliance. Changes of suppliers or modifications of methods of manufacturing may require amending our application(s) to the FDA or such comparable foreign agencies and acceptance of the change by the FDA or such comparable foreign agencies prior to release of product(s). Because we produce multiple products and product candidates at our facilities in Rensselaer, New York and Limerick, Ireland, there are increased risks associated with cGMP compliance. Our inability, or the inability of our collaborators and third-party fill/finish or other service providers, to demonstrate ongoing cGMP compliance could require us to engage in lengthy and expensive remediation efforts, withdraw or recall product, halt or interrupt clinical trials, and/or interrupt commercial supply of any marketed products, and could also delay or prevent our obtaining regulatory approval for our product candidates or new indications for our marketed products. Any delay, interruption, or other issue that arises in the manufacture, fill/finish, packaging, or storage of any drug product or product candidate as a result of a failure of our facilities or the facilities or operations of our collaborators or other third parties to pass any regulatory agency inspection or maintain cGMP compliance could significantly impair our ability to develop, obtain approval for, and successfully commercialize our products, which would substantially harm our business, prospects, operating results, and financial condition. Any finding of non-compliance could also increase our costs, cause us to delay the development of our product candidates, result in delay in our obtaining, or our not obtaining, regulatory approval of product candidates or new indications for our marketed products, and cause us to lose revenue from any marketed products, which could be seriously detrimental to our business, prospects, operating results, and financial condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Regulatory and Litigation Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing, manufacturing, marketing, and sale of drugs for use in people expose us to product liability risk. Any informed consent or waivers obtained from people who enroll in our clinical trials may not protect us from liability or the cost of litigation. We may also be subject to claims by patients who use our approved products, or our product candidates if those product candidates receive regulatory approval and become commercially available, that they have been injured by a side effect associated with the drug. Even in a circumstance in which we do not believe that an adverse event is related to our products or product candidates, the related investigation may be time consuming or inconclusive and may have a negative impact on our reputation or business. We may face product liability claims and be found responsible even if injury arises from the acts or omissions of third parties who provide fill/finish or other services. To the extent we maintain product liability insurance in relevant periods, such insurance may not cover all potential liabilities or may not completely cover any liability arising from any such litigation. Moreover, in the future we may not have access to liability insurance or be able to maintain our insurance on acceptable terms.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business activities have been, and may in the future be, challenged under federal or state healthcare laws, which may subject us to civil or criminal proceedings, investigations, or penalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the marketing and promotion of our products, which must comply with the Food, Drug, and Cosmetic Act and applicable FDA implementing standards. The FDA's review of promotional activities includes healthcare provider-directed and direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and sales representatives' communications. Failure to comply with applicable FDA requirements and restrictions in this area may subject a company to adverse publicity and enforcement action by the FDA, the Department of Justice, or the Office of the Inspector General of the HHS, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes a drug. The FDA may take enforcement action for promoting unapproved uses of a product or other violations of its advertising laws and regulations. The applicable regulations in countries outside the U.S. grant similar powers to the competent authorities and impose similar obligations on companies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA and related regulatory requirements, we are subject to health care "fraud and abuse" laws, such as the federal civil False Claims Act, the anti-kickback provisions of the federal Social Security Act, and other state and federal laws and regulations. The U.S. federal healthcare program anti-kickback statute (the "AKS") prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving payments or other remuneration, directly or indirectly, to induce or reward someone to purchase, prescribe, endorse, arrange for, or recommend a product or service that is reimbursed under federal  healthcare programs such as Medicare or Medicaid. If we provide payments or other remuneration to a healthcare professional to induce the prescribing of our products, we could face liability under state and federal anti-kickback laws. Recently, the Bipartisan Budget Act of 2018 increased the criminal and civil penalties that can be imposed for violating certain federal health care laws, including the federal anti-kickback statute.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The federal civil False Claims Act prohibits any person from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. The False Claims Act also permits a private individual acting as a "whistleblower" to bring actions on behalf of the federal government alleging violations of the statute and to share in any monetary recovery. Pharmaceutical companies have been investigated and/or prosecuted under these laws for a variety of alleged promotional and marketing activities, such as allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in promotion for uses that the FDA has not approved, known as off-label uses, that caused claims to be submitted to Medicaid for non-covered off-label uses; and submitting inflated best price information to the Medicaid Rebate program. Pharmaceutical and other healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal fraud and false statement statutes that extend to non-government health benefit programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Sanctions under these federal and state laws may include civil monetary penalties, damages, exclusion of a manufacturer's products from reimbursement under government programs, criminal fines, and imprisonment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for individuals and the curtailment or restructuring of operations. Even if it is determined that we have not violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which would harm our business, prospects, operating results, and financial condition. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be challenged under one or more of such laws. As described further in Note 12 to our Condensed Consolidated Financial Statements included in this report, we are party to a civil complaint filed in June 2020 by the U.S. Attorney's Office for the District of Massachusetts concerning our support of 501(c)(3) organizations that provide financial assistance to patients; and we are cooperating with pending government investigations concerning certain other business activities. Any adverse decision, finding, allegation, or exercise of enforcement or regulatory discretion in any such</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceedings or investigations could harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the PPACA, the federal government requires that pharmaceutical manufacturers record any "transfers of value" made to U.S. licensed physicians and teaching hospitals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as well as ownership and investment interests held by physicians and their immediate family members. Information provided by companies is aggregated and posted annually on an "Open Payments" website, which is managed by CMS, the agency responsible for implementing these disclosure requirements. Beginning in 2022, applicable manufacturers also will be required to report information (starting with information collected during 2021) regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants, and certified nurse-midwives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to dedicate significant resources to comply with these requirements and need to be prepared to comply with additional reporting obligations outside of the United States that may apply in the future. In addition, several states have legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with the state, or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities; restrict when pharmaceutical companies may provide meals or gifts to prescribers or engage in other marketing-related activities; require identification or licensing of sales representatives; and restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs. Many of these requirements and standards are new or uncertain, and the penalties for failure to comply with these requirements may be unclear. If we are found not to be in full compliance with these laws, we could face enforcement actions, fines, and other penalties, and could receive adverse publicity, which would harm our business, prospects, operating results, and financial condition. Additionally, access to such data by fraud-and-abuse investigators and industry critics may draw scrutiny to our collaborations with reported entities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations, and future prospects.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in the Medicaid Drug Rebate program, the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public Health Service's 340B drug pricing program (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"340B program"), the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Department of Veterans Affairs (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"VA") </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal Supply Schedule (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"FSS")  pricing program, and the Tricare Retail Pharmacy Program.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts. Such interpretation can change and evolve over time. In the case of our Medicaid pricing data, if we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid Drug Rebate program and could result in an overage or underage in our rebate liability for past quarters. Price recalculations also may affect the ceiling price at which we are required to offer our products under the 340B program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of our average sales price, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also decide to terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to comply with our reporting and payment obligations under the Medicaid Drug Rebate program and other governmental programs could negatively impact our financial results. CMS issued a final regulation, which became effective on April 1, 2016, to implement the changes to the Medicaid Drug Rebate program under the PPACA. The final regulation has increased and will continue to increase our costs and the complexity of compliance, has been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations, particularly if CMS challenges the approach we have taken in our implementation of the final regulation. Other regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate program may have a similar impact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HRSA issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January 1, 2019. Implementation of this regulation has affected our obligations and potential liability under the 340B program. We are also required to report the 340B ceiling prices for our covered outpatient drugs to HRSA, which then publishes them to 340B covered entities. Any charge by HRSA that we have violated the requirements of the program or the regulation could negatively impact our financial results. Moreover, under a final regulation effective January 13, 2021, HRSA newly established an administrative dispute resolution ("ADR") process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that could be appealed only in federal court. An ADR proceeding could subject us to onerous procedural requirements and could result in additional liability. Further, any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under the PPACA or otherwise could affect our 340B ceiling price calculations and negatively impact our results of operations.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obligations to report the average sales price for certain of our drugs to the Medicare program. Statutory or regulatory changes or CMS guidance could affect the average sales price calculations for our products and the resulting Medicare payment rate, and could negatively impact our results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to applicable law, knowing provision of false information in connection with price reporting or contract&#8209;based requirements under the VA/FSS and/or Tricare programs can subject a manufacturer to civil monetary penalties. These program and contract-based obligations also contain extensive disclosure and certification requirements. If we overcharge the government in connection with our arrangements with FSS or Tricare, we are required to refund the difference to the government. Failure to make necessary disclosures or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and/or response to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations, and future prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks from the improper conduct of employees, agents, contractors, or collaborators could adversely affect our reputation and our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, agents, contractors, or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, healthcare, employment, foreign corrupt practices, trade restrictions and sanctions, environmental, competition, and privacy laws and regulations. Such improper actions could subject us to civil or criminal investigations, and monetary and injunctive penalties, and could adversely impact our ability to conduct business, operating results, and reputation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, our business activities outside of the United States are subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our ability to expand internationally, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations are subject to environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a fully integrated biotechnology company with significant research and development and manufacturing operations, we are subject to extensive environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Our research and development and manufacturing activities involve the controlled use of chemicals, infectious agents (such as viruses, bacteria, and fungi), radioactive compounds, and other hazardous materials. The cost of compliance with environmental, health, and safety regulations is substantial. If an accident involving these materials or an environmental discharge were to occur, we could be held liable for any resulting damages, or face regulatory actions, which could exceed our resources or insurance coverage.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to increasingly complex corporate governance, public disclosure, and accounting requirements and regulations that could adversely affect our business, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to changing rules and regulations of various federal and state governmental authorities as well as the stock exchange on which our Common Stock is listed. These entities, including the SEC and The NASDAQ Stock Market LLC, have issued a significant number of new and increasingly complex requirements and regulations over the course of the last several years and continue to develop additional requirements and regulations. For example, there are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Wall Street Reform and Protection Act that expressly authorized or required the SEC to adopt additional rules in these areas, a number of which have yet to be fully implemented. Our efforts to comply with these requirements and regulations (as well as corporate governance and disclosure expectations of investors and other stakeholders) have resulted in, and are likely to continue to result in, an increase in expenses and a diversion of management's time from other business activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in laws and regulations affecting the healthcare industry could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All aspects of our business, including research and development, manufacturing, marketing, pricing, sales, intellectual property rights, and the framework for dispute resolution and asserting our rights against others, are subject to extensive legislation and regulation. Changes in applicable federal and state laws and agency regulations could have a materially negative impact on our business. These include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the FDA and foreign regulatory processes for new therapeutics that may delay or prevent the approval of any of our current or future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new laws, regulations, or judicial decisions related to healthcare availability or the payment for healthcare products and services, including prescription drugs, that would make it more difficult for us to market and sell products once they are approved by the FDA or foreign regulatory agencies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in FDA and foreign regulations that may require additional safety monitoring prior to or after the introduction of new products to market, which could materially increase our costs of doing business; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in FDA and foreign cGMP requirements that may make it more difficult and costly for us to maintain regulatory compliance and/or manufacture our marketed product and product candidates in accordance with cGMPs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, the PPACA and potential regulations thereunder easing the entry of competing follow-on biologics into the marketplace, other new legislation or implementation of existing statutory provisions on importation of lower-cost competing drugs from other jurisdictions, and legislation on comparative effectiveness research are examples of previously enacted and possible future changes in laws that could adversely affect our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. government could carry out other significant changes in legislation, regulation, and government policy, including with respect to government reimbursement changes and drug price control measures (such as those discussed above under "Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales of our marketed products are dependent on the availability and extent of reimbursement from third-party payors, and changes to such reimbursement may materially harm our business, prospects, operating results, and financial condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"). While it is not possible to predict whether and when any such changes will occur, changes in the laws, regulations, and policies governing the development and approval of our product candidates and the commercialization, importation, and reimbursement of our products could adversely affect our business. In addition, our development and commercialization activities could be harmed or delayed by a shutdown of the U.S. government, including the FDA. For example, a prolonged shutdown may significantly delay the FDA's ability to timely review and process any submissions we have filed or may file or cause other regulatory delays, which could materially and adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks associated with our operations outside of the United States could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations and conduct business outside the United States and we plan to expand these activities. For example, we recently commenced co-commercialization activities under the Antibody Collaboration related to Dupixent in certain jurisdictions outside the United States. Consequently, we are, and will continue to be, subject to risks related to operating in foreign countries, which include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfamiliar foreign laws or regulatory requirements or unexpected changes to those laws or requirements, including those with which we and/or our collaborators must comply in order to maintain our marketing authorizations outside of the United States;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other laws and regulatory requirements to which our business activities abroad are subject, such as the FCPA and the U.K. Bribery Act (discussed in greater detail above under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks from the improper conduct of employees, agents, contractors, or collaborators could adversely affect our reputation and our business, prospects, operating results, and financial condition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">");</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the political or economic condition of a specific country or region;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the value of foreign currency versus the U.S. dollar;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tariffs, trade protection measures, import or export licensing requirements, trade embargoes, and sanctions (including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury), and other trade barriers; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in attracting and retaining qualified personnel; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cultural differences in the conduct of business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, effective January 31, 2020, the United Kingdom commenced an exit from the EU, commonly referred to as "Brexit." The transition period for Brexit expired on December 31, 2020 following the entry into a trade agreement that now governs the United Kingdom's relationship with the EU. We do not know to what extent Brexit will ultimately impact the business and regulatory environment in the United Kingdom, the rest of the EU, or other countries. For example, the impact of Brexit on the ongoing validity in the United Kingdom of current EU authorizations for medicinal products and on the future </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">process for obtaining and maintaining marketing authorization for pharmaceutical products manufactured or sold in the United Kingdom remains uncertain. We have large-scale manufacturing operations in Limerick, Ireland and have also established an office in the vicinity of London. Changes impacting our ability to conduct business in the United Kingdom or other EU countries, or changes to the regulatory regime applicable to our operations in those countries (such as with respect to the approval of our product candidates), may materially and adversely impact our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur additional tax liabilities related to our operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income tax in the United States and various foreign jurisdictions. Significant judgment is required in determining our worldwide tax liabilities, and our effective tax rate is derived from a combination of the applicable statutory rates in the various jurisdictions in which we operate. We record liabilities for uncertain tax positions that involve significant management judgment as to the application of law. The Internal Revenue Service or other domestic or foreign taxing authorities have previously disagreed, and may in the future disagree, with our interpretation of tax law as applied to the operations of Regeneron and its subsidiaries or with the positions we may take with respect to particular tax issues on our tax returns (see also Note 9 to our Condensed Consolidated Financial Statements included in this report). Consequently, our reported effective tax rate and our after-tax cash flows may be materially and adversely affected by tax assessments or judgments in excess of accrued amounts we have estimated in preparing our financial statements. Further, our effective tax rate may also be adversely affected by numerous other factors, including changes in the mix of our profitability from country to country, changes in tax laws and regulations, and tax effects of the accounting for stock-based compensation (which depend in part on the price of our stock and, therefore, are beyond our control). There are various U.S. tax law changes under consideration, including increases to the corporate income tax rates on both domestic and foreign income, that could have significant impact on our tax liability.&#8239;Increases to the income tax rate or other changes to the tax law could materially impact our tax provision, cash tax liability, and effective tax rate. In addition, recommendations by the Organization for Economic Co-operation and Development and the EU could require companies to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny. Even though we regularly assess the information provided to tax authorities in determining the appropriateness of our tax reserves, such tax authorities could take a position that is contrary to our expectations, and the result could adversely affect our provision for income tax and our current rate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential liability related to the personal information we collect from individuals, data brokers, or research institutions or obtain from clinical trials sponsored by us or our collaborators.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most U.S. health care providers, including research institutions from which we or our collaborators obtain clinical trial data, are subject to privacy and security regulations promulgated under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"). For example, as part of our human genetics initiative, our wholly-owned subsidiary, Regeneron Genetics Center LLC, has entered into collaborations with research institutions, including the Geisinger Health System, which are subject to such regulations. Regeneron is not currently classified as a covered entity or business associate under HIPAA and thus is not subject to its requirements or penalties. However, we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered health care provider or research institution that has not satisfied HIPAA's requirements for disclosure of individually identifiable health information. There are instances where we collect and maintain sensitive personally identifiable information, which may include health information outside of the scope of HIPAA. This information may be received throughout the clinical trial process, in the course of our research collaborations, directly from individuals who enroll in our patient assistance programs, and from our own employees in a pandemic response process (such as in connection with the COVID-19 pandemic). In the case of a breach of personal information we may be subject to state breach notification laws requiring notification of affected individuals and state regulators. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our patient assistance programs and product marketing activities as part of which we collect California resident personal data are subject to the California Consumer Privacy Act of 2018 (the "CCPA"). The CCPA, which became effective on January 1, 2020, is a consumer protection law that establishes certain requirements for data use and sharing transparency and provides California residents with personal data privacy rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">regarding the use, disclosure, and retention of their personal data. The CCPA requires us, among other things, to update our notices and develop new processes internally and with our partners. Amendments to the CCPA and legislative proposals at the federal and state level could impose new obligations or limitations in areas affecting our business. These laws and regulations are constantly evolving and may impose limitations on our business activities. Several other U.S. states have introduced similar consumer protection laws that may go into effect in the near future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial programs and research collaborations outside the U.S. (such as our consortium with a group of companies to fund the generation of genetic exome sequence data from the UK Biobank health resource) implicate international data </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protection laws, including the EU's General Data Protection Regulation (the "GDPR"). The GDPR has created a range of new compliance obligations, including increased transparency requirements and new data subject rights. Violations of the GDPR carry significant financial penalties for noncompliance (including possible fines of up to 4% of global annual turnover for the preceding financial year or &#8364;20 million (whichever is higher)). In addition to the GDPR, certain EU Member States have issued or will be issuing their own implementation legislation. While we continue to monitor these developments, there remains some uncertainty surrounding the legal and regulatory environment for these evolving privacy and data protection laws. Complying with varying jurisdictional requirements could increase the costs and complexity of compliance, including the risk of substantial financial penalties for insufficient notice and consent, failure to respond to data subject rights requests, lack of a legal basis for the transfer of personal information out of the EU, or improper processing of personal data under the GDPR. Failure by our collaborators to comply with the strict rules on the transfer of personal data outside of the EU into the U.S. may result in the imposition of criminal and administrative sanctions on such collaborators, which could adversely affect our business and could create liability for us. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, health privacy laws, data breach notification laws, consumer protection laws, data localization laws, and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use, and dissemination of individuals' health and other personal information. Moreover, individuals about whom we or our collaborators obtain health or other personal information, as well as the providers and third parties who share this information with us, may have statutory or contractual limits that impact our ability to use and disclose the information. We are likely to be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws both inside and outside the United States. Many of these laws differ from each other in significant ways and have different effects. Many of the state laws enable a state attorney general to bring actions and provide private rights of action to consumers as enforcement mechanisms. Compliance with these laws requires a flexible privacy framework as they are constantly evolving. Failure to comply with these laws and regulations could result in government enforcement actions and create liability for us (which could include civil and/or criminal penalties), private litigation, and/or adverse publicity. Federal regulators, state attorneys general, and plaintiffs' attorneys have been active in this space. Claims that we have violated individuals' privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any collaborators fail to comply with applicable federal, state, local, or foreign regulatory requirements, we could be subject to a range of regulatory actions that could affect our or any collaborators' ability to commercialize our products and could harm, prevent, or substantially increase the cost of marketing and sales of any affected products that we are able to commercialize. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our employees are increasingly utilizing social media tools as a means of communication both internally and externally. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is a risk that the use of social media by us or our employees to communicate about our products or business may cause us to be found in violation of applicable requirements. In addition, our employees may knowingly or inadvertently make use of social media in ways that may not comply with our social media policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or other legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial patients, customers, and others. Furthermore, negative posts or comments about us or our products in social media could seriously damage our reputation, brand image, and goodwill.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could have a material adverse effect on our business, prospects, operating results, and financial condition and could adversely affect the price of our Common Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our Antibody Collaboration or our IO Collaboration with Sanofi is terminated, our business, prospects, operating results, and financial condition, and our ability to develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, would be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on funding and support from Sanofi to develop, manufacture, and commercialize certain of our products and product candidates. With respect to the products that we are co-developing with Sanofi under our Antibody Collaboration (currently consisting of Dupixent, Kevzara, and itepekimab), Sanofi funds a significant portion of development expenses incurred in connection with the development of these products. In addition, we rely on Sanofi to lead much of the clinical development efforts, assist with or lead efforts to obtain and maintain regulatory approvals, and lead the commercialization efforts for these products and product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under our IO Collaboration, Sanofi also funds half of the development expenses incurred in connection with the clinical development of Libtayo, subject to an agreed-upon development budget. We also rely on Sanofi to lead commercialization efforts outside the United States for Libtayo and to assist us to comply with the necessary requirements related to Libtayo's regulatory approvals in the EU. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Sanofi terminates the Antibody Collaboration or the IO Collaboration or fails to comply with its payment obligations under any of our collaborations, our business, prospects, operating results, and financial condition would be materially harmed. We would be required to either expend substantially more resources than we have anticipated to support our research and development efforts, which could require us to seek additional funding that might not be available on favorable terms or at all, or materially cut back on such activities. If Sanofi does not perform its obligations with respect to the product candidates it is co-developing with us, our ability to develop, manufacture, and commercialize these product candidates will be significantly adversely affected. We have limited commercial capabilities outside the United States and would have to develop or outsource these capabilities for products commercialized under our Antibody Collaboration or our IO Collaboration (see also "Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to establish commercial capabilities outside the United States for products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely affected</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" above). Termination of the Antibody Collaboration or the IO Collaboration would create substantial new and additional risks to the successful development and commercialization of the products subject to such collaborations, particularly outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our collaboration with Bayer for EYLEA is terminated, or Bayer materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to continue to commercialize EYLEA outside the United States would be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely heavily on Bayer with respect to the commercialization of EYLEA outside the United States. Bayer is responsible for obtaining and maintaining regulatory approval outside the United States, as well as providing all sales, marketing, and commercial support for the product outside the United States. In particular, Bayer has responsibility for selling EYLEA outside the United States using its sales force and, in Japan, in cooperation with Santen pursuant to a Co-Promotion and Distribution Agreement, as in effect from time to time, with Bayer's Japanese affiliate. If Bayer and, in Japan, Santen do not perform their obligations in a timely manner, or at all, our ability to commercialize EYLEA outside the United States will be significantly adversely affected. Bayer has the right to terminate its collaboration agreement with us at any time upon six or twelve months' advance notice, depending on the circumstances giving rise to termination. If Bayer were to terminate its collaboration agreement with us, we may not have the resources or skills to replace those of our collaborator, which could require us to seek another collaboration that might not be available on favorable terms or at all, and could cause significant issues for the commercialization of EYLEA outside the United States and result in substantial additional costs and/or lower revenues to us. We have limited commercial capabilities outside the United States and would have to develop or outsource these capabilities (see also "Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to establish commercial capabilities outside the United States for products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely affected</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" above). Termination of the Bayer collaboration agreement would create substantial new and additional risks to the successful commercialization of EYLEA outside the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collaborators and service providers may fail to perform adequately in their efforts to support the development, manufacture, and commercialization of our drug candidates and current and future products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend upon third-party collaborators, including Sanofi and Bayer, and service providers such as CROs, outside testing laboratories, clinical investigator sites, third-party manufacturers, fill/finish providers, and product packagers and labelers, to assist us in the manufacture and preclinical and clinical development of our product candidates. We also depend, or will depend, on some of these third parties in connection with the commercialization of our marketed products and our product candidates and new indications for our marketed products if they are approved for marketing. If any of our existing collaborators or service providers breaches or terminates its agreement with us or does not perform its development or manufacturing services under an agreement in a timely manner (including as a result of its inability to perform due to financial or other relevant constraints) or in compliance with applicable GMPs, GLPs, or GCP standards, we could experience additional costs, delays, and difficulties in the manufacture or development of, or in obtaining approval by regulatory authorities for, or successfully commercializing our product candidates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators rely on third-party service providers to support the distribution of our marketed products and for many other related activities in connection with the commercialization of these marketed products. Despite our or our collaborators' arrangements with them, these third parties may not perform adequately. If these service providers do not perform their services adequately, sales of our marketed products will suffer.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Related to Employees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our key personnel and if we cannot recruit and retain leaders in our research, development, manufacturing, and commercial organizations, our business will be harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on certain of our executive officers, other key members of our senior management team, and our Chairman. If we are not able to retain (or for any other reason lose the services of) any of these persons, our business may suffer. In particular, we depend on the services of P. Roy Vagelos, M.D., the Chairman of our board of directors; Leonard S. Schleifer, M.D., Ph.D., our President and Chief Executive Officer; and George D. Yancopoulos, M.D., Ph.D., our President and Chief Scientific Officer. We are also highly dependent on the expertise and services of other senior management members leading our research, development, manufacturing, and commercialization efforts. There is intense competition in the biotechnology industry for qualified scientists and managerial personnel in the research, development, manufacture, and commercialization of drugs. We may not be able to continue to attract and retain the qualified personnel necessary to continue to advance our business and achieve our strategic objectives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information Technology Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant disruptions of information technology systems or breaches of data security could adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is increasingly dependent on critical, complex, and interdependent information technology systems, including Internet-based systems, to support business processes as well as internal and external communications. These systems are also critical to enable remote working arrangements, which have been growing in importance due in part to the COVID-19 pandemic and our implementation of work-from-home policies for a significant part of our employees. The size and complexity of our computer systems make us potentially vulnerable to IT system breakdowns, internal and external malicious intrusion, and computer viruses and ransomware, which may impact product production and key business processes. We also have outsourced significant elements of our information technology infrastructure and operations to third parties, which may allow them to access our confidential information and may also make our systems vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by such third parties or others.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our systems are potentially vulnerable to data security breaches - whether by employees or others - which may expose sensitive data to unauthorized persons. Data security breaches could lead to the loss of trade secrets or other intellectual property, result in demands for ransom or other forms of blackmail, or lead to the public exposure of personal information (including sensitive personal information) of our employees, clinical trial patients, customers, and others. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including industrial espionage or extortion) and expertise, including by organized criminal groups, "hacktivists," nation states, and others. As a company with an increasingly global presence, our systems are subject to frequent attacks. Due to the nature of some of these attacks, there is a risk that an attack may remain undetected for a period of time. While we continue to make investments to improve the protection of data and information technology, and to oversee and monitor the security measures of our suppliers and/or service providers, there can be no assurance that our efforts will prevent service interruptions or security breaches. In addition, we depend in part on third-party security measures over which we do not have full control to protect against data security breaches.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our suppliers and/or service providers fail to maintain or protect our information technology systems and data security effectively, or fail to anticipate, plan for, or manage significant disruptions to these systems, we or our suppliers and/or service providers could have difficulty preventing, detecting, or controlling such disruptions or security breaches, which could result in legal proceedings, liability under laws that protect the privacy of personal information, disruptions to our operations, government investigations, breach of contract claims, and damage to our reputation, which could have a material adverse effect on our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Results, Liquidity, and Need for Additional Financing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot sustain profitability, our business, prospects, operating results, and financial condition would be materially harmed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot sustain profitability, we may be unable to continue our operations. In the absence of substantial revenue from the sale of products on an ongoing basis, including our net product sales of EYLEA and funding we receive under our collaboration agreements (including our share of profits in connection with commercialization of EYLEA and Dupixent under our collaboration agreements with Bayer and Sanofi, respectively), or from other sources, the amount, timing, nature, or source of which cannot be predicted, we may incur substantial losses again as we conduct our research and development activities, commercialize our approved products, and prepare for possible commercialization of our other product candidates and new indications of our marketed products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional funding in the future, which may not be available to us, and which may force us to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expend substantial resources for research and development, including costs associated with clinical testing of our product candidates and new indications of our marketed products, the commercialization of products, and capital expenditures. We believe our existing capital resources and borrowing availability under our revolving credit facility, together with funds generated by our current and anticipated EYLEA net product sales and funding we are entitled to receive under our collaboration agreements and other similar agreements (including our share of profits in connection with commercialization of EYLEA and Dupixent under our collaboration agreements with Bayer and Sanofi, respectively), will enable us to meet our anticipated operating needs for the foreseeable future. However, one or more of our collaboration agreements may terminate, our revenues may fall short of our projections or be delayed, or our expenses may increase, any of which could result in our capital being consumed significantly faster than anticipated. Our expenses may increase for many reasons, including expenses in connection with the commercialization of our marketed products and the potential commercial launches of our product candidates and new indications for our marketed products, manufacturing scale-up, expenses related to clinical trials testing of antibody-based product candidates we are developing on our own (without a collaborator), and expenses for which we are responsible in accordance with the terms of our collaboration agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that our existing capital resources and our current and anticipated revenues will be sufficient to meet our operating needs. We may require additional financing in the future and we may not be able to raise additional funds on acceptable terms or at all. For example, there is no guarantee that we will have the ability to pay the principal amount due on the Notes at maturity or redeem, repurchase, or refinance the Notes prior to maturity on acceptable terms or at all. In addition, in March 2017, we completed a $720.0 million lease financing for our existing corporate headquarters and other rentable area consisting of approximately 150 acres of predominately office buildings and laboratory space located in Tarrytown, New York, which will become due and payable in full in March 2022 unless extended with the consent of all the participants and subject to certain other conditions. Our ability to refinance or to obtain additional financing could be adversely affected if there is a significant decline in the demand for our products or other significantly unfavorable changes in economic conditions. Volatility in the financial markets could increase borrowing costs or affect our ability to raise capital. If additional financing is necessary and we obtain it through the sale of equity securities, such sales will likely be dilutive to our shareholders. Debt financing arrangements may require us to pledge certain assets or enter into covenants that would restrict our business activities or our ability to incur further indebtedness and may be at interest rates and contain other terms that are not favorable to our shareholders. Should we require and be unable to raise sufficient funds (i) to complete the development of our product candidates, (ii) to successfully commercialize our product candidates or new indications for our marketed products if they obtain regulatory approval, and (iii) to continue our manufacturing and marketing of our marketed products, we may face delay, reduction, or elimination of our research and development or preclinical or clinical programs and our commercialization activities, which would significantly limit our potential to generate revenue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our indebtedness could adversely impact our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have certain indebtedness and contingent liabilities, including milestone and royalty payment obligations. As of September 30, 2021, we had an aggregate of $2.699 billion of outstanding indebtedness under the Notes and the lease financing facility. We may also incur additional debt in the future. Any such indebtedness could:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development, and mergers and acquisitions; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to competitors that have less debt.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in foreign currency exchange rates could have a material adverse effect on our operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue from outside of the United States will increase as our products, whether marketed or otherwise commercialized by us or our collaborators, gain marketing approval in such jurisdictions. Our primary foreign currency exposure relates to movements in the Japanese yen, euro, British pound sterling, Canadian dollar, and Australian dollar. If the U.S. dollar weakens against a specific foreign currency, our revenues will increase, having a positive impact on net income, but our overall expenses will increase, having a negative impact. Conversely, if the U.S. dollar strengthens against a specific foreign currency, our revenues will decrease, having a negative impact on net income, but our overall expenses will decrease, having a positive impact. Therefore, significant changes in foreign exchange rates can impact our operating results and the financial condition of our Company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments are subject to risks and other external factors that may result in losses or affect the liquidity of these investments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we had $3.432 billion in cash and cash equivalents and $7.987 billion in marketable securities (including $1.372 billion in equity securities). Our investments consist primarily of debt securities, including investment-grade corporate bonds. These fixed-income investments are subject to external factors that may adversely affect their market value or liquidity, such as interest rate, liquidity, market, and issuer credit risks, including actual or anticipated changes in credit ratings. The equity securities we hold may experience significant volatility and may decline in value or become worthless if the issuer experiences an adverse development. Furthermore, our equity investments could be subject to dilution (and decline in value) as a result of the issuance of additional equity interests by the applicable issuer. If any of our investments suffer market price declines, such declines may have an adverse effect on our financial condition and operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The elimination of LIBOR could adversely affect our business, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks related to uncertainty regarding the London Interbank Offered Rate ("LIBOR"). LIBOR is the subject of recent national, international, and other regulatory guidance and proposals for reform, which may cause LIBOR to cease to exist, or no longer be available for new contracts, after 2021 or to perform differently than in the past. On March 5, 2021, the Financial Conduct Authority in the U.K. announced that all LIBOR settings will either cease to be provided or no longer be representative (i) immediately after December 31, 2021, in the case of the one-week and two-month U.S. dollar LIBOR terms and all sterling, euro, Swiss franc, and Japanese yen settings, and (ii) immediately after June 30, 2023, in the case of the one-, three-, six-, and 12-month U.S. dollar LIBOR terms. While regulators in various jurisdictions have been working to replace LIBOR prior to the 2021 and 2023 target dates, uncertainty exists in the markets as to the adoption and implementation of alternative reference rates. We cannot predict the consequences and timing of these developments or other market or regulatory changes related to the phase-out of LIBOR. The U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee (a steering committee comprised of large U.S. financial institutions), has identified the Secured Overnight Financing Rate ("SOFR"), a new index calculated by short-term repurchase agreements, backed by Treasury securities, as its preferred alternative rate for LIBOR. At this time, it is not possible to predict how markets will respond to SOFR or other alternative reference rates as the transition away from LIBOR is anticipated in coming years. There is currently limited information regarding the future utilization of LIBOR or of any particular replacement rate. A transition away from&#160;LIBOR&#160;as a benchmark for establishing the applicable interest rate may&#160;adversely&#160;affect our outstanding variable-rate indebtedness (if any), as well as floating-rate debt securities in our investment portfolio. For example, if a published U.S. dollar LIBOR is unavailable after 2021 or 2023, interest for borrowings (if any) with an interest rate based on LIBOR under our revolving credit facility, which are indexed to LIBOR, will be determined using various alternative methods, any of which may result in interest obligations which are more than, or do not otherwise correlate over time with, the payments that would have been made on such debt if U.S. dollar LIBOR was available in its current form.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price is extremely volatile.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been significant volatility in our stock price and generally in the market prices of biotechnology companies' securities. Various factors and events may have a significant impact on the market price of our Common Stock. These factors include, by way of example:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">net product sales of our marketed products (as recorded by us or our collaborators), in particular EYLEA, Dupixent, and Libtayo, as well as our overall operating results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our product candidates or our new indications for our marketed products receive regulatory approval, net product sales of, and profits from, these product candidates and new indications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of, and the market share for, our marketed products, especially EYLEA, Dupixent, and Libtayo;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our net product sales and net profits underperform, meet, or exceed the expectations of investors or analysts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement of actions by the FDA or foreign regulatory authorities or their respective advisory committees regarding our, or our collaborators', or our competitors', currently pending or future application(s) for regulatory approval of product candidate(s) or new indications for marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement of submission of an application for regulatory approval of one or more of our, or our competitors', product candidates or new indications for marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress, delays, or results in clinical trials of our or our competitors' product candidates or new indications for marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impact of the COVID-19 pandemic on our business, including future sales of REGEN-COV;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement of technological innovations or product candidates by us or competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">claims by others that our products or technologies infringe their patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges by others to our patents in the EPO and in the USPTO;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety or effectiveness of any of our marketed products or product candidates or new indications for our marketed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing or reimbursement actions, decisions, or recommendations by government authorities, insurers, or other organizations (such as health maintenance organizations and PBMs) affecting the coverage, reimbursement, or use of any of our marketed products or competitors' products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital as needed on favorable terms;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in our relationships with collaborators or key customers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in the biotechnology industry or in government regulation of healthcare, including those relating to compounding (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a practice in which a pharmacist, a physician, or, in the case of an outsourcing facility, a person under the supervision of a pharmacist, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">large sales of our Common Stock by our executive officers or other employees, directors, or significant shareholders (or the expectation of any such sales);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in tax rates, laws, or interpretation of tax laws;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">arrivals and departures of key personnel; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to repurchase our Common Stock under any share repurchase program on favorable terms or at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading activity that results from the rebalancing of stock indices in which our Common Stock is included, or the inclusion or exclusion of our Common Stock from such indices; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors identified in these "Risk Factors"; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception by the investment community or our shareholders of any of the foregoing factors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our Common Stock has been, and could continue to be, subject to wide fluctuations in response to these and other factors, including the sale or attempted sale of a large amount of our Common Stock in the market. As discussed in greater detail under "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future sales of our Common Stock by our significant shareholders or us may depress our stock price and impair our ability to raise funds in new share offerings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" below, a large percentage of our Common Stock is owned by a small number of our principal shareholders. As a result, the public float of our Common Stock (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the portion of our Common Stock held by public investors, as opposed to the Common Stock held by our directors, officers, and principal shareholders) may be lower than the public float of other large public companies with broader public ownership. Therefore, the trading price of our Common Stock may fluctuate significantly more than the stock market as a whole. These factors may exacerbate the volatility in the trading price of our Common Stock and may negatively impact your ability to liquidate your investment in Regeneron at the time you wish at a price you consider satisfactory. Broad market fluctuations may also adversely affect the market price of our Common Stock. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management's attention and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation, which may harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of our Common Stock by our significant shareholders or us may depress our stock price and impair our ability to raise funds in new share offerings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A small number of our shareholders beneficially own a substantial amount of our Common Stock. As of September&#160;30, 2021, our five largest shareholders plus Dr. Schleifer, our Chief Executive Officer, beneficially owned approximately 37.6% of our outstanding shares of Common Stock, assuming, in the case of our Chief Executive Officer, the conversion of his Class A Stock into Common Stock and the exercise of all options held by him which are exercisable within 60 days of September&#160;30, 2021. If our significant shareholders or we sell substantial amounts of our Common Stock in the public market, or there is a perception that such sales may occur, the market price of our Common Stock could fall. Sales of Common Stock by our significant shareholders also might make it more difficult for us to raise funds by selling equity or equity-related securities in the future at a time and price that we deem appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will repurchase shares of our Common Stock or that we will repurchase shares at favorable prices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, our board of directors authorized a share repurchase program to repurchase up to $1.5&#160;billion of our Common Stock. There can be no assurance of any future share repurchases or share repurchase program authorizations. Any share repurchases will depend upon, among other factors, our cash balances and potential future capital requirements, our results of operations and financial condition, the price of our Common Stock on the NASDAQ Global Select Market, and other factors that we may deem relevant. We can provide no assurance that we will repurchase shares of our Common Stock at favorable prices, if at all.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing shareholders may be able to exert substantial influence over matters requiring shareholder approval and over our management.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Class A Stock, who are generally the shareholders who purchased their stock from us before our initial public offering, are entitled to ten votes per share, while holders of Common Stock are entitled to one vote per share. As of September&#160;30, 2021, holders of Class A Stock held 14.8% of the combined voting power of all shares of Common Stock and Class A Stock then outstanding. These shareholders, if acting together, would be in a position to substantially influence the election of our directors and the vote on certain corporate transactions that require majority or supermajority approval of the combined classes, including mergers and other business combinations. This may result in our taking corporate actions that other shareholders may not consider to be in their best interest and may affect the price of our Common Stock. As of September&#160;30, 2021:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our current executive officers and directors beneficially owned 7.7% of our outstanding shares of Common Stock, assuming conversion of their Class A Stock into Common Stock and the exercise of all options held by such persons which are exercisable within 60 days of September&#160;30, 2021, and 19.0% of the combined voting power of our outstanding shares of Common Stock and Class A Stock, assuming the exercise of all options held by such persons which are exercisable within 60 days of September&#160;30, 2021; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our five largest shareholders plus Dr. Schleifer, our Chief Executive Officer, beneficially owned approximately 37.6% of our outstanding shares of Common Stock, assuming, in the case of our Chief Executive Officer, the conversion of his Class A Stock into Common Stock and the exercise of all options held by him which are exercisable within 60 days of September&#160;30, 2021. In addition, these five shareholders plus our Chief Executive Officer held approximately 44.9% of the combined voting power of our outstanding shares of Common Stock and Class A Stock, assuming the exercise of all options held by our Chief Executive Officer which are exercisable within 60 days of September&#160;30, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The anti-takeover effects of provisions of our charter, by-laws, and of New York corporate law, as well as the contractual provisions in our investor and collaboration agreements and certain provisions of our compensation plans and agreements, could deter, delay, or prevent an acquisition or other "change of control" of us and could adversely affect the price of our Common Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation, our by-laws, and the New York Business Corporation Law contain various provisions that could have the effect of delaying or preventing a change in control of our Company or our management that shareholders may consider favorable or beneficial. Some of these provisions could discourage proxy contests and make it more difficult for shareholders to elect directors and take other corporate actions. These provisions could also limit the price that investors might be willing to pay in the future for shares of our Common Stock. These provisions include:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorization to issue "blank check" preferred stock, which is preferred stock that can be created and issued by the board of directors without prior shareholder approval, with rights senior to those of our Common Stock and Class A Stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a staggered board of directors, so that it would take three successive annual shareholder meetings to replace all of our directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that removal of directors may only be effected for cause and only upon the affirmative vote of at least eighty percent (80%) of the outstanding shares entitled to vote for directors, as well as a requirement that any vacancy on the board of directors may be filled only by the remaining directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a provision whereby any action required or permitted to be taken at any meeting of shareholders may be taken without a meeting, only if, prior to such action, all of our shareholders consent, the effect of which is to require that shareholder action may only be taken at a duly convened meeting;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement that any shareholder seeking to bring business before an annual meeting of shareholders must provide timely notice of this intention in writing and meet various other requirements; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">under the New York Business Corporation Law, in addition to certain restrictions which may apply to "business combinations" involving our Company and an "interested shareholder," a plan of merger or consolidation of our Company must be approved by two-thirds of the votes of all outstanding shares entitled to vote thereon. See the risk factor above captioned "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our existing shareholders may be able to exert significant influence over matters requiring shareholder approval and over our management.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, Sanofi, Bayer, and Teva are currently bound by certain "standstill" provisions under the January 2014 amended and restated investor agreement between us and Sanofi, as amended; our 2016 ANG2 license and collaboration agreement and our 2014 PDGFR-beta license and collaboration agreement with Bayer; and our 2016 collaboration agreement with Teva, respectively. These provisions contractually prohibit Sanofi, Bayer, and Teva from seeking to directly or indirectly exert control of our Company or acquiring more than a specified percentage of our Class A Stock and Common Stock, taken together (30% in the case of Sanofi, 20% in the case of Bayer, and 5% in the case of Teva). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our Change in Control Severance Plan and the employment agreement with our Chief Executive Officer, each as amended and restated, provide for severance benefits in the event of termination as a result of a change in control of our Company. Also, equity awards issued under our long-term incentive plans may become fully vested in connection with a "change in control" of our Company, as defined in the plans. These contractual provisions may also have the effect of deterring, delaying, or preventing an acquisition or other change in control.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reflects shares of Common Stock we repurchased under our share repurchase program, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans, during the three months ended September&#160;30, 2021. Refer to Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations &#8211; Liquidity and Capital Resources" for further details of the share repurchase program.</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of a Publicly Announced Program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/1/2021&#8211;8/31/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,772,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/1/2021&#8211;9/30/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697,337,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program relates to Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans.</span></div></td></tr></table></div><div id="iae35796f039b495ba4b10877e85a1c6f_112"></div><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.380%"><tr><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.942%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regen-ex_101x9302021x10q.htm">Modification P00004 to Supply Agreement, dated as of July 26, 2021, by and between Regeneron Pharmaceuticals, Inc. (the "Registrant") and the U.S. Army Contracting Command, New Jersey.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regen-ex_102x9302021x10q.htm">Modification P00005 to Supply Agreement, dated as of September 14, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex_311x09302021x10q.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex_312x09302021x10q.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="regn-ex_32x09302021x10q.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"): (i) the Registrant's Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020; (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2021 and 2020; (iii) the Registrant's Condensed Consolidated Statements of Stockholders&#8217; Equity for the three and nine months ended September 30, 2021 and 2020; (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2021 and 2020; and (v) the notes to the Registrant's Condensed Consolidated Financial Statements.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Certain confidential portions of this exhibit were omitted in accordance with Item 601(b)(10) of Regulation S-K</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="iae35796f039b495ba4b10877e85a1c6f_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iae35796f039b495ba4b10877e85a1c6f_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURE</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.572%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGENERON PHARMACEUTICALS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Robert E. Landry</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Landry</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance and </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Duly Authorized Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>regen-ex_101x9302021x10q.htm
<DESCRIPTION>MOD. P00004 TO SUPPLY AGREEMENT - REGENERON AND US ARMY CONTRACTING COMMAND
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i33ab2870e6534efab59d4ae8b6bb706c_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 10.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED.</font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.760%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.315%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="51" rowspan="2" style="border-bottom:0.25pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1. Contract ID Code</font></td><td colspan="9" style="border-left:0.25pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Firm Fixed Price</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8194;&#8194;</font></td></tr><tr><td colspan="15" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2. Amendment&#47;Modification No.</font></td><td colspan="15" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3. Effective Date</font></td><td colspan="24" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4. Requisition&#47;Purchase Req No.</font></td><td colspan="12" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5. Project No. (If applicable)</font></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00004</font></td><td colspan="15" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">2021JUL26</font></td><td colspan="24" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SEE SCHEDULE</font></td><td colspan="12" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6. Issued By</font></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 4.12pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Code</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W58P05</font></td><td colspan="30" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">7. Administered By (If other than Item 6)</font></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Code</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"><div style="padding-right:3.1pt"><font><br></font></div></td></tr><tr><td colspan="27" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:19.6pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">U.S. ACC, APG , NCD <br></font></div><div style="padding-left:19.6pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%"><br>NATICK, MA 01760-5011</font></div><div style="padding-left:19.6pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%"><br><br><br><br>EMAIL&#58; </font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="39" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8. Name And Address Of Contractor (No., Street, City, County, State and Zip Code)</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9744;</font></td><td colspan="18" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9A. Amendment Of Solicitation No.</font></td></tr><tr style="height:11pt"><td colspan="39" rowspan="6" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 20.62pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">REGENERON PHARMACEUTICALS, INC.<br>777 OLD SAW MILL RIVER RD<br>TARRYTOWN, NY 10591-6717</font></td><td colspan="9" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:10pt"><td colspan="9" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9B. Dated (See Item 11)</font></td></tr><tr style="height:10pt"><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9746;</font></td><td colspan="18" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10A. Modification Of Contract&#47;Order No.</font></td></tr><tr style="height:9pt"><td colspan="9" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td></tr><tr style="height:12pt"><td colspan="9" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10B. Dated (See Item 13)</font></td></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Code</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">544P9</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Facility Code</font></td><td colspan="27" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">2021JAN12</font></td></tr><tr><td colspan="66" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11.THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></td></tr><tr><td colspan="66" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:3pt;padding-left:20.4pt;padding-right:3.1pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:114%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">  The above numbered solicitation is amended as set forth in item 14. The hour and date specified for receipt of Offers</font></div><div style="padding-left:20.4pt;padding-right:3.1pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:109%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:109%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:109%"> is extended, </font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:109%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:109%"> is not extended.</font></div><div style="padding-left:15.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58;</font></div><div style="padding-left:15.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) By completing items 8 and 15, and returning </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> copies of the amendments&#58; (b) By acknowledging receipt of this amendment on each copy of the<br>offer submitted&#59; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR<br>ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE <br>SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change <br>may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening <br>hour and date specified.</font></div></td></tr><tr><td colspan="66" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12.  Accounting And Appropriation Data (If required)</font></td></tr><tr><td colspan="66" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 16.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">NO CHANGE TO OBLIGATION DATA</font></td></tr><tr><td colspan="66" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">13.  THIS ITEM ONLY APPLIES TO MODIFICATIONS OF CONTRACTS&#47;ORDERS<br>It Modifies The Contract&#47;Order No. As Described In Item 14.</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  </font></div></td><td colspan="21" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">A. This Change Order is Issued Pursuant To&#58;</font></div><div style="padding-left:11.4pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">The Contract&#47;Order No. In Item 10A.</font></div></td><td colspan="21" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">The Changes Set Forth In Item 14 Are Made In</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  </font></div></td><td colspan="63" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">B. The Above Numbered Contract&#47;Order Is Modified To Reflect The Administrative Changes (such as changes in paying office, appropriation data, etc.) Set Forth In Item 14, Pursuant To The Authority of FAR 43.103(b).</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  </font></div></td><td colspan="33" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">C. This Supplemental Agreement Is Entered Into Pursuant To Authority Of&#58;</font></td><td colspan="30" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">FAR 52.243-1</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  </font></div></td><td colspan="63" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">D. Other (Specify type of modification and authority)</font></td></tr><tr><td colspan="66" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">E. IMPORTANT&#58; Contractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">   </font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> is not,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    </font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">is required to sign this document and return</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">copies to the Issuing Office.</font></div></td></tr><tr><td colspan="66" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14. Description Of Amendment&#47;Modification (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.)</font></td></tr><tr><td colspan="66" style="padding:2px 1pt 2px 21.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SEE SECOND PAGE FOR DESCRIPTION</font></td></tr><tr><td colspan="66" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Except as provided herein, all terms and conditions of the document referenced in item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></td></tr><tr><td colspan="30" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">15A. Name And Title Of Signer (Type or print)</font></td><td colspan="36" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16A. Name And Title Of Contracting Officer (Type or print)</font></td></tr><tr><td colspan="30" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Joseph LaRosa&#160;&#160;&#160;&#160;EVP, General Counsel and Secretary</font></td><td colspan="36" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">15B. Contractor&#47;Offeror</font></td><td colspan="9" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">15C. Date Signed</font></td><td colspan="30" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16B. United States Of America</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16C. Date Signed</font></td></tr><tr><td colspan="21" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.1pt;padding-right:15.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#47;s&#47; Joseph LaRosa</font></div></td><td colspan="9" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">23-Jul-2021</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">By</font></td><td colspan="27" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#47;s&#47;</font></div></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">2021JUL26</font></td></tr><tr><td colspan="21" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Signature of person authorized to sign)</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="30" style="border-bottom:1pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Signature of Contracting Officer)</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NSN 7540-01-152-8070</font></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">30-105-02</font></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt 2px 30.72pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">STANDARD FORM 30 (REV. 10-83)</font></td></tr><tr><td colspan="18" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PREVIOUS EDITIONS UNUSABLE</font></td><td colspan="24" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt 2px 30.72pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Prescribed by GSA FAR (48 CFR) 53.243</font></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.680%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="6" rowspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="12" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference No. of Document Being Continued</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 6</font></div></td></tr><tr style="height:9pt"><td colspan="12" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MOD&#47;AMD</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00004</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Offeror or Contractor&#58;</font></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">REGENERON PHARMACEUTICALS, INC.</font></td></tr><tr><td colspan="21" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SECTION A - SUPPLEMENTAL INFORMATION</font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">Buyer Name&#58; </font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">Buyer Office Symbol&#47;Telephone Number&#58; CCAP&#47; </font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">Type of Contract 1&#58; Firm Fixed Price</font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">Kind of Contract&#58; Other </font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">Kind of Modification&#58; G</font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">Type of Business&#58; Large Business Performing in U.S. </font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">Surveillance Criticality Designator&#58; A</font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">Weapon System&#58; No Identified Army Weapons Systems </font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">Contract Expiration Date&#58; 2022JAN11</font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">Paying Office&#58; HQ0490</font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;DFAS-INDY VP GFEBS </font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;8899 E. 56TH STREET</font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">&#160;&#160;&#160;&#160;INDIANAPOLIS IN 46249-3800</font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="padding-left:3.1pt;padding-right:3.1pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">*** End of Narrative A0000 ***</font></div><div style="padding-left:3.1pt;padding-right:3.1pt;text-align:center"><font><br></font></div><div style="padding-left:3.1pt;padding-right:3.1pt;text-align:center"><font><br></font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">The purpose of this modification is to&#58;</font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">1)  Revise CLIN 0001AC delivery date from &#91;* * *&#93; to &#91;* * *&#93;. This change is for administrative purposes only as delivery was complete on or before &#91;* * *&#93;.</font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">2)  Add the following sentences to paragraph C.3.1&#58; &#34;The Government will make every effort to ensure appropriate utilization of Government purchased product based on clinical need. Prior to the anticipated time of FDA approval of a Biologics License Application (BLA) for REGEN-COV, the parties will plan and coordinate to ensure efficient and effective distribution of commercial and non- commercial product.&#34;</font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">3)  Revise paragraph C.8 to state, &#34;Authorized or Approved Uses&#58; Product sold to the Government may be distributed for use in any indication approved or authorized by the FDA.&#34;</font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">All other terms and conditions of this contract remain in full force and effect.</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">*** END OF NARRATIVE A0005 ***</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.003%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.903%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.150%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="21" rowspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="27" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference No. of Document Being Continued</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 6</font></div></td></tr><tr style="height:9pt"><td colspan="27" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1pt;padding-right:1pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></div></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN</font></td><td colspan="9" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MOD&#47;AMD</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00004</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="18" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Offeror or Contractor&#58;</font></td><td colspan="36" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">REGENERON PHARMACEUTICALS, INC.</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ITEM NO</font></td><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SUPPLIES&#47;SERVICES</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">QUANTITY</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT PRICE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AMOUNT</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">0001AC</font></div></td><td colspan="30" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SECTION B - SUPPLIES OR SERVICES AND PRICES&#47;COSTS</font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 THERAPEUTIC (REGN10987 AND REGN1093</font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font><br></font></div><div style="padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">COMMODITY NAME&#58; COVID THERAPEUTIC </font></div><div style="padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">CLIN CONTRACT TYPE&#58;</font></div><div style="padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Firm Fixed Price</font></div><div style="padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">PRON&#58; CB1RD41544 &#160;&#160;&#160;&#160;PRON AMD&#58; 04 ACRN&#58; AC </font></div><div style="padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">PSC&#58; 6505</font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font><br></font></div><div style="padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">Packaging and Marking</font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font><br></font></div><div style="padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Inspection and Acceptance</font></div><div style="padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">INSPECTION&#58; Destination ACCEPTANCE&#58; Destination</font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font><br></font></div><div style="padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">Deliveries or Performance</font></div></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">EA</font></div></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">$2,100.00000</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">$</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">DOC<br></font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">REL CD</font></div></td><td colspan="3" style="padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">MILSTRIP</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1pt;padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;SUPPL<br>   </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">ADDR&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">SIG CD</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">MARK FOR</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">TP CD</font></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">001</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W56XNH10011003</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W90ZQ2</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">J</font></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">3</font></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">DEL REL CD</font></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">QUANTITY</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">DEL DATE</font></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">001</font></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="30" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">FOB POINT&#58; Destination</font></div><div style="margin-top:3pt;padding-left:0.25pt;padding-right:0.25pt"><font><br></font></div><div style="padding-left:0.25pt;padding-right:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SHIP TO&#58;</font></div><div style="padding-left:38pt;padding-right:0.25pt;text-indent:-37.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">(W90ZQ2)&#160;&#160;&#160;&#160;XR JOINT PROGRAM EX OFC FOR CHEM, B <br>HQ JPEO<br>5101 HOADLEY ROAD<br>ABERDEEN PROVING GROUND,MD,21010-54</font></div></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.651%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="9" rowspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="21" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference No. of Document Being Continued</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 4 of 6</font></div></td></tr><tr style="height:9pt"><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MOD&#47;AMD</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00004</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Offeror or Contractor&#58;</font></td><td colspan="30" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">REGENERON PHARMACEUTICALS, INC.</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ITEM NO</font></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SUPPLIES&#47;SERVICES</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">QUANTITY</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT PRICE</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AMOUNT</font></td></tr><tr><td colspan="36" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:121%">SECTION C - DESCRIPTION&#47;SPECIFICATIONS&#47;WORK STATEMENT </font></div><div style="margin-bottom:9pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:121%">STATEMENT OF WORK</font></div><div style="margin-bottom:9pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:121%">Production of Regeneron Therapeutic in Support of National Emergency Response to Coronavirus 2019 (COVID-19)</font></div><div style="margin-bottom:9pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:121%">C.1&#160;&#160;&#160;&#160;Scope&#58; The Department of Defense (DoD) and Department of Health and Human Services (DHHS), in support of Operation Warp Speed (OWS) and national emergency response to the Coronavirus Disease 2019 (COVID-19), requires the production of Regeneron therapeutic cocktail REGN10987 and REGN10933 (casirivimab and imdevimab) on a commercial item basis, up to 1,250,000 doses to treat members of the DoD and the general population infected with the SARS CoV-2 Virus.</font></div><div style="margin-bottom:9pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:121%">C.1.1&#160;&#160;&#160;&#160;Background&#58; The DHHS continuously monitors emerging infectious disease risk and prepares to respond to the threat of novel emerging infectious disease outbreaks in the United States. DHHS is responding to an outbreak of respiratory disease caused by a novel coronavirus that was first detected in China, and which has now spread worldwide, including in the United States. The virus has been named SARS-CoV-2 and the disease it causes has been named Coronavirus Disease 2019 (abbreviated COVID-19).</font></div><div style="margin-bottom:9pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:121%">On January 30, 2020, the International Health Regulations Emergency Committee of the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern (PHEIC). On January 31, Health and Human Services Secretary Alex M. Azar II declared a Public Health Emergency (PHE) for the United States to aid the nations healthcare community in responding to COVID-19. On March 11, WHO publicly characterized COVID-19 as a pandemic. On March 13, the President of the United States declared the COVID-19 outbreak a national emergency.</font></div><div style="margin-bottom:9pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:121%">In July 2020, the DoD awarded an Other Transaction Agreement under the authority of 10 USC 2371b to Regeneron to manufacture and sell drug product to the Government, and to distribute such drug product for the Government in the U.S. These manufacturing production activities included manufacturing at-scale, filling and finishing, and storage and shipping of REGN10987 and REGN10933 as a therapeutic cocktail to treat COVID-19 infected patients. On November 21, 2020, Regeneron announced that the antibody cocktail casirivimab and imdevimab administered together, has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).</font></div><div style="margin-bottom:9pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:121%">As part of DHHS preparedness and response activities, DHHS seeks to purchase up to 1,250,000 doses of the EUA authorized (or Biologics License Application (BLA) approved) casirivimab and imdevimab therapeutic, enough to treat much of the targeted US population currently or projected to be infected over the coming months.</font></div><div style="margin-bottom:9pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:121%">C.2&#160;&#160;&#160;&#160;Objectives and Quantity&#58; The contractor shall produce up to 1,250,000 doses of therapeutic, and the Government will purchase all such doses available in Vendor-Managed Inventory (VMI) by the applicable date set forth below&#58;</font></div><div style="margin-bottom:9pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:121%">No Later Than (NLT) June 30, 2021. The Government will consider extending the time for delivery to NLT September 30, 2021, if the contractor is unable to complete delivery to VMI by June 30, 2021, after making a good faith effort to do so. However, prior to any extension to the delivery schedule, the contractor shall coordinate with the Government to determine an appropriate path forward, aligning with Government needs. The contractor shall comply with the procedures of FAR 52.212-4(f), Excusable Delays.</font></div><div style="margin-bottom:9pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:121%">C.3&#160;&#160;&#160;&#160;Requirements&#58;</font></div><div style="margin-bottom:9pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:121%">C.3.1&#160;&#160;&#160;&#160;Therapeutic&#58; The contractor shall distribute the product to Government designated sites as directed by the Government, EUA authorized finished drug product in vials in accordance with the products storage and handling requirements in the EUA, including temperature controls. This shall include storage and distribution activities. Regeneron will engage one or more third party service providers (each a Distributor) to perform storage and distribution activities for drug product at the direction of the Government. The Government will be solely responsible for all allocation determinations related to drug product, including allocation to end users and communication of such allocation determinations to the Distributor. Unless otherwise mutually agreed upon by the parties, drug product shall be shipped to the Government or distributed, as applicable, solely within the United States (including its territories and possessions). The contractor shall &#91;* * *&#93;, until the product is distributed to the end user (e.g., the hospital, infusion center or other end-user). To the extent that Regeneron is responsible for the correction, repair or replacement of Government property held in vendor-managed inventory or in distribution and in the possession of the Distributor, &#91;* * *&#93; the Government &#91;* * *&#93; of such property. The parties will coordinate ordering through centralized distribution via the established Memorandum of Understanding between Regeneron, Assistant Secretary for Preparedness and Response (ASPR), and AmerisourceBergen. Storage and distribution activities under the EUA shall be supported under this agreement through the end of the period of performance. The Government will make every effort to ensure appropriate utilization of Government purchased product based on clinical need. Prior to the anticipated time of FDA approval of a Biologics License Application (BLA) for REGEN-COV, the parties will plan and coordinate to ensure efficient and effective distribution of commercial and non-commercial product.</font></div><div style="margin-bottom:9pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:121%">C.3.2&#160;&#160;&#160;&#160;Product Development Manufacturing Reports and Projections&#58; Regeneron will provide manufacturing reports and manufacturing dose tracking projections&#47;actuals, in the format and having the content mutually agreed upon by the Government and Regeneron. Regeneron will update the reports &#91;* * *&#93; during manufacturing campaigns and upon manufacturing deliverable submission during COVID-19 response operations (where a Public Health Emergency has been declared), with the first deliverable submission within &#91;* * *&#93; of award. For clarity, the reports described in this section apply to Formulated Drug Substance and Drug Product prior to delivery and acceptance by the Government. Tracking reports for product following delivery and acceptance, shall be set forth in the Memorandum of Understanding between Regeneron, ASPR, and AmerisourceBergen.</font></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.651%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="9" rowspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="21" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference No. of Document Being Continued</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 5 of 6</font></div></td></tr><tr style="height:9pt"><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.85pt;padding-right:4.85pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></div></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MOD&#47;AMD</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00004</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Offeror or Contractor&#58;</font></td><td colspan="30" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:700;line-height:120%">REGENERON PHARMACEUTICALS, INC.</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ITEM NO</font></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SUPPLIES&#47;SERVICES</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">QUANTITY</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT PRICE</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AMOUNT</font></td></tr><tr><td colspan="36" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">C.4&#160;&#160;&#160;&#160;Reporting&#58; The contractor shall provide the following reports&#47;deliverables in accordance with Exhibit A&#58;</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">CDRL #</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">Title</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A001&#160;&#160;&#160;&#160;Post Award Teleconference Minutes</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A002&#160;&#160;&#160;&#160;Kickoff Meeting Agenda and Minutes </font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A003&#160;&#160;&#160;&#160;Teleconference Minutes</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A004&#160;&#160;&#160;&#160;Quarterly Meetings </font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A005&#160;&#160;&#160;&#160;FDA Meeting Minutes</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A006&#160;&#160;&#160;&#160;Daily Check-in with Project Staff for COVID-19 Agreement </font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A007&#160;&#160;&#160;&#160;Monthly Progress Reports</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A008&#160;&#160;&#160;&#160;Milestone Reports</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A009&#160;&#160;&#160;&#160;Draft Technical Progress Report </font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A010&#160;&#160;&#160;&#160;Final Technical Progress Report</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A011&#160;&#160;&#160;&#160;Product Development Source Material and Manufacturing Report </font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A012&#160;&#160;&#160;&#160;Contractor Locations</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A013&#160;&#160;&#160;&#160;Pandemic Management Plan</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A014&#160;&#160;&#160;&#160;Supply Chain and Distribution Tracking </font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A015&#160;&#160;&#160;&#160;Distribution Plan</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A016&#160;&#160;&#160;&#160;Manufacturing Development Plan </font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A017&#160;&#160;&#160;&#160;Quality Management Plan</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A018&#160;&#160;&#160;&#160;Quality Agreement</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A019&#160;&#160;&#160;&#160;Release Documentation for Doses to be Delivered </font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A020&#160;&#160;&#160;&#160;Manufacturing and Distribution Records</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A021&#160;&#160;&#160;&#160;Security Plan</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A022&#160;&#160;&#160;&#160;Supply Chain Resiliency Plan </font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A023&#160;&#160;&#160;&#160;Manufacturing Data Requirements </font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A024&#160;&#160;&#160;&#160;BARDA Audit</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A025&#160;&#160;&#160;&#160;FDA Inspections </font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A026&#160;&#160;&#160;&#160;QA Audits</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A027&#160;&#160;&#160;&#160;FDA Submissions </font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A028&#160;&#160;&#160;&#160;EUA Filing</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A029&#160;&#160;&#160;&#160;Provision of Public Law 115-92 SPONSOR Authorization Letter </font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A030&#160;&#160;&#160;&#160;Press Releases</font></div><div style="margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">C.5&#160;&#160;&#160;&#160;Period of Performance&#58; The period of performance for this contract is twelve (12) months.</font></div><div style="margin-bottom:5pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">C.6&#160;&#160;&#160;&#160;Inspection&#47;Acceptance&#58;</font></div><div style="margin-bottom:5pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">C.6.1&#160;&#160;&#160;&#160;Inspection&#58; The Technical Point of Contact (TPOC) is a duly authorized representative of the Government, and is responsible for the inspection and&#47;or acceptance of all items&#47;activities to be delivered and&#47;or completed under this contract. The parties acknowledge that acceptance may depend on the compliance with FDA regulations at 21 CFR 600-680 regarding the BLA, current Good Manufacturing Practice (cGMP) regulations at 21 CFR 210, 211, and other FDA regulations.</font></div><div style="margin-bottom:5pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">C.6.2&#160;&#160;&#160;&#160;Acceptance&#58; Title to drug product will pass to the Government upon delivery of such drug product to VMI, and the Governments corresponding written acceptance of such drug product. The Government shall accept product that conforms to contract requirements based on a Certificate of Analysis (COA) and any other quality documentation required to be provided by Regeneron, as set forth in the Quality Agreement (&#34;Required Documents&#34;), and the parties shall perform their obligations relating to product delivery set forth in the applicable Quality Agreement for the product. The Government's acceptance of drug product will be &#91;* * *&#93; provide written notice of acceptance or rejection within &#91;* * *&#93;. Any visibly damaged product will be rejected immediately. The contractor will transfer product from VMI to the Distributor for distribution directed by the Government&#59; provided that, product shall not be provided to the Distributor until it is accepted by the Government. The contractor shall provide a shipment temperature tracking report within &#91;* * *&#93; of contractors receipt of such report from its storage vendor, or otherwise in accordance with the applicable Quality Agreement. Any product subject to a temperature excursion outside of acceptable tolerances, shall be rejected. Any rejected product shall be returned to the contractor or otherwise disposed of according to contractor instructions. The Government will not be obligated to pay for rejected vials, nor will rejected vials count toward the delivery requirement. The contractor shall establish a notification mechanism for delivery sites to contact the Government regarding rejected vials.</font></div><div style="margin-bottom:5pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">C.7&#160;&#160;&#160;&#160;Packaging and Marking&#58; The contractor shall label product according to FDA guidance&#47;instructions. Packaging shall be in shipping containers according to the contractors standard commercial practice.</font></div><div style="margin-bottom:5pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">C.8&#160;&#160;&#160;&#160;Authorized and Approved Uses&#58; Product sold to the Government may be distributed for use in any indication approved or authorized by the FDA.</font></div></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.651%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="9" rowspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="21" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference No. of Document Being Continued</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 6 of 6</font></div></td></tr><tr style="height:9pt"><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MOD&#47;AMD</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00004</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Offeror or Contractor&#58;</font></td><td colspan="30" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">REGENERON PHARMACEUTICALS, INC.</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ITEM NO</font></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SUPPLIES&#47;SERVICES</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">QUANTITY</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT PRICE</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AMOUNT</font></td></tr><tr><td colspan="36" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;margin-top:4pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">Public Disclosures&#58; Notwithstanding any other provision in this contract, the contractor may publicly release any information related to this contract without prior approval to the extent necessary to satisfy or address regulatory requirements, contractual obligations to third parties, and the public interest in data about the safety or efficacy of the product.</font></div><div style="margin-bottom:10pt;margin-top:4pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">Public Readiness and Emergency Preparedness (PREP) Act&#58; The Government will ensure that no product purchased under this contract is used outside the United States (including its territories or possessions) or in a way that is not protected from liability by a declaration issued under the PREP Act that is active at the time of use.</font></div><div style="margin-bottom:10pt;margin-top:4pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">C.9&#160;&#160;&#160;&#160;Government Technical Point of Contact&#58;</font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">HHS BARDA </font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt"><font><br></font></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:3.1pt;padding-right:3.1pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">*** END OF NARRATIVE C0001 ***</font></div></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>regen-ex_102x9302021x10q.htm
<DESCRIPTION>MOD. P00005 TO SUPPLY AGREEMENT - REGENERON AND US ARMY CONTRACTING COMMAND
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7dd8655f2f0247d983262d67be43de82_1"></div><div style="min-height:71.24pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 10.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED.</font></div></div><div style="margin-bottom:6pt;padding-left:13.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.674%"><tr><td style="width:1.0%"></td><td style="width:9.339%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.339%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.339%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.323%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="21" rowspan="2" style="border-bottom:0.25pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1. Contract ID Code</font></td><td colspan="6" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 1 of 12</font></td></tr><tr style="height:9pt"><td colspan="6" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Firm Fixed Price</font></td></tr><tr style="height:12pt"><td colspan="9" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2. Amendment&#47;Modification No.</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3. Effective Date</font></td><td colspan="9" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4. Requisition&#47;Purchase Req No.</font></td><td colspan="9" rowspan="2" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5. Project No. (If applicable)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00005</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 33.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">2021SEP14</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 42.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SEE SCHEDULE</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.65pt;padding-left:5.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:103%">6. Issued By&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 6.75pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Code</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W58P05</font></td><td colspan="12" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:103%">7. Administered By (If other than Item 6)</font></div></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 6.4pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Code</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="15" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.2pt;padding-left:22.3pt;padding-right:166.45pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">U.S. ACC, APG , NCD </font></div><div style="padding-left:22.3pt;padding-right:166.45pt"><font><br></font></div><div style="padding-left:22.3pt;padding-right:166.45pt"><font><br></font></div><div style="padding-left:22.3pt;padding-right:101.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">NATICK, MA 01760-5011</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:22.3pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">EMAIL&#58; </font></div></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="18" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8. Name And Address Of Contractor (No., Street, City, County, State and Zip Code)</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9744;</font></td><td colspan="12" rowspan="2" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 5.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9A. Amendment Of Solicitation No.</font></td></tr><tr style="height:15pt"><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.2pt;padding-right:12.6pt;text-indent:9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">REGENERON PHARMACEUTICALS, INC. </font></div><div style="padding-right:12.6pt;text-indent:9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">777 OLD SAW MILL RIVER RD </font></div><div style="padding-right:12.6pt;text-indent:9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">TARRYTOWN, NY 10591-6717</font></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-right:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 5.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9B. Dated (See Item 11)</font></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9746;</font></td><td colspan="12" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 5.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10A. Modification Of Contract&#47;Order No.</font></td></tr><tr style="height:9pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 5.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 5.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10B. Dated (See Item 13)</font></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Code</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 17.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">544P9</font></td><td colspan="12" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Facility Code</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 5.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">2021JAN12</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3.45pt;padding-left:160.6pt;text-indent:-12.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></div><div style="padding-left:35.8pt;text-align:justify;text-indent:-17.1pt"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:119%">&#9744;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:119%">The above numbered solicitation is amended as set forth in item 14. The hour and date specified for receipt of Offers</font></div><div style="padding-left:51pt;text-indent:-15.05pt"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:130%">&#9744;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">is extended, </font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:130%">&#9744; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:130%">is not extended.</font></div><div style="padding-left:30.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:106%">Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58;</font></div><div style="padding-left:30.75pt;padding-right:35.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) By completing items 8 and 15, and returning</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> copies of the amendments&#58; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE</font></div><div style="margin-bottom:0.2pt;padding-left:30.75pt;padding-right:16.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div><div style="padding-left:12.75pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:0px;margin-bottom:5pt;vertical-align:text-bottom;width:720px"></div><div style="padding-left:32.9pt;text-align:justify;text-indent:-14.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;Accounting And Appropriation Data (If required)</font></div><div style="margin-bottom:0.95pt;margin-top:1.55pt;padding-left:30.75pt;text-align:justify"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SEE SECTION G (IF APPLICABLE)</font></div><div style="padding-left:12.75pt"><img alt="image_2a.jpg" src="image_2a.jpg" style="height:0px;margin-bottom:5pt;vertical-align:text-bottom;width:720px"></div><div style="margin-bottom:0.1pt;padding-left:178.2pt;padding-right:125.35pt;text-indent:-45.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;THIS ITEM ONLY APPLIES TO MODIFICATIONS OF CONTRACTS&#47;ORDERS It Modifies The Contract&#47;Order No. As Described In Item 14.</font></div><div style="margin-bottom:6pt;padding-left:13.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.869%"><tr><td style="width:1.0%"></td><td style="width:3.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.222%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9744;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:13.75pt;padding-right:112.6pt;text-indent:-8.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">A. This Change Order is Issued Pursuant To&#58; The Contract&#47;Order No. In Item 10A.</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 70.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">The Changes Set Forth In Item 14 Are Made In</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9744;</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:113%">B. The Above Numbered Contract&#47;Order Is Modified To Reflect The Administrative Changes (such as changes in paying office, appropriation</font></div><div style="margin-top:0.05pt;padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:103%">data, etc.) Set Forth In Item 14, Pursuant To The Authority of FAR 43.103(b).</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9746;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">C. This Supplemental Agreement Is Entered Into Pursuant To Authority Of&#58;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:96%">FAR 6.302-2</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9744;</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">D. Other (Specify type of modification and authority)</font></td></tr></table></div><div style="margin-top:0.2pt;padding-left:18.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">E. IMPORTANT&#58; Contractor </font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9744; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">is not, </font><font style="color:#000000;font-family:'MS Gothic',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#9746; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">is required to sign this document and return copies to the Issuing Office.</font></div><div style="padding-left:12.75pt"><img alt="image_2a.jpg" src="image_2a.jpg" style="height:0px;margin-bottom:5pt;vertical-align:text-bottom;width:720px"></div><div style="margin-top:2.1pt;padding-left:30.85pt;text-align:justify;text-indent:-12.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;Description Of Amendment&#47;Modification (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.)</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:35.65pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SEE SECOND PAGE FOR DESCRIPTION</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;padding-left:18.75pt;padding-right:19.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Except as provided herein, all terms and conditions of the document referenced in item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div><div style="height:48.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:71.24pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:13.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.003%"><tr><td style="width:1.0%"></td><td style="width:34.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.148%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="6" rowspan="2" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">15A. Name And Title Of Signer (Type or print)</font></div><div style="padding-left:5.75pt"><font><br></font></div><div style="padding-left:5.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:131%">Robert Landry     EVP-Finance and CFO</font></div></td><td colspan="9" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16A. Name And Title Of Contracting Officer (Type or print)</font></td></tr><tr style="height:16pt"><td colspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">15B. Contractor&#47;Offeror</font></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">15C. Date Signed</font></div><div style="padding-left:5.45pt"><font><br></font></div><div style="padding-left:5.45pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:131%">14-Sept-2021</font></div></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">16B. United States Of America</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.72pt;padding-right:7.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">16C. Date Signed</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.95pt;padding-left:0.4pt;padding-right:83.05pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:101%">&#47;s&#47; Robert Landry</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">By</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.95pt;padding-left:0.25pt;padding-right:67.5pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:101%">&#47;s&#47;</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:4.75pt;padding-right:4.75pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:82%">2021SEPT14</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 33.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Signature of person authorized to sign)</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 42.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Signature of Contracting Officer)</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:18.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NSN 7540-01-152-8070&#160;&#160;&#160;&#160;30-105-02&#160;&#160;&#160;&#160;STANDARD FORM 30 (REV. 10-83)</font></div><div style="margin-top:0.05pt;padding-left:18.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PREVIOUS EDITIONS UNUSABLE&#160;&#160;&#160;&#160;Prescribed by GSA FAR (48 CFR) 53.243</font></div><div style="height:48.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7dd8655f2f0247d983262d67be43de82_4"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:13.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.869%"><tr><td style="width:1.0%"></td><td style="width:27.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 74.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference No. of Document Being Continued</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 2 of 12</font></td></tr><tr><td colspan="3" style="padding:2px 1.1pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 45.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MOD&#47;AMD</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 11.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00005</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-0.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;Name of Offeror or Contractor&#58;&#160;&#160;&#160;&#160;</font></div></td><td colspan="12" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">REGENERON PHARMACEUTICALS, INC.&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3.35pt;padding-left:5.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SECTION A - SUPPLEMENTAL INFORMATION</font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Buyer Name&#58; </font></div><div style="margin-top:1.05pt;padding-left:5.75pt;padding-right:298.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:131%">Buyer Office Symbol&#47;Telephone Number&#58; CCAP&#47; </font></div><div style="margin-top:1.05pt;padding-left:5.75pt;padding-right:298.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:131%">Type of Contract 1&#58; Firm Fixed Price</font></div><div style="margin-top:0.1pt;padding-left:5.75pt;padding-right:436.7pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:131%">Kind of Contract&#58; Other Kind of Modification&#58; G</font></div><div style="margin-top:0.05pt;padding-left:5.75pt;padding-right:298.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:131%">Type of Business&#58; Large Business Performing in U.S. Surveillance Criticality Designator&#58; A</font></div><div style="margin-top:0.1pt;padding-left:5.75pt;padding-right:298.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:131%">Weapon System&#58; No Identified Army Weapons Systems Contract Expiration Date&#58; 2022JUL31</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:5.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Paying Office&#58; HQ0490</font></div><div style="margin-top:1.05pt;padding-left:76.65pt;padding-right:382.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:131%">DFAS-INDY VP GFEBS 8899 E. 56TH STREET</font></div><div style="margin-top:0.1pt;padding-left:76.65pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">INDIANAPOLIS IN 46249-3800</font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:205.95pt;padding-right:205.95pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">*** End of Narrative A0000 ***</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">The purpose of this modification is to&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-16.8pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">1)&#160;&#160;&#160;&#160;Procure an additional 1,400,000 doses of antibody therapeutic (REGEN-COV) to treat COVID-19 in the general population.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.75pt;padding-right:13.7pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:131%">2)&#160;&#160;&#160;&#160;Vendor Managed Inventory (VMI) and distribution activities shall continue for &#91;* * *&#93;, with a completion date of &#91;* * *&#93;. See Section B.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-16.8pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">3)&#160;&#160;&#160;&#160;Update the contract expiration date from 11 January 2022 to 31 July 2022.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.75pt;padding-right:34.85pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:131%">4)&#160;&#160;&#160;&#160;Update the Statement of Work to reflect new total contract deliverable quantities, delivery requirements, period of performance, and administrative language.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-16.8pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">5)&#160;&#160;&#160;&#160;Add Attachment 0003, Contingencies and Operational Requirements.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:22.5pt;text-indent:-16.8pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">6)&#160;&#160;&#160;&#160;See Section B and Section C for quantities and delivery schedule.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">7)      Increases obligation by $2,940,000,000 from $2,625,000,000 to $5,565,000,000.00.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6.65pt;padding-left:205.95pt;padding-right:205.95pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:99%">*** END OF NARRATIVE A0006 ***</font></div></td></tr></table></div><div><font><br></font></div><div style="height:48.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7dd8655f2f0247d983262d67be43de82_7"></div><hr style="page-break-after:always"><div style="min-height:95pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:12.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.869%"><tr><td style="width:1.0%"></td><td style="width:27.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 74.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference No. of Document Being Continued</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 3 of 12</font></td></tr><tr><td colspan="3" style="padding:2px 1.1pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 45.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MOD&#47;AMD</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 11.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00005</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-0.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;Name of Offeror or Contractor&#58;&#160;&#160;&#160;&#160;</font></div></td><td colspan="12" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">REGENERON PHARMACEUTICALS, INC.&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:12.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.735%"><tr><td style="width:1.0%"></td><td style="width:7.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.219%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 8.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ITEM NO</font></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.65pt;padding-left:1.42pt;padding-right:1.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SUPPLIES&#47;SERVICES</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 8.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">QUANTITY</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 15.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 7.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT PRICE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 19.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AMOUNT</font></td></tr><tr style="height:297pt"><td colspan="3" rowspan="10" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">0003</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:12.7pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">0003AA</font></div></td><td colspan="18" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3.15pt;padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SECTION B - SUPPLIES OR SERVICES AND PRICES&#47;COSTS</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6.55pt;padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">subCLIN 00003AA</font></div><div style="margin-top:3pt;padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">NSN&#58; 9999-99-999-99999</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">REGEN-COV DOSES</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:5.35pt;padding-left:2.6pt;padding-right:106.7pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">COMMODITY NAME&#58; subCLIN 0003AA CLIN CONTRACT TYPE&#58;</font></div><div style="margin-top:0.1pt;padding-left:69.92pt;padding-right:69.92pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Firm Fixed Price</font></div><div style="padding-left:2.6pt;padding-right:87.9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">PRON&#58; X21ZS484W1 PRON AMD&#58; 01 ACRN&#58; AD PSC&#58; 6505</font></div><div><font><br></font></div><div style="margin-top:4.7pt;padding-left:2.6pt;padding-right:1.7pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Modification P00005 establishes CLIN 0003AA for a quantity of 476,190 doses for $999,999,000. Binding Delivery Schedule is located below.</font></div><div style="margin-top:3pt;padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">The Goal Delivery Schedule can be found in Section C.2.</font></div><div><font><br></font></div><div style="margin-top:4.7pt;padding-left:2.6pt;padding-right:76.15pt;text-indent:74.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:276%">(End of narrative B00l)</font></div><div style="padding-right:76.15pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">Packaging and Marking</font></div><div style="margin-top:0.05pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="padding-right:142.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">Inspection and Acceptance</font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">INSPECTION&#58; Destination&#160;&#160;&#160;&#160;ACCEPTANCE&#58; Destination</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:1.6pt;padding-right:142.45pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:102%;text-decoration:underline">Deliveries or Performance</font></div></td><td colspan="3" rowspan="10" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6.1pt;padding-left:16.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">476190</font></div></td><td colspan="3" rowspan="10" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6.1pt;padding-left:19.25pt;padding-right:19.25pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">EA</font></div></td><td colspan="3" rowspan="10" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6.1pt;padding-left:3.2pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">$2,100.00000</font></div></td><td colspan="3" rowspan="10" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6.1pt;padding-left:3.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">$999,999,000.00</font></div></td></tr><tr style="height:26pt"><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.15pt;padding-left:2.6pt;padding-right:6.8pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:114%">DOC </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:114%;text-decoration:underline">REL CD</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:11.35pt;padding-right:11.35pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%;text-decoration:underline">MILSTRIP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.15pt;padding-left:6.05pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:114%">SUPPL </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:114%;text-decoration:underline">ADDR </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:3.62pt;padding-right:3.62pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%;text-decoration:underline">SIG CD</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%;text-decoration:underline">MARK FOR</font></div></td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:7.72pt;padding-right:7.72pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%;text-decoration:underline">TP CD</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 7.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">001</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-right:-0.25pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:109%">W15BW91256ZD21</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W90ZQ2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:0.3pt;padding-right:0.3pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:109%">J</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:109%">3</font></div></td></tr><tr style="height:18pt"><td colspan="6" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">DEL REL CD</font></td><td colspan="3" style="padding:2px 1pt 2px 5.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">QUANTITY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 27.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">DEL DATE</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">001</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">100,000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 20.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">30-SEP-2021</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">002</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">100,000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 20.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">31-OCT-2021</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">003</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">100,000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 20.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">30-NOV-2021</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">004</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">100,000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 20.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">31-DEC-2021</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">005</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 7.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">76,190</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 20.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">31-JAN-2022</font></td></tr><tr style="height:102pt"><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3.55pt;padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">FOB POINT&#58; Destination</font></div><div><font><br></font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SHIP TO&#58;</font></div><div style="padding-left:40.4pt;padding-right:17.75pt;text-indent:-37.8pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">(W90ZQ2) XR JOINT PROGRAM EX OFC FOR CHEM, B HQ JPEO</font></div><div style="padding-left:40.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:113%">5101 HOADLEY ROAD</font></div><div style="padding-left:40.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">ABERDEEN PROVING GROUND, MD, 21010-54</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">The parties will coordinate ordering through centralized distribution via the established</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7dd8655f2f0247d983262d67be43de82_10"></div><hr style="page-break-after:always"><div style="min-height:95pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:12.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.869%"><tr><td style="width:1.0%"></td><td style="width:27.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 74.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference No. of Document Being Continued</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 4 of 12</font></td></tr><tr><td colspan="3" style="padding:2px 1.1pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 45.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MOD&#47;AMD</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 11.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00005</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-0.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;Name of Offeror or Contractor&#58;&#160;&#160;&#160;&#160;</font></div></td><td colspan="12" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">REGENERON PHARMACEUTICALS, INC.&#160;&#160;&#160;&#160;</font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.003%"><tr><td style="width:1.0%"></td><td style="width:8.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.933%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 8.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ITEM NO</font></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.65pt;padding-left:1.47pt;padding-right:1.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SUPPLIES&#47;SERVICES</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 8.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">QUANTITY</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 15.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT PRICE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 18.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AMOUNT</font></td></tr><tr style="height:313pt"><td colspan="3" rowspan="6" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6.1pt;padding-left:12.7pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">0003AB</font></div></td><td colspan="18" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:2.6pt;padding-right:6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:117%">Memorandum of Understanding between Regeneron, ASPR, and AmerisourceBergen. Exact ship-to locations for product will be identified through this coordinated process.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:77.35pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">(End of narrative F00l)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">REGEN-COV DOSES</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:5.35pt;padding-left:2.6pt;padding-right:106.8pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:117%">COMMODITY NAME&#58; subCLIN 0003AB CLIN CONTRACT TYPE&#58;</font></div><div style="padding-left:23.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:112%">Firm Fixed Price</font></div><div style="padding-left:2.6pt;padding-right:88pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">PRON&#58; X21ZS484W1 PRON AMD&#58; 01 ACRN&#58; AE PSC&#58; 6505</font></div><div><font><br></font></div><div style="padding-left:2.6pt;padding-right:1.8pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Modification P00005 establishes CLIN 0003AB for a quantity of 476,190 doses for $999,999,000. Binding Delivery Schedule is located below.</font></div><div style="margin-top:2.95pt;padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">The Goal Delivery Schedule can be found in Section C.2.</font></div><div><font><br></font></div><div style="margin-top:4.75pt;padding-left:2.6pt;padding-right:76.25pt;text-indent:74.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:276%">(End of narrative B00l) </font></div><div style="padding-left:4.5pt;padding-right:76.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">Packaging and Marking</font></div><div style="padding-left:2.6pt;padding-right:76.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">Inspection and Acceptance</font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">INSPECTION&#58; Destination&#160;&#160;&#160;&#160;ACCEPTANCE&#58; Destination</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">Deliveries or Performance</font></div></td><td colspan="3" rowspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6.1pt;padding-left:16.65pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">476190</font></div></td><td colspan="3" rowspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6.1pt;padding-left:13.37pt;padding-right:13.37pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">EA</font></div></td><td colspan="3" rowspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6.1pt;padding-left:3pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">$2,100.00000</font></div></td><td colspan="3" rowspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6.1pt;padding-left:3.05pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">$999,999,000.00</font></div></td></tr><tr style="height:26pt"><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:2.6pt;padding-right:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:114%">DOC </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:114%;text-decoration:underline">REL CD</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:3.37pt;padding-right:3.37pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%;text-decoration:underline">MILSTRIP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:3.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:114%">SUPPL </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:114%;text-decoration:underline">ADDR </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:3.85pt;padding-right:3.85pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%;text-decoration:underline">SIG CD</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%;text-decoration:underline">MARK FOR</font></div></td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:7.75pt;padding-right:7.75pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%;text-decoration:underline">TP CD</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 7.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">001</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:2.07pt;padding-right:2.07pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%">W15BW91256ZD22</font></div></td><td colspan="3" style="padding:2px 1pt 2px 7.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W90ZQ2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:0.07pt;padding-right:0.07pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%">J</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:1.2pt;padding-right:1.2pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%">3</font></div></td></tr><tr style="height:9pt"><td colspan="6" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">DEL REL CD</font></td><td colspan="6" style="padding:2px 1pt 2px 14.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">QUANTITY</font></td><td colspan="6" style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 27.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">DEL DATE</font></td></tr><tr style="height:9pt"><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 14.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">001</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 16.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">476,190</font></td><td colspan="6" style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 20.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">31-JAN-2022</font></td></tr><tr style="height:183pt"><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">FOB POINT&#58; Destination</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SHIP TO&#58;</font></div><div style="padding-left:40.4pt;padding-right:56.4pt;text-indent:-37.8pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">(W90ZQ2) XR JOINT PROGRAM EX OFC FOR CHEM, B HQ JPEO</font></div><div style="padding-left:40.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:113%">5101 HOADLEY ROAD</font></div><div style="padding-left:40.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">ABERDEEN PROVING GROUND, MD, 21010-54</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:5.35pt;padding-left:2.6pt;padding-right:6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">The parties will coordinate ordering through centralized distribution via the established Memorandum of Understanding between Regeneron, ASPR, and AmerisourceBergen. Exact ship-to locations for product will be identified through this coordinated process.</font></div><div><font><br></font></div><div style="margin-top:6.7pt;padding-left:77.35pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">(End of narrative F00l)</font></div></td></tr></table></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7dd8655f2f0247d983262d67be43de82_13"></div><hr style="page-break-after:always"><div style="min-height:95pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:12.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.869%"><tr><td style="width:1.0%"></td><td style="width:27.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 74.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference No. of Document Being Continued</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 5 of 12</font></td></tr><tr><td colspan="3" style="padding:2px 1.1pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 45.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MOD&#47;AMD</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 11.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00005</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-0.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;Name of Offeror or Contractor&#58;&#160;&#160;&#160;&#160;</font></div></td><td colspan="12" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">REGENERON PHARMACEUTICALS, INC.&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:12.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.345%"><tr><td style="width:1.0%"></td><td style="width:8.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 8.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ITEM NO</font></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.65pt;padding-left:1.47pt;padding-right:1.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SUPPLIES&#47;SERVICES</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.65pt;padding-left:6.4pt;padding-right:6.4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">QUANTITY</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.65pt;padding-left:13.45pt;padding-right:13.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.65pt;padding-left:1.6pt;padding-right:1.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT PRICE</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 18.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AMOUNT</font></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:12.7pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">0003AC</font></div></td><td colspan="18" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">REGEN-COV DOSES</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:5.35pt;padding-left:2.6pt;padding-right:106.8pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">COMMODITY NAME&#58; subCLIN 0003AC CLIN CONTRACT TYPE&#58;</font></div><div style="padding-left:69.97pt;padding-right:69.97pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:113%">Firm Fixed Price</font></div><div style="padding-left:2.6pt;padding-right:88pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">PRON&#58; X21ZS486W1 PRON AMD&#58; 01 ACRN&#58; AF PSC&#58; 6505</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:2.6pt;padding-right:4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:117%">Modification P00005 establishes CLIN 0003AC for a quantity of 447,620 doses for $940,002,000. Binding Delivery Schedule is located below.</font></div><div style="margin-top:2.85pt;padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">The Goal Delivery Schedule can be found in Section C.2.</font></div><div><font><br></font></div><div style="margin-top:4.7pt;padding-left:2.6pt;padding-right:76.25pt;text-indent:74.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:276%">(End of narrative B00l) </font></div><div style="padding-right:76.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">Packaging and Marking</font></div><div style="padding-right:76.25pt"><font><br></font></div><div style="padding-left:1.6pt;padding-right:142.55pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:112%;text-decoration:underline">Inspection and Acceptance</font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">INSPECTION&#58; Destination&#160;&#160;&#160;&#160;ACCEPTANCE&#58; Destination</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">Deliveries or Performance</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6.37pt;padding-right:6.37pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">447620</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:13.4pt;padding-right:13.4pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">EA</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:2.7pt;padding-right:2.7pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">$2,100.00000</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:3.05pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">$940,002,000.00</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.4pt;padding-left:2.6pt;padding-right:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">DOC </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">REL CD</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:3.37pt;padding-right:3.37pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">MILSTRIP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.4pt;padding-left:3.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SUPPL </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">ADDR </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:3.85pt;padding-right:3.85pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">SIG CD</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.35pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">MARK FOR</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:7.75pt;padding-right:7.75pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">TP CD</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 7.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">001</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:2.07pt;padding-right:2.07pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:113%">W15BW91256ZD23</font></div></td><td colspan="3" style="padding:2px 1pt 2px 7.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W90ZQ2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:0.07pt;padding-right:0.07pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:113%">J</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1pt;padding-left:1.2pt;padding-right:1.2pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:113%">3</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">DEL REL CD</font></td><td colspan="6" style="padding:2px 1pt 2px 14.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">QUANTITY</font></td><td colspan="6" style="padding:2px 1pt 2px 27.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">DEL DATE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 14.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">001</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 16.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">476,620</font></td><td colspan="6" style="padding:2px 1pt 2px 20.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">31-JAN-2022</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">FOB POINT&#58; Destination</font></div><div><font><br></font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SHIP TO&#58;</font></div><div style="padding-left:40.4pt;padding-right:56.4pt;text-indent:-37.8pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">(W90ZQ2) XR JOINT PROGRAM EX OFC FOR CHEM, B HQ JPEO</font></div><div style="padding-left:40.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:113%">5101 HOADLEY ROAD</font></div><div style="padding-left:40.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">ABERDEEN PROVING GROUND, MD, 21010-54</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:5.45pt;padding-left:2.6pt;padding-right:6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">The parties will coordinate ordering through centralized distribution via the established Memorandum of Understanding between Regeneron, ASPR, and AmerisourceBergen. Exact ship-to locations for product will be identified through this coordinated process.</font></div><div><font><br></font></div><div style="margin-top:6.6pt;padding-left:77.35pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">(End of narrative F00l)</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:3.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">0004</font></div></td><td colspan="9" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">VENDOR MANAGED INVENTORY (VMI)</font></div><div><font><br></font></div><div style="margin-top:6.65pt;padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:96%">COMMODITY NAME&#58; VMI</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:0.2pt;padding-right:0.2pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">1</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:13.37pt;padding-right:13.37pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">EA</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:4.8pt;padding-right:4.8pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">$ </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:3.05pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">$ </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div></td></tr></table></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7dd8655f2f0247d983262d67be43de82_16"></div><hr style="page-break-after:always"><div style="min-height:95pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:12.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.869%"><tr><td style="width:1.0%"></td><td style="width:27.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 74.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference No. of Document Being Continued</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 6 of 12</font></td></tr><tr><td colspan="3" style="padding:2px 1.1pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 45.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MOD&#47;AMD</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 11.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00005</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-0.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;Name of Offeror or Contractor&#58;&#160;&#160;&#160;&#160;</font></div></td><td colspan="12" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.05pt;padding-left:0.25pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">REGENERON PHARMACEUTICALS, INC.&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:12.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.271%"><tr><td style="width:1.0%"></td><td style="width:8.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 8.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ITEM NO</font></td><td colspan="18" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.65pt;padding-left:1.6pt;padding-right:1.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SUPPLIES&#47;SERVICES</font></div></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 8.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">QUANTITY</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 15.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">UNIT PRICE</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 18.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AMOUNT</font></td></tr><tr style="height:165pt"><td colspan="3" rowspan="6" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.15pt;padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">PSC&#58; 6505</font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">CLIN CONTRACT TYPE&#58;</font></div><div style="margin-top:0.1pt;padding-left:70.12pt;padding-right:70.12pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Firm Fixed Price</font></div><div><font><br></font></div><div style="margin-top:4.7pt;padding-left:2.6pt;padding-right:2.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">This CLIN applies to Vendor Managed Inventory (VMI) that shall continue for &#91;* * *&#93;.</font></div><div><font><br></font></div><div style="margin-top:4.7pt;padding-left:77.35pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">(End of narrative B00l)</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:2.6pt;padding-right:142.9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:264%;text-decoration:underline">Packaging and Marking</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:264%"> </font></div><div style="padding-right:142.9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-right:142.9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">I</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">nspection and Acceptance</font></div><div style="margin-top:0.45pt;padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">INSPECTION&#58; Destination&#160;&#160;&#160;&#160;ACCEPTANCE&#58; Destination</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:72.22pt;padding-right:72.22pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">Deliveries or Performance</font></div></td><td colspan="3" rowspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr style="height:26pt"><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:2.6pt;padding-right:16.65pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:114%">DOC </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:114%;text-decoration:underline">REL CD</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.35pt"><font><br></font></div><div><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%;text-decoration:underline">MILSTRIP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.45pt;padding-left:10.5pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:114%">SUPPL </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:114%;text-decoration:underline">ADDR </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:4.3pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%;text-decoration:underline">SIG CD</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.15pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%;text-decoration:underline">MARK FOR</font></div></td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:7.52pt;padding-right:7.52pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%;text-decoration:underline">TP CD</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 7.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">001</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:1.47pt;padding-right:1.47pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%">3</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:2.6pt;padding-right:-0.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%;text-decoration:underline">DEL REL CD</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">QUANTITY</font></td><td colspan="6" style="border-right:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">DEL DATE</font></td></tr><tr style="height:9pt"><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 14.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">001</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-right:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></td></tr><tr style="height:171pt"><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">FOB POINT&#58; Destination</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:2.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SHIP TO&#58;</font></div><div style="padding-left:40.4pt;padding-right:18.05pt;text-indent:-37.8pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">(W90ZQ2) XR JOINT PROGRAM EX OFC FOR CHEM, B HQ JPEO</font></div><div style="padding-left:40.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:113%">5101 HOADLEY ROAD</font></div><div style="padding-left:40.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">ABERDEEN PROVING GROUND, MD, 21010-54</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7dd8655f2f0247d983262d67be43de82_19"></div><hr style="page-break-after:always"><div style="min-height:95pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:13.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.747%"><tr><td style="width:1.0%"></td><td style="width:27.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 74.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference No. of Document Being Continued</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 2.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 7 of 12</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 27.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 51.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 89.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MOD&#47;AMD</font></td><td colspan="3" style="padding:2px 1pt 2px 11.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00005</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Offeror or Contractor&#58;</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 1.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">REGENERON PHARMACEUTICALS, INC.</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="18" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3.25pt;padding-left:5.75pt;padding-right:274.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:247%">SECTION C - DESCRIPTION&#47;SPECIFICATIONS&#47;WORK STATEMENT </font></div><div style="padding-left:4.5pt;padding-right:274.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">STATEMENT OF WORK</font></div><div style="padding-left:5.75pt;padding-right:274.75pt"><font><br></font></div><div style="margin-top:0.1pt;padding-left:5.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Production of Regeneron Therapeutic in Support of National Emergency Response to Coronavirus 2019 (COVID-19)</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">C.l Scope&#58; The Department of Defense (DoD) and Department of Health and Human Services (DHHS), in support of the national emergency response to the Coronavirus Disease 2019 (COVID-19), requires the production of Regeneron therapeutic cocktail REGN10987 and REGN10933 (casirivimab and imdevimab, REGEN-COV) on a commercial item basis, up to 2,650,000 doses, to prevent infection or treat members of the DoD and the general population against the SARS COV-2 Virus.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.7pt;padding-right:15.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">C.1.1 Background&#58; The DHHS continuously monitors emerging infectious disease risk and prepares to respond to the threat of novel emerging infectious disease outbreaks in the United States. DHHS is responding to an outbreak of respiratory disease caused by a novel coronavirus that was first detected in China, and which has now spread worldwide, including in the United States. The virus has been named SARS-CoV-2 and the disease it causes has been named Coronavirus Disease 2019 (abbreviated COVID-19).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.7pt;padding-right:9.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">On January 30, 2020, the International Health Regulations Emergency Committee of the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern (PHEIC). On January 31, Health and Human Services Secretary Alex M. Azar II declared a Public Health Emergency (PHE) for the United States to aid the nations healthcare community in responding to COVID-19. On March 11, 2020, the WHO publicly characterized COVID-19 as a pandemic. On March 13, 2020, the President of the United States declared the COVID-19 outbreak a national emergency.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.7pt;padding-right:9.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">In July 2020, the DoD awarded an Other Transaction Agreement under the authority of 10 USC 2371b to Regeneron to manufacture and sell drug product to the Government, and to distribute such drug product for the Government in the U.S. These manufacturing production activities included manufacturing at-scale, filling and finishing, and storage and shipping of the REGEN-COV cocktail. On November 21, 2020, Regeneron announced that the antibody cocktail casirivimab and imdevimab administered together, had received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). On July 30, 2021, the FDA revised the EUA for the Product, authorizing the Product for emergency use as post-exposure prophylaxis (prevention) for COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.7pt;padding-right:20.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">As part of DHHS preparedness and response activities, DHHS seeks to purchase 2,650,000 doses of the EUA authorized (or Biologics License Application (BLA) approved) casirivimab and imdevimab, administered together (REGEN-COV or the product), enough to prevent infection of or treat much of the targeted US population currently or projected to be infected over the coming months.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.7pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">C.2 Objectives and Quantity&#58; The contractor shall supply and the Government will purchase 2,650,000 doses of the product, as follows&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.7pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Prior Purchases&#58; As of the date of modification P00005 to this contract, the contractor has supplied, and the Government has purchased, 1,250,000 doses of the product.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.7pt;padding-right:9.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Purchase of Additional Quantities&#58; Following the date of modification P00005 to this contract, the contractor shall supply and the Government will purchase, an additional 1,400,000 doses of the product. The Government will purchase all of such additional 1,400,000 doses that are delivered to Vendor-Managed Inventory (VMI) by January 31, 2022 (the period from the date of execution of modification P00005 to this contract through January 31, 2022, the Delivery Period).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.7pt;padding-right:10.15pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Delivery of Additional Quantities&#58; See Section B for binding delivery schedule. To meet the anticipated public health need, the contractor will work in good faith to accelerate deliveries to meet the Goal Delivery Schedule below. The contractor shall use commercially reasonable efforts to deliver doses early and shall keep the Government reasonably informed of its progress against such schedule in accordance with Section C.3.2. Excess deliveries in any month will count towards the minimum amount for the next months. Prior to any extension to the Delivery Period, the contractor shall coordinate with the Government to determine an appropriate path forward, aligning with Government needs. The parties shall comply with the procedures of FAR 52.212-4(f), Excusable Delays. For clarity, payments will be made for partial deliveries.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:11.3pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Goal Delivery Schedule*&#160;&#160;&#160;&#160;&#91;* * *&#93;&#160;&#160;&#160;&#160;&#91;* * *&#93;&#160;&#160;&#160;&#160;&#91;* * *&#93;&#160;&#160;&#160;&#160;&#91;* * *&#93;</font></div><div style="margin-top:4.7pt;padding-left:5.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:131%">&#160;&#160;&#160;&#160; </font></div><div style="margin-top:4.7pt;padding-left:5.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:131%">* The Goal delivery schedule above is non-binding and for illustrative purposes only and is subject to the contingencies and operational requirements located in Attachment 0003.</font></div><div style="margin-top:5pt;padding-left:5.75pt;padding-right:5.9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:129%">Doses&#58; For purposes of contractors obligation to supply, and the Governments obligation to purchase, the product, a dose of the product means, at the time of delivery of product, the lowest volume approved or authorized dose of REGEN-COV for adult therapeutic use, as identified in the Treatment section of the EUA or subsequent corresponding section in the BLA. Accordingly, at the date of modification P00005, the lowest volume approved or authorized dose of the product for therapeutic use is 1.2 grams of the Product (600 mg of casirivimab and 600 mg of imdevimab). If in the future a lower dose of REGEN-COV were to be approved or authorized for therapeutic use exclusive of a pediatric dose authorization, then for purposes of all deliveries and purchases of product under this contract following such approval or authorization, a dose would be such lower dose. The Product may be delivered in a co-formulated presentation or in a presentation consisting of each antibody in separate vials, provided the formulation is consistent with the FDA approval or authorization. For clarity, any product delivered in a presentation (including any dose pack) containing greater than the then-current dose of the product, shall be purchased based on the number of doses contained in such presentation, provided the FDA has authorized or approved multiple doses to be prepared from the presentation. For example, if, at the time of delivery of product, the lowest volume approved or authorized dose of the product for therapeutic use is 1.2 grams of the product (600 mg of casirivimab and 600 mg of imdevimab) and the product is delivered in a presentation consisting of 2.4 grams (1.2 grams of casirivimab and 1.2 grams of imdevimab) and the FDA has authorized or approved the preparation of multiple doses from such presentation, then such delivery shall be counted as 2 doses delivered for purposes of this contract.</font></div></td></tr></table></div><div style="margin-top:6.05pt;padding-left:18.75pt;padding-right:11.95pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">EUA Wind-Down. If a BLA is issued during the term of this Contract for REGEN-COV, contractor shall ensure that any doses subsequently provided to the Government under this Contract are appropriately labeled under the terms of the EUA (before expiration)or the BLA and are otherwise suitable for use in the United States under the terms of the EUA (before expiration) or the BLA.</font></div><div style="margin-top:5.95pt;padding-left:35.5pt;text-indent:-16.8pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">C.3&#160;&#160;&#160;&#160;Requirements&#58;</font></div><div style="margin-top:6pt;padding-left:18.75pt;padding-right:15.55pt"><font><br></font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:15.55pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.869%"><tr><td style="width:1.0%"></td><td style="width:28.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 74.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference No. of Document Being Continued</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 2.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 8 of 12</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 27.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 51.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 89.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MOD&#47;AMD</font></td><td colspan="3" style="padding:2px 1pt 2px 11.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00005</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Offeror or Contractor&#58;</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 1.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">REGENERON PHARMACEUTICALS, INC.</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;padding-right:15.55pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">C.3.1&#160;&#160;&#160;&#160;Distribution&#58; The contractor shall distribute the product to Government designated sites as directed by the Government, EUA authorized or BLA approved finished drug product in vials in accordance with the products storage and handling requirements in the EUA (and, if granted, the BLA as applicable), including temperature controls. This shall include storage and distribution activities. Regeneron will engage one or more third party service providers (each a Distributor) to perform storage and distribution activities for drug product at the direction and on behalf of the Government. The Government will be solely responsible for all allocation determinations related to drug product sold hereunder, including allocation to end users and communication of such allocation determinations to the Distributor. Unless otherwise mutually agreed upon by the parties, drug product shall be shipped to the Government or distributed, as applicable, solely within the United States (including its territories and possessions) .The contractor &#91;* * *&#93;, until the product is distributed to the end user (e.g., the hospital, infusion center or other end-user). To the extent that Regeneron is responsible for the correction, repair or replacement of Government property held in vendor-managed inventory or in distribution and in the possession of the Distributor, &#91;* * *&#93;, the Government &#91;* * *&#93; of such property. The parties will coordinate ordering through centralized distribution via the established Memorandum of Understanding between Regeneron, Assistant Secretary for Preparedness and Response (ASPR), and AmerisourceBergen (or any other ordering process mutually agreed by such entities). Storage and distribution activities shall be supported under this agreement through the end of the period of performance. The Government will make every effort to ensure appropriate delivery and utilization of Government purchased product based on clinical need. Prior to the anticipated time of FDA approval of a Biologics License Application (BLA) for REGEN-COV, the parties will plan and coordinate to ensure efficient and effective distribution of commercial and noncommercial product.</font></div><div style="margin-top:5.95pt;padding-left:18pt;padding-right:19.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">C.3.2  Product Development Manufacturing Reports and Projections&#58; Regeneron will provide manufacturing reports and manufacturing dose tracking projections&#47;actuals, in the format and having the content mutually agreed upon by the Government and Regeneron. Regeneron will update the reports &#91;* * *&#93; during manufacturing campaigns and upon manufacturing deliverable submission during COVID-19 response operations (where a Public Health Emergency has been declared), with the first deliverable submission within &#91;* * *&#93; of award. For clarity, the reports described in this section apply to Formulated Drug Substance and Drug Product prior to delivery and acceptance by the Government. Tracking reports for product following delivery and acceptance, shall be set forth in the Memorandum of Understanding between Regeneron, ASPR, and AmerisourceBergen.</font></div><div style="margin-top:6pt;padding-left:35.5pt;text-indent:-16.85pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">C.4&#160;&#160;&#160;&#160;Reporting&#58; The contractor shall provide the following reports&#47;deliverables in accordance with Exhibit A&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.556%"><tr><td style="width:1.0%"></td><td style="width:15.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.6pt;padding-right:-9.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:110%;text-decoration:underline">&#160;&#160;CDRL #&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">Title</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A001</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Post Award Teleconference Minutes</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A002</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Kickoff Meeting Agenda and Minutes</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A003</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Teleconference Minutes</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A004</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Quarterly Meetings</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A005</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">FDA Meeting Minutes</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A006</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Daily Check-in with Project Staff for COVID-19 Agreement</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A007</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Monthly Progress Reports</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A008</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Milestone Reports</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A009</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Draft Technical Progress Report</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A010</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Final Technical Progress Report</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A011</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Product Development Source Material and Manufacturing Report</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A012</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Contractor Locations</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A013</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Pandemic Management Plan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A014</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Supply Chain and Distribution Tracking</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A015</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Distribution Plan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A016</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Manufacturing Development Plan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A017</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Quality Management Plan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A018</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Quality Agreement</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A019</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Release Documentation for Doses to be Delivered</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A020</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Manufacturing and Distribution Records</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A021</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Security Plan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A022</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Supply Chain Resiliency Plan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A023</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Manufacturing Data Requirements</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A024</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">BARDA Audit</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A025</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">FDA Inspections</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A026</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">QA Audits</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A027</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">FDA Submissions</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A028</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">EUA Filing</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A029</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Provision of Public Law 115-92 SPONSOR Authorization Letter</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A030</font></td><td colspan="3" style="padding:2px 1pt 2px 10.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Press Releases</font></td></tr></table></div><div style="margin-top:4.95pt;padding-left:13pt;padding-right:29.75pt"><font><br></font></div><div style="padding-right:29.75pt"><font><br></font></div><div style="padding-left:27pt;padding-right:29.75pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">C.5&#160;&#160;&#160;&#160;Period of Performance&#58; The period of performance for this contract is from date of award through &#91;* * *&#93;.</font></div><div style="margin-top:6pt;padding-left:29.75pt;text-indent:-16.8pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">C.6&#160;&#160;&#160;&#160;Inspection&#47;Acceptance&#58;</font></div><div style="margin-top:6pt;padding-left:13pt;padding-right:16.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">C.6.1&#160;&#160;&#160;&#160;Inspection&#58; The Technical Point of Contact (TPOC) is a duly authorized representative of the Government, and is responsible for the inspection and&#47;or acceptance of all items&#47;activities to be delivered and&#47;or completed under this contract. The parties acknowledge that acceptance may depend on the compliance with FDA regulations at 21 CFR 600-680 regarding the BLA, current Good Manufacturing Practice (cGMP) regulations at 21 CFR 210, 211, and other FDA regulations.</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6.1pt;padding-left:13pt;padding-right:41.9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:13.5pt;padding-right:7.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.869%"><tr><td style="width:1.0%"></td><td style="width:28.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 74.05pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference No. of Document Being Continued</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 2.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 9 of 12</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 27.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 51.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 32.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 89.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MOD&#47;AMD</font></td><td colspan="3" style="padding:2px 1pt 2px 11.45pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00005</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Offeror or Contractor&#58;</font></td><td colspan="6" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 1.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">REGENERON PHARMACEUTICALS, INC.</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6.1pt;padding-left:13pt;padding-right:41.9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">C.6.2&#160;&#160;&#160;&#160;Acceptance&#58; Title to drug product will pass to the Government upon delivery of such drug product to Vendor-Managed Inventory</font></div><div style="margin-top:5.95pt;padding-left:13pt;padding-right:7.3pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">(VMI), and the Governments corresponding acceptance of such drug product, as described in this paragraph. The Government shall accept product that conforms to contract requirements based on a Certificate of Analysis (COA) and any other quality documentation required to be provided by Regeneron as set forth in the Quality Agreement (Required Documents), and the parties shall perform their obligations relating to product delivery set forth in the applicable Quality Agreement for the product. The Governments acceptance of drug product &#91;* * *&#93; the Governments written acceptance of such drug product or, &#91;* * *&#93; provide written notice of acceptance or rejection of such drug product, within &#91;* * *&#93;. Any visibly damaged product will be rejected immediately. The contractor will transfer product from VMI to the Distributor for distribution directed by the Government&#59; provided that, product shall not be provided to the Distributor until it is accepted by the Government. The contractor shall provide a shipment temperature tracking report within &#91;* * *&#93; of contractors receipt of such report from its storage vendor, or otherwise in accordance with the applicable Quality Agreement. Any product subject to a temperature excursion outside of acceptable tolerances, shall be rejected. Any rejected product shall be returned to the contractor or otherwise disposed of according to contractor instructions. The Government will not be obligated to pay for rejected vials, nor will rejected vials count toward the delivery requirement. The contractor shall establish a notification mechanism for delivery sites to contact the Government regarding rejected vials.</font></div><div style="margin-top:6pt;padding-left:13pt;padding-right:29.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">C.7&#160;&#160;&#160;&#160;Packaging and Marking&#58; The contractor shall label product according to FDA guidance&#47;instructions. Packaging shall be in shipping containers according to the contractors standard commercial practice.</font></div><div style="margin-top:5.95pt;padding-left:13pt;padding-right:38.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">C.8&#160;&#160;&#160;&#160;Authorized and Approved Uses&#58; Product sold to the Government may be distributed for use in any indication approved or authorized by the FDA.</font></div><div style="margin-top:6pt;padding-left:13pt;padding-right:19.05pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Public Disclosures&#58; Notwithstanding any other provision in this contract, the contractor may publicly release any information related to this contract without prior approval to the extent necessary to satisfy or address regulatory requirements, contractual obligations to third parties, and the public interest in data about the safety or efficacy of the product.</font></div><div style="margin-top:5.95pt;padding-left:13pt;padding-right:7.3pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Public Readiness and Emergency Preparedness (PREP) Act&#58; The Government will ensure that no product purchased under this contract is used outside the United States (including its territories or possessions) or in a way that is not protected from liability by a declaration issued under the PREP Act that is active at the time of use, except as provided in Special Contract Requirements Paragraph 4., Donation of Excess Product, which remains in effect.</font></div><div style="margin-top:6.1pt;padding-left:29.75pt;text-indent:-16.8pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">C.9&#160;&#160;&#160;&#160;Government Technical Point of Contact&#58;</font></div><div><font><br></font></div><div style="margin-top:4.85pt;padding-left:13pt;padding-right:487.1pt"><font><br></font></div><div style="padding-left:13pt;padding-right:487.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">HHS BARDA </font></div><div style="padding-left:12.95pt"><font><br></font></div><div style="padding-left:12.95pt"><font><br></font></div><div style="padding-left:12.95pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:215.47pt;padding-right:215.47pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">*** END OF NARRATIVE C000l ***</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7dd8655f2f0247d983262d67be43de82_22"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:13.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.955%"><tr><td style="width:1.0%"></td><td style="width:3.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.168%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.924%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="9" rowspan="2" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 27.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="12" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 62.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference No. of Document Being Continued</font></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 10 of 12</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 10.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 18.65pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.45pt;padding-right:4.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:96%">MOD&#47;AMD</font></div></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 10.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00005</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%;text-decoration:underline">&#160;Name of Offeror or Contractor&#58;&#160;&#160;&#160;&#160;</font></div></td><td colspan="21" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:17.2pt;padding-right:-0.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">REGENERON PHARMACEUTICALS, INC.&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:558.75pt"><tr><td style="width:1.0pt"></td><td style="width:55.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:92.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:99.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:30.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:76.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:82.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:9pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SECTION G - CONTRACT ADMINISTRATION DATA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:5.9pt;padding-left:16.2pt;padding-right:17.9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:157%">LINE </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:157%;text-decoration:underline">ITEM</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.2pt;padding-left:21pt;padding-right:36.2pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">PRON&#47; AMS CD&#47; MIPR&#47;</font></div><div style="padding-left:15.8pt;padding-right:31pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:113%;text-decoration:underline">GFEBS ATA</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:5.9pt;padding-right:9.6pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:157%">OBLG </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:157%;text-decoration:underline">STAT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:5.9pt;padding-right:23.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:157%">JO NO&#47; </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:157%;text-decoration:underline">ACCT ASSIGN</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">ACNR</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="padding-left:6.9pt;padding-right:4.45pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">PRIOR AMOUNT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:5.9pt;padding-left:24.5pt;padding-right:7.15pt;text-indent:-2.05pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:157%">INCREASE&#47; </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:157%;text-decoration:underline">DECREASE</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:5.9pt;padding-right:27.35pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:157%">CUMULATIVE A</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:157%;text-decoration:underline">MOUNT</font></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">0003AA</font></td><td colspan="3" style="padding:2px 1pt 2px 15.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">X21ZD484W1</font></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:112%">S. 0074658.7.4.1.1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:8.55pt;padding-right:6.85pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">AD</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:6.9pt;padding-right:4.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">$ 0.00</font></div></td><td colspan="3" style="padding:2px 1pt 2px 8.7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">$ 999,999,000.00</font></td><td colspan="3" style="padding:2px 1pt 2px 12.55pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">$ 999,999,000.00</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">0003AB</font></td><td colspan="3" style="padding:2px 1pt 2px 15.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">X21ZD485W1</font></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="padding:2px 1pt 2px 10.4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">S. 0074658.7.4.1.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:8.55pt;padding-right:6.85pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">AE</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:6.9pt;padding-right:4.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">$ 0.00</font></div></td><td colspan="3" style="padding:2px 1pt 2px 8.7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">$ 999,999,000.00</font></td><td colspan="3" style="padding:2px 1pt 2px 12.55pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">$ 999,999,000.00</font></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">0003AC</font></td><td colspan="3" style="padding:2px 1pt 2px 15.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">X21ZD486W1</font></td><td colspan="3" style="padding:2px 1pt 2px 6.45pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="padding:2px 1pt 2px 10.4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">S. 0074658.7.4.1.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:8.55pt;padding-right:6.85pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">AF</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.75pt;padding-left:6.9pt;padding-right:4.4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">$ 0.00</font></div></td><td colspan="3" style="padding:2px 1pt 2px 8.7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">$ 940,002,000.00</font></td><td colspan="3" style="padding:2px 1pt 2px 12.55pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">$ 940,002,000.00</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6.7pt;padding-left:5.67pt;padding-right:5.67pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:102%">NET CHANGE</font></div></td><td colspan="3" style="padding:2px 1pt 2px 6.65pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">$2,940,000,000.00</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.257%"><tr><td style="width:1.0%"></td><td style="width:6.702%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:8.65pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:113%;text-decoration:underline">ACRN</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">ACCOUNTING CLASSIFICATION</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">INCREASE&#47;DECREASE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-right:8.65pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">AD</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">021 202120222040</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-right:3.9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A5XAH 643627E79RG04</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">2550</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-right:4.3pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">L074890014</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">S.0074658.7.4.1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-right:12.05pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">021001</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">999,999,000.00</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-right:8.65pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">AE</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">021 202120222040</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-right:3.9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A5XAH 643627E79RG04</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">2550</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-right:4.3pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">L074890022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">S.0074658.7.4.1.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-right:12.05pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">021001</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">999,999,000.00</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-right:8.65pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">AF</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">021 202120222040</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-right:3.9pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A5XAH 643627E79RG04</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">2550</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-right:4.3pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">L074890199</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">S.0074658.7.4.1.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-right:12.05pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">021001</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">940,002,000.00</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6.95pt;padding-right:12.05pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:99%">NET CHANGE</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">2,940,000,000.00</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:6.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:476.25pt"><tr><td style="width:1.0pt"></td><td style="width:108.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:98.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:132.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:129.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;padding-right:24pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:113%">PRIOR AMOUNT</font></div><div style="margin-top:3pt;padding-left:23.92pt;padding-right:23.92pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">OF WARD</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:30.17pt;padding-right:30.17pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:113%">INCREASE&#47;DECREASE</font></div><div style="margin-top:3pt;padding-left:30.1pt;padding-right:30.1pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">AMOUNT</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:62.2pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:113%">CUMULATIVE</font></div><div style="margin-top:3pt;padding-left:64.2pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">OBLIG AMT</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">NET CHANGE FOR AWARD&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 12.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">$ 2,625,000,000.00</font></td><td colspan="3" style="padding:2px 1pt 2px 13.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">$ 2,940,000,000.00</font></td><td colspan="3" style="padding:2px 1pt 2px 46.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">$ 5,565,000,000.00</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:6.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:530.25pt"><tr><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:34.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:126.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:126.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:30.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:113%">LINE</font></div><div style="margin-top:3pt;padding-left:10pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">ITEM</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:0.72pt;padding-right:0.72pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;ACRN </font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:4pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">EDI&#47;SFIS ACCOUNTING CLASSIFICATION&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:10pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:9.37pt;padding-right:9.37pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">0003AA</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:10.6pt;padding-right:10.6pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">AD</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:8.25pt;padding-right:8.25pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">021 202120222040</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A5XAH 643627E79RG04</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.7pt;padding-left:5.42pt;padding-right:5.42pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">2550</font></div></td><td colspan="3" style="padding:2px 5.15pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">L074890014</font></td><td colspan="3" style="padding:2px 1pt 2px 5.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">S.0074658.7.4.1.1</font></td><td colspan="3" style="padding:2px 10.85pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">021001</font></td></tr><tr style="height:10pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:9.37pt;padding-right:9.37pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">0003AB</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:10.6pt;padding-right:10.6pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">AE</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:8.25pt;padding-right:8.25pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">021 202120222040</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A5XAH 643627E79RG04</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:5.42pt;padding-right:5.42pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">2550</font></div></td><td colspan="3" style="padding:2px 5.15pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">L074890022</font></td><td colspan="3" style="padding:2px 1pt 2px 5.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">S.0074658.7.4.1.2</font></td><td colspan="3" style="padding:2px 10.85pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">021001</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:9.37pt;padding-right:9.37pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:99%">0003AC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:10.6pt;padding-right:10.6pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:99%">AF</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:8.25pt;padding-right:8.25pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:99%">021 202120222040</font></div></td><td colspan="3" style="padding:2px 1pt 2px 9.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">A5XAH 643627E79RG04</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.45pt;padding-left:5.42pt;padding-right:5.42pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:99%">2550</font></div></td><td colspan="3" style="padding:2px 5.15pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">L074890199</font></td><td colspan="3" style="padding:2px 1pt 2px 5.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">S.0074658.7.4.1.3</font></td><td colspan="3" style="padding:2px 10.85pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">021001</font></td></tr></table></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7dd8655f2f0247d983262d67be43de82_25"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:14.05pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.735%"><tr><td style="width:1.0%"></td><td style="width:11.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.875%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="9" rowspan="2" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 26.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTINUATION SHEET</font></td><td colspan="12" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 73.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference No. of Document Being Continued</font></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 11 of 12</font></td></tr><tr style="height:9pt"><td colspan="9" style="padding:2px 1pt 2px 117.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 29.1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 9.3pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MOD&#47;AMD</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 9.55pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">P00005</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-1.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%;text-decoration:underline">&#160;Name of Offeror or Contractor&#58;&#160;&#160;&#160;&#160;</font></div></td><td colspan="15" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.85pt;padding-left:1.1pt;padding-right:-1.45pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%;text-decoration:underline">REGENERON PHARMACEUTICALS, INC.&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="24" style="padding:2px 1pt 2px 3.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">SECTION J - LIST OF ATTACHMENTS</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3.6pt;padding-left:18.2pt;padding-right:16.65pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:157%">List of Addenda</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:4.2pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:111%">Title</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:11.07pt;padding-right:11.07pt;text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:111%">Date</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:8.9pt;padding-right:-1.45pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:111%">Number of Pages</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:29.85pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:111%">Transmitted By</font></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 4.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">Attachment 003</font></td><td colspan="9" style="padding:2px 1pt 2px 16.2pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">CONTINGENCIES AND OPERATIONAL REQUIREMENTS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 7.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">13-SEP-2021</font></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.2pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">002</font></div></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.2pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#160;EMAIL</font></div></td></tr></table></div><div><font><br></font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7dd8655f2f0247d983262d67be43de82_28"></div><hr style="page-break-after:always"><div style="min-height:77pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.844%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:20.55pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></div><div style="padding-right:1pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attachment 0003</font></div><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dated 13 September 2021</font></div></td></tr></table></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.955%"><tr><td style="width:1.0%"></td><td style="width:73.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PIIN&#47;SIIN </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">W15QKN-21-C-0014</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MOD&#47;AMD</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">P00005</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ATT&#47;EXH ID</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Attachment 0003</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PAGE</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:222.25pt;padding-right:165.95pt;text-indent:-48.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">Contingencies and Operational Requirements Goal Delivery Schedule*</font></div><div style="padding-left:85pt;text-indent:-18.05pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:154%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:154%">&#160;&#160;&#160;&#160;Approximately </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:154%">&#91;* * *&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:154%"> doses delivered in </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:154%">&#91;* * *&#93;</font></div><div style="padding-left:85pt;text-indent:-18.05pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:154%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:154%">&#160;&#160;&#160;&#160;Approximately </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:154%">&#91;* * *&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:154%"> doses delivered in </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:154%">&#91;* * *&#93;</font></div><div style="padding-left:85pt;text-indent:-18.05pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:154%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:154%">&#160;&#160;&#160;&#160;Approximately </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:154%">&#91;* * *&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:154%"> doses delivered in </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:154%">&#91;* * *&#93;</font></div><div style="padding-left:85pt;text-indent:-18.05pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:154%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:154%">&#160;&#160;&#160;&#160;Approximately </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:154%">&#91;* * *&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:154%"> doses delivered in </font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:154%">&#91;* * *&#93;</font></div><div style="margin-top:12.1pt;padding-left:48.95pt;padding-right:51.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">* The delivery schedule is non-binding and for illustrative purposes only and it is subject to the following contingencies and operational requirements&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:85pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.&#160;&#160;&#160;&#160;FDA action on submissions currently under review</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:102.95pt;padding-right:42.75pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:84.95pt;padding-right:65.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.&#160;&#160;&#160;&#160;Additional Regulatory Actions</font><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:103pt;padding-right:84.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:85pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C.&#160;&#160;&#160;&#160;Operational Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:102.95pt;padding-right:55.1pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:7pt;font-weight:400;line-height:120%">&#91;* * *&#93;</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>regn-ex_311x09302021x10q.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id0155469a4f94829b68e454372cc3608_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 13a-14(a) under the Securities Exchange Act</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of 1934, as Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Leonard S. Schleifer, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Regeneron Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Leonard S. Schleifer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard S. Schleifer, M.D., Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #666666;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>regn-ex_312x09302021x10q.htm
<DESCRIPTION>CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i02646d99b7b84529ab3644f355a3f34f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 13a-14(a) under the Securities Exchange Act</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of 1934, as Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert E. Landry, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Regeneron Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:underline">&#47;s&#47; Robert E. Landry</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Landry</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>regn-ex_32x09302021x10q.htm
<DESCRIPTION>CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6b5c782fc64e4b0f8fc19f79e815eedd_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Regeneron Pharmaceuticals, Inc. (the &#34;Company&#34;) on Form 10-Q for the quarterly period ended September&#160;30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), Leonard S. Schleifer, M.D., Ph.D., as Principal Executive Officer of the Company, and Robert E. Landry, as Principal Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Leonard S. Schleifer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leonard S. Schleifer, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Robert E. Landry</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Landry</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Finance and Chief Financial Officer </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>regn-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:08b52028-35ad-4384-abb4-ffa84b7c541b,g:79516084-017d-4f01-b220-9a6b8eb4ad51-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:regn="http://www.regeneron.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.regeneron.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="regn-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.regeneron.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimFinancialStatements" roleURI="http://www.regeneron.com/role/InterimFinancialStatements">
        <link:definition>2101101 - Disclosure - Interim Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimFinancialStatementsPolicies" roleURI="http://www.regeneron.com/role/InterimFinancialStatementsPolicies">
        <link:definition>2202201 - Disclosure - Interim Financial Statements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSales" roleURI="http://www.regeneron.com/role/ProductSales">
        <link:definition>2103102 - Disclosure - Product Sales</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesTables" roleURI="http://www.regeneron.com/role/ProductSalesTables">
        <link:definition>2304301 - Disclosure - Product Sales (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesScheduleofNetProductSalesDetails" roleURI="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails">
        <link:definition>2405401 - Disclosure - Product Sales - Schedule of Net Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" roleURI="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails">
        <link:definition>2406402 - Disclosure - Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesNarrativeDetails" roleURI="http://www.regeneron.com/role/ProductSalesNarrativeDetails">
        <link:definition>2407403 - Disclosure - Product Sales - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreements" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements">
        <link:definition>2108103 - Disclosure - Collaboration, License, and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsTables" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables">
        <link:definition>2309302 - Disclosure - Collaboration, License, and Other Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails">
        <link:definition>2410404 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails">
        <link:definition>2411405 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails">
        <link:definition>2412406 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails">
        <link:definition>2413407 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, IO Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails">
        <link:definition>2414408 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails">
        <link:definition>2415409 - Disclosure - Collaboration, License, and Other Agreements - Bayer Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" roleURI="http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails">
        <link:definition>2416410 - Disclosure - Collaboration Agreements - Amounts Recognized in Statement of Operations with Bayer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails">
        <link:definition>2417411 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails">
        <link:definition>2418412 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails">
        <link:definition>2419413 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails">
        <link:definition>2420414 - Disclosure - Collaboration, License, and Other Agreements - Teva Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails">
        <link:definition>2421415 - Disclosure - Collaboration, License, and Other Agreements - U.S. Government Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails">
        <link:definition>2422416 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails">
        <link:definition>2423417 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Roche Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails">
        <link:definition>2424418 - Disclosure - Collaboration, License, and Other Agreements - Intellia Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.regeneron.com/role/NetIncomePerShare">
        <link:definition>2125104 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.regeneron.com/role/NetIncomePerShareTables">
        <link:definition>2326303 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails">
        <link:definition>2427419 - Disclosure - Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails">
        <link:definition>2428420 - Disclosure - Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.regeneron.com/role/MarketableSecurities">
        <link:definition>2129105 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.regeneron.com/role/MarketableSecuritiesTables">
        <link:definition>2330304 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails">
        <link:definition>2431421 - Disclosure - Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails">
        <link:definition>2432422 - Disclosure - Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails">
        <link:definition>2433423 - Disclosure - Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesNarrativeDetails" roleURI="http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails">
        <link:definition>2434424 - Disclosure - Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.regeneron.com/role/FairValueMeasurements">
        <link:definition>2135106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.regeneron.com/role/FairValueMeasurementsTables">
        <link:definition>2336305 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2437425 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2438426 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.regeneron.com/role/Inventories">
        <link:definition>2139107 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.regeneron.com/role/InventoriesTables">
        <link:definition>2340306 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>2441427 - Disclosure - Inventories - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.regeneron.com/role/InventoriesNarrativeDetails">
        <link:definition>2442428 - Disclosure - Inventories - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.regeneron.com/role/Debt">
        <link:definition>2143108 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.regeneron.com/role/DebtTables">
        <link:definition>2344307 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.regeneron.com/role/DebtNarrativeDetails">
        <link:definition>2445429 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryofIssuedSeniorUnsecuredNotesDetails" roleURI="http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails">
        <link:definition>2446430 - Disclosure - Debt - Summary of Issued Senior Unsecured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.regeneron.com/role/IncomeTaxes">
        <link:definition>2147109 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.regeneron.com/role/IncomeTaxesDetails">
        <link:definition>2448431 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.regeneron.com/role/StockholdersEquity">
        <link:definition>2149110 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.regeneron.com/role/StockholdersEquityTables">
        <link:definition>2350308 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2451432 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofRepurchasedSharesDetails" roleURI="http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails">
        <link:definition>2452433 - Disclosure - Stockholders' Equity - Schedule of Repurchased Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofCashFlows" roleURI="http://www.regeneron.com/role/StatementofCashFlows">
        <link:definition>2153111 - Disclosure - Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofCashFlowsTables" roleURI="http://www.regeneron.com/role/StatementofCashFlowsTables">
        <link:definition>2354309 - Disclosure - Statement of Cash Flows (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2455434 - Disclosure - Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails" roleURI="http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails">
        <link:definition>2456435 - Disclosure - Statement of Cash Flows - Summary of Non-cash Investing and Financing Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalMatters" roleURI="http://www.regeneron.com/role/LegalMatters">
        <link:definition>2157112 - Disclosure - Legal Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalMattersDetails" roleURI="http://www.regeneron.com/role/LegalMattersDetails">
        <link:definition>2458436 - Disclosure - Legal Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="regn_BARDAOtherTransactionAgreementMember" abstract="true" name="BARDAOtherTransactionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_IntelliaMember" abstract="true" name="IntelliaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" abstract="false" name="RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_GainContingencyInterPartesReviewFiledNumber" abstract="false" name="GainContingencyInterPartesReviewFiledNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="regn_NetProfitInConnectionWithCommercializationMember" abstract="true" name="NetProfitInConnectionWithCommercializationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RegeneronsShareOfCommercialExpensesMember" abstract="true" name="RegeneronsShareOfCommercialExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_BesseMedicalMember" abstract="true" name="BesseMedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RocheCollaborationAgreementMember" abstract="true" name="RocheCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_MaximumTransactionAgreementPayments" abstract="false" name="MaximumTransactionAgreementPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_LossContingencyClaimsInvalidNumber" abstract="false" name="LossContingencyClaimsInvalidNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="regn_PraluentNetProductSalesMember" abstract="true" name="PraluentNetProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_UnrestrictedMember" abstract="true" name="UnrestrictedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" abstract="false" name="StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="regn_SalesBasedMilestoneEarnedMember" abstract="true" name="SalesBasedMilestoneEarnedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_MarketableSecuritiesRealizedLoss" abstract="false" name="MarketableSecuritiesRealizedLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_ReimbursementOfResearchAndDevelopmentExpense" abstract="false" name="ReimbursementOfResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_MarketableSecuritiesRealizedGain" abstract="false" name="MarketableSecuritiesRealizedGain" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_ClassificationOfInvestmentAxis" abstract="true" name="ClassificationOfInvestmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="regn_SanofiCollaborationAgreementAntibodyMember" abstract="true" name="SanofiCollaborationAgreementAntibodyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_CasirivimabAndImdevimabMember" abstract="true" name="CasirivimabAndImdevimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_Amgenv.s.RegeneronMember" abstract="true" name="Amgenv.s.RegeneronMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_CostOfGoodsSoldMember" abstract="true" name="CostOfGoodsSoldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ClassificationOfInvestmentDomain" abstract="true" name="ClassificationOfInvestmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_REGENCOVMember" abstract="true" name="REGENCOVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RevenueBasedOnPercentageOfAnnualSalesInJapan" abstract="false" name="RevenueBasedOnPercentageOfAnnualSalesInJapan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesMilestonesDomain" abstract="true" name="SalesMilestonesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" abstract="false" name="CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="regn_RestrictedMember" abstract="true" name="RestrictedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ShareOfProfitLossesInConnectionWithCommercializationMember" abstract="true" name="ShareOfProfitLossesInConnectionWithCommercializationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_A631PatentMember" abstract="true" name="A631PatentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesMilestonesAxis" abstract="true" name="SalesMilestonesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="regn_A165PatentMember" abstract="true" name="A165PatentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" abstract="false" name="StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_SeniorUnsecuredNotesDue2030Member" abstract="true" name="SeniorUnsecuredNotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_A226PatentAnd992PatentMember" abstract="true" name="A226PatentAnd992PatentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ArcalystNetProductSalesMember" abstract="true" name="ArcalystNetProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_DupilumabREGN3500EligibleInvestmentsMember" abstract="true" name="DupilumabREGN3500EligibleInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_EyleaNetProductSalesMember" abstract="true" name="EyleaNetProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" abstract="false" name="PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="regn_PercentageOfRoyaltyPaymentThatCanBeOffset" abstract="false" name="PercentageOfRoyaltyPaymentThatCanBeOffset" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_LIBTAYONetProductSalesMember" abstract="true" name="LIBTAYONetProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesMilestoneTwoMember" abstract="true" name="SalesMilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_BayerCollaborationAgreementMember" abstract="true" name="BayerCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ReimbursementOfResearchAndDevelopmentExpensesMember" abstract="true" name="ReimbursementOfResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_BridgeFacilityMember" abstract="true" name="BridgeFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_GrossProductRevenueMember" abstract="true" name="GrossProductRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_USGovernmentMember" abstract="true" name="USGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_LossContingencyExParteReexaminationFiledNumber" abstract="false" name="LossContingencyExParteReexaminationFiledNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="regn_CollaborativeArrangementUpfrontPaymentMade" abstract="false" name="CollaborativeArrangementUpfrontPaymentMade" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_GainContingencyClaimsInvalidatedNumber" abstract="false" name="GainContingencyClaimsInvalidatedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" abstract="false" name="RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_ShareRepurchaseProgramJanuary2021Member" abstract="true" name="ShareRepurchaseProgramJanuary2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_TevaPharmaceuticalsCollaborationAgreementMember" abstract="true" name="TevaPharmaceuticalsCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ResearchCollaborationAndLicensingArrangementsLineItems" abstract="true" name="ResearchCollaborationAndLicensingArrangementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="regn_ShareRepurchaseProgram2019Member" abstract="true" name="ShareRepurchaseProgram2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_EvkeezaMember" abstract="true" name="EvkeezaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" abstract="false" name="PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" abstract="true" name="AmountsRecognizedInConnectionWithUpFrontPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ReimbursementOfCommercializationRelatedExpensesMember" abstract="true" name="ReimbursementOfCommercializationRelatedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SanofiCollaborationAgreementImmunooncologyMember" abstract="true" name="SanofiCollaborationAgreementImmunooncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ReimbursementForManufacturingOfCommercialSuppliesMember" abstract="true" name="ReimbursementForManufacturingOfCommercialSuppliesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" abstract="false" name="LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="regn_PraluentCrossLicenseAndCommercializationAgreementMember" abstract="true" name="PraluentCrossLicenseAndCommercializationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SanofisShareofLibtayoU.S.GrossProfitsMember" abstract="true" name="SanofisShareofLibtayoU.S.GrossProfitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" abstract="true" name="RegeneronsShareOfResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SeniorUnsecuredNotesDue2050Member" abstract="true" name="SeniorUnsecuredNotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_SalesMilestoneOneMember" abstract="true" name="SalesMilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_LossContingencyPercentageOfDamagesResponsibleFor" abstract="false" name="LossContingencyPercentageOfDamagesResponsibleFor" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="regn_A487PatentMember" abstract="true" name="A487PatentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_CollaborationandContractManufacturingMember" abstract="true" name="CollaborationandContractManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_LibtayoDevelopmentMember" abstract="true" name="LibtayoDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_A741PatentMember" abstract="true" name="A741PatentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_EYLEAAfliberceptInjectionMember" abstract="true" name="EYLEAAfliberceptInjectionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="regn_ResearchCollaborationAndLicensingArrangementsTable" abstract="true" name="ResearchCollaborationAndLicensingArrangementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>regn-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:08b52028-35ad-4384-abb4-ffa84b7c541b,g:79516084-017d-4f01-b220-9a6b8eb4ad51-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="regn-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9393f162-f888-4096-86cc-816489e4823f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_883b8c4a-8810-495e-bca1-fa738738ade5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9393f162-f888-4096-86cc-816489e4823f" xlink:to="loc_us-gaap_LiabilitiesCurrent_883b8c4a-8810-495e-bca1-fa738738ade5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f67bde54-4443-4c06-8330-d50c41abc17c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9393f162-f888-4096-86cc-816489e4823f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f67bde54-4443-4c06-8330-d50c41abc17c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_95afb893-360c-4d8a-ac42-028b1af570ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9393f162-f888-4096-86cc-816489e4823f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_95afb893-360c-4d8a-ac42-028b1af570ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fe0d33f1-3815-49a9-a511-76e37ce3e740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9393f162-f888-4096-86cc-816489e4823f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fe0d33f1-3815-49a9-a511-76e37ce3e740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e92e1f67-3c0e-42e5-8626-0dabc52ddb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9393f162-f888-4096-86cc-816489e4823f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e92e1f67-3c0e-42e5-8626-0dabc52ddb5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c429aa59-94e5-4fbe-8524-fb8e8daa2894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ae2bead5-7db1-4967-81ca-2307511f8a92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c429aa59-94e5-4fbe-8524-fb8e8daa2894" xlink:to="loc_us-gaap_PreferredStockValue_ae2bead5-7db1-4967-81ca-2307511f8a92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2ef6dbbe-3fe9-4b98-a484-dbcd5c5a3b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c429aa59-94e5-4fbe-8524-fb8e8daa2894" xlink:to="loc_us-gaap_CommonStockValue_2ef6dbbe-3fe9-4b98-a484-dbcd5c5a3b94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f5ed6736-04d3-425e-b362-b7981da1cced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c429aa59-94e5-4fbe-8524-fb8e8daa2894" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f5ed6736-04d3-425e-b362-b7981da1cced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_878bd230-3443-43cd-82b6-a406e3a5a79e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c429aa59-94e5-4fbe-8524-fb8e8daa2894" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_878bd230-3443-43cd-82b6-a406e3a5a79e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d7969121-7f1e-4f18-a40b-c32c5256c803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c429aa59-94e5-4fbe-8524-fb8e8daa2894" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d7969121-7f1e-4f18-a40b-c32c5256c803" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_2fd76771-8a9f-48cf-9f9c-ef43b19bdc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c429aa59-94e5-4fbe-8524-fb8e8daa2894" xlink:to="loc_us-gaap_TreasuryStockValue_2fd76771-8a9f-48cf-9f9c-ef43b19bdc0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_634072c3-d63e-49be-bc3e-0cc1fff1f604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a55a387-72b1-4f3a-aec4-f25544756773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_634072c3-d63e-49be-bc3e-0cc1fff1f604" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a55a387-72b1-4f3a-aec4-f25544756773" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_42377761-a136-4488-9931-387b4895fa2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_634072c3-d63e-49be-bc3e-0cc1fff1f604" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_42377761-a136-4488-9931-387b4895fa2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_63e0b254-ca37-4f51-841e-57259301ce79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_634072c3-d63e-49be-bc3e-0cc1fff1f604" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_63e0b254-ca37-4f51-841e-57259301ce79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c78f89ab-dd66-4e15-aa51-a9893efcb259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_634072c3-d63e-49be-bc3e-0cc1fff1f604" xlink:to="loc_us-gaap_InventoryNet_c78f89ab-dd66-4e15-aa51-a9893efcb259" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a05bb83f-2e93-4f44-a952-4934a51ab7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_634072c3-d63e-49be-bc3e-0cc1fff1f604" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a05bb83f-2e93-4f44-a952-4934a51ab7a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_523d6a6d-cab8-4cd2-9d76-05e62aca1ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_18c64199-259e-4f49-884a-6eb98bfee78d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_523d6a6d-cab8-4cd2-9d76-05e62aca1ce9" xlink:to="loc_us-gaap_Liabilities_18c64199-259e-4f49-884a-6eb98bfee78d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0e7557ae-6218-4d19-b164-b71c32a8c63d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_523d6a6d-cab8-4cd2-9d76-05e62aca1ce9" xlink:to="loc_us-gaap_StockholdersEquity_0e7557ae-6218-4d19-b164-b71c32a8c63d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f898798f-e1df-46ca-9bad-e5a175fc1e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_2131bb2f-5dd1-4350-9d31-227f484fe888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f898798f-e1df-46ca-9bad-e5a175fc1e00" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_2131bb2f-5dd1-4350-9d31-227f484fe888" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_5a364907-62ec-4455-9a6c-62a4c6b31c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f898798f-e1df-46ca-9bad-e5a175fc1e00" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_5a364907-62ec-4455-9a6c-62a4c6b31c9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_674b794f-1c93-498d-8711-58318acaf0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f898798f-e1df-46ca-9bad-e5a175fc1e00" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_674b794f-1c93-498d-8711-58318acaf0dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_78be4165-e979-460f-924d-4df9bc59aaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f898798f-e1df-46ca-9bad-e5a175fc1e00" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_78be4165-e979-460f-924d-4df9bc59aaa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_515d68b7-42f5-415b-86c5-d9b35151514e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7a26b712-2fef-4430-b995-f2aafd01150d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_515d68b7-42f5-415b-86c5-d9b35151514e" xlink:to="loc_us-gaap_AssetsCurrent_7a26b712-2fef-4430-b995-f2aafd01150d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_ed63e488-8fa8-480f-b89d-f554324406a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_515d68b7-42f5-415b-86c5-d9b35151514e" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_ed63e488-8fa8-480f-b89d-f554324406a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6dc98096-f2f1-4148-9125-9201411f6c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_515d68b7-42f5-415b-86c5-d9b35151514e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6dc98096-f2f1-4148-9125-9201411f6c7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_243cd879-5bb1-433c-9281-d0ea7449ec12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_515d68b7-42f5-415b-86c5-d9b35151514e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_243cd879-5bb1-433c-9281-d0ea7449ec12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_18e66d05-e217-437a-bff7-dd5e07fbfcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_515d68b7-42f5-415b-86c5-d9b35151514e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_18e66d05-e217-437a-bff7-dd5e07fbfcc6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="simple" xlink:href="regn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_59594faa-3e20-4bef-8d05-3cbf8c43725c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bb23c7ec-10ed-4b50-9e1d-6dddc75fc91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_59594faa-3e20-4bef-8d05-3cbf8c43725c" xlink:to="loc_us-gaap_NetIncomeLoss_bb23c7ec-10ed-4b50-9e1d-6dddc75fc91d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a08dbe85-249f-48e1-8285-7472289a0117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_59594faa-3e20-4bef-8d05-3cbf8c43725c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a08dbe85-249f-48e1-8285-7472289a0117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_68734179-a3b0-4b6f-8766-39ffc12e16ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_59594faa-3e20-4bef-8d05-3cbf8c43725c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_68734179-a3b0-4b6f-8766-39ffc12e16ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1390fd35-3db1-4290-a533-d1109b8aa6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8b7eaac0-7273-434d-9cfa-71631fa46af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1390fd35-3db1-4290-a533-d1109b8aa6a8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8b7eaac0-7273-434d-9cfa-71631fa46af2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f9706368-4ed1-4bec-aca9-3429ad1267e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1390fd35-3db1-4290-a533-d1109b8aa6a8" xlink:to="loc_us-gaap_InterestExpense_f9706368-4ed1-4bec-aca9-3429ad1267e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_14bb973a-8f7e-407a-a370-e335b4c20f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c8b7424-b834-48dd-acc6-ec45981aad50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_14bb973a-8f7e-407a-a370-e335b4c20f4d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1c8b7424-b834-48dd-acc6-ec45981aad50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_118bed0d-40ee-440b-bf22-975a35b91a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_14bb973a-8f7e-407a-a370-e335b4c20f4d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_118bed0d-40ee-440b-bf22-975a35b91a32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d3270dcc-0898-444f-a701-c8d69152cb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4916bf04-5575-4d95-899a-f5e7771f8b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d3270dcc-0898-444f-a701-c8d69152cb8a" xlink:to="loc_us-gaap_OperatingIncomeLoss_4916bf04-5575-4d95-899a-f5e7771f8b32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_530912db-9441-495a-b261-6873bd947e92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d3270dcc-0898-444f-a701-c8d69152cb8a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_530912db-9441-495a-b261-6873bd947e92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f44e5590-21c5-445a-a29f-ed19b3b50a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2d21d43e-7abd-4560-9920-88e594900a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f44e5590-21c5-445a-a29f-ed19b3b50a5a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2d21d43e-7abd-4560-9920-88e594900a62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3c4c4f36-8c64-4346-b035-a8c03b4dda79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f44e5590-21c5-445a-a29f-ed19b3b50a5a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3c4c4f36-8c64-4346-b035-a8c03b4dda79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_06b48b69-3faa-4f22-a9b4-b302193603ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f44e5590-21c5-445a-a29f-ed19b3b50a5a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_06b48b69-3faa-4f22-a9b4-b302193603ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_0bc82068-353a-45d1-9ec9-81468603fd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f44e5590-21c5-445a-a29f-ed19b3b50a5a" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_0bc82068-353a-45d1-9ec9-81468603fd5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9f9b56de-0d20-4a86-a3c8-b1af6e322cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06c75dae-f6ab-4484-8de8-42f984ef2877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9f9b56de-0d20-4a86-a3c8-b1af6e322cb0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06c75dae-f6ab-4484-8de8-42f984ef2877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_04bead92-91b9-4e18-aeea-b2a610a41c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9f9b56de-0d20-4a86-a3c8-b1af6e322cb0" xlink:to="loc_us-gaap_CostsAndExpenses_04bead92-91b9-4e18-aeea-b2a610a41c38" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="regn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2847f701-e446-44bd-8955-c33f96f07119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2bab1bee-f58c-4b86-8a6e-d120a8094451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2847f701-e446-44bd-8955-c33f96f07119" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2bab1bee-f58c-4b86-8a6e-d120a8094451" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_88aa0ac7-0f6b-46cb-8db6-c9aa5ca0e654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2847f701-e446-44bd-8955-c33f96f07119" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_88aa0ac7-0f6b-46cb-8db6-c9aa5ca0e654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_43657941-e0e4-4549-bcf0-a5aa210f79be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2847f701-e446-44bd-8955-c33f96f07119" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_43657941-e0e4-4549-bcf0-a5aa210f79be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6262799d-5d61-4bd0-bb7c-3b0bfbe3b4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4c8a01c1-1be4-457a-ae09-59e2c1aeb526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6262799d-5d61-4bd0-bb7c-3b0bfbe3b4b6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4c8a01c1-1be4-457a-ae09-59e2c1aeb526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8dec438c-8012-4904-b725-4f467e41e1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6262799d-5d61-4bd0-bb7c-3b0bfbe3b4b6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8dec438c-8012-4904-b725-4f467e41e1a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64de8ef4-dcdc-44a7-a7c7-31af1d061c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6262799d-5d61-4bd0-bb7c-3b0bfbe3b4b6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64de8ef4-dcdc-44a7-a7c7-31af1d061c28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_8e35ef9a-4f71-4b14-b0e0-ed152afc3843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_848927f7-0e4a-4a04-b189-e1567aff7fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_8e35ef9a-4f71-4b14-b0e0-ed152afc3843" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_848927f7-0e4a-4a04-b189-e1567aff7fc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2fde01ff-9ccc-456e-8ae5-1df2b3594423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_8e35ef9a-4f71-4b14-b0e0-ed152afc3843" xlink:to="loc_us-gaap_ShareBasedCompensation_2fde01ff-9ccc-456e-8ae5-1df2b3594423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesGainLoss_dcdc98d2-77d5-496d-9c95-9c8743cbd1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_8e35ef9a-4f71-4b14-b0e0-ed152afc3843" xlink:to="loc_us-gaap_MarketableSecuritiesGainLoss_dcdc98d2-77d5-496d-9c95-9c8743cbd1c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_7981ea80-adfc-4d4a-9784-2b82c6ea8639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_8e35ef9a-4f71-4b14-b0e0-ed152afc3843" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_7981ea80-adfc-4d4a-9784-2b82c6ea8639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ded8710d-5774-41fc-b74d-4387c3be78e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_8e35ef9a-4f71-4b14-b0e0-ed152afc3843" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ded8710d-5774-41fc-b74d-4387c3be78e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e22b6b09-4687-430d-8bf2-7b69fda2b9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_8e35ef9a-4f71-4b14-b0e0-ed152afc3843" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e22b6b09-4687-430d-8bf2-7b69fda2b9cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d5aca072-d75d-4076-b286-5835fbe2f9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_8e35ef9a-4f71-4b14-b0e0-ed152afc3843" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d5aca072-d75d-4076-b286-5835fbe2f9d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_182d6748-4ae9-4a44-8628-38aefd87f965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_8e35ef9a-4f71-4b14-b0e0-ed152afc3843" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_182d6748-4ae9-4a44-8628-38aefd87f965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1adc4b4f-6319-4436-a1d6-4ea4dae5b186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_8e35ef9a-4f71-4b14-b0e0-ed152afc3843" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1adc4b4f-6319-4436-a1d6-4ea4dae5b186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b6ec3f96-066b-4d47-9758-365d7c938bef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_8e35ef9a-4f71-4b14-b0e0-ed152afc3843" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b6ec3f96-066b-4d47-9758-365d7c938bef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2fbac9f6-8cac-4e3e-bbb2-7e4917a766d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_af2f8733-5148-4f50-8b75-24e42179e053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2fbac9f6-8cac-4e3e-bbb2-7e4917a766d5" xlink:to="loc_us-gaap_NetIncomeLoss_af2f8733-5148-4f50-8b75-24e42179e053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a8e28c2c-ae6f-4aaf-814b-5cf8737b1c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2fbac9f6-8cac-4e3e-bbb2-7e4917a766d5" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a8e28c2c-ae6f-4aaf-814b-5cf8737b1c1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_519cf199-09cf-46c1-848a-c0135eca82e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_039e2870-9b61-4b0d-956c-765b76697e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_519cf199-09cf-46c1-848a-c0135eca82e2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_039e2870-9b61-4b0d-956c-765b76697e4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_38d597af-d000-4f95-8711-07366377b68c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_519cf199-09cf-46c1-848a-c0135eca82e2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_38d597af-d000-4f95-8711-07366377b68c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f990f9cf-76ac-463d-bcb1-ae0bbb3b809e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_519cf199-09cf-46c1-848a-c0135eca82e2" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f990f9cf-76ac-463d-bcb1-ae0bbb3b809e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2dea4141-19c9-4cb9-8437-1b112cc37f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_519cf199-09cf-46c1-848a-c0135eca82e2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2dea4141-19c9-4cb9-8437-1b112cc37f32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_be458871-bd57-40b0-a1bc-e56865b8f8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_519cf199-09cf-46c1-848a-c0135eca82e2" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_be458871-bd57-40b0-a1bc-e56865b8f8a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_32f23758-c418-4365-bf61-13e038eb6d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_519cf199-09cf-46c1-848a-c0135eca82e2" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_32f23758-c418-4365-bf61-13e038eb6d10" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1d6e1dee-bc4b-4aac-9380-4d1674bf97fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_df28a7da-32fe-4477-b393-9f8b4f742582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1d6e1dee-bc4b-4aac-9380-4d1674bf97fa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_df28a7da-32fe-4477-b393-9f8b4f742582" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d59d6a7c-3521-4b49-92d2-bf835191cafd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1d6e1dee-bc4b-4aac-9380-4d1674bf97fa" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d59d6a7c-3521-4b49-92d2-bf835191cafd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5bb72412-488e-4113-b520-fd9383f8cc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c946e61e-3231-4a9e-acac-3320317bb118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5bb72412-488e-4113-b520-fd9383f8cc5a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c946e61e-3231-4a9e-acac-3320317bb118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_19d4d071-8309-4347-a070-c43ef2c98ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5bb72412-488e-4113-b520-fd9383f8cc5a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_19d4d071-8309-4347-a070-c43ef2c98ca7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a580acce-c54b-4b1a-9c06-faeaca230661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5bb72412-488e-4113-b520-fd9383f8cc5a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a580acce-c54b-4b1a-9c06-faeaca230661" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c7ec929-f4b2-41eb-84fe-962514bc8a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0e3c6111-cd15-4606-8f9b-d109bd62459d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c7ec929-f4b2-41eb-84fe-962514bc8a76" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0e3c6111-cd15-4606-8f9b-d109bd62459d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e9949069-29e3-4c0b-b5bf-ecbe252ebff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c7ec929-f4b2-41eb-84fe-962514bc8a76" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e9949069-29e3-4c0b-b5bf-ecbe252ebff2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_802eb54c-8e07-493d-b35e-65c3c6e248c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_97ad85b8-64c6-4773-9131-f8cb01c1ece4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_802eb54c-8e07-493d-b35e-65c3c6e248c4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_97ad85b8-64c6-4773-9131-f8cb01c1ece4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6c79a1c1-b0f2-49cc-8990-ae7a6acf6e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_802eb54c-8e07-493d-b35e-65c3c6e248c4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6c79a1c1-b0f2-49cc-8990-ae7a6acf6e8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_d367ea72-7fff-4704-8143-a62fa05d5cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a37ea076-dc91-4473-97e2-51ca625acbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_d367ea72-7fff-4704-8143-a62fa05d5cac" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a37ea076-dc91-4473-97e2-51ca625acbaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_901cdeec-89eb-42d3-82fa-62f81598e6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_d367ea72-7fff-4704-8143-a62fa05d5cac" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_901cdeec-89eb-42d3-82fa-62f81598e6a4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_ac721796-5efb-4b33-9091-bebe0b57338b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_11d8ea0a-26fb-4ed1-92fe-d1100c0758bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketableSecurities_ac721796-5efb-4b33-9091-bebe0b57338b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_11d8ea0a-26fb-4ed1-92fe-d1100c0758bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_79174059-5c68-4f1d-a2cc-8bfab3867eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_MarketableSecurities_ac721796-5efb-4b33-9091-bebe0b57338b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_79174059-5c68-4f1d-a2cc-8bfab3867eb0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a02a7914-99aa-4494-9a8e-98dda3b2e077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d8c171b3-2324-4237-94bc-b70703c7cfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a02a7914-99aa-4494-9a8e-98dda3b2e077" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d8c171b3-2324-4237-94bc-b70703c7cfaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_41e2f0f9-62d8-4692-9689-f7df148b4e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a02a7914-99aa-4494-9a8e-98dda3b2e077" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_41e2f0f9-62d8-4692-9689-f7df148b4e15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_be357895-1916-4647-a91a-14c42aee87c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a02a7914-99aa-4494-9a8e-98dda3b2e077" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_be357895-1916-4647-a91a-14c42aee87c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryNetOfReserves_1c5ac485-fe56-40fc-8f1f-37edf77cc5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_a02a7914-99aa-4494-9a8e-98dda3b2e077" xlink:to="loc_us-gaap_OtherInventoryNetOfReserves_1c5ac485-fe56-40fc-8f1f-37edf77cc5d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1eb2dd1e-5a97-4447-b0ed-674374080bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb5c3c6c-0082-40c8-8d3e-f8630a1471a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1eb2dd1e-5a97-4447-b0ed-674374080bb0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb5c3c6c-0082-40c8-8d3e-f8630a1471a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_e92638a4-3c1c-4571-89d3-2853419822b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1eb2dd1e-5a97-4447-b0ed-674374080bb0" xlink:to="loc_us-gaap_RestrictedCash_e92638a4-3c1c-4571-89d3-2853419822b6" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>regn-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:08b52028-35ad-4384-abb4-ffa84b7c541b,g:79516084-017d-4f01-b220-9a6b8eb4ad51-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.regeneron.com/role/Cover" xlink:type="simple" xlink:href="regn-20210930.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/Cover" xlink:type="extended" id="iea85e69ca71a4e39a8c0f6b1a73055fd_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_99a3d01d-2365-42fe-92c2-96fa00cb5644" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_DocumentType_99a3d01d-2365-42fe-92c2-96fa00cb5644" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c1093a31-fecb-45a3-b51c-aa8fce6c7bd0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_DocumentQuarterlyReport_c1093a31-fecb-45a3-b51c-aa8fce6c7bd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_eb19a6ea-ce02-4cc2-91ee-ccaa9805ef90" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_DocumentPeriodEndDate_eb19a6ea-ce02-4cc2-91ee-ccaa9805ef90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f01c187e-b253-4ced-83b8-12e36d68b340" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_DocumentTransitionReport_f01c187e-b253-4ced-83b8-12e36d68b340" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5532f5ab-e5c4-4e3f-a9ef-668348548e89" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityFileNumber_5532f5ab-e5c4-4e3f-a9ef-668348548e89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_58a0c1a2-9cbd-4069-8ed9-5473438e1779" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityRegistrantName_58a0c1a2-9cbd-4069-8ed9-5473438e1779" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_13fb1f7d-fd7e-4e7c-8423-f4d95b4e7fca" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityIncorporationStateCountryCode_13fb1f7d-fd7e-4e7c-8423-f4d95b4e7fca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9ea713e1-a93c-4908-8fcd-ca59f14bf5c1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityTaxIdentificationNumber_9ea713e1-a93c-4908-8fcd-ca59f14bf5c1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_121e1192-c4e0-4d37-9706-784779ccdaf4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityAddressAddressLine1_121e1192-c4e0-4d37-9706-784779ccdaf4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_48b44240-5abe-41b6-a1a7-b8d2e7f212e0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityAddressCityOrTown_48b44240-5abe-41b6-a1a7-b8d2e7f212e0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1d80e397-4746-4096-8eab-3c0a99495c7f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityAddressStateOrProvince_1d80e397-4746-4096-8eab-3c0a99495c7f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6870fc81-7375-4835-9803-feaa60c3578b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityAddressPostalZipCode_6870fc81-7375-4835-9803-feaa60c3578b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_733f772b-6434-4db3-8998-400949eaf67a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_CityAreaCode_733f772b-6434-4db3-8998-400949eaf67a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7490e758-e899-40cd-9712-8070889fe0f3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_LocalPhoneNumber_7490e758-e899-40cd-9712-8070889fe0f3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cad244db-a9a4-4ddf-b720-6cc97c4f6861" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_Security12bTitle_cad244db-a9a4-4ddf-b720-6cc97c4f6861" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fe4fe08b-c793-4131-9936-c6f213fe5020" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_TradingSymbol_fe4fe08b-c793-4131-9936-c6f213fe5020" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_70384767-f7ba-41fe-9a5f-4801fdf37016" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_SecurityExchangeName_70384767-f7ba-41fe-9a5f-4801fdf37016" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_697b79ab-a9af-4d47-a748-6bef7c77e59f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityCurrentReportingStatus_697b79ab-a9af-4d47-a748-6bef7c77e59f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4e3fd272-6a85-41f8-a50e-16db7f354786" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityInteractiveDataCurrent_4e3fd272-6a85-41f8-a50e-16db7f354786" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a5be1869-e3d7-4947-8a66-e8bd00996eca" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityFilerCategory_a5be1869-e3d7-4947-8a66-e8bd00996eca" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_cb19f6dc-649c-4ec4-84c7-c0decaba593b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntitySmallBusiness_cb19f6dc-649c-4ec4-84c7-c0decaba593b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cd2fb9c7-9009-4fbe-9dd5-6dd5a49430eb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityEmergingGrowthCompany_cd2fb9c7-9009-4fbe-9dd5-6dd5a49430eb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_623ebdbc-7382-4c2f-9b99-959fbcd8e317" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityShellCompany_623ebdbc-7382-4c2f-9b99-959fbcd8e317" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b5f95ad0-7024-4d54-806f-bb152c1fed5b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b5f95ad0-7024-4d54-806f-bb152c1fed5b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_85b18077-d0d7-4781-8dba-ca94ae4788d1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityCentralIndexKey_85b18077-d0d7-4781-8dba-ca94ae4788d1" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2c93d003-be96-465d-b042-13ec5f63b1e1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_CurrentFiscalYearEndDate_2c93d003-be96-465d-b042-13ec5f63b1e1" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_db060940-0ce1-4a9c-9d1f-40e5f7ff824a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_DocumentFiscalYearFocus_db060940-0ce1-4a9c-9d1f-40e5f7ff824a" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_429b3704-3d64-428d-a0ea-de6e0aca380a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_DocumentFiscalPeriodFocus_429b3704-3d64-428d-a0ea-de6e0aca380a" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7ca0d7ac-6365-4964-b5cb-0803ca64c21d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_AmendmentFlag_7ca0d7ac-6365-4964-b5cb-0803ca64c21d" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_9b070c4e-94a7-4554-948e-265296fbb475" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntitiesTable_9b070c4e-94a7-4554-948e-265296fbb475" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f4ad8a8a-3bc0-46bc-9660-4ba025eec3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_9b070c4e-94a7-4554-948e-265296fbb475" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f4ad8a8a-3bc0-46bc-9660-4ba025eec3e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f4ad8a8a-3bc0-46bc-9660-4ba025eec3e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f4ad8a8a-3bc0-46bc-9660-4ba025eec3e2" xlink:to="loc_us-gaap_ClassOfStockDomain_f4ad8a8a-3bc0-46bc-9660-4ba025eec3e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7e53fd26-76c2-4c4a-ae82-85bcd266f929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f4ad8a8a-3bc0-46bc-9660-4ba025eec3e2" xlink:to="loc_us-gaap_ClassOfStockDomain_7e53fd26-76c2-4c4a-ae82-85bcd266f929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_cde4f2e7-f76c-4568-87a1-f09a90ba43b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7e53fd26-76c2-4c4a-ae82-85bcd266f929" xlink:to="loc_us-gaap_CommonClassAMember_cde4f2e7-f76c-4568-87a1-f09a90ba43b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_67ef099c-bc66-45c1-bdfc-d3d86943669d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7e53fd26-76c2-4c4a-ae82-85bcd266f929" xlink:to="loc_us-gaap_CommonStockMember_67ef099c-bc66-45c1-bdfc-d3d86943669d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="regn-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended" id="ib5a50a29cd7343bc8d46ed60280668cc_CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_66c776d8-1339-4825-ba2f-7289a2df956f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_66c776d8-1339-4825-ba2f-7289a2df956f" xlink:to="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:to="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b6cd7edb-7b36-4b9d-8100-bd0748287ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b6cd7edb-7b36-4b9d-8100-bd0748287ba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2bc730e2-1921-4557-8bb2-f8019e1f475c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2bc730e2-1921-4557-8bb2-f8019e1f475c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_66b87ab1-8782-49be-9ebb-75a6989c25dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_66b87ab1-8782-49be-9ebb-75a6989c25dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_da53a5dd-4928-41ef-8b4b-e9cb154f09e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:to="loc_us-gaap_InventoryNet_da53a5dd-4928-41ef-8b4b-e9cb154f09e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d2e006b7-eb60-4162-88e1-fb2491fb94d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d2e006b7-eb60-4162-88e1-fb2491fb94d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_397be058-2044-477e-86b9-eb27f07b91e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:to="loc_us-gaap_AssetsCurrent_397be058-2044-477e-86b9-eb27f07b91e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_650fcc89-0914-493f-a5be-eafa193e5345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_650fcc89-0914-493f-a5be-eafa193e5345" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ddf6b7c9-2772-404d-8b4d-65c627e0df17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ddf6b7c9-2772-404d-8b4d-65c627e0df17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_f171ca28-a008-4d37-9ad6-82cd073100a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_f171ca28-a008-4d37-9ad6-82cd073100a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_537f247d-0904-466e-952b-014d888fcc17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_537f247d-0904-466e-952b-014d888fcc17" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ce4d7907-0919-41f0-8c7c-ddfb5140b6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:to="loc_us-gaap_Assets_ce4d7907-0919-41f0-8c7c-ddfb5140b6d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_66c776d8-1339-4825-ba2f-7289a2df956f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1f7befb3-9f65-4c83-94e1-6865cafd4d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1f7befb3-9f65-4c83-94e1-6865cafd4d88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_090b3927-4c39-4a68-9f3e-9bb24f3618a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f7befb3-9f65-4c83-94e1-6865cafd4d88" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_090b3927-4c39-4a68-9f3e-9bb24f3618a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a02dde28-b03d-46e6-973b-76f2c172a624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f7befb3-9f65-4c83-94e1-6865cafd4d88" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a02dde28-b03d-46e6-973b-76f2c172a624" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f8195033-2f7c-4a7d-8788-36443ba676b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f7befb3-9f65-4c83-94e1-6865cafd4d88" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f8195033-2f7c-4a7d-8788-36443ba676b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_06d66827-2259-400e-b350-816ca358f5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f7befb3-9f65-4c83-94e1-6865cafd4d88" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_06d66827-2259-400e-b350-816ca358f5eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7c308152-c1ff-4746-bb6a-f2703711ef8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f7befb3-9f65-4c83-94e1-6865cafd4d88" xlink:to="loc_us-gaap_LiabilitiesCurrent_7c308152-c1ff-4746-bb6a-f2703711ef8f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c9a0fb9f-1f58-4848-9d9b-d57c0a6f18bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c9a0fb9f-1f58-4848-9d9b-d57c0a6f18bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b11cc4a8-9d91-4bff-82d3-2ace2fbc919d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b11cc4a8-9d91-4bff-82d3-2ace2fbc919d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_929938a6-87f8-45c7-86ea-11e9b8396837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_929938a6-87f8-45c7-86ea-11e9b8396837" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b7fe043b-5d9c-43da-b4d9-dec2027f59de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b7fe043b-5d9c-43da-b4d9-dec2027f59de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_10c1cda9-3163-441d-9814-21b243ef5bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_Liabilities_10c1cda9-3163-441d-9814-21b243ef5bcc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7bef9020-74fd-40b9-8a1a-5f72f15f445a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:to="loc_us-gaap_PreferredStockValue_7bef9020-74fd-40b9-8a1a-5f72f15f445a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_81517a3f-0d9c-4d12-829a-479bb00f676d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:to="loc_us-gaap_CommonStockValue_81517a3f-0d9c-4d12-829a-479bb00f676d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ca22062f-31ac-418f-861d-cd1281b73d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ca22062f-31ac-418f-861d-cd1281b73d37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bb274e70-53f9-4807-adff-dc3eda0a79f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bb274e70-53f9-4807-adff-dc3eda0a79f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_190d8012-d72a-47a2-9548-69826a9790fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_190d8012-d72a-47a2-9548-69826a9790fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_8613912f-1511-470e-8d6c-2bcc5d9fb3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:to="loc_us-gaap_TreasuryStockValue_8613912f-1511-470e-8d6c-2bcc5d9fb3ad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8ad01911-6500-4d22-82b2-1b1c25c2afdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:to="loc_us-gaap_StockholdersEquity_8ad01911-6500-4d22-82b2-1b1c25c2afdf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8951bfc0-13c1-4341-b4cf-6c5ae322bef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8951bfc0-13c1-4341-b4cf-6c5ae322bef4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8bdd57db-e6ca-42a6-a512-f0c8df2ebcab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_66c776d8-1339-4825-ba2f-7289a2df956f" xlink:to="loc_us-gaap_StatementTable_8bdd57db-e6ca-42a6-a512-f0c8df2ebcab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6730da1b-4574-486b-ae4c-2f45ca0f66a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8bdd57db-e6ca-42a6-a512-f0c8df2ebcab" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6730da1b-4574-486b-ae4c-2f45ca0f66a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6730da1b-4574-486b-ae4c-2f45ca0f66a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6730da1b-4574-486b-ae4c-2f45ca0f66a4" xlink:to="loc_us-gaap_ClassOfStockDomain_6730da1b-4574-486b-ae4c-2f45ca0f66a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_38ee120c-3a97-4f14-971f-bb0407567560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6730da1b-4574-486b-ae4c-2f45ca0f66a4" xlink:to="loc_us-gaap_ClassOfStockDomain_38ee120c-3a97-4f14-971f-bb0407567560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c337b6e0-f6f8-4fd2-a14e-b0ccd80abf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_38ee120c-3a97-4f14-971f-bb0407567560" xlink:to="loc_us-gaap_CommonClassAMember_c337b6e0-f6f8-4fd2-a14e-b0ccd80abf9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5bc5d659-4197-4a8c-8389-22310c521415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_38ee120c-3a97-4f14-971f-bb0407567560" xlink:to="loc_us-gaap_CommonStockMember_5bc5d659-4197-4a8c-8389-22310c521415" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" xlink:href="regn-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="extended" id="i32bc9e1a99754c7282e1cf54c2beb964_CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0fa305a1-6b45-401e-94cf-5808663029b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2caeea61-0e05-4e39-91a6-ce5deca3195f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0fa305a1-6b45-401e-94cf-5808663029b8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2caeea61-0e05-4e39-91a6-ce5deca3195f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2caeea61-0e05-4e39-91a6-ce5deca3195f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d9c7770f-5b31-4f54-acd5-d6fc816f4c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d9c7770f-5b31-4f54-acd5-d6fc816f4c82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0639f9b2-11ee-46d6-99ff-6e33968e0fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0639f9b2-11ee-46d6-99ff-6e33968e0fb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_44ffd945-f1e5-4183-a02b-c87de3db65d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_PreferredStockSharesIssued_44ffd945-f1e5-4183-a02b-c87de3db65d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_91d1b254-3042-4167-a1ad-eec8f75ba419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_91d1b254-3042-4167-a1ad-eec8f75ba419" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9f34565f-b04e-4496-a693-06e0ce562ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9f34565f-b04e-4496-a693-06e0ce562ece" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_aa7463d0-7c09-4424-ac6e-80bb9e9c990e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_aa7463d0-7c09-4424-ac6e-80bb9e9c990e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_25777587-f61c-4d1e-96e2-c6ea6922776c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_CommonStockSharesIssued_25777587-f61c-4d1e-96e2-c6ea6922776c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_80f31ada-2513-414c-b8f4-62f7537947e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_80f31ada-2513-414c-b8f4-62f7537947e8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_deaa54ca-cd4f-41bf-8c34-b1f60f90bef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_TreasuryStockShares_deaa54ca-cd4f-41bf-8c34-b1f60f90bef7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_19f45e27-1f86-449d-b4b6-77d597f54018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0fa305a1-6b45-401e-94cf-5808663029b8" xlink:to="loc_us-gaap_StatementTable_19f45e27-1f86-449d-b4b6-77d597f54018" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_86cb7e6b-20f9-4bd6-b546-9c9d7be76fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_19f45e27-1f86-449d-b4b6-77d597f54018" xlink:to="loc_us-gaap_StatementClassOfStockAxis_86cb7e6b-20f9-4bd6-b546-9c9d7be76fbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_86cb7e6b-20f9-4bd6-b546-9c9d7be76fbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_86cb7e6b-20f9-4bd6-b546-9c9d7be76fbe" xlink:to="loc_us-gaap_ClassOfStockDomain_86cb7e6b-20f9-4bd6-b546-9c9d7be76fbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9ca7e376-c7ab-4cca-a693-225c6e33e528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_86cb7e6b-20f9-4bd6-b546-9c9d7be76fbe" xlink:to="loc_us-gaap_ClassOfStockDomain_9ca7e376-c7ab-4cca-a693-225c6e33e528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_af4c3278-be40-450f-acba-c06981389bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9ca7e376-c7ab-4cca-a693-225c6e33e528" xlink:to="loc_us-gaap_CommonClassAMember_af4c3278-be40-450f-acba-c06981389bb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_21576eac-a6d6-4ecf-ab58-80b6da72af8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9ca7e376-c7ab-4cca-a693-225c6e33e528" xlink:to="loc_us-gaap_CommonStockMember_21576eac-a6d6-4ecf-ab58-80b6da72af8e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="simple" xlink:href="regn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="extended" id="ibc27c70a065f491a8ca0016431d7d35e_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4f26b83c-cd25-4d69-9e23-55aea2385542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4f26b83c-cd25-4d69-9e23-55aea2385542" xlink:to="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_226f139b-b1d0-4ec2-a8ae-b6b085c0667a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_RevenuesAbstract_226f139b-b1d0-4ec2-a8ae-b6b085c0667a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eea134e1-7c84-41f8-b292-bb495f9e80d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_226f139b-b1d0-4ec2-a8ae-b6b085c0667a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eea134e1-7c84-41f8-b292-bb495f9e80d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_779b92cf-86c3-4879-aefb-6414e708a807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_779b92cf-86c3-4879-aefb-6414e708a807" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a8b80a07-4cdf-4ebc-9507-4c2d8358ea79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_779b92cf-86c3-4879-aefb-6414e708a807" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a8b80a07-4cdf-4ebc-9507-4c2d8358ea79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d9ee4afe-c117-4974-99b5-0d97f91bd164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_779b92cf-86c3-4879-aefb-6414e708a807" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d9ee4afe-c117-4974-99b5-0d97f91bd164" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1191f285-29ff-47ee-b635-109122d57768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_779b92cf-86c3-4879-aefb-6414e708a807" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1191f285-29ff-47ee-b635-109122d57768" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_4303b386-46b3-4c10-b2ec-6c66c49e63c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_779b92cf-86c3-4879-aefb-6414e708a807" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_4303b386-46b3-4c10-b2ec-6c66c49e63c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_daf0e631-96fc-4d36-8ef7-21739916e668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_779b92cf-86c3-4879-aefb-6414e708a807" xlink:to="loc_us-gaap_CostsAndExpenses_daf0e631-96fc-4d36-8ef7-21739916e668" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7b783093-8372-425d-a165-55cb41bc8311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_OperatingIncomeLoss_7b783093-8372-425d-a165-55cb41bc8311" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_37ff2441-d5f9-4a77-818d-377c6a17ae88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_37ff2441-d5f9-4a77-818d-377c6a17ae88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4b237238-9678-472a-afcc-bb31f0fae9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_37ff2441-d5f9-4a77-818d-377c6a17ae88" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4b237238-9678-472a-afcc-bb31f0fae9c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6e813ed6-b693-4191-aa03-24affa0d49fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_37ff2441-d5f9-4a77-818d-377c6a17ae88" xlink:to="loc_us-gaap_InterestExpense_6e813ed6-b693-4191-aa03-24affa0d49fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d8e8c906-33f0-4583-97d4-f852abce7314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_37ff2441-d5f9-4a77-818d-377c6a17ae88" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d8e8c906-33f0-4583-97d4-f852abce7314" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d5dc2b1-7c96-45c7-83c7-4bcbbc99098f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d5dc2b1-7c96-45c7-83c7-4bcbbc99098f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_53a609c8-54f5-4356-b63a-4275181fe2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_53a609c8-54f5-4356-b63a-4275181fe2b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_04cca0fc-3b4f-488c-8626-a14ad43c2a92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_NetIncomeLoss_04cca0fc-3b4f-488c-8626-a14ad43c2a92" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1f1abca5-4b64-47b1-876a-dacce50eea90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_EarningsPerShareBasic_1f1abca5-4b64-47b1-876a-dacce50eea90" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2774097b-489f-4cb0-b8fa-fa8034304a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2774097b-489f-4cb0-b8fa-fa8034304a60" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2a1ac6a1-bc15-457b-b917-1572124c0368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2a1ac6a1-bc15-457b-b917-1572124c0368" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_acf9622e-08e5-43cb-8c75-a8a736acc9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_acf9622e-08e5-43cb-8c75-a8a736acc9bb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_540e6d60-f921-419d-82e6-cebdc773cb45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4f26b83c-cd25-4d69-9e23-55aea2385542" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_540e6d60-f921-419d-82e6-cebdc773cb45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_34fa3cb8-4b1e-4d8b-9675-c3bc6681117f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0264e8eb-bc21-4e8f-b2ed-464a04e920d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_540e6d60-f921-419d-82e6-cebdc773cb45" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0264e8eb-bc21-4e8f-b2ed-464a04e920d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b5848059-8711-464b-a6f8-42e17c26678d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0264e8eb-bc21-4e8f-b2ed-464a04e920d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b5848059-8711-464b-a6f8-42e17c26678d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_d5927db3-7b13-45ac-b881-b0baa5998b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0264e8eb-bc21-4e8f-b2ed-464a04e920d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_d5927db3-7b13-45ac-b881-b0baa5998b18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d24ebabf-5afe-4b9e-a4ea-644ebbf81625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_540e6d60-f921-419d-82e6-cebdc773cb45" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_d24ebabf-5afe-4b9e-a4ea-644ebbf81625" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_eade2c32-5def-40ed-8404-8a737f03c5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4f26b83c-cd25-4d69-9e23-55aea2385542" xlink:to="loc_us-gaap_StatementTable_eade2c32-5def-40ed-8404-8a737f03c5d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ddc73463-9ebd-405e-a10e-0b454c933117" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_eade2c32-5def-40ed-8404-8a737f03c5d6" xlink:to="loc_srt_ProductOrServiceAxis_ddc73463-9ebd-405e-a10e-0b454c933117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ddc73463-9ebd-405e-a10e-0b454c933117_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ddc73463-9ebd-405e-a10e-0b454c933117" xlink:to="loc_srt_ProductsAndServicesDomain_ddc73463-9ebd-405e-a10e-0b454c933117_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e960cae0-e9f0-4bc2-b25e-7d19c3e2e502" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ddc73463-9ebd-405e-a10e-0b454c933117" xlink:to="loc_srt_ProductsAndServicesDomain_e960cae0-e9f0-4bc2-b25e-7d19c3e2e502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4265bd0a-a31d-4d56-9ffe-7ad83dbd2e51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e960cae0-e9f0-4bc2-b25e-7d19c3e2e502" xlink:to="loc_us-gaap_ProductMember_4265bd0a-a31d-4d56-9ffe-7ad83dbd2e51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_ea9a38c7-84cc-456c-a06e-8dbc76002f51" xlink:href="regn-20210930.xsd#regn_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e960cae0-e9f0-4bc2-b25e-7d19c3e2e502" xlink:to="loc_regn_CollaborationRevenueMember_ea9a38c7-84cc-456c-a06e-8dbc76002f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_0e2cb654-3331-4e63-9243-fddf692fd4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e960cae0-e9f0-4bc2-b25e-7d19c3e2e502" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_0e2cb654-3331-4e63-9243-fddf692fd4e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationandContractManufacturingMember_86bebaa9-860c-41c8-9c80-33da6b978039" xlink:href="regn-20210930.xsd#regn_CollaborationandContractManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e960cae0-e9f0-4bc2-b25e-7d19c3e2e502" xlink:to="loc_regn_CollaborationandContractManufacturingMember_86bebaa9-860c-41c8-9c80-33da6b978039" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="regn-20210930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended" id="i6d55c782961d43fd9ab44da3b6dd2974_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_666b8e76-52b8-465a-aec1-153cbb80be09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_666b8e76-52b8-465a-aec1-153cbb80be09" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_36e2c421-33de-4983-a686-8e80ff3d25f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_SharesOutstanding_36e2c421-33de-4983-a686-8e80ff3d25f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f3106cdf-6aec-4a69-816c-6f9932aea17b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_StockholdersEquity_f3106cdf-6aec-4a69-816c-6f9932aea17b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4f56d450-63bc-4c46-a1ac-eed0bf5bc2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4f56d450-63bc-4c46-a1ac-eed0bf5bc2a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637614ed-1bac-49dd-9c97-498c4b1168d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637614ed-1bac-49dd-9c97-498c4b1168d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_31b197cd-fb04-4c10-a42f-4492dbadf879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_31b197cd-fb04-4c10-a42f-4492dbadf879" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8b897e00-5ef2-4ef1-9998-daf360cdf2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8b897e00-5ef2-4ef1-9998-daf360cdf2d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_21bdb2a2-58ac-4d35-9043-f62882fad7fb" xlink:href="regn-20210930.xsd#regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_21bdb2a2-58ac-4d35-9043-f62882fad7fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_87d47cb5-af86-469d-8803-cad44e8cdd1f" xlink:href="regn-20210930.xsd#regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_87d47cb5-af86-469d-8803-cad44e8cdd1f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_b01b185e-1da1-4503-baa4-52885902d258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_b01b185e-1da1-4503-baa4-52885902d258" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f317b3fd-402b-4c9b-a0c3-a6b7f1549f65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f317b3fd-402b-4c9b-a0c3-a6b7f1549f65" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ff3515f4-fc05-40b5-bff4-faee47fbdc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ff3515f4-fc05-40b5-bff4-faee47fbdc0d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d9697112-802e-4752-a066-6538fc21ae50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_NetIncomeLoss_d9697112-802e-4752-a066-6538fc21ae50" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3e0d75ea-0370-42a9-997c-263da48bebb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3e0d75ea-0370-42a9-997c-263da48bebb1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7bbff30a-6880-41fc-b555-706eb3cba31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8b386323-53dc-48da-82ab-c3ed1e281677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_99dbb391-08dd-4495-8ee7-76494fe7df8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_666b8e76-52b8-465a-aec1-153cbb80be09" xlink:to="loc_us-gaap_StatementTable_99dbb391-08dd-4495-8ee7-76494fe7df8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c4aa6d39-3ed9-417e-9395-739852846711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_99dbb391-08dd-4495-8ee7-76494fe7df8b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c4aa6d39-3ed9-417e-9395-739852846711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c4aa6d39-3ed9-417e-9395-739852846711_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c4aa6d39-3ed9-417e-9395-739852846711" xlink:to="loc_us-gaap_ClassOfStockDomain_c4aa6d39-3ed9-417e-9395-739852846711_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ce7b8f5b-1453-43a0-a27a-1854f61e0da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c4aa6d39-3ed9-417e-9395-739852846711" xlink:to="loc_us-gaap_ClassOfStockDomain_ce7b8f5b-1453-43a0-a27a-1854f61e0da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c57fff00-b947-43b8-a9ba-a436f764d8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ce7b8f5b-1453-43a0-a27a-1854f61e0da4" xlink:to="loc_us-gaap_CommonClassAMember_c57fff00-b947-43b8-a9ba-a436f764d8d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_210db01e-0613-4aac-be25-7ec31e2fa6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_99dbb391-08dd-4495-8ee7-76494fe7df8b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_210db01e-0613-4aac-be25-7ec31e2fa6ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_210db01e-0613-4aac-be25-7ec31e2fa6ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_210db01e-0613-4aac-be25-7ec31e2fa6ae" xlink:to="loc_us-gaap_EquityComponentDomain_210db01e-0613-4aac-be25-7ec31e2fa6ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0e94cf58-61af-458a-928e-eabbcd0482d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_210db01e-0613-4aac-be25-7ec31e2fa6ae" xlink:to="loc_us-gaap_EquityComponentDomain_0e94cf58-61af-458a-928e-eabbcd0482d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_575236b9-b09d-4a92-b3d3-d11e9a8dfded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0e94cf58-61af-458a-928e-eabbcd0482d2" xlink:to="loc_us-gaap_CommonStockMember_575236b9-b09d-4a92-b3d3-d11e9a8dfded" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e5eb3b72-3e6e-404c-8cc7-9e13c4c8f209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0e94cf58-61af-458a-928e-eabbcd0482d2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e5eb3b72-3e6e-404c-8cc7-9e13c4c8f209" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_77219912-8787-417f-ab48-b3edb043dd01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0e94cf58-61af-458a-928e-eabbcd0482d2" xlink:to="loc_us-gaap_RetainedEarningsMember_77219912-8787-417f-ab48-b3edb043dd01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7aba608d-2235-4fb4-9284-d3e599ebb2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0e94cf58-61af-458a-928e-eabbcd0482d2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7aba608d-2235-4fb4-9284-d3e599ebb2bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_248257b3-9ecb-45a3-8288-4ceab906e5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0e94cf58-61af-458a-928e-eabbcd0482d2" xlink:to="loc_us-gaap_TreasuryStockMember_248257b3-9ecb-45a3-8288-4ceab906e5b8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#ProductSalesScheduleofNetProductSalesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="extended" id="ib91f7a9962bb4ecaa6ceacde4a8182de_ProductSalesScheduleofNetProductSalesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_165e986f-103d-475f-aa26-db2c6f94941a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5171ff65-f1fd-4630-8f49-e41f69eee68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_165e986f-103d-475f-aa26-db2c6f94941a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5171ff65-f1fd-4630-8f49-e41f69eee68a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e0e7cf7c-1d51-4c7b-86eb-453608235c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_165e986f-103d-475f-aa26-db2c6f94941a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e0e7cf7c-1d51-4c7b-86eb-453608235c2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_731ca552-9ac5-41ef-b8b5-8d27a4732b06" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e0e7cf7c-1d51-4c7b-86eb-453608235c2a" xlink:to="loc_srt_StatementGeographicalAxis_731ca552-9ac5-41ef-b8b5-8d27a4732b06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_731ca552-9ac5-41ef-b8b5-8d27a4732b06_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_731ca552-9ac5-41ef-b8b5-8d27a4732b06" xlink:to="loc_srt_SegmentGeographicalDomain_731ca552-9ac5-41ef-b8b5-8d27a4732b06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ede0ee21-86ea-439d-86dd-e4870598af1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_731ca552-9ac5-41ef-b8b5-8d27a4732b06" xlink:to="loc_srt_SegmentGeographicalDomain_ede0ee21-86ea-439d-86dd-e4870598af1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c27db790-a6c0-4863-8942-2ebd3a850573" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ede0ee21-86ea-439d-86dd-e4870598af1e" xlink:to="loc_country_US_c27db790-a6c0-4863-8942-2ebd3a850573" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7822ec3c-1ac1-4a35-8f19-ce331ad616e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e0e7cf7c-1d51-4c7b-86eb-453608235c2a" xlink:to="loc_srt_ProductOrServiceAxis_7822ec3c-1ac1-4a35-8f19-ce331ad616e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7822ec3c-1ac1-4a35-8f19-ce331ad616e3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7822ec3c-1ac1-4a35-8f19-ce331ad616e3" xlink:to="loc_srt_ProductsAndServicesDomain_7822ec3c-1ac1-4a35-8f19-ce331ad616e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7822ec3c-1ac1-4a35-8f19-ce331ad616e3" xlink:to="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EyleaNetProductSalesMember_b18bd14d-8e14-4ed7-bf17-12e9b542134a" xlink:href="regn-20210930.xsd#regn_EyleaNetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:to="loc_regn_EyleaNetProductSalesMember_b18bd14d-8e14-4ed7-bf17-12e9b542134a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LIBTAYONetProductSalesMember_680d28b5-d426-4f1e-855f-811ba6e58ac7" xlink:href="regn-20210930.xsd#regn_LIBTAYONetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:to="loc_regn_LIBTAYONetProductSalesMember_680d28b5-d426-4f1e-855f-811ba6e58ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentNetProductSalesMember_f09a6ab9-bf83-4d9e-924b-d2991b8bbaa3" xlink:href="regn-20210930.xsd#regn_PraluentNetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:to="loc_regn_PraluentNetProductSalesMember_f09a6ab9-bf83-4d9e-924b-d2991b8bbaa3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_REGENCOVMember_3587e347-346d-441f-85f5-67ede1a89b59" xlink:href="regn-20210930.xsd#regn_REGENCOVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:to="loc_regn_REGENCOVMember_3587e347-346d-441f-85f5-67ede1a89b59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EvkeezaMember_8150b78b-4ba6-4522-b68a-c74826b562ef" xlink:href="regn-20210930.xsd#regn_EvkeezaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:to="loc_regn_EvkeezaMember_8150b78b-4ba6-4522-b68a-c74826b562ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ArcalystNetProductSalesMember_b8184efc-9dd9-41d2-a991-c7a0ee6e6ccd" xlink:href="regn-20210930.xsd#regn_ArcalystNetProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:to="loc_regn_ArcalystNetProductSalesMember_b8184efc-9dd9-41d2-a991-c7a0ee6e6ccd" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="extended" id="idd9c3691e5ef4706a63d6f540a9eae12_ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_03524800-5b28-46ae-b9ce-376fe23cbff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0075e6f1-78b2-4394-bc7a-da9e71ab2764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_03524800-5b28-46ae-b9ce-376fe23cbff8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_0075e6f1-78b2-4394-bc7a-da9e71ab2764" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_dacc57bd-c4cd-4e3a-bda6-27862b9d62b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_03524800-5b28-46ae-b9ce-376fe23cbff8" xlink:to="loc_us-gaap_ConcentrationRiskTable_dacc57bd-c4cd-4e3a-bda6-27862b9d62b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7628e99d-449e-4634-a467-aec1a38bb280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_dacc57bd-c4cd-4e3a-bda6-27862b9d62b8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7628e99d-449e-4634-a467-aec1a38bb280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7628e99d-449e-4634-a467-aec1a38bb280_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7628e99d-449e-4634-a467-aec1a38bb280" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7628e99d-449e-4634-a467-aec1a38bb280_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_770edeec-ec41-4378-9c8b-823ba53c0058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7628e99d-449e-4634-a467-aec1a38bb280" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_770edeec-ec41-4378-9c8b-823ba53c0058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GrossProductRevenueMember_228b898e-1fef-4217-9e47-9924b62e24b9" xlink:href="regn-20210930.xsd#regn_GrossProductRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_770edeec-ec41-4378-9c8b-823ba53c0058" xlink:to="loc_regn_GrossProductRevenueMember_228b898e-1fef-4217-9e47-9924b62e24b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4b5fad3b-dcb4-467c-87fd-830686d1232c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_dacc57bd-c4cd-4e3a-bda6-27862b9d62b8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4b5fad3b-dcb4-467c-87fd-830686d1232c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4b5fad3b-dcb4-467c-87fd-830686d1232c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4b5fad3b-dcb4-467c-87fd-830686d1232c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4b5fad3b-dcb4-467c-87fd-830686d1232c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_66ed8733-cdf9-4b28-84f4-2c5694b3bd48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4b5fad3b-dcb4-467c-87fd-830686d1232c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_66ed8733-cdf9-4b28-84f4-2c5694b3bd48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d2ef89f5-366a-446a-871a-58e132f3915b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_66ed8733-cdf9-4b28-84f4-2c5694b3bd48" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d2ef89f5-366a-446a-871a-58e132f3915b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_06a56e3e-5e3b-4921-9cdb-26e46154ef5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_dacc57bd-c4cd-4e3a-bda6-27862b9d62b8" xlink:to="loc_srt_MajorCustomersAxis_06a56e3e-5e3b-4921-9cdb-26e46154ef5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_06a56e3e-5e3b-4921-9cdb-26e46154ef5f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_06a56e3e-5e3b-4921-9cdb-26e46154ef5f" xlink:to="loc_srt_NameOfMajorCustomerDomain_06a56e3e-5e3b-4921-9cdb-26e46154ef5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_61bd8a79-bb71-4225-98da-a3367954390c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_06a56e3e-5e3b-4921-9cdb-26e46154ef5f" xlink:to="loc_srt_NameOfMajorCustomerDomain_61bd8a79-bb71-4225-98da-a3367954390c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BesseMedicalMember_7a94b38e-1a48-49e7-8f93-402ae497e537" xlink:href="regn-20210930.xsd#regn_BesseMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_61bd8a79-bb71-4225-98da-a3367954390c" xlink:to="loc_regn_BesseMedicalMember_7a94b38e-1a48-49e7-8f93-402ae497e537" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_McKessonCorporationMember_2cf54a0b-f37d-429e-9b29-e1668953e453" xlink:href="regn-20210930.xsd#regn_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_61bd8a79-bb71-4225-98da-a3367954390c" xlink:to="loc_regn_McKessonCorporationMember_2cf54a0b-f37d-429e-9b29-e1668953e453" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_USGovernmentMember_28a0a0b6-3497-4fda-8b64-66445f376697" xlink:href="regn-20210930.xsd#regn_USGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_61bd8a79-bb71-4225-98da-a3367954390c" xlink:to="loc_regn_USGovernmentMember_28a0a0b6-3497-4fda-8b64-66445f376697" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#ProductSalesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/ProductSalesNarrativeDetails" xlink:type="extended" id="i119c37e12adf41a08d29a06d4eb72988_ProductSalesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_1bfea7fe-009e-4827-b22f-f1b9f8a8a461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c30cc302-79fd-4819-a675-0a9cc13387cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_1bfea7fe-009e-4827-b22f-f1b9f8a8a461" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c30cc302-79fd-4819-a675-0a9cc13387cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_8c0d1cd6-f1f7-4ca4-824e-b40c121bf628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_1bfea7fe-009e-4827-b22f-f1b9f8a8a461" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_8c0d1cd6-f1f7-4ca4-824e-b40c121bf628" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8aac83de-3358-40ea-8dab-c09cf6819d33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_8c0d1cd6-f1f7-4ca4-824e-b40c121bf628" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8aac83de-3358-40ea-8dab-c09cf6819d33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_8aac83de-3358-40ea-8dab-c09cf6819d33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8aac83de-3358-40ea-8dab-c09cf6819d33" xlink:to="loc_us-gaap_ReceivableTypeDomain_8aac83de-3358-40ea-8dab-c09cf6819d33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_844ba31c-5302-445e-bb88-533b40d32541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8aac83de-3358-40ea-8dab-c09cf6819d33" xlink:to="loc_us-gaap_ReceivableTypeDomain_844ba31c-5302-445e-bb88-533b40d32541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_4c2c796c-e19f-42ee-857b-fe767aff8f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_844ba31c-5302-445e-bb88-533b40d32541" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_4c2c796c-e19f-42ee-857b-fe767aff8f42" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" xlink:type="extended" id="i8eeeb51ff19c4bed842a70174c266852_CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4ec6e709-74d7-4b17-8748-f2d042b844b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_10f9101b-59a5-442c-b82a-d6a6172def98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4ec6e709-74d7-4b17-8748-f2d042b844b5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_10f9101b-59a5-442c-b82a-d6a6172def98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_483e0d20-1747-46d3-9cf5-500ed3e327cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4ec6e709-74d7-4b17-8748-f2d042b844b5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_483e0d20-1747-46d3-9cf5-500ed3e327cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_d6e76beb-99e4-4e38-b47e-4d220aecff70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_483e0d20-1747-46d3-9cf5-500ed3e327cc" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_d6e76beb-99e4-4e38-b47e-4d220aecff70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_d6e76beb-99e4-4e38-b47e-4d220aecff70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_d6e76beb-99e4-4e38-b47e-4d220aecff70" xlink:to="loc_us-gaap_ProjectMember_d6e76beb-99e4-4e38-b47e-4d220aecff70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_53e328d5-3724-4cf4-8662-c9429fb37cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_d6e76beb-99e4-4e38-b47e-4d220aecff70" xlink:to="loc_us-gaap_ProjectMember_53e328d5-3724-4cf4-8662-c9429fb37cf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_bba08d72-9d4c-437d-99bd-38a790fdafb3" xlink:href="regn-20210930.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_53e328d5-3724-4cf4-8662-c9429fb37cf8" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_bba08d72-9d4c-437d-99bd-38a790fdafb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_c8a677c0-ee54-4334-861f-d3ac052f7cfe" xlink:href="regn-20210930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_53e328d5-3724-4cf4-8662-c9429fb37cf8" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_c8a677c0-ee54-4334-861f-d3ac052f7cfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3cbeed6a-b073-45c4-9c75-96d7e17ea081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_483e0d20-1747-46d3-9cf5-500ed3e327cc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3cbeed6a-b073-45c4-9c75-96d7e17ea081" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3cbeed6a-b073-45c4-9c75-96d7e17ea081_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3cbeed6a-b073-45c4-9c75-96d7e17ea081" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3cbeed6a-b073-45c4-9c75-96d7e17ea081_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d4ef3846-4320-4c51-9f64-4ac272f57033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3cbeed6a-b073-45c4-9c75-96d7e17ea081" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d4ef3846-4320-4c51-9f64-4ac272f57033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_be9dd7ff-41eb-4062-964f-6087a4dd5f88" xlink:href="regn-20210930.xsd#regn_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4ef3846-4320-4c51-9f64-4ac272f57033" xlink:to="loc_regn_CollaborationRevenueMember_be9dd7ff-41eb-4062-964f-6087a4dd5f88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_11b2e3ff-6336-4247-96b2-4706701e0ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4ef3846-4320-4c51-9f64-4ac272f57033" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_11b2e3ff-6336-4247-96b2-4706701e0ced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_094ba517-a900-46ec-b2c3-58f0a3dcac4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4ef3846-4320-4c51-9f64-4ac272f57033" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_094ba517-a900-46ec-b2c3-58f0a3dcac4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CostOfGoodsSoldMember_caf3a9e1-9524-48e6-adac-260dfe5f6b1e" xlink:href="regn-20210930.xsd#regn_CostOfGoodsSoldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4ef3846-4320-4c51-9f64-4ac272f57033" xlink:to="loc_regn_CostOfGoodsSoldMember_caf3a9e1-9524-48e6-adac-260dfe5f6b1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_9c670c25-7a83-4c28-a734-edd9f0946d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4ef3846-4320-4c51-9f64-4ac272f57033" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_9c670c25-7a83-4c28-a734-edd9f0946d51" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_830328d5-cc41-4eb9-8ca1-b9a5c0cef749" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_483e0d20-1747-46d3-9cf5-500ed3e327cc" xlink:to="loc_srt_ProductOrServiceAxis_830328d5-cc41-4eb9-8ca1-b9a5c0cef749" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_830328d5-cc41-4eb9-8ca1-b9a5c0cef749_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_830328d5-cc41-4eb9-8ca1-b9a5c0cef749" xlink:to="loc_srt_ProductsAndServicesDomain_830328d5-cc41-4eb9-8ca1-b9a5c0cef749_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_830328d5-cc41-4eb9-8ca1-b9a5c0cef749" xlink:to="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_4131a729-2e6f-4f43-bb5b-4d22d65f3e4e" xlink:href="regn-20210930.xsd#regn_ShareOfProfitLossesInConnectionWithCommercializationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_4131a729-2e6f-4f43-bb5b-4d22d65f3e4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneEarnedMember_3986522d-99cb-4ba6-a35c-62d5d3d8f806" xlink:href="regn-20210930.xsd#regn_SalesBasedMilestoneEarnedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_SalesBasedMilestoneEarnedMember_3986522d-99cb-4ba6-a35c-62d5d3d8f806" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_5a9518f5-0d6d-4dd2-b678-88ef62035adb" xlink:href="regn-20210930.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_5a9518f5-0d6d-4dd2-b678-88ef62035adb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_c3ef2b30-db45-402c-ab37-e4dbb49f7a85" xlink:href="regn-20210930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_c3ef2b30-db45-402c-ab37-e4dbb49f7a85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_e4c68882-8d88-4639-89c8-c4219f3caa24" xlink:href="regn-20210930.xsd#regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_e4c68882-8d88-4639-89c8-c4219f3caa24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_7f375cb8-5ac4-4bb0-84db-8ae08463f43d" xlink:href="regn-20210930.xsd#regn_ReimbursementOfCommercializationRelatedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_7f375cb8-5ac4-4bb0-84db-8ae08463f43d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfCommercialExpensesMember_4170f75e-e0c6-428a-9150-05a3e72ab63c" xlink:href="regn-20210930.xsd#regn_RegeneronsShareOfCommercialExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_RegeneronsShareOfCommercialExpensesMember_4170f75e-e0c6-428a-9150-05a3e72ab63c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_af091665-def9-4f06-9326-525ac81f5ef6" xlink:href="regn-20210930.xsd#regn_SanofisShareofLibtayoU.S.GrossProfitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_af091665-def9-4f06-9326-525ac81f5ef6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_e5d163e5-a0b1-4f98-aed1-0e68b77d774a" xlink:href="regn-20210930.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_e5d163e5-a0b1-4f98-aed1-0e68b77d774a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6e942bfb-cd37-492f-b5d6-37e53dd1c06d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_483e0d20-1747-46d3-9cf5-500ed3e327cc" xlink:to="loc_srt_StatementGeographicalAxis_6e942bfb-cd37-492f-b5d6-37e53dd1c06d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6e942bfb-cd37-492f-b5d6-37e53dd1c06d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6e942bfb-cd37-492f-b5d6-37e53dd1c06d" xlink:to="loc_srt_SegmentGeographicalDomain_6e942bfb-cd37-492f-b5d6-37e53dd1c06d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d45d233b-7f1c-44f3-b80a-15ae120e6ebb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6e942bfb-cd37-492f-b5d6-37e53dd1c06d" xlink:to="loc_srt_SegmentGeographicalDomain_d45d233b-7f1c-44f3-b80a-15ae120e6ebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_f0b8a03e-2128-4721-abd5-af44488d6172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d45d233b-7f1c-44f3-b80a-15ae120e6ebb" xlink:to="loc_us-gaap_NonUsMember_f0b8a03e-2128-4721-abd5-af44488d6172" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="extended" id="i3e148531f91f463fb662a7fa8c9115a2_CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_9335d1de-4e4c-4712-8947-40b02c5eab40" xlink:href="regn-20210930.xsd#regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_9335d1de-4e4c-4712-8947-40b02c5eab40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e5ad8dfc-bf31-45e5-8c76-a54c4e77fc66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e5ad8dfc-bf31-45e5-8c76-a54c4e77fc66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived_3bab8398-87a5-4c77-8b29-9804841f39cf" xlink:href="regn-20210930.xsd#regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived_3bab8398-87a5-4c77-8b29-9804841f39cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_5ddd64a4-8a4f-4a5c-8069-b5546f710a10" xlink:href="regn-20210930.xsd#regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_5ddd64a4-8a4f-4a5c-8069-b5546f710a10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_d55da772-e399-438f-ad23-2d2c5b86aef1" xlink:href="regn-20210930.xsd#regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_d55da772-e399-438f-ad23-2d2c5b86aef1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_bb6e6c33-0dad-43bf-bfb4-5993e87ce9ae" xlink:href="regn-20210930.xsd#regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_bb6e6c33-0dad-43bf-bfb4-5993e87ce9ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_378db7c9-f1fc-40f6-addc-5808e5d4bc65" xlink:href="regn-20210930.xsd#regn_PercentageOfRoyaltyPaymentThatCanBeOffset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_378db7c9-f1fc-40f6-addc-5808e5d4bc65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor_77cfd26b-d74d-4ab3-9133-706237cacdc9" xlink:href="regn-20210930.xsd#regn_LossContingencyPercentageOfDamagesResponsibleFor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor_77cfd26b-d74d-4ab3-9133-706237cacdc9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b15be8ad-e952-4e13-ac54-da27883bc3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b15be8ad-e952-4e13-ac54-da27883bc3e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_f1306f41-6416-496c-a9a9-19c489cdbe37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b15be8ad-e952-4e13-ac54-da27883bc3e4" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_f1306f41-6416-496c-a9a9-19c489cdbe37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_f1306f41-6416-496c-a9a9-19c489cdbe37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_f1306f41-6416-496c-a9a9-19c489cdbe37" xlink:to="loc_us-gaap_ProjectMember_f1306f41-6416-496c-a9a9-19c489cdbe37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_01224434-57b8-46e0-b51a-52f1b475fa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_f1306f41-6416-496c-a9a9-19c489cdbe37" xlink:to="loc_us-gaap_ProjectMember_01224434-57b8-46e0-b51a-52f1b475fa6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_24c02cdb-ed06-4b44-a876-2b05f3ef2fe7" xlink:href="regn-20210930.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_01224434-57b8-46e0-b51a-52f1b475fa6d" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_24c02cdb-ed06-4b44-a876-2b05f3ef2fe7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_5212544e-4681-403f-8077-03b5552164d7" xlink:href="regn-20210930.xsd#regn_PraluentCrossLicenseAndCommercializationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_01224434-57b8-46e0-b51a-52f1b475fa6d" xlink:to="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_5212544e-4681-403f-8077-03b5552164d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9e0ff294-90d5-4378-96f5-8e4a4c27b854" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b15be8ad-e952-4e13-ac54-da27883bc3e4" xlink:to="loc_srt_RangeAxis_9e0ff294-90d5-4378-96f5-8e4a4c27b854" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e0ff294-90d5-4378-96f5-8e4a4c27b854_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9e0ff294-90d5-4378-96f5-8e4a4c27b854" xlink:to="loc_srt_RangeMember_9e0ff294-90d5-4378-96f5-8e4a4c27b854_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_20c3138f-3a1f-4836-a2db-d4daa12ee3bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9e0ff294-90d5-4378-96f5-8e4a4c27b854" xlink:to="loc_srt_RangeMember_20c3138f-3a1f-4836-a2db-d4daa12ee3bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_20adbb5c-4277-4bc4-805a-7335260eea59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_20c3138f-3a1f-4836-a2db-d4daa12ee3bc" xlink:to="loc_srt_MinimumMember_20adbb5c-4277-4bc4-805a-7335260eea59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_31a403bd-2e14-413e-a744-8000ac5c0039" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_20c3138f-3a1f-4836-a2db-d4daa12ee3bc" xlink:to="loc_srt_MaximumMember_31a403bd-2e14-413e-a744-8000ac5c0039" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a238f593-21f6-468f-8b5c-a740fab4c287" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b15be8ad-e952-4e13-ac54-da27883bc3e4" xlink:to="loc_dei_LegalEntityAxis_a238f593-21f6-468f-8b5c-a740fab4c287" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a238f593-21f6-468f-8b5c-a740fab4c287_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a238f593-21f6-468f-8b5c-a740fab4c287" xlink:to="loc_dei_EntityDomain_a238f593-21f6-468f-8b5c-a740fab4c287_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_46a2b86e-8e5b-422b-b77f-63ad717c40e3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a238f593-21f6-468f-8b5c-a740fab4c287" xlink:to="loc_dei_EntityDomain_46a2b86e-8e5b-422b-b77f-63ad717c40e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_ad5051e6-f36f-4c08-ada3-a716395175a0" xlink:href="regn-20210930.xsd#regn_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_46a2b86e-8e5b-422b-b77f-63ad717c40e3" xlink:to="loc_regn_SanofiMember_ad5051e6-f36f-4c08-ada3-a716395175a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesAxis_b367edf9-6a76-4d49-ba97-4186131282ad" xlink:href="regn-20210930.xsd#regn_SalesMilestonesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b15be8ad-e952-4e13-ac54-da27883bc3e4" xlink:to="loc_regn_SalesMilestonesAxis_b367edf9-6a76-4d49-ba97-4186131282ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesDomain_b367edf9-6a76-4d49-ba97-4186131282ad_default" xlink:href="regn-20210930.xsd#regn_SalesMilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_regn_SalesMilestonesAxis_b367edf9-6a76-4d49-ba97-4186131282ad" xlink:to="loc_regn_SalesMilestonesDomain_b367edf9-6a76-4d49-ba97-4186131282ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesDomain_724729e2-f275-4afb-a015-f128549cdbf5" xlink:href="regn-20210930.xsd#regn_SalesMilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_regn_SalesMilestonesAxis_b367edf9-6a76-4d49-ba97-4186131282ad" xlink:to="loc_regn_SalesMilestonesDomain_724729e2-f275-4afb-a015-f128549cdbf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneOneMember_b49415e8-db1f-4cbc-bb41-53e02f6c4d7a" xlink:href="regn-20210930.xsd#regn_SalesMilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_SalesMilestonesDomain_724729e2-f275-4afb-a015-f128549cdbf5" xlink:to="loc_regn_SalesMilestoneOneMember_b49415e8-db1f-4cbc-bb41-53e02f6c4d7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneTwoMember_bd47c6fa-358f-4f58-8dce-82e0b078db84" xlink:href="regn-20210930.xsd#regn_SalesMilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_SalesMilestonesDomain_724729e2-f275-4afb-a015-f128549cdbf5" xlink:to="loc_regn_SalesMilestoneTwoMember_bd47c6fa-358f-4f58-8dce-82e0b078db84" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" xlink:type="extended" id="i14504eae3bdb4c3cad25543a1b4b26e4_CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c90e9cc8-65b0-4f6f-9dfe-3a9d21ba229e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_68cf2e5a-a2b4-45de-8a36-722e2a4e07c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c90e9cc8-65b0-4f6f-9dfe-3a9d21ba229e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_68cf2e5a-a2b4-45de-8a36-722e2a4e07c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_af1e0e64-5a13-4d77-b7ae-5bb3e488146c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c90e9cc8-65b0-4f6f-9dfe-3a9d21ba229e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_af1e0e64-5a13-4d77-b7ae-5bb3e488146c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_98140b39-5fb8-4cfe-8504-b8bef92ac476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c90e9cc8-65b0-4f6f-9dfe-3a9d21ba229e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_98140b39-5fb8-4cfe-8504-b8bef92ac476" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_86850399-0443-45b8-86ad-8900d0f856db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_98140b39-5fb8-4cfe-8504-b8bef92ac476" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_86850399-0443-45b8-86ad-8900d0f856db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_86850399-0443-45b8-86ad-8900d0f856db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_86850399-0443-45b8-86ad-8900d0f856db" xlink:to="loc_us-gaap_ProjectMember_86850399-0443-45b8-86ad-8900d0f856db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_c7db4e28-fc55-4d27-a4da-41f4c6946cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_86850399-0443-45b8-86ad-8900d0f856db" xlink:to="loc_us-gaap_ProjectMember_c7db4e28-fc55-4d27-a4da-41f4c6946cfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_1bfeb826-4a1d-433e-8cfd-f4d7d43e7cb1" xlink:href="regn-20210930.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_c7db4e28-fc55-4d27-a4da-41f4c6946cfc" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_1bfeb826-4a1d-433e-8cfd-f4d7d43e7cb1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails" xlink:type="extended" id="i8fdbf9c1988045238e9a174ba0fd2a8b_CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_46a25883-347c-4c2e-a3f7-d121cf44b339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_10d55f44-2269-4645-ac11-618ac95c26d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_46a25883-347c-4c2e-a3f7-d121cf44b339" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_10d55f44-2269-4645-ac11-618ac95c26d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cf754a14-1b05-4507-aa74-02f5b4561af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_46a25883-347c-4c2e-a3f7-d121cf44b339" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cf754a14-1b05-4507-aa74-02f5b4561af7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_b0aa5e7f-1861-4476-b404-73ba7c895799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_46a25883-347c-4c2e-a3f7-d121cf44b339" xlink:to="loc_us-gaap_OtherLiabilities_b0aa5e7f-1861-4476-b404-73ba7c895799" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_09b538d7-a401-42e2-bb75-a90bcd427f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_46a25883-347c-4c2e-a3f7-d121cf44b339" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_09b538d7-a401-42e2-bb75-a90bcd427f7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_a8858ebf-31e5-488a-8f88-d7b6254a8826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_09b538d7-a401-42e2-bb75-a90bcd427f7f" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_a8858ebf-31e5-488a-8f88-d7b6254a8826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_a8858ebf-31e5-488a-8f88-d7b6254a8826_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_a8858ebf-31e5-488a-8f88-d7b6254a8826" xlink:to="loc_us-gaap_ProjectMember_a8858ebf-31e5-488a-8f88-d7b6254a8826_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_a641476b-8711-4920-8245-e1e893c803ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_a8858ebf-31e5-488a-8f88-d7b6254a8826" xlink:to="loc_us-gaap_ProjectMember_a641476b-8711-4920-8245-e1e893c803ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_67b8a2ef-a2d1-4d49-ac50-aa0209f435b7" xlink:href="regn-20210930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_a641476b-8711-4920-8245-e1e893c803ea" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_67b8a2ef-a2d1-4d49-ac50-aa0209f435b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="extended" id="i61fd8c2fb5c444c4a1deae1b948da994_CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3d703495-ce4f-4dab-b387-c4da571c726e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_253fc6b2-306c-4420-8b7b-501189f552bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d703495-ce4f-4dab-b387-c4da571c726e" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_253fc6b2-306c-4420-8b7b-501189f552bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_fc7f97a1-270f-4733-92ae-5454ec4b8f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d703495-ce4f-4dab-b387-c4da571c726e" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_fc7f97a1-270f-4733-92ae-5454ec4b8f4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5bf6758b-4eb2-42f7-956a-7f1f89e7f2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d703495-ce4f-4dab-b387-c4da571c726e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5bf6758b-4eb2-42f7-956a-7f1f89e7f2e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7d7de780-67c5-489d-849d-70f5b6ce69d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5bf6758b-4eb2-42f7-956a-7f1f89e7f2e3" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7d7de780-67c5-489d-849d-70f5b6ce69d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_7d7de780-67c5-489d-849d-70f5b6ce69d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7d7de780-67c5-489d-849d-70f5b6ce69d6" xlink:to="loc_us-gaap_ProjectMember_7d7de780-67c5-489d-849d-70f5b6ce69d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_55b3e75f-98c1-4272-85c7-06c762179d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7d7de780-67c5-489d-849d-70f5b6ce69d6" xlink:to="loc_us-gaap_ProjectMember_55b3e75f-98c1-4272-85c7-06c762179d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_89dd33cf-312f-48a1-b858-f52a6129e23d" xlink:href="regn-20210930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_55b3e75f-98c1-4272-85c7-06c762179d20" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_89dd33cf-312f-48a1-b858-f52a6129e23d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsBayerNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" xlink:type="extended" id="i1b5cfbb582994b1aac3691968f66c601_CollaborationLicenseandOtherAgreementsBayerNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_43fc90a7-499c-460a-ad8a-f048a04e9cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan_e5670335-8294-4e42-af96-d2c0dca36929" xlink:href="regn-20210930.xsd#regn_RevenueBasedOnPercentageOfAnnualSalesInJapan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_43fc90a7-499c-460a-ad8a-f048a04e9cd7" xlink:to="loc_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan_e5670335-8294-4e42-af96-d2c0dca36929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3a95e576-0584-4544-a7e6-e7464fd84b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_43fc90a7-499c-460a-ad8a-f048a04e9cd7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3a95e576-0584-4544-a7e6-e7464fd84b23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_05717a8d-20d8-4291-b384-43d8063c3872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3a95e576-0584-4544-a7e6-e7464fd84b23" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_05717a8d-20d8-4291-b384-43d8063c3872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_05717a8d-20d8-4291-b384-43d8063c3872_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_05717a8d-20d8-4291-b384-43d8063c3872" xlink:to="loc_us-gaap_ProjectMember_05717a8d-20d8-4291-b384-43d8063c3872_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_f712c7c8-d0d0-47eb-859b-02815812a1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_05717a8d-20d8-4291-b384-43d8063c3872" xlink:to="loc_us-gaap_ProjectMember_f712c7c8-d0d0-47eb-859b-02815812a1b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_eff649cd-475d-423c-a288-e6a5484b9ae3" xlink:href="regn-20210930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_f712c7c8-d0d0-47eb-859b-02815812a1b0" xlink:to="loc_regn_BayerCollaborationAgreementMember_eff649cd-475d-423c-a288-e6a5484b9ae3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_526dfe15-89e9-4224-942a-04da924fd081" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3a95e576-0584-4544-a7e6-e7464fd84b23" xlink:to="loc_srt_RangeAxis_526dfe15-89e9-4224-942a-04da924fd081" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_526dfe15-89e9-4224-942a-04da924fd081_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_526dfe15-89e9-4224-942a-04da924fd081" xlink:to="loc_srt_RangeMember_526dfe15-89e9-4224-942a-04da924fd081_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eac56747-3e72-4d80-9b4e-5ea7f53bad68" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_526dfe15-89e9-4224-942a-04da924fd081" xlink:to="loc_srt_RangeMember_eac56747-3e72-4d80-9b4e-5ea7f53bad68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bdcfd406-25dc-4618-844c-0e348a1d5957" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eac56747-3e72-4d80-9b4e-5ea7f53bad68" xlink:to="loc_srt_MinimumMember_bdcfd406-25dc-4618-844c-0e348a1d5957" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f7416214-33cf-4980-9033-d4e8741da5dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eac56747-3e72-4d80-9b4e-5ea7f53bad68" xlink:to="loc_srt_MaximumMember_f7416214-33cf-4980-9033-d4e8741da5dc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" xlink:type="extended" id="i6d2aade9725e4cf182528d3a66bdeac2_CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6934104b-3f7f-487a-88c3-348c59ca5787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8447e21a-8b8c-44ce-b8cc-16db7fdda289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6934104b-3f7f-487a-88c3-348c59ca5787" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8447e21a-8b8c-44ce-b8cc-16db7fdda289" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_152325dd-d670-4530-8a46-771dd692e4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6934104b-3f7f-487a-88c3-348c59ca5787" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_152325dd-d670-4530-8a46-771dd692e4a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2a5787e4-1b6e-4c2c-8683-cfea720bf2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_152325dd-d670-4530-8a46-771dd692e4a6" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2a5787e4-1b6e-4c2c-8683-cfea720bf2c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_2a5787e4-1b6e-4c2c-8683-cfea720bf2c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2a5787e4-1b6e-4c2c-8683-cfea720bf2c7" xlink:to="loc_us-gaap_ProjectMember_2a5787e4-1b6e-4c2c-8683-cfea720bf2c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_00e81a7d-a330-41cf-ba0b-225c36bc404f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2a5787e4-1b6e-4c2c-8683-cfea720bf2c7" xlink:to="loc_us-gaap_ProjectMember_00e81a7d-a330-41cf-ba0b-225c36bc404f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_99312532-9835-4878-9b83-2ad0713d635b" xlink:href="regn-20210930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_00e81a7d-a330-41cf-ba0b-225c36bc404f" xlink:to="loc_regn_BayerCollaborationAgreementMember_99312532-9835-4878-9b83-2ad0713d635b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7f3792c7-2c7e-4744-bcca-3931e4a451f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_152325dd-d670-4530-8a46-771dd692e4a6" xlink:to="loc_srt_StatementGeographicalAxis_7f3792c7-2c7e-4744-bcca-3931e4a451f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7f3792c7-2c7e-4744-bcca-3931e4a451f3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7f3792c7-2c7e-4744-bcca-3931e4a451f3" xlink:to="loc_srt_SegmentGeographicalDomain_7f3792c7-2c7e-4744-bcca-3931e4a451f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1bff1796-06f9-40fc-b6d2-4627fb8d4aae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7f3792c7-2c7e-4744-bcca-3931e4a451f3" xlink:to="loc_srt_SegmentGeographicalDomain_1bff1796-06f9-40fc-b6d2-4627fb8d4aae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_96d47d4c-e6bd-4326-8312-1b4def092f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1bff1796-06f9-40fc-b6d2-4627fb8d4aae" xlink:to="loc_us-gaap_NonUsMember_96d47d4c-e6bd-4326-8312-1b4def092f2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ae3474e8-e33a-48f8-91a4-2f103186da9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_152325dd-d670-4530-8a46-771dd692e4a6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ae3474e8-e33a-48f8-91a4-2f103186da9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ae3474e8-e33a-48f8-91a4-2f103186da9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ae3474e8-e33a-48f8-91a4-2f103186da9e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ae3474e8-e33a-48f8-91a4-2f103186da9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_151c7aaf-6191-4389-a231-d8f73af43035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ae3474e8-e33a-48f8-91a4-2f103186da9e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_151c7aaf-6191-4389-a231-d8f73af43035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_6aadadea-c9d8-44ce-8e39-5f6a1054e504" xlink:href="regn-20210930.xsd#regn_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_151c7aaf-6191-4389-a231-d8f73af43035" xlink:to="loc_regn_CollaborationRevenueMember_6aadadea-c9d8-44ce-8e39-5f6a1054e504" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c057a775-4b66-4126-baae-6f04cf80a803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_151c7aaf-6191-4389-a231-d8f73af43035" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c057a775-4b66-4126-baae-6f04cf80a803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5aacf1bf-8d2a-408a-86f0-abc54b1f9f18" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_152325dd-d670-4530-8a46-771dd692e4a6" xlink:to="loc_srt_ProductOrServiceAxis_5aacf1bf-8d2a-408a-86f0-abc54b1f9f18" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5aacf1bf-8d2a-408a-86f0-abc54b1f9f18_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5aacf1bf-8d2a-408a-86f0-abc54b1f9f18" xlink:to="loc_srt_ProductsAndServicesDomain_5aacf1bf-8d2a-408a-86f0-abc54b1f9f18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8a7daff2-4ebc-40b2-97f9-1ae21b3debe8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5aacf1bf-8d2a-408a-86f0-abc54b1f9f18" xlink:to="loc_srt_ProductsAndServicesDomain_8a7daff2-4ebc-40b2-97f9-1ae21b3debe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NetProfitInConnectionWithCommercializationMember_91084d0f-0b3f-4bb0-9bfd-91912869400a" xlink:href="regn-20210930.xsd#regn_NetProfitInConnectionWithCommercializationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a7daff2-4ebc-40b2-97f9-1ae21b3debe8" xlink:to="loc_regn_NetProfitInConnectionWithCommercializationMember_91084d0f-0b3f-4bb0-9bfd-91912869400a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_9b6a9f41-2ed3-44da-9437-fb6489c8a0be" xlink:href="regn-20210930.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a7daff2-4ebc-40b2-97f9-1ae21b3debe8" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_9b6a9f41-2ed3-44da-9437-fb6489c8a0be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_7ba3e326-e975-487d-80e5-8b8f3fb85d3f" xlink:href="regn-20210930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a7daff2-4ebc-40b2-97f9-1ae21b3debe8" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_7ba3e326-e975-487d-80e5-8b8f3fb85d3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_d051a517-fd91-41c1-9b68-a92cfd1729a0" xlink:href="regn-20210930.xsd#regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a7daff2-4ebc-40b2-97f9-1ae21b3debe8" xlink:to="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_d051a517-fd91-41c1-9b68-a92cfd1729a0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" xlink:type="extended" id="i78a1f5de0f6146e3bf4f7946092ce3e7_CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2fa3abe8-605c-449a-bf18-375af403436e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_72e8d218-e428-4c10-8f3e-a971e2ef0ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2fa3abe8-605c-449a-bf18-375af403436e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_72e8d218-e428-4c10-8f3e-a971e2ef0ef8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c6ed5fa2-b81b-4711-9645-7322769cea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2fa3abe8-605c-449a-bf18-375af403436e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c6ed5fa2-b81b-4711-9645-7322769cea5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_efac2159-e762-4734-b006-24597034b9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2fa3abe8-605c-449a-bf18-375af403436e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_efac2159-e762-4734-b006-24597034b9c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b0874ea2-a1ec-4c52-9703-5c79e1760b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_efac2159-e762-4734-b006-24597034b9c6" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b0874ea2-a1ec-4c52-9703-5c79e1760b96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_b0874ea2-a1ec-4c52-9703-5c79e1760b96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b0874ea2-a1ec-4c52-9703-5c79e1760b96" xlink:to="loc_us-gaap_ProjectMember_b0874ea2-a1ec-4c52-9703-5c79e1760b96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_ff004896-2725-43bb-8827-9c8b50e6976a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b0874ea2-a1ec-4c52-9703-5c79e1760b96" xlink:to="loc_us-gaap_ProjectMember_ff004896-2725-43bb-8827-9c8b50e6976a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_5d280ae1-d395-4541-8984-c8de4e0181d7" xlink:href="regn-20210930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_ff004896-2725-43bb-8827-9c8b50e6976a" xlink:to="loc_regn_BayerCollaborationAgreementMember_5d280ae1-d395-4541-8984-c8de4e0181d7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" xlink:type="extended" id="i2059862d86ea494ea8c898ff3f11e855_CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0509eaaa-4a7c-42a3-9823-564bcda4c228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_be3ae7d3-27e4-4b9b-aa70-6aa3dbd90976" xlink:href="regn-20210930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0509eaaa-4a7c-42a3-9823-564bcda4c228" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_be3ae7d3-27e4-4b9b-aa70-6aa3dbd90976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_9e668d64-a695-498f-aeb0-25dd8852377c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0509eaaa-4a7c-42a3-9823-564bcda4c228" xlink:to="loc_us-gaap_OtherOperatingIncome_9e668d64-a695-498f-aeb0-25dd8852377c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d6c337b9-b967-4b05-a42d-dfa23988c742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0509eaaa-4a7c-42a3-9823-564bcda4c228" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d6c337b9-b967-4b05-a42d-dfa23988c742" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_65e6d5ce-6e31-44e0-8233-2ccffea7152a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d6c337b9-b967-4b05-a42d-dfa23988c742" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_65e6d5ce-6e31-44e0-8233-2ccffea7152a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_65e6d5ce-6e31-44e0-8233-2ccffea7152a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_65e6d5ce-6e31-44e0-8233-2ccffea7152a" xlink:to="loc_us-gaap_ProjectMember_65e6d5ce-6e31-44e0-8233-2ccffea7152a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_8643d75e-0e2a-4cfe-bca3-ce010ba30325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_65e6d5ce-6e31-44e0-8233-2ccffea7152a" xlink:to="loc_us-gaap_ProjectMember_8643d75e-0e2a-4cfe-bca3-ce010ba30325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_46b72348-4e55-4d88-8c36-ed044471b976" xlink:href="regn-20210930.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_8643d75e-0e2a-4cfe-bca3-ce010ba30325" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_46b72348-4e55-4d88-8c36-ed044471b976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c2084df3-4970-4a7c-8c5c-30fde81a1b6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d6c337b9-b967-4b05-a42d-dfa23988c742" xlink:to="loc_srt_ProductOrServiceAxis_c2084df3-4970-4a7c-8c5c-30fde81a1b6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c2084df3-4970-4a7c-8c5c-30fde81a1b6e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c2084df3-4970-4a7c-8c5c-30fde81a1b6e" xlink:to="loc_srt_ProductsAndServicesDomain_c2084df3-4970-4a7c-8c5c-30fde81a1b6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3c922605-2270-47ef-8169-bc8001e224f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c2084df3-4970-4a7c-8c5c-30fde81a1b6e" xlink:to="loc_srt_ProductsAndServicesDomain_3c922605-2270-47ef-8169-bc8001e224f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_fb8734c3-a12c-449c-a4df-4cba1dc146e2" xlink:href="regn-20210930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3c922605-2270-47ef-8169-bc8001e224f1" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_fb8734c3-a12c-449c-a4df-4cba1dc146e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_a2e270b2-99aa-409e-9897-b2651ad9724a" xlink:href="regn-20210930.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3c922605-2270-47ef-8169-bc8001e224f1" xlink:to="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_a2e270b2-99aa-409e-9897-b2651ad9724a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_83713259-a74d-42e3-9992-0e7553cf3030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d6c337b9-b967-4b05-a42d-dfa23988c742" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_83713259-a74d-42e3-9992-0e7553cf3030" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_83713259-a74d-42e3-9992-0e7553cf3030_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_83713259-a74d-42e3-9992-0e7553cf3030" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_83713259-a74d-42e3-9992-0e7553cf3030_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bc125eb5-b1b2-4d34-acec-15f353ee8482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_83713259-a74d-42e3-9992-0e7553cf3030" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bc125eb5-b1b2-4d34-acec-15f353ee8482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8790cee9-2416-4553-9a34-6dc2f1d6361d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc125eb5-b1b2-4d34-acec-15f353ee8482" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8790cee9-2416-4553-9a34-6dc2f1d6361d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_32ae4811-1639-40c3-91da-8903132e3d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc125eb5-b1b2-4d34-acec-15f353ee8482" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_32ae4811-1639-40c3-91da-8903132e3d00" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" xlink:type="extended" id="i3195725d212f4df8bc4050479bec4dea_CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8c02b95d-041e-4a8b-bdaf-ea001975249a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a8bcc767-92e4-46f4-8495-0ae8da46a0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8c02b95d-041e-4a8b-bdaf-ea001975249a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a8bcc767-92e4-46f4-8495-0ae8da46a0e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_5b32f06f-5307-4a7a-8fc6-b666232431fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8c02b95d-041e-4a8b-bdaf-ea001975249a" xlink:to="loc_us-gaap_OtherLiabilities_5b32f06f-5307-4a7a-8fc6-b666232431fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_22d6a6be-888b-471c-807d-3d1c0098e237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8c02b95d-041e-4a8b-bdaf-ea001975249a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_22d6a6be-888b-471c-807d-3d1c0098e237" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0eb971f1-c414-490c-9a83-70d31e7b57c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_22d6a6be-888b-471c-807d-3d1c0098e237" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0eb971f1-c414-490c-9a83-70d31e7b57c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_0eb971f1-c414-490c-9a83-70d31e7b57c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0eb971f1-c414-490c-9a83-70d31e7b57c8" xlink:to="loc_us-gaap_ProjectMember_0eb971f1-c414-490c-9a83-70d31e7b57c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_1ac6727f-7f05-4add-8bff-0303e30e130c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0eb971f1-c414-490c-9a83-70d31e7b57c8" xlink:to="loc_us-gaap_ProjectMember_1ac6727f-7f05-4add-8bff-0303e30e130c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_6ee387d5-ec57-4968-9861-50d7b8e01cf5" xlink:href="regn-20210930.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_1ac6727f-7f05-4add-8bff-0303e30e130c" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_6ee387d5-ec57-4968-9861-50d7b8e01cf5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" xlink:type="extended" id="i5652273ef2a84b16b68b341945f306e0_CollaborationLicenseandOtherAgreementsTevaNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_949c24da-95af-458e-9dae-1584f0324eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_3274dd43-51e0-4c2a-a4dc-ce3a798c142e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_949c24da-95af-458e-9dae-1584f0324eee" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_3274dd43-51e0-4c2a-a4dc-ce3a798c142e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b2761d97-ebbc-4719-9968-f123f6df9ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_949c24da-95af-458e-9dae-1584f0324eee" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b2761d97-ebbc-4719-9968-f123f6df9ca2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_811092b8-aa83-4f05-b40a-97a8d4fa92f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b2761d97-ebbc-4719-9968-f123f6df9ca2" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_811092b8-aa83-4f05-b40a-97a8d4fa92f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_811092b8-aa83-4f05-b40a-97a8d4fa92f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_811092b8-aa83-4f05-b40a-97a8d4fa92f6" xlink:to="loc_us-gaap_ProjectMember_811092b8-aa83-4f05-b40a-97a8d4fa92f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_2e6b8cac-36b0-4add-98c7-95fc22dd4841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_811092b8-aa83-4f05-b40a-97a8d4fa92f6" xlink:to="loc_us-gaap_ProjectMember_2e6b8cac-36b0-4add-98c7-95fc22dd4841" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_ca9b61d9-7139-4f1f-bef4-e6c10c4eb8e0" xlink:href="regn-20210930.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_2e6b8cac-36b0-4add-98c7-95fc22dd4841" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_ca9b61d9-7139-4f1f-bef4-e6c10c4eb8e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails" xlink:type="extended" id="icc5d2b7252b44e76979c81ab07c0ddcf_CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a2b01678-d24a-44d2-b81d-7dc3abd90005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase_1ec6f261-bbd0-4f99-afee-569e3be93c7b" xlink:href="regn-20210930.xsd#regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2b01678-d24a-44d2-b81d-7dc3abd90005" xlink:to="loc_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase_1ec6f261-bbd0-4f99-afee-569e3be93c7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumTransactionAgreementPayments_6c76c092-c902-4104-875d-7a8c54a9eea0" xlink:href="regn-20210930.xsd#regn_MaximumTransactionAgreementPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2b01678-d24a-44d2-b81d-7dc3abd90005" xlink:to="loc_regn_MaximumTransactionAgreementPayments_6c76c092-c902-4104-875d-7a8c54a9eea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b5b2131d-f861-4674-8e86-d02c972e2fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2b01678-d24a-44d2-b81d-7dc3abd90005" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b5b2131d-f861-4674-8e86-d02c972e2fe5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_28acb465-1866-4967-acbe-711334762fd2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5b2131d-f861-4674-8e86-d02c972e2fe5" xlink:to="loc_srt_ProductOrServiceAxis_28acb465-1866-4967-acbe-711334762fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_28acb465-1866-4967-acbe-711334762fd2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_28acb465-1866-4967-acbe-711334762fd2" xlink:to="loc_srt_ProductsAndServicesDomain_28acb465-1866-4967-acbe-711334762fd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7cd9cabb-b296-4328-b5e8-3ac6a74f125b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_28acb465-1866-4967-acbe-711334762fd2" xlink:to="loc_srt_ProductsAndServicesDomain_7cd9cabb-b296-4328-b5e8-3ac6a74f125b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_REGENCOVMember_1b60c075-3afa-44d4-b31b-407b0958c427" xlink:href="regn-20210930.xsd#regn_REGENCOVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7cd9cabb-b296-4328-b5e8-3ac6a74f125b" xlink:to="loc_regn_REGENCOVMember_1b60c075-3afa-44d4-b31b-407b0958c427" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4d50f479-0363-46d2-b74a-f44e0b461580" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5b2131d-f861-4674-8e86-d02c972e2fe5" xlink:to="loc_srt_CounterpartyNameAxis_4d50f479-0363-46d2-b74a-f44e0b461580" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d50f479-0363-46d2-b74a-f44e0b461580_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4d50f479-0363-46d2-b74a-f44e0b461580" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d50f479-0363-46d2-b74a-f44e0b461580_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9d794c5-5698-4ed5-a393-a0bb0ba804c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4d50f479-0363-46d2-b74a-f44e0b461580" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9d794c5-5698-4ed5-a393-a0bb0ba804c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_USGovernmentMember_1d4dcf3c-ba25-4a2d-b519-f8f4320905eb" xlink:href="regn-20210930.xsd#regn_USGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9d794c5-5698-4ed5-a393-a0bb0ba804c6" xlink:to="loc_regn_USGovernmentMember_1d4dcf3c-ba25-4a2d-b519-f8f4320905eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_73d1a01c-e812-480e-ba1b-cc0286101384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5b2131d-f861-4674-8e86-d02c972e2fe5" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_73d1a01c-e812-480e-ba1b-cc0286101384" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_73d1a01c-e812-480e-ba1b-cc0286101384_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_73d1a01c-e812-480e-ba1b-cc0286101384" xlink:to="loc_us-gaap_ProjectMember_73d1a01c-e812-480e-ba1b-cc0286101384_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_537ab54b-ac86-470e-9295-460e72f80c77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_73d1a01c-e812-480e-ba1b-cc0286101384" xlink:to="loc_us-gaap_ProjectMember_537ab54b-ac86-470e-9295-460e72f80c77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BARDAOtherTransactionAgreementMember_930f1e56-ef02-439a-8763-69d1f5cb2072" xlink:href="regn-20210930.xsd#regn_BARDAOtherTransactionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_537ab54b-ac86-470e-9295-460e72f80c77" xlink:to="loc_regn_BARDAOtherTransactionAgreementMember_930f1e56-ef02-439a-8763-69d1f5cb2072" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b34aef45-5132-4161-99cd-53e5061e7467" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5b2131d-f861-4674-8e86-d02c972e2fe5" xlink:to="loc_srt_StatementScenarioAxis_b34aef45-5132-4161-99cd-53e5061e7467" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b34aef45-5132-4161-99cd-53e5061e7467_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_b34aef45-5132-4161-99cd-53e5061e7467" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b34aef45-5132-4161-99cd-53e5061e7467_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_621f0fdc-30fd-40be-b333-eba0fc295704" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_b34aef45-5132-4161-99cd-53e5061e7467" xlink:to="loc_srt_ScenarioUnspecifiedDomain_621f0fdc-30fd-40be-b333-eba0fc295704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b5b70908-37aa-4fd7-baa1-9e6c33789551" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_621f0fdc-30fd-40be-b333-eba0fc295704" xlink:to="loc_srt_ScenarioForecastMember_b5b70908-37aa-4fd7-baa1-9e6c33789551" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails" xlink:type="extended" id="i3164c215dd4a4d7a841bc3f9c0e188a7_CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c08f061f-d46f-4257-ae0a-50061617c237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6887ca49-34b0-4cb8-b690-9f33329297e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c08f061f-d46f-4257-ae0a-50061617c237" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6887ca49-34b0-4cb8-b690-9f33329297e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_4df3c743-e207-4345-abd2-f2cb9bd03842" xlink:href="regn-20210930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c08f061f-d46f-4257-ae0a-50061617c237" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_4df3c743-e207-4345-abd2-f2cb9bd03842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_01e4431c-f741-4936-a69e-17f4c3dba204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c08f061f-d46f-4257-ae0a-50061617c237" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_01e4431c-f741-4936-a69e-17f4c3dba204" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c3217227-e1e0-4ba0-b59d-d38b8af7e7ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01e4431c-f741-4936-a69e-17f4c3dba204" xlink:to="loc_srt_ProductOrServiceAxis_c3217227-e1e0-4ba0-b59d-d38b8af7e7ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c3217227-e1e0-4ba0-b59d-d38b8af7e7ed_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c3217227-e1e0-4ba0-b59d-d38b8af7e7ed" xlink:to="loc_srt_ProductsAndServicesDomain_c3217227-e1e0-4ba0-b59d-d38b8af7e7ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_410a9305-9a27-4e20-8619-ef5afe8e01e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c3217227-e1e0-4ba0-b59d-d38b8af7e7ed" xlink:to="loc_srt_ProductsAndServicesDomain_410a9305-9a27-4e20-8619-ef5afe8e01e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CasirivimabAndImdevimabMember_2908d777-7d40-4049-9b00-e63e78e96a23" xlink:href="regn-20210930.xsd#regn_CasirivimabAndImdevimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_410a9305-9a27-4e20-8619-ef5afe8e01e2" xlink:to="loc_regn_CasirivimabAndImdevimabMember_2908d777-7d40-4049-9b00-e63e78e96a23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_40b6d3ec-c40b-446f-bad7-3137d049e836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01e4431c-f741-4936-a69e-17f4c3dba204" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_40b6d3ec-c40b-446f-bad7-3137d049e836" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_40b6d3ec-c40b-446f-bad7-3137d049e836_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_40b6d3ec-c40b-446f-bad7-3137d049e836" xlink:to="loc_us-gaap_ProjectMember_40b6d3ec-c40b-446f-bad7-3137d049e836_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_5b814867-8a17-463f-86bc-2502b397ffc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_40b6d3ec-c40b-446f-bad7-3137d049e836" xlink:to="loc_us-gaap_ProjectMember_5b814867-8a17-463f-86bc-2502b397ffc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RocheCollaborationAgreementMember_5c51f9a3-d2db-488f-93d7-87e08e0ec8b8" xlink:href="regn-20210930.xsd#regn_RocheCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_5b814867-8a17-463f-86bc-2502b397ffc9" xlink:to="loc_regn_RocheCollaborationAgreementMember_5c51f9a3-d2db-488f-93d7-87e08e0ec8b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_26b687cd-4e3e-45b0-a312-5bccf9289236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01e4431c-f741-4936-a69e-17f4c3dba204" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_26b687cd-4e3e-45b0-a312-5bccf9289236" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_26b687cd-4e3e-45b0-a312-5bccf9289236_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_26b687cd-4e3e-45b0-a312-5bccf9289236" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_26b687cd-4e3e-45b0-a312-5bccf9289236_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_69b871bd-aa1b-4ca2-8aaa-ade679d111a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_26b687cd-4e3e-45b0-a312-5bccf9289236" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_69b871bd-aa1b-4ca2-8aaa-ade679d111a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_0beec5b8-cdd5-4538-8c84-0f8853a6c4a9" xlink:href="regn-20210930.xsd#regn_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_69b871bd-aa1b-4ca2-8aaa-ade679d111a7" xlink:to="loc_regn_CollaborationRevenueMember_0beec5b8-cdd5-4538-8c84-0f8853a6c4a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c3e9c2af-e3b5-4e9c-92d8-f2b5c7796302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_69b871bd-aa1b-4ca2-8aaa-ade679d111a7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c3e9c2af-e3b5-4e9c-92d8-f2b5c7796302" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails" xlink:type="extended" id="i7ccf4b23080b4ca582558f70f2a10ad6_CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_14e61258-7364-425c-8938-b0a2782296d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_50ff520e-ba1b-48e0-b18e-a7e0be098155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_14e61258-7364-425c-8938-b0a2782296d8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_50ff520e-ba1b-48e0-b18e-a7e0be098155" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_708b7acb-caff-4d56-ac9f-471535640869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_14e61258-7364-425c-8938-b0a2782296d8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_708b7acb-caff-4d56-ac9f-471535640869" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_70ba4c82-9e66-4298-b28d-13f7a30ce4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_708b7acb-caff-4d56-ac9f-471535640869" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_70ba4c82-9e66-4298-b28d-13f7a30ce4cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_70ba4c82-9e66-4298-b28d-13f7a30ce4cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_70ba4c82-9e66-4298-b28d-13f7a30ce4cd" xlink:to="loc_us-gaap_ProjectMember_70ba4c82-9e66-4298-b28d-13f7a30ce4cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_f25edd37-2c3b-4b36-b0f4-5e944d8afa23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_70ba4c82-9e66-4298-b28d-13f7a30ce4cd" xlink:to="loc_us-gaap_ProjectMember_f25edd37-2c3b-4b36-b0f4-5e944d8afa23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RocheCollaborationAgreementMember_ee2f91ff-4830-4a50-bc19-7435e3f9dc36" xlink:href="regn-20210930.xsd#regn_RocheCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_f25edd37-2c3b-4b36-b0f4-5e944d8afa23" xlink:to="loc_regn_RocheCollaborationAgreementMember_ee2f91ff-4830-4a50-bc19-7435e3f9dc36" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" xlink:type="extended" id="i362e51ccb22645d6aee4b9c51fb9a6fd_CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_68ba0235-d5de-415e-8601-b4c4d6261074" xlink:href="regn-20210930.xsd#regn_ResearchCollaborationAndLicensingArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementUpfrontPaymentMade_7a1fbf8e-060c-4446-8f72-4f94e31fddd3" xlink:href="regn-20210930.xsd#regn_CollaborativeArrangementUpfrontPaymentMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_68ba0235-d5de-415e-8601-b4c4d6261074" xlink:to="loc_regn_CollaborativeArrangementUpfrontPaymentMade_7a1fbf8e-060c-4446-8f72-4f94e31fddd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_63dff231-5c22-45b5-ac18-2e9ede4baa76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_68ba0235-d5de-415e-8601-b4c4d6261074" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_63dff231-5c22-45b5-ac18-2e9ede4baa76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ce66c761-f18f-4c56-b398-9811e964271e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_68ba0235-d5de-415e-8601-b4c4d6261074" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ce66c761-f18f-4c56-b398-9811e964271e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_1359cd70-613d-4547-9b51-087db83e4fac" xlink:href="regn-20210930.xsd#regn_ResearchCollaborationAndLicensingArrangementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_68ba0235-d5de-415e-8601-b4c4d6261074" xlink:to="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_1359cd70-613d-4547-9b51-087db83e4fac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ad90b634-07bc-4964-ae5a-6713b0666625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_1359cd70-613d-4547-9b51-087db83e4fac" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ad90b634-07bc-4964-ae5a-6713b0666625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_ad90b634-07bc-4964-ae5a-6713b0666625_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ad90b634-07bc-4964-ae5a-6713b0666625" xlink:to="loc_us-gaap_ProjectMember_ad90b634-07bc-4964-ae5a-6713b0666625_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_fc5c8341-38a4-4862-a508-33be41f06495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ad90b634-07bc-4964-ae5a-6713b0666625" xlink:to="loc_us-gaap_ProjectMember_fc5c8341-38a4-4862-a508-33be41f06495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_IntelliaMember_292da28b-0c1f-4270-83c0-8084c1813e95" xlink:href="regn-20210930.xsd#regn_IntelliaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_fc5c8341-38a4-4862-a508-33be41f06495" xlink:to="loc_regn_IntelliaMember_292da28b-0c1f-4270-83c0-8084c1813e95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c4ee5b62-c198-4385-894c-93500039f6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_1359cd70-613d-4547-9b51-087db83e4fac" xlink:to="loc_us-gaap_InvestmentTypeAxis_c4ee5b62-c198-4385-894c-93500039f6a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c4ee5b62-c198-4385-894c-93500039f6a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_c4ee5b62-c198-4385-894c-93500039f6a7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c4ee5b62-c198-4385-894c-93500039f6a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_096451ee-220f-4d5f-b97c-425726833aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_c4ee5b62-c198-4385-894c-93500039f6a7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_096451ee-220f-4d5f-b97c-425726833aa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0ed40abc-2186-4e14-98de-8fca5b163621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_096451ee-220f-4d5f-b97c-425726833aa7" xlink:to="loc_us-gaap_CommonStockMember_0ed40abc-2186-4e14-98de-8fca5b163621" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended" id="i18c2c43160d94664a609e5e6786113bd_NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_45a6d765-b326-4c02-9492-61e1a01c4030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:to="loc_us-gaap_NetIncomeLoss_45a6d765-b326-4c02-9492-61e1a01c4030" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b1060ab4-a1bd-434f-81c4-33c57fdfaccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b1060ab4-a1bd-434f-81c4-33c57fdfaccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_62c63c9a-c1c0-4e87-bb54-68d04d9d27ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_62c63c9a-c1c0-4e87-bb54-68d04d9d27ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_71cb599d-ab52-4eff-adc1-af89a72b0157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_71cb599d-ab52-4eff-adc1-af89a72b0157" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_27ed0ea5-82e3-43cf-b871-2903ea6a3bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:to="loc_us-gaap_EarningsPerShareBasic_27ed0ea5-82e3-43cf-b871-2903ea6a3bf8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_294607b8-3b54-4f5f-8a28-47f998831368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_294607b8-3b54-4f5f-8a28-47f998831368" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2729938f-1d60-4302-88bd-54d4ba17abd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2729938f-1d60-4302-88bd-54d4ba17abd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_83d61316-d512-4cf9-baca-623ca1261947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2729938f-1d60-4302-88bd-54d4ba17abd1" xlink:to="loc_us-gaap_AwardTypeAxis_83d61316-d512-4cf9-baca-623ca1261947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d61316-d512-4cf9-baca-623ca1261947_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_83d61316-d512-4cf9-baca-623ca1261947" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d61316-d512-4cf9-baca-623ca1261947_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ce02c87-435c-40e6-b254-4de4a4f56fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_83d61316-d512-4cf9-baca-623ca1261947" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ce02c87-435c-40e6-b254-4de4a4f56fcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_102a5386-d929-49ea-85ed-7677df64cb53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ce02c87-435c-40e6-b254-4de4a4f56fcf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_102a5386-d929-49ea-85ed-7677df64cb53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f130ce4a-81d3-4be8-b52d-30e002a8df1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ce02c87-435c-40e6-b254-4de4a4f56fcf" xlink:to="loc_us-gaap_RestrictedStockMember_f130ce4a-81d3-4be8-b52d-30e002a8df1f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="extended" id="iae7233cf83c749828795cd954792432e_NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0182f58b-a9ac-44a9-87c5-af1cab1bf7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_dc583c2a-a6f9-4f41-a478-820eff2ff1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0182f58b-a9ac-44a9-87c5-af1cab1bf7ff" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_dc583c2a-a6f9-4f41-a478-820eff2ff1d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d620452e-44f9-4305-977d-1f6b2ed496d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0182f58b-a9ac-44a9-87c5-af1cab1bf7ff" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d620452e-44f9-4305-977d-1f6b2ed496d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_92344ae0-e87b-434f-9769-92ae83fc1628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d620452e-44f9-4305-977d-1f6b2ed496d9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_92344ae0-e87b-434f-9769-92ae83fc1628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_92344ae0-e87b-434f-9769-92ae83fc1628_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_92344ae0-e87b-434f-9769-92ae83fc1628" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_92344ae0-e87b-434f-9769-92ae83fc1628_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d458410a-df33-4257-a9d8-43fd13d1a419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_92344ae0-e87b-434f-9769-92ae83fc1628" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d458410a-df33-4257-a9d8-43fd13d1a419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fa424d32-bc16-4a92-b249-fa10d5b24839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d458410a-df33-4257-a9d8-43fd13d1a419" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fa424d32-bc16-4a92-b249-fa10d5b24839" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="extended" id="i17f5a184d8d340c19f1e28a82c131150_MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_540e1363-a478-4951-963d-8195cc84024b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_17150823-8408-439f-b58f-92b49aa57aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_540e1363-a478-4951-963d-8195cc84024b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_17150823-8408-439f-b58f-92b49aa57aa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7c1f48d8-14a9-48ec-b5da-82df42df0941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_540e1363-a478-4951-963d-8195cc84024b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7c1f48d8-14a9-48ec-b5da-82df42df0941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ef859199-c102-44a0-94b4-8278a08d49ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_540e1363-a478-4951-963d-8195cc84024b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ef859199-c102-44a0-94b4-8278a08d49ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cf9270bd-086f-4f6e-ad67-77bf5ccf2220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_540e1363-a478-4951-963d-8195cc84024b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cf9270bd-086f-4f6e-ad67-77bf5ccf2220" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c86731e-5ccd-410f-8651-35f2225766b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_540e1363-a478-4951-963d-8195cc84024b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c86731e-5ccd-410f-8651-35f2225766b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0116be7e-7f16-441f-8618-eb9ec5e1de40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c86731e-5ccd-410f-8651-35f2225766b6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0116be7e-7f16-441f-8618-eb9ec5e1de40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0116be7e-7f16-441f-8618-eb9ec5e1de40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0116be7e-7f16-441f-8618-eb9ec5e1de40" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0116be7e-7f16-441f-8618-eb9ec5e1de40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0116be7e-7f16-441f-8618-eb9ec5e1de40" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_1fb5ab11-ac72-4cba-a276-24759f41e73c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_1fb5ab11-ac72-4cba-a276-24759f41e73c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_cfb2c1f1-ec38-48dc-916d-8985175b195c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_cfb2c1f1-ec38-48dc-916d-8985175b195c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_82556c70-bcb7-4e3e-96a4-8305a2de6c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_82556c70-bcb7-4e3e-96a4-8305a2de6c29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_acdad8ab-9a30-494f-ad1e-14ce6574802a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:to="loc_us-gaap_CommercialPaperMember_acdad8ab-9a30-494f-ad1e-14ce6574802a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_16ba73fa-3d7b-4af4-94d6-bf5417bf6623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:to="loc_us-gaap_CertificatesOfDepositMember_16ba73fa-3d7b-4af4-94d6-bf5417bf6623" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_ceff3069-e101-4713-88dc-5a5bdbaad5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_ceff3069-e101-4713-88dc-5a5bdbaad5b7" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="extended" id="ic27e9babeee940b6908ecf5ad24b648f_MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_380d00bd-01c1-4b1e-89c5-5a1f28eb1f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_380d00bd-01c1-4b1e-89c5-5a1f28eb1f25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a44ef326-4c49-4bd3-ace5-53acd1598c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a44ef326-4c49-4bd3-ace5-53acd1598c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_09555a91-a43c-40f0-92ef-e136011b7f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_09555a91-a43c-40f0-92ef-e136011b7f39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_81b94305-ea33-4726-a04d-1b1ea083b7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_81b94305-ea33-4726-a04d-1b1ea083b7f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2bfc2b27-8dad-472c-8c71-9e97321b572f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2bfc2b27-8dad-472c-8c71-9e97321b572f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f8581325-d7de-4632-8b68-86c3eff64c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f8581325-d7de-4632-8b68-86c3eff64c48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_53826df3-6036-4ca3-86c3-554e53c38da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_53826df3-6036-4ca3-86c3-554e53c38da1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5c793de4-bda0-4990-93a0-6d80bedc1c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_53826df3-6036-4ca3-86c3-554e53c38da1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5c793de4-bda0-4990-93a0-6d80bedc1c7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5c793de4-bda0-4990-93a0-6d80bedc1c7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5c793de4-bda0-4990-93a0-6d80bedc1c7b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5c793de4-bda0-4990-93a0-6d80bedc1c7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e97407d-93cf-4ff0-97de-af154df9ebf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5c793de4-bda0-4990-93a0-6d80bedc1c7b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e97407d-93cf-4ff0-97de-af154df9ebf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_3f33b093-08b3-4024-8244-a739d8564bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e97407d-93cf-4ff0-97de-af154df9ebf3" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_3f33b093-08b3-4024-8244-a739d8564bae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_d294aea6-04f7-4ec0-af75-e067d7abaa89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e97407d-93cf-4ff0-97de-af154df9ebf3" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_d294aea6-04f7-4ec0-af75-e067d7abaa89" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i8dedc32503f54efd984c4efb13eddf3b_FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f388642f-529a-45ef-89b7-1da3b1b200e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a4ce32a-2bfd-4253-86f7-223d30ba7832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f388642f-529a-45ef-89b7-1da3b1b200e6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a4ce32a-2bfd-4253-86f7-223d30ba7832" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7bd1e9f4-8d30-4f3a-8cb0-17d2368ddb86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a4ce32a-2bfd-4253-86f7-223d30ba7832" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7bd1e9f4-8d30-4f3a-8cb0-17d2368ddb86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_e85f74d3-04db-4362-979e-1cdf43056884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f388642f-529a-45ef-89b7-1da3b1b200e6" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_e85f74d3-04db-4362-979e-1cdf43056884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_4dfeaca8-fd9f-47ca-b27e-2a3a3a7e5dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f388642f-529a-45ef-89b7-1da3b1b200e6" xlink:to="loc_us-gaap_MarketableSecurities_4dfeaca8-fd9f-47ca-b27e-2a3a3a7e5dd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7ed92f25-dde9-4f36-bd48-03520875714c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f388642f-529a-45ef-89b7-1da3b1b200e6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7ed92f25-dde9-4f36-bd48-03520875714c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca981289-9fee-4b1a-8b57-4190708deb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7ed92f25-dde9-4f36-bd48-03520875714c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca981289-9fee-4b1a-8b57-4190708deb8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca981289-9fee-4b1a-8b57-4190708deb8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca981289-9fee-4b1a-8b57-4190708deb8c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca981289-9fee-4b1a-8b57-4190708deb8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2261dcd-f37b-4d08-998b-319432d432c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca981289-9fee-4b1a-8b57-4190708deb8c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2261dcd-f37b-4d08-998b-319432d432c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8951d3e7-3fdb-4cd0-bd24-989a8de12fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2261dcd-f37b-4d08-998b-319432d432c4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8951d3e7-3fdb-4cd0-bd24-989a8de12fa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50731f0a-8967-48c7-b781-0704bbb7b679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7ed92f25-dde9-4f36-bd48-03520875714c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50731f0a-8967-48c7-b781-0704bbb7b679" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50731f0a-8967-48c7-b781-0704bbb7b679_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50731f0a-8967-48c7-b781-0704bbb7b679" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50731f0a-8967-48c7-b781-0704bbb7b679_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55d812ef-0a92-49f4-a2a1-97ee14c71819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50731f0a-8967-48c7-b781-0704bbb7b679" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55d812ef-0a92-49f4-a2a1-97ee14c71819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_47ea88fb-6412-4d8d-8f29-21779e5dcaed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55d812ef-0a92-49f4-a2a1-97ee14c71819" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_47ea88fb-6412-4d8d-8f29-21779e5dcaed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7a403ec0-b600-4f55-b7fb-44d76d8aab37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55d812ef-0a92-49f4-a2a1-97ee14c71819" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7a403ec0-b600-4f55-b7fb-44d76d8aab37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fb197ebe-8f71-437d-88b0-dc45e4aebccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7ed92f25-dde9-4f36-bd48-03520875714c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fb197ebe-8f71-437d-88b0-dc45e4aebccc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb197ebe-8f71-437d-88b0-dc45e4aebccc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fb197ebe-8f71-437d-88b0-dc45e4aebccc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fb197ebe-8f71-437d-88b0-dc45e4aebccc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fb197ebe-8f71-437d-88b0-dc45e4aebccc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_84e269d5-d970-48c0-8fcd-55eeab2f45e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_84e269d5-d970-48c0-8fcd-55eeab2f45e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_877e0ddf-26f4-494a-a72e-370e34c0ebcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_877e0ddf-26f4-494a-a72e-370e34c0ebcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_269d36a3-2042-44b8-94a8-b25043465516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_269d36a3-2042-44b8-94a8-b25043465516" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6019cadf-265d-4f2c-adf5-dc5c17a66d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:to="loc_us-gaap_CommercialPaperMember_6019cadf-265d-4f2c-adf5-dc5c17a66d0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_1520e0b3-dcb6-43d5-8dd6-8181386608b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:to="loc_us-gaap_CertificatesOfDepositMember_1520e0b3-dcb6-43d5-8dd6-8181386608b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_7cf26bb9-a59e-4ab3-a285-8e767ac29d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_7cf26bb9-a59e-4ab3-a285-8e767ac29d03" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentAxis_b1ba8190-28ec-4f8c-b2da-6df5e3a49e49" xlink:href="regn-20210930.xsd#regn_ClassificationOfInvestmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7ed92f25-dde9-4f36-bd48-03520875714c" xlink:to="loc_regn_ClassificationOfInvestmentAxis_b1ba8190-28ec-4f8c-b2da-6df5e3a49e49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain_b1ba8190-28ec-4f8c-b2da-6df5e3a49e49_default" xlink:href="regn-20210930.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_regn_ClassificationOfInvestmentAxis_b1ba8190-28ec-4f8c-b2da-6df5e3a49e49" xlink:to="loc_regn_ClassificationOfInvestmentDomain_b1ba8190-28ec-4f8c-b2da-6df5e3a49e49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain_9a598870-e773-4095-ac49-93822c018182" xlink:href="regn-20210930.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_regn_ClassificationOfInvestmentAxis_b1ba8190-28ec-4f8c-b2da-6df5e3a49e49" xlink:to="loc_regn_ClassificationOfInvestmentDomain_9a598870-e773-4095-ac49-93822c018182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrestrictedMember_504cc9cc-b3e1-4fa0-8a73-292333328e6a" xlink:href="regn-20210930.xsd#regn_UnrestrictedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ClassificationOfInvestmentDomain_9a598870-e773-4095-ac49-93822c018182" xlink:to="loc_regn_UnrestrictedMember_504cc9cc-b3e1-4fa0-8a73-292333328e6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestrictedMember_ba35269f-37a2-4781-9d00-42e33a020a17" xlink:href="regn-20210930.xsd#regn_RestrictedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_regn_ClassificationOfInvestmentDomain_9a598870-e773-4095-ac49-93822c018182" xlink:to="loc_regn_RestrictedMember_ba35269f-37a2-4781-9d00-42e33a020a17" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/DebtNarrativeDetails" xlink:type="extended" id="i98b9655bf5cd4aee8b77e429042c6461_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_77c7dc73-cdc1-44ed-8288-89fba9430857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c09cb088-5e2b-453b-bb44-424fb7523e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_77c7dc73-cdc1-44ed-8288-89fba9430857" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c09cb088-5e2b-453b-bb44-424fb7523e63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_4ce2fc88-7ee8-491d-ac0d-e65a8cc46dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_77c7dc73-cdc1-44ed-8288-89fba9430857" xlink:to="loc_us-gaap_InterestExpenseDebt_4ce2fc88-7ee8-491d-ac0d-e65a8cc46dd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_bd479617-512b-4a30-856a-6188443b0e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_77c7dc73-cdc1-44ed-8288-89fba9430857" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_bd479617-512b-4a30-856a-6188443b0e8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_83de639c-4bf0-4862-93a7-fd193fe51863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_bd479617-512b-4a30-856a-6188443b0e8d" xlink:to="loc_us-gaap_DebtInstrumentAxis_83de639c-4bf0-4862-93a7-fd193fe51863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_83de639c-4bf0-4862-93a7-fd193fe51863_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_83de639c-4bf0-4862-93a7-fd193fe51863" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_83de639c-4bf0-4862-93a7-fd193fe51863_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8c9ad82d-6978-4984-94f3-10955e55781b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_83de639c-4bf0-4862-93a7-fd193fe51863" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8c9ad82d-6978-4984-94f3-10955e55781b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BridgeFacilityMember_9e2bafbc-1e7e-41f3-bd08-0bea82450ba6" xlink:href="regn-20210930.xsd#regn_BridgeFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8c9ad82d-6978-4984-94f3-10955e55781b" xlink:to="loc_regn_BridgeFacilityMember_9e2bafbc-1e7e-41f3-bd08-0bea82450ba6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2030Member_57cfcee2-a95b-4b87-a64b-c4a5e2e587ee" xlink:href="regn-20210930.xsd#regn_SeniorUnsecuredNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8c9ad82d-6978-4984-94f3-10955e55781b" xlink:to="loc_regn_SeniorUnsecuredNotesDue2030Member_57cfcee2-a95b-4b87-a64b-c4a5e2e587ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2050Member_391a38c5-573b-4409-b559-da5e649298b5" xlink:href="regn-20210930.xsd#regn_SeniorUnsecuredNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8c9ad82d-6978-4984-94f3-10955e55781b" xlink:to="loc_regn_SeniorUnsecuredNotesDue2050Member_391a38c5-573b-4409-b559-da5e649298b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_a443b150-790e-46b8-9b35-63efbd395179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_bd479617-512b-4a30-856a-6188443b0e8d" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_a443b150-790e-46b8-9b35-63efbd395179" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_a443b150-790e-46b8-9b35-63efbd395179_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_a443b150-790e-46b8-9b35-63efbd395179" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_a443b150-790e-46b8-9b35-63efbd395179_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_147e62d7-6abd-4fad-b6cb-381dce1aceb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_a443b150-790e-46b8-9b35-63efbd395179" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_147e62d7-6abd-4fad-b6cb-381dce1aceb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_4737ab04-43aa-4609-9acb-fde387508f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_147e62d7-6abd-4fad-b6cb-381dce1aceb5" xlink:to="loc_us-gaap_BridgeLoanMember_4737ab04-43aa-4609-9acb-fde387508f4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3b120a4e-d698-4dfb-9585-7443b9dba301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_bd479617-512b-4a30-856a-6188443b0e8d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3b120a4e-d698-4dfb-9585-7443b9dba301" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3b120a4e-d698-4dfb-9585-7443b9dba301_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3b120a4e-d698-4dfb-9585-7443b9dba301" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3b120a4e-d698-4dfb-9585-7443b9dba301_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f7483ef2-f64a-4891-8445-6e4a3ef333f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3b120a4e-d698-4dfb-9585-7443b9dba301" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f7483ef2-f64a-4891-8445-6e4a3ef333f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_44c21ff8-2ea5-420a-86f3-97143dbef3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f7483ef2-f64a-4891-8445-6e4a3ef333f2" xlink:to="loc_us-gaap_SeniorNotesMember_44c21ff8-2ea5-420a-86f3-97143dbef3ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#DebtSummaryofIssuedSeniorUnsecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails" xlink:type="extended" id="i89ea372672684a3cb0d6e0ce5a644c6f_DebtSummaryofIssuedSeniorUnsecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8dfec994-5627-41a2-931d-736df866a6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4663c7a4-7c6c-4b6e-b270-323396c5be58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8dfec994-5627-41a2-931d-736df866a6db" xlink:to="loc_us-gaap_LongTermDebt_4663c7a4-7c6c-4b6e-b270-323396c5be58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1c6a3e79-699a-4058-a1fa-a30a0d8e3a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8dfec994-5627-41a2-931d-736df866a6db" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1c6a3e79-699a-4058-a1fa-a30a0d8e3a70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_50aad31e-3152-44cb-9db6-40262cd09115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8dfec994-5627-41a2-931d-736df866a6db" xlink:to="loc_us-gaap_DebtInstrumentTable_50aad31e-3152-44cb-9db6-40262cd09115" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2ae9e9bc-b6bf-43be-8260-a84065b00f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_50aad31e-3152-44cb-9db6-40262cd09115" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2ae9e9bc-b6bf-43be-8260-a84065b00f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2ae9e9bc-b6bf-43be-8260-a84065b00f11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2ae9e9bc-b6bf-43be-8260-a84065b00f11" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2ae9e9bc-b6bf-43be-8260-a84065b00f11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_173f4ce8-d5ba-4d2d-a77e-024e5e3dba61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2ae9e9bc-b6bf-43be-8260-a84065b00f11" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_173f4ce8-d5ba-4d2d-a77e-024e5e3dba61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ca0f86dd-9744-46d3-bfc4-42bf2b07aac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_173f4ce8-d5ba-4d2d-a77e-024e5e3dba61" xlink:to="loc_us-gaap_SeniorNotesMember_ca0f86dd-9744-46d3-bfc4-42bf2b07aac3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f93d6131-9f58-497e-addb-1ea07f081ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_50aad31e-3152-44cb-9db6-40262cd09115" xlink:to="loc_us-gaap_DebtInstrumentAxis_f93d6131-9f58-497e-addb-1ea07f081ba2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f93d6131-9f58-497e-addb-1ea07f081ba2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f93d6131-9f58-497e-addb-1ea07f081ba2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f93d6131-9f58-497e-addb-1ea07f081ba2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42e6bf8f-2312-4f12-ada5-4526b32120ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f93d6131-9f58-497e-addb-1ea07f081ba2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42e6bf8f-2312-4f12-ada5-4526b32120ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2030Member_4bd5a307-4210-457b-ad69-c25e87160ad5" xlink:href="regn-20210930.xsd#regn_SeniorUnsecuredNotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42e6bf8f-2312-4f12-ada5-4526b32120ad" xlink:to="loc_regn_SeniorUnsecuredNotesDue2030Member_4bd5a307-4210-457b-ad69-c25e87160ad5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2050Member_4119ddff-ba3c-4131-9424-634cde9328c3" xlink:href="regn-20210930.xsd#regn_SeniorUnsecuredNotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42e6bf8f-2312-4f12-ada5-4526b32120ad" xlink:to="loc_regn_SeniorUnsecuredNotesDue2050Member_4119ddff-ba3c-4131-9424-634cde9328c3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="if262970b42af46ccbaf11e6b0f8d430f_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d237651f-0b4d-4b2c-b036-2ebc6c93f236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d237651f-0b4d-4b2c-b036-2ebc6c93f236" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_19a7100d-6779-46a7-aa0d-a7871ec275fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_19a7100d-6779-46a7-aa0d-a7871ec275fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c83685bd-f6cb-4942-822f-da022a622e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c83685bd-f6cb-4942-822f-da022a622e77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_ce6bd8e3-7cb3-436b-b740-83343e197f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_ce6bd8e3-7cb3-436b-b740-83343e197f45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7b0eacea-306b-4646-a385-6dffdaa0edc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7b0eacea-306b-4646-a385-6dffdaa0edc4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_45c2cef0-45af-4a88-ad0f-620f6afff7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_45c2cef0-45af-4a88-ad0f-620f6afff7d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_189cdd92-93d5-41de-830f-e54e35ef8007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_189cdd92-93d5-41de-830f-e54e35ef8007" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_34652e37-f091-4b3d-a7f2-cd5175e8c6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_189cdd92-93d5-41de-830f-e54e35ef8007" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_34652e37-f091-4b3d-a7f2-cd5175e8c6c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_34652e37-f091-4b3d-a7f2-cd5175e8c6c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_34652e37-f091-4b3d-a7f2-cd5175e8c6c9" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_34652e37-f091-4b3d-a7f2-cd5175e8c6c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_07c7cec9-bf4b-4cf9-9da1-11520b7139a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_34652e37-f091-4b3d-a7f2-cd5175e8c6c9" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_07c7cec9-bf4b-4cf9-9da1-11520b7139a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgram2019Member_a7d55c04-b95f-44c7-945a-d13eec56820b" xlink:href="regn-20210930.xsd#regn_ShareRepurchaseProgram2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_07c7cec9-bf4b-4cf9-9da1-11520b7139a2" xlink:to="loc_regn_ShareRepurchaseProgram2019Member_a7d55c04-b95f-44c7-945a-d13eec56820b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramJanuary2021Member_a65ae666-7ab8-47f0-92ef-778c1cfcaeb9" xlink:href="regn-20210930.xsd#regn_ShareRepurchaseProgramJanuary2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_07c7cec9-bf4b-4cf9-9da1-11520b7139a2" xlink:to="loc_regn_ShareRepurchaseProgramJanuary2021Member_a65ae666-7ab8-47f0-92ef-778c1cfcaeb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_28ad8464-b7e5-4f92-a0ed-97a6094b1acc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_189cdd92-93d5-41de-830f-e54e35ef8007" xlink:to="loc_dei_LegalEntityAxis_28ad8464-b7e5-4f92-a0ed-97a6094b1acc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_28ad8464-b7e5-4f92-a0ed-97a6094b1acc_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_28ad8464-b7e5-4f92-a0ed-97a6094b1acc" xlink:to="loc_dei_EntityDomain_28ad8464-b7e5-4f92-a0ed-97a6094b1acc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1dc2fe8f-f93d-4daa-8d3e-c42b62c794ce" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_28ad8464-b7e5-4f92-a0ed-97a6094b1acc" xlink:to="loc_dei_EntityDomain_1dc2fe8f-f93d-4daa-8d3e-c42b62c794ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_3056f1ae-83bf-4c17-9db2-a3fc57fd3987" xlink:href="regn-20210930.xsd#regn_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1dc2fe8f-f93d-4daa-8d3e-c42b62c794ce" xlink:to="loc_regn_SanofiMember_3056f1ae-83bf-4c17-9db2-a3fc57fd3987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_54444fb6-8e37-46ef-af53-05a6432b8eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_189cdd92-93d5-41de-830f-e54e35ef8007" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_54444fb6-8e37-46ef-af53-05a6432b8eb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_54444fb6-8e37-46ef-af53-05a6432b8eb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_54444fb6-8e37-46ef-af53-05a6432b8eb1" xlink:to="loc_us-gaap_ProjectMember_54444fb6-8e37-46ef-af53-05a6432b8eb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_cf6db72b-ee5a-41c7-99bf-d54f02ff2c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_54444fb6-8e37-46ef-af53-05a6432b8eb1" xlink:to="loc_us-gaap_ProjectMember_cf6db72b-ee5a-41c7-99bf-d54f02ff2c16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LibtayoDevelopmentMember_119763eb-83e9-42f0-886c-28d08d71808c" xlink:href="regn-20210930.xsd#regn_LibtayoDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_cf6db72b-ee5a-41c7-99bf-d54f02ff2c16" xlink:to="loc_regn_LibtayoDevelopmentMember_119763eb-83e9-42f0-886c-28d08d71808c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DupilumabREGN3500EligibleInvestmentsMember_36498839-e1c8-494b-a605-1c88f2fbee07" xlink:href="regn-20210930.xsd#regn_DupilumabREGN3500EligibleInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_cf6db72b-ee5a-41c7-99bf-d54f02ff2c16" xlink:to="loc_regn_DupilumabREGN3500EligibleInvestmentsMember_36498839-e1c8-494b-a605-1c88f2fbee07" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#LegalMattersDetails"/>
  <link:definitionLink xlink:role="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="extended" id="i6271bba899b346fc9c2511a66fa28540_LegalMattersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_dff9b997-7e4b-4ffd-9aea-9025a583c065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_6d4464ac-fae9-410e-941f-0fc860b0fe87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dff9b997-7e4b-4ffd-9aea-9025a583c065" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_6d4464ac-fae9-410e-941f-0fc860b0fe87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyClaimsInvalidNumber_93fa31c2-0263-44ae-b2a8-06b0d5d405ee" xlink:href="regn-20210930.xsd#regn_LossContingencyClaimsInvalidNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dff9b997-7e4b-4ffd-9aea-9025a583c065" xlink:to="loc_regn_LossContingencyClaimsInvalidNumber_93fa31c2-0263-44ae-b2a8-06b0d5d405ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GainContingencyInterPartesReviewFiledNumber_9b176d83-a22f-4be9-8d0c-49b7167eed79" xlink:href="regn-20210930.xsd#regn_GainContingencyInterPartesReviewFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dff9b997-7e4b-4ffd-9aea-9025a583c065" xlink:to="loc_regn_GainContingencyInterPartesReviewFiledNumber_9b176d83-a22f-4be9-8d0c-49b7167eed79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GainContingencyClaimsInvalidatedNumber_3d26cef6-0d0f-43a6-b2c2-eaad15d514d5" xlink:href="regn-20210930.xsd#regn_GainContingencyClaimsInvalidatedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dff9b997-7e4b-4ffd-9aea-9025a583c065" xlink:to="loc_regn_GainContingencyClaimsInvalidatedNumber_3d26cef6-0d0f-43a6-b2c2-eaad15d514d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyExParteReexaminationFiledNumber_0ff91d55-1a7d-4cc3-92f3-b73aeba51eb8" xlink:href="regn-20210930.xsd#regn_LossContingencyExParteReexaminationFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_dff9b997-7e4b-4ffd-9aea-9025a583c065" xlink:to="loc_regn_LossContingencyExParteReexaminationFiledNumber_0ff91d55-1a7d-4cc3-92f3-b73aeba51eb8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e071b74d-d63f-4847-a2a9-96726f497f53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_dff9b997-7e4b-4ffd-9aea-9025a583c065" xlink:to="loc_us-gaap_LossContingenciesTable_e071b74d-d63f-4847-a2a9-96726f497f53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa573981-ea8f-4d25-bfff-73019099fb44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e071b74d-d63f-4847-a2a9-96726f497f53" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa573981-ea8f-4d25-bfff-73019099fb44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_aa573981-ea8f-4d25-bfff-73019099fb44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa573981-ea8f-4d25-bfff-73019099fb44" xlink:to="loc_us-gaap_LossContingencyNatureDomain_aa573981-ea8f-4d25-bfff-73019099fb44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_c55c3380-db9f-40eb-b6ee-dcc6fc09d3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa573981-ea8f-4d25-bfff-73019099fb44" xlink:to="loc_us-gaap_LossContingencyNatureDomain_c55c3380-db9f-40eb-b6ee-dcc6fc09d3c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A165PatentMember_659bee74-2a87-419e-96ba-4cd410c1c4ed" xlink:href="regn-20210930.xsd#regn_A165PatentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_c55c3380-db9f-40eb-b6ee-dcc6fc09d3c0" xlink:to="loc_regn_A165PatentMember_659bee74-2a87-419e-96ba-4cd410c1c4ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A741PatentMember_efbd237c-d18c-4995-8fe0-b490daedc288" xlink:href="regn-20210930.xsd#regn_A741PatentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_c55c3380-db9f-40eb-b6ee-dcc6fc09d3c0" xlink:to="loc_regn_A741PatentMember_efbd237c-d18c-4995-8fe0-b490daedc288" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A487PatentMember_365b022a-9689-461b-949f-a5ddd42aed76" xlink:href="regn-20210930.xsd#regn_A487PatentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_c55c3380-db9f-40eb-b6ee-dcc6fc09d3c0" xlink:to="loc_regn_A487PatentMember_365b022a-9689-461b-949f-a5ddd42aed76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A631PatentMember_a88d677e-99fb-4e0d-8e33-7bcb412b7e67" xlink:href="regn-20210930.xsd#regn_A631PatentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_c55c3380-db9f-40eb-b6ee-dcc6fc09d3c0" xlink:to="loc_regn_A631PatentMember_a88d677e-99fb-4e0d-8e33-7bcb412b7e67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A226PatentAnd992PatentMember_44e7430a-f663-436e-8a8b-1a2952fed391" xlink:href="regn-20210930.xsd#regn_A226PatentAnd992PatentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_c55c3380-db9f-40eb-b6ee-dcc6fc09d3c0" xlink:to="loc_regn_A226PatentAnd992PatentMember_44e7430a-f663-436e-8a8b-1a2952fed391" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_fee964f9-76c6-446d-ad76-9231eb0fcdd2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e071b74d-d63f-4847-a2a9-96726f497f53" xlink:to="loc_srt_LitigationCaseAxis_fee964f9-76c6-446d-ad76-9231eb0fcdd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_fee964f9-76c6-446d-ad76-9231eb0fcdd2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_fee964f9-76c6-446d-ad76-9231eb0fcdd2" xlink:to="loc_srt_LitigationCaseTypeDomain_fee964f9-76c6-446d-ad76-9231eb0fcdd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_32251bb3-3c80-4d67-a0bb-1bc6186fa938" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_fee964f9-76c6-446d-ad76-9231eb0fcdd2" xlink:to="loc_srt_LitigationCaseTypeDomain_32251bb3-3c80-4d67-a0bb-1bc6186fa938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_Amgenv.s.RegeneronMember_3c8588d2-134a-485c-8371-d39747538a40" xlink:href="regn-20210930.xsd#regn_Amgenv.s.RegeneronMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_32251bb3-3c80-4d67-a0bb-1bc6186fa938" xlink:to="loc_regn_Amgenv.s.RegeneronMember_3c8588d2-134a-485c-8371-d39747538a40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_3660090f-7876-4483-8762-edce9ec5349b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e071b74d-d63f-4847-a2a9-96726f497f53" xlink:to="loc_us-gaap_LitigationStatusAxis_3660090f-7876-4483-8762-edce9ec5349b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3660090f-7876-4483-8762-edce9ec5349b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_3660090f-7876-4483-8762-edce9ec5349b" xlink:to="loc_us-gaap_LitigationStatusDomain_3660090f-7876-4483-8762-edce9ec5349b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_2565a0df-6daa-4f2f-a8b8-aa5d7a266ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_3660090f-7876-4483-8762-edce9ec5349b" xlink:to="loc_us-gaap_LitigationStatusDomain_2565a0df-6daa-4f2f-a8b8-aa5d7a266ef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_a54fa232-2163-46d8-b97a-71b6bfffe76f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_2565a0df-6daa-4f2f-a8b8-aa5d7a266ef7" xlink:to="loc_us-gaap_PendingLitigationMember_a54fa232-2163-46d8-b97a-71b6bfffe76f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_90a0d8f5-44b1-4c91-82b6-ae85fb232174" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e071b74d-d63f-4847-a2a9-96726f497f53" xlink:to="loc_srt_ProductOrServiceAxis_90a0d8f5-44b1-4c91-82b6-ae85fb232174" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_90a0d8f5-44b1-4c91-82b6-ae85fb232174_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_90a0d8f5-44b1-4c91-82b6-ae85fb232174" xlink:to="loc_srt_ProductsAndServicesDomain_90a0d8f5-44b1-4c91-82b6-ae85fb232174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_567af92e-9c99-48a7-8f84-7d6132097a5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_90a0d8f5-44b1-4c91-82b6-ae85fb232174" xlink:to="loc_srt_ProductsAndServicesDomain_567af92e-9c99-48a7-8f84-7d6132097a5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EYLEAAfliberceptInjectionMember_8da639c8-57a9-428e-a07f-f51d328ea791" xlink:href="regn-20210930.xsd#regn_EYLEAAfliberceptInjectionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_567af92e-9c99-48a7-8f84-7d6132097a5d" xlink:to="loc_regn_EYLEAAfliberceptInjectionMember_8da639c8-57a9-428e-a07f-f51d328ea791" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>regn-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:08b52028-35ad-4384-abb4-ffa84b7c541b,g:79516084-017d-4f01-b220-9a6b8eb4ad51-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_f0c3e7a0-2d46-453d-ad99-b27e770f77c3_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_12533d24-a288-4098-8ebc-1fdc87c36903_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_7d0a8af9-ca6e-4d75-b554-64fbbf30b411_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_f4263c2e-f17e-493d-9c9f-3aefadb9972b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Repurchased</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7983f346-4616-409a-af24-bdebb5fd7716_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_04cb08ba-8f2f-4835-ab49-23ca25901f05_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f7939daa-e081-4d00-80ff-2c360ab299e2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c92cdd59-5bee-4929-ab7d-75dc4d89a1f3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income - basic and diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_da1048a0-fe1a-43b3-bb29-1d2b2a7761b1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6992f3a2-7a26-4a4d-bcd8-4f9479e98fb9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_28aa8121-5d1a-4b03-be58-e0e30a10061e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6ba43e97-99b4-4d0c-8a1c-13427c46f37d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_71a32bad-0c6c-4a6b-bfe3-e2a71284481a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6cad456c-3f36-44fc-84a8-969a0e4b1a9f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_7993d280-83db-4ba4-af21-071e8d557f12_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_abd59afd-d0e3-4b50-a412-8d1c318f7536_terseLabel_en-US" xlink:label="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percentage to be received on net product sales outside of the United States</link:label>
    <link:label id="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_label_en-US" xlink:label="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Percentage To Be Received On Net Product Sales Outside Of United States</link:label>
    <link:label id="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_documentation_en-US" xlink:label="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Percentage To Be Received On Net Product Sales Outside Of United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:href="regn-20210930.xsd#regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:to="lab_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_436cf7ba-8eea-434a-aac2-897fbe8beb8f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_034f7779-e7c2-4122-a17e-e8609c274be7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accounts receivable and deferred revenue information</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_1dd54aad-3803-475c-9e08-36f11bd337a2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_A226PatentAnd992PatentMember_55765b48-455e-46fd-a8f6-947749b2f48d_terseLabel_en-US" xlink:label="lab_regn_A226PatentAnd992PatentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'226 and '992 Patents</link:label>
    <link:label id="lab_regn_A226PatentAnd992PatentMember_label_en-US" xlink:label="lab_regn_A226PatentAnd992PatentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'226 Patent And '992 Patent [Member]</link:label>
    <link:label id="lab_regn_A226PatentAnd992PatentMember_documentation_en-US" xlink:label="lab_regn_A226PatentAnd992PatentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'226 Patent And '992 Patent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A226PatentAnd992PatentMember" xlink:href="regn-20210930.xsd#regn_A226PatentAnd992PatentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_A226PatentAnd992PatentMember" xlink:to="lab_regn_A226PatentAnd992PatentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c2bf5959-5dc5-4a0c-bb74-b118897a4d31_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_076a15d1-22d0-41ce-88f2-673bd18fb0ea_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1981e423-83e2-482a-9777-874ca1b5612e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation charges</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_154f4596-a580-4c4d-b7e0-f7b95450268b_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_7fc7f069-200c-4430-a197-aab38e152af8_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_f3f7bac3-893c-448c-88af-648c39961e4a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_A487PatentMember_8f4931be-4792-451c-815b-b12242138234_terseLabel_en-US" xlink:label="lab_regn_A487PatentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'487 Patent</link:label>
    <link:label id="lab_regn_A487PatentMember_label_en-US" xlink:label="lab_regn_A487PatentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'487 Patent [Member]</link:label>
    <link:label id="lab_regn_A487PatentMember_documentation_en-US" xlink:label="lab_regn_A487PatentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'487 Patent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A487PatentMember" xlink:href="regn-20210930.xsd#regn_A487PatentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_A487PatentMember" xlink:to="lab_regn_A487PatentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_87e428cc-0eb8-4fad-836c-03c94fc24a49_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_352757ad-6f6e-46ae-85ea-30c569269a15_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_dee7dc31-8b28-4219-895d-dbae57b82928_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_085de91b-dcc0-40df-9cd5-cdfe231389f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_513aa20a-9608-41fb-b7b4-b06bdff97eaf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive weighted average number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9bca37d7-d676-4e40-a1f4-7eeac6255fe4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesBasedMilestoneEarnedMember_382d976e-6085-4900-a9a6-d60ce4948581_terseLabel_en-US" xlink:label="lab_regn_SalesBasedMilestoneEarnedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone earned</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneEarnedMember_label_en-US" xlink:label="lab_regn_SalesBasedMilestoneEarnedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone Earned [Member]</link:label>
    <link:label id="lab_regn_SalesBasedMilestoneEarnedMember_documentation_en-US" xlink:label="lab_regn_SalesBasedMilestoneEarnedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestone Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneEarnedMember" xlink:href="regn-20210930.xsd#regn_SalesBasedMilestoneEarnedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesBasedMilestoneEarnedMember" xlink:to="lab_regn_SalesBasedMilestoneEarnedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8a57e037-ac09-4493-a382-06c36ac142f8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f98e870e-dddd-4b8f-a9dd-014ffa254f72_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_1f1efa3c-a3da-4d4b-921d-c3ccebcd2264_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_McKessonCorporationMember_a9527629-afc2-4fe3-82ce-d4a431e14ccc_terseLabel_en-US" xlink:label="lab_regn_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_regn_McKessonCorporationMember_label_en-US" xlink:label="lab_regn_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:label id="lab_regn_McKessonCorporationMember_documentation_en-US" xlink:label="lab_regn_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_McKessonCorporationMember" xlink:href="regn-20210930.xsd#regn_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_McKessonCorporationMember" xlink:to="lab_regn_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_EvkeezaMember_b9d267c5-e75d-4e77-b250-fcdf71e22446_terseLabel_en-US" xlink:label="lab_regn_EvkeezaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evkeeza</link:label>
    <link:label id="lab_regn_EvkeezaMember_label_en-US" xlink:label="lab_regn_EvkeezaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evkeeza [Member]</link:label>
    <link:label id="lab_regn_EvkeezaMember_documentation_en-US" xlink:label="lab_regn_EvkeezaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evkeeza</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EvkeezaMember" xlink:href="regn-20210930.xsd#regn_EvkeezaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_EvkeezaMember" xlink:to="lab_regn_EvkeezaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7ba09b43-0ea3-4c0c-8981-c141bbcc171a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_fd1d9bdc-4fcf-46d7-84e9-e22e7e408cfe_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Based on Contractual Maturity Dates</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a0473908-82ea-492a-816b-d8f80cb2bd08_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_8a1a7c75-b345-4438-9e4a-c43ac4a9b93a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6c44fca2-6f89-468b-83e8-56fed9fd74c9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LIBTAYONetProductSalesMember_4aa41d52-9c50-4902-af36-f8ad45850d8e_terseLabel_en-US" xlink:label="lab_regn_LIBTAYONetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Libtayo</link:label>
    <link:label id="lab_regn_LIBTAYONetProductSalesMember_label_en-US" xlink:label="lab_regn_LIBTAYONetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBTAYO Net Product Sales [Member]</link:label>
    <link:label id="lab_regn_LIBTAYONetProductSalesMember_documentation_en-US" xlink:label="lab_regn_LIBTAYONetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBTAYO Net Product Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LIBTAYONetProductSalesMember" xlink:href="regn-20210930.xsd#regn_LIBTAYONetProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LIBTAYONetProductSalesMember" xlink:to="lab_regn_LIBTAYONetProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_515cf8af-184e-4448-b054-235b4966ed8e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e68494c0-c6ff-433f-83d2-84f092eaf3af_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_644400c3-11e0-44b9-a0bd-3bb91b545fd9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_3f867d7a-11db-4416-ba1b-c51b7aa537e2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_942b89d1-90bb-4df3-abe5-c47c46274d37_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAccountsReceivableMember" xlink:to="lab_us-gaap_TradeAccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cb7888cf-4770-40b3-9871-e0029213e7ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_a61fc57b-90f6-4a9f-be8f-4e57381aa47f_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_EyleaNetProductSalesMember_dbe8594b-98ed-4144-b502-f17e759e2b17_terseLabel_en-US" xlink:label="lab_regn_EyleaNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA</link:label>
    <link:label id="lab_regn_EyleaNetProductSalesMember_label_en-US" xlink:label="lab_regn_EyleaNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA Net Product Sales [Member]</link:label>
    <link:label id="lab_regn_EyleaNetProductSalesMember_documentation_en-US" xlink:label="lab_regn_EyleaNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue during the period derived from a specified product line (EYLEA), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EyleaNetProductSalesMember" xlink:href="regn-20210930.xsd#regn_EyleaNetProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_EyleaNetProductSalesMember" xlink:to="lab_regn_EyleaNetProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_NetProfitInConnectionWithCommercializationMember_8086195d-2029-42d6-a3ec-9f4dafb15a93_terseLabel_en-US" xlink:label="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's net profit in connection with commercialization of EYLEA outside the United States</link:label>
    <link:label id="lab_regn_NetProfitInConnectionWithCommercializationMember_label_en-US" xlink:label="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Profit In Connection With Commercialization [Member]</link:label>
    <link:label id="lab_regn_NetProfitInConnectionWithCommercializationMember_documentation_en-US" xlink:label="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Profit In Connection With Commercialization [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NetProfitInConnectionWithCommercializationMember" xlink:href="regn-20210930.xsd#regn_NetProfitInConnectionWithCommercializationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_NetProfitInConnectionWithCommercializationMember" xlink:to="lab_regn_NetProfitInConnectionWithCommercializationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_bc6a0766-dc94-4619-aece-640c0f15fb2f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value and Unrealized Losses of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesGainLoss_5a2931f7-4ef7-413f-821c-fba5038f137c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains on marketable and other securities, net</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6dbead77-414d-4d2e-9934-31b98623397f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_aec06d5c-4ea3-4315-bc9f-5ffc7a22b17e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_11a8903b-a8cb-4879-8103-e3594807cf9c_terseLabel_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/distribution of Common Stock for 401(k) Savings Plan</link:label>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_label_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued/Distributed During Period, Value, Employee Benefit Plan</link:label>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_documentation_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued/Distributed During Period, Value, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:href="regn-20210930.xsd#regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:to="lab_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_e5538367-b996-449c-a94f-5e6cb5b99e53_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_27443395-c130-42c5-bf96-93c1b860307b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7b356b13-e84e-4a81-bfec-390831b35789_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_7213e55a-4743-4208-acde-c08d37f498a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of bridge loan facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_30f2032f-cadc-460a-a4e3-f2238ad21361_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesMilestoneOneMember_b40e332a-7885-4bbb-951d-d4006cc5f2bb_terseLabel_en-US" xlink:label="lab_regn_SalesMilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Sales Milestone</link:label>
    <link:label id="lab_regn_SalesMilestoneOneMember_label_en-US" xlink:label="lab_regn_SalesMilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone One [Member]</link:label>
    <link:label id="lab_regn_SalesMilestoneOneMember_documentation_en-US" xlink:label="lab_regn_SalesMilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneOneMember" xlink:href="regn-20210930.xsd#regn_SalesMilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesMilestoneOneMember" xlink:to="lab_regn_SalesMilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_a006ce59-4599-47ae-ab62-9f7d13009662_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_fb3e8079-c00f-4fc9-901c-e72b598769ab_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and government agency obligations</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_add9ac1d-4dd9-4308-b969-fb2dc26cad17_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and government agency obligations</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_81afaf60-8ebb-4f44-9e09-026cd34a20de_netLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and government agency obligations</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_9b0b39a0-2ae7-43be-bf6f-3963b76393d3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5255d890-5767-493b-833e-325bef62f054_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_38f98f9a-cc47-4e23-8f57-a85ef8822c9c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_a8f08000-6c92-40fa-abdb-f0a0ae5d946e_verboseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of product sales</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_5bd81c26-5f99-440d-8373-65358aae5284_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of collaborative revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_82c2a031-afa9-48b7-a93f-42f2e77d9121_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_8a516b01-7fae-43a1-a3e6-b8fd36ac4fc8_terseLabel_en-US" xlink:label="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of trial costs required to be funded by collaborating party</link:label>
    <link:label id="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_label_en-US" xlink:label="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Trial Costs Required To Be Funded By Collaborating Party</link:label>
    <link:label id="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_documentation_en-US" xlink:label="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Trial Costs Required To Be Funded By Collaborating Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:href="regn-20210930.xsd#regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:to="lab_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_292e18e8-7788-4b25-a3a3-c2c773f8b8ec_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchase price</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, at Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtCost" xlink:to="lab_us-gaap_InvestmentOwnedAtCost" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems_04c2694d-92d8-4c7c-baef-8b2abf1dda4d_terseLabel_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Arrangements [Line Items]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems_label_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Arrangements [Line Items]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems_documentation_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:href="regn-20210930.xsd#regn_ResearchCollaborationAndLicensingArrangementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:to="lab_regn_ResearchCollaborationAndLicensingArrangementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_44e06f3d-fa84-4266-a760-ee2d6f27da17_terseLabel_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/distribution of Common Stock for 401(k) Savings Plan (in shares)</link:label>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_label_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued/Distributed During Period, Shares, Employee Benefit Plan</link:label>
    <link:label id="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_documentation_en-US" xlink:label="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued/Distributed During Period, Shares, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="regn-20210930.xsd#regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="lab_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_c8d80eff-3bd7-4552-9a5e-86b987ad6023_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_f95a5544-c990-4728-b398-0c2d0d19376e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_01d185b2-ba59-4f6a-866e-76ea100b0fcc_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_87394b9b-0aca-4d43-bc54-e299d78bf91c_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ClassificationOfInvestmentAxis_51972266-4e89-4b65-a770-165b8f2cff57_terseLabel_en-US" xlink:label="lab_regn_ClassificationOfInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Axis]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentAxis_label_en-US" xlink:label="lab_regn_ClassificationOfInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Axis]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentAxis_documentation_en-US" xlink:label="lab_regn_ClassificationOfInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the general categories of investments, which may be classified as Unrestricted or Restricted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentAxis" xlink:href="regn-20210930.xsd#regn_ClassificationOfInvestmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ClassificationOfInvestmentAxis" xlink:to="lab_regn_ClassificationOfInvestmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_6b457188-c752-46ff-831a-81c5c488a497_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_BesseMedicalMember_8bf9f4ad-9ddc-4c8a-bd4f-acce406940b4_terseLabel_en-US" xlink:label="lab_regn_BesseMedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besse Medical, a subsidiary of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_regn_BesseMedicalMember_label_en-US" xlink:label="lab_regn_BesseMedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besse Medical [Member]</link:label>
    <link:label id="lab_regn_BesseMedicalMember_documentation_en-US" xlink:label="lab_regn_BesseMedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besse Medical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BesseMedicalMember" xlink:href="regn-20210930.xsd#regn_BesseMedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_BesseMedicalMember" xlink:to="lab_regn_BesseMedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_75f3f8ef-248f-48c5-a25e-0be7ce0f381c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f686ea1c-5b59-4bd8-a28f-26cf1669209f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17a032ba-0ef1-4d9a-b3cc-7fc3dc88552b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilities_2c694a4f-2500-4967-a38d-1276144ab7d0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities" xlink:to="lab_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a8f20534-dcae-4e78-8ced-f9897af9b179_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_99a9c066-9b2b-45a0-87a7-c6e20e988d91_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_A165PatentMember_7cc5cfb5-a8aa-4955-a1f9-866b48b84fbf_terseLabel_en-US" xlink:label="lab_regn_A165PatentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'165 Patent</link:label>
    <link:label id="lab_regn_A165PatentMember_label_en-US" xlink:label="lab_regn_A165PatentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'165 Patent [Member]</link:label>
    <link:label id="lab_regn_A165PatentMember_documentation_en-US" xlink:label="lab_regn_A165PatentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'165 Patent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A165PatentMember" xlink:href="regn-20210930.xsd#regn_A165PatentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_A165PatentMember" xlink:to="lab_regn_A165PatentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_62fc8715-4831-4e3c-899c-a3824d2a6809_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_20f1d923-5635-49ce-bce2-2ff4bc59a9fd_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2b5eabe4-7fae-40e1-9cd1-829b4939effd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived_52a7b78e-233e-443c-a247-088b2fb17509_terseLabel_en-US" xlink:label="lab_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of twelve-month sales at which sales milestone payments would be received</link:label>
    <link:label id="lab_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived_label_en-US" xlink:label="lab_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels Of Twelve Month Sales At Which Sales Milestone Payments Would Be Received</link:label>
    <link:label id="lab_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived_documentation_en-US" xlink:label="lab_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels Of Twelve Month Sales At Which Sales Milestone Payments Would Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" xlink:href="regn-20210930.xsd#regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" xlink:to="lab_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_144d7b12-c1b8-480b-bfff-b28c42a1bc27_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_9e0be1a5-e31d-4c91-b5ad-72bd72705127_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_76ebe2fb-fc82-40a0-b219-e37b1193b932_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_71bcf516-ee93-480c-a800-2f584f6cdc4f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_78e4b090-f7a7-4cde-b674-a1d46d99feeb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LossContingencyClaimsInvalidNumber_90f5008d-28ae-4599-a12f-5eeb7cafb03a_terseLabel_en-US" xlink:label="lab_regn_LossContingencyClaimsInvalidNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invalid claims</link:label>
    <link:label id="lab_regn_LossContingencyClaimsInvalidNumber_label_en-US" xlink:label="lab_regn_LossContingencyClaimsInvalidNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Invalid, Number</link:label>
    <link:label id="lab_regn_LossContingencyClaimsInvalidNumber_documentation_en-US" xlink:label="lab_regn_LossContingencyClaimsInvalidNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Invalid, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyClaimsInvalidNumber" xlink:href="regn-20210930.xsd#regn_LossContingencyClaimsInvalidNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LossContingencyClaimsInvalidNumber" xlink:to="lab_regn_LossContingencyClaimsInvalidNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_8e568e0e-bff8-407b-a6cb-800132cd081b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_92e1879a-84b2-439f-b4d9-fcc1496a6308_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aa840ead-f8de-43ab-8637-493dc813c002_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_c653812a-ef50-4d3f-8ed1-15a5499d8dbc_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_18e61758-c14b-45aa-b839-4a1a68c5011a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of treasury stock received</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_8714ea89-036a-4253-a50d-96923fb00e87_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of shares received</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_8e4834f7-f037-48c9-a7a9-34b2b290fe00_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofiMember_af0cb3e9-3906-4f30-a88b-65a4663710d5_terseLabel_en-US" xlink:label="lab_regn_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_regn_SanofiMember_label_en-US" xlink:label="lab_regn_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_regn_SanofiMember_documentation_en-US" xlink:label="lab_regn_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember" xlink:href="regn-20210930.xsd#regn_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofiMember" xlink:to="lab_regn_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareRepurchaseProgram2019Member_e991084a-6491-484e-9ddd-c011625303ed_terseLabel_en-US" xlink:label="lab_regn_ShareRepurchaseProgram2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgram2019Member_label_en-US" xlink:label="lab_regn_ShareRepurchaseProgram2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, 2019 [Member]</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgram2019Member_documentation_en-US" xlink:label="lab_regn_ShareRepurchaseProgram2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgram2019Member" xlink:href="regn-20210930.xsd#regn_ShareRepurchaseProgram2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareRepurchaseProgram2019Member" xlink:to="lab_regn_ShareRepurchaseProgram2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_412b3a4a-378a-40e0-9279-3ea3c5112fa6_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_4ef89652-17e1-43c6-b6f2-70fe9c704ab0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Financial Statements</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_04073a94-40d4-450d-8eca-b9a2719b9b3f_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RocheCollaborationAgreementMember_729b422f-9a06-4807-8f0b-87050c21a2e1_terseLabel_en-US" xlink:label="lab_regn_RocheCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Collaboration Agreement</link:label>
    <link:label id="lab_regn_RocheCollaborationAgreementMember_label_en-US" xlink:label="lab_regn_RocheCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_RocheCollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_RocheCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RocheCollaborationAgreementMember" xlink:href="regn-20210930.xsd#regn_RocheCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RocheCollaborationAgreementMember" xlink:to="lab_regn_RocheCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_2c142dc4-bf4c-4560-af02-258050ad827c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_d5a9dd1a-1b36-4fbf-8456-755186e71f3c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9bc44ef9-cf08-4b31-8d1d-2d1baf3d6284_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6be5f24a-7b0a-4227-bcd8-5a9e801b5d98_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_37687bb2-2d03-4a92-b3fd-fabc185293b1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b2f8af45-b5c0-411e-ac84-72e8c5b10d30_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value - 12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4ab8f633-cfd4-4ed0-90aa-6f98fe392505_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_0fe86d90-47e0-4dc5-93fa-fa5fae82c325_terseLabel_en-US" xlink:label="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recognized in connection with up-front payments received</link:label>
    <link:label id="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_619860e6-3909-4b98-ba4e-aaa761e76259_verboseLabel_en-US" xlink:label="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recognized in connection with up-front and development milestone payments received</link:label>
    <link:label id="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_label_en-US" xlink:label="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Recognized In Connection With Up-Front Payments [Member]</link:label>
    <link:label id="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_documentation_en-US" xlink:label="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Recognized In Connection With Up-Front Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:href="regn-20210930.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:to="lab_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_1e52f2e2-0718-440c-aa39-cc1e3a26640c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b3147fba-96a6-4231-8c42-5c3688cafbd2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_7030fcbc-ec46-4f30-a663-dd572cddeeaa_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_81b5edd1-f77e-432c-ac5c-6a2c0eaafc99_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_0bd4169d-4c87-4927-a8ea-952945b8d177_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_3d7d2fdc-8940-43f9-9dc7-bbdc19ad75a4_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_ac473c69-0dd2-4de7-b981-46d470261c8d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_e0eefdc5-e90c-4ef4-9bda-83c776a9bf3c_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_1149addd-0a6a-46bc-8e18-c6f884f50f1a_terseLabel_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of research and development expenses</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_ac7f2e02-2382-4cad-a9f5-55a372fe03bf_verboseLabel_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of research and development expenses</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_label_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expenses [Member]</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_documentation_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:href="regn-20210930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:to="lab_regn_ReimbursementOfResearchAndDevelopmentExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_811c695c-647a-4600-87f1-ce8b4ef8fdfe_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember_0230afcc-4ec4-48e6-b411-57f3d454abce_terseLabel_en-US" xlink:label="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of commercialization-related expenses</link:label>
    <link:label id="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember_label_en-US" xlink:label="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Commercialization-Related Expenses [Member]</link:label>
    <link:label id="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember_documentation_en-US" xlink:label="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Commercialization-Related Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:href="regn-20210930.xsd#regn_ReimbursementOfCommercializationRelatedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:to="lab_regn_ReimbursementOfCommercializationRelatedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9e93844d-0722-4e66-8bcb-298e9d208008_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_14876cc0-d534-4426-bd5d-031be70440d0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_5a8d2586-59b4-4a77-94f2-98fc9f74c7ee_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_31953d9e-8725-4551-9777-4dfe621ebc4c_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_99601d0e-2e55-4f0c-87ae-df598c00d920_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesMilestoneTwoMember_9715df45-d264-4d09-9e23-c992cea6ce5a_terseLabel_en-US" xlink:label="lab_regn_SalesMilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Sales Milestone</link:label>
    <link:label id="lab_regn_SalesMilestoneTwoMember_label_en-US" xlink:label="lab_regn_SalesMilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Two [Member]</link:label>
    <link:label id="lab_regn_SalesMilestoneTwoMember_documentation_en-US" xlink:label="lab_regn_SalesMilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneTwoMember" xlink:href="regn-20210930.xsd#regn_SalesMilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesMilestoneTwoMember" xlink:to="lab_regn_SalesMilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1047cb69-6aca-4b98-96c5-ba0d13363e2e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_f7ffa6bf-45a5-4e71-9bfc-996b30d6e802_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-offs and reserves</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareRepurchaseProgramJanuary2021Member_e92617c9-ea22-488b-9b66-6f4ebefc5287_terseLabel_en-US" xlink:label="lab_regn_ShareRepurchaseProgramJanuary2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2021 Share Repurchase Program</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramJanuary2021Member_label_en-US" xlink:label="lab_regn_ShareRepurchaseProgramJanuary2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, January 2021 [Member]</link:label>
    <link:label id="lab_regn_ShareRepurchaseProgramJanuary2021Member_documentation_en-US" xlink:label="lab_regn_ShareRepurchaseProgramJanuary2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program, January 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramJanuary2021Member" xlink:href="regn-20210930.xsd#regn_ShareRepurchaseProgramJanuary2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareRepurchaseProgramJanuary2021Member" xlink:to="lab_regn_ShareRepurchaseProgramJanuary2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_a95afcea-22b2-479b-8ab2-b489ed8dc249_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards and restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember_4b5397d6-54fe-49fa-99b4-0ff46f104614_terseLabel_en-US" xlink:label="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva</link:label>
    <link:label id="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember_label_en-US" xlink:label="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva Pharmaceuticals Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Teva Pharmaceuticals Collaboration Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:href="regn-20210930.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:to="lab_regn_TevaPharmaceuticalsCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a1660a70-19e6-4492-bb25-0b55631a1fb7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e1931d98-28d2-443a-ad8b-87747412d5f9_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_12b3cf0a-8052-403b-b154-eccc1f6b0a5d_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_de3cef39-40b0-4ded-becd-c1b3a74e8a04_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase_f55bfb27-aa83-4fbd-9dc4-d4c8b039ac0f_terseLabel_en-US" xlink:label="lab_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of doses</link:label>
    <link:label id="lab_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase_label_en-US" xlink:label="lab_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Doses Counterparty To Purchase</link:label>
    <link:label id="lab_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase_documentation_en-US" xlink:label="lab_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Doses Counterparty To Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" xlink:href="regn-20210930.xsd#regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" xlink:to="lab_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_28ebfe6a-9e51-432b-b1bb-e435374e16e8_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses, total</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_21958ad8-2534-4236-89d4-8c412ac3f8e1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_USGovernmentMember_f5049a92-6c03-4079-a53c-ae0615d320ee_terseLabel_en-US" xlink:label="lab_regn_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government</link:label>
    <link:label id="lab_regn_USGovernmentMember_label_en-US" xlink:label="lab_regn_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government [Member]</link:label>
    <link:label id="lab_regn_USGovernmentMember_documentation_en-US" xlink:label="lab_regn_USGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_USGovernmentMember" xlink:href="regn-20210930.xsd#regn_USGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_USGovernmentMember" xlink:to="lab_regn_USGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b4cf7ec4-249a-4729-9a5b-7aa392b37f2e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_408e8688-79cd-4c03-83a9-82551d79149b_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_6c410eb4-c011-4def-9b41-0652ff5c9129_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_20b0b5d3-a007-4286-9105-7170ed8d2209_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_761eb66b-dd41-47e2-8aa1-6eccc82d62ed_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_8ba4ff89-fa09-49cd-9b9d-b4070f119e10_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d8a88521-ea06-4fb8-8e30-c140537623f6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f7227c9c-936c-4ced-a8e0-6fb673fb9976_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9018fe89-5e2f-459c-bcb9-836eab6ea54d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_9bbebd97-59e1-4bcc-a0d2-89a282305528_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryNetOfReserves_5d24732a-f76d-445e-9683-129576e28f18_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred costs</link:label>
    <link:label id="lab_us-gaap_OtherInventoryNetOfReserves_label_en-US" xlink:label="lab_us-gaap_OtherInventoryNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryNetOfReserves" xlink:to="lab_us-gaap_OtherInventoryNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2ae6fa80-4ebd-4e16-aae1-c0f84ccd9a4d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_86589609-67ae-4a07-8cf7-a1c1dfb88e6d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_44260a44-ea20-420f-bb50-658963c69bca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_BridgeFacilityMember_e0790d9d-a1b9-48eb-82ae-27736614743b_terseLabel_en-US" xlink:label="lab_regn_BridgeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Facility</link:label>
    <link:label id="lab_regn_BridgeFacilityMember_label_en-US" xlink:label="lab_regn_BridgeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Facility [Member]</link:label>
    <link:label id="lab_regn_BridgeFacilityMember_documentation_en-US" xlink:label="lab_regn_BridgeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BridgeFacilityMember" xlink:href="regn-20210930.xsd#regn_BridgeFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_BridgeFacilityMember" xlink:to="lab_regn_BridgeFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_2f173b92-a27b-4f9a-a926-4594241bb6ea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value - Less than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b81e9060-b290-4fc9-bf98-1b4f9e7a0f10_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_b55170e9-f2a8-4851-9cbe-96f4a29277d0_netLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_c1277a6e-0763-43e6-a20d-4dc7f5124173_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5e22da7a-1f7b-4394-98c7-3f4c7a12d029_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CostOfGoodsSoldMember_e26c4627-29a6-4903-92ca-fb1c29d34dd9_terseLabel_en-US" xlink:label="lab_regn_CostOfGoodsSoldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_regn_CostOfGoodsSoldMember_label_en-US" xlink:label="lab_regn_CostOfGoodsSoldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods Sold [Member]</link:label>
    <link:label id="lab_regn_CostOfGoodsSoldMember_documentation_en-US" xlink:label="lab_regn_CostOfGoodsSoldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CostOfGoodsSoldMember" xlink:href="regn-20210930.xsd#regn_CostOfGoodsSoldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CostOfGoodsSoldMember" xlink:to="lab_regn_CostOfGoodsSoldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0617f993-7f0f-4bb2-b843-bfefa4664c22_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_98cffd5e-8e0e-4792-ba27-e176398f9e61_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_89573939-a0e6-4a37-9689-d1de37be7d03_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_8c483caa-8b89-4f5d-9f46-38f67043d351_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration, License, and Other Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6688c23f-9448-4fe9-a450-5d4b91611750_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RegeneronsShareOfCommercialExpensesMember_5692c7a0-9ecd-463d-bdde-f6567c0e7104_terseLabel_en-US" xlink:label="lab_regn_RegeneronsShareOfCommercialExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's obligation for its share of Sanofi commercial expenses</link:label>
    <link:label id="lab_regn_RegeneronsShareOfCommercialExpensesMember_label_en-US" xlink:label="lab_regn_RegeneronsShareOfCommercialExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's Share Of Commercial Expenses [Member]</link:label>
    <link:label id="lab_regn_RegeneronsShareOfCommercialExpensesMember_documentation_en-US" xlink:label="lab_regn_RegeneronsShareOfCommercialExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's Share Of Commercial Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfCommercialExpensesMember" xlink:href="regn-20210930.xsd#regn_RegeneronsShareOfCommercialExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RegeneronsShareOfCommercialExpensesMember" xlink:to="lab_regn_RegeneronsShareOfCommercialExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ad48dd8c-15fd-4043-b8b6-6f73de798640_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofiCollaborationAgreementAntibodyMember_f5157d49-f6f7-40da-b567-8e13c6629ab2_terseLabel_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Antibody</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementAntibodyMember_label_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Antibody [Member]</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementAntibodyMember_documentation_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Antibody [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember" xlink:href="regn-20210930.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofiCollaborationAgreementAntibodyMember" xlink:to="lab_regn_SanofiCollaborationAgreementAntibodyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2c3ec5b3-0d13-43f1-821e-68f7d50edc9a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2f57d3e6-136e-4d54-aeef-daf3715fa635_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9a404ec5-e7ed-47d1-95e1-bfafb54a63d9_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5fbe1d98-921e-47d4-a898-fad56431f7ed_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_35957110-e3a2-496e-948e-869486e6b525_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_1ec181ec-788b-419f-8391-b14f4652385a_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4c5c8c71-c90f-4916-8025-40b2aca9c9cb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_3ffe8351-4b2c-4247-b9e1-798a4647a950_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CollaborativeArrangementUpfrontPaymentMade_35ceb064-dc9d-4e6b-8133-baa51061a0fe_terseLabel_en-US" xlink:label="lab_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment made for collaboration agreement</link:label>
    <link:label id="lab_regn_CollaborativeArrangementUpfrontPaymentMade_label_en-US" xlink:label="lab_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Payment Made</link:label>
    <link:label id="lab_regn_CollaborativeArrangementUpfrontPaymentMade_documentation_en-US" xlink:label="lab_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment made under a collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:href="regn-20210930.xsd#regn_CollaborativeArrangementUpfrontPaymentMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:to="lab_regn_CollaborativeArrangementUpfrontPaymentMade" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7551a3c4-3008-4c09-ab57-caed7684f0cc_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_532dfd45-bdab-45c6-bc10-a2f6dd7cc27e_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_7b0255b6-238c-40b5-b941-f322c675f147_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_04f53f45-1f43-409f-8edf-15365d4bcd00_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_1accc6d1-2519-4fac-bfbc-c27b8c47060d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_22852554-e96e-45b0-a0ba-687c149f6e1e_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_EYLEAAfliberceptInjectionMember_00bf61cd-2ca3-4d68-8637-ce582a09f8f5_terseLabel_en-US" xlink:label="lab_regn_EYLEAAfliberceptInjectionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA</link:label>
    <link:label id="lab_regn_EYLEAAfliberceptInjectionMember_label_en-US" xlink:label="lab_regn_EYLEAAfliberceptInjectionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA Aflibercept Injection [Member]</link:label>
    <link:label id="lab_regn_EYLEAAfliberceptInjectionMember_documentation_en-US" xlink:label="lab_regn_EYLEAAfliberceptInjectionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EYLEA Aflibercept Injection</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EYLEAAfliberceptInjectionMember" xlink:href="regn-20210930.xsd#regn_EYLEAAfliberceptInjectionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_EYLEAAfliberceptInjectionMember" xlink:to="lab_regn_EYLEAAfliberceptInjectionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_348a2872-5e3a-4489-bc18-32c135b053ab_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e95a0b6b-64a0-46c5-957e-42ee98f25529_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesMilestonesAxis_cb0c89a1-27db-4f9a-b768-25dc6c1bcb72_terseLabel_en-US" xlink:label="lab_regn_SalesMilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Axis]</link:label>
    <link:label id="lab_regn_SalesMilestonesAxis_label_en-US" xlink:label="lab_regn_SalesMilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Axis]</link:label>
    <link:label id="lab_regn_SalesMilestonesAxis_documentation_en-US" xlink:label="lab_regn_SalesMilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesAxis" xlink:href="regn-20210930.xsd#regn_SalesMilestonesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesMilestonesAxis" xlink:to="lab_regn_SalesMilestonesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_52fe5457-fb86-4abf-9efa-5d0469af87a3_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ffadd668-f56c-446d-9c44-9ce5a1298244_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_95a7d5f5-c61b-4215-b4ba-5a8be0f39fa6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7cedba6f-320a-4609-9199-45ee9a95d9fa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0ec119ee-362a-47fc-b668-307256635d99_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f3b08b29-4d99-4dd6-9f4a-1f55d5cba21e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts payable, accrued expenses, and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_Amgenv.s.RegeneronMember_94bce8b4-a697-45bf-a51d-39496dbb609f_terseLabel_en-US" xlink:label="lab_regn_Amgenv.s.RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen v.s. Regeneron</link:label>
    <link:label id="lab_regn_Amgenv.s.RegeneronMember_label_en-US" xlink:label="lab_regn_Amgenv.s.RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen v.s. Regeneron [Member]</link:label>
    <link:label id="lab_regn_Amgenv.s.RegeneronMember_documentation_en-US" xlink:label="lab_regn_Amgenv.s.RegeneronMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen v.s. Regeneron [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_Amgenv.s.RegeneronMember" xlink:href="regn-20210930.xsd#regn_Amgenv.s.RegeneronMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_Amgenv.s.RegeneronMember" xlink:to="lab_regn_Amgenv.s.RegeneronMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_04b63cd0-12fc-45eb-af2d-47b35312663d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Non-Cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LossContingencyExParteReexaminationFiledNumber_0836e52e-95f6-4481-b236-3b8f24352cf3_terseLabel_en-US" xlink:label="lab_regn_LossContingencyExParteReexaminationFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ex parte reexamination requests</link:label>
    <link:label id="lab_regn_LossContingencyExParteReexaminationFiledNumber_label_en-US" xlink:label="lab_regn_LossContingencyExParteReexaminationFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Ex Parte Reexamination, Filed, Number</link:label>
    <link:label id="lab_regn_LossContingencyExParteReexaminationFiledNumber_documentation_en-US" xlink:label="lab_regn_LossContingencyExParteReexaminationFiledNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Ex Parte Reexamination, Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyExParteReexaminationFiledNumber" xlink:href="regn-20210930.xsd#regn_LossContingencyExParteReexaminationFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LossContingencyExParteReexaminationFiledNumber" xlink:to="lab_regn_LossContingencyExParteReexaminationFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_0727fbfc-829e-499d-8488-ec278affbf87_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of Common Stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_d5bc2e8a-bdd3-4c8d-b012-c10c5b5df6f0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0528e1c3-5cfe-4ee7-9f91-ab197d3313f1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_a2816b73-2f4e-41c7-8de0-dfba35c5842f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6c48a467-dde1-4fc6-8bab-30aecdd8a184_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_UnrestrictedMember_43908557-1907-46fb-b797-7056759da315_terseLabel_en-US" xlink:label="lab_regn_UnrestrictedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted</link:label>
    <link:label id="lab_regn_UnrestrictedMember_label_en-US" xlink:label="lab_regn_UnrestrictedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted [Member]</link:label>
    <link:label id="lab_regn_UnrestrictedMember_documentation_en-US" xlink:label="lab_regn_UnrestrictedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments whose use is not restricted in whole or in part, by contractual agreements or regulatory requirements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrestrictedMember" xlink:href="regn-20210930.xsd#regn_UnrestrictedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_UnrestrictedMember" xlink:to="lab_regn_UnrestrictedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_1ef844e9-9a88-4d21-b862-74850aa01615_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_359c6a09-7406-4133-81c9-b87f3e18efcb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from bridge loan facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_410eb2a7-acdf-46e4-877b-0f3ef08a0670_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a2ce6a79-ccd1-43c9-9ab3-e4876049748f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_973783d5-bb6b-4dde-abdb-2fd8381f3ae9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_881d46ce-3c1e-4296-abdc-d80bd523ac88_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_35b66165-9998-4a91-8f03-bfdad73cfeed_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_8c595a83-bb2e-445d-9c33-2f55896d8fbc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_3fbc0679-f06c-4065-b2ce-280cb8a70d94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5389f232-ed00-404e-b52c-567e07998fb0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2f1b4c20-8397-4fd5-8acd-e4febade78c0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_399de23c-6940-4bcc-be9d-0fb85b9eaf29_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_ec94341f-71fa-4a9a-ae45-f6e2c421d0c2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_552dd0b4-de80-4a04-884c-5465d31ea229_terseLabel_en-US" xlink:label="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's share of profits (losses) in connection with commercialization</link:label>
    <link:label id="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_label_en-US" xlink:label="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Profit (Losses) In Connection With Commercialization [Member]</link:label>
    <link:label id="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_documentation_en-US" xlink:label="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Profit (Losses) In Connection With Commercialization [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:href="regn-20210930.xsd#regn_ShareOfProfitLossesInConnectionWithCommercializationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:to="lab_regn_ShareOfProfitLossesInConnectionWithCommercializationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncome_283b1401-5249-46a8-95f4-d8dbd224e901_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome" xlink:to="lab_us-gaap_OtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_b9531e88-3c49-4cc0-b530-27a0cb1c1985_terseLabel_en-US" xlink:label="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's obligation for its share of Sanofi research and development expenses</link:label>
    <link:label id="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_d36c0168-5f1e-41e4-9e57-606f16313864_verboseLabel_en-US" xlink:label="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's obligation for its share of Bayer research and development expenses</link:label>
    <link:label id="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_label_en-US" xlink:label="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's Share Of Research And Development Expenses [Member]</link:label>
    <link:label id="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_documentation_en-US" xlink:label="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's Share Of Research And Development Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:href="regn-20210930.xsd#regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:to="lab_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RestrictedMember_0ae5f036-a86f-47a4-b212-8fe2b1da3d04_terseLabel_en-US" xlink:label="lab_regn_RestrictedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted</link:label>
    <link:label id="lab_regn_RestrictedMember_label_en-US" xlink:label="lab_regn_RestrictedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted [Member]</link:label>
    <link:label id="lab_regn_RestrictedMember_documentation_en-US" xlink:label="lab_regn_RestrictedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestrictedMember" xlink:href="regn-20210930.xsd#regn_RestrictedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RestrictedMember" xlink:to="lab_regn_RestrictedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a613334a-f50b-47e6-9b5f-a93628c91ed5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_bb1b2bfb-f56b-42e2-a550-023a1a954b68_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_487bb2e9-a6f3-46d0-884d-6d58e3bb2a84_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_863d430a-e723-40f5-ae1f-25894846ddca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9c7a25fc-d272-4e5f-aac9-c91bf07235e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c548f84d-3c94-45b8-9577-22e1f5400616_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_4a7cfe9c-2085-40e6-8aa7-94f89912b4a8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_76028b03-ca82-4291-a579-c11240c3c721_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_bb9ddf80-686c-48c6-8604-c1a75d2987ad_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_c62ab6d9-35d3-4b20-a84a-f1574f3ff1a5_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_4e78c48b-3ef8-43fe-b790-6ecf91db727d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_00c28d70-0247-4205-9f7f-aa859734bd3f_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_6ee80d47-1b6f-4ea1-992e-7c797cf0349f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_53eb45f1-0f8e-4a16-99b0-a173eb23470e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_67eaf104-03d6-476f-a90a-47d823c83d8e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of Common Stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b6c1d1f6-1941-40be-8dfb-f1d81efae86c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_0812b261-9893-4b3a-804b-eb9a7c682887_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_A741PatentMember_afa8eae4-79fa-4139-934b-3b4b5ccb0348_terseLabel_en-US" xlink:label="lab_regn_A741PatentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'741 Patent</link:label>
    <link:label id="lab_regn_A741PatentMember_label_en-US" xlink:label="lab_regn_A741PatentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'741 Patent [Member]</link:label>
    <link:label id="lab_regn_A741PatentMember_documentation_en-US" xlink:label="lab_regn_A741PatentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'741 Patent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A741PatentMember" xlink:href="regn-20210930.xsd#regn_A741PatentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_A741PatentMember" xlink:to="lab_regn_A741PatentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_2c175cb1-5ebb-4153-aebd-a45684f06ee4_totalLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total adjustments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_c74bf9a7-286b-4848-b31a-e706bc9746c4_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_492115bf-7253-4e99-b979-e926a0d1d0b7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_89246318-410c-4f63-ad87-719adc379ce2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c39cce83-6ed2-409e-bda8-ab57d2bf798b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_0bf08a82-bd8d-43fe-82f9-ffb831725902_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities owned not readily marketable</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9c24c3e2-8e6a-4320-b8ba-9f180c9f7b7a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_MaximumTransactionAgreementPayments_ddafcc34-f790-4f2a-84d4-c016da9b9c95_terseLabel_en-US" xlink:label="lab_regn_MaximumTransactionAgreementPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum agreement payments</link:label>
    <link:label id="lab_regn_MaximumTransactionAgreementPayments_label_en-US" xlink:label="lab_regn_MaximumTransactionAgreementPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Transaction Agreement Payments</link:label>
    <link:label id="lab_regn_MaximumTransactionAgreementPayments_documentation_en-US" xlink:label="lab_regn_MaximumTransactionAgreementPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Transaction Agreement Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumTransactionAgreementPayments" xlink:href="regn-20210930.xsd#regn_MaximumTransactionAgreementPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_MaximumTransactionAgreementPayments" xlink:to="lab_regn_MaximumTransactionAgreementPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_fe0fd27e-32f3-4d6c-acca-f7a704292ba1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2735601c-e0e9-4b71-ab22-b2d33b1e2978_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_9b026eb5-75e4-49f1-a11b-9eae1286698d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of Common Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d8a9bb4d-f272-46ad-b4ac-fa53d2a9e2b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CollaborationandContractManufacturingMember_408a9d23-6922-455f-8748-194348e26452_terseLabel_en-US" xlink:label="lab_regn_CollaborationandContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of collaboration and contract manufacturing</link:label>
    <link:label id="lab_regn_CollaborationandContractManufacturingMember_label_en-US" xlink:label="lab_regn_CollaborationandContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Contract Manufacturing [Member]</link:label>
    <link:label id="lab_regn_CollaborationandContractManufacturingMember_documentation_en-US" xlink:label="lab_regn_CollaborationandContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Contract Manufacturing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationandContractManufacturingMember" xlink:href="regn-20210930.xsd#regn_CollaborationandContractManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CollaborationandContractManufacturingMember" xlink:to="lab_regn_CollaborationandContractManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_70c9f763-8b48-4f07-8581-f6b00dc0c08c_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_45f6445f-3c82-4db4-a10e-2b3871e863ce_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_57f5e0d4-5415-4e0a-8ce5-d53cb413f2ce_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8cc87f41-c42a-4e79-b246-6adeba80bb49_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_1d20cf9a-fffc-4f1c-b8fb-8e88c5e9c140_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f595b1d3-c9b3-4932-afd7-958f2dbe43aa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Common Stock for equity awards granted under long-term incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_3e7b463c-2a23-49f6-9622-72eede5566fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2dd07ce1-9aa9-4626-9bf8-8b8ef6869c6a_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dce6427f-54c3-499d-bc6f-552f25fc41d4_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_75877b8c-740f-4f17-9692-778b3c8633c0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_d7f6380c-2a02-4039-9042-215a846a9fd3_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_b7370261-a47e-4dc0-964e-e1304f74c5d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e5e9f7da-5bb3-40c0-bc6d-d0d80913a31f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_684b9817-000d-43f1-b629-2a2e8590e27f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable and other securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_be566922-7fd1-41d4-b01a-d7966fb3f42d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ArcalystNetProductSalesMember_a1369a5f-a865-4ce7-8193-20d2cd4b67c1_terseLabel_en-US" xlink:label="lab_regn_ArcalystNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARCALYST</link:label>
    <link:label id="lab_regn_ArcalystNetProductSalesMember_label_en-US" xlink:label="lab_regn_ArcalystNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcalyst Net Product Sales [Member]</link:label>
    <link:label id="lab_regn_ArcalystNetProductSalesMember_documentation_en-US" xlink:label="lab_regn_ArcalystNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue during the period derived from a specified product line (ARCALYST), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ArcalystNetProductSalesMember" xlink:href="regn-20210930.xsd#regn_ArcalystNetProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ArcalystNetProductSalesMember" xlink:to="lab_regn_ArcalystNetProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a538dbf1-f1ec-4344-a86e-ae1462533808_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c7e13c83-9fa6-4f3a-8646-d2bed3c197b9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_GrossProductRevenueMember_b631ca39-2415-4678-9ce8-c26844a5c354_terseLabel_en-US" xlink:label="lab_regn_GrossProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenue</link:label>
    <link:label id="lab_regn_GrossProductRevenueMember_label_en-US" xlink:label="lab_regn_GrossProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Product Revenue [Member]</link:label>
    <link:label id="lab_regn_GrossProductRevenueMember_documentation_en-US" xlink:label="lab_regn_GrossProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Sales Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GrossProductRevenueMember" xlink:href="regn-20210930.xsd#regn_GrossProductRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_GrossProductRevenueMember" xlink:to="lab_regn_GrossProductRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_de5fcbac-d761-4c82-aa5f-d7e9cf047cda_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative catch-up adjustment to revenue, change in estimate of transaction price</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:to="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_03ef2785-a486-47bd-a4ba-3b0c0420f5e6_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a2e55556-0a25-4c2a-b035-21231b6f2641_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value - Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_56f41694-8ee5-40e3-939f-82b26365ce7f_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ff597823-549a-44b7-9c8f-c7933aeb857f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_eb5b49a7-3794-4d00-8778-ce1578a43659_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_GainContingencyClaimsInvalidatedNumber_1241c980-b09f-4404-a5ca-cb4417109cd9_terseLabel_en-US" xlink:label="lab_regn_GainContingencyClaimsInvalidatedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims invalidated</link:label>
    <link:label id="lab_regn_GainContingencyClaimsInvalidatedNumber_label_en-US" xlink:label="lab_regn_GainContingencyClaimsInvalidatedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Claims Invalidated, Number</link:label>
    <link:label id="lab_regn_GainContingencyClaimsInvalidatedNumber_documentation_en-US" xlink:label="lab_regn_GainContingencyClaimsInvalidatedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Claims Invalidated, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GainContingencyClaimsInvalidatedNumber" xlink:href="regn-20210930.xsd#regn_GainContingencyClaimsInvalidatedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_GainContingencyClaimsInvalidatedNumber" xlink:to="lab_regn_GainContingencyClaimsInvalidatedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_67e73554-064c-425c-b250-3d549bfd20e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_73422ad7-6d47-4d52-b66c-0916e38890c8_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1178ada2-0c08-4245-9d28-50c3a662e304_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_16a5e46a-c0cb-48aa-b5a8-56374e334888_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6fb4cc06-44bd-4896-b643-5817822835b5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of Common Stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_509d2a1a-3eae-4cca-a09c-6069c72c509f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d142ecbc-0f8e-4bd1-b7ab-f5f09fe2f7e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor_f970e0d8-90e9-48ee-bbf7-f8d25c85e104_terseLabel_en-US" xlink:label="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of damages company is responsible for</link:label>
    <link:label id="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor_label_en-US" xlink:label="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Percentage Of Damages Responsible For</link:label>
    <link:label id="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor_documentation_en-US" xlink:label="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Percentage Of Damages Responsible For</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:href="regn-20210930.xsd#regn_LossContingencyPercentageOfDamagesResponsibleFor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:to="lab_regn_LossContingencyPercentageOfDamagesResponsibleFor" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_617d0bfa-3f25-4b39-985d-25dbfd76bbe9_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4c682331-31ce-45c8-adb8-d5c2374b135a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_cb491089-887c-4ea9-8ca8-329ef7d8533c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ab38e8de-069f-465b-9679-3eb2c32e2be8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember_ad1eaf26-f2a8-482d-92b2-6eb688f46b55_terseLabel_en-US" xlink:label="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Agreement</link:label>
    <link:label id="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember_label_en-US" xlink:label="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Cross License And Commercialization Agreement [Member]</link:label>
    <link:label id="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember_documentation_en-US" xlink:label="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Cross License And Commercialization Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:href="regn-20210930.xsd#regn_PraluentCrossLicenseAndCommercializationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:to="lab_regn_PraluentCrossLicenseAndCommercializationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsTable_d8712d3b-b2b3-42e5-8778-94b367739c65_terseLabel_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Arrangements [Table]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsTable_label_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and Licensing Arrangements [Table]</link:label>
    <link:label id="lab_regn_ResearchCollaborationAndLicensingArrangementsTable_documentation_en-US" xlink:label="lab_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:href="regn-20210930.xsd#regn_ResearchCollaborationAndLicensingArrangementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:to="lab_regn_ResearchCollaborationAndLicensingArrangementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4b4b75b6-b8df-400b-8cad-0081e682435f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_75cfa9d7-a7b7-476d-aa01-55348631d9f4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_42dbb6a4-fb1c-4323-accd-b59f57aede6b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_017961d1-e85d-4ed0-855b-55f5f2ca1d7f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_a3c5b38b-4218-4f77-af42-d2e5b6034a68_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_60460cf3-8160-4ed5-b0a5-9e1cd2dc6a4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Issued Senior Unsecured Notes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_16885fd9-9c8d-46bd-aa6c-f99826c2d002_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_2c04c972-9b08-4eda-bf3a-79345410ecfa_terseLabel_en-US" xlink:label="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for achieving sales target for milestone payment, rolling basis</link:label>
    <link:label id="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_label_en-US" xlink:label="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for Achieving Sales Target for Milestone Payment, Rolling Basis</link:label>
    <link:label id="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_documentation_en-US" xlink:label="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for Achieving Sales Target for Milestone Payment, Rolling Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:href="regn-20210930.xsd#regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:to="lab_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_cd428a17-5d40-4b36-bdd0-f969cc748d34_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c93d7716-4cbc-4317-bdd2-0c53cbd8ce5a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_7741b0e0-1b16-4b7d-b148-3321f1fe6510_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_158dfe91-4f9c-494a-a988-53293e26b75a_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_6173ebb4-d0de-4aa1-8381-acd7f7b6b31b_netLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_8074dd6c-d728-41e9-b6a0-8099819506ca_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_629e0085-c383-4638-bb8b-cf835f6ba2d1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_55c14ba0-668b-4884-a621-c9a20af65383_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_be93512c-8366-48c6-b890-1662f71a29e3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7264e231-8ccb-48ee-9d2f-09b121d14822_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_108a3ffa-10e6-4270-88b8-f9e850b0c451_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e2bb2f69-0161-4b14-9390-1ca53459ceb1_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_79a85935-7655-4a06-9531-fdee6ed50346_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside United States</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_d2055770-5ec7-45a7-bfed-fb39cb990434_terseLabel_en-US" xlink:label="lab_regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amount of sales milestone payments if total sales achieve specific levels</link:label>
    <link:label id="lab_regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_label_en-US" xlink:label="lab_regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Amount Of Sales Milestone Payments If Total Sales Achieve Specific Levels</link:label>
    <link:label id="lab_regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_documentation_en-US" xlink:label="lab_regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Amount Of Sales Milestone Payments If Total Sales Achieve Specific Levels</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:href="regn-20210930.xsd#regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:to="lab_regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c18dee25-a77d-47cb-8c55-0ef2f9dd4aac_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_883b27de-617e-471c-9ded-3739a6939ace_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d58e50c0-bc5e-49e7-8353-12b8897e5902_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_fc333489-504a-4d50-9649-315f45d8f981_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, at cost; 17,930,390 shares in 2021 and 16,431,520 shares in 2020</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_1d1382e5-9847-462c-8853-7402cddb6421_terseLabel_en-US" xlink:label="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty payment that can be used to offset litigation proceedings (up to)</link:label>
    <link:label id="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_label_en-US" xlink:label="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Royalty Payment That Can Be Offset</link:label>
    <link:label id="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_documentation_en-US" xlink:label="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Royalty Payment That Can Be Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:href="regn-20210930.xsd#regn_PercentageOfRoyaltyPaymentThatCanBeOffset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:to="lab_regn_PercentageOfRoyaltyPaymentThatCanBeOffset" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_A631PatentMember_0eb22cc4-afcf-4261-b086-75edb30d319d_terseLabel_en-US" xlink:label="lab_regn_A631PatentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'631 Patent</link:label>
    <link:label id="lab_regn_A631PatentMember_label_en-US" xlink:label="lab_regn_A631PatentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'631 Patent [Member]</link:label>
    <link:label id="lab_regn_A631PatentMember_documentation_en-US" xlink:label="lab_regn_A631PatentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">'631 Patent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A631PatentMember" xlink:href="regn-20210930.xsd#regn_A631PatentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_A631PatentMember" xlink:to="lab_regn_A631PatentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e112b855-4a24-47cf-a22e-92c74f55d2d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_118e4dac-0782-4d00-9946-babcbdfaf90b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_65fc6a7f-e2e4-4f4d-844d-bc5949401993_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2050Member_f4b9207a-3ef7-4258-89e7-a0094e1dbf6c_terseLabel_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.800% Senior Notes due September 2050</link:label>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2050Member_label_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2050 [Member]</link:label>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2050Member_documentation_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2050Member" xlink:href="regn-20210930.xsd#regn_SeniorUnsecuredNotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SeniorUnsecuredNotesDue2050Member" xlink:to="lab_regn_SeniorUnsecuredNotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_bb0b9631-153a-4b2b-a7ba-ea9c961b9d9f_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ddbfa778-3c47-40a5-b9a8-2612cf106310_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_c4239f64-e404-4cfa-b1b4-c8e3e319e7b3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_77591ef7-ae96-4c1b-89be-08fa0652da0a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_30be3358-e7f3-476f-8750-8210d5f83c21_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05507f98-2596-4d73-8d80-dabafd2f8854_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CasirivimabAndImdevimabMember_eda1f453-a197-4c2d-b2fe-63837226a138_terseLabel_en-US" xlink:label="lab_regn_CasirivimabAndImdevimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Casirivimab and imdevimab</link:label>
    <link:label id="lab_regn_CasirivimabAndImdevimabMember_label_en-US" xlink:label="lab_regn_CasirivimabAndImdevimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Casirivimab and imdevimab [Member]</link:label>
    <link:label id="lab_regn_CasirivimabAndImdevimabMember_documentation_en-US" xlink:label="lab_regn_CasirivimabAndImdevimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Casirivimab and imdevimab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CasirivimabAndImdevimabMember" xlink:href="regn-20210930.xsd#regn_CasirivimabAndImdevimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CasirivimabAndImdevimabMember" xlink:to="lab_regn_CasirivimabAndImdevimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_601fda91-3a9e-46bb-8395-37dffbfe5df6_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods, collaboration and contract manufacturing</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_25b7d8c0-d7c0-4877-9e5e-311ce610fefb_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_REGENCOVMember_da4d6253-cf61-4544-89b5-4ed703d78205_terseLabel_en-US" xlink:label="lab_regn_REGENCOVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REGEN-COV</link:label>
    <link:label id="lab_regn_REGENCOVMember_label_en-US" xlink:label="lab_regn_REGENCOVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REGEN-COV [Member]</link:label>
    <link:label id="lab_regn_REGENCOVMember_documentation_en-US" xlink:label="lab_regn_REGENCOVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REGEN-COV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_REGENCOVMember" xlink:href="regn-20210930.xsd#regn_REGENCOVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_REGENCOVMember" xlink:to="lab_regn_REGENCOVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_c8f2ad31-6fb1-4396-99d6-a03d5d301051_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4643a5b1-07be-44e4-8f87-80f27d538a83_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_1f4999e9-f4b9-4512-a49c-e7c3c7a841b8_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_c105f7f3-2b91-405d-bb85-2e74816a4b99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4c11c6cd-9205-4587-993f-a0acddfeff3f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BridgeLoanMember_53e7f134-3174-48a5-bb1b-aed5712af407_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Facility</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember" xlink:to="lab_us-gaap_BridgeLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_f442e390-f3a3-436a-b8b0-7a04da0782ab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_70ab5cc0-b3e5-4e2c-a390-b7dcceb5752f_terseLabel_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement for manufacturing of commercial supplies</link:label>
    <link:label id="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_label_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement For Manufacturing Of Commercial Supplies [Member]</link:label>
    <link:label id="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_documentation_en-US" xlink:label="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement For Manufacturing Of Commercial Supplies [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:href="regn-20210930.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:to="lab_regn_ReimbursementForManufacturingOfCommercialSuppliesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_2c416f9d-5ede-44c8-b0e8-f816c8ea07b6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_29f36e44-037d-4609-b053-2535c6ddd911_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_IntelliaMember_7ef7b777-204c-48e5-9247-fcafb9ae1dd9_terseLabel_en-US" xlink:label="lab_regn_IntelliaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellia</link:label>
    <link:label id="lab_regn_IntelliaMember_label_en-US" xlink:label="lab_regn_IntelliaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellia [Member]</link:label>
    <link:label id="lab_regn_IntelliaMember_documentation_en-US" xlink:label="lab_regn_IntelliaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_IntelliaMember" xlink:href="regn-20210930.xsd#regn_IntelliaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_IntelliaMember" xlink:to="lab_regn_IntelliaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3d76b842-f304-4a8f-a162-6dcf585573fc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_c55d5c2e-c15c-4165-8092-418f493195e0_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d4d260d3-fe13-4de3-b52b-de994797721a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_a59876a7-ad62-4744-a3af-7452af8c7d92_totalLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_43c183ae-1e90-42fd-be67-5bc44b23b6a1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_886f2363-2b54-466d-9b0b-a5f81bf2ebb6_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2030Member_a104b60a-6902-47a0-9e2b-26974856f74e_terseLabel_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.750% Senior Notes due September 2030</link:label>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2030Member_label_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2030 [Member]</link:label>
    <link:label id="lab_regn_SeniorUnsecuredNotesDue2030Member_documentation_en-US" xlink:label="lab_regn_SeniorUnsecuredNotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2030Member" xlink:href="regn-20210930.xsd#regn_SeniorUnsecuredNotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SeniorUnsecuredNotesDue2030Member" xlink:to="lab_regn_SeniorUnsecuredNotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_BARDAOtherTransactionAgreementMember_49bc446f-f607-4973-8a15-a0f1694a6a84_terseLabel_en-US" xlink:label="lab_regn_BARDAOtherTransactionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Transaction Agreement</link:label>
    <link:label id="lab_regn_BARDAOtherTransactionAgreementMember_label_en-US" xlink:label="lab_regn_BARDAOtherTransactionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA, Other Transaction Agreement [Member]</link:label>
    <link:label id="lab_regn_BARDAOtherTransactionAgreementMember_documentation_en-US" xlink:label="lab_regn_BARDAOtherTransactionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA, Other Transaction Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BARDAOtherTransactionAgreementMember" xlink:href="regn-20210930.xsd#regn_BARDAOtherTransactionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_BARDAOtherTransactionAgreementMember" xlink:to="lab_regn_BARDAOtherTransactionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_15666d1a-6ecb-4362-8f8e-bbac7e64681a_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a4ce5ba5-00ca-4bf8-8e84-89b8d410bc61_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss - Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_CollaborationRevenueMember_d469ae1f-23d7-4401-b4bd-d73fa9656b56_terseLabel_en-US" xlink:label="lab_regn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_regn_CollaborationRevenueMember_label_en-US" xlink:label="lab_regn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_regn_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_regn_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember" xlink:href="regn-20210930.xsd#regn_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_CollaborationRevenueMember" xlink:to="lab_regn_CollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ClassificationOfInvestmentDomain_b9c88a15-1785-4152-b984-4783ac12dfad_terseLabel_en-US" xlink:label="lab_regn_ClassificationOfInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Domain]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentDomain_label_en-US" xlink:label="lab_regn_ClassificationOfInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of Investment [Domain]</link:label>
    <link:label id="lab_regn_ClassificationOfInvestmentDomain_documentation_en-US" xlink:label="lab_regn_ClassificationOfInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provides general categories of investments for which information is required or determined to be disclosed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain" xlink:href="regn-20210930.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ClassificationOfInvestmentDomain" xlink:to="lab_regn_ClassificationOfInvestmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_PraluentNetProductSalesMember_58986570-6b73-4f96-a333-2b472b227d4b_terseLabel_en-US" xlink:label="lab_regn_PraluentNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent</link:label>
    <link:label id="lab_regn_PraluentNetProductSalesMember_label_en-US" xlink:label="lab_regn_PraluentNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Net Product Sales [Member]</link:label>
    <link:label id="lab_regn_PraluentNetProductSalesMember_documentation_en-US" xlink:label="lab_regn_PraluentNetProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Praluent Net Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentNetProductSalesMember" xlink:href="regn-20210930.xsd#regn_PraluentNetProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_PraluentNetProductSalesMember" xlink:to="lab_regn_PraluentNetProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_6f241ec9-7481-41e2-956e-17db62a8c8be_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan_6a556e78-a987-480e-ada5-bf91ff61a23e_terseLabel_en-US" xlink:label="lab_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue based on percentage of annual sales in Japan</link:label>
    <link:label id="lab_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan_label_en-US" xlink:label="lab_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Based On Percentage Of Annual Sales In Japan</link:label>
    <link:label id="lab_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan_documentation_en-US" xlink:label="lab_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage on annual sales in Japan that the Company is entitled to receive, subject to certain potential adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan" xlink:href="regn-20210930.xsd#regn_RevenueBasedOnPercentageOfAnnualSalesInJapan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan" xlink:to="lab_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_395a5225-8e87-40de-a155-8f6194a0f140_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_LibtayoDevelopmentMember_ba66677c-2303-42fd-91e7-ae010a303102_terseLabel_en-US" xlink:label="lab_regn_LibtayoDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Libtayo development</link:label>
    <link:label id="lab_regn_LibtayoDevelopmentMember_label_en-US" xlink:label="lab_regn_LibtayoDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Libtayo Development [Member]</link:label>
    <link:label id="lab_regn_LibtayoDevelopmentMember_documentation_en-US" xlink:label="lab_regn_LibtayoDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Libtayo Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LibtayoDevelopmentMember" xlink:href="regn-20210930.xsd#regn_LibtayoDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_LibtayoDevelopmentMember" xlink:to="lab_regn_LibtayoDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_11b8acd0-1654-472d-b66e-03f6660f9e0f_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_7fa82979-81eb-4113-bcb5-33ee620f970b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_21ee61b6-2a78-4ab2-b29a-dfbd2f52879c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_ec75fad8-5a91-4a34-bf30-2159eca88c57_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_GainContingencyInterPartesReviewFiledNumber_703f9334-e2bc-4407-94ff-cc09d4aaee3a_terseLabel_en-US" xlink:label="lab_regn_GainContingencyInterPartesReviewFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of IPR filed</link:label>
    <link:label id="lab_regn_GainContingencyInterPartesReviewFiledNumber_label_en-US" xlink:label="lab_regn_GainContingencyInterPartesReviewFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Inter Partes Review Filed, Number</link:label>
    <link:label id="lab_regn_GainContingencyInterPartesReviewFiledNumber_documentation_en-US" xlink:label="lab_regn_GainContingencyInterPartesReviewFiledNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Inter Partes Review Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GainContingencyInterPartesReviewFiledNumber" xlink:href="regn-20210930.xsd#regn_GainContingencyInterPartesReviewFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_GainContingencyInterPartesReviewFiledNumber" xlink:to="lab_regn_GainContingencyInterPartesReviewFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_52c1c9cf-b7b9-4a85-9ca8-52ae616f309f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SalesMilestonesDomain_fe5af3ec-116b-4022-b70a-c019992614c1_terseLabel_en-US" xlink:label="lab_regn_SalesMilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Domain]</link:label>
    <link:label id="lab_regn_SalesMilestonesDomain_label_en-US" xlink:label="lab_regn_SalesMilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Domain]</link:label>
    <link:label id="lab_regn_SalesMilestonesDomain_documentation_en-US" xlink:label="lab_regn_SalesMilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestones [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesDomain" xlink:href="regn-20210930.xsd#regn_SalesMilestonesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SalesMilestonesDomain" xlink:to="lab_regn_SalesMilestonesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_60c7b6f3-4f11-472e-84a2-19b59648ab1e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_BayerCollaborationAgreementMember_e9b552d5-ce37-48ea-8e69-0a9b94facc3d_terseLabel_en-US" xlink:label="lab_regn_BayerCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer</link:label>
    <link:label id="lab_regn_BayerCollaborationAgreementMember_label_en-US" xlink:label="lab_regn_BayerCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Collaboration Agreement [Member]</link:label>
    <link:label id="lab_regn_BayerCollaborationAgreementMember_documentation_en-US" xlink:label="lab_regn_BayerCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Collaboration Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember" xlink:href="regn-20210930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_BayerCollaborationAgreementMember" xlink:to="lab_regn_BayerCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_MarketableSecuritiesRealizedGain_640ec806-ab11-4e36-912e-e8d99e7cafee_terseLabel_en-US" xlink:label="lab_regn_MarketableSecuritiesRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, realized gain</link:label>
    <link:label id="lab_regn_MarketableSecuritiesRealizedGain_label_en-US" xlink:label="lab_regn_MarketableSecuritiesRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain</link:label>
    <link:label id="lab_regn_MarketableSecuritiesRealizedGain_documentation_en-US" xlink:label="lab_regn_MarketableSecuritiesRealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MarketableSecuritiesRealizedGain" xlink:href="regn-20210930.xsd#regn_MarketableSecuritiesRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_MarketableSecuritiesRealizedGain" xlink:to="lab_regn_MarketableSecuritiesRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_0ba101f9-9d4e-473e-ade3-2726a44e04c2_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_41f4ceae-0672-4bab-a15e-78fe7c4e02c2_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales or maturities of marketable and other securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_fd33a781-24a2-4450-9eac-deb4df1f829a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f82fa2b5-cba5-4c65-b69f-1fbdf9fbe0c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_74907669-842a-4b7f-8f03-219f2b6bcfcb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c689155f-a135-4d84-b82d-301e775295f5_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_d33d32e7-d919-421b-9da4-b572ba11c02c_terseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign bonds</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_38055612-c710-4e3e-a6e4-375c0f90be5b_verboseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign bonds</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:to="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6047b61d-b928-41dc-8d18-bed77d37eb44_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_b9dcf01f-53e1-4bec-a21e-fbab65ab2fda_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6f60d961-20d1-4ce8-bcd1-a32a639ba06d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_d8f975cd-2049-4515-af8f-119c38b1d92e_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of sales to customers as percentage of total gross product revenue</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3da51ae5-ce17-4240-9f0b-b590f738d347_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2447adc3-9be9-4194-a854-c0a045f754cb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_32b2dc38-7f62-4186-9996-eb13ebb7bf34_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_adfbfbec-de82-47d9-88ce-4a13968f3cbc_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpense_41cdd057-3a02-438e-b862-4ff17663c10c_terseLabel_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of Research and development expense</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expense</link:label>
    <link:label id="lab_regn_ReimbursementOfResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_regn_ReimbursementOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpense" xlink:href="regn-20210930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_ReimbursementOfResearchAndDevelopmentExpense" xlink:to="lab_regn_ReimbursementOfResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e1cbb03-12b1-4e2f-9e4a-5a5cb6d95278_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_65eef01b-c4f9-471b-ac09-ac7aa28fff2c_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_DupilumabREGN3500EligibleInvestmentsMember_5445ed2e-60d7-408a-8497-0bf75193fd55_terseLabel_en-US" xlink:label="lab_regn_DupilumabREGN3500EligibleInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dupilumab/REGN3500 Eligible Investments</link:label>
    <link:label id="lab_regn_DupilumabREGN3500EligibleInvestmentsMember_label_en-US" xlink:label="lab_regn_DupilumabREGN3500EligibleInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dupilumab/REGN3500 Eligible Investments [Member]</link:label>
    <link:label id="lab_regn_DupilumabREGN3500EligibleInvestmentsMember_documentation_en-US" xlink:label="lab_regn_DupilumabREGN3500EligibleInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dupilumab/REGN3500 Eligible Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DupilumabREGN3500EligibleInvestmentsMember" xlink:href="regn-20210930.xsd#regn_DupilumabREGN3500EligibleInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_DupilumabREGN3500EligibleInvestmentsMember" xlink:to="lab_regn_DupilumabREGN3500EligibleInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_MarketableSecuritiesRealizedLoss_63d850e4-1e0a-4cb3-8fac-0ee5a7f5d736_terseLabel_en-US" xlink:label="lab_regn_MarketableSecuritiesRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, realized loss</link:label>
    <link:label id="lab_regn_MarketableSecuritiesRealizedLoss_label_en-US" xlink:label="lab_regn_MarketableSecuritiesRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Loss</link:label>
    <link:label id="lab_regn_MarketableSecuritiesRealizedLoss_documentation_en-US" xlink:label="lab_regn_MarketableSecuritiesRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MarketableSecuritiesRealizedLoss" xlink:href="regn-20210930.xsd#regn_MarketableSecuritiesRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_MarketableSecuritiesRealizedLoss" xlink:to="lab_regn_MarketableSecuritiesRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cdf79dc2-6888-41e7-a4f9-9e55d539ca58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_b6d8c54f-42c1-4a47-b041-eedb727eaced_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_0bcd67b0-97ea-4c7a-989f-81dbcde0c1cb_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_8d3cd4f2-fd08-4b25-bdcf-e50fd77923db_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_528c3e6f-df3f-44a3-ab5b-dcec03df8283_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b9ee6556-78c7-4529-8d48-65238d90fe68_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7b41e80b-d8cc-49dc-9b56-dba23b775dbc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_960382f0-dff7-4be2-9d9c-52e221de2cb2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_3bde52ce-5190-43f9-874b-e801b3ed2372_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_29f059c0-d2c5-4758-87b8-0d9cb9a9d45f_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, realized gain (loss)</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_38b7256e-d1be-4e0e-9150-7a47a7c88868_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1a48e19c-d90f-4833-8e7e-b40acb6170cc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3204f316-ac5c-461e-a749-a1f90516ceca_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08003921-58b9-4536-a220-766e2a3e49aa_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_311fc27b-b81d-4de5-a692-bd814be72b8e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a3298676-c232-42fa-8da0-013a17f88ce5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments in connection with Common Stock tendered for employee tax obligations</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c54b77a6-94f8-446c-a461-7f7bf6747565_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_b15e9422-bf06-4297-903a-109a239b8432_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_294a0f72-8446-4860-8850-03722db984f3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6a856b8e-c2a7-4c49-b43d-df14493133bc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_805499ed-c33a-4b06-b583-64664f266361_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_4657eaa7-61f2-4c8c-9142-7a983ba91f01_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_39617e0d-3755-4b9e-90bc-59ce78a08994_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3d0c5392-ab59-479b-b898-4688f42e016e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f77bbea1-b59b-47ae-aba0-8096caafcd6a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_a0b83488-df34-4f53-9ec6-42cee12f6f96_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9dc05a5d-c115-43bd-a53e-510710bc604b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_79143769-24db-4c58-8c12-aa1a6092d4a4_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_c796dfd8-1567-475b-9043-7cbe5ededc36_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_688c6a34-8c17-4e69-9854-e303760494f0_terseLabel_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_70d71cd8-198a-4fe4-958f-b676aaa05723_netLabel_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_6b1ec319-0f25-4380-a793-ca1a89702d42_verboseLabel_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_label_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology [Member]</link:label>
    <link:label id="lab_regn_SanofiCollaborationAgreementImmunooncologyMember_documentation_en-US" xlink:label="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Collaboration Agreement, Immuno-oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:href="regn-20210930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:to="lab_regn_SanofiCollaborationAgreementImmunooncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_83805f68-d595-4657-b84d-fe397af41eea_terseLabel_en-US" xlink:label="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</link:label>
    <link:label id="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_label_en-US" xlink:label="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi's Share of Libtayo U.S. Gross Profits [Member]</link:label>
    <link:label id="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_documentation_en-US" xlink:label="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi's Share of Libtayo U.S. Gross Profits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:href="regn-20210930.xsd#regn_SanofisShareofLibtayoU.S.GrossProfitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:to="lab_regn_SanofisShareofLibtayoU.S.GrossProfitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_48e8f5ea-c8c0-46d4-9da6-1f63305dce17_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss - Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_8af57175-7f9e-4321-921b-513ab062a03b_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_71aa669f-7164-422b-bf3e-30e5675b0771_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_64f32ded-104c-4232-9760-ed6814d91d4c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_6df0cb36-f85c-4cce-a344-d37bf16c7939_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_55f4bc85-a11f-4461-b732-d5b21307e04e_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss - 12 Months or Greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>regn-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:08b52028-35ad-4384-abb4-ffa84b7c541b,g:79516084-017d-4f01-b220-9a6b8eb4ad51-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.regeneron.com/role/Cover" xlink:type="simple" xlink:href="regn-20210930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_02feac1e-8ea7-4aad-ad5d-79ac680b900f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_9b070c4e-94a7-4554-948e-265296fbb475" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_02feac1e-8ea7-4aad-ad5d-79ac680b900f" xlink:to="loc_dei_EntitiesTable_9b070c4e-94a7-4554-948e-265296fbb475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f4ad8a8a-3bc0-46bc-9660-4ba025eec3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_9b070c4e-94a7-4554-948e-265296fbb475" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f4ad8a8a-3bc0-46bc-9660-4ba025eec3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7e53fd26-76c2-4c4a-ae82-85bcd266f929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f4ad8a8a-3bc0-46bc-9660-4ba025eec3e2" xlink:to="loc_us-gaap_ClassOfStockDomain_7e53fd26-76c2-4c4a-ae82-85bcd266f929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_cde4f2e7-f76c-4568-87a1-f09a90ba43b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7e53fd26-76c2-4c4a-ae82-85bcd266f929" xlink:to="loc_us-gaap_CommonClassAMember_cde4f2e7-f76c-4568-87a1-f09a90ba43b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_67ef099c-bc66-45c1-bdfc-d3d86943669d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7e53fd26-76c2-4c4a-ae82-85bcd266f929" xlink:to="loc_us-gaap_CommonStockMember_67ef099c-bc66-45c1-bdfc-d3d86943669d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_9b070c4e-94a7-4554-948e-265296fbb475" xlink:to="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_99a3d01d-2365-42fe-92c2-96fa00cb5644" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_DocumentType_99a3d01d-2365-42fe-92c2-96fa00cb5644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c1093a31-fecb-45a3-b51c-aa8fce6c7bd0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_DocumentQuarterlyReport_c1093a31-fecb-45a3-b51c-aa8fce6c7bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_eb19a6ea-ce02-4cc2-91ee-ccaa9805ef90" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_DocumentPeriodEndDate_eb19a6ea-ce02-4cc2-91ee-ccaa9805ef90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f01c187e-b253-4ced-83b8-12e36d68b340" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_DocumentTransitionReport_f01c187e-b253-4ced-83b8-12e36d68b340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5532f5ab-e5c4-4e3f-a9ef-668348548e89" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityFileNumber_5532f5ab-e5c4-4e3f-a9ef-668348548e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_58a0c1a2-9cbd-4069-8ed9-5473438e1779" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityRegistrantName_58a0c1a2-9cbd-4069-8ed9-5473438e1779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_13fb1f7d-fd7e-4e7c-8423-f4d95b4e7fca" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityIncorporationStateCountryCode_13fb1f7d-fd7e-4e7c-8423-f4d95b4e7fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9ea713e1-a93c-4908-8fcd-ca59f14bf5c1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityTaxIdentificationNumber_9ea713e1-a93c-4908-8fcd-ca59f14bf5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_121e1192-c4e0-4d37-9706-784779ccdaf4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityAddressAddressLine1_121e1192-c4e0-4d37-9706-784779ccdaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_48b44240-5abe-41b6-a1a7-b8d2e7f212e0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityAddressCityOrTown_48b44240-5abe-41b6-a1a7-b8d2e7f212e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1d80e397-4746-4096-8eab-3c0a99495c7f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityAddressStateOrProvince_1d80e397-4746-4096-8eab-3c0a99495c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6870fc81-7375-4835-9803-feaa60c3578b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityAddressPostalZipCode_6870fc81-7375-4835-9803-feaa60c3578b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_733f772b-6434-4db3-8998-400949eaf67a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_CityAreaCode_733f772b-6434-4db3-8998-400949eaf67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7490e758-e899-40cd-9712-8070889fe0f3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_LocalPhoneNumber_7490e758-e899-40cd-9712-8070889fe0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cad244db-a9a4-4ddf-b720-6cc97c4f6861" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_Security12bTitle_cad244db-a9a4-4ddf-b720-6cc97c4f6861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fe4fe08b-c793-4131-9936-c6f213fe5020" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_TradingSymbol_fe4fe08b-c793-4131-9936-c6f213fe5020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_70384767-f7ba-41fe-9a5f-4801fdf37016" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_SecurityExchangeName_70384767-f7ba-41fe-9a5f-4801fdf37016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_697b79ab-a9af-4d47-a748-6bef7c77e59f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityCurrentReportingStatus_697b79ab-a9af-4d47-a748-6bef7c77e59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4e3fd272-6a85-41f8-a50e-16db7f354786" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityInteractiveDataCurrent_4e3fd272-6a85-41f8-a50e-16db7f354786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a5be1869-e3d7-4947-8a66-e8bd00996eca" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityFilerCategory_a5be1869-e3d7-4947-8a66-e8bd00996eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_cb19f6dc-649c-4ec4-84c7-c0decaba593b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntitySmallBusiness_cb19f6dc-649c-4ec4-84c7-c0decaba593b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cd2fb9c7-9009-4fbe-9dd5-6dd5a49430eb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityEmergingGrowthCompany_cd2fb9c7-9009-4fbe-9dd5-6dd5a49430eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_623ebdbc-7382-4c2f-9b99-959fbcd8e317" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityShellCompany_623ebdbc-7382-4c2f-9b99-959fbcd8e317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b5f95ad0-7024-4d54-806f-bb152c1fed5b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b5f95ad0-7024-4d54-806f-bb152c1fed5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_85b18077-d0d7-4781-8dba-ca94ae4788d1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_EntityCentralIndexKey_85b18077-d0d7-4781-8dba-ca94ae4788d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2c93d003-be96-465d-b042-13ec5f63b1e1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_CurrentFiscalYearEndDate_2c93d003-be96-465d-b042-13ec5f63b1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_db060940-0ce1-4a9c-9d1f-40e5f7ff824a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_DocumentFiscalYearFocus_db060940-0ce1-4a9c-9d1f-40e5f7ff824a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_429b3704-3d64-428d-a0ea-de6e0aca380a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_DocumentFiscalPeriodFocus_429b3704-3d64-428d-a0ea-de6e0aca380a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7ca0d7ac-6365-4964-b5cb-0803ca64c21d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_74bb63ee-38d8-41c4-b638-06a5dc5ed4ee" xlink:to="loc_dei_AmendmentFlag_7ca0d7ac-6365-4964-b5cb-0803ca64c21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="regn-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1c6dab07-3276-485f-a826-bf008b4d45c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8bdd57db-e6ca-42a6-a512-f0c8df2ebcab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1c6dab07-3276-485f-a826-bf008b4d45c8" xlink:to="loc_us-gaap_StatementTable_8bdd57db-e6ca-42a6-a512-f0c8df2ebcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6730da1b-4574-486b-ae4c-2f45ca0f66a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8bdd57db-e6ca-42a6-a512-f0c8df2ebcab" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6730da1b-4574-486b-ae4c-2f45ca0f66a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_38ee120c-3a97-4f14-971f-bb0407567560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6730da1b-4574-486b-ae4c-2f45ca0f66a4" xlink:to="loc_us-gaap_ClassOfStockDomain_38ee120c-3a97-4f14-971f-bb0407567560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c337b6e0-f6f8-4fd2-a14e-b0ccd80abf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_38ee120c-3a97-4f14-971f-bb0407567560" xlink:to="loc_us-gaap_CommonClassAMember_c337b6e0-f6f8-4fd2-a14e-b0ccd80abf9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5bc5d659-4197-4a8c-8389-22310c521415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_38ee120c-3a97-4f14-971f-bb0407567560" xlink:to="loc_us-gaap_CommonStockMember_5bc5d659-4197-4a8c-8389-22310c521415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_66c776d8-1339-4825-ba2f-7289a2df956f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8bdd57db-e6ca-42a6-a512-f0c8df2ebcab" xlink:to="loc_us-gaap_StatementLineItems_66c776d8-1339-4825-ba2f-7289a2df956f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_66c776d8-1339-4825-ba2f-7289a2df956f" xlink:to="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:to="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b6cd7edb-7b36-4b9d-8100-bd0748287ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b6cd7edb-7b36-4b9d-8100-bd0748287ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2bc730e2-1921-4557-8bb2-f8019e1f475c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2bc730e2-1921-4557-8bb2-f8019e1f475c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_66b87ab1-8782-49be-9ebb-75a6989c25dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_66b87ab1-8782-49be-9ebb-75a6989c25dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_da53a5dd-4928-41ef-8b4b-e9cb154f09e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:to="loc_us-gaap_InventoryNet_da53a5dd-4928-41ef-8b4b-e9cb154f09e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d2e006b7-eb60-4162-88e1-fb2491fb94d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d2e006b7-eb60-4162-88e1-fb2491fb94d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_397be058-2044-477e-86b9-eb27f07b91e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04032d05-db7d-48eb-b12a-0a6f8362c262" xlink:to="loc_us-gaap_AssetsCurrent_397be058-2044-477e-86b9-eb27f07b91e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_650fcc89-0914-493f-a5be-eafa193e5345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_650fcc89-0914-493f-a5be-eafa193e5345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ddf6b7c9-2772-404d-8b4d-65c627e0df17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ddf6b7c9-2772-404d-8b4d-65c627e0df17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_f171ca28-a008-4d37-9ad6-82cd073100a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_f171ca28-a008-4d37-9ad6-82cd073100a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_537f247d-0904-466e-952b-014d888fcc17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_537f247d-0904-466e-952b-014d888fcc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ce4d7907-0919-41f0-8c7c-ddfb5140b6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fa2f204a-0829-4e34-8c4a-09560b34e4fe" xlink:to="loc_us-gaap_Assets_ce4d7907-0919-41f0-8c7c-ddfb5140b6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_66c776d8-1339-4825-ba2f-7289a2df956f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1f7befb3-9f65-4c83-94e1-6865cafd4d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1f7befb3-9f65-4c83-94e1-6865cafd4d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_090b3927-4c39-4a68-9f3e-9bb24f3618a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f7befb3-9f65-4c83-94e1-6865cafd4d88" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_090b3927-4c39-4a68-9f3e-9bb24f3618a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a02dde28-b03d-46e6-973b-76f2c172a624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f7befb3-9f65-4c83-94e1-6865cafd4d88" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a02dde28-b03d-46e6-973b-76f2c172a624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f8195033-2f7c-4a7d-8788-36443ba676b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f7befb3-9f65-4c83-94e1-6865cafd4d88" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f8195033-2f7c-4a7d-8788-36443ba676b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_06d66827-2259-400e-b350-816ca358f5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f7befb3-9f65-4c83-94e1-6865cafd4d88" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_06d66827-2259-400e-b350-816ca358f5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7c308152-c1ff-4746-bb6a-f2703711ef8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1f7befb3-9f65-4c83-94e1-6865cafd4d88" xlink:to="loc_us-gaap_LiabilitiesCurrent_7c308152-c1ff-4746-bb6a-f2703711ef8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c9a0fb9f-1f58-4848-9d9b-d57c0a6f18bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c9a0fb9f-1f58-4848-9d9b-d57c0a6f18bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b11cc4a8-9d91-4bff-82d3-2ace2fbc919d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b11cc4a8-9d91-4bff-82d3-2ace2fbc919d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_929938a6-87f8-45c7-86ea-11e9b8396837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_929938a6-87f8-45c7-86ea-11e9b8396837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b7fe043b-5d9c-43da-b4d9-dec2027f59de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b7fe043b-5d9c-43da-b4d9-dec2027f59de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_10c1cda9-3163-441d-9814-21b243ef5bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_Liabilities_10c1cda9-3163-441d-9814-21b243ef5bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7bef9020-74fd-40b9-8a1a-5f72f15f445a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:to="loc_us-gaap_PreferredStockValue_7bef9020-74fd-40b9-8a1a-5f72f15f445a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_81517a3f-0d9c-4d12-829a-479bb00f676d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:to="loc_us-gaap_CommonStockValue_81517a3f-0d9c-4d12-829a-479bb00f676d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ca22062f-31ac-418f-861d-cd1281b73d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ca22062f-31ac-418f-861d-cd1281b73d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bb274e70-53f9-4807-adff-dc3eda0a79f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bb274e70-53f9-4807-adff-dc3eda0a79f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_190d8012-d72a-47a2-9548-69826a9790fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_190d8012-d72a-47a2-9548-69826a9790fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_8613912f-1511-470e-8d6c-2bcc5d9fb3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:to="loc_us-gaap_TreasuryStockValue_8613912f-1511-470e-8d6c-2bcc5d9fb3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8ad01911-6500-4d22-82b2-1b1c25c2afdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e6040ad0-a8b1-4caf-b0ac-97e7e1a9ea64" xlink:to="loc_us-gaap_StockholdersEquity_8ad01911-6500-4d22-82b2-1b1c25c2afdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8951bfc0-13c1-4341-b4cf-6c5ae322bef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a728e4a1-14d7-4e80-9d02-c780215c55e7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8951bfc0-13c1-4341-b4cf-6c5ae322bef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" xlink:href="regn-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6c705682-6805-4140-8695-841589c06ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_19f45e27-1f86-449d-b4b6-77d597f54018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6c705682-6805-4140-8695-841589c06ec9" xlink:to="loc_us-gaap_StatementTable_19f45e27-1f86-449d-b4b6-77d597f54018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_86cb7e6b-20f9-4bd6-b546-9c9d7be76fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_19f45e27-1f86-449d-b4b6-77d597f54018" xlink:to="loc_us-gaap_StatementClassOfStockAxis_86cb7e6b-20f9-4bd6-b546-9c9d7be76fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9ca7e376-c7ab-4cca-a693-225c6e33e528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_86cb7e6b-20f9-4bd6-b546-9c9d7be76fbe" xlink:to="loc_us-gaap_ClassOfStockDomain_9ca7e376-c7ab-4cca-a693-225c6e33e528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_af4c3278-be40-450f-acba-c06981389bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9ca7e376-c7ab-4cca-a693-225c6e33e528" xlink:to="loc_us-gaap_CommonClassAMember_af4c3278-be40-450f-acba-c06981389bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_21576eac-a6d6-4ecf-ab58-80b6da72af8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9ca7e376-c7ab-4cca-a693-225c6e33e528" xlink:to="loc_us-gaap_CommonStockMember_21576eac-a6d6-4ecf-ab58-80b6da72af8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0fa305a1-6b45-401e-94cf-5808663029b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_19f45e27-1f86-449d-b4b6-77d597f54018" xlink:to="loc_us-gaap_StatementLineItems_0fa305a1-6b45-401e-94cf-5808663029b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2caeea61-0e05-4e39-91a6-ce5deca3195f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0fa305a1-6b45-401e-94cf-5808663029b8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2caeea61-0e05-4e39-91a6-ce5deca3195f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2caeea61-0e05-4e39-91a6-ce5deca3195f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d9c7770f-5b31-4f54-acd5-d6fc816f4c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d9c7770f-5b31-4f54-acd5-d6fc816f4c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0639f9b2-11ee-46d6-99ff-6e33968e0fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0639f9b2-11ee-46d6-99ff-6e33968e0fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_44ffd945-f1e5-4183-a02b-c87de3db65d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_PreferredStockSharesIssued_44ffd945-f1e5-4183-a02b-c87de3db65d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_91d1b254-3042-4167-a1ad-eec8f75ba419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_91d1b254-3042-4167-a1ad-eec8f75ba419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9f34565f-b04e-4496-a693-06e0ce562ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9f34565f-b04e-4496-a693-06e0ce562ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_aa7463d0-7c09-4424-ac6e-80bb9e9c990e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_aa7463d0-7c09-4424-ac6e-80bb9e9c990e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_25777587-f61c-4d1e-96e2-c6ea6922776c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_CommonStockSharesIssued_25777587-f61c-4d1e-96e2-c6ea6922776c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_80f31ada-2513-414c-b8f4-62f7537947e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_80f31ada-2513-414c-b8f4-62f7537947e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_deaa54ca-cd4f-41bf-8c34-b1f60f90bef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2e53ac3c-3417-4ddd-9090-35c3e6bb4f90" xlink:to="loc_us-gaap_TreasuryStockShares_deaa54ca-cd4f-41bf-8c34-b1f60f90bef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="simple" xlink:href="regn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_322b2662-539d-4abb-8e8b-0399458598ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_eade2c32-5def-40ed-8404-8a737f03c5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_322b2662-539d-4abb-8e8b-0399458598ec" xlink:to="loc_us-gaap_StatementTable_eade2c32-5def-40ed-8404-8a737f03c5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ddc73463-9ebd-405e-a10e-0b454c933117" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_eade2c32-5def-40ed-8404-8a737f03c5d6" xlink:to="loc_srt_ProductOrServiceAxis_ddc73463-9ebd-405e-a10e-0b454c933117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e960cae0-e9f0-4bc2-b25e-7d19c3e2e502" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ddc73463-9ebd-405e-a10e-0b454c933117" xlink:to="loc_srt_ProductsAndServicesDomain_e960cae0-e9f0-4bc2-b25e-7d19c3e2e502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4265bd0a-a31d-4d56-9ffe-7ad83dbd2e51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e960cae0-e9f0-4bc2-b25e-7d19c3e2e502" xlink:to="loc_us-gaap_ProductMember_4265bd0a-a31d-4d56-9ffe-7ad83dbd2e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_ea9a38c7-84cc-456c-a06e-8dbc76002f51" xlink:href="regn-20210930.xsd#regn_CollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e960cae0-e9f0-4bc2-b25e-7d19c3e2e502" xlink:to="loc_regn_CollaborationRevenueMember_ea9a38c7-84cc-456c-a06e-8dbc76002f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_0e2cb654-3331-4e63-9243-fddf692fd4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e960cae0-e9f0-4bc2-b25e-7d19c3e2e502" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_0e2cb654-3331-4e63-9243-fddf692fd4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationandContractManufacturingMember_86bebaa9-860c-41c8-9c80-33da6b978039" xlink:href="regn-20210930.xsd#regn_CollaborationandContractManufacturingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e960cae0-e9f0-4bc2-b25e-7d19c3e2e502" xlink:to="loc_regn_CollaborationandContractManufacturingMember_86bebaa9-860c-41c8-9c80-33da6b978039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4f26b83c-cd25-4d69-9e23-55aea2385542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_eade2c32-5def-40ed-8404-8a737f03c5d6" xlink:to="loc_us-gaap_StatementLineItems_4f26b83c-cd25-4d69-9e23-55aea2385542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4f26b83c-cd25-4d69-9e23-55aea2385542" xlink:to="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_226f139b-b1d0-4ec2-a8ae-b6b085c0667a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_RevenuesAbstract_226f139b-b1d0-4ec2-a8ae-b6b085c0667a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eea134e1-7c84-41f8-b292-bb495f9e80d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_226f139b-b1d0-4ec2-a8ae-b6b085c0667a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eea134e1-7c84-41f8-b292-bb495f9e80d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_779b92cf-86c3-4879-aefb-6414e708a807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_779b92cf-86c3-4879-aefb-6414e708a807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a8b80a07-4cdf-4ebc-9507-4c2d8358ea79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_779b92cf-86c3-4879-aefb-6414e708a807" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a8b80a07-4cdf-4ebc-9507-4c2d8358ea79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d9ee4afe-c117-4974-99b5-0d97f91bd164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_779b92cf-86c3-4879-aefb-6414e708a807" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d9ee4afe-c117-4974-99b5-0d97f91bd164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1191f285-29ff-47ee-b635-109122d57768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_779b92cf-86c3-4879-aefb-6414e708a807" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1191f285-29ff-47ee-b635-109122d57768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_4303b386-46b3-4c10-b2ec-6c66c49e63c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_779b92cf-86c3-4879-aefb-6414e708a807" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_4303b386-46b3-4c10-b2ec-6c66c49e63c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_daf0e631-96fc-4d36-8ef7-21739916e668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_779b92cf-86c3-4879-aefb-6414e708a807" xlink:to="loc_us-gaap_CostsAndExpenses_daf0e631-96fc-4d36-8ef7-21739916e668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7b783093-8372-425d-a165-55cb41bc8311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_OperatingIncomeLoss_7b783093-8372-425d-a165-55cb41bc8311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_37ff2441-d5f9-4a77-818d-377c6a17ae88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_37ff2441-d5f9-4a77-818d-377c6a17ae88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4b237238-9678-472a-afcc-bb31f0fae9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_37ff2441-d5f9-4a77-818d-377c6a17ae88" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4b237238-9678-472a-afcc-bb31f0fae9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6e813ed6-b693-4191-aa03-24affa0d49fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_37ff2441-d5f9-4a77-818d-377c6a17ae88" xlink:to="loc_us-gaap_InterestExpense_6e813ed6-b693-4191-aa03-24affa0d49fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d8e8c906-33f0-4583-97d4-f852abce7314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_37ff2441-d5f9-4a77-818d-377c6a17ae88" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d8e8c906-33f0-4583-97d4-f852abce7314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d5dc2b1-7c96-45c7-83c7-4bcbbc99098f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d5dc2b1-7c96-45c7-83c7-4bcbbc99098f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_53a609c8-54f5-4356-b63a-4275181fe2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_53a609c8-54f5-4356-b63a-4275181fe2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_04cca0fc-3b4f-488c-8626-a14ad43c2a92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_NetIncomeLoss_04cca0fc-3b4f-488c-8626-a14ad43c2a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1f1abca5-4b64-47b1-876a-dacce50eea90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_EarningsPerShareBasic_1f1abca5-4b64-47b1-876a-dacce50eea90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2774097b-489f-4cb0-b8fa-fa8034304a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2774097b-489f-4cb0-b8fa-fa8034304a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2a1ac6a1-bc15-457b-b917-1572124c0368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2a1ac6a1-bc15-457b-b917-1572124c0368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_acf9622e-08e5-43cb-8c75-a8a736acc9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_be5cbd8a-faea-403f-92fe-3a4e62c1921a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_acf9622e-08e5-43cb-8c75-a8a736acc9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_540e6d60-f921-419d-82e6-cebdc773cb45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4f26b83c-cd25-4d69-9e23-55aea2385542" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_540e6d60-f921-419d-82e6-cebdc773cb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_34fa3cb8-4b1e-4d8b-9675-c3bc6681117f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_540e6d60-f921-419d-82e6-cebdc773cb45" xlink:to="loc_us-gaap_NetIncomeLoss_34fa3cb8-4b1e-4d8b-9675-c3bc6681117f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0264e8eb-bc21-4e8f-b2ed-464a04e920d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_540e6d60-f921-419d-82e6-cebdc773cb45" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0264e8eb-bc21-4e8f-b2ed-464a04e920d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b5848059-8711-464b-a6f8-42e17c26678d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0264e8eb-bc21-4e8f-b2ed-464a04e920d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b5848059-8711-464b-a6f8-42e17c26678d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_d5927db3-7b13-45ac-b881-b0baa5998b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0264e8eb-bc21-4e8f-b2ed-464a04e920d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_d5927db3-7b13-45ac-b881-b0baa5998b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d24ebabf-5afe-4b9e-a4ea-644ebbf81625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_540e6d60-f921-419d-82e6-cebdc773cb45" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_d24ebabf-5afe-4b9e-a4ea-644ebbf81625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="regn-20210930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7b3b108d-92ee-424c-9be8-325e3699b132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_99dbb391-08dd-4495-8ee7-76494fe7df8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7b3b108d-92ee-424c-9be8-325e3699b132" xlink:to="loc_us-gaap_StatementTable_99dbb391-08dd-4495-8ee7-76494fe7df8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c4aa6d39-3ed9-417e-9395-739852846711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_99dbb391-08dd-4495-8ee7-76494fe7df8b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c4aa6d39-3ed9-417e-9395-739852846711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ce7b8f5b-1453-43a0-a27a-1854f61e0da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c4aa6d39-3ed9-417e-9395-739852846711" xlink:to="loc_us-gaap_ClassOfStockDomain_ce7b8f5b-1453-43a0-a27a-1854f61e0da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c57fff00-b947-43b8-a9ba-a436f764d8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ce7b8f5b-1453-43a0-a27a-1854f61e0da4" xlink:to="loc_us-gaap_CommonClassAMember_c57fff00-b947-43b8-a9ba-a436f764d8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_210db01e-0613-4aac-be25-7ec31e2fa6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_99dbb391-08dd-4495-8ee7-76494fe7df8b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_210db01e-0613-4aac-be25-7ec31e2fa6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0e94cf58-61af-458a-928e-eabbcd0482d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_210db01e-0613-4aac-be25-7ec31e2fa6ae" xlink:to="loc_us-gaap_EquityComponentDomain_0e94cf58-61af-458a-928e-eabbcd0482d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_575236b9-b09d-4a92-b3d3-d11e9a8dfded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0e94cf58-61af-458a-928e-eabbcd0482d2" xlink:to="loc_us-gaap_CommonStockMember_575236b9-b09d-4a92-b3d3-d11e9a8dfded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e5eb3b72-3e6e-404c-8cc7-9e13c4c8f209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0e94cf58-61af-458a-928e-eabbcd0482d2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e5eb3b72-3e6e-404c-8cc7-9e13c4c8f209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_77219912-8787-417f-ab48-b3edb043dd01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0e94cf58-61af-458a-928e-eabbcd0482d2" xlink:to="loc_us-gaap_RetainedEarningsMember_77219912-8787-417f-ab48-b3edb043dd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7aba608d-2235-4fb4-9284-d3e599ebb2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0e94cf58-61af-458a-928e-eabbcd0482d2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7aba608d-2235-4fb4-9284-d3e599ebb2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_248257b3-9ecb-45a3-8288-4ceab906e5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0e94cf58-61af-458a-928e-eabbcd0482d2" xlink:to="loc_us-gaap_TreasuryStockMember_248257b3-9ecb-45a3-8288-4ceab906e5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_666b8e76-52b8-465a-aec1-153cbb80be09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_99dbb391-08dd-4495-8ee7-76494fe7df8b" xlink:to="loc_us-gaap_StatementLineItems_666b8e76-52b8-465a-aec1-153cbb80be09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_666b8e76-52b8-465a-aec1-153cbb80be09" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_36e2c421-33de-4983-a686-8e80ff3d25f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_SharesOutstanding_36e2c421-33de-4983-a686-8e80ff3d25f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f3106cdf-6aec-4a69-816c-6f9932aea17b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_StockholdersEquity_f3106cdf-6aec-4a69-816c-6f9932aea17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4f56d450-63bc-4c46-a1ac-eed0bf5bc2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4f56d450-63bc-4c46-a1ac-eed0bf5bc2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637614ed-1bac-49dd-9c97-498c4b1168d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637614ed-1bac-49dd-9c97-498c4b1168d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_31b197cd-fb04-4c10-a42f-4492dbadf879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_31b197cd-fb04-4c10-a42f-4492dbadf879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8b897e00-5ef2-4ef1-9998-daf360cdf2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8b897e00-5ef2-4ef1-9998-daf360cdf2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_21bdb2a2-58ac-4d35-9043-f62882fad7fb" xlink:href="regn-20210930.xsd#regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan_21bdb2a2-58ac-4d35-9043-f62882fad7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_87d47cb5-af86-469d-8803-cad44e8cdd1f" xlink:href="regn-20210930.xsd#regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan_87d47cb5-af86-469d-8803-cad44e8cdd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_b01b185e-1da1-4503-baa4-52885902d258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_b01b185e-1da1-4503-baa4-52885902d258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f317b3fd-402b-4c9b-a0c3-a6b7f1549f65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f317b3fd-402b-4c9b-a0c3-a6b7f1549f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ff3515f4-fc05-40b5-bff4-faee47fbdc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ff3515f4-fc05-40b5-bff4-faee47fbdc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d9697112-802e-4752-a066-6538fc21ae50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_NetIncomeLoss_d9697112-802e-4752-a066-6538fc21ae50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3e0d75ea-0370-42a9-997c-263da48bebb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3e0d75ea-0370-42a9-997c-263da48bebb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7bbff30a-6880-41fc-b555-706eb3cba31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_SharesOutstanding_7bbff30a-6880-41fc-b555-706eb3cba31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8b386323-53dc-48da-82ab-c3ed1e281677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c048bc50-a93e-4ba5-af6b-b0d7a112a4ad" xlink:to="loc_us-gaap_StockholdersEquity_8b386323-53dc-48da-82ab-c3ed1e281677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="regn-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2f655d87-6285-4f4a-9931-eb2d2a127407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_449dc18c-6236-4c90-bbde-e68a14831bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2f655d87-6285-4f4a-9931-eb2d2a127407" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_449dc18c-6236-4c90-bbde-e68a14831bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d8e287aa-a24c-4441-80a4-7fa473e4c530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_449dc18c-6236-4c90-bbde-e68a14831bd7" xlink:to="loc_us-gaap_NetIncomeLoss_d8e287aa-a24c-4441-80a4-7fa473e4c530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f938c60-2757-453a-9eef-b9c6faacf6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_449dc18c-6236-4c90-bbde-e68a14831bd7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f938c60-2757-453a-9eef-b9c6faacf6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e6a3caac-e480-496a-8988-da0a03d44471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f938c60-2757-453a-9eef-b9c6faacf6d5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e6a3caac-e480-496a-8988-da0a03d44471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_23805673-01a3-4233-806b-fa802f109ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f938c60-2757-453a-9eef-b9c6faacf6d5" xlink:to="loc_us-gaap_ShareBasedCompensation_23805673-01a3-4233-806b-fa802f109ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesGainLoss_515c02bc-9f80-4e1d-9bb0-59a4d2e03625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f938c60-2757-453a-9eef-b9c6faacf6d5" xlink:to="loc_us-gaap_MarketableSecuritiesGainLoss_515c02bc-9f80-4e1d-9bb0-59a4d2e03625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c6c77f67-7acf-40a5-8eee-e714a42d277d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f938c60-2757-453a-9eef-b9c6faacf6d5" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c6c77f67-7acf-40a5-8eee-e714a42d277d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_190950cb-2e42-4127-b522-b48f93148a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f938c60-2757-453a-9eef-b9c6faacf6d5" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_190950cb-2e42-4127-b522-b48f93148a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9c894adb-a279-4452-b7e3-7236de42a2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f938c60-2757-453a-9eef-b9c6faacf6d5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9c894adb-a279-4452-b7e3-7236de42a2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f786da56-fa68-4233-9c57-42fc74c8b366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9c894adb-a279-4452-b7e3-7236de42a2ef" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f786da56-fa68-4233-9c57-42fc74c8b366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7b5b06f0-29df-4fa0-8843-71b0c430bbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9c894adb-a279-4452-b7e3-7236de42a2ef" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7b5b06f0-29df-4fa0-8843-71b0c430bbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b906dd63-2fbc-4206-aa62-060ec69e1470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9c894adb-a279-4452-b7e3-7236de42a2ef" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b906dd63-2fbc-4206-aa62-060ec69e1470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_74e4b8a3-b467-420b-a534-c07972abf957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9c894adb-a279-4452-b7e3-7236de42a2ef" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_74e4b8a3-b467-420b-a534-c07972abf957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b3be8b98-9c56-40a4-bc2b-40514bc22b44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9c894adb-a279-4452-b7e3-7236de42a2ef" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b3be8b98-9c56-40a4-bc2b-40514bc22b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_e52309e7-47b6-4267-a33d-d62d40c28da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f938c60-2757-453a-9eef-b9c6faacf6d5" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_e52309e7-47b6-4267-a33d-d62d40c28da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b30d1a24-345f-4ad4-9cd0-ab8cb3ae6c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_449dc18c-6236-4c90-bbde-e68a14831bd7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b30d1a24-345f-4ad4-9cd0-ab8cb3ae6c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_240f56ba-9284-47e1-8e8d-95d52897b27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2f655d87-6285-4f4a-9931-eb2d2a127407" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_240f56ba-9284-47e1-8e8d-95d52897b27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3b52355b-8ba2-4cb9-8bf6-e936730dc393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_240f56ba-9284-47e1-8e8d-95d52897b27d" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3b52355b-8ba2-4cb9-8bf6-e936730dc393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c47fecca-3d51-4495-bef8-4237d615cb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_240f56ba-9284-47e1-8e8d-95d52897b27d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c47fecca-3d51-4495-bef8-4237d615cb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_0299081b-99d4-4a3f-a79a-895ecf165250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_240f56ba-9284-47e1-8e8d-95d52897b27d" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_0299081b-99d4-4a3f-a79a-895ecf165250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_04d38f50-58ee-497e-be27-c78dcf369c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_240f56ba-9284-47e1-8e8d-95d52897b27d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_04d38f50-58ee-497e-be27-c78dcf369c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c373a50b-5675-428b-a324-69d25340bc11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2f655d87-6285-4f4a-9931-eb2d2a127407" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c373a50b-5675-428b-a324-69d25340bc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5a1d8875-61cf-430b-84fe-8b19cc0171cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c373a50b-5675-428b-a324-69d25340bc11" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5a1d8875-61cf-430b-84fe-8b19cc0171cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b26bb9da-1a71-49e3-b783-f69823b9a1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c373a50b-5675-428b-a324-69d25340bc11" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b26bb9da-1a71-49e3-b783-f69823b9a1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5bd37896-ad57-49a5-8c71-5e7ba3316694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c373a50b-5675-428b-a324-69d25340bc11" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5bd37896-ad57-49a5-8c71-5e7ba3316694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ea443add-4854-40b5-93e9-8c886b88b6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c373a50b-5675-428b-a324-69d25340bc11" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ea443add-4854-40b5-93e9-8c886b88b6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_83320e5a-6022-4513-8ea0-776ab95449d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c373a50b-5675-428b-a324-69d25340bc11" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_83320e5a-6022-4513-8ea0-776ab95449d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_28de8851-0957-4cf4-92a2-8461a1df55d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c373a50b-5675-428b-a324-69d25340bc11" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_28de8851-0957-4cf4-92a2-8461a1df55d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c52c9a72-617e-4a5f-8dcc-9bf186aced5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c373a50b-5675-428b-a324-69d25340bc11" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c52c9a72-617e-4a5f-8dcc-9bf186aced5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1fd86aca-d040-45c0-831d-3a8ccceb4ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2f655d87-6285-4f4a-9931-eb2d2a127407" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1fd86aca-d040-45c0-831d-3a8ccceb4ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5af606e8-3c62-49ae-baf1-d3f0c3bfc1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2f655d87-6285-4f4a-9931-eb2d2a127407" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5af606e8-3c62-49ae-baf1-d3f0c3bfc1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b4affef9-aa28-4b70-9325-3af88a6eadba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2f655d87-6285-4f4a-9931-eb2d2a127407" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b4affef9-aa28-4b70-9325-3af88a6eadba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatements" xlink:type="simple" xlink:href="regn-20210930.xsd#InterimFinancialStatements"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_972d8611-5b86-46ff-a405-db7d723bb233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_cd6ba18a-dbb8-4d23-a144-348e8e7fcb61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_972d8611-5b86-46ff-a405-db7d723bb233" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_cd6ba18a-dbb8-4d23-a144-348e8e7fcb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InterimFinancialStatementsPolicies" xlink:type="simple" xlink:href="regn-20210930.xsd#InterimFinancialStatementsPolicies"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InterimFinancialStatementsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22d24895-017c-4d72-9441-fb4d26bbb40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_39c7dde6-7a35-4f76-8d32-3d304b18f332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22d24895-017c-4d72-9441-fb4d26bbb40c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_39c7dde6-7a35-4f76-8d32-3d304b18f332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_749770d5-a265-4ff5-8a29-e094397845f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22d24895-017c-4d72-9441-fb4d26bbb40c" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_749770d5-a265-4ff5-8a29-e094397845f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSales" xlink:type="simple" xlink:href="regn-20210930.xsd#ProductSales"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSales" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_56c18832-d20f-473f-ad59-ccfe35703bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2c140d70-8678-44d9-aeac-064e6ae90622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_56c18832-d20f-473f-ad59-ccfe35703bcd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2c140d70-8678-44d9-aeac-064e6ae90622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesTables" xlink:type="simple" xlink:href="regn-20210930.xsd#ProductSalesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d1b3a9ee-a4a7-4202-9ff7-cc0c5565a80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3632b02e-9b26-4130-9d80-debdab448574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d1b3a9ee-a4a7-4202-9ff7-cc0c5565a80d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3632b02e-9b26-4130-9d80-debdab448574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_ac7b2134-61d0-4fee-bd6e-ff953521170f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d1b3a9ee-a4a7-4202-9ff7-cc0c5565a80d" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_ac7b2134-61d0-4fee-bd6e-ff953521170f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#ProductSalesScheduleofNetProductSalesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4a06db96-6dd1-45c0-9993-d784903ece10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e0e7cf7c-1d51-4c7b-86eb-453608235c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4a06db96-6dd1-45c0-9993-d784903ece10" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e0e7cf7c-1d51-4c7b-86eb-453608235c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_731ca552-9ac5-41ef-b8b5-8d27a4732b06" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e0e7cf7c-1d51-4c7b-86eb-453608235c2a" xlink:to="loc_srt_StatementGeographicalAxis_731ca552-9ac5-41ef-b8b5-8d27a4732b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ede0ee21-86ea-439d-86dd-e4870598af1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_731ca552-9ac5-41ef-b8b5-8d27a4732b06" xlink:to="loc_srt_SegmentGeographicalDomain_ede0ee21-86ea-439d-86dd-e4870598af1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c27db790-a6c0-4863-8942-2ebd3a850573" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ede0ee21-86ea-439d-86dd-e4870598af1e" xlink:to="loc_country_US_c27db790-a6c0-4863-8942-2ebd3a850573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7822ec3c-1ac1-4a35-8f19-ce331ad616e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e0e7cf7c-1d51-4c7b-86eb-453608235c2a" xlink:to="loc_srt_ProductOrServiceAxis_7822ec3c-1ac1-4a35-8f19-ce331ad616e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7822ec3c-1ac1-4a35-8f19-ce331ad616e3" xlink:to="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EyleaNetProductSalesMember_b18bd14d-8e14-4ed7-bf17-12e9b542134a" xlink:href="regn-20210930.xsd#regn_EyleaNetProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:to="loc_regn_EyleaNetProductSalesMember_b18bd14d-8e14-4ed7-bf17-12e9b542134a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LIBTAYONetProductSalesMember_680d28b5-d426-4f1e-855f-811ba6e58ac7" xlink:href="regn-20210930.xsd#regn_LIBTAYONetProductSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:to="loc_regn_LIBTAYONetProductSalesMember_680d28b5-d426-4f1e-855f-811ba6e58ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentNetProductSalesMember_f09a6ab9-bf83-4d9e-924b-d2991b8bbaa3" xlink:href="regn-20210930.xsd#regn_PraluentNetProductSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:to="loc_regn_PraluentNetProductSalesMember_f09a6ab9-bf83-4d9e-924b-d2991b8bbaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_REGENCOVMember_3587e347-346d-441f-85f5-67ede1a89b59" xlink:href="regn-20210930.xsd#regn_REGENCOVMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:to="loc_regn_REGENCOVMember_3587e347-346d-441f-85f5-67ede1a89b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EvkeezaMember_8150b78b-4ba6-4522-b68a-c74826b562ef" xlink:href="regn-20210930.xsd#regn_EvkeezaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:to="loc_regn_EvkeezaMember_8150b78b-4ba6-4522-b68a-c74826b562ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ArcalystNetProductSalesMember_b8184efc-9dd9-41d2-a991-c7a0ee6e6ccd" xlink:href="regn-20210930.xsd#regn_ArcalystNetProductSalesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_abb6c340-b616-4ad6-b791-769d7089bece" xlink:to="loc_regn_ArcalystNetProductSalesMember_b8184efc-9dd9-41d2-a991-c7a0ee6e6ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_165e986f-103d-475f-aa26-db2c6f94941a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e0e7cf7c-1d51-4c7b-86eb-453608235c2a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_165e986f-103d-475f-aa26-db2c6f94941a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5171ff65-f1fd-4630-8f49-e41f69eee68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_165e986f-103d-475f-aa26-db2c6f94941a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5171ff65-f1fd-4630-8f49-e41f69eee68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_249f43ca-e580-4a78-b95e-0f15865701af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_dacc57bd-c4cd-4e3a-bda6-27862b9d62b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_249f43ca-e580-4a78-b95e-0f15865701af" xlink:to="loc_us-gaap_ConcentrationRiskTable_dacc57bd-c4cd-4e3a-bda6-27862b9d62b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7628e99d-449e-4634-a467-aec1a38bb280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dacc57bd-c4cd-4e3a-bda6-27862b9d62b8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7628e99d-449e-4634-a467-aec1a38bb280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_770edeec-ec41-4378-9c8b-823ba53c0058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7628e99d-449e-4634-a467-aec1a38bb280" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_770edeec-ec41-4378-9c8b-823ba53c0058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GrossProductRevenueMember_228b898e-1fef-4217-9e47-9924b62e24b9" xlink:href="regn-20210930.xsd#regn_GrossProductRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_770edeec-ec41-4378-9c8b-823ba53c0058" xlink:to="loc_regn_GrossProductRevenueMember_228b898e-1fef-4217-9e47-9924b62e24b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4b5fad3b-dcb4-467c-87fd-830686d1232c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dacc57bd-c4cd-4e3a-bda6-27862b9d62b8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4b5fad3b-dcb4-467c-87fd-830686d1232c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_66ed8733-cdf9-4b28-84f4-2c5694b3bd48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4b5fad3b-dcb4-467c-87fd-830686d1232c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_66ed8733-cdf9-4b28-84f4-2c5694b3bd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d2ef89f5-366a-446a-871a-58e132f3915b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_66ed8733-cdf9-4b28-84f4-2c5694b3bd48" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d2ef89f5-366a-446a-871a-58e132f3915b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_06a56e3e-5e3b-4921-9cdb-26e46154ef5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dacc57bd-c4cd-4e3a-bda6-27862b9d62b8" xlink:to="loc_srt_MajorCustomersAxis_06a56e3e-5e3b-4921-9cdb-26e46154ef5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_61bd8a79-bb71-4225-98da-a3367954390c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_06a56e3e-5e3b-4921-9cdb-26e46154ef5f" xlink:to="loc_srt_NameOfMajorCustomerDomain_61bd8a79-bb71-4225-98da-a3367954390c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BesseMedicalMember_7a94b38e-1a48-49e7-8f93-402ae497e537" xlink:href="regn-20210930.xsd#regn_BesseMedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_61bd8a79-bb71-4225-98da-a3367954390c" xlink:to="loc_regn_BesseMedicalMember_7a94b38e-1a48-49e7-8f93-402ae497e537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_McKessonCorporationMember_2cf54a0b-f37d-429e-9b29-e1668953e453" xlink:href="regn-20210930.xsd#regn_McKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_61bd8a79-bb71-4225-98da-a3367954390c" xlink:to="loc_regn_McKessonCorporationMember_2cf54a0b-f37d-429e-9b29-e1668953e453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_USGovernmentMember_28a0a0b6-3497-4fda-8b64-66445f376697" xlink:href="regn-20210930.xsd#regn_USGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_61bd8a79-bb71-4225-98da-a3367954390c" xlink:to="loc_regn_USGovernmentMember_28a0a0b6-3497-4fda-8b64-66445f376697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_03524800-5b28-46ae-b9ce-376fe23cbff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dacc57bd-c4cd-4e3a-bda6-27862b9d62b8" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_03524800-5b28-46ae-b9ce-376fe23cbff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0075e6f1-78b2-4394-bc7a-da9e71ab2764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_03524800-5b28-46ae-b9ce-376fe23cbff8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_0075e6f1-78b2-4394-bc7a-da9e71ab2764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/ProductSalesNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#ProductSalesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/ProductSalesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c11d73a5-ee55-46dc-b9f9-77ff131ee0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_8c0d1cd6-f1f7-4ca4-824e-b40c121bf628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c11d73a5-ee55-46dc-b9f9-77ff131ee0d2" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_8c0d1cd6-f1f7-4ca4-824e-b40c121bf628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8aac83de-3358-40ea-8dab-c09cf6819d33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_8c0d1cd6-f1f7-4ca4-824e-b40c121bf628" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8aac83de-3358-40ea-8dab-c09cf6819d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_844ba31c-5302-445e-bb88-533b40d32541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8aac83de-3358-40ea-8dab-c09cf6819d33" xlink:to="loc_us-gaap_ReceivableTypeDomain_844ba31c-5302-445e-bb88-533b40d32541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_4c2c796c-e19f-42ee-857b-fe767aff8f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_844ba31c-5302-445e-bb88-533b40d32541" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_4c2c796c-e19f-42ee-857b-fe767aff8f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_1bfea7fe-009e-4827-b22f-f1b9f8a8a461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_8c0d1cd6-f1f7-4ca4-824e-b40c121bf628" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_1bfea7fe-009e-4827-b22f-f1b9f8a8a461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c30cc302-79fd-4819-a675-0a9cc13387cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_1bfea7fe-009e-4827-b22f-f1b9f8a8a461" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c30cc302-79fd-4819-a675-0a9cc13387cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreements"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aa0bc28b-0cc7-49aa-ad9a-71b50cc070df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f067cdd7-8736-4b58-970a-e10b38b484b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aa0bc28b-0cc7-49aa-ad9a-71b50cc070df" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f067cdd7-8736-4b58-970a-e10b38b484b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f9e72be5-e343-42de-8b7c-1db34adf1932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f9776f14-8d9e-4a67-af58-f3c7021a48f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f9e72be5-e343-42de-8b7c-1db34adf1932" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f9776f14-8d9e-4a67-af58-f3c7021a48f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_199120ed-04d6-49b7-89c6-b16282a771b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f9e72be5-e343-42de-8b7c-1db34adf1932" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_199120ed-04d6-49b7-89c6-b16282a771b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_658bccad-a3ea-4b6f-8e6d-28007235bb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_483e0d20-1747-46d3-9cf5-500ed3e327cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_658bccad-a3ea-4b6f-8e6d-28007235bb4a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_483e0d20-1747-46d3-9cf5-500ed3e327cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_d6e76beb-99e4-4e38-b47e-4d220aecff70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_483e0d20-1747-46d3-9cf5-500ed3e327cc" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_d6e76beb-99e4-4e38-b47e-4d220aecff70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_53e328d5-3724-4cf4-8662-c9429fb37cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_d6e76beb-99e4-4e38-b47e-4d220aecff70" xlink:to="loc_us-gaap_ProjectMember_53e328d5-3724-4cf4-8662-c9429fb37cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_bba08d72-9d4c-437d-99bd-38a790fdafb3" xlink:href="regn-20210930.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_53e328d5-3724-4cf4-8662-c9429fb37cf8" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_bba08d72-9d4c-437d-99bd-38a790fdafb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_c8a677c0-ee54-4334-861f-d3ac052f7cfe" xlink:href="regn-20210930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_53e328d5-3724-4cf4-8662-c9429fb37cf8" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_c8a677c0-ee54-4334-861f-d3ac052f7cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3cbeed6a-b073-45c4-9c75-96d7e17ea081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_483e0d20-1747-46d3-9cf5-500ed3e327cc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3cbeed6a-b073-45c4-9c75-96d7e17ea081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d4ef3846-4320-4c51-9f64-4ac272f57033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3cbeed6a-b073-45c4-9c75-96d7e17ea081" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d4ef3846-4320-4c51-9f64-4ac272f57033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_be9dd7ff-41eb-4062-964f-6087a4dd5f88" xlink:href="regn-20210930.xsd#regn_CollaborationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4ef3846-4320-4c51-9f64-4ac272f57033" xlink:to="loc_regn_CollaborationRevenueMember_be9dd7ff-41eb-4062-964f-6087a4dd5f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_11b2e3ff-6336-4247-96b2-4706701e0ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4ef3846-4320-4c51-9f64-4ac272f57033" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_11b2e3ff-6336-4247-96b2-4706701e0ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_094ba517-a900-46ec-b2c3-58f0a3dcac4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4ef3846-4320-4c51-9f64-4ac272f57033" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_094ba517-a900-46ec-b2c3-58f0a3dcac4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CostOfGoodsSoldMember_caf3a9e1-9524-48e6-adac-260dfe5f6b1e" xlink:href="regn-20210930.xsd#regn_CostOfGoodsSoldMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4ef3846-4320-4c51-9f64-4ac272f57033" xlink:to="loc_regn_CostOfGoodsSoldMember_caf3a9e1-9524-48e6-adac-260dfe5f6b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_9c670c25-7a83-4c28-a734-edd9f0946d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4ef3846-4320-4c51-9f64-4ac272f57033" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_9c670c25-7a83-4c28-a734-edd9f0946d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_830328d5-cc41-4eb9-8ca1-b9a5c0cef749" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_483e0d20-1747-46d3-9cf5-500ed3e327cc" xlink:to="loc_srt_ProductOrServiceAxis_830328d5-cc41-4eb9-8ca1-b9a5c0cef749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_830328d5-cc41-4eb9-8ca1-b9a5c0cef749" xlink:to="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_4131a729-2e6f-4f43-bb5b-4d22d65f3e4e" xlink:href="regn-20210930.xsd#regn_ShareOfProfitLossesInConnectionWithCommercializationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_ShareOfProfitLossesInConnectionWithCommercializationMember_4131a729-2e6f-4f43-bb5b-4d22d65f3e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesBasedMilestoneEarnedMember_3986522d-99cb-4ba6-a35c-62d5d3d8f806" xlink:href="regn-20210930.xsd#regn_SalesBasedMilestoneEarnedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_SalesBasedMilestoneEarnedMember_3986522d-99cb-4ba6-a35c-62d5d3d8f806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_5a9518f5-0d6d-4dd2-b678-88ef62035adb" xlink:href="regn-20210930.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_5a9518f5-0d6d-4dd2-b678-88ef62035adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_c3ef2b30-db45-402c-ab37-e4dbb49f7a85" xlink:href="regn-20210930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_c3ef2b30-db45-402c-ab37-e4dbb49f7a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_e4c68882-8d88-4639-89c8-c4219f3caa24" xlink:href="regn-20210930.xsd#regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_e4c68882-8d88-4639-89c8-c4219f3caa24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_7f375cb8-5ac4-4bb0-84db-8ae08463f43d" xlink:href="regn-20210930.xsd#regn_ReimbursementOfCommercializationRelatedExpensesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_ReimbursementOfCommercializationRelatedExpensesMember_7f375cb8-5ac4-4bb0-84db-8ae08463f43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfCommercialExpensesMember_4170f75e-e0c6-428a-9150-05a3e72ab63c" xlink:href="regn-20210930.xsd#regn_RegeneronsShareOfCommercialExpensesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_RegeneronsShareOfCommercialExpensesMember_4170f75e-e0c6-428a-9150-05a3e72ab63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_af091665-def9-4f06-9326-525ac81f5ef6" xlink:href="regn-20210930.xsd#regn_SanofisShareofLibtayoU.S.GrossProfitsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_SanofisShareofLibtayoU.S.GrossProfitsMember_af091665-def9-4f06-9326-525ac81f5ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_e5d163e5-a0b1-4f98-aed1-0e68b77d774a" xlink:href="regn-20210930.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5ab66da-855e-4fa6-a800-2a42a69dae93" xlink:to="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_e5d163e5-a0b1-4f98-aed1-0e68b77d774a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6e942bfb-cd37-492f-b5d6-37e53dd1c06d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_483e0d20-1747-46d3-9cf5-500ed3e327cc" xlink:to="loc_srt_StatementGeographicalAxis_6e942bfb-cd37-492f-b5d6-37e53dd1c06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d45d233b-7f1c-44f3-b80a-15ae120e6ebb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6e942bfb-cd37-492f-b5d6-37e53dd1c06d" xlink:to="loc_srt_SegmentGeographicalDomain_d45d233b-7f1c-44f3-b80a-15ae120e6ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_f0b8a03e-2128-4721-abd5-af44488d6172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d45d233b-7f1c-44f3-b80a-15ae120e6ebb" xlink:to="loc_us-gaap_NonUsMember_f0b8a03e-2128-4721-abd5-af44488d6172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4ec6e709-74d7-4b17-8748-f2d042b844b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_483e0d20-1747-46d3-9cf5-500ed3e327cc" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4ec6e709-74d7-4b17-8748-f2d042b844b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_10f9101b-59a5-442c-b82a-d6a6172def98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4ec6e709-74d7-4b17-8748-f2d042b844b5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_10f9101b-59a5-442c-b82a-d6a6172def98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_99b5d9b8-5a43-4888-9a3f-93c4b15c2b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b15be8ad-e952-4e13-ac54-da27883bc3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_99b5d9b8-5a43-4888-9a3f-93c4b15c2b1b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b15be8ad-e952-4e13-ac54-da27883bc3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_f1306f41-6416-496c-a9a9-19c489cdbe37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b15be8ad-e952-4e13-ac54-da27883bc3e4" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_f1306f41-6416-496c-a9a9-19c489cdbe37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_01224434-57b8-46e0-b51a-52f1b475fa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_f1306f41-6416-496c-a9a9-19c489cdbe37" xlink:to="loc_us-gaap_ProjectMember_01224434-57b8-46e0-b51a-52f1b475fa6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_24c02cdb-ed06-4b44-a876-2b05f3ef2fe7" xlink:href="regn-20210930.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_01224434-57b8-46e0-b51a-52f1b475fa6d" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_24c02cdb-ed06-4b44-a876-2b05f3ef2fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_5212544e-4681-403f-8077-03b5552164d7" xlink:href="regn-20210930.xsd#regn_PraluentCrossLicenseAndCommercializationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_01224434-57b8-46e0-b51a-52f1b475fa6d" xlink:to="loc_regn_PraluentCrossLicenseAndCommercializationAgreementMember_5212544e-4681-403f-8077-03b5552164d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9e0ff294-90d5-4378-96f5-8e4a4c27b854" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b15be8ad-e952-4e13-ac54-da27883bc3e4" xlink:to="loc_srt_RangeAxis_9e0ff294-90d5-4378-96f5-8e4a4c27b854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_20c3138f-3a1f-4836-a2db-d4daa12ee3bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9e0ff294-90d5-4378-96f5-8e4a4c27b854" xlink:to="loc_srt_RangeMember_20c3138f-3a1f-4836-a2db-d4daa12ee3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_20adbb5c-4277-4bc4-805a-7335260eea59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_20c3138f-3a1f-4836-a2db-d4daa12ee3bc" xlink:to="loc_srt_MinimumMember_20adbb5c-4277-4bc4-805a-7335260eea59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_31a403bd-2e14-413e-a744-8000ac5c0039" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_20c3138f-3a1f-4836-a2db-d4daa12ee3bc" xlink:to="loc_srt_MaximumMember_31a403bd-2e14-413e-a744-8000ac5c0039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a238f593-21f6-468f-8b5c-a740fab4c287" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b15be8ad-e952-4e13-ac54-da27883bc3e4" xlink:to="loc_dei_LegalEntityAxis_a238f593-21f6-468f-8b5c-a740fab4c287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_46a2b86e-8e5b-422b-b77f-63ad717c40e3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a238f593-21f6-468f-8b5c-a740fab4c287" xlink:to="loc_dei_EntityDomain_46a2b86e-8e5b-422b-b77f-63ad717c40e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_ad5051e6-f36f-4c08-ada3-a716395175a0" xlink:href="regn-20210930.xsd#regn_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_46a2b86e-8e5b-422b-b77f-63ad717c40e3" xlink:to="loc_regn_SanofiMember_ad5051e6-f36f-4c08-ada3-a716395175a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesAxis_b367edf9-6a76-4d49-ba97-4186131282ad" xlink:href="regn-20210930.xsd#regn_SalesMilestonesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b15be8ad-e952-4e13-ac54-da27883bc3e4" xlink:to="loc_regn_SalesMilestonesAxis_b367edf9-6a76-4d49-ba97-4186131282ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestonesDomain_724729e2-f275-4afb-a015-f128549cdbf5" xlink:href="regn-20210930.xsd#regn_SalesMilestonesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_SalesMilestonesAxis_b367edf9-6a76-4d49-ba97-4186131282ad" xlink:to="loc_regn_SalesMilestonesDomain_724729e2-f275-4afb-a015-f128549cdbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneOneMember_b49415e8-db1f-4cbc-bb41-53e02f6c4d7a" xlink:href="regn-20210930.xsd#regn_SalesMilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_SalesMilestonesDomain_724729e2-f275-4afb-a015-f128549cdbf5" xlink:to="loc_regn_SalesMilestoneOneMember_b49415e8-db1f-4cbc-bb41-53e02f6c4d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SalesMilestoneTwoMember_bd47c6fa-358f-4f58-8dce-82e0b078db84" xlink:href="regn-20210930.xsd#regn_SalesMilestoneTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_SalesMilestonesDomain_724729e2-f275-4afb-a015-f128549cdbf5" xlink:to="loc_regn_SalesMilestoneTwoMember_bd47c6fa-358f-4f58-8dce-82e0b078db84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b15be8ad-e952-4e13-ac54-da27883bc3e4" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_9335d1de-4e4c-4712-8947-40b02c5eab40" xlink:href="regn-20210930.xsd#regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty_9335d1de-4e4c-4712-8947-40b02c5eab40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e5ad8dfc-bf31-45e5-8c76-a54c4e77fc66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e5ad8dfc-bf31-45e5-8c76-a54c4e77fc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived_3bab8398-87a5-4c77-8b29-9804841f39cf" xlink:href="regn-20210930.xsd#regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived_3bab8398-87a5-4c77-8b29-9804841f39cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_5ddd64a4-8a4f-4a5c-8069-b5546f710a10" xlink:href="regn-20210930.xsd#regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis_5ddd64a4-8a4f-4a5c-8069-b5546f710a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_d55da772-e399-438f-ad23-2d2c5b86aef1" xlink:href="regn-20210930.xsd#regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_d55da772-e399-438f-ad23-2d2c5b86aef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_bb6e6c33-0dad-43bf-bfb4-5993e87ce9ae" xlink:href="regn-20210930.xsd#regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates_bb6e6c33-0dad-43bf-bfb4-5993e87ce9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_378db7c9-f1fc-40f6-addc-5808e5d4bc65" xlink:href="regn-20210930.xsd#regn_PercentageOfRoyaltyPaymentThatCanBeOffset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_regn_PercentageOfRoyaltyPaymentThatCanBeOffset_378db7c9-f1fc-40f6-addc-5808e5d4bc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor_77cfd26b-d74d-4ab3-9133-706237cacdc9" xlink:href="regn-20210930.xsd#regn_LossContingencyPercentageOfDamagesResponsibleFor"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2803a08e-81ae-43d3-9208-1cd21bf26701" xlink:to="loc_regn_LossContingencyPercentageOfDamagesResponsibleFor_77cfd26b-d74d-4ab3-9133-706237cacdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4253bdd5-16b1-4d16-98f4-1d08e1133209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_98140b39-5fb8-4cfe-8504-b8bef92ac476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4253bdd5-16b1-4d16-98f4-1d08e1133209" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_98140b39-5fb8-4cfe-8504-b8bef92ac476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_86850399-0443-45b8-86ad-8900d0f856db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_98140b39-5fb8-4cfe-8504-b8bef92ac476" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_86850399-0443-45b8-86ad-8900d0f856db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_c7db4e28-fc55-4d27-a4da-41f4c6946cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_86850399-0443-45b8-86ad-8900d0f856db" xlink:to="loc_us-gaap_ProjectMember_c7db4e28-fc55-4d27-a4da-41f4c6946cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementAntibodyMember_1bfeb826-4a1d-433e-8cfd-f4d7d43e7cb1" xlink:href="regn-20210930.xsd#regn_SanofiCollaborationAgreementAntibodyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_c7db4e28-fc55-4d27-a4da-41f4c6946cfc" xlink:to="loc_regn_SanofiCollaborationAgreementAntibodyMember_1bfeb826-4a1d-433e-8cfd-f4d7d43e7cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c90e9cc8-65b0-4f6f-9dfe-3a9d21ba229e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_98140b39-5fb8-4cfe-8504-b8bef92ac476" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c90e9cc8-65b0-4f6f-9dfe-3a9d21ba229e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_68cf2e5a-a2b4-45de-8a36-722e2a4e07c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c90e9cc8-65b0-4f6f-9dfe-3a9d21ba229e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_68cf2e5a-a2b4-45de-8a36-722e2a4e07c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_af1e0e64-5a13-4d77-b7ae-5bb3e488146c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c90e9cc8-65b0-4f6f-9dfe-3a9d21ba229e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_af1e0e64-5a13-4d77-b7ae-5bb3e488146c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cbf9efa3-b3e0-4c27-8f2e-f1e374d361a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_09b538d7-a401-42e2-bb75-a90bcd427f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cbf9efa3-b3e0-4c27-8f2e-f1e374d361a6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_09b538d7-a401-42e2-bb75-a90bcd427f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_a8858ebf-31e5-488a-8f88-d7b6254a8826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_09b538d7-a401-42e2-bb75-a90bcd427f7f" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_a8858ebf-31e5-488a-8f88-d7b6254a8826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_a641476b-8711-4920-8245-e1e893c803ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_a8858ebf-31e5-488a-8f88-d7b6254a8826" xlink:to="loc_us-gaap_ProjectMember_a641476b-8711-4920-8245-e1e893c803ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_67b8a2ef-a2d1-4d49-ac50-aa0209f435b7" xlink:href="regn-20210930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_a641476b-8711-4920-8245-e1e893c803ea" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_67b8a2ef-a2d1-4d49-ac50-aa0209f435b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_46a25883-347c-4c2e-a3f7-d121cf44b339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_09b538d7-a401-42e2-bb75-a90bcd427f7f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_46a25883-347c-4c2e-a3f7-d121cf44b339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_10d55f44-2269-4645-ac11-618ac95c26d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_46a25883-347c-4c2e-a3f7-d121cf44b339" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_10d55f44-2269-4645-ac11-618ac95c26d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cf754a14-1b05-4507-aa74-02f5b4561af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_46a25883-347c-4c2e-a3f7-d121cf44b339" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cf754a14-1b05-4507-aa74-02f5b4561af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_b0aa5e7f-1861-4476-b404-73ba7c895799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_46a25883-347c-4c2e-a3f7-d121cf44b339" xlink:to="loc_us-gaap_OtherLiabilities_b0aa5e7f-1861-4476-b404-73ba7c895799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ea96fa01-0cf5-413b-9fe9-f176ac615452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5bf6758b-4eb2-42f7-956a-7f1f89e7f2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ea96fa01-0cf5-413b-9fe9-f176ac615452" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5bf6758b-4eb2-42f7-956a-7f1f89e7f2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7d7de780-67c5-489d-849d-70f5b6ce69d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5bf6758b-4eb2-42f7-956a-7f1f89e7f2e3" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7d7de780-67c5-489d-849d-70f5b6ce69d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_55b3e75f-98c1-4272-85c7-06c762179d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_7d7de780-67c5-489d-849d-70f5b6ce69d6" xlink:to="loc_us-gaap_ProjectMember_55b3e75f-98c1-4272-85c7-06c762179d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_89dd33cf-312f-48a1-b858-f52a6129e23d" xlink:href="regn-20210930.xsd#regn_SanofiCollaborationAgreementImmunooncologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_55b3e75f-98c1-4272-85c7-06c762179d20" xlink:to="loc_regn_SanofiCollaborationAgreementImmunooncologyMember_89dd33cf-312f-48a1-b858-f52a6129e23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3d703495-ce4f-4dab-b387-c4da571c726e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5bf6758b-4eb2-42f7-956a-7f1f89e7f2e3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3d703495-ce4f-4dab-b387-c4da571c726e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_253fc6b2-306c-4420-8b7b-501189f552bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d703495-ce4f-4dab-b387-c4da571c726e" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_253fc6b2-306c-4420-8b7b-501189f552bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_fc7f97a1-270f-4733-92ae-5454ec4b8f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d703495-ce4f-4dab-b387-c4da571c726e" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_fc7f97a1-270f-4733-92ae-5454ec4b8f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsBayerNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b913629e-6ef1-46d2-a5b5-df595975fa24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3a95e576-0584-4544-a7e6-e7464fd84b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b913629e-6ef1-46d2-a5b5-df595975fa24" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3a95e576-0584-4544-a7e6-e7464fd84b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_05717a8d-20d8-4291-b384-43d8063c3872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3a95e576-0584-4544-a7e6-e7464fd84b23" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_05717a8d-20d8-4291-b384-43d8063c3872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_f712c7c8-d0d0-47eb-859b-02815812a1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_05717a8d-20d8-4291-b384-43d8063c3872" xlink:to="loc_us-gaap_ProjectMember_f712c7c8-d0d0-47eb-859b-02815812a1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_eff649cd-475d-423c-a288-e6a5484b9ae3" xlink:href="regn-20210930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_f712c7c8-d0d0-47eb-859b-02815812a1b0" xlink:to="loc_regn_BayerCollaborationAgreementMember_eff649cd-475d-423c-a288-e6a5484b9ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_526dfe15-89e9-4224-942a-04da924fd081" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3a95e576-0584-4544-a7e6-e7464fd84b23" xlink:to="loc_srt_RangeAxis_526dfe15-89e9-4224-942a-04da924fd081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eac56747-3e72-4d80-9b4e-5ea7f53bad68" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_526dfe15-89e9-4224-942a-04da924fd081" xlink:to="loc_srt_RangeMember_eac56747-3e72-4d80-9b4e-5ea7f53bad68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bdcfd406-25dc-4618-844c-0e348a1d5957" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eac56747-3e72-4d80-9b4e-5ea7f53bad68" xlink:to="loc_srt_MinimumMember_bdcfd406-25dc-4618-844c-0e348a1d5957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f7416214-33cf-4980-9033-d4e8741da5dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eac56747-3e72-4d80-9b4e-5ea7f53bad68" xlink:to="loc_srt_MaximumMember_f7416214-33cf-4980-9033-d4e8741da5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_43fc90a7-499c-460a-ad8a-f048a04e9cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3a95e576-0584-4544-a7e6-e7464fd84b23" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_43fc90a7-499c-460a-ad8a-f048a04e9cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan_e5670335-8294-4e42-af96-d2c0dca36929" xlink:href="regn-20210930.xsd#regn_RevenueBasedOnPercentageOfAnnualSalesInJapan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_43fc90a7-499c-460a-ad8a-f048a04e9cd7" xlink:to="loc_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan_e5670335-8294-4e42-af96-d2c0dca36929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_43ab26f7-f05a-46b2-a793-d22329b7275b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_152325dd-d670-4530-8a46-771dd692e4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_43ab26f7-f05a-46b2-a793-d22329b7275b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_152325dd-d670-4530-8a46-771dd692e4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2a5787e4-1b6e-4c2c-8683-cfea720bf2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_152325dd-d670-4530-8a46-771dd692e4a6" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2a5787e4-1b6e-4c2c-8683-cfea720bf2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_00e81a7d-a330-41cf-ba0b-225c36bc404f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2a5787e4-1b6e-4c2c-8683-cfea720bf2c7" xlink:to="loc_us-gaap_ProjectMember_00e81a7d-a330-41cf-ba0b-225c36bc404f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_99312532-9835-4878-9b83-2ad0713d635b" xlink:href="regn-20210930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_00e81a7d-a330-41cf-ba0b-225c36bc404f" xlink:to="loc_regn_BayerCollaborationAgreementMember_99312532-9835-4878-9b83-2ad0713d635b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7f3792c7-2c7e-4744-bcca-3931e4a451f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_152325dd-d670-4530-8a46-771dd692e4a6" xlink:to="loc_srt_StatementGeographicalAxis_7f3792c7-2c7e-4744-bcca-3931e4a451f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1bff1796-06f9-40fc-b6d2-4627fb8d4aae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7f3792c7-2c7e-4744-bcca-3931e4a451f3" xlink:to="loc_srt_SegmentGeographicalDomain_1bff1796-06f9-40fc-b6d2-4627fb8d4aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_96d47d4c-e6bd-4326-8312-1b4def092f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1bff1796-06f9-40fc-b6d2-4627fb8d4aae" xlink:to="loc_us-gaap_NonUsMember_96d47d4c-e6bd-4326-8312-1b4def092f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ae3474e8-e33a-48f8-91a4-2f103186da9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_152325dd-d670-4530-8a46-771dd692e4a6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ae3474e8-e33a-48f8-91a4-2f103186da9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_151c7aaf-6191-4389-a231-d8f73af43035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ae3474e8-e33a-48f8-91a4-2f103186da9e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_151c7aaf-6191-4389-a231-d8f73af43035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_6aadadea-c9d8-44ce-8e39-5f6a1054e504" xlink:href="regn-20210930.xsd#regn_CollaborationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_151c7aaf-6191-4389-a231-d8f73af43035" xlink:to="loc_regn_CollaborationRevenueMember_6aadadea-c9d8-44ce-8e39-5f6a1054e504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c057a775-4b66-4126-baae-6f04cf80a803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_151c7aaf-6191-4389-a231-d8f73af43035" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c057a775-4b66-4126-baae-6f04cf80a803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5aacf1bf-8d2a-408a-86f0-abc54b1f9f18" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_152325dd-d670-4530-8a46-771dd692e4a6" xlink:to="loc_srt_ProductOrServiceAxis_5aacf1bf-8d2a-408a-86f0-abc54b1f9f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8a7daff2-4ebc-40b2-97f9-1ae21b3debe8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5aacf1bf-8d2a-408a-86f0-abc54b1f9f18" xlink:to="loc_srt_ProductsAndServicesDomain_8a7daff2-4ebc-40b2-97f9-1ae21b3debe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_NetProfitInConnectionWithCommercializationMember_91084d0f-0b3f-4bb0-9bfd-91912869400a" xlink:href="regn-20210930.xsd#regn_NetProfitInConnectionWithCommercializationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a7daff2-4ebc-40b2-97f9-1ae21b3debe8" xlink:to="loc_regn_NetProfitInConnectionWithCommercializationMember_91084d0f-0b3f-4bb0-9bfd-91912869400a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_9b6a9f41-2ed3-44da-9437-fb6489c8a0be" xlink:href="regn-20210930.xsd#regn_ReimbursementForManufacturingOfCommercialSuppliesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a7daff2-4ebc-40b2-97f9-1ae21b3debe8" xlink:to="loc_regn_ReimbursementForManufacturingOfCommercialSuppliesMember_9b6a9f41-2ed3-44da-9437-fb6489c8a0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_7ba3e326-e975-487d-80e5-8b8f3fb85d3f" xlink:href="regn-20210930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a7daff2-4ebc-40b2-97f9-1ae21b3debe8" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_7ba3e326-e975-487d-80e5-8b8f3fb85d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_d051a517-fd91-41c1-9b68-a92cfd1729a0" xlink:href="regn-20210930.xsd#regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a7daff2-4ebc-40b2-97f9-1ae21b3debe8" xlink:to="loc_regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember_d051a517-fd91-41c1-9b68-a92cfd1729a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6934104b-3f7f-487a-88c3-348c59ca5787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_152325dd-d670-4530-8a46-771dd692e4a6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6934104b-3f7f-487a-88c3-348c59ca5787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8447e21a-8b8c-44ce-b8cc-16db7fdda289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6934104b-3f7f-487a-88c3-348c59ca5787" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8447e21a-8b8c-44ce-b8cc-16db7fdda289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_040ebe48-14aa-4f25-8096-785eca201512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_efac2159-e762-4734-b006-24597034b9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_040ebe48-14aa-4f25-8096-785eca201512" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_efac2159-e762-4734-b006-24597034b9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b0874ea2-a1ec-4c52-9703-5c79e1760b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_efac2159-e762-4734-b006-24597034b9c6" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b0874ea2-a1ec-4c52-9703-5c79e1760b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_ff004896-2725-43bb-8827-9c8b50e6976a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_b0874ea2-a1ec-4c52-9703-5c79e1760b96" xlink:to="loc_us-gaap_ProjectMember_ff004896-2725-43bb-8827-9c8b50e6976a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BayerCollaborationAgreementMember_5d280ae1-d395-4541-8984-c8de4e0181d7" xlink:href="regn-20210930.xsd#regn_BayerCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_ff004896-2725-43bb-8827-9c8b50e6976a" xlink:to="loc_regn_BayerCollaborationAgreementMember_5d280ae1-d395-4541-8984-c8de4e0181d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2fa3abe8-605c-449a-bf18-375af403436e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_efac2159-e762-4734-b006-24597034b9c6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_2fa3abe8-605c-449a-bf18-375af403436e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_72e8d218-e428-4c10-8f3e-a971e2ef0ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2fa3abe8-605c-449a-bf18-375af403436e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_72e8d218-e428-4c10-8f3e-a971e2ef0ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c6ed5fa2-b81b-4711-9645-7322769cea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2fa3abe8-605c-449a-bf18-375af403436e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c6ed5fa2-b81b-4711-9645-7322769cea5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6a7337ca-8c92-4782-a9d3-1ea7278498cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d6c337b9-b967-4b05-a42d-dfa23988c742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6a7337ca-8c92-4782-a9d3-1ea7278498cd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d6c337b9-b967-4b05-a42d-dfa23988c742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_65e6d5ce-6e31-44e0-8233-2ccffea7152a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d6c337b9-b967-4b05-a42d-dfa23988c742" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_65e6d5ce-6e31-44e0-8233-2ccffea7152a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_8643d75e-0e2a-4cfe-bca3-ce010ba30325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_65e6d5ce-6e31-44e0-8233-2ccffea7152a" xlink:to="loc_us-gaap_ProjectMember_8643d75e-0e2a-4cfe-bca3-ce010ba30325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_46b72348-4e55-4d88-8c36-ed044471b976" xlink:href="regn-20210930.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_8643d75e-0e2a-4cfe-bca3-ce010ba30325" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_46b72348-4e55-4d88-8c36-ed044471b976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c2084df3-4970-4a7c-8c5c-30fde81a1b6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d6c337b9-b967-4b05-a42d-dfa23988c742" xlink:to="loc_srt_ProductOrServiceAxis_c2084df3-4970-4a7c-8c5c-30fde81a1b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3c922605-2270-47ef-8169-bc8001e224f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c2084df3-4970-4a7c-8c5c-30fde81a1b6e" xlink:to="loc_srt_ProductsAndServicesDomain_3c922605-2270-47ef-8169-bc8001e224f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_fb8734c3-a12c-449c-a4df-4cba1dc146e2" xlink:href="regn-20210930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3c922605-2270-47ef-8169-bc8001e224f1" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpensesMember_fb8734c3-a12c-449c-a4df-4cba1dc146e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_a2e270b2-99aa-409e-9897-b2651ad9724a" xlink:href="regn-20210930.xsd#regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3c922605-2270-47ef-8169-bc8001e224f1" xlink:to="loc_regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember_a2e270b2-99aa-409e-9897-b2651ad9724a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_83713259-a74d-42e3-9992-0e7553cf3030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d6c337b9-b967-4b05-a42d-dfa23988c742" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_83713259-a74d-42e3-9992-0e7553cf3030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bc125eb5-b1b2-4d34-acec-15f353ee8482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_83713259-a74d-42e3-9992-0e7553cf3030" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bc125eb5-b1b2-4d34-acec-15f353ee8482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8790cee9-2416-4553-9a34-6dc2f1d6361d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc125eb5-b1b2-4d34-acec-15f353ee8482" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8790cee9-2416-4553-9a34-6dc2f1d6361d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_32ae4811-1639-40c3-91da-8903132e3d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bc125eb5-b1b2-4d34-acec-15f353ee8482" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_32ae4811-1639-40c3-91da-8903132e3d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0509eaaa-4a7c-42a3-9823-564bcda4c228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d6c337b9-b967-4b05-a42d-dfa23988c742" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0509eaaa-4a7c-42a3-9823-564bcda4c228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_be3ae7d3-27e4-4b9b-aa70-6aa3dbd90976" xlink:href="regn-20210930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0509eaaa-4a7c-42a3-9823-564bcda4c228" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_be3ae7d3-27e4-4b9b-aa70-6aa3dbd90976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_9e668d64-a695-498f-aeb0-25dd8852377c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0509eaaa-4a7c-42a3-9823-564bcda4c228" xlink:to="loc_us-gaap_OtherOperatingIncome_9e668d64-a695-498f-aeb0-25dd8852377c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a5398835-edbb-497a-a3b9-e7db3116ee4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_22d6a6be-888b-471c-807d-3d1c0098e237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a5398835-edbb-497a-a3b9-e7db3116ee4a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_22d6a6be-888b-471c-807d-3d1c0098e237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0eb971f1-c414-490c-9a83-70d31e7b57c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_22d6a6be-888b-471c-807d-3d1c0098e237" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0eb971f1-c414-490c-9a83-70d31e7b57c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_1ac6727f-7f05-4add-8bff-0303e30e130c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_0eb971f1-c414-490c-9a83-70d31e7b57c8" xlink:to="loc_us-gaap_ProjectMember_1ac6727f-7f05-4add-8bff-0303e30e130c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_6ee387d5-ec57-4968-9861-50d7b8e01cf5" xlink:href="regn-20210930.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_1ac6727f-7f05-4add-8bff-0303e30e130c" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_6ee387d5-ec57-4968-9861-50d7b8e01cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8c02b95d-041e-4a8b-bdaf-ea001975249a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_22d6a6be-888b-471c-807d-3d1c0098e237" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8c02b95d-041e-4a8b-bdaf-ea001975249a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a8bcc767-92e4-46f4-8495-0ae8da46a0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8c02b95d-041e-4a8b-bdaf-ea001975249a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a8bcc767-92e4-46f4-8495-0ae8da46a0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_5b32f06f-5307-4a7a-8fc6-b666232431fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8c02b95d-041e-4a8b-bdaf-ea001975249a" xlink:to="loc_us-gaap_OtherLiabilities_5b32f06f-5307-4a7a-8fc6-b666232431fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ad7cda78-3384-44ad-b324-417742597c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b2761d97-ebbc-4719-9968-f123f6df9ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ad7cda78-3384-44ad-b324-417742597c53" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b2761d97-ebbc-4719-9968-f123f6df9ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_811092b8-aa83-4f05-b40a-97a8d4fa92f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b2761d97-ebbc-4719-9968-f123f6df9ca2" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_811092b8-aa83-4f05-b40a-97a8d4fa92f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_2e6b8cac-36b0-4add-98c7-95fc22dd4841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_811092b8-aa83-4f05-b40a-97a8d4fa92f6" xlink:to="loc_us-gaap_ProjectMember_2e6b8cac-36b0-4add-98c7-95fc22dd4841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_ca9b61d9-7139-4f1f-bef4-e6c10c4eb8e0" xlink:href="regn-20210930.xsd#regn_TevaPharmaceuticalsCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_2e6b8cac-36b0-4add-98c7-95fc22dd4841" xlink:to="loc_regn_TevaPharmaceuticalsCollaborationAgreementMember_ca9b61d9-7139-4f1f-bef4-e6c10c4eb8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_949c24da-95af-458e-9dae-1584f0324eee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b2761d97-ebbc-4719-9968-f123f6df9ca2" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_949c24da-95af-458e-9dae-1584f0324eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_3274dd43-51e0-4c2a-a4dc-ce3a798c142e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_949c24da-95af-458e-9dae-1584f0324eee" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_3274dd43-51e0-4c2a-a4dc-ce3a798c142e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_595ab15b-690d-48f7-a9a5-3df0562e65d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b5b2131d-f861-4674-8e86-d02c972e2fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_595ab15b-690d-48f7-a9a5-3df0562e65d8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b5b2131d-f861-4674-8e86-d02c972e2fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_28acb465-1866-4967-acbe-711334762fd2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5b2131d-f861-4674-8e86-d02c972e2fe5" xlink:to="loc_srt_ProductOrServiceAxis_28acb465-1866-4967-acbe-711334762fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7cd9cabb-b296-4328-b5e8-3ac6a74f125b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_28acb465-1866-4967-acbe-711334762fd2" xlink:to="loc_srt_ProductsAndServicesDomain_7cd9cabb-b296-4328-b5e8-3ac6a74f125b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_REGENCOVMember_1b60c075-3afa-44d4-b31b-407b0958c427" xlink:href="regn-20210930.xsd#regn_REGENCOVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7cd9cabb-b296-4328-b5e8-3ac6a74f125b" xlink:to="loc_regn_REGENCOVMember_1b60c075-3afa-44d4-b31b-407b0958c427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4d50f479-0363-46d2-b74a-f44e0b461580" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5b2131d-f861-4674-8e86-d02c972e2fe5" xlink:to="loc_srt_CounterpartyNameAxis_4d50f479-0363-46d2-b74a-f44e0b461580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9d794c5-5698-4ed5-a393-a0bb0ba804c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4d50f479-0363-46d2-b74a-f44e0b461580" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9d794c5-5698-4ed5-a393-a0bb0ba804c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_USGovernmentMember_1d4dcf3c-ba25-4a2d-b519-f8f4320905eb" xlink:href="regn-20210930.xsd#regn_USGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9d794c5-5698-4ed5-a393-a0bb0ba804c6" xlink:to="loc_regn_USGovernmentMember_1d4dcf3c-ba25-4a2d-b519-f8f4320905eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_73d1a01c-e812-480e-ba1b-cc0286101384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5b2131d-f861-4674-8e86-d02c972e2fe5" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_73d1a01c-e812-480e-ba1b-cc0286101384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_537ab54b-ac86-470e-9295-460e72f80c77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_73d1a01c-e812-480e-ba1b-cc0286101384" xlink:to="loc_us-gaap_ProjectMember_537ab54b-ac86-470e-9295-460e72f80c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BARDAOtherTransactionAgreementMember_930f1e56-ef02-439a-8763-69d1f5cb2072" xlink:href="regn-20210930.xsd#regn_BARDAOtherTransactionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_537ab54b-ac86-470e-9295-460e72f80c77" xlink:to="loc_regn_BARDAOtherTransactionAgreementMember_930f1e56-ef02-439a-8763-69d1f5cb2072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b34aef45-5132-4161-99cd-53e5061e7467" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5b2131d-f861-4674-8e86-d02c972e2fe5" xlink:to="loc_srt_StatementScenarioAxis_b34aef45-5132-4161-99cd-53e5061e7467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_621f0fdc-30fd-40be-b333-eba0fc295704" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_b34aef45-5132-4161-99cd-53e5061e7467" xlink:to="loc_srt_ScenarioUnspecifiedDomain_621f0fdc-30fd-40be-b333-eba0fc295704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b5b70908-37aa-4fd7-baa1-9e6c33789551" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_621f0fdc-30fd-40be-b333-eba0fc295704" xlink:to="loc_srt_ScenarioForecastMember_b5b70908-37aa-4fd7-baa1-9e6c33789551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a2b01678-d24a-44d2-b81d-7dc3abd90005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5b2131d-f861-4674-8e86-d02c972e2fe5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a2b01678-d24a-44d2-b81d-7dc3abd90005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase_1ec6f261-bbd0-4f99-afee-569e3be93c7b" xlink:href="regn-20210930.xsd#regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2b01678-d24a-44d2-b81d-7dc3abd90005" xlink:to="loc_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase_1ec6f261-bbd0-4f99-afee-569e3be93c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MaximumTransactionAgreementPayments_6c76c092-c902-4104-875d-7a8c54a9eea0" xlink:href="regn-20210930.xsd#regn_MaximumTransactionAgreementPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2b01678-d24a-44d2-b81d-7dc3abd90005" xlink:to="loc_regn_MaximumTransactionAgreementPayments_6c76c092-c902-4104-875d-7a8c54a9eea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61e94d0f-33be-4498-aeff-c148ddef8c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_01e4431c-f741-4936-a69e-17f4c3dba204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61e94d0f-33be-4498-aeff-c148ddef8c98" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_01e4431c-f741-4936-a69e-17f4c3dba204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c3217227-e1e0-4ba0-b59d-d38b8af7e7ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01e4431c-f741-4936-a69e-17f4c3dba204" xlink:to="loc_srt_ProductOrServiceAxis_c3217227-e1e0-4ba0-b59d-d38b8af7e7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_410a9305-9a27-4e20-8619-ef5afe8e01e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c3217227-e1e0-4ba0-b59d-d38b8af7e7ed" xlink:to="loc_srt_ProductsAndServicesDomain_410a9305-9a27-4e20-8619-ef5afe8e01e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CasirivimabAndImdevimabMember_2908d777-7d40-4049-9b00-e63e78e96a23" xlink:href="regn-20210930.xsd#regn_CasirivimabAndImdevimabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_410a9305-9a27-4e20-8619-ef5afe8e01e2" xlink:to="loc_regn_CasirivimabAndImdevimabMember_2908d777-7d40-4049-9b00-e63e78e96a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_40b6d3ec-c40b-446f-bad7-3137d049e836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01e4431c-f741-4936-a69e-17f4c3dba204" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_40b6d3ec-c40b-446f-bad7-3137d049e836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_5b814867-8a17-463f-86bc-2502b397ffc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_40b6d3ec-c40b-446f-bad7-3137d049e836" xlink:to="loc_us-gaap_ProjectMember_5b814867-8a17-463f-86bc-2502b397ffc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RocheCollaborationAgreementMember_5c51f9a3-d2db-488f-93d7-87e08e0ec8b8" xlink:href="regn-20210930.xsd#regn_RocheCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_5b814867-8a17-463f-86bc-2502b397ffc9" xlink:to="loc_regn_RocheCollaborationAgreementMember_5c51f9a3-d2db-488f-93d7-87e08e0ec8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_26b687cd-4e3e-45b0-a312-5bccf9289236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01e4431c-f741-4936-a69e-17f4c3dba204" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_26b687cd-4e3e-45b0-a312-5bccf9289236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_69b871bd-aa1b-4ca2-8aaa-ade679d111a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_26b687cd-4e3e-45b0-a312-5bccf9289236" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_69b871bd-aa1b-4ca2-8aaa-ade679d111a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborationRevenueMember_0beec5b8-cdd5-4538-8c84-0f8853a6c4a9" xlink:href="regn-20210930.xsd#regn_CollaborationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_69b871bd-aa1b-4ca2-8aaa-ade679d111a7" xlink:to="loc_regn_CollaborationRevenueMember_0beec5b8-cdd5-4538-8c84-0f8853a6c4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c3e9c2af-e3b5-4e9c-92d8-f2b5c7796302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_69b871bd-aa1b-4ca2-8aaa-ade679d111a7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c3e9c2af-e3b5-4e9c-92d8-f2b5c7796302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c08f061f-d46f-4257-ae0a-50061617c237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_01e4431c-f741-4936-a69e-17f4c3dba204" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c08f061f-d46f-4257-ae0a-50061617c237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6887ca49-34b0-4cb8-b690-9f33329297e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c08f061f-d46f-4257-ae0a-50061617c237" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6887ca49-34b0-4cb8-b690-9f33329297e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_4df3c743-e207-4345-abd2-f2cb9bd03842" xlink:href="regn-20210930.xsd#regn_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c08f061f-d46f-4257-ae0a-50061617c237" xlink:to="loc_regn_ReimbursementOfResearchAndDevelopmentExpense_4df3c743-e207-4345-abd2-f2cb9bd03842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_41af3ba5-a894-4010-b881-730bf38e5bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_708b7acb-caff-4d56-ac9f-471535640869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_41af3ba5-a894-4010-b881-730bf38e5bfc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_708b7acb-caff-4d56-ac9f-471535640869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_70ba4c82-9e66-4298-b28d-13f7a30ce4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_708b7acb-caff-4d56-ac9f-471535640869" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_70ba4c82-9e66-4298-b28d-13f7a30ce4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_f25edd37-2c3b-4b36-b0f4-5e944d8afa23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_70ba4c82-9e66-4298-b28d-13f7a30ce4cd" xlink:to="loc_us-gaap_ProjectMember_f25edd37-2c3b-4b36-b0f4-5e944d8afa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RocheCollaborationAgreementMember_ee2f91ff-4830-4a50-bc19-7435e3f9dc36" xlink:href="regn-20210930.xsd#regn_RocheCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_f25edd37-2c3b-4b36-b0f4-5e944d8afa23" xlink:to="loc_regn_RocheCollaborationAgreementMember_ee2f91ff-4830-4a50-bc19-7435e3f9dc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_14e61258-7364-425c-8938-b0a2782296d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_708b7acb-caff-4d56-ac9f-471535640869" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_14e61258-7364-425c-8938-b0a2782296d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_50ff520e-ba1b-48e0-b18e-a7e0be098155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_14e61258-7364-425c-8938-b0a2782296d8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_50ff520e-ba1b-48e0-b18e-a7e0be098155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_95e99c3f-d8db-4c0f-a0bb-f0e557ffeaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_1359cd70-613d-4547-9b51-087db83e4fac" xlink:href="regn-20210930.xsd#regn_ResearchCollaborationAndLicensingArrangementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_95e99c3f-d8db-4c0f-a0bb-f0e557ffeaa6" xlink:to="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_1359cd70-613d-4547-9b51-087db83e4fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ad90b634-07bc-4964-ae5a-6713b0666625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_1359cd70-613d-4547-9b51-087db83e4fac" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ad90b634-07bc-4964-ae5a-6713b0666625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_fc5c8341-38a4-4862-a508-33be41f06495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_ad90b634-07bc-4964-ae5a-6713b0666625" xlink:to="loc_us-gaap_ProjectMember_fc5c8341-38a4-4862-a508-33be41f06495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_IntelliaMember_292da28b-0c1f-4270-83c0-8084c1813e95" xlink:href="regn-20210930.xsd#regn_IntelliaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_fc5c8341-38a4-4862-a508-33be41f06495" xlink:to="loc_regn_IntelliaMember_292da28b-0c1f-4270-83c0-8084c1813e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c4ee5b62-c198-4385-894c-93500039f6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_1359cd70-613d-4547-9b51-087db83e4fac" xlink:to="loc_us-gaap_InvestmentTypeAxis_c4ee5b62-c198-4385-894c-93500039f6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_096451ee-220f-4d5f-b97c-425726833aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_c4ee5b62-c198-4385-894c-93500039f6a7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_096451ee-220f-4d5f-b97c-425726833aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0ed40abc-2186-4e14-98de-8fca5b163621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_096451ee-220f-4d5f-b97c-425726833aa7" xlink:to="loc_us-gaap_CommonStockMember_0ed40abc-2186-4e14-98de-8fca5b163621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_68ba0235-d5de-415e-8601-b4c4d6261074" xlink:href="regn-20210930.xsd#regn_ResearchCollaborationAndLicensingArrangementsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsTable_1359cd70-613d-4547-9b51-087db83e4fac" xlink:to="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_68ba0235-d5de-415e-8601-b4c4d6261074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_CollaborativeArrangementUpfrontPaymentMade_7a1fbf8e-060c-4446-8f72-4f94e31fddd3" xlink:href="regn-20210930.xsd#regn_CollaborativeArrangementUpfrontPaymentMade"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_68ba0235-d5de-415e-8601-b4c4d6261074" xlink:to="loc_regn_CollaborativeArrangementUpfrontPaymentMade_7a1fbf8e-060c-4446-8f72-4f94e31fddd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_63dff231-5c22-45b5-ac18-2e9ede4baa76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_68ba0235-d5de-415e-8601-b4c4d6261074" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_63dff231-5c22-45b5-ac18-2e9ede4baa76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ce66c761-f18f-4c56-b398-9811e964271e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ResearchCollaborationAndLicensingArrangementsLineItems_68ba0235-d5de-415e-8601-b4c4d6261074" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ce66c761-f18f-4c56-b398-9811e964271e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="regn-20210930.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8ef76063-ed53-434b-a420-c59cc80c819d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_a1a1cf86-79a8-42a8-9b4a-86d7c941cf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8ef76063-ed53-434b-a420-c59cc80c819d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_a1a1cf86-79a8-42a8-9b4a-86d7c941cf6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="regn-20210930.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d2762057-85c5-4cca-a660-781ae7a352aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_784f5057-8de1-4c76-994a-4f397ea52cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d2762057-85c5-4cca-a660-781ae7a352aa" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_784f5057-8de1-4c76-994a-4f397ea52cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3d98bdf7-07b4-4d40-9739-55fa84460e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d2762057-85c5-4cca-a660-781ae7a352aa" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3d98bdf7-07b4-4d40-9739-55fa84460e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_821cc6ec-f885-4cf3-a2de-fdc9433239c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2729938f-1d60-4302-88bd-54d4ba17abd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_821cc6ec-f885-4cf3-a2de-fdc9433239c0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2729938f-1d60-4302-88bd-54d4ba17abd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_83d61316-d512-4cf9-baca-623ca1261947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2729938f-1d60-4302-88bd-54d4ba17abd1" xlink:to="loc_us-gaap_AwardTypeAxis_83d61316-d512-4cf9-baca-623ca1261947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ce02c87-435c-40e6-b254-4de4a4f56fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_83d61316-d512-4cf9-baca-623ca1261947" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ce02c87-435c-40e6-b254-4de4a4f56fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_102a5386-d929-49ea-85ed-7677df64cb53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ce02c87-435c-40e6-b254-4de4a4f56fcf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_102a5386-d929-49ea-85ed-7677df64cb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f130ce4a-81d3-4be8-b52d-30e002a8df1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ce02c87-435c-40e6-b254-4de4a4f56fcf" xlink:to="loc_us-gaap_RestrictedStockMember_f130ce4a-81d3-4be8-b52d-30e002a8df1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2729938f-1d60-4302-88bd-54d4ba17abd1" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_45a6d765-b326-4c02-9492-61e1a01c4030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:to="loc_us-gaap_NetIncomeLoss_45a6d765-b326-4c02-9492-61e1a01c4030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b1060ab4-a1bd-434f-81c4-33c57fdfaccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b1060ab4-a1bd-434f-81c4-33c57fdfaccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_62c63c9a-c1c0-4e87-bb54-68d04d9d27ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_62c63c9a-c1c0-4e87-bb54-68d04d9d27ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_71cb599d-ab52-4eff-adc1-af89a72b0157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_71cb599d-ab52-4eff-adc1-af89a72b0157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_27ed0ea5-82e3-43cf-b871-2903ea6a3bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:to="loc_us-gaap_EarningsPerShareBasic_27ed0ea5-82e3-43cf-b871-2903ea6a3bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_294607b8-3b54-4f5f-8a28-47f998831368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_70e490f9-b304-49cb-9433-d2de18440f7f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_294607b8-3b54-4f5f-8a28-47f998831368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b0a54223-25f7-4ef4-8827-506327b4d8da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d620452e-44f9-4305-977d-1f6b2ed496d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b0a54223-25f7-4ef4-8827-506327b4d8da" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d620452e-44f9-4305-977d-1f6b2ed496d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_92344ae0-e87b-434f-9769-92ae83fc1628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d620452e-44f9-4305-977d-1f6b2ed496d9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_92344ae0-e87b-434f-9769-92ae83fc1628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d458410a-df33-4257-a9d8-43fd13d1a419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_92344ae0-e87b-434f-9769-92ae83fc1628" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d458410a-df33-4257-a9d8-43fd13d1a419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fa424d32-bc16-4a92-b249-fa10d5b24839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d458410a-df33-4257-a9d8-43fd13d1a419" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fa424d32-bc16-4a92-b249-fa10d5b24839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0182f58b-a9ac-44a9-87c5-af1cab1bf7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d620452e-44f9-4305-977d-1f6b2ed496d9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0182f58b-a9ac-44a9-87c5-af1cab1bf7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_dc583c2a-a6f9-4f41-a478-820eff2ff1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0182f58b-a9ac-44a9-87c5-af1cab1bf7ff" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_dc583c2a-a6f9-4f41-a478-820eff2ff1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecurities" xlink:type="simple" xlink:href="regn-20210930.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4d64e470-2d35-4559-a5a8-62465d2f97fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_db55ce6c-fa0c-479e-97e5-2ba05df659e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4d64e470-2d35-4559-a5a8-62465d2f97fc" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_db55ce6c-fa0c-479e-97e5-2ba05df659e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="regn-20210930.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_728f24b2-46ab-47e1-b407-b8994eb760a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_db58fedf-bb80-4f1b-8a79-a80462fece3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_728f24b2-46ab-47e1-b407-b8994eb760a8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_db58fedf-bb80-4f1b-8a79-a80462fece3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_bee7843b-8ad8-4949-81fc-761f764b1985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_728f24b2-46ab-47e1-b407-b8994eb760a8" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_bee7843b-8ad8-4949-81fc-761f764b1985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_424ac070-9d87-4e44-86cc-31386860776e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_728f24b2-46ab-47e1-b407-b8994eb760a8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_424ac070-9d87-4e44-86cc-31386860776e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d59fa046-e02f-4438-bbe3-122fb6eee976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c86731e-5ccd-410f-8651-35f2225766b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d59fa046-e02f-4438-bbe3-122fb6eee976" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c86731e-5ccd-410f-8651-35f2225766b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0116be7e-7f16-441f-8618-eb9ec5e1de40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c86731e-5ccd-410f-8651-35f2225766b6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0116be7e-7f16-441f-8618-eb9ec5e1de40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0116be7e-7f16-441f-8618-eb9ec5e1de40" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_1fb5ab11-ac72-4cba-a276-24759f41e73c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_1fb5ab11-ac72-4cba-a276-24759f41e73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_cfb2c1f1-ec38-48dc-916d-8985175b195c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_cfb2c1f1-ec38-48dc-916d-8985175b195c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_82556c70-bcb7-4e3e-96a4-8305a2de6c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_82556c70-bcb7-4e3e-96a4-8305a2de6c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_acdad8ab-9a30-494f-ad1e-14ce6574802a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:to="loc_us-gaap_CommercialPaperMember_acdad8ab-9a30-494f-ad1e-14ce6574802a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_16ba73fa-3d7b-4af4-94d6-bf5417bf6623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:to="loc_us-gaap_CertificatesOfDepositMember_16ba73fa-3d7b-4af4-94d6-bf5417bf6623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_ceff3069-e101-4713-88dc-5a5bdbaad5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fab996b7-6d53-47a0-af9b-5a5054b6a355" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_ceff3069-e101-4713-88dc-5a5bdbaad5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_540e1363-a478-4951-963d-8195cc84024b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1c86731e-5ccd-410f-8651-35f2225766b6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_540e1363-a478-4951-963d-8195cc84024b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_17150823-8408-439f-b58f-92b49aa57aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_540e1363-a478-4951-963d-8195cc84024b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_17150823-8408-439f-b58f-92b49aa57aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7c1f48d8-14a9-48ec-b5da-82df42df0941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_540e1363-a478-4951-963d-8195cc84024b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7c1f48d8-14a9-48ec-b5da-82df42df0941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ef859199-c102-44a0-94b4-8278a08d49ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_540e1363-a478-4951-963d-8195cc84024b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ef859199-c102-44a0-94b4-8278a08d49ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cf9270bd-086f-4f6e-ad67-77bf5ccf2220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_540e1363-a478-4951-963d-8195cc84024b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cf9270bd-086f-4f6e-ad67-77bf5ccf2220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_273a04c3-9939-4bea-91c3-c50718f25703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_77eda32d-24a5-4974-bebd-53e0f045929c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_273a04c3-9939-4bea-91c3-c50718f25703" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_77eda32d-24a5-4974-bebd-53e0f045929c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_dcb6a2ba-cda5-4006-9f55-3b6d66400f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_273a04c3-9939-4bea-91c3-c50718f25703" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_dcb6a2ba-cda5-4006-9f55-3b6d66400f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5c68ff55-63b5-494f-99c5-0ace7fc1cc36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_273a04c3-9939-4bea-91c3-c50718f25703" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5c68ff55-63b5-494f-99c5-0ace7fc1cc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_aa241d6a-185d-42b4-b943-83d181a75334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_53826df3-6036-4ca3-86c3-554e53c38da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_aa241d6a-185d-42b4-b943-83d181a75334" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_53826df3-6036-4ca3-86c3-554e53c38da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5c793de4-bda0-4990-93a0-6d80bedc1c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_53826df3-6036-4ca3-86c3-554e53c38da1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5c793de4-bda0-4990-93a0-6d80bedc1c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e97407d-93cf-4ff0-97de-af154df9ebf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5c793de4-bda0-4990-93a0-6d80bedc1c7b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e97407d-93cf-4ff0-97de-af154df9ebf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_3f33b093-08b3-4024-8244-a739d8564bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e97407d-93cf-4ff0-97de-af154df9ebf3" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_3f33b093-08b3-4024-8244-a739d8564bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_d294aea6-04f7-4ec0-af75-e067d7abaa89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e97407d-93cf-4ff0-97de-af154df9ebf3" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_d294aea6-04f7-4ec0-af75-e067d7abaa89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_53826df3-6036-4ca3-86c3-554e53c38da1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_380d00bd-01c1-4b1e-89c5-5a1f28eb1f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_380d00bd-01c1-4b1e-89c5-5a1f28eb1f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a44ef326-4c49-4bd3-ace5-53acd1598c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a44ef326-4c49-4bd3-ace5-53acd1598c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_09555a91-a43c-40f0-92ef-e136011b7f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_09555a91-a43c-40f0-92ef-e136011b7f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_81b94305-ea33-4726-a04d-1b1ea083b7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_81b94305-ea33-4726-a04d-1b1ea083b7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2bfc2b27-8dad-472c-8c71-9e97321b572f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2bfc2b27-8dad-472c-8c71-9e97321b572f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f8581325-d7de-4632-8b68-86c3eff64c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bfd1db62-f077-4433-a855-0f903cb9bec6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_f8581325-d7de-4632-8b68-86c3eff64c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#MarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_87f278fa-5421-4ddb-85b1-910b5151d5db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_99b70204-56d4-4d3a-baf4-f12e9acb7fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_87f278fa-5421-4ddb-85b1-910b5151d5db" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_99b70204-56d4-4d3a-baf4-f12e9acb7fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MarketableSecuritiesRealizedGain_2eb3316c-6cae-4443-b090-5c03dca8f99c" xlink:href="regn-20210930.xsd#regn_MarketableSecuritiesRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_87f278fa-5421-4ddb-85b1-910b5151d5db" xlink:to="loc_regn_MarketableSecuritiesRealizedGain_2eb3316c-6cae-4443-b090-5c03dca8f99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_MarketableSecuritiesRealizedLoss_cb883a68-4ae9-4797-b6c3-178ed7d8b2b0" xlink:href="regn-20210930.xsd#regn_MarketableSecuritiesRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_87f278fa-5421-4ddb-85b1-910b5151d5db" xlink:to="loc_regn_MarketableSecuritiesRealizedLoss_cb883a68-4ae9-4797-b6c3-178ed7d8b2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="regn-20210930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_37790435-48cd-4b72-9ae4-b423efaaa0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_bba7a27a-a5e5-4110-b323-d471d8f68ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_37790435-48cd-4b72-9ae4-b423efaaa0cf" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_bba7a27a-a5e5-4110-b323-d471d8f68ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="regn-20210930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_799de055-29f6-41fb-9109-458d8fa94bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3199130c-36f1-4591-8ec8-adb7bd44e581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_799de055-29f6-41fb-9109-458d8fa94bbd" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3199130c-36f1-4591-8ec8-adb7bd44e581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c004d1b3-7440-45af-a253-2e84cd6995d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7ed92f25-dde9-4f36-bd48-03520875714c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c004d1b3-7440-45af-a253-2e84cd6995d8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7ed92f25-dde9-4f36-bd48-03520875714c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca981289-9fee-4b1a-8b57-4190708deb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7ed92f25-dde9-4f36-bd48-03520875714c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca981289-9fee-4b1a-8b57-4190708deb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2261dcd-f37b-4d08-998b-319432d432c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca981289-9fee-4b1a-8b57-4190708deb8c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2261dcd-f37b-4d08-998b-319432d432c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8951d3e7-3fdb-4cd0-bd24-989a8de12fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f2261dcd-f37b-4d08-998b-319432d432c4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8951d3e7-3fdb-4cd0-bd24-989a8de12fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50731f0a-8967-48c7-b781-0704bbb7b679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7ed92f25-dde9-4f36-bd48-03520875714c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50731f0a-8967-48c7-b781-0704bbb7b679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55d812ef-0a92-49f4-a2a1-97ee14c71819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50731f0a-8967-48c7-b781-0704bbb7b679" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55d812ef-0a92-49f4-a2a1-97ee14c71819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_47ea88fb-6412-4d8d-8f29-21779e5dcaed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55d812ef-0a92-49f4-a2a1-97ee14c71819" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_47ea88fb-6412-4d8d-8f29-21779e5dcaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7a403ec0-b600-4f55-b7fb-44d76d8aab37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55d812ef-0a92-49f4-a2a1-97ee14c71819" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7a403ec0-b600-4f55-b7fb-44d76d8aab37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fb197ebe-8f71-437d-88b0-dc45e4aebccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7ed92f25-dde9-4f36-bd48-03520875714c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fb197ebe-8f71-437d-88b0-dc45e4aebccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fb197ebe-8f71-437d-88b0-dc45e4aebccc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_84e269d5-d970-48c0-8fcd-55eeab2f45e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_84e269d5-d970-48c0-8fcd-55eeab2f45e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_877e0ddf-26f4-494a-a72e-370e34c0ebcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_877e0ddf-26f4-494a-a72e-370e34c0ebcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_269d36a3-2042-44b8-94a8-b25043465516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_269d36a3-2042-44b8-94a8-b25043465516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_6019cadf-265d-4f2c-adf5-dc5c17a66d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:to="loc_us-gaap_CommercialPaperMember_6019cadf-265d-4f2c-adf5-dc5c17a66d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_1520e0b3-dcb6-43d5-8dd6-8181386608b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:to="loc_us-gaap_CertificatesOfDepositMember_1520e0b3-dcb6-43d5-8dd6-8181386608b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_7cf26bb9-a59e-4ab3-a285-8e767ac29d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a09d991-e832-4a07-8c52-602d37d28d8e" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_7cf26bb9-a59e-4ab3-a285-8e767ac29d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentAxis_b1ba8190-28ec-4f8c-b2da-6df5e3a49e49" xlink:href="regn-20210930.xsd#regn_ClassificationOfInvestmentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7ed92f25-dde9-4f36-bd48-03520875714c" xlink:to="loc_regn_ClassificationOfInvestmentAxis_b1ba8190-28ec-4f8c-b2da-6df5e3a49e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ClassificationOfInvestmentDomain_9a598870-e773-4095-ac49-93822c018182" xlink:href="regn-20210930.xsd#regn_ClassificationOfInvestmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ClassificationOfInvestmentAxis_b1ba8190-28ec-4f8c-b2da-6df5e3a49e49" xlink:to="loc_regn_ClassificationOfInvestmentDomain_9a598870-e773-4095-ac49-93822c018182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_UnrestrictedMember_504cc9cc-b3e1-4fa0-8a73-292333328e6a" xlink:href="regn-20210930.xsd#regn_UnrestrictedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ClassificationOfInvestmentDomain_9a598870-e773-4095-ac49-93822c018182" xlink:to="loc_regn_UnrestrictedMember_504cc9cc-b3e1-4fa0-8a73-292333328e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_RestrictedMember_ba35269f-37a2-4781-9d00-42e33a020a17" xlink:href="regn-20210930.xsd#regn_RestrictedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_regn_ClassificationOfInvestmentDomain_9a598870-e773-4095-ac49-93822c018182" xlink:to="loc_regn_RestrictedMember_ba35269f-37a2-4781-9d00-42e33a020a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f388642f-529a-45ef-89b7-1da3b1b200e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7ed92f25-dde9-4f36-bd48-03520875714c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f388642f-529a-45ef-89b7-1da3b1b200e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a4ce32a-2bfd-4253-86f7-223d30ba7832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f388642f-529a-45ef-89b7-1da3b1b200e6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a4ce32a-2bfd-4253-86f7-223d30ba7832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7bd1e9f4-8d30-4f3a-8cb0-17d2368ddb86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a4ce32a-2bfd-4253-86f7-223d30ba7832" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7bd1e9f4-8d30-4f3a-8cb0-17d2368ddb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_e85f74d3-04db-4362-979e-1cdf43056884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f388642f-529a-45ef-89b7-1da3b1b200e6" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_e85f74d3-04db-4362-979e-1cdf43056884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_4dfeaca8-fd9f-47ca-b27e-2a3a3a7e5dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f388642f-529a-45ef-89b7-1da3b1b200e6" xlink:to="loc_us-gaap_MarketableSecurities_4dfeaca8-fd9f-47ca-b27e-2a3a3a7e5dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_110cbc9b-5c5d-48ee-9f07-b6e7c01d4400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_871bd360-fb2d-4f20-8a26-00b87acdeb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_110cbc9b-5c5d-48ee-9f07-b6e7c01d4400" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_871bd360-fb2d-4f20-8a26-00b87acdeb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b7401129-a699-4b41-909a-9574bc953a97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_110cbc9b-5c5d-48ee-9f07-b6e7c01d4400" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b7401129-a699-4b41-909a-9574bc953a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_10199bd6-b8ee-45e7-b13a-7ae04c5d8823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_110cbc9b-5c5d-48ee-9f07-b6e7c01d4400" xlink:to="loc_us-gaap_LongTermDebtFairValue_10199bd6-b8ee-45e7-b13a-7ae04c5d8823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/Inventories" xlink:type="simple" xlink:href="regn-20210930.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d936e275-128f-459f-a92a-ce39ac5ac8de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_7f8a06d7-8493-4f2f-900b-915a0aa37dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d936e275-128f-459f-a92a-ce39ac5ac8de" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_7f8a06d7-8493-4f2f-900b-915a0aa37dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesTables" xlink:type="simple" xlink:href="regn-20210930.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d248e5c4-91f7-43a7-93d1-4c24916073f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0d9a5039-abdf-425b-a85e-1f462942f944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d248e5c4-91f7-43a7-93d1-4c24916073f5" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0d9a5039-abdf-425b-a85e-1f462942f944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_00b26cfc-ba1a-4f13-9e23-edf5be9a05fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_9eddf2e6-b650-4ee1-9f85-2e1ab78f80d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_00b26cfc-ba1a-4f13-9e23-edf5be9a05fc" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_9eddf2e6-b650-4ee1-9f85-2e1ab78f80d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_50f31657-6cbc-44b8-b51b-5fded0f0cf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_00b26cfc-ba1a-4f13-9e23-edf5be9a05fc" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_50f31657-6cbc-44b8-b51b-5fded0f0cf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5a88d893-18f2-471f-906d-500589765193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_00b26cfc-ba1a-4f13-9e23-edf5be9a05fc" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5a88d893-18f2-471f-906d-500589765193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryNetOfReserves_6b223921-4fbe-40fe-a66c-04758f5feafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventoryNetOfReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_00b26cfc-ba1a-4f13-9e23-edf5be9a05fc" xlink:to="loc_us-gaap_OtherInventoryNetOfReserves_6b223921-4fbe-40fe-a66c-04758f5feafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2f0120f1-f206-4a7f-b01e-0b424210caac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_00b26cfc-ba1a-4f13-9e23-edf5be9a05fc" xlink:to="loc_us-gaap_InventoryNet_2f0120f1-f206-4a7f-b01e-0b424210caac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_70f88d1f-5d56-42eb-a4d6-c034cdb020e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_203d64ca-e670-4303-b241-03574b852299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_70f88d1f-5d56-42eb-a4d6-c034cdb020e4" xlink:to="loc_us-gaap_InventoryWriteDown_203d64ca-e670-4303-b241-03574b852299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/Debt" xlink:type="simple" xlink:href="regn-20210930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8fc9dfdf-abc7-411e-b2ff-8cc697735fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_522ff18e-8724-4ed9-a165-8bd572a58e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8fc9dfdf-abc7-411e-b2ff-8cc697735fbf" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_522ff18e-8724-4ed9-a165-8bd572a58e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/DebtTables" xlink:type="simple" xlink:href="regn-20210930.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a23d0199-4b84-4d79-a347-17234038591f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_cf7f2c50-9712-4e2b-a811-26e2913521a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a23d0199-4b84-4d79-a347-17234038591f" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_cf7f2c50-9712-4e2b-a811-26e2913521a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7312822f-22ae-4bba-92c0-155ac7f08ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_bd479617-512b-4a30-856a-6188443b0e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7312822f-22ae-4bba-92c0-155ac7f08ba0" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_bd479617-512b-4a30-856a-6188443b0e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_83de639c-4bf0-4862-93a7-fd193fe51863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_bd479617-512b-4a30-856a-6188443b0e8d" xlink:to="loc_us-gaap_DebtInstrumentAxis_83de639c-4bf0-4862-93a7-fd193fe51863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8c9ad82d-6978-4984-94f3-10955e55781b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_83de639c-4bf0-4862-93a7-fd193fe51863" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8c9ad82d-6978-4984-94f3-10955e55781b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_BridgeFacilityMember_9e2bafbc-1e7e-41f3-bd08-0bea82450ba6" xlink:href="regn-20210930.xsd#regn_BridgeFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8c9ad82d-6978-4984-94f3-10955e55781b" xlink:to="loc_regn_BridgeFacilityMember_9e2bafbc-1e7e-41f3-bd08-0bea82450ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2030Member_57cfcee2-a95b-4b87-a64b-c4a5e2e587ee" xlink:href="regn-20210930.xsd#regn_SeniorUnsecuredNotesDue2030Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8c9ad82d-6978-4984-94f3-10955e55781b" xlink:to="loc_regn_SeniorUnsecuredNotesDue2030Member_57cfcee2-a95b-4b87-a64b-c4a5e2e587ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2050Member_391a38c5-573b-4409-b559-da5e649298b5" xlink:href="regn-20210930.xsd#regn_SeniorUnsecuredNotesDue2050Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8c9ad82d-6978-4984-94f3-10955e55781b" xlink:to="loc_regn_SeniorUnsecuredNotesDue2050Member_391a38c5-573b-4409-b559-da5e649298b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_a443b150-790e-46b8-9b35-63efbd395179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_bd479617-512b-4a30-856a-6188443b0e8d" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_a443b150-790e-46b8-9b35-63efbd395179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_147e62d7-6abd-4fad-b6cb-381dce1aceb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_a443b150-790e-46b8-9b35-63efbd395179" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_147e62d7-6abd-4fad-b6cb-381dce1aceb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_4737ab04-43aa-4609-9acb-fde387508f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_147e62d7-6abd-4fad-b6cb-381dce1aceb5" xlink:to="loc_us-gaap_BridgeLoanMember_4737ab04-43aa-4609-9acb-fde387508f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3b120a4e-d698-4dfb-9585-7443b9dba301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_bd479617-512b-4a30-856a-6188443b0e8d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3b120a4e-d698-4dfb-9585-7443b9dba301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f7483ef2-f64a-4891-8445-6e4a3ef333f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3b120a4e-d698-4dfb-9585-7443b9dba301" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f7483ef2-f64a-4891-8445-6e4a3ef333f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_44c21ff8-2ea5-420a-86f3-97143dbef3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f7483ef2-f64a-4891-8445-6e4a3ef333f2" xlink:to="loc_us-gaap_SeniorNotesMember_44c21ff8-2ea5-420a-86f3-97143dbef3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_77c7dc73-cdc1-44ed-8288-89fba9430857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_bd479617-512b-4a30-856a-6188443b0e8d" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_77c7dc73-cdc1-44ed-8288-89fba9430857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c09cb088-5e2b-453b-bb44-424fb7523e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_77c7dc73-cdc1-44ed-8288-89fba9430857" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c09cb088-5e2b-453b-bb44-424fb7523e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_4ce2fc88-7ee8-491d-ac0d-e65a8cc46dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_77c7dc73-cdc1-44ed-8288-89fba9430857" xlink:to="loc_us-gaap_InterestExpenseDebt_4ce2fc88-7ee8-491d-ac0d-e65a8cc46dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#DebtSummaryofIssuedSeniorUnsecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9e506051-6c6b-4c77-b0ae-520be3dbde61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_50aad31e-3152-44cb-9db6-40262cd09115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9e506051-6c6b-4c77-b0ae-520be3dbde61" xlink:to="loc_us-gaap_DebtInstrumentTable_50aad31e-3152-44cb-9db6-40262cd09115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2ae9e9bc-b6bf-43be-8260-a84065b00f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_50aad31e-3152-44cb-9db6-40262cd09115" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2ae9e9bc-b6bf-43be-8260-a84065b00f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_173f4ce8-d5ba-4d2d-a77e-024e5e3dba61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2ae9e9bc-b6bf-43be-8260-a84065b00f11" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_173f4ce8-d5ba-4d2d-a77e-024e5e3dba61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ca0f86dd-9744-46d3-bfc4-42bf2b07aac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_173f4ce8-d5ba-4d2d-a77e-024e5e3dba61" xlink:to="loc_us-gaap_SeniorNotesMember_ca0f86dd-9744-46d3-bfc4-42bf2b07aac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f93d6131-9f58-497e-addb-1ea07f081ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_50aad31e-3152-44cb-9db6-40262cd09115" xlink:to="loc_us-gaap_DebtInstrumentAxis_f93d6131-9f58-497e-addb-1ea07f081ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42e6bf8f-2312-4f12-ada5-4526b32120ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f93d6131-9f58-497e-addb-1ea07f081ba2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42e6bf8f-2312-4f12-ada5-4526b32120ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2030Member_4bd5a307-4210-457b-ad69-c25e87160ad5" xlink:href="regn-20210930.xsd#regn_SeniorUnsecuredNotesDue2030Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42e6bf8f-2312-4f12-ada5-4526b32120ad" xlink:to="loc_regn_SeniorUnsecuredNotesDue2030Member_4bd5a307-4210-457b-ad69-c25e87160ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SeniorUnsecuredNotesDue2050Member_4119ddff-ba3c-4131-9424-634cde9328c3" xlink:href="regn-20210930.xsd#regn_SeniorUnsecuredNotesDue2050Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_42e6bf8f-2312-4f12-ada5-4526b32120ad" xlink:to="loc_regn_SeniorUnsecuredNotesDue2050Member_4119ddff-ba3c-4131-9424-634cde9328c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8dfec994-5627-41a2-931d-736df866a6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_50aad31e-3152-44cb-9db6-40262cd09115" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8dfec994-5627-41a2-931d-736df866a6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4663c7a4-7c6c-4b6e-b270-323396c5be58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8dfec994-5627-41a2-931d-736df866a6db" xlink:to="loc_us-gaap_LongTermDebt_4663c7a4-7c6c-4b6e-b270-323396c5be58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1c6a3e79-699a-4058-a1fa-a30a0d8e3a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8dfec994-5627-41a2-931d-736df866a6db" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1c6a3e79-699a-4058-a1fa-a30a0d8e3a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxes" xlink:type="simple" xlink:href="regn-20210930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_17ffb640-7bd5-4ec3-96c1-cc2e1f656508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_91bc9d37-e67c-4638-a981-f96579d62ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_17ffb640-7bd5-4ec3-96c1-cc2e1f656508" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_91bc9d37-e67c-4638-a981-f96579d62ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_96f76e9c-cfe4-46ae-a856-661e14b302a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3cdb00ff-bcea-4b87-bacb-94b6d32250a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_96f76e9c-cfe4-46ae-a856-661e14b302a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3cdb00ff-bcea-4b87-bacb-94b6d32250a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquity" xlink:type="simple" xlink:href="regn-20210930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_16fdeaa7-bfd4-466e-9eba-d41ad151d143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cca96118-718b-452f-b25e-5c34eded288f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_16fdeaa7-bfd4-466e-9eba-d41ad151d143" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cca96118-718b-452f-b25e-5c34eded288f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="regn-20210930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0ebd807a-1ef6-4d7d-b70a-ca91315d3829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_60a71cab-09b2-4cc9-b5cc-abe969c2141f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0ebd807a-1ef6-4d7d-b70a-ca91315d3829" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_60a71cab-09b2-4cc9-b5cc-abe969c2141f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_be4a85da-c6ea-4206-8a14-415025780a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_189cdd92-93d5-41de-830f-e54e35ef8007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_be4a85da-c6ea-4206-8a14-415025780a26" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_189cdd92-93d5-41de-830f-e54e35ef8007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_34652e37-f091-4b3d-a7f2-cd5175e8c6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_189cdd92-93d5-41de-830f-e54e35ef8007" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_34652e37-f091-4b3d-a7f2-cd5175e8c6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_07c7cec9-bf4b-4cf9-9da1-11520b7139a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_34652e37-f091-4b3d-a7f2-cd5175e8c6c9" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_07c7cec9-bf4b-4cf9-9da1-11520b7139a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgram2019Member_a7d55c04-b95f-44c7-945a-d13eec56820b" xlink:href="regn-20210930.xsd#regn_ShareRepurchaseProgram2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_07c7cec9-bf4b-4cf9-9da1-11520b7139a2" xlink:to="loc_regn_ShareRepurchaseProgram2019Member_a7d55c04-b95f-44c7-945a-d13eec56820b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_ShareRepurchaseProgramJanuary2021Member_a65ae666-7ab8-47f0-92ef-778c1cfcaeb9" xlink:href="regn-20210930.xsd#regn_ShareRepurchaseProgramJanuary2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_07c7cec9-bf4b-4cf9-9da1-11520b7139a2" xlink:to="loc_regn_ShareRepurchaseProgramJanuary2021Member_a65ae666-7ab8-47f0-92ef-778c1cfcaeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_28ad8464-b7e5-4f92-a0ed-97a6094b1acc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_189cdd92-93d5-41de-830f-e54e35ef8007" xlink:to="loc_dei_LegalEntityAxis_28ad8464-b7e5-4f92-a0ed-97a6094b1acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1dc2fe8f-f93d-4daa-8d3e-c42b62c794ce" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_28ad8464-b7e5-4f92-a0ed-97a6094b1acc" xlink:to="loc_dei_EntityDomain_1dc2fe8f-f93d-4daa-8d3e-c42b62c794ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_SanofiMember_3056f1ae-83bf-4c17-9db2-a3fc57fd3987" xlink:href="regn-20210930.xsd#regn_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1dc2fe8f-f93d-4daa-8d3e-c42b62c794ce" xlink:to="loc_regn_SanofiMember_3056f1ae-83bf-4c17-9db2-a3fc57fd3987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_54444fb6-8e37-46ef-af53-05a6432b8eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_189cdd92-93d5-41de-830f-e54e35ef8007" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_54444fb6-8e37-46ef-af53-05a6432b8eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_cf6db72b-ee5a-41c7-99bf-d54f02ff2c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_54444fb6-8e37-46ef-af53-05a6432b8eb1" xlink:to="loc_us-gaap_ProjectMember_cf6db72b-ee5a-41c7-99bf-d54f02ff2c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LibtayoDevelopmentMember_119763eb-83e9-42f0-886c-28d08d71808c" xlink:href="regn-20210930.xsd#regn_LibtayoDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_cf6db72b-ee5a-41c7-99bf-d54f02ff2c16" xlink:to="loc_regn_LibtayoDevelopmentMember_119763eb-83e9-42f0-886c-28d08d71808c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_DupilumabREGN3500EligibleInvestmentsMember_36498839-e1c8-494b-a605-1c88f2fbee07" xlink:href="regn-20210930.xsd#regn_DupilumabREGN3500EligibleInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_cf6db72b-ee5a-41c7-99bf-d54f02ff2c16" xlink:to="loc_regn_DupilumabREGN3500EligibleInvestmentsMember_36498839-e1c8-494b-a605-1c88f2fbee07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_189cdd92-93d5-41de-830f-e54e35ef8007" xlink:to="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d237651f-0b4d-4b2c-b036-2ebc6c93f236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d237651f-0b4d-4b2c-b036-2ebc6c93f236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_19a7100d-6779-46a7-aa0d-a7871ec275fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_19a7100d-6779-46a7-aa0d-a7871ec275fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c83685bd-f6cb-4942-822f-da022a622e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c83685bd-f6cb-4942-822f-da022a622e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_ce6bd8e3-7cb3-436b-b740-83343e197f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_ce6bd8e3-7cb3-436b-b740-83343e197f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7b0eacea-306b-4646-a385-6dffdaa0edc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7b0eacea-306b-4646-a385-6dffdaa0edc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_45c2cef0-45af-4a88-ad0f-620f6afff7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ae91f1fd-56cd-4015-963f-97318793f629" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_45c2cef0-45af-4a88-ad0f-620f6afff7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#StockholdersEquityScheduleofRepurchasedSharesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_72a49043-1b8b-41bd-9e6c-0191f38f10c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_31bb5164-2045-4465-854d-8cbd2cfa376a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_72a49043-1b8b-41bd-9e6c-0191f38f10c7" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_31bb5164-2045-4465-854d-8cbd2cfa376a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b162e56c-85ec-4d71-8023-18b5514a52b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_72a49043-1b8b-41bd-9e6c-0191f38f10c7" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b162e56c-85ec-4d71-8023-18b5514a52b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlows" xlink:type="simple" xlink:href="regn-20210930.xsd#StatementofCashFlows"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_fb0659aa-4205-420f-a385-1349ae668665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_14361cca-59c4-4c73-b36d-af0832b5a866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_fb0659aa-4205-420f-a385-1349ae668665" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_14361cca-59c4-4c73-b36d-af0832b5a866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsTables" xlink:type="simple" xlink:href="regn-20210930.xsd#StatementofCashFlowsTables"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_876383d4-8824-48d6-897b-a7715981dabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_bd192fc6-6f42-4bdb-b47e-5da6b6321e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_876383d4-8824-48d6-897b-a7715981dabc" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_bd192fc6-6f42-4bdb-b47e-5da6b6321e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_bac956c3-7aad-4450-85fc-9d1c01b1a577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_876383d4-8824-48d6-897b-a7715981dabc" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_bac956c3-7aad-4450-85fc-9d1c01b1a577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_70b6f7c6-3f0a-49de-8565-90b9c546f4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_876383d4-8824-48d6-897b-a7715981dabc" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_70b6f7c6-3f0a-49de-8565-90b9c546f4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_1d0b5c78-4a4a-4c13-8a58-73144218b677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_09dc6804-4d22-4f1a-8a54-1af1dbe6762e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_1d0b5c78-4a4a-4c13-8a58-73144218b677" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_09dc6804-4d22-4f1a-8a54-1af1dbe6762e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_120079fc-978c-490b-8405-20a0046585d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_1d0b5c78-4a4a-4c13-8a58-73144218b677" xlink:to="loc_us-gaap_RestrictedCash_120079fc-978c-490b-8405-20a0046585d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30c4033f-d689-4553-a8a7-6cb4917455eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_1d0b5c78-4a4a-4c13-8a58-73144218b677" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30c4033f-d689-4553-a8a7-6cb4917455eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_60dc07c9-9e5d-4e4e-a329-13253affb89a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_357c761c-39ab-4513-815a-415f29899c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_60dc07c9-9e5d-4e4e-a329-13253affb89a" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_357c761c-39ab-4513-815a-415f29899c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LegalMatters" xlink:type="simple" xlink:href="regn-20210930.xsd#LegalMatters"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LegalMatters" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fb631172-49a3-4c91-80e5-e8441f87105d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_8c933606-fab3-486d-9e7a-1854e6c7fb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fb631172-49a3-4c91-80e5-e8441f87105d" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_8c933606-fab3-486d-9e7a-1854e6c7fb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="simple" xlink:href="regn-20210930.xsd#LegalMattersDetails"/>
  <link:presentationLink xlink:role="http://www.regeneron.com/role/LegalMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_08a9166d-2987-412c-91a1-3e5435a21025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e071b74d-d63f-4847-a2a9-96726f497f53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_08a9166d-2987-412c-91a1-3e5435a21025" xlink:to="loc_us-gaap_LossContingenciesTable_e071b74d-d63f-4847-a2a9-96726f497f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa573981-ea8f-4d25-bfff-73019099fb44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e071b74d-d63f-4847-a2a9-96726f497f53" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa573981-ea8f-4d25-bfff-73019099fb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_c55c3380-db9f-40eb-b6ee-dcc6fc09d3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa573981-ea8f-4d25-bfff-73019099fb44" xlink:to="loc_us-gaap_LossContingencyNatureDomain_c55c3380-db9f-40eb-b6ee-dcc6fc09d3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A165PatentMember_659bee74-2a87-419e-96ba-4cd410c1c4ed" xlink:href="regn-20210930.xsd#regn_A165PatentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_c55c3380-db9f-40eb-b6ee-dcc6fc09d3c0" xlink:to="loc_regn_A165PatentMember_659bee74-2a87-419e-96ba-4cd410c1c4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A741PatentMember_efbd237c-d18c-4995-8fe0-b490daedc288" xlink:href="regn-20210930.xsd#regn_A741PatentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_c55c3380-db9f-40eb-b6ee-dcc6fc09d3c0" xlink:to="loc_regn_A741PatentMember_efbd237c-d18c-4995-8fe0-b490daedc288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A487PatentMember_365b022a-9689-461b-949f-a5ddd42aed76" xlink:href="regn-20210930.xsd#regn_A487PatentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_c55c3380-db9f-40eb-b6ee-dcc6fc09d3c0" xlink:to="loc_regn_A487PatentMember_365b022a-9689-461b-949f-a5ddd42aed76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A631PatentMember_a88d677e-99fb-4e0d-8e33-7bcb412b7e67" xlink:href="regn-20210930.xsd#regn_A631PatentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_c55c3380-db9f-40eb-b6ee-dcc6fc09d3c0" xlink:to="loc_regn_A631PatentMember_a88d677e-99fb-4e0d-8e33-7bcb412b7e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_A226PatentAnd992PatentMember_44e7430a-f663-436e-8a8b-1a2952fed391" xlink:href="regn-20210930.xsd#regn_A226PatentAnd992PatentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_c55c3380-db9f-40eb-b6ee-dcc6fc09d3c0" xlink:to="loc_regn_A226PatentAnd992PatentMember_44e7430a-f663-436e-8a8b-1a2952fed391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_fee964f9-76c6-446d-ad76-9231eb0fcdd2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e071b74d-d63f-4847-a2a9-96726f497f53" xlink:to="loc_srt_LitigationCaseAxis_fee964f9-76c6-446d-ad76-9231eb0fcdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_32251bb3-3c80-4d67-a0bb-1bc6186fa938" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_fee964f9-76c6-446d-ad76-9231eb0fcdd2" xlink:to="loc_srt_LitigationCaseTypeDomain_32251bb3-3c80-4d67-a0bb-1bc6186fa938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_Amgenv.s.RegeneronMember_3c8588d2-134a-485c-8371-d39747538a40" xlink:href="regn-20210930.xsd#regn_Amgenv.s.RegeneronMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_32251bb3-3c80-4d67-a0bb-1bc6186fa938" xlink:to="loc_regn_Amgenv.s.RegeneronMember_3c8588d2-134a-485c-8371-d39747538a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_3660090f-7876-4483-8762-edce9ec5349b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e071b74d-d63f-4847-a2a9-96726f497f53" xlink:to="loc_us-gaap_LitigationStatusAxis_3660090f-7876-4483-8762-edce9ec5349b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_2565a0df-6daa-4f2f-a8b8-aa5d7a266ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_3660090f-7876-4483-8762-edce9ec5349b" xlink:to="loc_us-gaap_LitigationStatusDomain_2565a0df-6daa-4f2f-a8b8-aa5d7a266ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_a54fa232-2163-46d8-b97a-71b6bfffe76f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_2565a0df-6daa-4f2f-a8b8-aa5d7a266ef7" xlink:to="loc_us-gaap_PendingLitigationMember_a54fa232-2163-46d8-b97a-71b6bfffe76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_90a0d8f5-44b1-4c91-82b6-ae85fb232174" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e071b74d-d63f-4847-a2a9-96726f497f53" xlink:to="loc_srt_ProductOrServiceAxis_90a0d8f5-44b1-4c91-82b6-ae85fb232174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_567af92e-9c99-48a7-8f84-7d6132097a5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_90a0d8f5-44b1-4c91-82b6-ae85fb232174" xlink:to="loc_srt_ProductsAndServicesDomain_567af92e-9c99-48a7-8f84-7d6132097a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_EYLEAAfliberceptInjectionMember_8da639c8-57a9-428e-a07f-f51d328ea791" xlink:href="regn-20210930.xsd#regn_EYLEAAfliberceptInjectionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_567af92e-9c99-48a7-8f84-7d6132097a5d" xlink:to="loc_regn_EYLEAAfliberceptInjectionMember_8da639c8-57a9-428e-a07f-f51d328ea791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_dff9b997-7e4b-4ffd-9aea-9025a583c065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e071b74d-d63f-4847-a2a9-96726f497f53" xlink:to="loc_us-gaap_LossContingenciesLineItems_dff9b997-7e4b-4ffd-9aea-9025a583c065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_6d4464ac-fae9-410e-941f-0fc860b0fe87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dff9b997-7e4b-4ffd-9aea-9025a583c065" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_6d4464ac-fae9-410e-941f-0fc860b0fe87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyClaimsInvalidNumber_93fa31c2-0263-44ae-b2a8-06b0d5d405ee" xlink:href="regn-20210930.xsd#regn_LossContingencyClaimsInvalidNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dff9b997-7e4b-4ffd-9aea-9025a583c065" xlink:to="loc_regn_LossContingencyClaimsInvalidNumber_93fa31c2-0263-44ae-b2a8-06b0d5d405ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GainContingencyInterPartesReviewFiledNumber_9b176d83-a22f-4be9-8d0c-49b7167eed79" xlink:href="regn-20210930.xsd#regn_GainContingencyInterPartesReviewFiledNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dff9b997-7e4b-4ffd-9aea-9025a583c065" xlink:to="loc_regn_GainContingencyInterPartesReviewFiledNumber_9b176d83-a22f-4be9-8d0c-49b7167eed79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_GainContingencyClaimsInvalidatedNumber_3d26cef6-0d0f-43a6-b2c2-eaad15d514d5" xlink:href="regn-20210930.xsd#regn_GainContingencyClaimsInvalidatedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dff9b997-7e4b-4ffd-9aea-9025a583c065" xlink:to="loc_regn_GainContingencyClaimsInvalidatedNumber_3d26cef6-0d0f-43a6-b2c2-eaad15d514d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_regn_LossContingencyExParteReexaminationFiledNumber_0ff91d55-1a7d-4cc3-92f3-b73aeba51eb8" xlink:href="regn-20210930.xsd#regn_LossContingencyExParteReexaminationFiledNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_dff9b997-7e4b-4ffd-9aea-9025a583c065" xlink:to="loc_regn_LossContingencyExParteReexaminationFiledNumber_0ff91d55-1a7d-4cc3-92f3-b73aeba51eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
MB5!.1PT*&@H    -24A$4@  #K$    +" (   #M;-"'    N$E$051X7NW:
ML1$ , @#,?9?.NFAH,5W4FUO\%4             P&%OTP\
MP"D] 1[Z 0             XI2? P[X              "[3! ,
M  ! -DTP             &33! ,           ! -DTP             &33
M! ,           ! -DTP             &33! ,           ! M@^7MJZ7
0N04Z;@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_2a.jpg
<TEXT>
begin 644 image_2a.jpg
MB5!.1PT*&@H    -24A$4@  #K$    +" (   #M;-"'    NDE$051X7NW:
ML0T 00@#0?IO^CXWP:=8F@D1[F#G 0            #-)@\
M0!5-,             !TTP0#            0#=-,             !TTP0#
M            0+<!             "[+!'C) 0            !P2B; 2PX
M            @%,R 5[^/P            " RS3!             -#M ]SY
2KI?\-IXD     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>regn-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:regn="http://www.regeneron.com/20210930"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="regn-20210930.xsd" xlink:type="simple"/>
    <context id="i252bf0019ce741548a01b718a72d854a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icc16664525144692bafad224736d7dbc_I20211022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-22</instant>
        </period>
    </context>
    <context id="ida653b0f9e874bc6a9d652fb00e0d46b_I20211022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-22</instant>
        </period>
    </context>
    <context id="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7e0582c9be764ded815021b5841e304e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1f2d0c6a01e40a1a132025d16ef17ca_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i65b94c6346a4410db40c1e51f2964b9d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i010ed964f154499ca13c88bdf3995dd6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1e6fff47dfed4a8890d58fd118bc6b39_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i701b6278270643ea9ea3e4f71bac2244_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i93da59ad5160490cb75eb85818530df4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if39174df528047a1a58851162c8756dc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic1d6c2cf98ab48708f23e1c442baff3a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibb855af148d44803bf5a5a397f72a4a6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i81ec7f922ada451f954d39c3398269f2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2011ff92b7314bba86afeec4eeaf8b4d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i38c63575c6ef4f41b900486402535348_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id10cdd0c27b642138616b7b32f4d6ee8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iebab4f2f32234aa480f0f8082f54bd53_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b8d7bccc16342b88d4e13958c1c3e11_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibabe614a09ed4deaa4de04435940de78_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibbfd301918c747ca84b057a5af415334_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i770f931b2ede4bdeb5ef82d0dd8a554d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1cb541cbbbef4d78a54cbec6a7e81726_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i76c0001967fc483996710f1c2b1392ce_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i463b28633c04475b8ede195911dcb3ce_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CollaborationandContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3239cd5923f34e0ca9e9ec38de051f2e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i035ed65f313f47239e1ba7a980f112a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i563d0a3bfa17497bbaf9ccff6e61e331_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0904b48c5834d8382585d98978efa6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ba799e31f25451293026f6a5a092606_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb59f0839edb41abb0134a8358db4753_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c94e3f729d1401291b50c0edf45498a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i224a9ebaa95b46c587b2caf10b449995_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i45a7c7a2a79f45b599510ec6d98f5234_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i771bf5f554d244a29f26c5501f4293f3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie140c8b387dc4645b81c9879149a8e9d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i49df9a95773d49e6967753fb9f9de580_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i970227f3acea4503918b252309b84460_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idcd2927b7554444faad537d5a6d30eb9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i99065775605c4e47ab2780914630a4e5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i95d0fd1cd63743f18bd2b4ef498d61b6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie2b9d9e8e8d94aafb8cf016d634bce00_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1db85b4dd6a74732adc71927ecf1a4b4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i485a4b467eae4806b0b1ebd35f44e2c2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0d895db990f24cf3a08e7953476d96f7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i90967a0a2559464e89e7ac0cf8e2bdbc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if027b47fcff24b09bc17374a79225282_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icdc7f3436f2d4c15be968a3a0446d58b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i01a22b1457534e58971e7c3840ce8a74_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9aca85854a7e44a4967c9de4200b7275_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib4692004524e482c94791bc9cdad2f45_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia5ee4bf1abbe4e4aa728bc791fd9e4be_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i58536bd9f96a400195ebcbf3b27c73ef_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idca5a9d3669d4ad4abd5502c841c9b83_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic8637e07a17044e3bc80d1b3f1ac3709_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3c2c8b599684423e810cce4bc7569486_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i81bba3e7b3f14597be97fbb190f9dbff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic22073ba422e4cd19578e069ff93a548_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia1af4b6d98674144aede03c90b76ecde_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa09e4ef649b446d8a986b009222a48c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iea16b9252afa422babee5f32af655235_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i31f7ae795859466f9949d77297734d41_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib5ea589759884ae08a57e4895180d768_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib4a9df31fbd2432eb37434ec52ac6097_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i241d3af3190948bebbe76ddd7a69650a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idc06747141a8415abdc99e415fd10ec4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i73dec6c7995c456c9140fce39007c0e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0bf589234254d1fa1a8439438ed348f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b0eaf7cc1b34bc3a8ce4fceda06456c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3f1bbe31c49144b58bd31a8fdaaa287b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i843aefe7a57e49a4b8057f411d68d2d6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idfb0c989543b47b4b84dfc63cacdb340_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if8be30bd45174fe1a757f0b806ef45ff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib3a84e5477f34a4fa157fc0ff96532f9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i67d9fc7c849641a29c4015bb2c26ff95_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia85c03a3ab92450c8de1356f1f1c58d3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0f1758a625d84d929d4de5bf11529687_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i98313781c6ec4d6b8b48f6da3becd23f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i51f918e0a47440ff9a42a36261a6d16d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i76b230224ec74a4ebd37c4fa613a51f6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id6c4ef5941f242a783b93fdf18b331b7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i93db50d47f1b4831b473f4caa658d588_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1448dfba64a24ca98ed5cca7a68f936c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if8e249a62ffd40df9c9149d8b996539c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3282a3bb766e427c92f46bd8d3cc7e59_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i57cb86b034e44ad089ebc3504d4d0411_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i82a2982cdc3744dfab46a0e3a207a741_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i90f143b898064fb1a010fcdce8a28b66_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5505226ac8da4156a58673a2fec740bd_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6fef85b8750b47bbb313ad7db28ce663_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iaedf97f07c304e0eb9b3fff6304ec0c1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ieb44990ceb62481894ef4f3997282c75_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iae6682412d744b10a6d5e33564d0af56_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i63120c4477c04522a145f1c834f52464_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i88e0d4f0e2bb4a66bbb456ea665d882d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib41afa111c3149648c0cc3bac7c5b435_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic9c7d2da9c9f4d09a60482a44e3c8ca7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i72a6a418d67447f6bf91301e4805ad9b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia83d2540d3bf4a078040cd71ec1f972b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4de7c52f2b7a4fe89360820891e3f073_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic71c7174d5cc448398e06391a7827688_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic16fc6f626e146c18705d2b1e22411bc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0102174142414cbd89010684f4e14032_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if7e951f6bc2b47f9a0f83bbc19cfee0b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9d580d7d41ab4c779d21e7ecf46f3208_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8e5ba528b04c4762aa61bced9949c785_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i782ae2009f954090860e6e0bb4a7039f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i960a6b708491473d9570c3942b7eef6c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i09b0b1c1c2a94afb988a7c59c235eee7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie5335858050745058b22cc99a0b825d8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7eb34b902a3d4092a2e3d84fafaf8db3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i12dab876c382416aaa473774a2318a69_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3a1e78634a724621bc14ad6838cb7aaa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EyleaNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia0b4d6b8672847c38f0dba0dde9118a6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i993e0c30b54544e0a4d7a1785fe7f5ec_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ide588defaf434359bba81a3f3acff2b8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icfb6acb24daa4045bfab3c8c4d9acd34_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:LIBTAYONetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id715132664af44b4a97c8f5b2eef6789_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibfdef107afb54ad899df3e57fa9ccb8f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0ce220d2cde34bf583732793c841cc94_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icf31cf4bebfa40e5868081cbe1915ba4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:PraluentNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iedfb0cf9c4594b929abde62607752ef2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia50d948a15194872b1d382957ed144d6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4b848f38b8a54f65bd9393c17a2aaed0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if965233833744f19a7d0aba74b97b8d6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9771830c61ff46c0ab9a5252ea2be0af_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4030650199fe4f198ed816c8ab79a91a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5ebaa7f4723242569b7922152e81345e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i19d89574821b49b9bdfa6137bd82652d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EvkeezaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if04488d631ba4e129b9e0f0fb3558a31_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i64fcfb6110c74cbe816d03379fae5d1d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i80f2e762be11477183ef6c02dba52897_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i39c987382ee344fca75a3010f34022b5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ArcalystNetProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia3f29614787e4465a5554d3f160fa259_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib58a328c7a1044db991b18bc06aec4ca_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i04e74fae60044b55bf008643f8ce273e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9f629c0363834da2a784610d8a5403af_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id628995c65e443418912b4df46bdf6a1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8bab1de7a18e431086c872b4f16dbf84_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1b54518517447e2976804aef2938a70_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9c91a96c8ea541df9b383e31edb76cdb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie9f3623e111f49f58059e4a3c761728b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic5418f4d22034df899d1576e95d98e46_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:BesseMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i785a29c3adcc4a36be31fef32659e71d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id3e92e56fe7a44e5a31ddecd1964e64a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie051ae25fb44472e83a56290575ab26c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i486929221d2f42f5919727d4483f7090_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if50c4763f6dc43428e8360ca23d39d0d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib5546196bf9d43679e3e52ddbffdfc7e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">regn:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">regn:GrossProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifded74cc07f44048a2c104e76b70e48e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i58ac074fe6864f70ba50e4e7c6e81c9b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i86244a8c59904b46967de22d14ea53dd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7a1190ae8ab3474b9e2213bc83518d76_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia0fffea9317f417ba61a67279b657180_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i12aa7e5e1d7b416bb27fbac0ea8d1e88_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibeab61feac444da7a016dd64df872cd9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i563d16d0ea8f4b1ea8c10c797482d489_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SalesBasedMilestoneEarnedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iad7689d0635c4905af67a87b5aaa5f3a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1aa5f2b1cbb14dbf9d951201819f5db2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idb5b96ecbed1428ab26d61c8aa6e8b67_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i554ab772b5d0462a803c80fd10072849_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4d920ab6a62942aab7073efd72dacef2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i94b188b561e248948e1916e16ec1f0f3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8f4316365c63469e84bbdb4402df49fa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if7a9b2764717433a815608cd7e18b125_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i791e6e6420e54c049daf6dd49164145f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic370d9cb5fd24bf799cbdf2177dacd50_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0e36a0ccdeb14ec984f4085858cbc3ee_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if02ac5fb5d2f4310931908004cbf9aa0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1800f040ae0e4df991d07fe38d222324_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic9efebbfd0f048c990bcc09d5b26f8c5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia4f2a3dc80794091ae61e4de88cdbc43_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide6a2ab36d5d4e759f8c6fe1ecff6f01_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i41696d03ccef49c2bf26d35317b03caa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ica632ffb58b44d6194988501bb54fc73_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3081e3ffc7954b088fc9cb4152e95c85_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5bbc219c44fc46859865214fb8165394_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ShareOfProfitLossesInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i546b0b3a556d452f8e64404ed081302b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iacfc81b93d7b4b4f8c6d7d4593e9dace_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9c484984a09a4caaa0b9d6543ec482d5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i419f91c33865447b9e9338dab3f66b55_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic6fc47b747054dab86fa5a363336c85e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i449513f8039f41138f8e72756af57c6d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifb63ff75d0aa4f96af3798e301bd5bf6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e787fec51894471bcabbf60f6051058_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4a756b10359641988b7f46edddeec13a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i53cb49561acd4537ba93ba5db20eb4f0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2b548827d54647c9ad6d75a0d12bb79f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icea40f4714334f43b2a0bc4763fd6bb4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfCommercializationRelatedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4ddacad667a94b23ac241aa7301b853a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5df0acd0f02348d3ba5d9669e15f2adb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib604dcd13e224121adb3a5c3b372b125_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4f6f1c8c4538460cb2956cf9359d3cae_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfCommercialExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i16ef0dd09ff34bd9832c510c5fcb9394_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3caafefa1d954278ad93efec805163b1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i27a6f9b6cec64cddae7a84326e0b5ffe_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7383412bc7ac4797bad32eb100cb0abb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:SanofisShareofLibtayoU.S.GrossProfitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CostOfGoodsSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i08ef15ce810b475c803431262514e1e9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0f689f71f8a240b2a33290b4e3bfa31b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i65d333ff83094f148e490ee53841f02f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iad6e8d74360c4e38b0f7e558981f7f7f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4a5801eab8e4442a8423dca2e534dad1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5a8ed766d24e4af78c21550a7b7302a3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if7432bde3ff84eafbcfb0af4b10fa31f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i78fb2bfa7e774e23970aa2139ee245db_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i75cfc29b08e54dbcb23f41eeb66d7d5e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:SalesMilestonesAxis">regn:SalesMilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i44705b78f91d457fb2bee63fb813ff55_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if9483a9e8f5b474ea373471543f0536b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibf63d465ccd3423187f9af7e8b4bc7e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementAntibodyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i182dd47bcec04ee292243a30a58dea41_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:PraluentCrossLicenseAndCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="i814fd946f5074904942acc5d9194d0fb_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:PraluentCrossLicenseAndCommercializationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="i89ca366da43e409298cf61eea017813d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie9bfe175438f49a9be01e98bcc545764_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iebfd12dc45514f458d53a2791ef44ec9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:SanofiCollaborationAgreementImmunooncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i509963cbbe784be8973a31df2b9a8963_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia985bae849b44c219201a836f385ce29_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic1ba982dde844a9c82475e880a5f75f0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i955142d326434513a46962fe495e0fa1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idaee3d49fec54b8a9e5fd65ae301bee3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i402f7f4cd8f04e6497716ec2e663706b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:NetProfitInConnectionWithCommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0e46aceade444644b9dd70d4cecbf25b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if94b654450124728b790785f2b2cde12_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib4e41d48528d49caae8c91f124239822_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie2bf015dbfa7438092254a9cd1ea14ed_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementForManufacturingOfCommercialSuppliesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idf88f57a03b140b780d64166b452794e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8ae6fd17f82a4bb6bdbe987bc274fbb2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5353a1ff784f4cf18d143c0765148747_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i073ce9da231842b3b7cd60b5bf3ca507_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i381b143df0d94c9a86aa2eeae5839128_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i11dfc2547ca74cfc84608cbde114c10d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idc5f19126e9840eb9029c6f52c25185b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa62c40f54c54ca1ad0abe0e53b2a453_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:RegeneronsShareOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2d7420067c744c329c85c868130a6ded_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9a1d208f0eb4428db5488e7d8ed9b2f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BayerCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6533a61e5ab4ad3a159b912aa4b022e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib3fe6a3db0be4a5184a1b7acc80f29d7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i86b44f35ec1c46cabb41e44d2197b227_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id21ae34bc9b64b5796aa956e68521d55_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:ReimbursementOfResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i784465fd68bc485f93061c14f0464626_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i20d13d4e4a7241f7b1b59f2578dfa67c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia7d0836ec7e74c33926c74712109896c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ice301c2478284e1590cd4fe592b2d490_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:AmountsRecognizedInConnectionWithUpFrontPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic802850933a14320a118ce1085b1dbcc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i64f2394a4ea74ae88bf23a677f4f957f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:TevaPharmaceuticalsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie940f37df2c049fd89c26eaeab0debe8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7f04700578124cab99fe2de9a5db10bc_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i859fc8964b6340f8bf9073e37098a30a_D20220131-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">regn:USGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:REGENCOVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:BARDAOtherTransactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i27c9ab022abc478d8f79666d02a78330_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3fcf5bf64c5f4e23b07547fddb4834c1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idae7c39276e247b99aa741d38663bd97_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie439420bfacb4ac3a711d43c21ed2b7a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">regn:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7481e994a8ef47a4bc764250f091d6be_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id222f9b1cb5248d9bc897bf0e1e74fad_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i820df2abc71243a09f1e9d12e9631bf0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic40440c4c14b457ebef02ad35de7b6ee_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:CasirivimabAndImdevimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8a7ab84ea29f4779b5a42b782dc5859e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i70d249e67e354239b79dd039bbf41c79_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:RocheCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe25403ae1ba406b8be348b085927476_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:IntelliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i171b9fb71e894402b6278e0d6cf6ed66_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:IntelliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i767fc2b3c91d49368bb428e956e1c15f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7a52920e795646119a53ceb1ce382a02_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i89f5b96bc5434e47892bfa9a96bc713f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia2fe8e8115b14acaab1a1d5efd01ab92_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4e9ea9623abe41a1afbf09779e3252b2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7a9416d782bf46e3aac5cafdd70af82a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia467795663df48f8839e66b5689ec354_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieb41ac995da4481eb5a2ee2048fd8b8e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i305115a444d14bd096edfc2b3a5fe574_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i79da790fd94b4499bae26a25903f21e4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic2b88f865b474f1fb605c319670ea555_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib08523f726914db6b88055d68a3804a8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9f29c06129fa4ad385d3c25e70264511_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if160a4c1aa8a4e9ca18c15065b56268a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idd87398154424f32abe288424051e254_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4ebccad4b04e45f2973de4acc552e081_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibd175f5bfcff4131b4291c7e886d11d0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3171b6f1e42044f6ad1521433ca23a16_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18110cf9fe854c0eac1362e59d0b3203_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f73b339b3634a3ab3b8e05805434ee9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60fa6e193603436099beee74e654012a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7188015c6d354b4aa4b026149b2f2dad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b306c67e2eb415eae154eec63a64166_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i709e307512f84f2d89f62a447afdbb84_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if15ed14fd37044feb3727eba888a012a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8fedc6825bfd4a59a2bd6c1543230955_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i169c45bce7e14e0ebf7c4d8391c33a67_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i92f4b800c8ac4853bc03e53e4b78405e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i51ee79229d4e4ebfb388e4a3ad90b0a5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id5f7030e51844bd39ff0f0a3b3ef5fb4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i63130650b22f42fea4fa33623b9ba1bd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i30e4687b375546d1af527e2a3df23ab3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i497ca48ecca04ba48c5d7ada2d2bbdc4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i318a17e861d840c98b3031789019aaea_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i72abcc35bfe04c718a639cb1f6b996a4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2f153fe081624b709016b5dcb2453c32_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9382f8343a0540b4a048b778c440d26b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1c0224b00f9c4667827991e766d2f703_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i879b9c7c242c4ed5aad14987370b0a55_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i26e6516b07ee48baac59da55f9ab9360_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8496a4fdf8714163a39d2735849938ce_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4bf2a5edcb4f4d9d9c943737ce0824f6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5fc9503772ed4063887ac7fa4b9d589f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0719e563f1ad45fe8cae8d7518999c47_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3c4b945e334d45e8ae01e61b5260ebdc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3bfd8f8a61bc4f3d99eaaf7d514b4d90_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i928f7d720b6248cd934975804e4ee21a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1011bfe7b3f241bdae36c2c04bdef602_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if1ec84991e2545a8b15f060aad624a82_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i073bb6c4ef1d4dfd94ffa5d20de5a81b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ideeb185943494d1d8c34874a74b6f176_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i718180e7a06c47d79ec5283f5004e756_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd8180afebff478b9f8bc963fa0e19d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee6b453205d44a0aa0e06f339c4344f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b0fb7a5bf6b4426b9c1f868210548d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf5e87dcd3a64a1da4267f0373377c04_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia20d85573fb143dd87f197ce54b7e399_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13a0befca2744f1e8f5c062d988ff10f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9263ef91fcc44315917f2dfc964e2ce2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2e7690d25b64054b80e2f57e6dc1292_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia21a946152114cde8edfdd4190cf231b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i371d5635a65d48f0b357645d217ce740_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6463b9ea289444d4a8a0c350da774f0e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if7beed26d4e7440baf4167a9e144bd8a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic9ccf4d0492c49158f8907609cacb785_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6361d9ec906c4de9bb2da4f5e1bb347a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i880c4f56f4bf49eaa68316dd64419c31_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:UnrestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04298c88b3394119bf9d1c4903dba435_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c66fdf4db544d99a6ab7cc74a9bba46_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b9114a5c0054c229df4345b7d59365a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="regn:ClassificationOfInvestmentAxis">regn:RestrictedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iebd67af6e4c44ae197f75086c30ed696_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d2aae955be14f268249627181155c1c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id6ae2cc961e14f028a26aaf88a03941b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic2b125c56e464e7d83e39ceed25911e1_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:BridgeFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="id293bfb3eddd4aff80d65cf0394b1943_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i8f0cbd4933e54839aa58d6992050314c_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="if0dfa4b658804eb3a16f8cee0ca8be17_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i534da4670c274a81ae3524fbdfe06604_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i650510a2eb214adc84a48e8722d60ddf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i518fc4089b494e66895c51aae0a95ae4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">regn:SeniorUnsecuredNotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1490f50984443fa9fc09db8661cd762_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id9fe51ad3f5d44d7b51f9c7d2bb1636b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07fe2aef96e54e809240ec9fba24d72c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaefeb3e5dbc2406c9e11d7dbcba3ee98_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e98493124404aad8a8c0e1cb049d5ec_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgram2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i8ca3ec3e33eb4ab29ddc909bd33e67d0_D20201231-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgram2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-31</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieef2a875d0184972869268bd64fb3df7_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramJanuary2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i69ddf6100ec6432d8b2d4ac0d6998971_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">regn:ShareRepurchaseProgramJanuary2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i31a864c8cc3a49e086a3fde76b1e1695_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:LibtayoDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5bfec289c7074f5282b731594a9587a9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:DupilumabREGN3500EligibleInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ied92924a0c784856bbf8ed8a35ac7f57_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">regn:LibtayoDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iec719ff1e7724d85bfffb28a5eac401e_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i0d93ce0ffcda4c05912416ab54808098_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">regn:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i5148f71a87a04e13ac8076f503a1425e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i222bcb21c9a4477ab7dc7af26e32e7ee_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2e4f524ab89b4891b4ccfbd3555e3a26_I20190225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">regn:Amgenv.s.RegeneronMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A165PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-25</instant>
        </period>
    </context>
    <context id="i870177ce53f7404e98979e8f07c9609f_I20190225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">regn:Amgenv.s.RegeneronMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A741PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-25</instant>
        </period>
    </context>
    <context id="iae9a73d5ea4745d09d9bbb09f273f524_D20170728-20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A487PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-28</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="i34e55477ad8e4cfebda758de4b6f0516_I20190214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A487PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-14</instant>
        </period>
    </context>
    <context id="i4c1e030c474b48ada51944d7eb45dbb7_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">regn:EYLEAAfliberceptInjectionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A226PatentAnd992PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="ib4b960d3dff6442ba38d7de8747b8883_D20200716-20200716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">regn:A631PatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-16</startDate>
            <endDate>2020-07-16</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="dose">
        <measure>regn:dose</measure>
    </unit>
    <unit id="claim">
        <measure>regn:claim</measure>
    </unit>
    <unit id="request">
        <measure>regn:request</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80L2ZyYWc6MWZlMmM0MzRjYjA1NDkxMTk1NjkzZjFiZGRiZGM4ZjAvdGFibGU6YzdhNWY5ZTUxZTczNGYzOWE2MDQzMDEyYjc5YzRmMzgvdGFibGVyYW5nZTpjN2E1ZjllNTFlNzM0ZjM5YTYwNDMwMTJiNzljNGYzOF80LTEtMS0xLTA_bf307d66-ef8b-43f5-942c-ca7965b67db4">0000872589</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80L2ZyYWc6MWZlMmM0MzRjYjA1NDkxMTk1NjkzZjFiZGRiZGM4ZjAvdGFibGU6YzdhNWY5ZTUxZTczNGYzOWE2MDQzMDEyYjc5YzRmMzgvdGFibGVyYW5nZTpjN2E1ZjllNTFlNzM0ZjM5YTYwNDMwMTJiNzljNGYzOF81LTEtMS0xLTA_7c2e1649-1a0a-45cc-9739-0bec29012009">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80L2ZyYWc6MWZlMmM0MzRjYjA1NDkxMTk1NjkzZjFiZGRiZGM4ZjAvdGFibGU6YzdhNWY5ZTUxZTczNGYzOWE2MDQzMDEyYjc5YzRmMzgvdGFibGVyYW5nZTpjN2E1ZjllNTFlNzM0ZjM5YTYwNDMwMTJiNzljNGYzOF85LTEtMS0xLTA_b5c7f3bb-f8fc-4028-a472-b4b26956cee5">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80L2ZyYWc6MWZlMmM0MzRjYjA1NDkxMTk1NjkzZjFiZGRiZGM4ZjAvdGFibGU6YzdhNWY5ZTUxZTczNGYzOWE2MDQzMDEyYjc5YzRmMzgvdGFibGVyYW5nZTpjN2E1ZjllNTFlNzM0ZjM5YTYwNDMwMTJiNzljNGYzOF8xMC0xLTEtMS0w_cb9fa15a-1e75-4b6e-95a6-3a5e53ff8bad">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80L2ZyYWc6MWZlMmM0MzRjYjA1NDkxMTk1NjkzZjFiZGRiZGM4ZjAvdGFibGU6YzdhNWY5ZTUxZTczNGYzOWE2MDQzMDEyYjc5YzRmMzgvdGFibGVyYW5nZTpjN2E1ZjllNTFlNzM0ZjM5YTYwNDMwMTJiNzljNGYzOF8xMS0xLTEtMS0w_7a49f6eb-415d-424f-b5f7-97bec046f818">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGV4dHJlZ2lvbjo2NGRjNGYxZDUzODE0YWY4YTBiZTAwNzZhNTEyODdkMF80MTk_0345316c-d122-4b5b-aa92-96efe7c18255">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6M2UwYzg4ZWNkOTUwNDI2YjgwZjgwNTdhZGEzZjBjYmEvdGFibGVyYW5nZTozZTBjODhlY2Q5NTA0MjZiODBmODA1N2FkYTNmMGNiYV8xLTAtMS0xLTA_6c9b9340-12de-42af-b9eb-e02a3c1e231a">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6M2UwYzg4ZWNkOTUwNDI2YjgwZjgwNTdhZGEzZjBjYmEvdGFibGVyYW5nZTozZTBjODhlY2Q5NTA0MjZiODBmODA1N2FkYTNmMGNiYV8yLTEtMS0xLTAvdGV4dHJlZ2lvbjo0MDJlMTdhYTg1NGY0MWZiYmE4OTU1NDA2OGE1ZTNmZV8zNQ_01f85dc9-93fd-4bac-9d5f-fe2584788ea3">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6M2UwYzg4ZWNkOTUwNDI2YjgwZjgwNTdhZGEzZjBjYmEvdGFibGVyYW5nZTozZTBjODhlY2Q5NTA0MjZiODBmODA1N2FkYTNmMGNiYV80LTAtMS0xLTA_da45c916-7ed0-4540-9be8-058a0610c178">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6NzNhOGZiNjE3ZGFkNDA3MTkyOWVmMzgxOGI0YzlkNjMvdGFibGVyYW5nZTo3M2E4ZmI2MTdkYWQ0MDcxOTI5ZWYzODE4YjRjOWQ2M18wLTEtMS0xLTAvdGV4dHJlZ2lvbjozNTFkNTE0OGNjNjI0OGE1YmNlZjA3YjBmNTE2NWFhM18yOQ_958cac48-d2f3-4b89-bc4d-035082ad3c11">0-19034</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGV4dHJlZ2lvbjo2NGRjNGYxZDUzODE0YWY4YTBiZTAwNzZhNTEyODdkMF80MjA_3fd13ddd-2a4e-4d51-9466-2f59e919da8a">REGENERON PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YzdkN2Q5YzQyMjYyNGRkNWFhZDE3Y2IwYmI3NjhiMWYvdGFibGVyYW5nZTpjN2Q3ZDljNDIyNjI0ZGQ1YWFkMTdjYjBiYjc2OGIxZl8wLTAtMS0xLTA_dd6e8bdd-e6c1-4c08-b1c3-83b8bf29e281">NY</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YzdkN2Q5YzQyMjYyNGRkNWFhZDE3Y2IwYmI3NjhiMWYvdGFibGVyYW5nZTpjN2Q3ZDljNDIyNjI0ZGQ1YWFkMTdjYjBiYjc2OGIxZl8wLTItMS0xLTA_2c544dc2-c036-42fd-a647-73adfe217811">13-3444607</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YjMzYWYwYjBhYjIzNDI4NzljNjA3OTQwODY4MjNiNDMvdGFibGVyYW5nZTpiMzNhZjBiMGFiMjM0Mjg3OWM2MDc5NDA4NjgyM2I0M18wLTAtMS0xLTAvdGV4dHJlZ2lvbjozM2IwOTAxMTA3YjQ0OTA0YTUzMjJiODNjOThhMmYwNF80_52d92c12-852b-49f6-87b6-cbdc201c0bb1">777 Old Saw Mill River Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YjMzYWYwYjBhYjIzNDI4NzljNjA3OTQwODY4MjNiNDMvdGFibGVyYW5nZTpiMzNhZjBiMGFiMjM0Mjg3OWM2MDc5NDA4NjgyM2I0M18wLTAtMS0xLTAvdGV4dHJlZ2lvbjozM2IwOTAxMTA3YjQ0OTA0YTUzMjJiODNjOThhMmYwNF85_de43b59c-89cb-4712-8b2b-778750be6c08">Tarrytown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YjMzYWYwYjBhYjIzNDI4NzljNjA3OTQwODY4MjNiNDMvdGFibGVyYW5nZTpiMzNhZjBiMGFiMjM0Mjg3OWM2MDc5NDA4NjgyM2I0M18wLTAtMS0xLTAvdGV4dHJlZ2lvbjozM2IwOTAxMTA3YjQ0OTA0YTUzMjJiODNjOThhMmYwNF8xNA_e802ac28-db52-4b05-a824-d962ea4c1201">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YjMzYWYwYjBhYjIzNDI4NzljNjA3OTQwODY4MjNiNDMvdGFibGVyYW5nZTpiMzNhZjBiMGFiMjM0Mjg3OWM2MDc5NDA4NjgyM2I0M18wLTAtMS0xLTAvdGV4dHJlZ2lvbjozM2IwOTAxMTA3YjQ0OTA0YTUzMjJiODNjOThhMmYwNF8xOA_798de8b7-7496-4a89-a87b-21a61bdadd09">10591-6707</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGV4dHJlZ2lvbjo2NGRjNGYxZDUzODE0YWY4YTBiZTAwNzZhNTEyODdkMF80MjE_7b465ca5-a4db-4eac-b6aa-4dc8c375391e">914</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGV4dHJlZ2lvbjo2NGRjNGYxZDUzODE0YWY4YTBiZTAwNzZhNTEyODdkMF80MjI_3ad88680-fd70-4a62-8207-781aa3aa9c73">847-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6NGRiZWMxZmNlYmFjNGJiZGI1MDBiYTFiODEwOTUxOGIvdGFibGVyYW5nZTo0ZGJlYzFmY2ViYWM0YmJkYjUwMGJhMWI4MTA5NTE4Yl8xLTAtMS0xLTA_9f1e2efc-c80b-43bf-8069-8314cb3a5e7e">Common Stock - par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6NGRiZWMxZmNlYmFjNGJiZGI1MDBiYTFiODEwOTUxOGIvdGFibGVyYW5nZTo0ZGJlYzFmY2ViYWM0YmJkYjUwMGJhMWI4MTA5NTE4Yl8xLTEtMS0xLTA_7794ec0c-c788-4bb2-9b33-4d20f0760590">REGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6NGRiZWMxZmNlYmFjNGJiZGI1MDBiYTFiODEwOTUxOGIvdGFibGVyYW5nZTo0ZGJlYzFmY2ViYWM0YmJkYjUwMGJhMWI4MTA5NTE4Yl8xLTItMS0xLTA_a7d06297-6220-41bb-a1ef-34fb96bae345">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YjBkMzljYzIyYTgwNGRkM2IzNjk0ZWRmM2NiNWNlODIvdGFibGVyYW5nZTpiMGQzOWNjMjJhODA0ZGQzYjM2OTRlZGYzY2I1Y2U4Ml8wLTEtMS0xLTA_87c4ab76-5bd4-4e05-89bb-a63a67ca6444">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YjBkMzljYzIyYTgwNGRkM2IzNjk0ZWRmM2NiNWNlODIvdGFibGVyYW5nZTpiMGQzOWNjMjJhODA0ZGQzYjM2OTRlZGYzY2I1Y2U4Ml8yLTEtMS0xLTA_e8ab895c-9d55-4d62-895f-8abd0ef0de19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6MTkyNmNkZDVhNzllNGVhNzk2MTk4MWMzM2MyYWI5ODQvdGFibGVyYW5nZToxOTI2Y2RkNWE3OWU0ZWE3OTYxOTgxYzMzYzJhYjk4NF8wLTAtMS0xLTA_5dd6a895-9543-428a-9305-21f6ddd11705">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6MTkyNmNkZDVhNzllNGVhNzk2MTk4MWMzM2MyYWI5ODQvdGFibGVyYW5nZToxOTI2Y2RkNWE3OWU0ZWE3OTYxOTgxYzMzYzJhYjk4NF8wLTEwLTEtMS0w_2d2063c1-d394-49b3-a383-25e6e3218f3a">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6MTkyNmNkZDVhNzllNGVhNzk2MTk4MWMzM2MyYWI5ODQvdGFibGVyYW5nZToxOTI2Y2RkNWE3OWU0ZWE3OTYxOTgxYzMzYzJhYjk4NF8wLTEzLTEtMS0w_de59b02a-23c6-4361-9f9c-17a6f6ebbfee">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6YjdmYWYxYzg1OGNjNGJjNjg2ZTkwMDdmYjUxMTM2YmEvdGFibGVyYW5nZTpiN2ZhZjFjODU4Y2M0YmM2ODZlOTAwN2ZiNTExMzZiYV8yLTQtMS0xLTA_ccdea811-6aff-4f13-872b-3119cd71a553">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="icc16664525144692bafad224736d7dbc_I20211022"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6NDcxNzBhYWJlOTUxNGY5NmFmNDZjOTI1NmM1NWNhYWIvdGFibGVyYW5nZTo0NzE3MGFhYmU5NTE0Zjk2YWY0NmM5MjU2YzU1Y2FhYl8xLTItMS0xLTA_2594461f-9116-4a55-a6a1-a17306e63a0c"
      unitRef="shares">1823283</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ida653b0f9e874bc6a9d652fb00e0d46b_I20211022"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xL2ZyYWc6NjRkYzRmMWQ1MzgxNGFmOGEwYmUwMDc2YTUxMjg3ZDAvdGFibGU6NDcxNzBhYWJlOTUxNGY5NmFmNDZjOTI1NmM1NWNhYWIvdGFibGVyYW5nZTo0NzE3MGFhYmU5NTE0Zjk2YWY0NmM5MjU2YzU1Y2FhYl8yLTItMS0xLTA_1058ae08-5c39-4dc2-9aa6-d0220c8968a3"
      unitRef="shares">105719735</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNC0xLTEtMS0w_ecd08079-ee47-4a13-8a2c-3d761c3b4069"
      unitRef="usd">3432400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNC0zLTEtMS0w_bc136d06-2515-47de-b2d5-fb92e4050b26"
      unitRef="usd">2193700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNS0xLTEtMS0w_05f3017e-e4d9-411d-bd34-deede09583da"
      unitRef="usd">2355200000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNS0zLTEtMS0w_e6e91b04-ba5f-4b07-a608-fac5d14b3c0a"
      unitRef="usd">1393300000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNi0xLTEtMS0w_c07fbd01-33ee-464e-aac6-ea28ef622bd3"
      unitRef="usd">5452000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNi0zLTEtMS0w_4e082629-7cf6-4a54-9c7e-db431620a6d3"
      unitRef="usd">4114700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNy0xLTEtMS0w_3bcedecf-1222-4c3e-aa45-f47db3345f7a"
      unitRef="usd">2053800000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNy0zLTEtMS0w_f9bcf2d6-64b0-45aa-8a7f-fc46ea28553c"
      unitRef="usd">1916600000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfOC0xLTEtMS0w_26c02cf5-3fe1-44e0-b8c2-dd6e16218c16"
      unitRef="usd">482000000.0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfOC0zLTEtMS0w_3bc2be9d-5ed7-4ecc-8563-e870b5383f1c"
      unitRef="usd">160800000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfOS0xLTEtMS0w_288f53ec-9ad1-428a-baf2-8af174d53f9a"
      unitRef="usd">13775400000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfOS0zLTEtMS0w_e2914ded-f3b0-462f-8f57-72bf21be778b"
      unitRef="usd">9779100000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTEtMS0xLTEtMA_f94ee12c-80c9-44fe-a4a5-e8b1dbc8186b"
      unitRef="usd">5631300000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTEtMy0xLTEtMA_722bd005-111c-4657-9390-44a0b1a0f8a9"
      unitRef="usd">3135600000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTItMS0xLTEtMA_a2d5ffc9-9832-4be7-8683-a1d170c339c0"
      unitRef="usd">3395700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTItMy0xLTEtMA_390a8586-3fe2-428d-a99f-aeef8409b7ea"
      unitRef="usd">3221600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTMtMS0xLTEtMA_c0775bef-f419-43f9-8a2d-cd922761919a"
      unitRef="usd">723200000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTMtMy0xLTEtMA_f4cee08d-140e-49e0-a780-9733d384e9c4"
      unitRef="usd">858900000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTQtMS0xLTEtMA_fd6710aa-c87e-44f2-9514-e651e44e7486"
      unitRef="usd">145900000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTQtMy0xLTEtMA_c02baafe-4503-44d3-ab46-4ff075d101f0"
      unitRef="usd">168100000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTUtMS0xLTEtMA_bff4d707-5052-4686-9b92-11d94a242eac"
      unitRef="usd">23671500000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTUtMy0xLTEtMA_5e0faf64-80c3-4ea0-82d6-161eda33e4c3"
      unitRef="usd">17163300000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTktMS0xLTEtMA_9c8b8c05-1a61-4841-9774-88c065980b5d"
      unitRef="usd">427000000.0</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMTktMy0xLTEtMA_500f1265-4c59-4617-bd34-4808550b4717"
      unitRef="usd">475500000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjAtMS0xLTEtMA_7b932754-9cc8-4c21-89ee-25a1b2ad0907"
      unitRef="usd">2061000000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjAtMy0xLTEtMA_54202786-662c-409b-ad38-587d6a5aff8e"
      unitRef="usd">1644200000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjEtMS0xLTEtMA_6e3e5ab4-c09d-4bcf-b67f-6b80ac706f60"
      unitRef="usd">719000000.0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjEtMy0xLTEtMA_512e95ae-b499-42ee-a723-baff3957883c"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjItMS0xLTEtMA_97e045ba-d0d3-49d4-9836-aa6a8ceac2f2"
      unitRef="usd">507800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjItMy0xLTEtMA_9c6a5465-8d13-40c9-ac52-7e8ea3f46983"
      unitRef="usd">577700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjMtMS0xLTEtMA_1b98d309-331b-4f96-accd-aa7c170334d1"
      unitRef="usd">3714800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjMtMy0xLTEtMA_073c3be9-c2eb-44b8-9985-8d3ef9ad0f64"
      unitRef="usd">2697400000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjUtMS0xLTEtMA_9f669d3a-a387-4395-ae96-5524464faa1e"
      unitRef="usd">1979600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjUtMy0xLTEtMA_42e0001c-5350-40e0-8588-412dcdf1fd79"
      unitRef="usd">1978500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjYtMS0xLTEtMA_2b53bee8-0f64-431b-8af1-37f9d461db8a"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjYtMy0xLTEtMA_ab29349d-5ca0-456a-8c05-a74ba65d641a"
      unitRef="usd">717200000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjctMS0xLTEtMA_188c9e2f-dbf4-4280-9fc4-e04707c73783"
      unitRef="usd">56500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjctMy0xLTEtMA_dc70d8e0-2d41-4504-ab24-5f35b8f4457c"
      unitRef="usd">57800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjgtMS0xLTEtMA_b353b92e-d71c-4788-9d09-e019af7f4bc1"
      unitRef="usd">662600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjgtMy0xLTEtMA_539d0cd0-366c-4469-b40c-f6d0527dea69"
      unitRef="usd">687100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjktMS0xLTEtMA_3f33389d-cd03-4341-b8fb-aecdce0a1e5b"
      unitRef="usd">6413500000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMjktMy0xLTEtMA_7b0bf68a-4729-4fd7-ad97-697fcbefc147"
      unitRef="usd">6138000000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3XzIy_0dedf0b4-1ea2-45c1-91fa-e2187973fb66"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3XzIy_10cd1e29-ae02-4002-a331-0e4e43158211"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3XzM2_6b8368c8-fd22-4d56-859e-031af8d9c8e8"
      unitRef="shares">30000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3XzM2_8d6baee4-7284-4f66-bd65-e9cc5d37cc10"
      unitRef="shares">30000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3Xzgz_3086c1d6-aaf0-4655-b827-cee536916a01"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3Xzgz_747a9d4b-23b2-44bc-9c0e-9a4b1b14e532"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3Xzgz_992a3cdd-8451-49da-81d9-c027f13b4a40"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmVhYjhkNDBmZDhkNjQ3ZTJhNGYxNzk5NDYxZDUwZmU3Xzgz_a3a78400-247a-406e-b383-19e2b98dcfa0"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMS0xLTEtMA_abb7ffdd-aae5-48a1-9b87-b0cdd72c6f41"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzItMy0xLTEtMA_1cb2125b-7b10-4d60-ba86-f127a358f7e0"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia1f2d0c6a01e40a1a132025d16ef17ca_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzMy_2fc72c31-5ec3-4335-9683-7e53b64cd788"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i65b94c6346a4410db40c1e51f2964b9d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzMy_b6ec77ca-e923-4860-bdaa-c294d9694c09"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i65b94c6346a4410db40c1e51f2964b9d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzQ2_e1cb586b-db2e-43e5-b553-c8a575dde886"
      unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia1f2d0c6a01e40a1a132025d16ef17ca_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzQ2_f26c104d-747c-4a5c-bf2d-db0894431415"
      unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i65b94c6346a4410db40c1e51f2964b9d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzEwMA_1f9aa019-ab02-48ea-a68b-8715623b6493"
      unitRef="shares">1848970</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia1f2d0c6a01e40a1a132025d16ef17ca_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzEwMA_9979bfbe-750d-4e87-9bd5-66e652684c74"
      unitRef="shares">1848970</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i65b94c6346a4410db40c1e51f2964b9d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzEwMA_c40fd984-59d4-4dbc-b262-6bd5c45e32d3"
      unitRef="shares">1848970</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia1f2d0c6a01e40a1a132025d16ef17ca_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjIyOWI5ZWZjNjlmNTRlYmViZDRkNjdjMGZlNDdjNzBmXzEwMA_e0222bfa-fef4-425c-9a75-ebdab8417ba9"
      unitRef="shares">1848970</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ia1f2d0c6a01e40a1a132025d16ef17ca_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMS0xLTEtMA_797c6efb-4e73-4e3b-a293-5a469cd6acec"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i65b94c6346a4410db40c1e51f2964b9d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzMtMy0xLTEtMA_aa70a882-9f99-4c4b-b38a-09e9ef96b509"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i010ed964f154499ca13c88bdf3995dd6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjFiYzI1OWYzYTZhYTQ4N2Q5ZmE1NWQzMWVmZTY4ZDVmXzE4_96b40aee-1f34-4eec-89a3-72bfa43b4304"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1e6fff47dfed4a8890d58fd118bc6b39_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjFiYzI1OWYzYTZhYTQ4N2Q5ZmE1NWQzMWVmZTY4ZDVmXzE4_a84154d7-83cd-4e09-ad05-4f9261c8eb9f"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1e6fff47dfed4a8890d58fd118bc6b39_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjFiYzI1OWYzYTZhYTQ4N2Q5ZmE1NWQzMWVmZTY4ZDVmXzMy_47bf5932-b45d-4fe4-994a-9f75caec087b"
      unitRef="shares">320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i010ed964f154499ca13c88bdf3995dd6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjFiYzI1OWYzYTZhYTQ4N2Q5ZmE1NWQzMWVmZTY4ZDVmXzMy_91ffb6d6-0d42-4fa6-928e-324b507efae2"
      unitRef="shares">320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i010ed964f154499ca13c88bdf3995dd6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjFiYzI1OWYzYTZhYTQ4N2Q5ZmE1NWQzMWVmZTY4ZDVmXzcw_a209e28c-07f9-46fb-a643-09dcb6a370aa"
      unitRef="shares">124608241</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1e6fff47dfed4a8890d58fd118bc6b39_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjFiYzI1OWYzYTZhYTQ4N2Q5ZmE1NWQzMWVmZTY4ZDVmXzg1_c89434a3-27bf-460b-88d1-d49cdd2386eb"
      unitRef="shares">121533460</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i010ed964f154499ca13c88bdf3995dd6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMS0xLTEtMA_5d28fac9-53b5-4f87-b69a-ec4fc0a6587a"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i1e6fff47dfed4a8890d58fd118bc6b39_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzQtMy0xLTEtMA_d4756339-1e8d-4bfe-aa00-1b94084f9921"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzUtMS0xLTEtMA_2a8e34d9-fdde-4b1a-8cb8-f66e0b6a226c"
      unitRef="usd">7919300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzUtMy0xLTEtMA_fe3db2ca-4fb6-4c65-a28d-aafce75ed795"
      unitRef="usd">6716200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzYtMS0xLTEtMA_c97001f6-df76-4da1-8c1e-549b83c6e46d"
      unitRef="usd">16739300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzYtMy0xLTEtMA_ddd6f3fb-03b7-4ea5-8597-c3e3cc016903"
      unitRef="usd">10893000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzctMS0xLTEtMA_d06b97e7-810a-462c-8537-46274a43ffbc"
      unitRef="usd">9500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzctMy0xLTEtMA_1551ef4e-e515-4233-a8a7-1c697947b9c7"
      unitRef="usd">29300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockShares
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjYyZTk4MTE5Y2EzMTQ4M2I4M2Y2ZjI1ZDNiOTlhZDEwXzI5_46e2810b-2824-43e0-92ac-61c0babcd2be"
      unitRef="shares">17930390</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzgtMC0xLTEtMC90ZXh0cmVnaW9uOjYyZTk4MTE5Y2EzMTQ4M2I4M2Y2ZjI1ZDNiOTlhZDEwXzUx_6cfc6193-0f57-48da-9486-202976b1f364"
      unitRef="shares">16431520</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzgtMS0xLTEtMA_6c94a006-4a91-4772-8c2d-0861a43a7644"
      unitRef="usd">7410200000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzgtMy0xLTEtMA_0f1a159f-7bc2-4c4b-b356-61d8c98cdcb0"
      unitRef="usd">6613300000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzktMS0xLTEtMA_c1fd5752-c1e8-499b-a9d1-1f36986100ad"
      unitRef="usd">17258000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfMzktMy0xLTEtMA_eba8c10d-f77b-4211-a1c9-52e0865c1048"
      unitRef="usd">11025300000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNDAtMS0xLTEtMA_6810afd8-a818-48b6-b39f-5181d8103689"
      unitRef="usd">23671500000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xNi9mcmFnOjgyMDA2NmZlMDkxOTRkN2VhNDc1YTczZDVhMTI3NjUwL3RhYmxlOjI3NTg1MTc3NWE2NjRmMjM5YzZiMWRhMjY0YTM2YzQ1L3RhYmxlcmFuZ2U6Mjc1ODUxNzc1YTY2NGYyMzljNmIxZGEyNjRhMzZjNDVfNDAtMy0xLTEtMA_a15c4699-e4a0-4986-b23c-de52baf109df"
      unitRef="usd">17163300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i701b6278270643ea9ea3e4f71bac2244_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNC0yLTEtMS0w_483723dc-d484-497c-97fc-3faa0e0fbbcc"
      unitRef="usd">2279900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93da59ad5160490cb75eb85818530df4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNC00LTEtMS0w_86dc1e09-eef6-4177-bd5e-a2e4edd88e45"
      unitRef="usd">1482200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if39174df528047a1a58851162c8756dc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNC02LTEtMS0w_4a29e826-e223-402e-b67d-6161941a5ddd"
      unitRef="usd">8142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1d6c2cf98ab48708f23e1c442baff3a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNC04LTEtMS0w_ea51742a-072d-4e4f-a62f-411884c18580"
      unitRef="usd">3945800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb855af148d44803bf5a5a397f72a4a6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNS0yLTEtMS0w_9af838f8-fa15-4df7-bef6-5dd59324bd69"
      unitRef="usd">1073900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81ec7f922ada451f954d39c3398269f2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNS00LTEtMS0w_c891afac-655e-4839-b4d6-c9bdd515e5cd"
      unitRef="usd">653200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2011ff92b7314bba86afeec4eeaf8b4d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNS02LTEtMS0w_b913205e-222b-4287-af03-cc13d8c4fc6b"
      unitRef="usd">2783000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38c63575c6ef4f41b900486402535348_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNS04LTEtMS0w_63dd2068-fccc-4106-bf55-2d777d453156"
      unitRef="usd">1694800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id10cdd0c27b642138616b7b32f4d6ee8_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNi0yLTEtMS0w_54e3e424-a6ad-415a-b65d-b3e0dc7be999"
      unitRef="usd">99000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iebab4f2f32234aa480f0f8082f54bd53_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNi00LTEtMS0w_f83a0d0e-8386-483a-9eea-9139146c77c9"
      unitRef="usd">158600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b8d7bccc16342b88d4e13958c1c3e11_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNi02LTEtMS0w_3474e13e-0fcb-4316-ac7b-8f83a58cf471"
      unitRef="usd">195000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibabe614a09ed4deaa4de04435940de78_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNi04LTEtMS0w_eb6b5c7c-45c7-414d-9e69-09f38b9acacf"
      unitRef="usd">433600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNy0yLTEtMS0w_ce3596b1-3013-4fc4-83ed-3307035b2276"
      unitRef="usd">3452800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNy00LTEtMS0w_1033f19b-2e7e-479f-b0e6-11cd65f434ae"
      unitRef="usd">2294000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNy02LTEtMS0w_3fa21cd5-e8f8-4375-8820-e80a6da64c2e"
      unitRef="usd">11120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNy04LTEtMS0w_786b41d5-099a-458b-9d51-e49461513536"
      unitRef="usd">6074200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTAtMi0xLTEtMA_0484c5b0-dcc5-4c50-b9bd-2a192bbf8070"
      unitRef="usd">665400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTAtNC0xLTEtMA_3d0aef58-ffcb-43a7-abfb-b8aa2889d80c"
      unitRef="usd">684600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTAtNi0xLTEtMA_cb748c11-a62a-4cdf-a945-729ace53a682"
      unitRef="usd">2122500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTAtOC0xLTEtMA_4489dfb9-3745-4bbc-b049-103468afd2c4"
      unitRef="usd">1990500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTEtMi0xLTEtMA_9d3084a0-51d0-4211-8f09-c476cf3ed7b4"
      unitRef="usd">445000000.0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTEtNC0xLTEtMA_514b1957-dad7-49af-8387-6156087f954e"
      unitRef="usd">326900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTEtNi0xLTEtMA_23358009-6527-4e70-a231-e6ae707af583"
      unitRef="usd">1265300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTEtOC0xLTEtMA_3790640f-3d62-48ab-adfd-673b9e03cc3b"
      unitRef="usd">1042500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i701b6278270643ea9ea3e4f71bac2244_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTItMi0xLTEtMA_8c55f518-f6f4-45b4-bdc5-1ef709b2cc2a"
      unitRef="usd">238800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i93da59ad5160490cb75eb85818530df4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTItNC0xLTEtMA_4355eca1-974e-4f18-8080-1918b1ad8b51"
      unitRef="usd">131000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if39174df528047a1a58851162c8756dc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTItNi0xLTEtMA_84b0c011-3a8f-42b5-9cf1-4a819a0926a2"
      unitRef="usd">961400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic1d6c2cf98ab48708f23e1c442baff3a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTItOC0xLTEtMA_9089452f-6366-4db4-912c-e511f481ef4b"
      unitRef="usd">312300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i770f931b2ede4bdeb5ef82d0dd8a554d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTMtMi0xLTEtMA_98f5a367-9db7-4364-9144-8c6db9a29ca9"
      unitRef="usd">214400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1cb541cbbbef4d78a54cbec6a7e81726_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTMtNC0xLTEtMA_2e6f9dea-bbe5-494e-ad8e-db860e9f05fc"
      unitRef="usd">143000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i76c0001967fc483996710f1c2b1392ce_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTMtNi0xLTEtMA_88cbf489-0662-4987-9d04-f2874564284c"
      unitRef="usd">493500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i463b28633c04475b8ede195911dcb3ce_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTMtOC0xLTEtMA_6e1e945f-985c-4fe8-94ee-72ce2d284fbe"
      unitRef="usd">454500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTQtMi0xLTEtMA_f0232eb5-58d1-472f-bb30-738025b7cbc1"
      unitRef="usd">-42000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTQtNC0xLTEtMA_ecef97cc-454b-4b03-beff-9e2605dee0ee"
      unitRef="usd">44600000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTQtNi0xLTEtMA_8bdbefa2-fa9c-4615-bafe-b96462daa0c9"
      unitRef="usd">29800000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTQtOC0xLTEtMA_9d13a289-7d12-419d-9c05-2006000e5341"
      unitRef="usd">135200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTUtMi0xLTEtMA_89e8fb1f-f9c8-458c-b19c-0245087729f4"
      unitRef="usd">1605600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTUtNC0xLTEtMA_1c38c7d2-9fd4-43b2-a106-589a99da9543"
      unitRef="usd">1240900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTUtNi0xLTEtMA_4ef4330a-54a5-4163-b82f-2f71d01762e5"
      unitRef="usd">4812900000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTUtOC0xLTEtMA_fc418b2e-f7fc-499e-a5fd-13367e8c88f4"
      unitRef="usd">3664600000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTctMi0xLTEtMA_eddc1998-ee8b-4d9e-8209-84d71a904579"
      unitRef="usd">1847200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTctNC0xLTEtMA_9d9ef7ab-a1d8-405e-a29d-b15291ff1f46"
      unitRef="usd">1053100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTctNi0xLTEtMA_05d5bc3c-f5bb-45bf-a121-600301409e05"
      unitRef="usd">6307100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMTctOC0xLTEtMA_c12e108b-3d97-4daa-a12d-471794c7a27c"
      unitRef="usd">2409600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjAtMi0xLTEtMA_1e41e0a5-9a54-40af-a93f-8c5c9931fd67"
      unitRef="usd">-16400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjAtNC0xLTEtMA_f2d30e84-e89a-4af8-a14d-0297447d865c"
      unitRef="usd">-28500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjAtNi0xLTEtMA_08ad9d83-e46d-4157-a67d-71ceb824171c"
      unitRef="usd">558500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjAtOC0xLTEtMA_322a42a1-0110-4f7c-974f-9beea2b1c4b4"
      unitRef="usd">218300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjEtMi0xLTEtMA_6cf690b3-0b54-4642-b930-a4012f745e79"
      unitRef="usd">14200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjEtNC0xLTEtMA_d27bb08c-f8a5-49c7-b054-7cae03e8ecdd"
      unitRef="usd">26300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjEtNi0xLTEtMA_4b63ad0c-1d99-4fda-a50e-52507735fb6e"
      unitRef="usd">43200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjEtOC0xLTEtMA_2fa25ed3-956b-4d73-b799-1a2829ce1998"
      unitRef="usd">42100000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjItMi0xLTEtMA_15128cfb-d7a8-4f17-a80d-8368e5fd9608"
      unitRef="usd">-30600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjItNC0xLTEtMA_fca2e55f-640c-47cf-bdb4-41041c3549b1"
      unitRef="usd">-54800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjItNi0xLTEtMA_edc14b53-42d4-4501-85bf-0d776f2e9059"
      unitRef="usd">515300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjItOC0xLTEtMA_624dcdd2-2a1e-45d7-8ed3-28168d49f8a1"
      unitRef="usd">176200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjQtMi0xLTEtMA_091c893e-5e6c-4597-87cd-c643f411fd93"
      unitRef="usd">1816600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjQtNC0xLTEtMA_fd10730c-0804-4881-a13b-a118c37dedc9"
      unitRef="usd">998300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjQtNi0xLTEtMA_4e33d7d8-1c2e-4b97-96f7-672ea6d1a92c"
      unitRef="usd">6822400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjQtOC0xLTEtMA_958dc159-80cb-4733-9e4f-041245b01cbf"
      unitRef="usd">2585800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjYtMi0xLTEtMA_8da1377a-9898-46a1-bcf4-02bb1f805229"
      unitRef="usd">184400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjYtNC0xLTEtMA_b748cb12-4ccd-45b4-a632-8c899c4b97ea"
      unitRef="usd">156200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjYtNi0xLTEtMA_03edd9e4-9d14-41e7-b41e-730921d977cd"
      unitRef="usd">976100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjYtOC0xLTEtMA_42e003e5-de5b-4799-bbab-cf3e1b038409"
      unitRef="usd">221800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjgtMi0xLTEtMA_c3d33da7-5980-4e0e-9d9e-0d06f223ee5e"
      unitRef="usd">1632200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjgtNC0xLTEtMA_9736ea86-8f84-4538-81ff-322a0e89821c"
      unitRef="usd">842100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjgtNi0xLTEtMA_92f5e1a8-e56a-4b80-b901-a7b3f3f04ea1"
      unitRef="usd">5846300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMjgtOC0xLTEtMA_8dfa1d41-d419-40ae-997a-933f281a460e"
      unitRef="usd">2364000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzAtMi0xLTEtMA_13a07884-1051-41ee-8d3d-71985de07e64"
      unitRef="usdPerShare">15.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzAtNC0xLTEtMA_af93f0fe-1ebb-4860-992a-47849241ce65"
      unitRef="usdPerShare">7.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzAtNi0xLTEtMA_becfe970-1755-41e2-8547-97ec7849bb0c"
      unitRef="usdPerShare">55.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzAtOC0xLTEtMA_78d0936e-10e3-4ddc-a0ae-bff606c307d3"
      unitRef="usdPerShare">21.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzEtMi0xLTEtMA_7d39cf31-d071-4cd2-aa87-069318d1aaf3"
      unitRef="usdPerShare">14.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzEtNC0xLTEtMA_a9ac5cda-5c5b-4fa3-a96c-0c87ad5f0e99"
      unitRef="usdPerShare">7.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzEtNi0xLTEtMA_a99ef49d-6403-4bcd-8917-3633615f60c3"
      unitRef="usdPerShare">52.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzEtOC0xLTEtMA_8cf9c909-d68f-48ee-86bb-611b8844566c"
      unitRef="usdPerShare">20.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzMtMi0xLTEtMA_24541e57-7939-4df3-a023-18a82320d638"
      unitRef="shares">106200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzMtNC0xLTEtMA_6caebecf-56ef-47fb-84bf-6f7c1a9ba544"
      unitRef="shares">105500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzMtNi0xLTEtMA_ba1f5c8d-0974-46d3-bb42-dfbaea80c1e2"
      unitRef="shares">105500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzMtOC0xLTEtMA_5a62a876-c5f1-44b4-b194-3c510a113f27"
      unitRef="shares">108300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzQtMi0xLTEtMA_2226ecbc-ac78-4ee2-9daf-74e4d9406156"
      unitRef="shares">113900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzQtNC0xLTEtMA_f9244828-e332-48b1-92c4-99621c8d3383"
      unitRef="shares">113900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzQtNi0xLTEtMA_1fbe7fde-f5de-462a-9636-41cea2b1e474"
      unitRef="shares">111800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzQtOC0xLTEtMA_f2ed91c8-adeb-4718-8b45-9955e5f5f096"
      unitRef="shares">116100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzctMi0xLTEtMA_3ba9e1dc-9124-4289-a8a0-09ab48efe403"
      unitRef="usd">1632200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzctNC0xLTEtMA_0af8566b-f9cd-477d-aa8b-2fd014d35d2f"
      unitRef="usd">842100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzctNi0xLTEtMA_f09ae306-1a7f-4635-9646-5473fdbeec72"
      unitRef="usd">5846300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzctOC0xLTEtMA_b125c730-85d3-4c4b-9bbf-c001ea8c80a7"
      unitRef="usd">2364000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzktMi0xLTEtMA_f974501c-076a-4e56-b7b4-ce30ae8cecfe"
      unitRef="usd">-6400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzktNC0xLTEtMA_a41dfb2e-16fe-436a-a2c4-cbf31c114a4f"
      unitRef="usd">-4900000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzktNi0xLTEtMA_22526bf8-e403-4251-b721-523b11a83398"
      unitRef="usd">-20500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfMzktOC0xLTEtMA_14e0a4b2-a797-4db6-af68-f3a7610ec508"
      unitRef="usd">10900000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDAtMi0xLTEtMA_3c260641-c4f2-44f3-bd37-697d198373e9"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDAtNC0xLTEtMA_d0d420da-c81d-42ef-be08-31f53a246d68"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDAtNi0xLTEtMA_159ff9e0-a289-45bb-8a8a-5c6f398c3f30"
      unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDAtOC0xLTEtMA_6dafbde0-6dc0-469b-8269-4a8ba214056a"
      unitRef="usd">-1200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDEtMi0xLTEtMA_917c587b-76c1-4791-b233-1fc4dadea317"
      unitRef="usd">1626000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDEtNC0xLTEtMA_dcfe6347-d0f5-4662-8176-0dc6512edf11"
      unitRef="usd">837400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDEtNi0xLTEtMA_2c35c084-dd67-471d-8cd9-a2c4a54d52bf"
      unitRef="usd">5826500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8xOS9mcmFnOmQ5MDQ2ZmUwMmQyMDRjZWE4ZTM5MzM0MzdjZGIyODQzL3RhYmxlOmI3MmMxNzkzMDUzNDRlMmViYTJjMTMwMGNlYTdiZjM3L3RhYmxlcmFuZ2U6YjcyYzE3OTMwNTM0NGUyZWJhMmMxMzAwY2VhN2JmMzdfNDEtOC0xLTEtMA_04fe43a4-8c17-4995-ad14-0a0734d8a183"
      unitRef="usd">2373700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i3239cd5923f34e0ca9e9ec38de051f2e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi0yLTEtMS0w_d8795d60-8de2-4665-a6ea-201a52bca272"
      unitRef="shares">1800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3239cd5923f34e0ca9e9ec38de051f2e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi00LTEtMS0w_b6d3da83-1b51-4f8f-b848-37ea22e1cda6"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i035ed65f313f47239e1ba7a980f112a4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi02LTEtMS0w_c80a9572-c806-479c-b6f7-96ec51481c03"
      unitRef="shares">121500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i035ed65f313f47239e1ba7a980f112a4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi04LTEtMS0w_9b9c2367-1c9b-4d4e-b7b2-d44a4b1bde84"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i563d0a3bfa17497bbaf9ccff6e61e331_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi0xMC0xLTEtMA_7d0c806b-030c-4037-8e05-b053ae16b0b5"
      unitRef="usd">6716200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id0904b48c5834d8382585d98978efa6b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi0xMi0xLTEtMA_be0e055f-cb9d-41ca-86a9-91f218a7c7c5"
      unitRef="usd">10893000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4ba799e31f25451293026f6a5a092606_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi0xNC0xLTEtMA_8c13d20c-5068-4755-87e0-742e7aa1e253"
      unitRef="usd">29300000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="icb59f0839edb41abb0134a8358db4753_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi0xNi0xLTEtMA_f7abec87-a47f-470f-9057-404dbac77d8d"
      unitRef="shares">-16400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icb59f0839edb41abb0134a8358db4753_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi0xOC0xLTEtMA_35018d3d-3151-40e3-936b-c3c3b44c3dea"
      unitRef="usd">-6613300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMi0yMC0xLTEtMA_acf2eae2-7635-48ce-9686-d841294283df"
      unitRef="usd">11025300000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i3c94e3f729d1401291b50c0edf45498a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMy02LTEtMS0w_9446363e-4159-467e-9e32-9d1a9da712bb"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i224a9ebaa95b46c587b2caf10b449995_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMy0xMC0xLTEtMA_5179e6c6-04f2-4b2d-87f2-4ece1178d794"
      unitRef="usd">93900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMy0yMC0xLTEtMA_cd17e4aa-ae76-4030-ade9-84cfd01fc659"
      unitRef="usd">93900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i3c94e3f729d1401291b50c0edf45498a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNC02LTEtMS0w_ca2aac3f-78b1-48d3-be01-fdb5f0525daf"
      unitRef="shares">100000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i224a9ebaa95b46c587b2caf10b449995_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNC0xMC0xLTEtMA_5e5b82ff-fde8-421d-883b-e3b7f313d41c"
      unitRef="usd">66400000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNC0yMC0xLTEtMA_837dcce0-71c6-42b2-8158-75fbfe991c52"
      unitRef="usd">66400000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i224a9ebaa95b46c587b2caf10b449995_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNS0xMC0xLTEtMA_8fa15896-68b7-41bb-a063-91f75d4ba515"
      unitRef="usd">8500000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i45a7c7a2a79f45b599510ec6d98f5234_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNS0xNi0xLTEtMA_b33914c0-ff34-435f-bf0d-2fbb6819dc30"
      unitRef="shares">0</regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i45a7c7a2a79f45b599510ec6d98f5234_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNS0xOC0xLTEtMA_27ecd922-416a-4cff-92f8-5167f550b3b3"
      unitRef="usd">1500000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNS0yMC0xLTEtMA_d8b11809-a556-4bad-841c-a364d995d32b"
      unitRef="usd">10000000.0</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i45a7c7a2a79f45b599510ec6d98f5234_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNi0xNi0xLTEtMA_be72f82e-ebf9-4c86-a90c-89eaec281248"
      unitRef="shares">700000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i45a7c7a2a79f45b599510ec6d98f5234_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNi0xOC0xLTEtMA_402e7a0b-6f49-4b76-b2f0-fa356ca0d5fd"
      unitRef="usd">323500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNi0yMC0xLTEtMA_63b1bd5e-4bfc-4d2c-9408-75592c451db5"
      unitRef="usd">323500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i224a9ebaa95b46c587b2caf10b449995_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNy0xMC0xLTEtMA_cf6a3772-be74-4e12-8f3a-2c88e5f48e57"
      unitRef="usd">135600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNy0yMC0xLTEtMA_a0270a38-1747-406a-86bd-a397074d874e"
      unitRef="usd">135600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i771bf5f554d244a29f26c5501f4293f3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfOC0xMi0xLTEtMA_88f9dc0f-8a66-4df5-b00e-ba792f27dd19"
      unitRef="usd">1115200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfOC0yMC0xLTEtMA_4468c4f4-3fd5-4325-815b-82761d41f4f9"
      unitRef="usd">1115200000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie140c8b387dc4645b81c9879149a8e9d_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfOS0xNC0xLTEtMA_6c45c514-4686-4fa3-9966-41779d7c6dc3"
      unitRef="usd">-13100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if4cb6c6e743d44a995eb40d90e89c2b8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfOS0yMC0xLTEtMA_68714259-5952-4aa5-859f-84d6e5f3d86f"
      unitRef="usd">-13100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i49df9a95773d49e6967753fb9f9de580_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtMi0xLTEtMA_ea167919-25f0-417e-8371-744d32c0b7b0"
      unitRef="shares">1800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i49df9a95773d49e6967753fb9f9de580_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtNC0xLTEtMA_7b086973-b54c-48c7-976c-397f1c7d867d"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i970227f3acea4503918b252309b84460_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtNi0xLTEtMA_6036af60-2f49-4742-8c50-15b271e4c47d"
      unitRef="shares">121900000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i970227f3acea4503918b252309b84460_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtOC0xLTEtMA_5317edee-6bae-4960-b593-2db37345fad0"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idcd2927b7554444faad537d5a6d30eb9_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtMTAtMS0xLTA_418ae38a-38be-4af7-ab59-ceb05b9030cd"
      unitRef="usd">6887800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99065775605c4e47ab2780914630a4e5_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtMTItMS0xLTA_3efdf689-78b7-412c-9e2b-6c9287c69d94"
      unitRef="usd">12008200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i95d0fd1cd63743f18bd2b4ef498d61b6_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtMTQtMS0xLTA_b32b6e63-16c2-4259-ba77-15a4ea6f8473"
      unitRef="usd">16200000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ie2b9d9e8e8d94aafb8cf016d634bce00_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtMTYtMS0xLTA_69e3cdcc-80c3-4717-b550-a86c3cf14027"
      unitRef="shares">-17100000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie2b9d9e8e8d94aafb8cf016d634bce00_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtMTgtMS0xLTA_570b7d16-4760-48ea-9585-8c1741194d6f"
      unitRef="usd">-6935300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1db85b4dd6a74732adc71927ecf1a4b4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTAtMjAtMS0xLTA_584ebe28-d8ad-4f4c-9588-f8c13387bcc7"
      unitRef="usd">11977000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i485a4b467eae4806b0b1ebd35f44e2c2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTEtNi0xLTEtMA_d965f191-9fcb-40b2-a0f5-dda60a53800b"
      unitRef="shares">700000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0d895db990f24cf3a08e7953476d96f7_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTEtMTAtMS0xLTA_ae6a50bf-e41a-45fc-81ff-7c3040f3213b"
      unitRef="usd">216600000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTEtMjAtMS0xLTA_f967078c-2b99-4261-b045-01bc9ee2b78b"
      unitRef="usd">216600000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i485a4b467eae4806b0b1ebd35f44e2c2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTItNi0xLTEtMA_16b65c99-c4cc-473b-a98b-93a2c9e2973b"
      unitRef="shares">100000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0d895db990f24cf3a08e7953476d96f7_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTItMTAtMS0xLTA_e05198bc-f089-4075-9fa1-b23a877d3208"
      unitRef="usd">26100000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTItMjAtMS0xLTA_5fe1a718-b1e8-4f24-a1c2-d5afa8656f19"
      unitRef="usd">26100000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i0d895db990f24cf3a08e7953476d96f7_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTMtMTAtMS0xLTA_ab56c031-2d02-4846-a327-02cb00012116"
      unitRef="usd">11600000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i90967a0a2559464e89e7ac0cf8e2bdbc_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTMtMTYtMS0xLTA_22d5d454-494f-43a5-a751-7685be91e28c"
      unitRef="shares">0</regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i90967a0a2559464e89e7ac0cf8e2bdbc_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTMtMTgtMS0xLTA_0363b95f-dffd-4d4e-a634-30ca6dfc7cb4"
      unitRef="usd">2500000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTMtMjAtMS0xLTA_5ca7349a-18ff-4339-bf26-b6c8834deec0"
      unitRef="usd">14100000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i90967a0a2559464e89e7ac0cf8e2bdbc_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTQtMTYtMS0xLTA_e66eb3c3-51ec-46d2-8de5-4b3baba1b374"
      unitRef="shares">600000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i90967a0a2559464e89e7ac0cf8e2bdbc_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTQtMTgtMS0xLTA_5abfc4bb-3d19-445b-8ff3-f0c8b2d1931e"
      unitRef="usd">288600000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTQtMjAtMS0xLTA_635d8036-bec0-4d2f-8cbf-885e88672b1a"
      unitRef="usd">288600000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0d895db990f24cf3a08e7953476d96f7_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTUtMTAtMS0xLTA_9fb4c035-c2a8-4646-8874-be0d6dd18ddb"
      unitRef="usd">135900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTUtMjAtMS0xLTA_11eb92e0-bc99-41b0-a860-e2e5ac270494"
      unitRef="usd">135900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="if027b47fcff24b09bc17374a79225282_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTYtMTItMS0xLTA_50cfbbf9-28c5-487b-a5cc-2feb71f74ecd"
      unitRef="usd">3098900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTYtMjAtMS0xLTA_40a5b591-ace7-4e94-ba51-df3ebd9dfca6"
      unitRef="usd">3098900000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icdc7f3436f2d4c15be968a3a0446d58b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTctMTQtMS0xLTA_79d666a1-06c1-40fa-9260-a5a507484640"
      unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic78fe6e3f1b94da6b378feaf3f3227b8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTctMjAtMS0xLTA_13cd8406-ccda-41f8-b7d4-bcf14b79c789"
      unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i01a22b1457534e58971e7c3840ce8a74_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtMi0xLTEtMA_949cb7ed-0a62-4c90-9df8-5f5dc5166100"
      unitRef="shares">1800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i01a22b1457534e58971e7c3840ce8a74_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtNC0xLTEtMA_ca123bb2-a5f4-4736-bbec-abc8b9c05483"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i9aca85854a7e44a4967c9de4200b7275_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtNi0xLTEtMA_8fe417bf-6f09-431e-b344-ec99119f2d1e"
      unitRef="shares">122500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9aca85854a7e44a4967c9de4200b7275_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtOC0xLTEtMA_ceca3e50-3667-4083-a46d-9ddc37836e51"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib4692004524e482c94791bc9cdad2f45_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtMTAtMS0xLTA_0432077a-81a4-43c1-847c-3ecd318b3e18"
      unitRef="usd">7225800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia5ee4bf1abbe4e4aa728bc791fd9e4be_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtMTItMS0xLTA_925efdf1-ac77-401d-8c5c-894bbfd7ea7d"
      unitRef="usd">15107100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i58536bd9f96a400195ebcbf3b27c73ef_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtMTQtMS0xLTA_7d851aa3-213f-457c-ae40-e3ba756e7ce1"
      unitRef="usd">15700000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="idca5a9d3669d4ad4abd5502c841c9b83_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtMTYtMS0xLTA_ea778630-b596-48bc-8260-de115c77cc67"
      unitRef="shares">-17700000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idca5a9d3669d4ad4abd5502c841c9b83_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtMTgtMS0xLTA_79d5476b-4bd2-4d7e-bee2-0ac8443983c0"
      unitRef="usd">-7221400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic8637e07a17044e3bc80d1b3f1ac3709_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTgtMjAtMS0xLTA_b81c58a7-9f03-4212-837c-6b7e530243df"
      unitRef="usd">15127300000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i3c2c8b599684423e810cce4bc7569486_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTktNi0xLTEtNDY_5cbd3028-3ba6-4500-8c52-308aac874e0a"
      unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i81bba3e7b3f14597be97fbb190f9dbff_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTktMTAtMS0xLTQ2_b41663f8-b9f5-4f9c-b428-c1ff0fb09d08"
      unitRef="usd">816500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMTktMjAtMS0xLTQ2_3d7955a5-68e6-4065-aa1e-16f041c6e789"
      unitRef="usd">816500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i3c2c8b599684423e810cce4bc7569486_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjAtNi0xLTEtNDY_11a51f81-1ad3-4d1a-a3b9-251cc809f91e"
      unitRef="shares">400000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i81bba3e7b3f14597be97fbb190f9dbff_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjAtMTAtMS0xLTQ2_914b7dc1-2269-4488-8dd1-e45083627710"
      unitRef="usd">269600000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjAtMjAtMS0xLTQ2_55c9af24-c7d5-4295-b0bc-91ec2eb7abac"
      unitRef="usd">269600000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i81bba3e7b3f14597be97fbb190f9dbff_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjEtMTAtMS0xLTQ2_981e77cb-5bbc-4458-9eb3-bbc37a1050d0"
      unitRef="usd">10200000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="ic22073ba422e4cd19578e069ff93a548_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjEtMTYtMS0xLTQ2_4a8ff7f5-1903-47be-b040-8e3f681b4b80"
      unitRef="shares">0</regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ic22073ba422e4cd19578e069ff93a548_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjEtMTgtMS0xLTQ2_bd94fee3-bfb6-44ac-b75f-88b3760c62d1"
      unitRef="usd">1800000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjEtMjAtMS0xLTQ2_d1c7b380-a5ce-49db-a7cb-dfb88034acb5"
      unitRef="usd">12000000.0</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ic22073ba422e4cd19578e069ff93a548_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjItMTYtMS0xLTQ2_4c5fbad6-765f-4d1a-a1e2-9a8cec5e8180"
      unitRef="shares">200000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic22073ba422e4cd19578e069ff93a548_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjItMTgtMS0xLTQ2_0ad5fb76-ad3f-4025-853b-e8319fd1e543"
      unitRef="usd">190600000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjItMjAtMS0xLTQ2_c0e46caf-5d05-47f6-bbad-1f5d7e2ee7f2"
      unitRef="usd">190600000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i81bba3e7b3f14597be97fbb190f9dbff_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMTAtMS0xLTQ2_cf883df3-39c7-4cd9-89a2-5f51e75de631"
      unitRef="usd">136400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMjAtMS0xLTQ2_7a8b13dc-24b3-4941-87f2-074f45501f3f"
      unitRef="usd">136400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ia1af4b6d98674144aede03c90b76ecde_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjQtMTItMS0xLTQ2_5d7da682-7336-4bd1-888a-54cdf9680c57"
      unitRef="usd">1632200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjQtMjAtMS0xLTQ2_806894ba-715d-4a2a-8e8e-231eb13fabc0"
      unitRef="usd">1632200000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifa09e4ef649b446d8a986b009222a48c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjUtMTQtMS0xLTQ2_a6289105-3ef3-4538-a65a-dbdec0ebc88c"
      unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjUtMjAtMS0xLTQ2_b9455959-2ebf-485b-a329-08bd407844ec"
      unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="iea16b9252afa422babee5f32af655235_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMi0xLTEtNDY_e506f8d9-793f-4368-946e-c635d7c260c6"
      unitRef="shares">1800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iea16b9252afa422babee5f32af655235_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtNC0xLTEtNDY_f246cbbd-df6f-481b-82c2-1a7ec3d2f76b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i31f7ae795859466f9949d77297734d41_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtNi0xLTEtNDY_465f991c-ac61-47f5-99d2-77630d15b82a"
      unitRef="shares">124600000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i31f7ae795859466f9949d77297734d41_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtOC0xLTEtNDY_702af6f1-7c3e-4400-9685-3cd7d64be57a"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5ea589759884ae08a57e4895180d768_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTAtMS0xLTQ2_ac3f868d-e263-4749-abed-f69b46892c5a"
      unitRef="usd">7919300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib4a9df31fbd2432eb37434ec52ac6097_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTItMS0xLTQ2_24a1e1ba-dab3-4bbb-95f5-73a0486b5d33"
      unitRef="usd">16739300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i241d3af3190948bebbe76ddd7a69650a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTQtMS0xLTQ2_a3af4aa1-6beb-4d19-b353-5a5fc07503f4"
      unitRef="usd">9500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="idc06747141a8415abdc99e415fd10ec4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTYtMS0xLTQ2_bae0bf94-c9fc-4c61-87b0-8dae447d30d4"
      unitRef="shares">-17900000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idc06747141a8415abdc99e415fd10ec4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTgtMS0xLTQ2_aff98bd1-8c1b-4396-b993-47b00c5a1886"
      unitRef="usd">-7410200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMjAtMS0xLTQ2_2fcb54c3-0b4a-4f39-9185-507152fc8fac"
      unitRef="usd">17258000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i73dec6c7995c456c9140fce39007c0e9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMi0xLTEtMA_156eaa0f-c17c-4e42-bf2a-61afe6038751"
      unitRef="shares">1800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i73dec6c7995c456c9140fce39007c0e9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtNC0xLTEtMA_f60bccb4-f1c4-4f1d-bca9-9fd6c146b9da"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ie0bf589234254d1fa1a8439438ed348f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtNi0xLTEtMA_42d4e466-00ed-44b8-955c-336446f6d381"
      unitRef="shares">113300000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie0bf589234254d1fa1a8439438ed348f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtOC0xLTEtMA_62472175-bcd5-400d-a947-3512a58cbbb2"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b0eaf7cc1b34bc3a8ce4fceda06456c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMTAtMS0xLTA_9dfe231b-b3ef-4931-8d06-19387254efa5"
      unitRef="usd">4428600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f1bbe31c49144b58bd31a8fdaaa287b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMTItMS0xLTA_ec30a13d-ef5d-4f76-8152-7a508cfff7ee"
      unitRef="usd">7379800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i843aefe7a57e49a4b8057f411d68d2d6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMTQtMS0xLTA_0111ce08-4228-4042-8f21-1581d70a5acf"
      unitRef="usd">21100000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="idfb0c989543b47b4b84dfc63cacdb340_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMTYtMS0xLTA_b36ba0dd-724e-4ae0-ba91-370abd46c938"
      unitRef="shares">-4900000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idfb0c989543b47b4b84dfc63cacdb340_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMTgtMS0xLTA_8e78af2b-eb98-4b0f-b62b-7d9857260479"
      unitRef="usd">-739900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if8be30bd45174fe1a757f0b806ef45ff_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjMtMjAtMS0xLTA_ff55b39b-253b-4d2b-84ba-628602da39ee"
      unitRef="usd">11089700000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib3a84e5477f34a4fa157fc0ff96532f9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjQtNi0xLTEtMA_a8eebcca-f1be-4e5d-891b-5092704aa128"
      unitRef="shares">3100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i67d9fc7c849641a29c4015bb2c26ff95_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjQtMTAtMS0xLTA_a7a2412a-05b5-4cbd-a658-0ecf1ae37a35"
      unitRef="usd">817400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjQtMjAtMS0xLTA_5b1d82cc-9821-4ecb-a1ee-f325d5fa4a9f"
      unitRef="usd">817400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ib3a84e5477f34a4fa157fc0ff96532f9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjUtNi0xLTEtMA_0208e1bc-6706-4a99-802a-683420308ed8"
      unitRef="shares">400000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i67d9fc7c849641a29c4015bb2c26ff95_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjUtMTAtMS0xLTA_aeab10b6-1c1f-4395-83a5-0ae31bdcec31"
      unitRef="usd">155100000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjUtMjAtMS0xLTA_c4849b85-4944-4bf3-a1f3-5f02a8c6dd58"
      unitRef="usd">155100000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i67d9fc7c849641a29c4015bb2c26ff95_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTAtMS0xLTA_43acf98e-1f28-4092-b796-b24609363427"
      unitRef="usd">12500000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="ia85c03a3ab92450c8de1356f1f1c58d3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTYtMS0xLTA_3a8bf02a-f18a-429d-ac99-72821e0dadab"
      unitRef="shares">0</regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ia85c03a3ab92450c8de1356f1f1c58d3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMTgtMS0xLTA_23a03bed-0561-48dc-85d3-74ad09f9f651"
      unitRef="usd">2100000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjYtMjAtMS0xLTA_1d6bcd67-1cde-47e1-9ce9-bc7dfc962d53"
      unitRef="usd">14600000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ia85c03a3ab92450c8de1356f1f1c58d3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjctMTYtMS0xLTA_d175d875-0c53-494b-be7f-aee6723ed209"
      unitRef="shares">800000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ia85c03a3ab92450c8de1356f1f1c58d3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjctMTgtMS0xLTA_d25a75e9-327b-45f7-9d84-aee0feb98798"
      unitRef="usd">336000000.0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjctMjAtMS0xLTA_d15a4ee1-de98-4996-a94d-843dc73d8b80"
      unitRef="usd">336000000.0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i67d9fc7c849641a29c4015bb2c26ff95_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjgtMTAtMS0xLTA_85ecbd4d-5951-450a-bb27-934da4fe52a1"
      unitRef="usd">108000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjgtMjAtMS0xLTA_9dcaa235-b047-49e6-b4ad-fbd8b5a8c859"
      unitRef="usd">108000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i0f1758a625d84d929d4de5bf11529687_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjktMTItMS0xLTA_29e7bea5-66a2-47a2-8e76-7f38c9b51074"
      unitRef="usd">624600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMjktMjAtMS0xLTA_59a96e26-b974-4049-87e5-1c1a2e41db96"
      unitRef="usd">624600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i98313781c6ec4d6b8b48f6da3becd23f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzAtMTQtMS0xLTA_ed439df6-a9c4-4477-9d65-37dbb10aea3a"
      unitRef="usd">-30200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic35d75c8fecc408889c0fe0271da0a85_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzAtMjAtMS0xLTA_7b0aab53-3640-4d57-bcea-8af87ce3b79e"
      unitRef="usd">-30200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i51f918e0a47440ff9a42a36261a6d16d_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtMi0xLTEtMA_34cc98cf-72de-4f72-8235-2add14bc05b1"
      unitRef="shares">1800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i51f918e0a47440ff9a42a36261a6d16d_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtNC0xLTEtMA_aceaadc5-1e30-47b2-aa6a-551040f3e7d0"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i76b230224ec74a4ebd37c4fa613a51f6_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtNi0xLTEtMA_8ef775f7-ee4a-4788-a1b9-8aaba1158da0"
      unitRef="shares">116000000.0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i76b230224ec74a4ebd37c4fa613a51f6_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtOC0xLTEtMA_f38bfa48-a511-4672-8a2d-73ab7e5afa11"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6c4ef5941f242a783b93fdf18b331b7_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtMTAtMS0xLTA_58bd9794-a6c0-45ff-863d-47bf4859d163"
      unitRef="usd">5211400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i93db50d47f1b4831b473f4caa658d588_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtMTItMS0xLTA_55bb3fad-e621-407a-8c6a-1e597c23ba3f"
      unitRef="usd">8004400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1448dfba64a24ca98ed5cca7a68f936c_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtMTQtMS0xLTA_87251474-59af-4282-853f-6ba56f43d9b2"
      unitRef="usd">-9100000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="if8e249a62ffd40df9c9149d8b996539c_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtMTYtMS0xLTA_c4586c56-2cd6-4998-ac85-04c3e1b0a8c5"
      unitRef="shares">-5700000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if8e249a62ffd40df9c9149d8b996539c_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtMTgtMS0xLTA_e21746e2-5076-41fe-8177-88fb5279ecd5"
      unitRef="usd">-1073800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3282a3bb766e427c92f46bd8d3cc7e59_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzEtMjAtMS0xLTA_4953e1a9-e74d-4f60-a7e5-ec4ba654dc7e"
      unitRef="usd">12133000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i57cb86b034e44ad089ebc3504d4d0411_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzItNi0xLTEtMA_ac070394-f4a2-41e4-b33a-e0bc0ccc6e00"
      unitRef="shares">4400000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i82a2982cdc3744dfab46a0e3a207a741_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzItMTAtMS0xLTA_362679c3-9255-4f57-b8f7-29ef8396dde6"
      unitRef="usd">1355500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzItMjAtMS0xLTA_95acbe7c-01c2-494b-85a4-eb9c69e9fc21"
      unitRef="usd">1355500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i57cb86b034e44ad089ebc3504d4d0411_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzMtNi0xLTEtMA_e6379d0d-37ed-4456-af92-b7c35de9943a"
      unitRef="shares">600000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i82a2982cdc3744dfab46a0e3a207a741_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzMtMTAtMS0xLTA_457389a0-eab1-4c02-85e8-b1ed4860e7c2"
      unitRef="usd">416500000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzMtMjAtMS0xLTA_68455b32-c091-45dd-9c7f-f7d771357f8a"
      unitRef="usd">416500000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i82a2982cdc3744dfab46a0e3a207a741_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzQtMTAtMS0xLTA_233b2d27-21e3-4a25-b4fc-d3052011c8b7"
      unitRef="usd">7400000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i90f143b898064fb1a010fcdce8a28b66_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzQtMTYtMS0xLTA_31857e56-009f-4778-845a-7a517d4cfa54"
      unitRef="shares">0</regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i90f143b898064fb1a010fcdce8a28b66_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzQtMTgtMS0xLTA_b1d9baa5-dfd9-446c-80e9-adff0950f34b"
      unitRef="usd">2700000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzQtMjAtMS0xLTA_ad4639c0-ca95-4373-a5a4-379bb3f5fa06"
      unitRef="usd">10100000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i90f143b898064fb1a010fcdce8a28b66_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzUtMTYtMS0xLTA_4e7312eb-d560-423b-a055-d824ca425b37"
      unitRef="shares">9900000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i90f143b898064fb1a010fcdce8a28b66_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzUtMTgtMS0xLTA_daa06afd-05a9-46af-9b6c-81750010b2ab"
      unitRef="usd">5071800000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzUtMjAtMS0xLTA_05b5dc87-574d-4aa0-a926-5c1428b4959e"
      unitRef="usd">5071800000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i82a2982cdc3744dfab46a0e3a207a741_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzYtMTAtMS0xLTA_9908b1f8-c1ca-44cd-9a51-6db05bc51bc7"
      unitRef="usd">105200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzYtMjAtMS0xLTA_d861b412-e59a-46ef-a9ef-e9873eb32033"
      unitRef="usd">105200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i5505226ac8da4156a58673a2fec740bd_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzctMTItMS0xLTA_71c1fed6-b24a-45a0-b23f-721730b4f388"
      unitRef="usd">897300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzctMjAtMS0xLTA_de2d934d-5c3b-4cf7-8bb1-2924fdf79732"
      unitRef="usd">897300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6fef85b8750b47bbb313ad7db28ce663_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzgtMTQtMS0xLTA_fe7db3bb-32f3-409e-a48d-9aa674422494"
      unitRef="usd">44600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i13c9d452dbcd46f1ac769990ca4cbfbe_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzgtMjAtMS0xLTA_986749bd-4b7f-4516-b4ca-b2786fa209d9"
      unitRef="usd">44600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="iaedf97f07c304e0eb9b3fff6304ec0c1_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktMi0xLTEtMA_b3348cb0-9273-43f7-8ca1-bbe39cd73c8d"
      unitRef="shares">1800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaedf97f07c304e0eb9b3fff6304ec0c1_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktNC0xLTEtMA_19a0a13a-ea52-47f2-bc15-6adc847efae3"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ieb44990ceb62481894ef4f3997282c75_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktNi0xLTEtMA_802808f1-eb2c-4606-bf7d-c2bcf26772db"
      unitRef="shares">119800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ieb44990ceb62481894ef4f3997282c75_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktOC0xLTEtMA_219b8d04-7482-46ef-9eb7-59849aa0d85b"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iae6682412d744b10a6d5e33564d0af56_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktMTAtMS0xLTA_9ba67f70-09d0-4c53-8fa3-0afa72382f2d"
      unitRef="usd">6263000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63120c4477c04522a145f1c834f52464_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktMTItMS0xLTA_bdc80d8d-a58b-46ca-bf54-408cbb280818"
      unitRef="usd">8901700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i88e0d4f0e2bb4a66bbb456ea665d882d_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktMTQtMS0xLTA_b8783d16-241e-4628-bbba-e84f9c93d538"
      unitRef="usd">35500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ib41afa111c3149648c0cc3bac7c5b435_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktMTYtMS0xLTA_a44767d4-c281-42e0-8ac7-a817a445055c"
      unitRef="shares">-15600000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib41afa111c3149648c0cc3bac7c5b435_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktMTgtMS0xLTA_74c5f920-5ea8-45c5-9e9f-385bc8c426cd"
      unitRef="usd">-6142900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic9c7d2da9c9f4d09a60482a44e3c8ca7_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfMzktMjAtMS0xLTA_70ec7c8a-a07c-4d0c-ab20-a4db8653764f"
      unitRef="usd">9057400000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i72a6a418d67447f6bf91301e4805ad9b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNDgtNi0xLTEtNjE_39dc3968-bbd2-405c-964e-0804e74cf2c5"
      unitRef="shares">900000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia83d2540d3bf4a078040cd71ec1f972b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNDgtMTAtMS0xLTYx_b9bdc080-fcb1-4efb-ac6b-b04cf74a32ea"
      unitRef="usd">297500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNDgtMjAtMS0xLTYx_84985772-1303-441a-b2b3-067a19e5e58c"
      unitRef="usd">297500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i72a6a418d67447f6bf91301e4805ad9b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNDktNi0xLTEtNjE_217b6c53-6c4f-4c15-9b3f-07cb67ebbbbe"
      unitRef="shares">200000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia83d2540d3bf4a078040cd71ec1f972b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNDktMTAtMS0xLTYx_e49827ec-478d-4817-9fc6-88ef8eef6991"
      unitRef="usd">80900000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNDktMjAtMS0xLTYx_c20691c7-bbe6-4adb-b92e-9573c08447f9"
      unitRef="usd">80900000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="ia83d2540d3bf4a078040cd71ec1f972b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTAtMTAtMS0xLTYx_365bc35f-b2e6-4f68-9de1-68d211cb9710"
      unitRef="usd">8600000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i4de7c52f2b7a4fe89360820891e3f073_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTAtMTYtMS0xLTYx_ad5fae71-4da1-4cc0-a67f-f67ebeabbfaf"
      unitRef="shares">0</regn:StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i4de7c52f2b7a4fe89360820891e3f073_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTAtMTgtMS0xLTYx_6601ae1b-a497-4149-af6f-57c99b85b707"
      unitRef="usd">1300000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTAtMjAtMS0xLTYx_4b2b8579-51ef-4716-8804-a7293d52f508"
      unitRef="usd">9900000</regn:StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i4de7c52f2b7a4fe89360820891e3f073_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTEtMTYtMS0xLTYx_88024743-cb87-4d71-9712-d5343bab0821"
      unitRef="shares">100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i4de7c52f2b7a4fe89360820891e3f073_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTEtMTgtMS0xLTYx_fdb5d63f-3ce7-4ca0-8a28-fd64c4400d94"
      unitRef="usd">100400000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTEtMjAtMS0xLTYx_c7162b25-c05a-4e46-8e9b-72a413db4dec"
      unitRef="usd">100400000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia83d2540d3bf4a078040cd71ec1f972b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTItMTAtMS0xLTYx_e65e6173-d11f-4b9a-af04-7747646c1fdd"
      unitRef="usd">104600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTItMjAtMS0xLTYx_5d0c13f4-60e3-4e23-b3bb-5aa1f732c5ee"
      unitRef="usd">104600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ic71c7174d5cc448398e06391a7827688_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTMtMTItMS0xLTYx_b979f23b-736e-4f47-8e44-6016fd2cc7a5"
      unitRef="usd">842100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTMtMjAtMS0xLTYx_9792e61a-6364-4e87-89f2-a24ce8e953ea"
      unitRef="usd">842100000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic16fc6f626e146c18705d2b1e22411bc_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTQtMTQtMS0xLTYx_d6f575b2-0946-4fad-a9ca-ccce9b61f72c"
      unitRef="usd">-4700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTQtMjAtMS0xLTYx_654159e4-fe9d-42cd-b347-175247b5b590"
      unitRef="usd">-4700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i0102174142414cbd89010684f4e14032_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtMi0xLTEtNjE_32b17897-2e4e-4b0c-8865-d4063f872784"
      unitRef="shares">1800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0102174142414cbd89010684f4e14032_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtNC0xLTEtNjE_a250d88e-d6b0-47ca-9d93-2c72f2f0153e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="if7e951f6bc2b47f9a0f83bbc19cfee0b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtNi0xLTEtNjE_22bafdcc-7ff4-479d-94a7-fca506c15dc5"
      unitRef="shares">120500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if7e951f6bc2b47f9a0f83bbc19cfee0b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtOC0xLTEtNjE_3687158b-069a-4e8c-8740-8d37cb3453fe"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9d580d7d41ab4c779d21e7ecf46f3208_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtMTAtMS0xLTYx_25c9f4b7-473e-4ea4-b759-1c85d5aa15ae"
      unitRef="usd">6592800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8e5ba528b04c4762aa61bced9949c785_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtMTItMS0xLTYx_b6aaeaf9-c253-421a-bd01-432910ab4655"
      unitRef="usd">9743800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i782ae2009f954090860e6e0bb4a7039f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtMTQtMS0xLTYx_8368852e-7736-4e00-a144-da1dea47a9df"
      unitRef="usd">30800000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i960a6b708491473d9570c3942b7eef6c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtMTYtMS0xLTYx_0d4b2844-168d-4e60-853a-6b901487eb4e"
      unitRef="shares">-15700000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i960a6b708491473d9570c3942b7eef6c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtMTgtMS0xLTYx_2a05ff78-9360-48df-909d-3b91f6797737"
      unitRef="usd">-6242000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i09b0b1c1c2a94afb988a7c59c235eee7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yMi9mcmFnOmJmZTQxNTBkMTQ1NDQ2ZDg5N2M5OWQ3ZjI3NjYyMjY3L3RhYmxlOjQ2MjkwNmY4NTFmMTQzZTY5ZDQ2YTA1ODg4ZDlkNTc0L3RhYmxlcmFuZ2U6NDYyOTA2Zjg1MWYxNDNlNjlkNDZhMDU4ODhkOWQ1NzRfNTUtMjAtMS0xLTYx_8e197b7b-a008-432f-b52c-1283069496b3"
      unitRef="usd">10125500000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMy0yLTEtMS0w_fc487412-161b-4c25-888b-1a5babdb19a0"
      unitRef="usd">5846300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMy00LTEtMS0w_148d4856-7902-4d9b-84fc-2c8cf101e6cc"
      unitRef="usd">2364000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfNS0yLTEtMS0w_84effa95-4b2e-4bb5-b603-b996cf79334f"
      unitRef="usd">211700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfNS00LTEtMS0w_a485711f-334a-44f8-af25-e986925a4b0c"
      unitRef="usd">174200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfNi0yLTEtMS0w_4a112fa4-3022-4044-87b3-3d861dd517bd"
      unitRef="usd">413300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfNi00LTEtMS0w_0511251f-3560-4ac4-b3c3-2e8e5500724c"
      unitRef="usd">310500000</us-gaap:ShareBasedCompensation>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfNy0yLTEtMS0w_483f6db1-5a34-421c-9d88-530a3728f85e"
      unitRef="usd">524600000</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfNy00LTEtMS0w_28441eff-9b2d-4879-b87b-749a0849d16c"
      unitRef="usd">162300000</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfOC0yLTEtMS0w_c577ed94-bb0a-4b16-a383-6f3960046239"
      unitRef="usd">-264400000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfOC00LTEtMS0w_b58e4d5d-31cc-4aac-82c2-c233f6ec1088"
      unitRef="usd">-51000000.0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfOS0yLTEtMS0w_52c75df6-41bc-42e4-a09a-5a001de17cda"
      unitRef="usd">-58800000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfOS00LTEtMS0w_97b8ab14-9e99-431b-83ef-e55a919ce5cf"
      unitRef="usd">-117900000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTEtMi0xLTEtMA_442469a4-4c07-4069-b95a-2b5b2c6e0c36"
      unitRef="usd">1342900000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTEtNC0xLTEtMA_0a71af61-1292-496e-91f2-30b689aea898"
      unitRef="usd">1275300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTItMi0xLTEtMA_f27148c1-01ec-45e7-9654-81d441941867"
      unitRef="usd">330600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTItNC0xLTEtMA_77947bb5-c4cb-4661-a1f4-4f7d8aa7918a"
      unitRef="usd">402400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTMtMi0xLTEtMA_b50a5920-db39-4f4f-9b13-16b8649fe85a"
      unitRef="usd">316800000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTMtNC0xLTEtMA_3675459e-b3bb-4a3a-87a7-49f057466e0c"
      unitRef="usd">-16400000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTQtMi0xLTEtMA_b15bf385-b2b9-4223-88b9-251987fcfac3"
      unitRef="usd">-71200000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTQtNC0xLTEtMA_42482feb-3d83-45f0-906f-b460ca8d07c7"
      unitRef="usd">112300000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTUtMi0xLTEtMA_619ecddb-84b9-4d92-a68e-7fcd65193b51"
      unitRef="usd">500400000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTUtNC0xLTEtMA_ac58c741-e7c6-4f09-81c1-ea3f81b940f7"
      unitRef="usd">80800000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTYtMi0xLTEtMA_7cf59cd6-fc07-48cc-83a1-063f4111569b"
      unitRef="usd">-1137500000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTYtNC0xLTEtMA_80753f23-8e80-4433-910a-8bbcea711002"
      unitRef="usd">-976900000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTctMi0xLTEtMA_e5cfb75d-9e74-4d15-ab2c-6c52f9238351"
      unitRef="usd">4708800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMTctNC0xLTEtMA_ee411231-04cf-4942-acc3-3cdb3d50e2f4"
      unitRef="usd">1387100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjAtMi0xLTEtMA_0ef0f54f-307e-4dec-b661-dd5a505164a1"
      unitRef="usd">4872300000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjAtNC0xLTEtMA_37438e9b-25f7-43f7-8da2-658166709142"
      unitRef="usd">2642700000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjEtMi0xLTEtMA_8ba644ea-bf9c-4667-be9a-337dbd339a8e"
      unitRef="usd">1897300000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjEtNC0xLTEtMA_91973c36-061f-49f3-894b-92fd54a77714"
      unitRef="usd">3330300000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjItMi0xLTEtMA_49df4e0f-d245-4d6e-8aab-35f174bc848f"
      unitRef="usd">397000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjItNC0xLTEtMA_9cf2571b-1136-410a-b869-1faed5f4c9b4"
      unitRef="usd">453200000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjMtMi0xLTEtMA_27b3f9df-0e64-478f-af8e-80caa2edbdd8"
      unitRef="usd">-3372000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjMtNC0xLTEtMA_ab56bb63-4c2e-411a-8c88-b3671d5df5ef"
      unitRef="usd">234400000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjctMi0xLTEtMA_2c87238e-2543-4a63-b2bf-6fa9a82fbbea"
      unitRef="usd">1129600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjctNC0xLTEtMA_32018ded-a4b9-4b0f-ab4e-8f08dbf4a2bc"
      unitRef="usd">2471100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjgtMi0xLTEtMA_9edc5fae-49b7-4969-9997-8a46d44ba979"
      unitRef="usd">450300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjgtNC0xLTEtMA_2955421d-1d4c-45ec-b568-12b1889023e8"
      unitRef="usd">652500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjktMi0xLTEtMA_e5808003-6339-49cb-943e-543a0d85f00e"
      unitRef="usd">778500000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMjktNC0xLTEtMA_6e81fb7b-d16c-4341-b592-daea45fd44b0"
      unitRef="usd">5465700000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzItMi0xLTEtNDAwNzg_940eef4c-f0b5-4722-a3b9-169ef20a0c23"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzItNC0xLTEtNDAwNzg_38a17305-fca0-404f-b8b9-2eb2c740e2d9"
      unitRef="usd">1981900000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzMtMi0xLTEtNDAwNzg_31431eaa-c38a-46e3-a391-9c01d985b305"
      unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzMtNC0xLTEtNDAwNzg_2bd5dc67-284e-40cd-9277-b4ced57ea258"
      unitRef="usd">1500000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzQtMi0xLTEtNDAwNzg_e944f0e4-cbbc-46e5-8850-581dc0c6ddd2"
      unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzQtNC0xLTEtNDAwNzg_ef110a35-b94c-4b86-a860-22a2e402d208"
      unitRef="usd">1500000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzAtMi0xLTEtMA_b2b7fa9a-3baf-4fe2-a10e-ce823bd3eca7"
      unitRef="usd">-99200000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzAtNC0xLTEtMA_fae5ecf7-50c0-4b23-88ed-55f06ff29729"
      unitRef="usd">-1665200000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzItMi0xLTEtMA_d7172aaa-230d-46ae-97db-1031d6649fe1"
      unitRef="usd">1237600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzItNC0xLTEtMA_b084493c-bfd1-4cfa-9b35-b7b82ed3c794"
      unitRef="usd">-43700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzQtMi0xLTEtMA_543014c9-c909-4338-b34f-39b8a7363b63"
      unitRef="usd">2207300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if8be30bd45174fe1a757f0b806ef45ff_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzQtNC0xLTEtMA_2a0c1a58-95f7-4076-b69a-dd589254fbc9"
      unitRef="usd">1630300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzYtMi0xLTEtMA_317c7112-9632-4753-90ba-6125a50da959"
      unitRef="usd">3444900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i09b0b1c1c2a94afb988a7c59c235eee7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8yNS9mcmFnOmZjZWU4ZjYzOGQxNTQzNWY5NTc1MzliNjAxZjU0YTM4L3RhYmxlOjJkOGQ1Njk2MmI0MDQ4OGViNzRmYWRiODc4YjJmMGVmL3RhYmxlcmFuZ2U6MmQ4ZDU2OTYyYjQwNDg4ZWI3NGZhZGI4NzhiMmYwZWZfMzYtNC0xLTEtMA_ec98a9dc-5324-43cf-8ed6-ba641788a4c5"
      unitRef="usd">1586600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zMS9mcmFnOjVlMDNiNWJmOTI3MTQxMWJiY2I2ZjZjNzFkYWZlNzY0L3RleHRyZWdpb246NWUwM2I1YmY5MjcxNDExYmJjYjZmNmM3MWRhZmU3NjRfMTQzNw_20b74fff-af0b-48e0-9a0c-a8575f3bca78">Interim Financial Statements&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December&#160;31, 2020 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zMS9mcmFnOjVlMDNiNWJmOTI3MTQxMWJiY2I2ZjZjNzFkYWZlNzY0L3RleHRyZWdpb246NWUwM2I1YmY5MjcxNDExYmJjYjZmNmM3MWRhZmU3NjRfMTQ0Mg_59746d96-b2ef-4260-9142-d8c88d5bda33">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December&#160;31, 2020 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RleHRyZWdpb246ZWM5Yzc5YjUxNzUyNGIwZDk1MmI5YzI4N2YxNmNhMTdfNDkw_473e2caf-e85d-4e4b-9cb2-611a2d1de956">Product Sales&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.309%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Net Product Sales in the United States&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EYLEA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,473.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,245.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,604.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Libtayo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Praluent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;REGEN-COV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,530.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evkeeza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ARCALYST&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,279.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,142.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Previously, Sanofi recorded net product sales of Praluent in the United States. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;**&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and December&#160;31, 2020, the Company had $4.086&#160;billion and $3.112&#160;billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for the three and nine months ended September&#160;30, 2021 and 2020. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Besse Medical, a subsidiary of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Sales to the U.S. Government represented less than 10% of total gross product revenue during the period.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RleHRyZWdpb246ZWM5Yzc5YjUxNzUyNGIwZDk1MmI5YzI4N2YxNmNhMTdfNDkx_0a716247-3186-4d05-811b-cfd8a23394e0">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.309%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.688%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Net Product Sales in the United States&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EYLEA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,473.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,245.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,604.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Libtayo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Praluent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;REGEN-COV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,530.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evkeeza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ARCALYST&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,279.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,142.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Previously, Sanofi recorded net product sales of Praluent in the United States. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;**&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Antibody:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits in connection with commercialization of antibodies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales-based milestone earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Sanofi research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immuno-oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of losses in connection with commercialization of Libtayo outside the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Sanofi commercial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in connection with up-front payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in our Statements of Operations in connection with our Bayer EYLEA collaboration are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's net profit in connection with commercialization of EYLEA outside the United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Bayer research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in our Statements of Operations in connection with our collaboration with Teva are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in connection with up-front and development milestone payments received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts recognized in our Statements of Operations in connection with the Roche Collaboration Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global gross profit true-up payment owed from Roche in connection with sales of casirivimab and imdevimab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5335858050745058b22cc99a0b825d8_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMi0yLTEtMS0w_78137a7e-86e4-4b16-b14d-278d3780ddea"
      unitRef="usd">1473400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7eb34b902a3d4092a2e3d84fafaf8db3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMi00LTEtMS0w_d792442b-4d5b-4b77-a881-b4a180d0c513"
      unitRef="usd">1318300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12dab876c382416aaa473774a2318a69_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMi02LTEtMS0w_e6d5c31e-51bf-4d73-b56b-8e6c03ebb5e5"
      unitRef="usd">4245100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a1e78634a724621bc14ad6838cb7aaa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMi04LTEtMS0w_c9a8bd2f-5c88-48a0-a53d-5091c56d667d"
      unitRef="usd">3604000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0b4d6b8672847c38f0dba0dde9118a6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMy0yLTEtMS0w_f15e991b-d245-499b-9b91-98f68e921109"
      unitRef="usd">78400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i993e0c30b54544e0a4d7a1785fe7f5ec_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMy00LTEtMS0w_d4b85bfe-8728-4597-a634-cfad181bc6f2"
      unitRef="usd">71600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide588defaf434359bba81a3f3acff2b8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMy02LTEtMS0w_9beafec4-7186-46fd-bdd1-f5ab6e947711"
      unitRef="usd">225500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfb6acb24daa4045bfab3c8c4d9acd34_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfMy04LTEtMS0w_90f9003d-2ccd-44e8-9aee-085d8c1b8651"
      unitRef="usd">196600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id715132664af44b4a97c8f5b2eef6789_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNC0yLTEtMS0w_1a12762e-3671-48f0-b471-6ec8da2d2b6e"
      unitRef="usd">44800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibfdef107afb54ad899df3e57fa9ccb8f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNC00LTEtMS0w_dd219c7b-1472-465b-85c5-3d72a5a6ab27"
      unitRef="usd">48500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ce220d2cde34bf583732793c841cc94_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNC02LTEtMS0w_29efe50e-478f-4a2d-a937-e4c798a6432a"
      unitRef="usd">130000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf31cf4bebfa40e5868081cbe1915ba4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNC04LTEtMS0w_b1f54381-1914-4d04-826e-cf96b57fc524"
      unitRef="usd">95700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedfb0cf9c4594b929abde62607752ef2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNS0yLTEtMS0w_e6c8a3d5-3d70-4739-80c0-8dc1c5a991d5"
      unitRef="usd">676700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia50d948a15194872b1d382957ed144d6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNS00LTEtMS0w_0372addf-9468-41f4-84e1-3caa9c71c34f"
      unitRef="usd">40200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b848f38b8a54f65bd9393c17a2aaed0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNS02LTEtMS0w_598d731c-8403-481c-84f2-38f22d288801"
      unitRef="usd">3530100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if965233833744f19a7d0aba74b97b8d6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNS04LTEtMS0w_2461a87a-ddb0-4ff5-baa3-69ea407766b0"
      unitRef="usd">40200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9771830c61ff46c0ab9a5252ea2be0af_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNi0yLTEtMS0w_c0815aed-4c82-48fc-915b-2b61bbe80756"
      unitRef="usd">6600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4030650199fe4f198ed816c8ab79a91a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNi00LTEtMS0w_bfd97b95-8ab2-4605-9e13-6b9edb927a73"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ebaa7f4723242569b7922152e81345e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNi02LTEtMS0w_4c66e2df-5494-4b26-842c-0e0a0e7a8d05"
      unitRef="usd">9100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19d89574821b49b9bdfa6137bd82652d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNi04LTEtMS0w_31ccf744-d030-46b6-addd-d1050cb5f683"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if04488d631ba4e129b9e0f0fb3558a31_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNy0yLTEtMS0w_c3eb510f-d2a7-4d97-908f-9dcc565a405b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64fcfb6110c74cbe816d03379fae5d1d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNy00LTEtMS0w_9776fa68-ce8b-4468-ab91-fe09d70a9be9"
      unitRef="usd">3600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80f2e762be11477183ef6c02dba52897_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNy02LTEtMS0w_0d523121-c36f-45d6-abc9-c458b4129c20"
      unitRef="usd">2200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39c987382ee344fca75a3010f34022b5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfNy04LTEtMS0w_515284f9-06fa-4f8a-a04b-b92888ceb1c0"
      unitRef="usd">9300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3f29614787e4465a5554d3f160fa259_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfOC0yLTEtMS0w_beb5a98e-0855-48a8-907b-42e8fe375465"
      unitRef="usd">2279900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib58a328c7a1044db991b18bc06aec4ca_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfOC00LTEtMS0w_7d52dfd8-f310-44a8-96fb-7d9f0d15d5bf"
      unitRef="usd">1482200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04e74fae60044b55bf008643f8ce273e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfOC02LTEtMS0w_9875ab96-0f8e-4e0c-b372-b55514b0f341"
      unitRef="usd">8142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f629c0363834da2a784610d8a5403af_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOjc0ZDg5NDY2ZjBiMjQ5ZGRiNTgyMDVjZmFlMGE2NzUzL3RhYmxlcmFuZ2U6NzRkODk0NjZmMGIyNDlkZGI1ODIwNWNmYWUwYTY3NTNfOC04LTEtMS0w_0184fb13-6502-485c-94e8-bcad15ded116"
      unitRef="usd">3945800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id628995c65e443418912b4df46bdf6a1_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RleHRyZWdpb246ZWM5Yzc5YjUxNzUyNGIwZDk1MmI5YzI4N2YxNmNhMTdfMTAx_b07cc301-138d-49ff-8939-51b1f024dc81"
      unitRef="usd">4086000000.000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8bab1de7a18e431086c872b4f16dbf84_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RleHRyZWdpb246ZWM5Yzc5YjUxNzUyNGIwZDk1MmI5YzI4N2YxNmNhMTdfMTA4_00933aa3-6875-46a1-9a95-76f10d2196cd"
      unitRef="usd">3112000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RleHRyZWdpb246ZWM5Yzc5YjUxNzUyNGIwZDk1MmI5YzI4N2YxNmNhMTdfNDg3_78e1a541-7dd1-4efe-bc1b-edff1ad9ae7f">Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Besse Medical, a subsidiary of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; Sales to the U.S. Government represented less than 10% of total gross product revenue during the period.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id1b54518517447e2976804aef2938a70_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMi0yLTEtMS0w_eba38be7-aec1-480d-930f-6f98f11d13ad"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9c91a96c8ea541df9b383e31edb76cdb_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMi00LTEtMS0w_9ded6364-3139-47a3-84d1-9926575a9409"
      unitRef="number">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie9f3623e111f49f58059e4a3c761728b_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMi02LTEtMS0w_af5e7c2b-71a2-4a16-b51d-560cc882ff6c"
      unitRef="number">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic5418f4d22034df899d1576e95d98e46_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMi04LTEtMS0w_34ea94d1-ff11-4e74-a541-623e360dee8a"
      unitRef="number">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i785a29c3adcc4a36be31fef32659e71d_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMy0yLTEtMS0w_4bcee2ad-9b19-4563-a2f5-166de98acc40"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id3e92e56fe7a44e5a31ddecd1964e64a_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMy00LTEtMS0w_8f024ef1-1092-4f4a-b8ed-1aa2117760b3"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie051ae25fb44472e83a56290575ab26c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMy02LTEtMS0w_ca64163c-3847-44eb-be60-be51da0af148"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i486929221d2f42f5919727d4483f7090_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfMy04LTEtMS0w_2623d03c-bc55-4d5d-9fd5-7302f1c79dbb"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if50c4763f6dc43428e8360ca23d39d0d_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfNC0yLTEtMS0w_dae11dca-1ad9-43e0-8d43-800b1c14cdfc"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib5546196bf9d43679e3e52ddbffdfc7e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNC9mcmFnOmVjOWM3OWI1MTc1MjRiMGQ5NTJiOWMyODdmMTZjYTE3L3RhYmxlOmYyNTZkOWJkYmFiOTRkYzc5ZjNiN2Q4YzE5MDA2YThiL3RhYmxlcmFuZ2U6ZjI1NmQ5YmRiYWI5NGRjNzlmM2I3ZDhjMTkwMDZhOGJfNC02LTEtMS0w_c2872fbb-53f0-43b9-8630-f8c094d0bb45"
      unitRef="number">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTE1MzE_1a1e578d-5a09-4c11-8c11-636900a60f4d">Collaboration, License, and Other Agreements&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;a. Sanofi &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Antibody:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of profits in connection with commercialization of antibodies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales-based milestone earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Sanofi research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immuno-oncology:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's share of losses in connection with commercialization of Libtayo outside the United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of commercialization-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Sanofi commercial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in connection with up-front payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antibody&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the "Antibody Collaboration"), which currently consists of Dupixent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (dupilumab), Kevzara&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (sarilumab), and itepekimab&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Antibody License and Collaboration Agreement ("LCA"), Sanofi is generally responsible for funding 80%&#x2013;100% of agreed-upon development costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sanofi leads commercialization activities for products under the Antibody Collaboration, subject to the Company's right to co-commercialize such products. In addition to profit and loss sharing, the Company is entitled to receive sales milestone payments from Sanofi. In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.0&#160;billion on a rolling twelve-month basis. In the third quarter of 2021, the Company earned, and recognized as revenue, the second $50.0&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.5&#160;billion on a rolling twelve-month basis. We are entitled to receive up to an aggregate of $150.0&#160;million in additional sales milestone payments from Sanofi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.502%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the Company and Sanofi entered into an amendment to the LCA in connection with, among other things, the removal of Praluent from the LCA such that (i) effective April 1, 2020, the LCA no longer governs the development, manufacture, or commercialization of Praluent and (ii) the quarterly period ended March 31, 2020 was the last quarter for which Sanofi and the Company shared profits and losses for Praluent under the LCA. The parties also entered into a Praluent Cross License &amp;amp; Commercialization Agreement (the "Praluent Agreement") pursuant to which, effective April 1, 2020, the Company, at its sole cost, became solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, became solely responsible for the development and commercialization of Praluent outside of the United States. Under the Praluent Agreement, Sanofi will pay the Company a 5% royalty on Sanofi&#x2019;s net product sales of Praluent outside the United States until March 31, 2032. The Company will not owe Sanofi royalties on the Company&#x2019;s net product sales of Praluent in the United States. Although each party will be responsible for manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for a certain transitional period, the Company will continue to supply drug substance to Sanofi and Sanofi will continue to supply finished product to Regeneron. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third-party royalty payments resulting from certain patent litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron). The parties will each bear 50% of any damages arising out of Praluent sales or other activities prior to April 1, 2020. See Note 12 for discussion of legal proceedings related to Praluent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Immuno-Oncology &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a collaboration with Sanofi to research, develop, and commercialize antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective December 31, 2018, the Company and Sanofi entered into an Amended and Restated Immuno-oncology Discovery and Development Agreement ("Amended IO Discovery Agreement"), which narrowed the scope of the existing discovery and development activities conducted by the Company under the 2015 IO Discovery Agreement to developing therapeutic bispecific antibodies targeting (i) BCMA and CD3 (the "BCMAxCD3 Program") and (ii) MUC16 and CD3 (the "MUC16xCD3 Program") through clinical proof-of-concept. During the first quarter of 2021, Sanofi did not exercise its options to license rights to these product candidates; as a result, we retain the exclusive right to develop and commercialize such product candidates and Sanofi will receive a royalty on sales (if any). In addition, the Company has no further obligations to develop drug product candidates under the Amended IO Discovery Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Immuno-oncology License and Collaboration Agreement, the parties are co-developing and co-commercializing Libtayo (cemiplimab). The parties share equally, on an ongoing basis, agreed-upon development and commercialization expenses for Libtayo. The Company has principal control over the development of Libtayo and leads commercialization activities in the United States (see Note 2 for related product sales information), while Sanofi leads commercialization activities outside of the United States. The parties share equally in profits and losses in connection with the commercialization of Libtayo.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2021, we updated our estimate of the total research and development costs expected to be incurred (which resulted in a change to the estimate of the stage of completion) in connection with the IO Collaboration, and, as a result, recorded a cumulative catch-up adjustment of $66.9&#160;million as a reduction to other operating income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.941%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.314%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.317%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities include up-front payments received from Sanofi for which recognition has been deferred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the estimated consideration under the IO Collaboration related to the Company's obligation that was unsatisfied (or partially unsatisfied) as of September&#160;30, 2021 was $591.4&#160;million. This amount is expected to be recognized over the remaining period in which the Company is obligated to satisfy its obligation in connection with performing development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;b. Bayer &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a license and collaboration agreement with Bayer for the global development and commercialization of EYLEA outside the United States. All agreed upon EYLEA development expenses incurred by the Company and Bayer are shared equally. Bayer markets EYLEA outside the United States, where, for countries other than Japan, the companies share equally in profits and losses from sales of EYLEA. In Japan, the Company is currently entitled to receive a tiered percentage of between 33.5% and 40.0% of EYLEA net product sales through 2021, and thereafter, the companies will share equally in profits and losses from sales of EYLEA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in our Statements of Operations in connection with our Bayer EYLEA collaboration are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's net profit in connection with commercialization of EYLEA outside the United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement for manufacturing of commercial supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regeneron's obligation for its share of Bayer research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with our Bayer EYLEA collaboration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;c. Teva&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Teva are parties to a collaboration agreement (the "Teva Collaboration Agreement") to develop and commercialize fasinumab globally, excluding certain Asian countries that are subject to our collaboration agreement with Mitsubishi Tanabe Pharma Corporation. The Company leads global development activities, and the parties share development costs equally, on an ongoing basis, under a global development plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized in our Statements of Operations in connection with our collaboration with Teva are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts recognized in connection with up-front and development milestone payments received&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Teva Collaboration Agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities include up-front and development milestone payments received from Teva for which recognition has been deferred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the estimated consideration under the Teva Collaboration Agreement related to the Company's obligation that was unsatisfied (or partially unsatisfied) as of September&#160;30, 2021 was $96.7&#160;million. This amount is expected to be recognized over the remaining period in which the Company is obligated to satisfy its obligation in connection with performing development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;d. U.S. Government &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;REGEN-COV (casirivimab and imdevimab)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, we announced an expansion of our Other Transaction Agreement with the Biomedical Advanced Research Development Authority ("BARDA"), pursuant to which the U.S. Department of Health and Human Services ("HHS") was obligated to fund certain of our costs incurred for research and development activities related to COVID-19 treatments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, we entered into an agreement with entities acting at the direction of BARDA and the U.S. Department of Defense to manufacture and deliver filled and finished drug product of REGEN-COV to the U.S. government. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company announced an agreement with an entity acting on behalf of the U.S. Department of Defense and HHS to manufacture and deliver additional filled and finished drug product of REGEN-COV to the U.S. government. Pursuant to the agreement, the U.S. government was obligated to purchase the 1.25&#160;million doses of drug product that we delivered by June 30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has completed its final deliveries of drug product under the agreements described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company announced an amendment to its January 2021 agreement to supply the U.S. government with an additional 1.4&#160;million doses of REGEN-COV. Pursuant to the agreement, the U.S. government is obligated to purchase all filled and finished doses of such additional drug product delivered by January 31, 2022, resulting in payments to the Company of up to $2.940&#160;billion in the aggregate. Additionally, Roche will supply a portion of the doses to Regeneron to fulfill our agreement with the U.S. government (see "Roche" below for further details regarding our collaboration agreement with Roche).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 2 for REGEN-COV net product sales recognized in connection with these agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;e. Roche&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020, we entered into a collaboration agreement (the "Roche Collaboration Agreement") with Roche to develop, manufacture, and distribute the casirivimab and imdevimab antibody cocktail (known as REGEN-COV in the United States and Ronapreve&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; in other countries). We lead global development activities for casirivimab and imdevimab, and the parties jointly fund certain ongoing studies, as well as any mutually agreed additional new global studies to evaluate further the potential of casirivimab and imdevimab in treating or preventing COVID-19. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under the terms of the agreement, each party is obligated to dedicate a certain amount of manufacturing capacity to casirivimab and imdevimab each year. We distribute the product in the United States and Roche distributes the product outside of the United States. The parties share gross profits from worldwide sales based on a pre-specified formula, depending on the amount of manufactured product supplied by each party to the market. Each quarter, a single payment is due from one party to the other to true-up the global gross profits between the parties. If Regeneron is to receive a true-up payment from Roche, such amount will be recorded to Collaboration revenue. If Regeneron is to make a true-up payment to Roche, such amount will be recorded to Cost of goods sold.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts recognized in our Statements of Operations in connection with the Roche Collaboration Agreement are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global gross profit true-up payment owed from Roche in connection with sales of casirivimab and imdevimab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement of research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Roche Collaboration Agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;f. Intellia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2016, we entered into a license and collaboration agreement with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; therapeutic development. The parties collaborate to conduct research for the discovery, development, and commercialization of new therapies, in addition to the research and technology development of the CRISPR/Cas9 platform.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2020, we expanded our existing collaboration with Intellia to provide us with rights to develop products for additional &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; CRISPR/Cas9-based therapeutic targets and for the parties to jointly develop potential products for the treatment of hemophilia A and B. In addition, we also received non-exclusive rights to independently develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; gene edited products. In connection with the agreement, we made a $70.0&#160;million up-front payment and purchased shares of Intellia common stock for an aggregate purchase price of $30.0&#160;million. The up-front payment and the amount paid in excess of the fair market value of the shares purchased, or $15.0&#160;million, were recorded to Research and development expense during the three months ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifded74cc07f44048a2c104e76b70e48e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMy00LTEtMS0w_486f0c5d-9e80-454b-a4fa-a02403ccdd9b"
      unitRef="usd">387000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58ac074fe6864f70ba50e4e7c6e81c9b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMy02LTEtMS0w_e05615ee-7b3a-4762-ac52-b711bf8fc8d6"
      unitRef="usd">212800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86244a8c59904b46967de22d14ea53dd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMy04LTEtMS0w_384c00e3-ff7c-48a1-9422-7b281c6fd50d"
      unitRef="usd">975200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a1190ae8ab3474b9e2213bc83518d76_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMy0xMC0xLTEtMA_d7bc0223-fb1e-4ad6-93f0-b58681ec0d57"
      unitRef="usd">555600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0fffea9317f417ba61a67279b657180_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC00LTEtMS0yNTI_829ab6f0-331a-4840-a93e-e1a3e886e174"
      unitRef="usd">50000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12aa7e5e1d7b416bb27fbac0ea8d1e88_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC02LTEtMS0yNTI_1265a6ef-b843-41e1-96db-ed3e03c4c1b0"
      unitRef="usd">50000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibeab61feac444da7a016dd64df872cd9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC04LTEtMS0yNTI_22460544-a30d-4bab-8ded-d61895782517"
      unitRef="usd">50000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i563d16d0ea8f4b1ea8c10c797482d489_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC0xMC0xLTEtMjUy_f5e68efc-94e4-4706-aeff-967469de908b"
      unitRef="usd">50000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad7689d0635c4905af67a87b5aaa5f3a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC00LTEtMS0w_546d7f8c-dbd4-4fd9-a093-35b6a689e0f6"
      unitRef="usd">144700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1aa5f2b1cbb14dbf9d951201819f5db2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC02LTEtMS0w_f871b6bf-d907-4629-940e-c532305e1c9c"
      unitRef="usd">94300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb5b96ecbed1428ab26d61c8aa6e8b67_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC04LTEtMS0w_3fd3d904-1858-4031-b8d2-4495489e5d0a"
      unitRef="usd">361200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i554ab772b5d0462a803c80fd10072849_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNC0xMC0xLTEtMA_b2616010-124e-42aa-9e74-ae563537849d"
      unitRef="usd">275000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d920ab6a62942aab7073efd72dacef2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNS00LTEtMS0w_d606209f-d60e-455c-b70c-d07259fdf03a"
      unitRef="usd">45200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94b188b561e248948e1916e16ec1f0f3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNS02LTEtMS0w_28a055ab-12c1-4bb5-95e1-350a6d60bb54"
      unitRef="usd">45500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f4316365c63469e84bbdb4402df49fa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNS04LTEtMS0w_ec0d102f-2b7e-4af2-a182-ab19d41d68e9"
      unitRef="usd">122300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7a9b2764717433a815608cd7e18b125_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNS0xMC0xLTEtMA_03c39598-6665-4034-80d5-40d5a4bb7161"
      unitRef="usd">174400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i791e6e6420e54c049daf6dd49164145f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNi00LTEtMS0w_6c39f23d-a6bd-4876-99ed-d156bc8b6fa4"
      unitRef="usd">-10300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic370d9cb5fd24bf799cbdf2177dacd50_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNi02LTEtMS0w_5c259783-7063-4939-9bd7-2790d00f6de4"
      unitRef="usd">-17500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e36a0ccdeb14ec984f4085858cbc3ee_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNi04LTEtMS0w_aebeebae-eb2e-4b06-96ab-1e806315c023"
      unitRef="usd">-32800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if02ac5fb5d2f4310931908004cbf9aa0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNi0xMC0xLTEtMA_2b4d8f19-ae30-466d-9980-9376595166d1"
      unitRef="usd">-59100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1800f040ae0e4df991d07fe38d222324_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNy00LTEtMS0w_7e77d240-9dd7-4203-9d60-20e75cd8dfa0"
      unitRef="usd">79000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9efebbfd0f048c990bcc09d5b26f8c5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNy02LTEtMS0w_edc88260-e0cc-4987-984d-62a844c073e3"
      unitRef="usd">83200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4f2a3dc80794091ae61e4de88cdbc43_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNy04LTEtMS0w_51fed96a-7ace-439d-beb1-fd6d9ed097be"
      unitRef="usd">216900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide6a2ab36d5d4e759f8c6fe1ecff6f01_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfNy0xMC0xLTEtMA_cda90c81-0685-48ab-ac04-28b9b5e280b0"
      unitRef="usd">260400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41696d03ccef49c2bf26d35317b03caa_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTAtNC0xLTEtMA_ee2e40ba-1d88-43c6-8d16-789b4eb7f91a"
      unitRef="usd">-3000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica632ffb58b44d6194988501bb54fc73_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTAtNi0xLTEtMA_f306c402-5ae0-4122-a5ce-2042ed18c7b6"
      unitRef="usd">-4700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3081e3ffc7954b088fc9cb4152e95c85_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTAtOC0xLTEtMA_016f9ec8-a69e-4c6d-a58e-808b65fd1a9a"
      unitRef="usd">-12600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bbc219c44fc46859865214fb8165394_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTAtMTAtMS0xLTA_db41855e-2116-4174-bf03-f421c14048fa"
      unitRef="usd">-17300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i546b0b3a556d452f8e64404ed081302b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTEtNC0xLTEtMA_ae501424-670a-4d37-b253-1e33b71e1819"
      unitRef="usd">3100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacfc81b93d7b4b4f8c6d7d4593e9dace_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTEtNi0xLTEtMA_4fe77cea-32dc-44f2-afc9-bf9c34d6cf62"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c484984a09a4caaa0b9d6543ec482d5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTEtOC0xLTEtMA_016b85ed-d136-467f-b675-4e136896ee88"
      unitRef="usd">10500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i419f91c33865447b9e9338dab3f66b55_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTEtMTAtMS0xLTA_9690ef0a-0d70-4324-a96e-50257c43a808"
      unitRef="usd">6000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6fc47b747054dab86fa5a363336c85e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTItNC0xLTEtMA_22985a48-7737-4339-be92-67d15948b689"
      unitRef="usd">21800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i449513f8039f41138f8e72756af57c6d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTItNi0xLTEtMA_e9bd6e07-02bf-4ced-a113-aa7c091df327"
      unitRef="usd">49800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb63ff75d0aa4f96af3798e301bd5bf6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTItOC0xLTEtMA_13533d36-f2f6-4e01-b110-e8cb163dc328"
      unitRef="usd">66200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e787fec51894471bcabbf60f6051058_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTItMTAtMS0xLTA_236409ee-afd2-4b22-83ca-21539fbabc12"
      unitRef="usd">136700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a756b10359641988b7f46edddeec13a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTMtNC0xLTEtMA_c0af4ecf-1705-4ec5-b011-b977a50ad9d3"
      unitRef="usd">22800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53cb49561acd4537ba93ba5db20eb4f0_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTMtNi0xLTEtMA_58081bf3-2a65-42a2-814e-53996bfb302c"
      unitRef="usd">14500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b548827d54647c9ad6d75a0d12bb79f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTMtOC0xLTEtMA_f8c741f9-2053-49cd-ac38-4f0a5d5bdcd1"
      unitRef="usd">62000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icea40f4714334f43b2a0bc4763fd6bb4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTMtMTAtMS0xLTA_20be7d3d-6179-4f57-a3cb-8a993f2c2fca"
      unitRef="usd">39200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ddacad667a94b23ac241aa7301b853a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTQtNC0xLTEtMA_3fb35e63-949f-4a81-8884-eb183fc59303"
      unitRef="usd">-9400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5df0acd0f02348d3ba5d9669e15f2adb_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTQtNi0xLTEtMA_e74568ae-d21e-40d8-95ee-a0d9c71291db"
      unitRef="usd">-6100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib604dcd13e224121adb3a5c3b372b125_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTQtOC0xLTEtMA_b03575c0-66c9-4ae6-89dc-f4ecb8fafe81"
      unitRef="usd">-28000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f6f1c8c4538460cb2956cf9359d3cae_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTQtMTAtMS0xLTA_b8a59a24-e065-49d1-a068-3f920f7477ab"
      unitRef="usd">-15000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16ef0dd09ff34bd9832c510c5fcb9394_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTUtNC0xLTEtMA_3c8187cc-7faa-40b5-9348-55081f81c2d3"
      unitRef="usd">-34600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3caafefa1d954278ad93efec805163b1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTUtNi0xLTEtMA_3caf5d7c-1216-4d5b-a856-8a1d2b67de85"
      unitRef="usd">-31500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27a6f9b6cec64cddae7a84326e0b5ffe_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTUtOC0xLTEtMA_236e1b65-978a-438d-90fa-d7b2e2b4cce1"
      unitRef="usd">-99400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7383412bc7ac4797bad32eb100cb0abb_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTUtMTAtMS0xLTA_c7161a3d-9c20-4a70-9a32-5736fd3f0d05"
      unitRef="usd">-86500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08ef15ce810b475c803431262514e1e9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTYtNC0xLTEtMA_5c819c9b-cfe9-45bf-87b1-fe443eb0edde"
      unitRef="usd">-47700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f689f71f8a240b2a33290b4e3bfa31b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTYtNi0xLTEtMA_34efef30-f95a-43ca-a132-646970559b47"
      unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65d333ff83094f148e490ee53841f02f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTYtOC0xLTEtMA_f988f3e7-9e90-4546-9574-8c6c5d862bd1"
      unitRef="usd">-4100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad6e8d74360c4e38b0f7e558981f7f7f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmJkYzUwMmRkZTA1NTQwMDI4MzVlNDlkYzc0NWYzODkzL3RhYmxlcmFuZ2U6YmRjNTAyZGRlMDU1NDAwMjgzNWU0OWRjNzQ1ZjM4OTNfMTYtMTAtMS0xLTA_090e3e51-5527-4499-ba9b-1e2fa1d3699c"
      unitRef="usd">57000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty
      contextRef="i4a5801eab8e4442a8423dca2e534dad1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNTgz_3fb0ae5b-8ec8-4929-8e1b-3f7bd5ca488b"
      unitRef="number">0.80</regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty>
    <regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty
      contextRef="i5a8ed766d24e4af78c21550a7b7302a3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNTg2_40721e6f-0f2b-4764-a779-2da9b795606c"
      unitRef="number">1</regn:PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7432bde3ff84eafbcfb0af4b10fa31f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTY0OTI2NzQ1NDIwMA_5382393f-8380-4794-9c4b-a8fa7deca112"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived
      contextRef="i78fb2bfa7e774e23970aa2139ee245db_D20200101-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTY0OTI2NzQ1NDI2Nw_76843a6e-2875-4030-90b9-d79e16b7a685"
      unitRef="usd">1000000000</regn:LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived>
    <regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
      contextRef="i78fb2bfa7e774e23970aa2139ee245db_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNDM5ODA0NjUyNDA5NQ_7b03e6dc-647b-4774-b530-d1d44c804b6e">P12M</regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75cfc29b08e54dbcb23f41eeb66d7d5e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTY0OTI2NzQ1NDU3Ng_32763bed-4fc8-449c-b134-19040d74951f"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived
      contextRef="i44705b78f91d457fb2bee63fb813ff55_D20210101-20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTY0OTI2NzQ1NDYwNA_eda93b35-dbb4-45b4-ab81-4022d84c307f"
      unitRef="usd">1500000000</regn:LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived>
    <regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
      contextRef="i44705b78f91d457fb2bee63fb813ff55_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNDM5ODA0NjUyNDA4Mg_601a3bfa-7185-439c-adca-fe4b63a3a3af">P12M</regn:PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis>
    <regn:RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels
      contextRef="i44705b78f91d457fb2bee63fb813ff55_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTY0OTI2NzQ1NDIzMA_2b652e0c-e6e7-4851-ac28-3454f5d72aff"
      unitRef="usd">150000000</regn:RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTE1MzM_a322bbad-e34c-435b-8a0e-180c784f9be4">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.502%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.941%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.314%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.317%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with our Bayer EYLEA collaboration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Teva Collaboration Agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes contract balances in connection with the Roche Collaboration Agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.511%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if9483a9e8f5b474ea373471543f0536b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFkZWI3ZTQzOGQ2NDQyMGFiZmJmNzNmNjQzYzM2OGM4L3RhYmxlcmFuZ2U6YWRlYjdlNDM4ZDY0NDIwYWJmYmY3M2Y2NDNjMzY4YzhfMi0yLTEtMS0w_43851c5f-d996-4937-a2ef-1cbd6c30f5b2"
      unitRef="usd">536000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibf63d465ccd3423187f9af7e8b4bc7e1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFkZWI3ZTQzOGQ2NDQyMGFiZmJmNzNmNjQzYzM2OGM4L3RhYmxlcmFuZ2U6YWRlYjdlNDM4ZDY0NDIwYWJmYmY3M2Y2NDNjMzY4YzhfMi00LTEtMS0w_aefa6a0f-734a-4231-b939-32a491bc1b49"
      unitRef="usd">407700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if9483a9e8f5b474ea373471543f0536b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFkZWI3ZTQzOGQ2NDQyMGFiZmJmNzNmNjQzYzM2OGM4L3RhYmxlcmFuZ2U6YWRlYjdlNDM4ZDY0NDIwYWJmYmY3M2Y2NDNjMzY4YzhfMy0yLTEtMS0w_67851fd5-b3c3-4657-9a31-c5747e3e1bbb"
      unitRef="usd">431700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibf63d465ccd3423187f9af7e8b4bc7e1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFkZWI3ZTQzOGQ2NDQyMGFiZmJmNzNmNjQzYzM2OGM4L3RhYmxlcmFuZ2U6YWRlYjdlNDM4ZDY0NDIwYWJmYmY3M2Y2NDNjMzY4YzhfMy00LTEtMS0w_24175dfb-2f68-4cd2-af5f-665691dad5a9"
      unitRef="usd">347700000</us-gaap:ContractWithCustomerLiability>
    <regn:RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates
      contextRef="i182dd47bcec04ee292243a30a58dea41_D20200401-20200401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTk0MQ_9a4fab45-1a4e-4173-a728-fc4078a707b1"
      unitRef="number">0.05</regn:RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates>
    <regn:PercentageOfRoyaltyPaymentThatCanBeOffset
      contextRef="i814fd946f5074904942acc5d9194d0fb_D20200401-20200401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMzA2Mw_29616a49-8652-4d20-9686-8d19fa6ced71"
      unitRef="number">0.50</regn:PercentageOfRoyaltyPaymentThatCanBeOffset>
    <regn:LossContingencyPercentageOfDamagesResponsibleFor
      contextRef="i182dd47bcec04ee292243a30a58dea41_D20200401-20200401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMzE0NQ_8f5f175d-813a-4a9e-bddc-ff676249d99c"
      unitRef="number">0.50</regn:LossContingencyPercentageOfDamagesResponsibleFor>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="i89ca366da43e409298cf61eea017813d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTY0OTI2NzQ1ODI5Ng_fdc04352-2a1d-4228-9ed3-5bd6a2f26b9e"
      unitRef="usd">66900000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie9bfe175438f49a9be01e98bcc545764_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjkyZTNhOGQxMDFjMTRmMTQ5NzgzYmMxZTExMTkzZTg4L3RhYmxlcmFuZ2U6OTJlM2E4ZDEwMWMxNGYxNDk3ODNiYzFlMTExOTNlODhfMi0yLTEtMS0w_3fb5cafd-ce14-4ce5-9025-83d8b15d8b74"
      unitRef="usd">100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iebfd12dc45514f458d53a2791ef44ec9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjkyZTNhOGQxMDFjMTRmMTQ5NzgzYmMxZTExMTkzZTg4L3RhYmxlcmFuZ2U6OTJlM2E4ZDEwMWMxNGYxNDk3ODNiYzFlMTExOTNlODhfMi00LTEtMS0w_9e074112-a7eb-4f84-9505-bb96bd250c14"
      unitRef="usd">6500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie9bfe175438f49a9be01e98bcc545764_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjkyZTNhOGQxMDFjMTRmMTQ5NzgzYmMxZTExMTkzZTg4L3RhYmxlcmFuZ2U6OTJlM2E4ZDEwMWMxNGYxNDk3ODNiYzFlMTExOTNlODhfMy0yLTEtMS0w_f950cce6-ba75-4232-a325-0b02f469678c"
      unitRef="usd">16200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iebfd12dc45514f458d53a2791ef44ec9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjkyZTNhOGQxMDFjMTRmMTQ5NzgzYmMxZTExMTkzZTg4L3RhYmxlcmFuZ2U6OTJlM2E4ZDEwMWMxNGYxNDk3ODNiYzFlMTExOTNlODhfMy00LTEtMS0w_5ee74d92-773c-4308-8d76-f1c8f6ed3e16"
      unitRef="usd">10700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:OtherLiabilities
      contextRef="ie9bfe175438f49a9be01e98bcc545764_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjkyZTNhOGQxMDFjMTRmMTQ5NzgzYmMxZTExMTkzZTg4L3RhYmxlcmFuZ2U6OTJlM2E4ZDEwMWMxNGYxNDk3ODNiYzFlMTExOTNlODhfNC0yLTEtMS0w_e04574fb-c675-4657-93de-b913b961a8e8"
      unitRef="usd">286000000.0</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="iebfd12dc45514f458d53a2791ef44ec9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjkyZTNhOGQxMDFjMTRmMTQ5NzgzYmMxZTExMTkzZTg4L3RhYmxlcmFuZ2U6OTJlM2E4ZDEwMWMxNGYxNDk3ODNiYzFlMTExOTNlODhfNC00LTEtMS0w_37ee6d38-4e1e-4646-881f-713650b66560"
      unitRef="usd">280900000</us-gaap:OtherLiabilities>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ie9bfe175438f49a9be01e98bcc545764_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNTUwOQ_b043b584-0343-4f32-8202-444b241e62bf"
      unitRef="usd">591400000</us-gaap:RevenueRemainingPerformanceObligation>
    <regn:RevenueBasedOnPercentageOfAnnualSalesInJapan
      contextRef="i509963cbbe784be8973a31df2b9a8963_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNjIwMg_0a1e6d39-6449-4acb-a2b2-d441ec00b8db"
      unitRef="number">0.335</regn:RevenueBasedOnPercentageOfAnnualSalesInJapan>
    <regn:RevenueBasedOnPercentageOfAnnualSalesInJapan
      contextRef="ia985bae849b44c219201a836f385ce29_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNjIwOQ_c0ecaffe-d1f1-4bae-b655-52d05de0fec3"
      unitRef="number">0.400</regn:RevenueBasedOnPercentageOfAnnualSalesInJapan>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1ba982dde844a9c82475e880a5f75f0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMi00LTEtMS0w_3f88ae2d-7f3a-4500-b8d4-35b4d8111618"
      unitRef="usd">351000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i955142d326434513a46962fe495e0fa1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMi02LTEtMS0w_7852dd04-5a38-47a2-99d6-cec76d60478a"
      unitRef="usd">287900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idaee3d49fec54b8a9e5fd65ae301bee3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMi04LTEtMS0w_0e78034b-b509-461d-b69b-2a51ff2dec89"
      unitRef="usd">995300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i402f7f4cd8f04e6497716ec2e663706b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMi0xMC0xLTEtMA_61bca3bb-1a9e-478d-b369-9f3f69f41f8f"
      unitRef="usd">772600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e46aceade444644b9dd70d4cecbf25b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMy00LTEtMS0w_4808ca9c-bcb6-4c28-86fe-88f40eabfee4"
      unitRef="usd">14000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if94b654450124728b790785f2b2cde12_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMy02LTEtMS0w_a911ff58-c41b-423d-b3dd-d906dd98383c"
      unitRef="usd">12000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4e41d48528d49caae8c91f124239822_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMy04LTEtMS0w_bfe8a144-e796-457b-a71c-ea6c88b31359"
      unitRef="usd">41600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2bf015dbfa7438092254a9cd1ea14ed_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfMy0xMC0xLTEtMA_6ad5dccd-ebfa-47fc-989f-03cb465aeb3d"
      unitRef="usd">52900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf88f57a03b140b780d64166b452794e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNC00LTEtMS0w_3d4082fe-b70c-4158-a926-daa20e18aae1"
      unitRef="usd">14500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ae6fd17f82a4bb6bdbe987bc274fbb2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNC02LTEtMS0w_fa7ccf25-bafe-4021-aa85-c35846ec1991"
      unitRef="usd">11500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5353a1ff784f4cf18d143c0765148747_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNC04LTEtMS0w_d39000b5-dacd-47ba-8bfd-9a1b35909aff"
      unitRef="usd">35200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i073ce9da231842b3b7cd60b5bf3ca507_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNC0xMC0xLTEtMA_2e28e33f-790d-4cb2-889d-9645ba205fa5"
      unitRef="usd">34300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i381b143df0d94c9a86aa2eeae5839128_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNS00LTEtMS0w_56365848-131c-41df-bafd-1eadf3f24ee2"
      unitRef="usd">-8000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11dfc2547ca74cfc84608cbde114c10d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNS02LTEtMS0w_e3da19c6-120b-43e4-a88f-46aec5d90799"
      unitRef="usd">-12900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc5f19126e9840eb9029c6f52c25185b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNS04LTEtMS0w_9073ec92-4764-43a4-b8a1-3c3b0fabaf8c"
      unitRef="usd">-31400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa62c40f54c54ca1ad0abe0e53b2a453_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOjQwZjVmZDhmNGI5NjRmMjg4ZjJjMDQ4NjQ5YjIxNTNlL3RhYmxlcmFuZ2U6NDBmNWZkOGY0Yjk2NGYyODhmMmMwNDg2NDliMjE1M2VfNS0xMC0xLTEtMA_1b46d63b-0fb9-4ac9-834d-6c5e1e0f89e3"
      unitRef="usd">-26300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2d7420067c744c329c85c868130a6ded_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmM3MzhhOTFhY2Q5MzQ4MjA4MmQwZTMxNGEzMmIwMWQ3L3RhYmxlcmFuZ2U6YzczOGE5MWFjZDkzNDgyMDgyZDBlMzE0YTMyYjAxZDdfMi0yLTEtMS0w_e41d8b79-5d10-4b96-9b3c-26aa765aed87"
      unitRef="usd">374800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9a1d208f0eb4428db5488e7d8ed9b2f0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmM3MzhhOTFhY2Q5MzQ4MjA4MmQwZTMxNGEzMmIwMWQ3L3RhYmxlcmFuZ2U6YzczOGE5MWFjZDkzNDgyMDgyZDBlMzE0YTMyYjAxZDdfMi00LTEtMS0w_eb607fb3-f003-4bb0-b386-2671d05b735e"
      unitRef="usd">336200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2d7420067c744c329c85c868130a6ded_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmM3MzhhOTFhY2Q5MzQ4MjA4MmQwZTMxNGEzMmIwMWQ3L3RhYmxlcmFuZ2U6YzczOGE5MWFjZDkzNDgyMDgyZDBlMzE0YTMyYjAxZDdfMy0yLTEtMS0w_2446c26f-e2ba-4bb8-909b-6a58a4db3655"
      unitRef="usd">115200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i9a1d208f0eb4428db5488e7d8ed9b2f0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmM3MzhhOTFhY2Q5MzQ4MjA4MmQwZTMxNGEzMmIwMWQ3L3RhYmxlcmFuZ2U6YzczOGE5MWFjZDkzNDgyMDgyZDBlMzE0YTMyYjAxZDdfMy00LTEtMS0w_16da0a6e-5e07-4680-b3b4-24b40d5dd2d1"
      unitRef="usd">99700000</us-gaap:ContractWithCustomerLiability>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="ie6533a61e5ab4ad3a159b912aa4b022e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMi00LTEtMS0w_bda3f296-8cdb-4edc-a795-21389dcb475d"
      unitRef="usd">5100000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="ib3fe6a3db0be4a5184a1b7acc80f29d7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMi02LTEtMS0w_3a9aebcd-d5a7-4980-bdb3-92fa13dc20a6"
      unitRef="usd">25900000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="i86b44f35ec1c46cabb41e44d2197b227_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMi04LTEtMS0w_c9540a61-057e-4440-9f96-5750a9318038"
      unitRef="usd">36600000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="id21ae34bc9b64b5796aa956e68521d55_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMi0xMC0xLTEtMA_c3df6a00-ebb6-4dee-b3de-f9e2e7c6b3d1"
      unitRef="usd">82100000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <us-gaap:OtherOperatingIncome
      contextRef="i784465fd68bc485f93061c14f0464626_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMy00LTEtMS0w_813e2a46-6e9d-4035-83e2-ffdf17955697"
      unitRef="usd">3200000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i20d13d4e4a7241f7b1b59f2578dfa67c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMy02LTEtMS0w_6ecc8737-ea3c-4b3e-aded-0ef68c5f6df4"
      unitRef="usd">17200000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="ia7d0836ec7e74c33926c74712109896c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMy04LTEtMS0w_a6abbf42-b61f-4f37-a18e-abb65832aae0"
      unitRef="usd">22600000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="ice301c2478284e1590cd4fe592b2d490_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmZiY2MzYzVmNDEzMjRiOTNiYmEzMjNmMTU1Y2RjNThlL3RhYmxlcmFuZ2U6ZmJjYzNjNWY0MTMyNGI5M2JiYTMyM2YxNTVjZGM1OGVfMy0xMC0xLTEtMA_d870eb85-6b13-4687-8db2-0f2e09157231"
      unitRef="usd">54500000</us-gaap:OtherOperatingIncome>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic802850933a14320a118ce1085b1dbcc_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFjOWNiOTI1ZjA4ODQxZDk4NjVkMTI3ZjRkNmMwZWQzL3RhYmxlcmFuZ2U6YWM5Y2I5MjVmMDg4NDFkOTg2NWQxMjdmNGQ2YzBlZDNfMi0yLTEtMS0w_16a663ac-e872-4fa3-a954-2abb20d662d2"
      unitRef="usd">5200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i64f2394a4ea74ae88bf23a677f4f957f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFjOWNiOTI1ZjA4ODQxZDk4NjVkMTI3ZjRkNmMwZWQzL3RhYmxlcmFuZ2U6YWM5Y2I5MjVmMDg4NDFkOTg2NWQxMjdmNGQ2YzBlZDNfMi00LTEtMS0w_8cd3128c-c296-4903-9e27-e4a98a704ea4"
      unitRef="usd">27700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherLiabilities
      contextRef="ic802850933a14320a118ce1085b1dbcc_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFjOWNiOTI1ZjA4ODQxZDk4NjVkMTI3ZjRkNmMwZWQzL3RhYmxlcmFuZ2U6YWM5Y2I5MjVmMDg4NDFkOTg2NWQxMjdmNGQ2YzBlZDNfMy0yLTEtMS0w_ed9dc6bb-39d2-4ed3-8a6b-2892a44726aa"
      unitRef="usd">43300000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="i64f2394a4ea74ae88bf23a677f4f957f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmFjOWNiOTI1ZjA4ODQxZDk4NjVkMTI3ZjRkNmMwZWQzL3RhYmxlcmFuZ2U6YWM5Y2I5MjVmMDg4NDFkOTg2NWQxMjdmNGQ2YzBlZDNfMy00LTEtMS0w_6ab38d33-ad1e-4e96-9643-2c3c301e8aac"
      unitRef="usd">66800000</us-gaap:OtherLiabilities>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ic802850933a14320a118ce1085b1dbcc_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNzUzNw_63895566-2557-407b-86c1-10c017950699"
      unitRef="usd">96700000</us-gaap:RevenueRemainingPerformanceObligation>
    <regn:CollaborativeArrangementNumberOfDosesCounterpartyToPurchase
      contextRef="ie940f37df2c049fd89c26eaeab0debe8_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNDM5ODA0NjUyNzM2NA_2e0d947c-0b04-4ea1-ab5d-ef0279f2f572"
      unitRef="dose">1250000</regn:CollaborativeArrangementNumberOfDosesCounterpartyToPurchase>
    <regn:CollaborativeArrangementNumberOfDosesCounterpartyToPurchase
      contextRef="i7f04700578124cab99fe2de9a5db10bc_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfNDM5ODA0NjUyMzI0OA_39f9d660-7d18-4a54-8a31-8c28b85dcb34"
      unitRef="dose">1400000</regn:CollaborativeArrangementNumberOfDosesCounterpartyToPurchase>
    <regn:MaximumTransactionAgreementPayments
      contextRef="i859fc8964b6340f8bf9073e37098a30a_D20220131-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTQyOTM2NTExNzQ1MTM_77220b72-a330-402e-96b5-daa33b87300a"
      unitRef="usd">2940000000</regn:MaximumTransactionAgreementPayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27c9ab022abc478d8f79666d02a78330_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMi00LTEtMS0w_6456e61c-00fc-4152-9664-ffacdc323feb"
      unitRef="usd">127100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fcf5bf64c5f4e23b07547fddb4834c1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMi02LTEtMS0w_111c06e0-34c1-4274-ba18-33f9391463c2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idae7c39276e247b99aa741d38663bd97_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMi04LTEtMS0w_13730cb0-ff3b-4925-8086-4664d16f410f"
      unitRef="usd">361800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie439420bfacb4ac3a711d43c21ed2b7a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMi0xMC0xLTEtMA_e6b91bd4-b446-4559-b4ed-a996915f5f53"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="i7481e994a8ef47a4bc764250f091d6be_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMy00LTEtMS0w_a1ed9509-1246-47fa-8e65-f4f4111a5a64"
      unitRef="usd">10500000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="id222f9b1cb5248d9bc897bf0e1e74fad_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMy02LTEtMS0w_8dddc900-9160-4e9c-a8c1-b3c5e71896c3"
      unitRef="usd">9500000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="i820df2abc71243a09f1e9d12e9631bf0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMy04LTEtMS0w_dd72e9f9-83ca-4edb-88e6-48abc6571406"
      unitRef="usd">138300000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <regn:ReimbursementOfResearchAndDevelopmentExpense
      contextRef="ic40440c4c14b457ebef02ad35de7b6ee_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmE1OTAxMGIxODM2YzRjYzc4MTJkNjMwZmI1YzBlOTk3L3RhYmxlcmFuZ2U6YTU5MDEwYjE4MzZjNGNjNzgxMmQ2MzBmYjVjMGU5OTdfMy0xMC0xLTEtMA_1f2b082b-50d5-493a-8cdf-23c53e2f3135"
      unitRef="usd">9500000</regn:ReimbursementOfResearchAndDevelopmentExpense>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8a7ab84ea29f4779b5a42b782dc5859e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmY4Y2ZiZGJhMjQ4MDQwOWU4NzhjYmY2NWJkNThiMTI0L3RhYmxlcmFuZ2U6ZjhjZmJkYmEyNDgwNDA5ZTg3OGNiZjY1YmQ1OGIxMjRfMi0yLTEtMS0w_71e9542b-9290-4648-a0d7-dc3d066a1fb2"
      unitRef="usd">305500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i70d249e67e354239b79dd039bbf41c79_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RhYmxlOmY4Y2ZiZGJhMjQ4MDQwOWU4NzhjYmY2NWJkNThiMTI0L3RhYmxlcmFuZ2U6ZjhjZmJkYmEyNDgwNDA5ZTg3OGNiZjY1YmQ1OGIxMjRfMi00LTEtMS0w_e594eeba-2e83-45a6-af56-0bc9a685a00a"
      unitRef="usd">77100000</us-gaap:AccountsReceivableNetCurrent>
    <regn:CollaborativeArrangementUpfrontPaymentMade
      contextRef="ibe25403ae1ba406b8be348b085927476_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTEyMTU_98745076-7424-46c3-b674-6d1a597aab78"
      unitRef="usd">70000000</regn:CollaborativeArrangementUpfrontPaymentMade>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="i171b9fb71e894402b6278e0d6cf6ed66_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTEzMTk_5928dcca-0a49-4f89-aba9-380f9f0ed603"
      unitRef="usd">30000000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibe25403ae1ba406b8be348b085927476_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl8zNy9mcmFnOmJhOTM3Y2U1OGY3NDRkZmFhZDllMTJkZjliZWU0OWJiL3RleHRyZWdpb246YmE5MzdjZTU4Zjc0NGRmYWFkOWUxMmRmOWJlZTQ5YmJfMTE0Mjc_8e40b1be-3f33-4253-9216-51ba2040cc2c"
      unitRef="usd">15000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RleHRyZWdpb246MjJjMDkyM2QwMjA1NGFiNWEyMGU4ZjZmZDIzZDNiZTlfNzU4_4aadcd1f-b17c-40a9-8173-e49f01bbf624">Net Income Per Share &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per share is computed by dividing net income by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net income per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. Diluted net income per share includes the potential dilutive effect of other securities as if such securities were converted or exercised during the period, when the effect is dilutive. The calculations of basic and diluted net income per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.799%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,846.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards and restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RleHRyZWdpb246MjJjMDkyM2QwMjA1NGFiNWEyMGU4ZjZmZDIzZDNiZTlfNzUx_dc871e95-f843-4c58-b6b3-3aeb3ca9b964">The calculations of basic and diluted net income per share are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.799%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,846.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards and restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMi0yLTEtMS0w_ee022e32-6bc1-4cf4-8f63-5f3df5121b91"
      unitRef="usd">1632200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMi00LTEtMS0w_9736ea86-8f84-4538-81ff-322a0e89821c"
      unitRef="usd">842100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMi02LTEtMS0w_fc487412-161b-4c25-888b-1a5babdb19a0"
      unitRef="usd">5846300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMi04LTEtMS0w_148d4856-7902-4d9b-84fc-2c8cf101e6cc"
      unitRef="usd">2364000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNC0yLTEtMS0w_dac0c0c9-04dc-4291-a564-15ef45b678df"
      unitRef="shares">106200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNC00LTEtMS0w_6caebecf-56ef-47fb-84bf-6f7c1a9ba544"
      unitRef="shares">105500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNC02LTEtMS0w_ba1f5c8d-0974-46d3-bb42-dfbaea80c1e2"
      unitRef="shares">105500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNC04LTEtMS0w_5a62a876-c5f1-44b4-b194-3c510a113f27"
      unitRef="shares">108300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i767fc2b3c91d49368bb428e956e1c15f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNi0yLTEtMS0w_cd2e5f27-6880-4056-9463-4f1620a0eeb1"
      unitRef="shares">6400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i7a52920e795646119a53ceb1ce382a02_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNi00LTEtMS0w_5e882070-4d22-4753-bfc3-f0cd27343731"
      unitRef="shares">7800000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i89f5b96bc5434e47892bfa9a96bc713f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNi02LTEtMS0w_9a96f4d8-a9d7-4ecc-a588-a93efc9a2bbe"
      unitRef="shares">5300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia2fe8e8115b14acaab1a1d5efd01ab92_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNi04LTEtMS0w_ccf2f519-ac71-4c47-a5f6-c9546497debd"
      unitRef="shares">7300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i4e9ea9623abe41a1afbf09779e3252b2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNy0yLTEtMS0w_4fe9121b-2b9e-4f68-bfb3-6f6db2c83cff"
      unitRef="shares">1300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i7a9416d782bf46e3aac5cafdd70af82a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNy00LTEtMS0w_d516228a-6455-41b7-b518-ace57724d7b0"
      unitRef="shares">600000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia467795663df48f8839e66b5689ec354_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNy02LTEtMS0w_80c6f120-92d3-4f7a-a192-c5a6568368a5"
      unitRef="shares">1000000.0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ieb41ac995da4481eb5a2ee2048fd8b8e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfNy04LTEtMS0w_d1f463a0-7ab3-4e10-a025-1feb48eaa46d"
      unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfOC0yLTEtMS0w_9825a7dc-7ef5-42f6-bdb7-445ed93f1d5c"
      unitRef="shares">113900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfOC00LTEtMS0w_ae149d99-c628-4410-a14b-cf585dd45061"
      unitRef="shares">113900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfOC02LTEtMS0w_bf2613bd-ce3e-4386-b419-10fe6d0003ab"
      unitRef="shares">111800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfOC04LTEtMS0w_5cecb20d-c04c-4361-9abc-bcc49cc53485"
      unitRef="shares">116100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTAtMi0xLTEtMA_13a07884-1051-41ee-8d3d-71985de07e64"
      unitRef="usdPerShare">15.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTAtNC0xLTEtMA_af93f0fe-1ebb-4860-992a-47849241ce65"
      unitRef="usdPerShare">7.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTAtNi0xLTEtMA_becfe970-1755-41e2-8547-97ec7849bb0c"
      unitRef="usdPerShare">55.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTAtOC0xLTEtMA_78d0936e-10e3-4ddc-a0ae-bff606c307d3"
      unitRef="usdPerShare">21.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTEtMi0xLTEtMA_7d39cf31-d071-4cd2-aa87-069318d1aaf3"
      unitRef="usdPerShare">14.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTEtNC0xLTEtMA_a9ac5cda-5c5b-4fa3-a96c-0c87ad5f0e99"
      unitRef="usdPerShare">7.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTEtNi0xLTEtMA_a99ef49d-6403-4bcd-8917-3633615f60c3"
      unitRef="usdPerShare">52.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOmY2ZWNhNmFiNTUyODQzZTRhMjYwY2E0ZTBiY2NjMGU3L3RhYmxlcmFuZ2U6ZjZlY2E2YWI1NTI4NDNlNGEyNjBjYTRlMGJjY2MwZTdfMTEtOC0xLTEtMA_8cf9c909-d68f-48ee-86bb-611b8844566c"
      unitRef="usdPerShare">20.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RleHRyZWdpb246MjJjMDkyM2QwMjA1NGFiNWEyMGU4ZjZmZDIzZDNiZTlfNzU5_0b688c29-9242-4e7f-aeb0-d3918ea52543">&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i305115a444d14bd096edfc2b3a5fe574_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOjk2YTU0YWMzNTJjMTQ1YzRiNGE5ZTUyYTIxZmRhZjEwL3RhYmxlcmFuZ2U6OTZhNTRhYzM1MmMxNDVjNGI0YTllNTJhMjFmZGFmMTBfMi0yLTEtMS0w_12bf92ce-c168-4314-badc-614d5c105641"
      unitRef="shares">400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i79da790fd94b4499bae26a25903f21e4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOjk2YTU0YWMzNTJjMTQ1YzRiNGE5ZTUyYTIxZmRhZjEwL3RhYmxlcmFuZ2U6OTZhNTRhYzM1MmMxNDVjNGI0YTllNTJhMjFmZGFmMTBfMi00LTEtMS0w_71f03417-19bd-4037-b022-91278bf50eff"
      unitRef="shares">100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic2b88f865b474f1fb605c319670ea555_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOjk2YTU0YWMzNTJjMTQ1YzRiNGE5ZTUyYTIxZmRhZjEwL3RhYmxlcmFuZ2U6OTZhNTRhYzM1MmMxNDVjNGI0YTllNTJhMjFmZGFmMTBfMi02LTEtMS0w_2f8367f0-9fbf-434a-8a09-189a2e5b5b65"
      unitRef="shares">4800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib08523f726914db6b88055d68a3804a8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80MC9mcmFnOjIyYzA5MjNkMDIwNTRhYjVhMjBlOGY2ZmQyM2QzYmU5L3RhYmxlOjk2YTU0YWMzNTJjMTQ1YzRiNGE5ZTUyYTIxZmRhZjEwL3RhYmxlcmFuZ2U6OTZhNTRhYzM1MmMxNDVjNGI0YTllNTJhMjFmZGFmMTBfMi04LTEtMS0w_c780f83a-a036-4b85-97cb-b8f928fab304"
      unitRef="shares">2600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfMTQxNw_a969ea90-3706-440d-9c64-deb3f8313ed3">Marketable Securities&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities as of September&#160;30, 2021 and December&#160;31, 2020 consist of both available-for-sale debt securities of investment grade issuers (see below and Note 6) as well as equity securities of publicly traded companies (see Note 6).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's investments in available-for-sale debt securities: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,911.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,924.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,600.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,614.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,090.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,649.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,689.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its investments in available-for-sale debt securities based on their contractual maturity dates. The available-for-sale debt securities listed as of September&#160;30, 2021 mature at various dates through September 2026. The fair values of available-for-sale debt securities by contractual maturity consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,355.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,259.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,295.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,614.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,689.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the fair value of the Company's available-for-sale debt securities&#160;that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,905.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,905.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,932.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,932.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2021, realized gains and losses on sales of marketable securities were not material. For the three months ended September&#160;30, 2020, realized gains and losses on sales of marketable securities were not material. Realized gains were $28.5 million and realized losses were not material for the nine months ended September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;With respect to marketable securities, for the three and nine months ended September&#160;30, 2021 and 2020, amounts reclassified from Accumulated other comprehensive income into Other (expense) income, net were related to realized gains and losses on sales of available-for-sale debt securities.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfMTQxMw_9de7cdff-2ac5-4a03-8d2d-f72b2d466c5a">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's investments in available-for-sale debt securities: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,911.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,924.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,600.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,614.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,090.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,649.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,689.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMi0yLTEtMS0w_3d9e7593-0f54-4f63-b694-86ee263e7234"
      unitRef="usd">5911800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMi00LTEtMS0w_1951087a-2235-4a5b-af1a-24bcfe65dd24"
      unitRef="usd">19900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMi02LTEtMS0w_e661f47b-30f8-475c-abfe-0613a0e6b990"
      unitRef="usd">6900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMi04LTEtMS0w_606e33d7-b54d-4e84-a1e2-f734c55e5380"
      unitRef="usd">5924800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMy0yLTEtMS0w_89a73ff6-5756-4951-8298-515e10ce7ebd"
      unitRef="usd">101200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMy00LTEtMS0w_bd872d97-1b8a-43d3-9fa3-19ea0e02b986"
      unitRef="usd">600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMy02LTEtMS0w_30b8fd02-03b3-4a66-9913-e54e30629d70"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMy04LTEtMS0w_4609fcde-1fac-44aa-8eed-deb5c6d5e201"
      unitRef="usd">101700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idd87398154424f32abe288424051e254_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNC0yLTEtMS0w_4f5bb37d-871f-4fa7-8f99-ac1aed8c2983"
      unitRef="usd">64600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idd87398154424f32abe288424051e254_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNC00LTEtMS0w_6064247d-9551-4b34-845d-c0ebbdfa122c"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idd87398154424f32abe288424051e254_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNC02LTEtMS0w_bffc957c-676c-4207-b5c5-693f88bc8655"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd87398154424f32abe288424051e254_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNC04LTEtMS0w_53c28d9f-5665-4e08-9c94-e181931bc746"
      unitRef="usd">65100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4ebccad4b04e45f2973de4acc552e081_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNS0yLTEtMS0w_bfbec6e2-ed18-4217-972b-6bb702d9d452"
      unitRef="usd">272600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4ebccad4b04e45f2973de4acc552e081_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNS00LTEtMS0w_0e41dfd5-0e6a-4914-87bd-e28dfbc5cd83"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4ebccad4b04e45f2973de4acc552e081_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNS02LTEtMS0w_1e718b9b-7d74-42bc-bf38-1e3c33b4ce55"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4ebccad4b04e45f2973de4acc552e081_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNS04LTEtMS0w_bd292402-7a2f-4a03-adbe-b74d84f9353d"
      unitRef="usd">272600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibd175f5bfcff4131b4291c7e886d11d0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNi0yLTEtMS0w_05524db7-3856-406c-a5b6-f5f1c43c8201"
      unitRef="usd">231700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibd175f5bfcff4131b4291c7e886d11d0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNi00LTEtMS0w_24099615-a7a2-461a-aa62-79f973e66d78"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibd175f5bfcff4131b4291c7e886d11d0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNi02LTEtMS0w_00bb4265-79a7-4e4d-a2e6-70f12b54b10d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibd175f5bfcff4131b4291c7e886d11d0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNi04LTEtMS0w_19cebd2b-b21c-4078-bd6f-3b25ae534e8e"
      unitRef="usd">231700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3171b6f1e42044f6ad1521433ca23a16_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy0yLTEtMS0zNzkzNw_7c75b5be-94bf-49f9-8f2b-7df5a73775a1"
      unitRef="usd">19000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3171b6f1e42044f6ad1521433ca23a16_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy00LTEtMS0zNzkzNw_283c572c-d0ac-44a7-82cd-54dee95be1d6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3171b6f1e42044f6ad1521433ca23a16_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy02LTEtMS0zNzkzNw_565f209b-a1f8-4b72-94d2-d2db241e87c6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3171b6f1e42044f6ad1521433ca23a16_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy04LTEtMS0zNzkzNw_ead020d5-644b-4c3d-9fc1-b0c40f0f1531"
      unitRef="usd">19000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy0yLTEtMS0w_ddd8cd65-94b8-4e62-8096-3d4db304d35a"
      unitRef="usd">6600900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy00LTEtMS0w_27a946ab-c01d-4f2b-a7ba-0b7c2c90f43c"
      unitRef="usd">21000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy02LTEtMS0w_29e2c3f1-3261-48e6-82c9-032b413affec"
      unitRef="usd">7000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfNy04LTEtMS0w_da2cc468-2c4a-4f2c-b14d-f59b974e0441"
      unitRef="usd">6614900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTAtMi0xLTEtMA_8bb45931-8d58-425a-92de-72631d48886b"
      unitRef="usd">3053000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTAtNC0xLTEtMA_b94fd1dc-8e51-4685-b82b-d703a891c19a"
      unitRef="usd">37500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTAtNi0xLTEtMA_064ce3e3-bf04-4405-83b4-0b3cefb38824"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTAtOC0xLTEtMA_fa6f3244-febe-4271-889e-37c5f06ad277"
      unitRef="usd">3090300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i18110cf9fe854c0eac1362e59d0b3203_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTEtMi0xLTEtMA_708a6c64-e096-4e4e-8002-d62ad164372c"
      unitRef="usd">127600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i18110cf9fe854c0eac1362e59d0b3203_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTEtNC0xLTEtMA_54388907-00ff-493a-bf49-5c067dcd348d"
      unitRef="usd">1300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i18110cf9fe854c0eac1362e59d0b3203_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTEtNi0xLTEtMA_fbbc2fe7-e088-4640-8211-833aa97a7cea"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i18110cf9fe854c0eac1362e59d0b3203_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTEtOC0xLTEtMA_fbe09896-20c7-46ed-9870-b808e0270a3d"
      unitRef="usd">128900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5f73b339b3634a3ab3b8e05805434ee9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTItMi0xLTEtMA_fddebe87-2948-43e9-bdfd-40158d65bc85"
      unitRef="usd">65200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5f73b339b3634a3ab3b8e05805434ee9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTItNC0xLTEtMA_bc8ce8ab-d125-4d37-8ce6-96bd3022894c"
      unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5f73b339b3634a3ab3b8e05805434ee9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTItNi0xLTEtMA_84dc1b46-3f96-4c76-8c38-09ac78e89e9f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5f73b339b3634a3ab3b8e05805434ee9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTItOC0xLTEtMA_6eb1ee6c-d75c-4aeb-9232-9859876709bd"
      unitRef="usd">66300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i60fa6e193603436099beee74e654012a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTMtMi0xLTEtMA_c81a9288-2e1b-4e84-a29a-006abfcbee9d"
      unitRef="usd">276000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i60fa6e193603436099beee74e654012a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTMtNC0xLTEtMA_482ff03c-67e2-4bc7-8888-8c13e013a774"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i60fa6e193603436099beee74e654012a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTMtNi0xLTEtMA_91e4a949-dbbe-49f0-824f-f32bc038d6d7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i60fa6e193603436099beee74e654012a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTMtOC0xLTEtMA_d45451e9-0ce1-4009-915d-052c86dac716"
      unitRef="usd">276100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7188015c6d354b4aa4b026149b2f2dad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTQtMi0xLTEtMA_cefa0f47-378a-4837-ae5b-4775218cdc2b"
      unitRef="usd">127400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7188015c6d354b4aa4b026149b2f2dad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTQtNC0xLTEtMA_65f13e4b-2145-49de-b2e3-0607c30a23d8"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7188015c6d354b4aa4b026149b2f2dad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTQtNi0xLTEtMA_b6224197-5106-43eb-81e2-f702d4d9d5ea"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7188015c6d354b4aa4b026149b2f2dad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTQtOC0xLTEtMA_8a04dc56-21b1-4493-9a51-24a041c6afb0"
      unitRef="usd">127500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTUtMi0xLTEtMA_df4dc8d1-72a6-43ec-a98c-79f6f67684f5"
      unitRef="usd">3649200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTUtNC0xLTEtMA_415f2c24-e012-4905-b6b9-d3fba657d1ef"
      unitRef="usd">40100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTUtNi0xLTEtMA_1c1a2601-7093-4144-bf24-17b935d9ee5f"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA2ZDE3ODlmYzlmZTRjZmQ5MGNmNjFkOTk4YzVlY2ZjL3RhYmxlcmFuZ2U6MDZkMTc4OWZjOWZlNGNmZDkwY2Y2MWQ5OThjNWVjZmNfMTUtOC0xLTEtMA_f9c933d2-e2cf-4b54-8cdb-d95fa12e78c3"
      unitRef="usd">3689100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfMTQyNw_5b4cfee8-1a0e-43de-96db-28bb8720a375">The fair values of available-for-sale debt securities by contractual maturity consist of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,355.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,259.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,295.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,614.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,689.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOmUxNTYzMjM1ZGM2ODQ5ZGY4YWRhMWE1YzExNTlmMzRhL3RhYmxlcmFuZ2U6ZTE1NjMyMzVkYzY4NDlkZjhhZGExYTVjMTE1OWYzNGFfMi0yLTEtMS0w_61e85cf7-e633-425a-be99-52f63fcad3a9"
      unitRef="usd">2355200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOmUxNTYzMjM1ZGM2ODQ5ZGY4YWRhMWE1YzExNTlmMzRhL3RhYmxlcmFuZ2U6ZTE1NjMyMzVkYzY4NDlkZjhhZGExYTVjMTE1OWYzNGFfMi00LTEtMS0w_93852da1-c128-4931-92f9-dfd405ac9914"
      unitRef="usd">1393300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOmUxNTYzMjM1ZGM2ODQ5ZGY4YWRhMWE1YzExNTlmMzRhL3RhYmxlcmFuZ2U6ZTE1NjMyMzVkYzY4NDlkZjhhZGExYTVjMTE1OWYzNGFfMy0yLTEtMS0w_41989b29-55b5-4208-8d7e-4beda76490e2"
      unitRef="usd">4259700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOmUxNTYzMjM1ZGM2ODQ5ZGY4YWRhMWE1YzExNTlmMzRhL3RhYmxlcmFuZ2U6ZTE1NjMyMzVkYzY4NDlkZjhhZGExYTVjMTE1OWYzNGFfMy00LTEtMS0w_22f4f9be-f177-4268-a257-8314c7afb8f9"
      unitRef="usd">2295800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOmUxNTYzMjM1ZGM2ODQ5ZGY4YWRhMWE1YzExNTlmMzRhL3RhYmxlcmFuZ2U6ZTE1NjMyMzVkYzY4NDlkZjhhZGExYTVjMTE1OWYzNGFfNC0yLTEtMS0w_4983c557-1d13-4b69-b02d-98707c612b05"
      unitRef="usd">6614900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOmUxNTYzMjM1ZGM2ODQ5ZGY4YWRhMWE1YzExNTlmMzRhL3RhYmxlcmFuZ2U6ZTE1NjMyMzVkYzY4NDlkZjhhZGExYTVjMTE1OWYzNGFfNC00LTEtMS0w_a3c364e4-b186-426c-84ed-2b265520d558"
      unitRef="usd">3689100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfMTQxNg_63f5ea12-9f9e-43c0-a7ae-93164f8d9172">&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the fair value of the Company's available-for-sale debt securities&#160;that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,905.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,905.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,932.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,932.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMi0xLTEtMS0w_f67a70fc-bbd2-421f-bb9d-a03a788e799e"
      unitRef="usd">2905900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMi0zLTEtMS0w_0457140b-6914-48aa-9988-c6ad98d6dae3"
      unitRef="usd">6900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMi01LTEtMS0w_f013c802-1085-4e5c-9d5b-0eea53a609a5"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMi03LTEtMS0w_93a601c0-5469-4092-8062-425df7e06fca"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMi05LTEtMS0w_32d0d53c-c748-4af9-9db8-aeb929c04f37"
      unitRef="usd">2905900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i9f29c06129fa4ad385d3c25e70264511_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMi0xMS0xLTEtMA_75d911ac-75f5-453f-a0ba-7626e7bcbec4"
      unitRef="usd">6900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMy0xLTEtMS0w_0eae5ca2-2bb1-4a9c-8808-8988fa154826"
      unitRef="usd">27000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMy0zLTEtMS0w_8fade018-75a9-4123-8264-9768ec609d5b"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMy01LTEtMS0w_f5241ad4-5d87-42b7-93e6-a05368c9a654"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMy03LTEtMS0w_6b9870f5-8a4c-4cc1-a630-510029c513b8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMy05LTEtMS0w_3ba09187-6090-424d-bf3c-2711b81c28f3"
      unitRef="usd">27000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="if160a4c1aa8a4e9ca18c15065b56268a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfMy0xMS0xLTEtMA_cc47d59f-6361-476e-a5f9-7d8a819a2a5c"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfNS0xLTEtMS0w_3c37786a-4598-4e5a-ae52-b7472822df76"
      unitRef="usd">2932900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfNS0zLTEtMS0w_7c090539-d631-4873-9c71-d599e7aed55c"
      unitRef="usd">7000000.0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfNS01LTEtMS0w_fcf4fe30-eeae-47ba-8d2b-5988d0c22aa3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfNS03LTEtMS0w_1d3d0d82-02c4-4f44-a85e-9748a94cc459"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfNS05LTEtMS0w_44d4ee71-6dc1-409c-a7ae-b620666e88a3"
      unitRef="usd">2932900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfNS0xMS0xLTEtMA_f723679d-636f-4e8f-a59f-7ef0f192f319"
      unitRef="usd">7000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfOC0xLTEtMS0w_8f2cf720-a98b-462b-889f-6c491f4a8cd0"
      unitRef="usd">364500000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfOC0zLTEtMS0w_604a5bc3-d762-4702-95c4-c46f2a9c46d0"
      unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfOC01LTEtMS0w_93112726-e60f-4600-8088-86cebcd9ad24"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfOC03LTEtMS0w_5ea4b1e3-eb96-4796-872e-6c4ec19a2d6e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfOC05LTEtMS0w_487cc68d-fe1b-4cfc-a644-d8ecce741c06"
      unitRef="usd">364500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i01f80e62c81d467087f2f2fdc9cab7ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RhYmxlOjA3NTg0MWFkOGI2ZTQ4Njg5NGQyYjVkZTA4MzA2MWQwL3RhYmxlcmFuZ2U6MDc1ODQxYWQ4YjZlNDg2ODk0ZDJiNWRlMDgzMDYxZDBfOC0xMS0xLTEtMA_30cd14d4-d6e6-4369-bcad-27ccb3c067d6"
      unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfNDM5ODA0NjUxNjAzNQ_3e1a05a8-60d1-4ab1-a396-c560b7151349"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfNDM5ODA0NjUxNjAzNQ_bef04b9f-32d1-48d6-9992-75c587058ee9"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfNDM5ODA0NjUxNjA0Mw_4504f061-6a81-4d13-97f0-76bea0b8abfd"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <regn:MarketableSecuritiesRealizedGain
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfMTA0NDUzNjA0Njg0ODA_9b161100-215b-4a92-8396-67d8b1f427bd"
      unitRef="usd">28500000</regn:MarketableSecuritiesRealizedGain>
    <regn:MarketableSecuritiesRealizedLoss
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80My9mcmFnOjcxYTVmMDJjM2FiZDQwYzFhMGM2M2E3ZjExYjVhZGY4L3RleHRyZWdpb246NzFhNWYwMmMzYWJkNDBjMWEwYzYzYTdmMTFiNWFkZjhfMTA0NDUzNjA0Njg1MTA_0064bdd8-7d1c-4c2c-98fd-efced827e140"
      unitRef="usd">0</regn:MarketableSecuritiesRealizedLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfMTQ5Mg_73bbdb0c-acc6-4fd2-9f44-fc315208d0dd">Fair Value Measurements&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Quoted prices in active markets for identical assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Significant other unobservable inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,924.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,924.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,986.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,371.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,614.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,090.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,090.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,528.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,689.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company held certain restricted equity securities as of September&#160;30, 2021 which are subject to transfer restrictions that expire at various dates through 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021, we recorded $29.1 million of net unrealized losses and $523.8 million of net unrealized gains, respectively, on equity securities in Other (expense) income, net. During the three and nine months ended September&#160;30, 2020, we recorded $37.5&#160;million of net unrealized losses and $133.8&#160;million of net unrealized gains, respectively, on equity securities in Other (expense) income, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the investments summarized in the table above,&#160;as of September&#160;30, 2021 and December&#160;31, 2020, the Company had $40.0 million and $59.2&#160;million, respectively, in equity investments that do not have a readily determinable fair value. These investments are recorded within Other noncurrent assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our long-term debt (see Note 8), which was determined based on Level 2 inputs, was estimated to be $1.891&#160;billion and $1.958 billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfMTQ5Mw_34329de7-982e-4663-ac5e-b5c92ff56478">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Quoted prices in active markets for identical assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Significant other unobservable inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,924.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,924.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,986.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,371.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,614.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,090.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,090.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and government agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sovereign bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (unrestricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities (restricted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,528.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,689.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5b306c67e2eb415eae154eec63a64166_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMy0xLTEtMS0w_c7c2e6a3-7c30-4233-a7de-bbc6a109dc68"
      unitRef="usd">5924800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i709e307512f84f2d89f62a447afdbb84_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMy0zLTEtMS0w_750343f0-62e5-44cf-8973-7fde22df8bc4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if15ed14fd37044feb3727eba888a012a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMy01LTEtMS0w_e1b9985f-e933-41cf-a60d-9144748e2358"
      unitRef="usd">5924800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8fedc6825bfd4a59a2bd6c1543230955_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNC0xLTEtMS0w_dcaf7738-44eb-4fa7-b936-1c387f0888eb"
      unitRef="usd">101700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i169c45bce7e14e0ebf7c4d8391c33a67_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNC0zLTEtMS0w_930c114f-39f6-4836-a28b-e6b634985bf8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i92f4b800c8ac4853bc03e53e4b78405e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNC01LTEtMS0w_fd0e0ab0-216e-47b4-95d4-9e24f3ea751f"
      unitRef="usd">101700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51ee79229d4e4ebfb388e4a3ad90b0a5_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNS0xLTEtMS0w_3bd58e8d-f779-458a-a2f2-342e8784b856"
      unitRef="usd">65100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id5f7030e51844bd39ff0f0a3b3ef5fb4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNS0zLTEtMS0w_293b8709-c6e7-46c7-88e7-60f620ff50b5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63130650b22f42fea4fa33623b9ba1bd_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNS01LTEtMS0w_2ca67344-037b-4321-9da9-d81ad307f10d"
      unitRef="usd">65100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i30e4687b375546d1af527e2a3df23ab3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNi0xLTEtMS0w_66256dac-bf9d-4145-ab1d-2e646d29bc00"
      unitRef="usd">272600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i497ca48ecca04ba48c5d7ada2d2bbdc4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNi0zLTEtMS0w_b0f23959-38da-4365-a7e5-dbc282e86a6c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i318a17e861d840c98b3031789019aaea_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNi01LTEtMS0w_ce608f32-53eb-4b04-8b47-d34233433225"
      unitRef="usd">272600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i72abcc35bfe04c718a639cb1f6b996a4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNy0xLTEtMS0w_612b27e0-30bd-4f90-a9a9-40a16a402267"
      unitRef="usd">231700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2f153fe081624b709016b5dcb2453c32_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNy0zLTEtMS0w_111a6f9a-b740-49f8-9d45-0c8567a01dd1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9382f8343a0540b4a048b778c440d26b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfNy01LTEtMS0w_8758324a-7d16-414e-9616-ab6be0f014c0"
      unitRef="usd">231700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c0224b00f9c4667827991e766d2f703_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOC0xLTEtMS0zODAzMw_9bc5e4b3-d9a8-4612-866d-68d4ef6566a2"
      unitRef="usd">19000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i879b9c7c242c4ed5aad14987370b0a55_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOC0zLTEtMS0zODAzMw_b837d9a2-32e2-4df8-8404-01cbd0227cfc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i26e6516b07ee48baac59da55f9ab9360_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOC01LTEtMS0zODAzMw_15ac050c-57ad-46cb-8a31-bcddd27059b9"
      unitRef="usd">19000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8496a4fdf8714163a39d2735849938ce_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOC0xLTEtMS0w_2293f4f4-988a-4e18-ae95-adcb33412856"
      unitRef="usd">35700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4bf2a5edcb4f4d9d9c943737ce0824f6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOC0zLTEtMS0w_5f67400e-c2b7-4ac1-a548-02c7d3c660cc"
      unitRef="usd">35700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5fc9503772ed4063887ac7fa4b9d589f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOC01LTEtMS0w_18e1b42f-f73e-45a2-b7aa-4de5602282d8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0719e563f1ad45fe8cae8d7518999c47_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOS0xLTEtMS0w_fdf45471-d499-4bcd-8177-335fa3f6fbb5"
      unitRef="usd">1335900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3c4b945e334d45e8ae01e61b5260ebdc_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOS0zLTEtMS0w_8058cbb2-7504-4b1b-b3a1-45d514a3abfb"
      unitRef="usd">1335900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3bfd8f8a61bc4f3d99eaaf7d514b4d90_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfOS01LTEtMS0w_9950e3eb-a0c7-4416-b8d8-3e215039fed2"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities
      contextRef="i928f7d720b6248cd934975804e4ee21a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTAtMS0xLTEtMA_43b4f7b3-f688-486a-ba91-5ae345333120"
      unitRef="usd">7986500000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i1011bfe7b3f241bdae36c2c04bdef602_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTAtMy0xLTEtMA_2cda7737-59f0-4460-a127-c21b8077e991"
      unitRef="usd">1371600000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="if1ec84991e2545a8b15f060aad624a82_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTAtNS0xLTEtMA_7497cb70-11a4-4722-9ca0-d7a568a91410"
      unitRef="usd">6614900000</us-gaap:MarketableSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i073bb6c4ef1d4dfd94ffa5d20de5a81b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTQtMS0xLTEtMA_ab471f84-12b3-46ea-b7ef-205a111e561f"
      unitRef="usd">3090300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ideeb185943494d1d8c34874a74b6f176_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTQtMy0xLTEtMA_0d6949dc-aa49-4f1a-8967-7d13cd36c639"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i718180e7a06c47d79ec5283f5004e756_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTQtNS0xLTEtMA_0c6358e1-3ef2-494f-afd4-637df9d31665"
      unitRef="usd">3090300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd8180afebff478b9f8bc963fa0e19d7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTUtMS0xLTEtMA_07e538f1-d6b2-44b6-88b1-bfaf65d50283"
      unitRef="usd">128900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee6b453205d44a0aa0e06f339c4344f5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTUtMy0xLTEtMA_c4299816-dafa-478c-bafe-047c8e085e9e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0b0fb7a5bf6b4426b9c1f868210548d6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTUtNS0xLTEtMA_b9fed11d-6133-4e19-9699-c4a692905168"
      unitRef="usd">128900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibf5e87dcd3a64a1da4267f0373377c04_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTYtMS0xLTEtMA_8d749662-71e0-48e5-a7de-94dc9b2e4d60"
      unitRef="usd">66300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia20d85573fb143dd87f197ce54b7e399_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTYtMy0xLTEtMA_cbeb6413-fa84-4e4c-ae51-456be4b40469"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i13a0befca2744f1e8f5c062d988ff10f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTYtNS0xLTEtMA_fc7468d2-2442-4a43-b806-c600dc4560d0"
      unitRef="usd">66300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9263ef91fcc44315917f2dfc964e2ce2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTctMS0xLTEtMA_81a30fc8-ec2d-458d-a8b8-9a4de87a9c7a"
      unitRef="usd">276100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib2e7690d25b64054b80e2f57e6dc1292_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTctMy0xLTEtMA_641e2023-99a0-4e1d-9b71-d3e69dfd3e0a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia21a946152114cde8edfdd4190cf231b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTctNS0xLTEtMA_307fde85-99d0-498e-aa9a-39fbf4e7d338"
      unitRef="usd">276100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i371d5635a65d48f0b357645d217ce740_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTgtMS0xLTEtMA_e7df2085-bc8d-4e59-b788-201bf7102c54"
      unitRef="usd">127500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6463b9ea289444d4a8a0c350da774f0e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTgtMy0xLTEtMA_59d40a91-51d9-4a4e-8f88-ff81fffd3cc5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if7beed26d4e7440baf4167a9e144bd8a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTgtNS0xLTEtMA_241c530f-70e7-408a-9cff-95abb8cabe01"
      unitRef="usd">127500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic9ccf4d0492c49158f8907609cacb785_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTktMS0xLTEtMA_270f56dd-eb57-4661-9bfd-383a76d09a20"
      unitRef="usd">48300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6361d9ec906c4de9bb2da4f5e1bb347a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTktMy0xLTEtMA_4a095bb5-0c62-4617-95af-22ea58619e47"
      unitRef="usd">48300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i880c4f56f4bf49eaa68316dd64419c31_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMTktNS0xLTEtMA_8946b547-d9de-4852-9880-87a4aa4dc0c6"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i04298c88b3394119bf9d1c4903dba435_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMjAtMS0xLTEtMA_5af9a5da-fa59-4e26-b105-d65850016485"
      unitRef="usd">791500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2c66fdf4db544d99a6ab7cc74a9bba46_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMjAtMy0xLTEtMA_0bbfa8b1-2628-46d5-95a9-51920f499cd1"
      unitRef="usd">791500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9b9114a5c0054c229df4345b7d59365a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMjAtNS0xLTEtMA_740e8e56-344e-4020-90f7-4efcb8e518dd"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:MarketableSecurities
      contextRef="iebd67af6e4c44ae197f75086c30ed696_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMjEtMS0xLTEtMA_d9975d21-4964-4219-8cc3-0e4afad1bf4e"
      unitRef="usd">4528900000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i5d2aae955be14f268249627181155c1c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMjEtMy0xLTEtMA_8635ee4a-cb0b-4a4c-b550-ef2ce2aee57c"
      unitRef="usd">839800000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="id6ae2cc961e14f028a26aaf88a03941b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RhYmxlOjFjMjg3YmQ5OGQ4MjRhZWE5YzJmODBjMzIzZDE1NzQ3L3RhYmxlcmFuZ2U6MWMyODdiZDk4ZDgyNGFlYTljMmY4MGMzMjNkMTU3NDdfMjEtNS0xLTEtMA_67f6ed89-fcc1-4c62-b132-a056130dcbf5"
      unitRef="usd">3689100000</us-gaap:MarketableSecurities>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfODY0_e684aaab-52db-45f5-9b7d-038d889f502b"
      unitRef="usd">-29100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfODcx_1e6b4f0c-7cb4-4084-9ce2-40f28cea0846"
      unitRef="usd">523800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfOTk1_6bc6ddbf-a2a0-476a-99f3-f2cda98dd53b"
      unitRef="usd">-37500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfMTAwMg_4df463d7-7c89-4de7-9d79-45dad11c9b14"
      unitRef="usd">133800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfMTE2OA_98384d76-1237-4b45-b183-1c8b1d4fa473"
      unitRef="usd">40000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfMTE3NQ_b509c9de-f015-4eda-87af-345ec56094d6"
      unitRef="usd">59200000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:LongTermDebtFairValue
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfMTQ0Nw_37b515b1-bd84-4148-9b9d-ca5bbc5650e1"
      unitRef="usd">1891000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80Ni9mcmFnOmI0NTY0ZmU5Yzk4NjRjYzU4OWZlZWVmZDkzYjZiNDM2L3RleHRyZWdpb246YjQ1NjRmZTljOTg2NGNjNTg5ZmVlZWZkOTNiNmI0MzZfMTQ1NA_706c7d41-cf58-4d75-89d7-5ca933040d20"
      unitRef="usd">1958000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RleHRyZWdpb246NGM3NWI3ZThlMDU3NDM3MGIyYmM3YWUzNGI2YzdlMGVfNDM2_9ce11c02-6109-4160-b85f-d56580db6b3e">Inventories&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,053.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred costs represent the costs of product manufactured and shipped to the Company's collaborators for which recognition of revenue has been deferred. For the three and nine months ended September&#160;30, 2021, Cost of goods sold included inventory write-offs and reserves totaling $38.7 million and $188.0 million, respectively. For the three and nine months ended September 30, 2020, Cost of goods sold included inventory write-offs and reserves totaling $11.8&#160;million and $23.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RleHRyZWdpb246NGM3NWI3ZThlMDU3NDM3MGIyYmM3YWUzNGI2YzdlMGVfNDQw_7405e377-8ecb-43bd-b307-e18fb65ad955">&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,053.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfMi0xLTEtMS0w_41f7f000-190e-40ac-9609-6612199d25df"
      unitRef="usd">646300000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfMi0zLTEtMS0w_ca09a1b4-51f6-42d6-8af4-50670727b75f"
      unitRef="usd">459400000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfMy0xLTEtMS0w_808ce70c-abdc-4469-8770-eee5b89b7992"
      unitRef="usd">843700000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfMy0zLTEtMS0w_6c917620-83f1-4097-8b0b-b519e3f5ff1c"
      unitRef="usd">904600000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfNC0xLTEtMS0w_8093df63-d1ea-4d5b-b3c3-94fd713a127f"
      unitRef="usd">60100000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfNC0zLTEtMS0w_ad3e08d5-8bd4-4da8-bd86-25f7b45134e8"
      unitRef="usd">121700000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:OtherInventoryNetOfReserves
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfNS0xLTEtMS0w_b341f6ef-1ad6-4292-a61d-187c36684f23"
      unitRef="usd">503700000</us-gaap:OtherInventoryNetOfReserves>
    <us-gaap:OtherInventoryNetOfReserves
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfNS0zLTEtMS0w_57399d98-19df-4c86-8994-32f5998bc15c"
      unitRef="usd">430900000</us-gaap:OtherInventoryNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfNi0xLTEtMS0w_58609aa5-a7a7-4764-983b-e1a6a7221726"
      unitRef="usd">2053800000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i7e0582c9be764ded815021b5841e304e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RhYmxlOjU5YTIwZTM4ZmEyYzQzMTg5NTEwNjYyMzE2MThkNGNkL3RhYmxlcmFuZ2U6NTlhMjBlMzhmYTJjNDMxODk1MTA2NjIzMTYxOGQ0Y2RfNi0zLTEtMS0w_ab9d9f3a-cd9e-41f8-b310-74386f42da06"
      unitRef="usd">1916600000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RleHRyZWdpb246NGM3NWI3ZThlMDU3NDM3MGIyYmM3YWUzNGI2YzdlMGVfMzI0_2db9baca-8d6e-40d9-b107-fa31caea91b8"
      unitRef="usd">38700000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RleHRyZWdpb246NGM3NWI3ZThlMDU3NDM3MGIyYmM3YWUzNGI2YzdlMGVfMzMx_47c78166-d787-4f01-b21a-4c89368fbd37"
      unitRef="usd">188000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RleHRyZWdpb246NGM3NWI3ZThlMDU3NDM3MGIyYmM3YWUzNGI2YzdlMGVfMTY0OTI2NzQ0MjM4NA_7fef15c3-1103-408e-9ca1-ba68e4dfc867"
      unitRef="usd">11800000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl80OS9mcmFnOjRjNzViN2U4ZTA1NzQzNzBiMmJjN2FlMzRiNmM3ZTBlL3RleHRyZWdpb246NGM3NWI3ZThlMDU3NDM3MGIyYmM3YWUzNGI2YzdlMGVfMTY0OTI2NzQ0MjM2OQ_add0fcc6-2805-4128-a898-58ca9011e829"
      unitRef="usd">23600000</us-gaap:InventoryWriteDown>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RleHRyZWdpb246NjEzZGUxOTZkMWM0NDI2ZWJmOTk0NDk4MDkzMTliNTlfMTM1OA_12622ccd-0a5f-411c-aed9-e439238f051d">Debt&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bridge Loan Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described in Note 10, in the second quarter of 2020, we purchased shares of our Common Stock from Sanofi in connection with Sanofi's secondary offering of our Common Stock held by Sanofi. This purchase was partially funded with proceeds from loans under a $1.5&#160;billion senior unsecured bridge loan facility (the "Bridge Facility") which was entered into in May 2020. The loans under the Bridge Facility bore interest at a variable interest rate based on either the London Interbank Offered Rate or the alternate base rate, plus an applicable margin that varied with our debt rating and total leverage ratio. The Bridge Facility was repaid in full during the third quarter of 2020 following the closing of the issuance and sale of the Company's senior notes (as described below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, we issued and sold $1.250&#160;billion aggregate principal amount of senior unsecured notes due 2030 and $750 million aggregate principal amount of senior unsecured notes due 2050. Long-term debt in connection with our senior unsecured notes (collectively, the "Notes"), net of underwriting discounts and offering expenses, consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.750% Senior Notes due September 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,238.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.800% Senior Notes due September 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,978.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense related to the Notes for the three and nine months ended September&#160;30, 2021 was $11.1&#160;million and $33.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic2b125c56e464e7d83e39ceed25911e1_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RleHRyZWdpb246NjEzZGUxOTZkMWM0NDI2ZWJmOTk0NDk4MDkzMTliNTlfMzEw_87a3d041-88bf-4d62-a587-caeb33e36049"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id293bfb3eddd4aff80d65cf0394b1943_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RleHRyZWdpb246NjEzZGUxOTZkMWM0NDI2ZWJmOTk0NDk4MDkzMTliNTlfOTQ4_0918820b-d5d5-4cb3-a03d-a6c69355e31f"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8f0cbd4933e54839aa58d6992050314c_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RleHRyZWdpb246NjEzZGUxOTZkMWM0NDI2ZWJmOTk0NDk4MDkzMTliNTlfMTAxNw_7431cffc-8351-41d3-b963-e9b5c20ef323"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RleHRyZWdpb246NjEzZGUxOTZkMWM0NDI2ZWJmOTk0NDk4MDkzMTliNTlfMTM1OQ_05017cd9-8f31-4bc9-94b6-2d9e880006a3">Long-term debt in connection with our senior unsecured notes (collectively, the "Notes"), net of underwriting discounts and offering expenses, consists of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.750% Senior Notes due September 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,238.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.800% Senior Notes due September 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,978.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if0dfa4b658804eb3a16f8cee0ca8be17_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfMi0wLTEtMS0wL3RleHRyZWdpb246N2FiMmRmMjMxY2NmNGY1NDhmZGEzMGJkYzQyZmQxOGVfNA_e7420dd0-8243-4f2e-a2cd-974943a14a60"
      unitRef="number">0.01750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if0dfa4b658804eb3a16f8cee0ca8be17_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfMi0xLTEtMS0w_b099e945-8b88-4484-823e-c1f59c99038c"
      unitRef="usd">1239600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i534da4670c274a81ae3524fbdfe06604_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfMi0zLTEtMS0w_0bf244dd-1d65-4bdc-9ebe-de12e4aa5d75"
      unitRef="usd">1238700000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i650510a2eb214adc84a48e8722d60ddf_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfMy0wLTEtMS0wL3RleHRyZWdpb246MjNmZTc5YTA0NTdmNGU1MzljNWMzZmNlMWMyNzUzNTFfNA_43c091d4-6d3c-4598-b930-9f60b2f671b6"
      unitRef="number">0.02800</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i650510a2eb214adc84a48e8722d60ddf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfMy0xLTEtMS0w_edff9a4b-9dc8-4cb4-a4d3-ed4d0f2d6f6a"
      unitRef="usd">740000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i518fc4089b494e66895c51aae0a95ae4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfMy0zLTEtMS0w_d66eb84e-77d3-4bba-ae48-9dde5c301a68"
      unitRef="usd">739800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id1490f50984443fa9fc09db8661cd762_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfNC0xLTEtMS0w_b2016fbd-1d66-4df1-b325-e5d058a20b3a"
      unitRef="usd">1979600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id9fe51ad3f5d44d7b51f9c7d2bb1636b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RhYmxlOjRlMWU3OTk1ODA1ZDQzOWFhNDU2Y2QwNTU0MTU5Y2Q5L3RhYmxlcmFuZ2U6NGUxZTc5OTU4MDVkNDM5YWE0NTZjZDA1NTQxNTljZDlfNC0zLTEtMS0w_50aecaed-691a-4aad-8d97-c51e8d06f007"
      unitRef="usd">1978500000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i07fe2aef96e54e809240ec9fba24d72c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RleHRyZWdpb246NjEzZGUxOTZkMWM0NDI2ZWJmOTk0NDk4MDkzMTliNTlfMTMzNQ_0f6abe11-24a2-4b38-be73-57485d014cf8"
      unitRef="usd">11100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="iaefeb3e5dbc2406c9e11d7dbcba3ee98_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81Mi9mcmFnOjYxM2RlMTk2ZDFjNDQyNmViZjk5NDQ5ODA5MzE5YjU5L3RleHRyZWdpb246NjEzZGUxOTZkMWM0NDI2ZWJmOTk0NDk4MDkzMTliNTlfMTM0Mg_821130a2-e334-4b90-897f-579719395d3b"
      unitRef="usd">33300000</us-gaap:InterestExpenseDebt>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81NS9mcmFnOmY1ZTliMWY5Y2EyNDQzMDg5MWRiN2ViYTE0OWZiMDdkL3RleHRyZWdpb246ZjVlOWIxZjljYTI0NDMwODkxZGI3ZWJhMTQ5ZmIwN2RfMTQxMQ_caee9877-466e-47a5-92ec-e26ce668735f">Income TaxesThe Company is subject to U.S. federal, state, and foreign income taxes. The Company's effective tax rate was 10.2% and 15.6% for the three months ended September&#160;30, 2021 and 2020, respectively, and 14.3% and 8.6% for the nine months ended September&#160;30, 2021 and 2020, respectively. The Company's effective tax rate for the three and nine months ended September&#160;30, 2021 was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation, income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate, the foreign-derived intangible income deduction, and federal tax credits for research activities. In addition, the effective tax rate for the nine months ended September 30, 2021 was positively impacted by the reversal of liabilities related to uncertain tax positions. During the nine months ended September&#160;30, 2021, we reduced the amount of liabilities for uncertain tax positions related to the Company&#x2019;s federal income tax returns for 2015 and 2016, as these audits are effectively settled. The Company's federal income tax returns for 2017 and 2018 are currently under audit by the Internal Revenue Service ("IRS"). The Company's effective tax rate for the three and nine months ended September&#160;30, 2020 was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation, and, to a lesser extent, income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate and federal tax credits for research activities.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81NS9mcmFnOmY1ZTliMWY5Y2EyNDQzMDg5MWRiN2ViYTE0OWZiMDdkL3RleHRyZWdpb246ZjVlOWIxZjljYTI0NDMwODkxZGI3ZWJhMTQ5ZmIwN2RfMTMx_ae8be8b9-c9da-4a8e-bd2b-0954791e6a81"
      unitRef="number">0.102</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81NS9mcmFnOmY1ZTliMWY5Y2EyNDQzMDg5MWRiN2ViYTE0OWZiMDdkL3RleHRyZWdpb246ZjVlOWIxZjljYTI0NDMwODkxZGI3ZWJhMTQ5ZmIwN2RfMTM4_026bd87c-72a1-46b3-85c3-d9c4aa75e409"
      unitRef="number">0.156</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81NS9mcmFnOmY1ZTliMWY5Y2EyNDQzMDg5MWRiN2ViYTE0OWZiMDdkL3RleHRyZWdpb246ZjVlOWIxZjljYTI0NDMwODkxZGI3ZWJhMTQ5ZmIwN2RfMTk3_fcdf2a42-6545-46ac-b2ab-0d861ee4a0e7"
      unitRef="number">0.143</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81NS9mcmFnOmY1ZTliMWY5Y2EyNDQzMDg5MWRiN2ViYTE0OWZiMDdkL3RleHRyZWdpb246ZjVlOWIxZjljYTI0NDMwODkxZGI3ZWJhMTQ5ZmIwN2RfMjA0_3c3845fb-074e-4eae-b3f5-8963276e95b1"
      unitRef="number">0.086</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMzY1OQ_28679b50-0f34-40e2-ba2b-52091fb56d94">Stockholders' Equity&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchase Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, our board of directors authorized a share repurchase program to repurchase up to&#160;$1.0 billion&#160;of our Common Stock. The share repurchase program permitted the Company to effect repurchases through a variety of methods, including open-market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in compliance with Rule 10b-18 of the Exchange Act. As of December&#160;31, 2020, the Company had repurchased the entire $1.0 billion it was authorized to repurchase under the program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, our board of directors authorized an additional share repurchase program to repurchase up to $1.5&#160;billion of our Common Stock. The share repurchase program was approved under terms substantially similar to the November 2019 share repurchase program described above. Repurchases may be made from time to time at management&#x2019;s discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. The program has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases in the future. As of September&#160;30, 2021, $697.3&#160;million remained available for share repurchases under the program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the shares of our Common Stock we repurchased under the programs during the three and nine months ended September&#160;30, 2021 and 2020 and the cost of the shares received, which were recorded as Treasury Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares repurchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of shares received &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sanofi Funding of Certain Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company and Sanofi entered into a letter agreement (the "Letter Agreement") in connection with, among other matters, the allocation of additional funds to certain activities relating to dupilumab and itepekimab (collectively, the "Dupilumab/Itepekimab Eligible Investments"). Pursuant to the Letter Agreement, we agreed to allow Sanofi to satisfy its funding obligations with respect to Dupilumab/Itepekimab Eligible Investments, as well as Libtayo development costs, for quarterly periods ending on September 30, 2020 by selling our Common Stock owned by Sanofi. During the nine months ended September&#160;30, 2020, Sanofi elected to sell, and we elected to purchase (by issuing a credit towards the amount owed by Sanofi), 77,677 shares of our Common Stock to satisfy Sanofi's funding obligation related to Libtayo development costs, and we recorded the cost of the shares received, or $41.7&#160;million, as Treasury Stock. During the nine months ended September&#160;30, 2020, Sanofi elected to sell, and we elected to purchase (in cash), 171,471 shares of our Common Stock in connection with Sanofi's funding obligation for Dupilumab/Itepekimab Eligible Investments, and we recorded the cost of the shares received, or $93.3&#160;million, as Treasury Stock. During the three months ended September&#160;30, 2020, there were no shares of our Common Stock purchased from Sanofi to satisfy Sanofi's funding obligations related to Libtayo development costs and/or Dupilumab/Itepekimab Eligible Investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Additional Stock Purchased from Sanofi&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, a secondary offering of 13,014,646 shares of our Common Stock (the "Secondary Offering") held by Sanofi was completed. In connection with the Secondary Offering, we also purchased 9,806,805 shares directly from Sanofi for an aggregate purchase amount of $5.0&#160;billion (the "Stock Purchase"). As a result of the Secondary Offering and the Stock Purchase, Sanofi disposed of all of its shares of our Common Stock, other than 400,000 shares that it retained as of the closing of the Secondary Offering and the Stock Purchase (a portion of which Sanofi used for the funding of certain Libtayo development costs and/or Dupilumab/Itepekimab Eligible Investments as described above).&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i4e98493124404aad8a8c0e1cb049d5ec_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMTU1_b757faec-38d7-4538-9a00-ed0b56713d03"
      unitRef="usd">1000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8ca3ec3e33eb4ab29ddc909bd33e67d0_D20201231-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfNjIw_2f2d104a-df4f-4841-851d-cd1ee5f129af"
      unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ieef2a875d0184972869268bd64fb3df7_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfNzc2_45cc7fe6-39f9-4a4a-9e34-219996c5be9a"
      unitRef="usd">1500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i69ddf6100ec6432d8b2d4ac0d6998971_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMTY0OTI2NzQ0NTQ5MA_004148e8-b63c-4fbd-90a0-93501a55b6f4"
      unitRef="usd">697300000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMzY1NQ_ab4bee26-d94c-4c1d-aec1-7e97bb12bd35">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the shares of our Common Stock we repurchased under the programs during the three and nine months ended September&#160;30, 2021 and 2020 and the cost of the shares received, which were recorded as Treasury Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.440%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of shares repurchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost of shares received &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMi0xLTEtMS0w_e0e1341b-9ff1-4098-9664-1767a603fc04"
      unitRef="shares">300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMi0zLTEtMS0w_9bf49aa8-69f8-441e-828f-be6c32ba4ae4"
      unitRef="shares">200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMi01LTEtMS0w_22d9ba1e-62a1-4f2f-b25c-f56907d5f64a"
      unitRef="shares">1600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMi03LTEtMS0w_944c0186-5e63-48b0-9319-75ba8edfb9fe"
      unitRef="shares">900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMy0xLTEtMS0w_f66f1063-0751-4b1b-ad41-218177a7f15a"
      unitRef="usd">190500000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i44583ac9d2ad42149cc7bfb5f4e6d32a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMy0zLTEtMS0w_15a42d99-b761-43d9-9bf7-f551a3941f52"
      unitRef="usd">100400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMy01LTEtMS0w_6ff7ecec-733b-412b-895a-bf0022701a51"
      unitRef="usd">802700000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RhYmxlOjYwMDA3YzQ5NjY5ODQ5YzRhMmU0NmQ2NWNmNjkzZjk3L3RhYmxlcmFuZ2U6NjAwMDdjNDk2Njk4NDljNGEyZTQ2ZDY1Y2Y2OTNmOTdfMy03LTEtMS0w_b629f993-2d57-48a8-a134-41c8c1062309"
      unitRef="usd">373300000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i31a864c8cc3a49e086a3fde76b1e1695_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMjQwMA_be3e16d9-30ce-4bbe-b0e4-aeac3d48b383"
      unitRef="shares">77677</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i31a864c8cc3a49e086a3fde76b1e1695_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMjU4MA_f4323459-a99f-45ab-83e2-ab92cf5f2986"
      unitRef="usd">41700000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i5bfec289c7074f5282b731594a9587a9_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMjcyOA_ef58e0d2-d031-45f6-a26c-a5e72fdf2a7a"
      unitRef="shares">171471</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i5bfec289c7074f5282b731594a9587a9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMjkyMg_99833c6e-901f-40d5-964a-ac0588d81731"
      unitRef="usd">93300000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ied92924a0c784856bbf8ed8a35ac7f57_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMTY0OTI2NzQ0NTQ5OA_c36718ac-72ce-4fec-9eea-7e904675dfb1"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iec719ff1e7724d85bfffb28a5eac401e_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMzAzNQ_a6304a51-bb8e-48cd-9329-b5fbc13de2b0"
      unitRef="shares">13014646</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="iec719ff1e7724d85bfffb28a5eac401e_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMzE4Mw_c5d1e3c0-00f6-403b-948b-f0c1784d6338"
      unitRef="shares">9806805</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iec719ff1e7724d85bfffb28a5eac401e_D20200501-20200531"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMzI1MA_1165631f-89b1-426e-9ede-329e5c63c693"
      unitRef="usd">5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0d93ce0ffcda4c05912416ab54808098_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl81OC9mcmFnOmQ0OTAzOWFkYzBkYjRkMjJiODQ3MjgyNGFmZjdhMmFhL3RleHRyZWdpb246ZDQ5MDM5YWRjMGRiNGQyMmI4NDcyODI0YWZmN2EyYWFfMzQwOA_0f597936-2a4d-4991-a386-ef0f53d7e366"
      unitRef="shares">400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RleHRyZWdpb246MmZlMGI3ZGNiNGE1NGRjN2FiY2EzZWIzMWQ2MWQ1MDBfODA3_36476b45-32d7-4ed5-bfbd-37f38688e31d">Statement of Cash Flows&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,432.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,573.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,444.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,586.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists of amounts held by financial institutions pursuant to contractual arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supplemental disclosure of non-cash investing and financing activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following amounts were included in accounts payable, accrued expenses, and other liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RleHRyZWdpb246MmZlMGI3ZGNiNGE1NGRjN2FiY2EzZWIzMWQ2MWQ1MDBfNzk5_ff6b9ce5-5f68-492c-a4e7-551e138df304">&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,432.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,573.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,444.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,586.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RleHRyZWdpb246MmZlMGI3ZGNiNGE1NGRjN2FiY2EzZWIzMWQ2MWQ1MDBfODAw_522a1cab-7475-476a-b513-2f56c4c7b0b2">&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,432.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,573.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash included in Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,444.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,586.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjI1ZTgzZDA4OTEzMTRmYTg4NDY2NjNmOTY0OWYzMTIxL3RhYmxlcmFuZ2U6MjVlODNkMDg5MTMxNGZhODg0NjY2M2Y5NjQ5ZjMxMjFfMi0yLTEtMS0w_ecd08079-ee47-4a13-8a2c-3d761c3b4069"
      unitRef="usd">3432400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i09b0b1c1c2a94afb988a7c59c235eee7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjI1ZTgzZDA4OTEzMTRmYTg4NDY2NjNmOTY0OWYzMTIxL3RhYmxlcmFuZ2U6MjVlODNkMDg5MTMxNGZhODg0NjY2M2Y5NjQ5ZjMxMjFfMi00LTEtMS0w_c58f5259-2891-4335-bf4a-798a46d646c3"
      unitRef="usd">1573000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjI1ZTgzZDA4OTEzMTRmYTg4NDY2NjNmOTY0OWYzMTIxL3RhYmxlcmFuZ2U6MjVlODNkMDg5MTMxNGZhODg0NjY2M2Y5NjQ5ZjMxMjFfMy0yLTEtMS0w_3d432eb3-242b-4f1d-a1e9-175236fd51b6"
      unitRef="usd">12500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i09b0b1c1c2a94afb988a7c59c235eee7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjI1ZTgzZDA4OTEzMTRmYTg4NDY2NjNmOTY0OWYzMTIxL3RhYmxlcmFuZ2U6MjVlODNkMDg5MTMxNGZhODg0NjY2M2Y5NjQ5ZjMxMjFfMy00LTEtMS0w_b28fc7e3-d3cb-42c7-ac88-e2912615b7b1"
      unitRef="usd">13600000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i67bb2d31f4c14f1993cd54b0a2406e75_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjI1ZTgzZDA4OTEzMTRmYTg4NDY2NjNmOTY0OWYzMTIxL3RhYmxlcmFuZ2U6MjVlODNkMDg5MTMxNGZhODg0NjY2M2Y5NjQ5ZjMxMjFfNC0yLTEtMS0w_34c6c890-aa58-4a27-ad7e-37a9fc9e2db6"
      unitRef="usd">3444900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i09b0b1c1c2a94afb988a7c59c235eee7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjI1ZTgzZDA4OTEzMTRmYTg4NDY2NjNmOTY0OWYzMTIxL3RhYmxlcmFuZ2U6MjVlODNkMDg5MTMxNGZhODg0NjY2M2Y5NjQ5ZjMxMjFfNC00LTEtMS0w_757e0697-0388-4531-a40d-0d6bc09f22fe"
      unitRef="usd">1586600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RleHRyZWdpb246MmZlMGI3ZGNiNGE1NGRjN2FiY2EzZWIzMWQ2MWQ1MDBfODAx_4efea0a0-e40d-4b50-a0fd-1ba531079a60">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following amounts were included in accounts payable, accrued expenses, and other liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjNkOWQwYWYyMTA4ODRmYTRhNGZiZTlhYzM1ZjA4YWZhL3RhYmxlcmFuZ2U6M2Q5ZDBhZjIxMDg4NGZhNGE0ZmJlOWFjMzVmMDhhZmFfMi0xLTEtMS0w_b131ca33-0235-4808-8068-74ddf40fd9f1"
      unitRef="usd">70100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i5148f71a87a04e13ac8076f503a1425e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjNkOWQwYWYyMTA4ODRmYTRhNGZiZTlhYzM1ZjA4YWZhL3RhYmxlcmFuZ2U6M2Q5ZDBhZjIxMDg4NGZhNGE0ZmJlOWFjMzVmMDhhZmFfMi0zLTEtMS0w_776cf5c6-f438-434a-a2f8-7aa8f4337b64"
      unitRef="usd">83600000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ibbfd301918c747ca84b057a5af415334_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjNkOWQwYWYyMTA4ODRmYTRhNGZiZTlhYzM1ZjA4YWZhL3RhYmxlcmFuZ2U6M2Q5ZDBhZjIxMDg4NGZhNGE0ZmJlOWFjMzVmMDhhZmFfMi01LTEtMS0w_ea85c977-caa2-4e8f-97f0-57aa68e8d6c5"
      unitRef="usd">100400000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i222bcb21c9a4477ab7dc7af26e32e7ee_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82MS9mcmFnOjJmZTBiN2RjYjRhNTRkYzdhYmNhM2ViMzFkNjFkNTAwL3RhYmxlOjNkOWQwYWYyMTA4ODRmYTRhNGZiZTlhYzM1ZjA4YWZhL3RhYmxlcmFuZ2U6M2Q5ZDBhZjIxMDg4NGZhNGE0ZmJlOWFjMzVmMDhhZmFfMi03LTEtMS0w_953d4293-b4d1-4276-91f4-ec7c03d11ce0"
      unitRef="usd">133700000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfMzUxMzI_4c027689-82fd-4689-b2d2-75b06e10532f">Legal Matters&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is a party to legal proceedings in the course of the Company's business. Costs associated with the Company's involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. The Company recognizes accruals for loss contingencies associated with such proceedings when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. As of September&#160;30, 2021 and December&#160;31, 2020, the Company's accruals for loss contingencies were not material. If the Company were unable to prevail in any such proceedings, its consolidated financial position, results of operations, and future cash flows may be materially impacted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to Praluent (alirocumab) Injection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described in greater detail below, the Company is currently a party to patent infringement actions initiated by Amgen Inc. (and/or its affiliated entities) against the Company and/or Sanofi (and/or the Company's and Sanofi's respective affiliated entities) in a number of jurisdictions relating to Praluent. See Note 3 for a description of the Company's and Sanofi's arrangement regarding the costs resulting from or associated with such actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the United States, Amgen asserted claims of U.S. Patent Nos. 8,829,165 (the "'165 Patent") and 8,859,741 (the "'741 Patent"), and sought a permanent injunction to prevent the Company and the Sanofi defendants from commercial manufacturing, using, offering to sell, or selling within the United States (as well as importing into the United States) (collectively, "Commercializing") Praluent. Amgen also sought a judgment of patent infringement of the asserted patents, monetary damages (together with interest), costs and expenses of the lawsuits, and attorneys' fees. As described in greater detail under "Second Jury Trial and Appeal" below, on February 11, 2021, the Federal Circuit (as defined below) affirmed the lower court's decision that certain of Amgen's asserted patent claims are invalid based on lack of enablement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Jury Trial and Appeal.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first jury trial in this litigation (the "First Trial") was held in the United States District Court for the District of Delaware (the "District Court") from March 8 to March 16, 2016. During the course of the First Trial, the District Court ruled as a matter of law in favor of Amgen that the asserted patent claims were not obvious, and in favor of the Company and the Sanofi defendants that there was no willful infringement of the asserted patent claims by the Company or the Sanofi defendants. On March 16, 2016, the jury returned a verdict in favor of Amgen in the First Trial, finding that the asserted claims of the '165 and '741 Patents were not invalid based on either a lack of written description or a lack of enablement. On October 5, 2017, the United States Court of Appeals for the Federal Circuit (the "Federal Circuit") reversed in part the District Court's decision and remanded for a new trial on the issues of written description and enablement. In addition, it affirmed the District Court's ruling that Amgen's patents were not obvious.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Second Jury Trial and Appeal.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 3, 2019, the District Court held oral argument in the remanded proceedings on the Company and the Sanofi defendants' motion for judgment on the pleadings regarding Amgen's willful infringement claim. On January 18, 2019, the District Court entered an order (i) denying the Company and the Sanofi defendants' motion for summary judgment on validity, (ii) denying Amgen's motion for partial summary judgment on estoppel, and (iii) granting the Company and the Sanofi defendants' cross-motion for summary judgment on estoppel. On February 8, 2019, the District Court granted the Company and the Sanofi defendants' motion for judgment on the pleadings, thereby dismissing Amgen's claim of willful infringement. The second jury trial in this litigation (the "Second Trial") was held before the District Court in February 2019 to determine the validity of Amgen's asserted patent claims. On February 25, 2019, the jury returned a verdict in the Second Trial generally in favor of Amgen, finding that two claims of the '165 Patent and one claim of the '741 Patent were not invalid. The jury also found that two claims of the '165 Patent were invalid for lack of adequate written description while rejecting the lack of enablement challenges to those two claims. On August 28, 2019, the District Court ruled as a matter of law that Amgen's asserted patent claims are invalid based on lack of enablement. The District Court also conditionally denied the Company and the Sanofi defendants' motion for a new trial. On October 23, 2019, Amgen filed a notice of appeal of the District Court's decision with the Federal Circuit. An oral hearing before the Federal Circuit was held on December 9, 2020. On February 11, 2021, the Federal Circuit affirmed the District Court's decision that certain of Amgen's asserted patent claims are invalid based on lack of enablement. On April 14, 2021, Amgen filed a petition for a rehearing en banc, which was denied on June 21, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Injunctive Relief Proceedings.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 18, 2019, Amgen filed a renewed motion for a permanent injunction to prohibit the Company and the Sanofi defendants from Commercializing Praluent in the United States (a "Permanent Injunction"), and an oral hearing on this motion was held in June 2019. Previously, the Federal Circuit stayed and then vacated a Permanent Injunction granted by the District Court in connection with the First Trial. On August 28, 2019, the District Court dismissed as moot Amgen's renewed motion for a Permanent Injunction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen has asserted European Patent No. 2,215,124 (the "'124 Patent"), which pertains to PCSK9 monoclonal antibodies, in the countries in Europe discussed below. In October 2020, the '124 Patent claims directed to compositions of matter and medical use relevant to Praluent were ruled invalid based on a lack of inventive step by the Technical Board of Appeal (the "TBA") of the European Patent Office (the "EPO"). This decision impacted each of the infringement proceedings based on the '124 Patent discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen filed lawsuits in Germany, the United Kingdom, and France in July 2016, July 2016, and September 2016,  respectively, against the Company and certain of Sanofi's affiliated entities for infringement of the relevant designation of the '124 Patent in each such jurisdiction; and these lawsuits were dismissed in November 2020, September 2021, and June 2021, respectively. The dismissal in Germany followed an earlier finding of infringement and granting of an injunction, both of which were subsequently overturned. In December 2019, Amgen also filed lawsuits in the Netherlands, Italy, and Spain for infringement of the relevant designation of the '124 Patent in each such jurisdiction; the Company was not named as a defendant in any of these actions, and each of these lawsuits was dismissed in February 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Japan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously reported, on March 31, 2020, Amgen filed a lawsuit in the Tokyo District Court against Sanofi K.K. seeking damages incurred by Amgen as a result of the earlier finding of infringement of Amgen's Japanese Patent Nos. 5,906,333 and 5,705,288 by the Tokyo District Court Civil Division. The Company has not been named as a defendant in this damages action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to Dupixent (dupilumab) Injection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 23, 2017, the Company, Sanofi-Aventis U.S. LLC, and Genzyme Corporation initiated an &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; review ("IPR") in the United States Patent and Trademark Office ("USPTO") seeking a declaration of invalidity of U.S. Patent No. 8,679,487 (the "'487 Patent") owned by Immunex Corporation relating to antibodies that bind the human interleukin-4 receptor and subsequently filed two additional IPR petitions in the USPTO seeking declarations of invalidity of the '487 Patent based on different grounds (the "Additional IPR Petitions"). The Patent Trial and Appeal Board ("PTAB") of the USPTO issued a final written decision on the Additional IPR Petitions on February 14, 2019, invalidating all 17 claims of the '487 Patent as obvious. This decision was subsequently affirmed by the Federal Circuit and Immunex's petition for writ of certiorari was denied by the United States Supreme Court. The '487 Patent expired in May 2020 following Immunex's filing of a terminal disclaimer with the USPTO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2017, Immunex Corporation filed a lawsuit against the Company, Sanofi, Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Aventisub LLC in the United States District Court for the Central District of California seeking a judgment of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;patent infringement of the '487 Patent and a declaratory judgment of infringement of the '487 Patent, in each case by the Company's and the other defendants' Commercializing of Dupixent; monetary damages (together with interest); an order of willful infringement of the '487 Patent, which would allow the court in its discretion to award damages up to three times the amount assessed; costs and expenses of the lawsuit; and attorneys' fees. The court subsequently granted a joint stipulation by the parties to stay the litigation pending resolution of the appeals of the PTAB's final written decisions on the Additional IPR Petitions discussed above; and, on August 3, 2021, granted a motion to dismiss the lawsuit, dismissing all of Immunex's claims with prejudice. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2016, Sanofi initiated a revocation proceeding in the United Kingdom to invalidate the U.K. counterpart of European Patent No. 2,292,665 (the "'665 Patent"), another patent owned by Immunex relating to antibodies that bind the human interleukin-4 receptor. At the joint request of the parties to the revocation proceeding, the U.K. Patents Court ordered on January 30, 2017 that the revocation action be stayed pending the final determination of the currently pending EPO opposition proceedings initiated by the Company and Sanofi in relation to the '665 Patent. The oral hearing before the EPO on the oppositions occurred on November 20, 2017, at which the claims of the '665 Patent were found invalid and the patent was revoked. A final written decision of revocation of the '665 Patent was issued by the EPO on January 4, 2018. Immunex filed a notice of appeal of the EPO's decision on January 31, 2018, and an oral hearing before the TBA has been scheduled for March 2022. On September 20, 2017 and September 21, 2017, respectively, the Company and Sanofi initiated opposition proceedings in the EPO against Immunex's European Patent No. 2,990,420 (the "'420 Patent"), a divisional patent of the '665 Patent (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a patent that shares the same priority date, disclosure, and patent term of the parent '665 Patent but contains claims to a different invention). The oral hearing before the EPO on the oppositions occurred on February 14&#x2013;15, 2019, at which the '420 Patent was revoked in its entirety. Immunex filed a notice of appeal of the EPO's decision on May 31, 2019, and an oral hearing before the TBA has been scheduled for March 2022. The original patent term of the Immunex patents expired in May 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to EYLEA (aflibercept) Injection&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 7, 2021, Chengdu Kanghong Pharmaceutical Group Co., Ltd. ("Chengdu Kanghong") filed an IPR petition in the USPTO against the Company' s U.S. Patent No. 10,464,992 (the "'992 Patent") and a post-grant review ("PGR") petition against the Company's U.S. Patent No. 10,828,345 (the "'345 Patent") seeking declarations of invalidity of the '992 Patent and '345 Patent. On June 23, 2021, Chengdu Kanghong filed motions to dismiss each of these petitions and terminate the respective proceedings, which were granted by the USPTO on June 25, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 11, 2020, anonymous parties filed two requests for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex parte&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; reexamination of the Company's U.S. Patent No. 10,406,226 and the '992 Patent, and the USPTO has granted both requests to initiate reexamination proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 5, 2021, Mylan Pharmaceuticals Inc. filed IPR petitions in the USPTO against the Company's U.S. Patent Nos. 9,254,338 (the "'338 Patent") and 9,669,069 (the "'069 Patent") seeking declarations of invalidity of the '338 Patent and the '069 Patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 7, 2021, Celltrion, Inc. filed a PGR petition in the USPTO against the Company's U.S. Patent No. 10,857,231 (the "'231 Patent") seeking a declaration of invalidity of the '231 Patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 26 and October 27, 2021, anonymous parties initiated opposition proceedings in the EPO against the Company's European Patent No. 2,944,306 (the "'306 Patent") seeking revocation of the '306 Patent in its entirety. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to EYLEA (aflibercept) Injection Pre-filled Syringe&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2020, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, "Novartis") filed a complaint with the U.S. International Trade Commission (the "ITC") pursuant to Section 337 of the Tariff Act of 1930 requesting that the ITC institute an investigation relating to the importation into the United States and/or sale within the United States after importation of EYLEA pre-filled syringes ("PFS") and/or components thereof which allegedly infringe Novartis&#x2019;s U.S. Patent No. 9,220,631 (the "'631 Patent"). Novartis also requested a permanent limited exclusion order forbidding entry into the United States of EYLEA PFS or components thereof; a permanent cease-and-desist order from the importation, sale, offer for sale, advertising, packaging, or solicitation of any sale by the Company of EYLEA PFS or components thereof; and a bond should the Company continue to import EYLEA PFS (if found to infringe) during, if applicable, any 60-day Presidential review period (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the period when the President of the United States (or his designee) can disapprove any ITC decision to issue an exclusion order or cease-and-desist order). The ITC instituted the investigation on July 22, 2020 and a trial was scheduled for April 19&#x2013;23, 2021. On March 26, 2021, the staff attorney appointed by the ITC's Office of Unfair Import Investigations ("OUII")&#x2014;an independent government party to the case representing the public interest&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determined that the '631 Patent is invalid on several grounds. On April 8, 2021, Novartis moved to terminate the ITC investigation in its entirety based on its withdrawal of the complaint; and, on May 3, 2021, the ITC terminated the investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2020, Novartis also filed a patent infringement lawsuit (as amended on August 2, 2021) in the U.S. District Court for the Northern District of New York asserting claims of the '631 Patent and seeking preliminary and permanent injunctions to prevent the Company from continuing to infringe the '631 Patent. Novartis also seeks a judgment of patent infringement of the '631 Patent, monetary damages (together with interest), an order of willful infringement of the '631 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuits, and attorneys' fees. On July 30, 2020, the court granted the Company's motion to stay these proceedings until a determination in the ITC proceedings discussed above, including any appeals therefrom, becomes final. On June 11, 2021, the court, at the request of Novartis, lifted the stay.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 16, 2020, the Company initiated two IPR petitions in the USPTO seeking a declaration of invalidity of the '631 Patent on two separate grounds. On January 15, 2021, the USPTO declined to institute an IPR proceeding on procedural grounds in light of the pending ITC investigation discussed above; the other IPR petition has been withdrawn. Following Novartis's motion to terminate the ITC investigation discussed above, on April 16, 2021 the Company filed a new IPR petition seeking a declaration of invalidity of the '631 Patent based on the same grounds that were the basis for the OUII staff attorney's determination discussed above. On October 26, 2021, the USPTO issued a decision instituting the IPR proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 17, 2020, the Company filed an antitrust lawsuit against Novartis and Vetter Pharma International Gmbh ("Vetter") in the United States District Court for the Southern District of New York seeking a declaration that the '631 Patent is unenforceable and a judgment that the defendants' conduct violates Sections 1 and 2 of the Sherman Antitrust Act of 1890, as amended (the "Sherman Antitrust Act"). The Company is also seeking injunctive relief and treble damages. On September 4, 2020, Novartis filed, and Vetter moved to join, a motion to dismiss the complaint, to transfer the lawsuit to the Northern District of New York, or to stay the suit; and on October 19, 2020, Novartis filed, and Vetter moved to join, a second motion to dismiss the complaint on different grounds. On January 25, 2021, the Company filed an amended complaint seeking a judgment that Novartis's conduct violates Section 2 of the Sherman Antitrust Act based on additional grounds, as well as a judgment of tortious interference with contract. On February 22, 2021, Novartis filed, and Vetter moved to join, a motion to dismiss the amended complaint. On September 21, 2021, the court granted Novartis and Vetter's motion to transfer this lawsuit to the Northern District of New York. As a result, this lawsuit was transferred to the same judge that had been assigned to the patent infringement lawsuit discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Related to "Most Favored Nation" Interim Final Rule&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 11, 2020, the Company filed a lawsuit in the United States District Court for the Southern District of New York against the U.S. Department of Health and Human Services, the Secretary of HHS, the Centers for Medicare &amp;amp; Medicaid Services ("CMS"), and the Administrator of CMS seeking declaratory and injunctive relief related to the interim final rule with comment period entitled "Most Favored Nation (MFN) Model" issued on November 20, 2020 by HHS, acting through CMS. On the same day, the Company filed a motion for a preliminary injunction and temporary restraining order, seeking to prevent implementation of the MFN Rule. On December 22, 2020, the court heard oral argument on the Company's motion for a preliminary injunction and temporary restraining order. On December 31, 2020, the court granted the Company's motion and issued a preliminary injunction. On February 2, 2021, the government stated to the court that the Solicitor General had determined not to appeal the preliminary injunction. On February 10, 2021, the court entered a 90-day stay of the litigation and subsequently extended the stay, with the most recent 30-day extension granted on October 11, 2021. On August 6, 2021, CMS issued a Notice of Proposed Rulemaking that proposes to rescind the MFN Rule.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to fasinumab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 21, 2020, the Company and Teva Pharmaceutical Industries Limited ("Teva") filed a lawsuit against Rinat Neurosciences Corp. ("Rinat"), a wholly owned subsidiary of Pfizer Inc., in the English High Court of Justice in London, seeking invalidation and revocation of Rinat's European Patent No. 2,270,048 (the "'048 Patent"), European Patent No. 1,871,416 (the "'416 Patent"), and European Patent No. 2,305,711 (the "'711 Patent"), each of which pertains to the use of NGF monoclonal antibodies to treat certain symptoms in patients suffering from osteoarthritis. On July 21, 2020, Rinat filed its defense and counterclaim seeking a declaration of infringement of the '048 Patent by fasinumab. The counterclaim also seeks a permanent injunction, damages, an accounting of profits, and costs and interest. On December 15, 2020, Rinat filed an amended defense and counterclaim seeking a declaration of infringement of the '711 Patent by fasinumab. On May 5, 2021, the court stayed this litigation on terms mutually agreed by the parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The '048 Patent is subject to opposition proceedings in the EPO, which were initiated by the Company on August 10, 2016 and two other opponents on August 11, 2016. On January 3, 2018, the Opposition Division of the EPO issued a preliminary, non-binding opinion regarding the validity of the '048 Patent, indicating that it considered the granted patent to be invalid. An oral &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hearing on the oppositions against the '048 Patent was held on November 29&#x2013;30, 2018, at which the Opposition Division upheld the validity of the '048 Patent's claims in amended form. The Company filed a notice of appeal to the TBA of the EPO on March 7, 2019. On October 21, 2020, Teva filed a notice of intervention with the TBA to take part in the appeal proceedings as an intervener. An oral hearing before the TBA has been scheduled for April 5&#x2013;6, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The '711 Patent is also subject to opposition proceedings in the EPO, which were initiated by the Company on May 1, 2018. On January 31, 2019, the Opposition Division of the EPO issued a preliminary, non-binding opinion regarding the validity of the '711 Patent, indicating that it considered the granted patent to be invalid. An oral hearing on the opposition against the '711 Patent was held on December 3, 2019, at which the Opposition Division upheld the validity of the '711 Patent's claims in amended form. The Company filed a notice of appeal to the TBA on December 20, 2019. On January 29, 2021, Teva filed a notice of intervention with the TBA to take part in the appeal proceedings as an intervener. An oral hearing before the TBA was held on July 29, 2021, at which the '711 Patent was revoked in its entirety. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to REGEN-COV (casirivimab and imdevimab)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 5, 2020, Allele Biotechnology and Pharmaceuticals, Inc. ("Allele") filed a lawsuit (as amended on April 8, 2021) against the Company in the United States District Court for the Southern District of New York, asserting infringement of U.S. Patent No. 10,221,221 (the "'221 Patent").&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allele seeks a judgment of patent infringement of the '221 Patent, an award of monetary damages (together with interest), an order of willful infringement of the '221 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuit, and attorneys' fees. On July 16, 2021, the Company filed a motion to dismiss the complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Justice Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating to its support of 501(c)(3) organizations that provide financial assistance to patients; documents concerning its provision of financial assistance to patients with respect to products sold or developed by Regeneron (including EYLEA, Praluent, ARCALYST, and ZALTRAP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;); and certain other related documents and communications. On June 24, 2020, the U.S. Attorney's Office for the District of Massachusetts filed a civil complaint in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. On August 24, 2020, the Company filed a motion to dismiss the complaint in its entirety. On December 4, 2020, the court denied the motion to dismiss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company and Regeneron Healthcare Solutions, Inc., a wholly-owned subsidiary of the Company, each received a civil investigative demand ("CID") from the U.S. Department of Justice pursuant to the federal False Claims Act relating to remuneration paid to physicians in the form of consulting fees, advisory boards, speaker fees, and payment or reimbursement for travel and entertainment allegedly in violation of the federal Anti-Kickback Statute. The CIDs relate to EYLEA, Praluent, Dupixent, ZALTRAP, ARCALYST, and Kevzara and cover the period from January 2015 to the present. On June 3, 2021, the United States District Court for the Central District of California unsealed a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; complaint filed against the Company, Regeneron Healthcare Solutions, Inc., and Sanofi-Aventis U.S. LLC by two &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; plaintiffs (known as relators) purportedly on behalf the United States and various states (the "State Plaintiffs"), asserting causes of action under the federal False Claims Act and state law. Also on June 3, 2021, the United States and the State Plaintiffs notified the court of their decision to decline to intervene in the case. On October 29, 2021, the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; plaintiffs filed an amended complaint in this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company received a CID from the U.S. Department of Justice pursuant to the federal False Claims Act. The CID states that the investigation concerns allegations that the Company (i) violated the False Claims Act by paying kickbacks to distributors and ophthalmology practices to induce purchase of EYLEA, including through discounts, rebates, credit card fees, free units of EYLEA, and inventory management systems; and (ii) inflated reimbursement rates for EYLEA by excluding applicable discounts, rebates, and benefits from the average sales price reported to CMS. The CID covers the period from January 2011 through June 2021. The Company is cooperating with this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Initiated by UnitedHealthcare&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 17, 2020, UnitedHealthcare Insurance Company and United Healthcare Services, Inc. (collectively, "UHC") filed a lawsuit against the Company in the United States District Court for the Southern District of New York alleging UHC has been damaged by the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. UHC alleges causes of action under state law and the federal Racketeer Influenced and Corrupt Organizations Act (the "RICO Act") and seeks monetary damages and equitable relief. On March 1, 2021, the Company filed a motion to dismiss the complaint in its entirety. On March 25, 2021, UHC filed an amended complaint; and, on April 22, 2021, the Company filed a motion to dismiss this amended complaint in its entirety. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Proceedings Initiated by Humana&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 22, 2021, Humana Inc. ("Humana") filed a lawsuit against the Company in the United States District Court for the Southern District of New York alleging Humana has been damaged by the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. Humana alleges causes of action under state law and the RICO Act and seeks monetary damages and equitable relief. On September 27, 2021, the Company filed a motion to dismiss the complaint in its entirety.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shareholder Demand&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or about September 30, 2020, the Company's board of directors received a demand letter from a purported shareholder of the Company. The demand alleges that Regeneron and its shareholders have been damaged by the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The demand letter requests that the Company's board of directors investigate alleged breaches of fiduciary duty by its officers and directors and other alleged violations of law and corporate governance practices and procedures; bring legal action against the persons responsible for causing the alleged damages; and implement and maintain an effective system of internal controls, compliance mechanisms, and corporate governance practices and procedures. The Company's board of directors, working with outside counsel, investigated and evaluated the allegations in the demand letter and has concluded that pursuing the claims alleged in the demand would not be in the Company's best interests at this time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Proceedings Relating to Shareholder Derivative Complaint&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 29, 2021, an alleged shareholder filed a shareholder derivative complaint in the New York Supreme Court, naming the current and certain former members of the Company's board of directors and certain current and former executive officers of the Company as defendants and Regeneron as a nominal defendant. The complaint asserts that the individual defendants breached their fiduciary duties in relation to the allegations in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The complaint seeks an award of damages allegedly sustained by the Company; an order requiring Regeneron to take all necessary actions to reform and improve its corporate governance and internal procedures; disgorgement from the individual defendants of all profits and benefits obtained by them resulting from their sales of Regeneron stock; and costs and disbursements of the action, including attorneys' fees. On July 28, 2021, the defendants filed a notice of removal, removing the case from the New York Supreme Court to the U.S. District Court for the Southern District of New York. On September 24, 2021, the individual defendants moved to dismiss the complaint in its entirety. Also on September 24, 2021, the plaintiff filed a motion to remand the case to the New York Supreme Court.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="i252bf0019ce741548a01b718a72d854a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfMzUxMjk_7d4ef2e1-ad07-448f-9fe0-e30046cc082c">Costs associated with the Company's involvement in legal proceedings are expensed as incurred.</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i2e4f524ab89b4891b4ccfbd3555e3a26_I20190225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfNDI0MA_0ae9c262-07fe-4b56-b7e4-102d23bd059c"
      unitRef="claim">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i870177ce53f7404e98979e8f07c9609f_I20190225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfNDI3Mw_646b4a82-893c-47f1-be94-129edfb0a88a"
      unitRef="claim">1</us-gaap:LossContingencyPendingClaimsNumber>
    <regn:LossContingencyClaimsInvalidNumber
      contextRef="i2e4f524ab89b4891b4ccfbd3555e3a26_I20190225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfNDM0NA_a4f30906-51a0-423e-b4f8-cd09aa7d7d9a"
      unitRef="claim">2</regn:LossContingencyClaimsInvalidNumber>
    <regn:GainContingencyInterPartesReviewFiledNumber
      contextRef="iae9a73d5ea4745d09d9bbb09f273f524_D20170728-20170731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfMTMwMTU_1c6b753a-8ca7-430d-9b86-0a5e4d9aadc7"
      unitRef="claim">2</regn:GainContingencyInterPartesReviewFiledNumber>
    <regn:GainContingencyClaimsInvalidatedNumber
      contextRef="i34e55477ad8e4cfebda758de4b6f0516_I20190214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfMTM3NzA_d6b53929-5945-4c00-ab32-2ad1ea7f4ef6"
      unitRef="claim">17</regn:GainContingencyClaimsInvalidatedNumber>
    <regn:LossContingencyExParteReexaminationFiledNumber
      contextRef="i4c1e030c474b48ada51944d7eb45dbb7_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfMTg4Njg_84405472-4ae9-481a-b32e-f27fd38e3033"
      unitRef="request">2</regn:LossContingencyExParteReexaminationFiledNumber>
    <regn:GainContingencyInterPartesReviewFiledNumber
      contextRef="ib4b960d3dff6442ba38d7de8747b8883_D20200716-20200716"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFlMzU3OTZmMDM5YjQ5NWJhNGIxMDg3N2U4NWExYzZmL3NlYzphZTM1Nzk2ZjAzOWI0OTViYTRiMTA4NzdlODVhMWM2Zl82NC9mcmFnOjcyY2U3Y2MzYWFhYTRlN2M5NDRiNjFlM2IyOTk0M2IzL3RleHRyZWdpb246NzJjZTdjYzNhYWFhNGU3Yzk0NGI2MWUzYjI5OTQzYjNfMjIxNjg_5910e297-28e3-4def-b648-3eefa669426c"
      unitRef="claim">2</regn:GainContingencyInterPartesReviewFiledNumber>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237222174344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 22, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">REGENERON PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3444607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">777 Old Saw Mill River Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tarrytown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10591-6707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">847-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock - par value $.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">REGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000872589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,823,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,719,735<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237222531352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,432.4<span></span>
</td>
<td class="nump">$ 2,193.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,355.2<span></span>
</td>
<td class="nump">1,393.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">5,452.0<span></span>
</td>
<td class="nump">4,114.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">2,053.8<span></span>
</td>
<td class="nump">1,916.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">482.0<span></span>
</td>
<td class="nump">160.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">13,775.4<span></span>
</td>
<td class="nump">9,779.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">5,631.3<span></span>
</td>
<td class="nump">3,135.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">3,395.7<span></span>
</td>
<td class="nump">3,221.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">723.2<span></span>
</td>
<td class="nump">858.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">145.9<span></span>
</td>
<td class="nump">168.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">23,671.5<span></span>
</td>
<td class="nump">17,163.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="nump">427.0<span></span>
</td>
<td class="nump">475.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,061.0<span></span>
</td>
<td class="nump">1,644.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">719.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">507.8<span></span>
</td>
<td class="nump">577.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,714.8<span></span>
</td>
<td class="nump">2,697.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">1,979.6<span></span>
</td>
<td class="nump">1,978.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">717.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">56.5<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">662.6<span></span>
</td>
<td class="nump">687.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,413.5<span></span>
</td>
<td class="nump">6,138.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">7,919.3<span></span>
</td>
<td class="nump">6,716.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">16,739.3<span></span>
</td>
<td class="nump">10,893.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, at cost; 17,930,390 shares in 2021 and 16,431,520 shares in 2020</a></td>
<td class="num">(7,410.2)<span></span>
</td>
<td class="num">(6,613.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">17,258.0<span></span>
</td>
<td class="nump">11,025.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">23,671.5<span></span>
</td>
<td class="nump">17,163.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237220420840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized (in shares)</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock (in shares)</a></td>
<td class="nump">17,930,390<span></span>
</td>
<td class="nump">16,431,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized (in shares)</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued (in shares)</a></td>
<td class="nump">1,848,970<span></span>
</td>
<td class="nump">1,848,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding (in shares)</a></td>
<td class="nump">1,848,970<span></span>
</td>
<td class="nump">1,848,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized (in shares)</a></td>
<td class="nump">320,000,000<span></span>
</td>
<td class="nump">320,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued (in shares)</a></td>
<td class="nump">124,608,241<span></span>
</td>
<td class="nump">121,533,460<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237306964792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,452.8<span></span>
</td>
<td class="nump">$ 2,294.0<span></span>
</td>
<td class="nump">$ 11,120.0<span></span>
</td>
<td class="nump">$ 6,074.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">665.4<span></span>
</td>
<td class="nump">684.6<span></span>
</td>
<td class="nump">2,122.5<span></span>
</td>
<td class="nump">1,990.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">445.0<span></span>
</td>
<td class="nump">326.9<span></span>
</td>
<td class="nump">1,265.3<span></span>
</td>
<td class="nump">1,042.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating expense (income), net</a></td>
<td class="nump">42.0<span></span>
</td>
<td class="num">(44.6)<span></span>
</td>
<td class="num">(29.8)<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs and expenses, total</a></td>
<td class="nump">1,605.6<span></span>
</td>
<td class="nump">1,240.9<span></span>
</td>
<td class="nump">4,812.9<span></span>
</td>
<td class="nump">3,664.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,847.2<span></span>
</td>
<td class="nump">1,053.1<span></span>
</td>
<td class="nump">6,307.1<span></span>
</td>
<td class="nump">2,409.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(16.4)<span></span>
</td>
<td class="num">(28.5)<span></span>
</td>
<td class="nump">558.5<span></span>
</td>
<td class="nump">218.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(14.2)<span></span>
</td>
<td class="num">(26.3)<span></span>
</td>
<td class="num">(43.2)<span></span>
</td>
<td class="num">(42.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(30.6)<span></span>
</td>
<td class="num">(54.8)<span></span>
</td>
<td class="nump">515.3<span></span>
</td>
<td class="nump">176.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">1,816.6<span></span>
</td>
<td class="nump">998.3<span></span>
</td>
<td class="nump">6,822.4<span></span>
</td>
<td class="nump">2,585.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">184.4<span></span>
</td>
<td class="nump">156.2<span></span>
</td>
<td class="nump">976.1<span></span>
</td>
<td class="nump">221.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,632.2<span></span>
</td>
<td class="nump">$ 842.1<span></span>
</td>
<td class="nump">$ 5,846.3<span></span>
</td>
<td class="nump">$ 2,364.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 15.37<span></span>
</td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="nump">$ 55.42<span></span>
</td>
<td class="nump">$ 21.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 14.33<span></span>
</td>
<td class="nump">$ 7.39<span></span>
</td>
<td class="nump">$ 52.29<span></span>
</td>
<td class="nump">$ 20.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">106.2<span></span>
</td>
<td class="nump">105.5<span></span>
</td>
<td class="nump">105.5<span></span>
</td>
<td class="nump">108.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">113.9<span></span>
</td>
<td class="nump">113.9<span></span>
</td>
<td class="nump">111.8<span></span>
</td>
<td class="nump">116.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Statements of Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,632.2<span></span>
</td>
<td class="nump">$ 842.1<span></span>
</td>
<td class="nump">$ 5,846.3<span></span>
</td>
<td class="nump">$ 2,364.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on debt securities</a></td>
<td class="num">(6.4)<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
<td class="num">(20.5)<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gain (loss) on cash flow hedges</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">1,626.0<span></span>
</td>
<td class="nump">837.4<span></span>
</td>
<td class="nump">5,826.5<span></span>
</td>
<td class="nump">2,373.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,279.9<span></span>
</td>
<td class="nump">1,482.2<span></span>
</td>
<td class="nump">8,142.0<span></span>
</td>
<td class="nump">3,945.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods, collaboration and contract manufacturing</a></td>
<td class="nump">238.8<span></span>
</td>
<td class="nump">131.0<span></span>
</td>
<td class="nump">961.4<span></span>
</td>
<td class="nump">312.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_CollaborationRevenueMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,073.9<span></span>
</td>
<td class="nump">653.2<span></span>
</td>
<td class="nump">2,783.0<span></span>
</td>
<td class="nump">1,694.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">158.6<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
<td class="nump">433.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_CollaborationandContractManufacturingMember', window );">Cost of collaboration and contract manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods, collaboration and contract manufacturing</a></td>
<td class="nump">$ 214.4<span></span>
</td>
<td class="nump">$ 143.0<span></span>
</td>
<td class="nump">$ 493.5<span></span>
</td>
<td class="nump">$ 454.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_CollaborationandContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_CollaborationandContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237220051704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th">
<div>Class A Stock </div>
<div>Common Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 11,089.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 4,428.6<span></span>
</td>
<td class="nump">$ 7,379.8<span></span>
</td>
<td class="nump">$ 21.1<span></span>
</td>
<td class="num">$ (739.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">817.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(155.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(155.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of Common Stock</a></td>
<td class="num">(336.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (336.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">108.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">624.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(30.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.7)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2020</a></td>
<td class="nump">12,133.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">5,211.4<span></span>
</td>
<td class="nump">8,004.4<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="num">$ (1,073.8)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">11,089.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">4,428.6<span></span>
</td>
<td class="nump">7,379.8<span></span>
</td>
<td class="nump">21.1<span></span>
</td>
<td class="num">$ (739.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">2,364.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.7)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">10,125.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">6,592.8<span></span>
</td>
<td class="nump">9,743.8<span></span>
</td>
<td class="nump">30.8<span></span>
</td>
<td class="num">$ (6,242.0)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.7)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2020</a></td>
<td class="nump">12,133.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">5,211.4<span></span>
</td>
<td class="nump">8,004.4<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="num">$ (1,073.8)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">1,355.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,355.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(416.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(416.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of Common Stock</a></td>
<td class="num">(5,071.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,071.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">105.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">897.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">44.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.6)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2020</a></td>
<td class="nump">9,057.4<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">6,263.0<span></span>
</td>
<td class="nump">8,901.7<span></span>
</td>
<td class="nump">35.5<span></span>
</td>
<td class="num">$ (6,142.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">297.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(80.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of Common Stock</a></td>
<td class="num">(100.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">104.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">842.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">842.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(4.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.7)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">10,125.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">6,592.8<span></span>
</td>
<td class="nump">9,743.8<span></span>
</td>
<td class="nump">30.8<span></span>
</td>
<td class="num">$ (6,242.0)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.4)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">11,025.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">6,716.2<span></span>
</td>
<td class="nump">10,893.0<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
<td class="num">$ (6,613.3)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">93.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(66.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of Common Stock</a></td>
<td class="num">(323.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (323.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">135.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">1,115.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,115.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(13.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.1)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">11,977.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">6,887.8<span></span>
</td>
<td class="nump">12,008.2<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="num">$ (6,935.3)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.4)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">11,025.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">6,716.2<span></span>
</td>
<td class="nump">10,893.0<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
<td class="num">$ (6,613.3)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">5,846.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.9)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2021</a></td>
<td class="nump">17,258.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">7,919.3<span></span>
</td>
<td class="nump">16,739.3<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="num">$ (7,410.2)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.1)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2021</a></td>
<td class="nump">11,977.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">6,887.8<span></span>
</td>
<td class="nump">12,008.2<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="num">$ (6,935.3)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">216.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(26.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">14.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of Common Stock</a></td>
<td class="num">(288.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (288.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">135.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">3,098.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,098.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.7)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2021</a></td>
<td class="nump">15,127.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">7,225.8<span></span>
</td>
<td class="nump">15,107.1<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
<td class="num">$ (7,221.4)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Common Stock for equity awards granted under long-term incentive plans</a></td>
<td class="nump">816.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">816.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations</a></td>
<td class="num">(269.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(269.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance/distribution of Common Stock for 401(k) Savings Plan</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of Common Stock</a></td>
<td class="num">(190.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (190.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation charges</a></td>
<td class="nump">136.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">1,632.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,632.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.9)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2021</a></td>
<td class="nump">$ 17,258.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 7,919.3<span></span>
</td>
<td class="nump">$ 16,739.3<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="num">$ (7,410.2)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued/Distributed During Period, Shares, Employee Benefit Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued/Distributed During Period, Value, Employee Benefit Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237225170840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 5,846.3<span></span>
</td>
<td class="nump">$ 2,364.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">211.7<span></span>
</td>
<td class="nump">174.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation expense</a></td>
<td class="nump">413.3<span></span>
</td>
<td class="nump">310.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Gains on marketable and other securities, net</a></td>
<td class="num">(524.6)<span></span>
</td>
<td class="num">(162.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items, net</a></td>
<td class="nump">264.4<span></span>
</td>
<td class="nump">51.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="nump">58.8<span></span>
</td>
<td class="nump">117.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable</a></td>
<td class="num">(1,342.9)<span></span>
</td>
<td class="num">(1,275.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(330.6)<span></span>
</td>
<td class="num">(402.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other assets</a></td>
<td class="num">(316.8)<span></span>
</td>
<td class="nump">16.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">(Decrease) increase in deferred revenue</a></td>
<td class="num">(71.2)<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable, accrued expenses, and other liabilities</a></td>
<td class="nump">500.4<span></span>
</td>
<td class="nump">80.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="num">(1,137.5)<span></span>
</td>
<td class="num">(976.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">4,708.8<span></span>
</td>
<td class="nump">1,387.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable and other securities</a></td>
<td class="num">(4,872.3)<span></span>
</td>
<td class="num">(2,642.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales or maturities of marketable and other securities</a></td>
<td class="nump">1,897.3<span></span>
</td>
<td class="nump">3,330.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(397.0)<span></span>
</td>
<td class="num">(453.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(3,372.0)<span></span>
</td>
<td class="nump">234.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of Common Stock</a></td>
<td class="nump">1,129.6<span></span>
</td>
<td class="nump">2,471.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments in connection with Common Stock tendered for employee tax obligations</a></td>
<td class="num">(450.3)<span></span>
</td>
<td class="num">(652.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of Common Stock</a></td>
<td class="num">(778.5)<span></span>
</td>
<td class="num">(5,465.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,981.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from bridge loan facility</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,500.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of bridge loan facility</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1,500.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(99.2)<span></span>
</td>
<td class="num">(1,665.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">1,237.6<span></span>
</td>
<td class="num">(43.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">2,207.3<span></span>
</td>
<td class="nump">1,630.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">$ 3,444.9<span></span>
</td>
<td class="nump">$ 1,586.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237316424952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Financial Statements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Interim Financial Statements</a></td>
<td class="text">Interim Financial Statements<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December&#160;31, 2020 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237224986824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Sales</a></td>
<td class="text">Product Sales<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.309%"><tr><td style="width:1.0%"/><td style="width:46.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Net Product Sales in the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,473.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,530.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,142.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Previously, Sanofi recorded net product sales of Praluent in the United States. See Note 3 for further details.</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company had $4.086&#160;billion and $3.112&#160;billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for the three and nine months ended September&#160;30, 2021 and 2020. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"/><td style="width:45.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Besse Medical, a subsidiary of AmerisourceBergen Corporation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government (see Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Sales to the U.S. Government represented less than 10% of total gross product revenue during the period.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237220008792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration, License, and Other Agreements</a></td>
<td class="text">Collaboration, License, and Other Agreements<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a. Sanofi </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.118%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestone earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of losses in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi commercial expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antibody</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies (the "Antibody Collaboration"), which currently consists of Dupixent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (dupilumab), Kevzara</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sarilumab), and itepekimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Antibody License and Collaboration Agreement ("LCA"), Sanofi is generally responsible for funding 80%&#8211;100% of agreed-upon development costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi leads commercialization activities for products under the Antibody Collaboration, subject to the Company's right to co-commercialize such products. In addition to profit and loss sharing, the Company is entitled to receive sales milestone payments from Sanofi. In the third quarter of 2020, the Company earned, and recognized as revenue, the first $50.0&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.0&#160;billion on a rolling twelve-month basis. In the third quarter of 2021, the Company earned, and recognized as revenue, the second $50.0&#160;million sales-based milestone from Sanofi, upon aggregate annual sales of antibodies outside the United States (including Praluent) exceeding $1.5&#160;billion on a rolling twelve-month basis. We are entitled to receive up to an aggregate of $150.0&#160;million in additional sales milestone payments from Sanofi.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.502%"><tr><td style="width:1.0%"/><td style="width:49.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.489%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company and Sanofi entered into an amendment to the LCA in connection with, among other things, the removal of Praluent from the LCA such that (i) effective April 1, 2020, the LCA no longer governs the development, manufacture, or commercialization of Praluent and (ii) the quarterly period ended March 31, 2020 was the last quarter for which Sanofi and the Company shared profits and losses for Praluent under the LCA. The parties also entered into a Praluent Cross License &amp; Commercialization Agreement (the "Praluent Agreement") pursuant to which, effective April 1, 2020, the Company, at its sole cost, became solely responsible for the development and commercialization of Praluent in the United States, and Sanofi, at its sole cost, became solely responsible for the development and commercialization of Praluent outside of the United States. Under the Praluent Agreement, Sanofi will pay the Company a 5% royalty on Sanofi&#8217;s net product sales of Praluent outside the United States until March 31, 2032. The Company will not owe Sanofi royalties on the Company&#8217;s net product sales of Praluent in the United States. Although each party will be responsible for manufacturing Praluent for its respective territory, the parties have entered into definitive supply agreements under which, for a certain transitional period, the Company will continue to supply drug substance to Sanofi and Sanofi will continue to supply finished product to Regeneron. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to any intellectual property or product liability litigation relating to Praluent, the parties have agreed that, effective April 1, 2020, Regeneron and Sanofi each will be solely responsible for any such litigation (including damages and other costs and expenses thereof) in the United States and outside the United States, respectively, arising out of Praluent sales or other activities on or after April 1, 2020 (subject to Sanofi's right to set off a portion of any third-party royalty payments resulting from certain patent litigation proceedings against up to 50% of any Praluent royalty payment owed to Regeneron). The parties will each bear 50% of any damages arising out of Praluent sales or other activities prior to April 1, 2020. See Note 12 for discussion of legal proceedings related to Praluent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-Oncology </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a collaboration with Sanofi to research, develop, and commercialize antibody-based cancer treatments in the field of immuno-oncology (the "IO Collaboration"). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective December 31, 2018, the Company and Sanofi entered into an Amended and Restated Immuno-oncology Discovery and Development Agreement ("Amended IO Discovery Agreement"), which narrowed the scope of the existing discovery and development activities conducted by the Company under the 2015 IO Discovery Agreement to developing therapeutic bispecific antibodies targeting (i) BCMA and CD3 (the "BCMAxCD3 Program") and (ii) MUC16 and CD3 (the "MUC16xCD3 Program") through clinical proof-of-concept. During the first quarter of 2021, Sanofi did not exercise its options to license rights to these product candidates; as a result, we retain the exclusive right to develop and commercialize such product candidates and Sanofi will receive a royalty on sales (if any). In addition, the Company has no further obligations to develop drug product candidates under the Amended IO Discovery Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Immuno-oncology License and Collaboration Agreement, the parties are co-developing and co-commercializing Libtayo (cemiplimab). The parties share equally, on an ongoing basis, agreed-upon development and commercialization expenses for Libtayo. The Company has principal control over the development of Libtayo and leads commercialization activities in the United States (see Note 2 for related product sales information), while Sanofi leads commercialization activities outside of the United States. The parties share equally in profits and losses in connection with the commercialization of Libtayo.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021, we updated our estimate of the total research and development costs expected to be incurred (which resulted in a change to the estimate of the stage of completion) in connection with the IO Collaboration, and, as a result, recorded a cumulative catch-up adjustment of $66.9&#160;million as a reduction to other operating income.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.941%"><tr><td style="width:1.0%"/><td style="width:49.631%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.314%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.317%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities include up-front payments received from Sanofi for which recognition has been deferred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the estimated consideration under the IO Collaboration related to the Company's obligation that was unsatisfied (or partially unsatisfied) as of September&#160;30, 2021 was $591.4&#160;million. This amount is expected to be recognized over the remaining period in which the Company is obligated to satisfy its obligation in connection with performing development activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">b. Bayer </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license and collaboration agreement with Bayer for the global development and commercialization of EYLEA outside the United States. All agreed upon EYLEA development expenses incurred by the Company and Bayer are shared equally. Bayer markets EYLEA outside the United States, where, for countries other than Japan, the companies share equally in profits and losses from sales of EYLEA. In Japan, the Company is currently entitled to receive a tiered percentage of between 33.5% and 40.0% of EYLEA net product sales through 2021, and thereafter, the companies will share equally in profits and losses from sales of EYLEA. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our Bayer EYLEA collaboration are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.286%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's net profit in connection with commercialization of EYLEA outside the United States</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="padding-left:15.75pt;text-indent:-9pt"><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Bayer research and development expenses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with our Bayer EYLEA collaboration:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"><tr><td style="width:1.0%"/><td style="width:49.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">c. Teva</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Teva are parties to a collaboration agreement (the "Teva Collaboration Agreement") to develop and commercialize fasinumab globally, excluding certain Asian countries that are subject to our collaboration agreement with Mitsubishi Tanabe Pharma Corporation. The Company leads global development activities, and the parties share development costs equally, on an ongoing basis, under a global development plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our collaboration with Teva are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.286%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front and development milestone payments received</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Teva Collaboration Agreement:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"><tr><td style="width:1.0%"/><td style="width:49.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities include up-front and development milestone payments received from Teva for which recognition has been deferred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the estimated consideration under the Teva Collaboration Agreement related to the Company's obligation that was unsatisfied (or partially unsatisfied) as of September&#160;30, 2021 was $96.7&#160;million. This amount is expected to be recognized over the remaining period in which the Company is obligated to satisfy its obligation in connection with performing development activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">d. U.S. Government </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">REGEN-COV (casirivimab and imdevimab)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, we announced an expansion of our Other Transaction Agreement with the Biomedical Advanced Research Development Authority ("BARDA"), pursuant to which the U.S. Department of Health and Human Services ("HHS") was obligated to fund certain of our costs incurred for research and development activities related to COVID-19 treatments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we entered into an agreement with entities acting at the direction of BARDA and the U.S. Department of Defense to manufacture and deliver filled and finished drug product of REGEN-COV to the U.S. government. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced an agreement with an entity acting on behalf of the U.S. Department of Defense and HHS to manufacture and deliver additional filled and finished drug product of REGEN-COV to the U.S. government. Pursuant to the agreement, the U.S. government was obligated to purchase the 1.25&#160;million doses of drug product that we delivered by June 30, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has completed its final deliveries of drug product under the agreements described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company announced an amendment to its January 2021 agreement to supply the U.S. government with an additional 1.4&#160;million doses of REGEN-COV. Pursuant to the agreement, the U.S. government is obligated to purchase all filled and finished doses of such additional drug product delivered by January 31, 2022, resulting in payments to the Company of up to $2.940&#160;billion in the aggregate. Additionally, Roche will supply a portion of the doses to Regeneron to fulfill our agreement with the U.S. government (see "Roche" below for further details regarding our collaboration agreement with Roche).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 for REGEN-COV net product sales recognized in connection with these agreements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">e. Roche</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, we entered into a collaboration agreement (the "Roche Collaboration Agreement") with Roche to develop, manufacture, and distribute the casirivimab and imdevimab antibody cocktail (known as REGEN-COV in the United States and Ronapreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in other countries). We lead global development activities for casirivimab and imdevimab, and the parties jointly fund certain ongoing studies, as well as any mutually agreed additional new global studies to evaluate further the potential of casirivimab and imdevimab in treating or preventing COVID-19. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the agreement, each party is obligated to dedicate a certain amount of manufacturing capacity to casirivimab and imdevimab each year. We distribute the product in the United States and Roche distributes the product outside of the United States. The parties share gross profits from worldwide sales based on a pre-specified formula, depending on the amount of manufactured product supplied by each party to the market. Each quarter, a single payment is due from one party to the other to true-up the global gross profits between the parties. If Regeneron is to receive a true-up payment from Roche, such amount will be recorded to Collaboration revenue. If Regeneron is to make a true-up payment to Roche, such amount will be recorded to Cost of goods sold.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts recognized in our Statements of Operations in connection with the Roche Collaboration Agreement are as follows:</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.411%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit true-up payment owed from Roche in connection with sales of casirivimab and imdevimab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Roche Collaboration Agreement:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"><tr><td style="width:1.0%"/><td style="width:49.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">f. Intellia</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2016, we entered into a license and collaboration agreement with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapeutic development. The parties collaborate to conduct research for the discovery, development, and commercialization of new therapies, in addition to the research and technology development of the CRISPR/Cas9 platform.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, we expanded our existing collaboration with Intellia to provide us with rights to develop products for additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CRISPR/Cas9-based therapeutic targets and for the parties to jointly develop potential products for the treatment of hemophilia A and B. In addition, we also received non-exclusive rights to independently develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> gene edited products. In connection with the agreement, we made a $70.0&#160;million up-front payment and purchased shares of Intellia common stock for an aggregate purchase price of $30.0&#160;million. The up-front payment and the amount paid in excess of the fair market value of the shares purchased, or $15.0&#160;million, were recorded to Research and development expense during the three months ended June 30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237216708792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share</a></td>
<td class="text">Net Income Per Share <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing net income by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net income per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. Diluted net income per share includes the potential dilutive effect of other securities as if such securities were converted or exercised during the period, when the effect is dilutive. The calculations of basic and diluted net income per share are as follows:</span></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"/><td style="width:48.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.799%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,846.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.181%"><tr><td style="width:1.0%"/><td style="width:36.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.257%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Shares in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237220340744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities as of September&#160;30, 2021 and December&#160;31, 2020 consist of both available-for-sale debt securities of investment grade issuers (see below and Note 6) as well as equity securities of publicly traded companies (see Note 6).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's investments in available-for-sale debt securities: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:46.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,911.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,924.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,600.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,614.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,649.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,689.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its investments in available-for-sale debt securities based on their contractual maturity dates. The available-for-sale debt securities listed as of September&#160;30, 2021 mature at various dates through September 2026. The fair values of available-for-sale debt securities by contractual maturity consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.473%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,355.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,259.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,295.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,614.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,689.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the fair value of the Company's available-for-sale debt securities&#160;that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.590%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,932.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,932.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2021, realized gains and losses on sales of marketable securities were not material. For the three months ended September&#160;30, 2020, realized gains and losses on sales of marketable securities were not material. Realized gains were $28.5 million and realized losses were not material for the nine months ended September&#160;30, 2020.</span></div>With respect to marketable securities, for the three and nine months ended September&#160;30, 2021 and 2020, amounts reclassified from Accumulated other comprehensive income into Other (expense) income, net were related to realized gains and losses on sales of available-for-sale debt securities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237216743688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Significant other unobservable inputs</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:48.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,924.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,924.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,614.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,528.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,689.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held certain restricted equity securities as of September&#160;30, 2021 which are subject to transfer restrictions that expire at various dates through 2024. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021, we recorded $29.1 million of net unrealized losses and $523.8 million of net unrealized gains, respectively, on equity securities in Other (expense) income, net. During the three and nine months ended September&#160;30, 2020, we recorded $37.5&#160;million of net unrealized losses and $133.8&#160;million of net unrealized gains, respectively, on equity securities in Other (expense) income, net. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the investments summarized in the table above,&#160;as of September&#160;30, 2021 and December&#160;31, 2020, the Company had $40.0 million and $59.2&#160;million, respectively, in equity investments that do not have a readily determinable fair value. These investments are recorded within Other noncurrent assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term debt (see Note 8), which was determined based on Level 2 inputs, was estimated to be $1.891&#160;billion and $1.958 billion as of September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237216680024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"><tr><td style="width:1.0%"/><td style="width:47.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred costs represent the costs of product manufactured and shipped to the Company's collaborators for which recognition of revenue has been deferred. For the three and nine months ended September&#160;30, 2021, Cost of goods sold included inventory write-offs and reserves totaling $38.7 million and $188.0 million, respectively. For the three and nine months ended September 30, 2020, Cost of goods sold included inventory write-offs and reserves totaling $11.8&#160;million and $23.6&#160;million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237328223352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bridge Loan Facility</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 10, in the second quarter of 2020, we purchased shares of our Common Stock from Sanofi in connection with Sanofi's secondary offering of our Common Stock held by Sanofi. This purchase was partially funded with proceeds from loans under a $1.5&#160;billion senior unsecured bridge loan facility (the "Bridge Facility") which was entered into in May 2020. The loans under the Bridge Facility bore interest at a variable interest rate based on either the London Interbank Offered Rate or the alternate base rate, plus an applicable margin that varied with our debt rating and total leverage ratio. The Bridge Facility was repaid in full during the third quarter of 2020 following the closing of the issuance and sale of the Company's senior notes (as described below).</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we issued and sold $1.250&#160;billion aggregate principal amount of senior unsecured notes due 2030 and $750 million aggregate principal amount of senior unsecured notes due 2050. Long-term debt in connection with our senior unsecured notes (collectively, the "Notes"), net of underwriting discounts and offering expenses, consists of the following:</span></div><div style="margin-bottom:1pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"/><td style="width:61.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.013%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.750% Senior Notes due September 2030</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.800% Senior Notes due September 2050</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to the Notes for the three and nine months ended September&#160;30, 2021 was $11.1&#160;million and $33.3&#160;million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218825144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesThe Company is subject to U.S. federal, state, and foreign income taxes. The Company's effective tax rate was 10.2% and 15.6% for the three months ended September&#160;30, 2021 and 2020, respectively, and 14.3% and 8.6% for the nine months ended September&#160;30, 2021 and 2020, respectively. The Company's effective tax rate for the three and nine months ended September&#160;30, 2021 was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation, income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate, the foreign-derived intangible income deduction, and federal tax credits for research activities. In addition, the effective tax rate for the nine months ended September 30, 2021 was positively impacted by the reversal of liabilities related to uncertain tax positions. During the nine months ended September&#160;30, 2021, we reduced the amount of liabilities for uncertain tax positions related to the Company&#8217;s federal income tax returns for 2015 and 2016, as these audits are effectively settled. The Company's federal income tax returns for 2017 and 2018 are currently under audit by the Internal Revenue Service ("IRS"). The Company's effective tax rate for the three and nine months ended September&#160;30, 2020 was positively impacted, compared to the U.S. federal statutory rate, primarily by stock-based compensation, and, to a lesser extent, income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate and federal tax credits for research activities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237216729496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, our board of directors authorized a share repurchase program to repurchase up to&#160;$1.0 billion&#160;of our Common Stock. The share repurchase program permitted the Company to effect repurchases through a variety of methods, including open-market transactions (including pursuant to a trading plan adopted in accordance with Rule 10b5-1 of the Exchange Act), privately negotiated transactions, accelerated share repurchases, block trades, and other transactions in compliance with Rule 10b-18 of the Exchange Act. As of December&#160;31, 2020, the Company had repurchased the entire $1.0 billion it was authorized to repurchase under the program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, our board of directors authorized an additional share repurchase program to repurchase up to $1.5&#160;billion of our Common Stock. The share repurchase program was approved under terms substantially similar to the November 2019 share repurchase program described above. Repurchases may be made from time to time at management&#8217;s discretion, and the timing and amount of any such repurchases will be determined based on share price, market conditions, legal requirements, and other relevant factors. The program has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases in the future. As of September&#160;30, 2021, $697.3&#160;million remained available for share repurchases under the program. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the shares of our Common Stock we repurchased under the programs during the three and nine months ended September&#160;30, 2021 and 2020 and the cost of the shares received, which were recorded as Treasury Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"><tr><td style="width:1.0%"/><td style="width:44.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares received </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi Funding of Certain Development Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company and Sanofi entered into a letter agreement (the "Letter Agreement") in connection with, among other matters, the allocation of additional funds to certain activities relating to dupilumab and itepekimab (collectively, the "Dupilumab/Itepekimab Eligible Investments"). Pursuant to the Letter Agreement, we agreed to allow Sanofi to satisfy its funding obligations with respect to Dupilumab/Itepekimab Eligible Investments, as well as Libtayo development costs, for quarterly periods ending on September 30, 2020 by selling our Common Stock owned by Sanofi. During the nine months ended September&#160;30, 2020, Sanofi elected to sell, and we elected to purchase (by issuing a credit towards the amount owed by Sanofi), 77,677 shares of our Common Stock to satisfy Sanofi's funding obligation related to Libtayo development costs, and we recorded the cost of the shares received, or $41.7&#160;million, as Treasury Stock. During the nine months ended September&#160;30, 2020, Sanofi elected to sell, and we elected to purchase (in cash), 171,471 shares of our Common Stock in connection with Sanofi's funding obligation for Dupilumab/Itepekimab Eligible Investments, and we recorded the cost of the shares received, or $93.3&#160;million, as Treasury Stock. During the three months ended September&#160;30, 2020, there were no shares of our Common Stock purchased from Sanofi to satisfy Sanofi's funding obligations related to Libtayo development costs and/or Dupilumab/Itepekimab Eligible Investments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Stock Purchased from Sanofi</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, a secondary offering of 13,014,646 shares of our Common Stock (the "Secondary Offering") held by Sanofi was completed. In connection with the Secondary Offering, we also purchased 9,806,805 shares directly from Sanofi for an aggregate purchase amount of $5.0&#160;billion (the "Stock Purchase"). As a result of the Secondary Offering and the Stock Purchase, Sanofi disposed of all of its shares of our Common Stock, other than 400,000 shares that it retained as of the closing of the Secondary Offering and the Stock Purchase (a portion of which Sanofi used for the funding of certain Libtayo development costs and/or Dupilumab/Itepekimab Eligible Investments as described above).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218825144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Cash Flows<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Statement of Cash Flows</a></td>
<td class="text">Statement of Cash Flows<div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"/><td style="width:58.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.172%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,432.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,586.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of amounts held by financial institutions pursuant to contractual arrangements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental disclosure of non-cash investing and financing activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts were included in accounts payable, accrued expenses, and other liabilities:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:26.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237216759544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Matters<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Matters</a></td>
<td class="text">Legal Matters<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to legal proceedings in the course of the Company's business. Costs associated with the Company's involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. The Company recognizes accruals for loss contingencies associated with such proceedings when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. As of September&#160;30, 2021 and December&#160;31, 2020, the Company's accruals for loss contingencies were not material. If the Company were unable to prevail in any such proceedings, its consolidated financial position, results of operations, and future cash flows may be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Praluent (alirocumab) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in greater detail below, the Company is currently a party to patent infringement actions initiated by Amgen Inc. (and/or its affiliated entities) against the Company and/or Sanofi (and/or the Company's and Sanofi's respective affiliated entities) in a number of jurisdictions relating to Praluent. See Note 3 for a description of the Company's and Sanofi's arrangement regarding the costs resulting from or associated with such actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Amgen asserted claims of U.S. Patent Nos. 8,829,165 (the "'165 Patent") and 8,859,741 (the "'741 Patent"), and sought a permanent injunction to prevent the Company and the Sanofi defendants from commercial manufacturing, using, offering to sell, or selling within the United States (as well as importing into the United States) (collectively, "Commercializing") Praluent. Amgen also sought a judgment of patent infringement of the asserted patents, monetary damages (together with interest), costs and expenses of the lawsuits, and attorneys' fees. As described in greater detail under "Second Jury Trial and Appeal" below, on February 11, 2021, the Federal Circuit (as defined below) affirmed the lower court's decision that certain of Amgen's asserted patent claims are invalid based on lack of enablement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Jury Trial and Appeal.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first jury trial in this litigation (the "First Trial") was held in the United States District Court for the District of Delaware (the "District Court") from March 8 to March 16, 2016. During the course of the First Trial, the District Court ruled as a matter of law in favor of Amgen that the asserted patent claims were not obvious, and in favor of the Company and the Sanofi defendants that there was no willful infringement of the asserted patent claims by the Company or the Sanofi defendants. On March 16, 2016, the jury returned a verdict in favor of Amgen in the First Trial, finding that the asserted claims of the '165 and '741 Patents were not invalid based on either a lack of written description or a lack of enablement. On October 5, 2017, the United States Court of Appeals for the Federal Circuit (the "Federal Circuit") reversed in part the District Court's decision and remanded for a new trial on the issues of written description and enablement. In addition, it affirmed the District Court's ruling that Amgen's patents were not obvious.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Jury Trial and Appeal.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2019, the District Court held oral argument in the remanded proceedings on the Company and the Sanofi defendants' motion for judgment on the pleadings regarding Amgen's willful infringement claim. On January 18, 2019, the District Court entered an order (i) denying the Company and the Sanofi defendants' motion for summary judgment on validity, (ii) denying Amgen's motion for partial summary judgment on estoppel, and (iii) granting the Company and the Sanofi defendants' cross-motion for summary judgment on estoppel. On February 8, 2019, the District Court granted the Company and the Sanofi defendants' motion for judgment on the pleadings, thereby dismissing Amgen's claim of willful infringement. The second jury trial in this litigation (the "Second Trial") was held before the District Court in February 2019 to determine the validity of Amgen's asserted patent claims. On February 25, 2019, the jury returned a verdict in the Second Trial generally in favor of Amgen, finding that two claims of the '165 Patent and one claim of the '741 Patent were not invalid. The jury also found that two claims of the '165 Patent were invalid for lack of adequate written description while rejecting the lack of enablement challenges to those two claims. On August 28, 2019, the District Court ruled as a matter of law that Amgen's asserted patent claims are invalid based on lack of enablement. The District Court also conditionally denied the Company and the Sanofi defendants' motion for a new trial. On October 23, 2019, Amgen filed a notice of appeal of the District Court's decision with the Federal Circuit. An oral hearing before the Federal Circuit was held on December 9, 2020. On February 11, 2021, the Federal Circuit affirmed the District Court's decision that certain of Amgen's asserted patent claims are invalid based on lack of enablement. On April 14, 2021, Amgen filed a petition for a rehearing en banc, which was denied on June 21, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Injunctive Relief Proceedings.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2019, Amgen filed a renewed motion for a permanent injunction to prohibit the Company and the Sanofi defendants from Commercializing Praluent in the United States (a "Permanent Injunction"), and an oral hearing on this motion was held in June 2019. Previously, the Federal Circuit stayed and then vacated a Permanent Injunction granted by the District Court in connection with the First Trial. On August 28, 2019, the District Court dismissed as moot Amgen's renewed motion for a Permanent Injunction. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Europe</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen has asserted European Patent No. 2,215,124 (the "'124 Patent"), which pertains to PCSK9 monoclonal antibodies, in the countries in Europe discussed below. In October 2020, the '124 Patent claims directed to compositions of matter and medical use relevant to Praluent were ruled invalid based on a lack of inventive step by the Technical Board of Appeal (the "TBA") of the European Patent Office (the "EPO"). This decision impacted each of the infringement proceedings based on the '124 Patent discussed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen filed lawsuits in Germany, the United Kingdom, and France in July 2016, July 2016, and September 2016,  respectively, against the Company and certain of Sanofi's affiliated entities for infringement of the relevant designation of the '124 Patent in each such jurisdiction; and these lawsuits were dismissed in November 2020, September 2021, and June 2021, respectively. The dismissal in Germany followed an earlier finding of infringement and granting of an injunction, both of which were subsequently overturned. In December 2019, Amgen also filed lawsuits in the Netherlands, Italy, and Spain for infringement of the relevant designation of the '124 Patent in each such jurisdiction; the Company was not named as a defendant in any of these actions, and each of these lawsuits was dismissed in February 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Japan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously reported, on March 31, 2020, Amgen filed a lawsuit in the Tokyo District Court against Sanofi K.K. seeking damages incurred by Amgen as a result of the earlier finding of infringement of Amgen's Japanese Patent Nos. 5,906,333 and 5,705,288 by the Tokyo District Court Civil Division. The Company has not been named as a defendant in this damages action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Dupixent (dupilumab) Injection</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2017, the Company, Sanofi-Aventis U.S. LLC, and Genzyme Corporation initiated an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review ("IPR") in the United States Patent and Trademark Office ("USPTO") seeking a declaration of invalidity of U.S. Patent No. 8,679,487 (the "'487 Patent") owned by Immunex Corporation relating to antibodies that bind the human interleukin-4 receptor and subsequently filed two additional IPR petitions in the USPTO seeking declarations of invalidity of the '487 Patent based on different grounds (the "Additional IPR Petitions"). The Patent Trial and Appeal Board ("PTAB") of the USPTO issued a final written decision on the Additional IPR Petitions on February 14, 2019, invalidating all 17 claims of the '487 Patent as obvious. This decision was subsequently affirmed by the Federal Circuit and Immunex's petition for writ of certiorari was denied by the United States Supreme Court. The '487 Patent expired in May 2020 following Immunex's filing of a terminal disclaimer with the USPTO.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2017, Immunex Corporation filed a lawsuit against the Company, Sanofi, Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Aventisub LLC in the United States District Court for the Central District of California seeking a judgment of </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent infringement of the '487 Patent and a declaratory judgment of infringement of the '487 Patent, in each case by the Company's and the other defendants' Commercializing of Dupixent; monetary damages (together with interest); an order of willful infringement of the '487 Patent, which would allow the court in its discretion to award damages up to three times the amount assessed; costs and expenses of the lawsuit; and attorneys' fees. The court subsequently granted a joint stipulation by the parties to stay the litigation pending resolution of the appeals of the PTAB's final written decisions on the Additional IPR Petitions discussed above; and, on August 3, 2021, granted a motion to dismiss the lawsuit, dismissing all of Immunex's claims with prejudice. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Europe</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2016, Sanofi initiated a revocation proceeding in the United Kingdom to invalidate the U.K. counterpart of European Patent No. 2,292,665 (the "'665 Patent"), another patent owned by Immunex relating to antibodies that bind the human interleukin-4 receptor. At the joint request of the parties to the revocation proceeding, the U.K. Patents Court ordered on January 30, 2017 that the revocation action be stayed pending the final determination of the currently pending EPO opposition proceedings initiated by the Company and Sanofi in relation to the '665 Patent. The oral hearing before the EPO on the oppositions occurred on November 20, 2017, at which the claims of the '665 Patent were found invalid and the patent was revoked. A final written decision of revocation of the '665 Patent was issued by the EPO on January 4, 2018. Immunex filed a notice of appeal of the EPO's decision on January 31, 2018, and an oral hearing before the TBA has been scheduled for March 2022. On September 20, 2017 and September 21, 2017, respectively, the Company and Sanofi initiated opposition proceedings in the EPO against Immunex's European Patent No. 2,990,420 (the "'420 Patent"), a divisional patent of the '665 Patent (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a patent that shares the same priority date, disclosure, and patent term of the parent '665 Patent but contains claims to a different invention). The oral hearing before the EPO on the oppositions occurred on February 14&#8211;15, 2019, at which the '420 Patent was revoked in its entirety. Immunex filed a notice of appeal of the EPO's decision on May 31, 2019, and an oral hearing before the TBA has been scheduled for March 2022. The original patent term of the Immunex patents expired in May 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to EYLEA (aflibercept) Injection</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2021, Chengdu Kanghong Pharmaceutical Group Co., Ltd. ("Chengdu Kanghong") filed an IPR petition in the USPTO against the Company' s U.S. Patent No. 10,464,992 (the "'992 Patent") and a post-grant review ("PGR") petition against the Company's U.S. Patent No. 10,828,345 (the "'345 Patent") seeking declarations of invalidity of the '992 Patent and '345 Patent. On June 23, 2021, Chengdu Kanghong filed motions to dismiss each of these petitions and terminate the respective proceedings, which were granted by the USPTO on June 25, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2020, anonymous parties filed two requests for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reexamination of the Company's U.S. Patent No. 10,406,226 and the '992 Patent, and the USPTO has granted both requests to initiate reexamination proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, Mylan Pharmaceuticals Inc. filed IPR petitions in the USPTO against the Company's U.S. Patent Nos. 9,254,338 (the "'338 Patent") and 9,669,069 (the "'069 Patent") seeking declarations of invalidity of the '338 Patent and the '069 Patent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2021, Celltrion, Inc. filed a PGR petition in the USPTO against the Company's U.S. Patent No. 10,857,231 (the "'231 Patent") seeking a declaration of invalidity of the '231 Patent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26 and October 27, 2021, anonymous parties initiated opposition proceedings in the EPO against the Company's European Patent No. 2,944,306 (the "'306 Patent") seeking revocation of the '306 Patent in its entirety. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to EYLEA (aflibercept) Injection Pre-filled Syringe</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, "Novartis") filed a complaint with the U.S. International Trade Commission (the "ITC") pursuant to Section 337 of the Tariff Act of 1930 requesting that the ITC institute an investigation relating to the importation into the United States and/or sale within the United States after importation of EYLEA pre-filled syringes ("PFS") and/or components thereof which allegedly infringe Novartis&#8217;s U.S. Patent No. 9,220,631 (the "'631 Patent"). Novartis also requested a permanent limited exclusion order forbidding entry into the United States of EYLEA PFS or components thereof; a permanent cease-and-desist order from the importation, sale, offer for sale, advertising, packaging, or solicitation of any sale by the Company of EYLEA PFS or components thereof; and a bond should the Company continue to import EYLEA PFS (if found to infringe) during, if applicable, any 60-day Presidential review period (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the period when the President of the United States (or his designee) can disapprove any ITC decision to issue an exclusion order or cease-and-desist order). The ITC instituted the investigation on July 22, 2020 and a trial was scheduled for April 19&#8211;23, 2021. On March 26, 2021, the staff attorney appointed by the ITC's Office of Unfair Import Investigations ("OUII")&#8212;an independent government party to the case representing the public interest&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined that the '631 Patent is invalid on several grounds. On April 8, 2021, Novartis moved to terminate the ITC investigation in its entirety based on its withdrawal of the complaint; and, on May 3, 2021, the ITC terminated the investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, Novartis also filed a patent infringement lawsuit (as amended on August 2, 2021) in the U.S. District Court for the Northern District of New York asserting claims of the '631 Patent and seeking preliminary and permanent injunctions to prevent the Company from continuing to infringe the '631 Patent. Novartis also seeks a judgment of patent infringement of the '631 Patent, monetary damages (together with interest), an order of willful infringement of the '631 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuits, and attorneys' fees. On July 30, 2020, the court granted the Company's motion to stay these proceedings until a determination in the ITC proceedings discussed above, including any appeals therefrom, becomes final. On June 11, 2021, the court, at the request of Novartis, lifted the stay.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, the Company initiated two IPR petitions in the USPTO seeking a declaration of invalidity of the '631 Patent on two separate grounds. On January 15, 2021, the USPTO declined to institute an IPR proceeding on procedural grounds in light of the pending ITC investigation discussed above; the other IPR petition has been withdrawn. Following Novartis's motion to terminate the ITC investigation discussed above, on April 16, 2021 the Company filed a new IPR petition seeking a declaration of invalidity of the '631 Patent based on the same grounds that were the basis for the OUII staff attorney's determination discussed above. On October 26, 2021, the USPTO issued a decision instituting the IPR proceeding.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, the Company filed an antitrust lawsuit against Novartis and Vetter Pharma International Gmbh ("Vetter") in the United States District Court for the Southern District of New York seeking a declaration that the '631 Patent is unenforceable and a judgment that the defendants' conduct violates Sections 1 and 2 of the Sherman Antitrust Act of 1890, as amended (the "Sherman Antitrust Act"). The Company is also seeking injunctive relief and treble damages. On September 4, 2020, Novartis filed, and Vetter moved to join, a motion to dismiss the complaint, to transfer the lawsuit to the Northern District of New York, or to stay the suit; and on October 19, 2020, Novartis filed, and Vetter moved to join, a second motion to dismiss the complaint on different grounds. On January 25, 2021, the Company filed an amended complaint seeking a judgment that Novartis's conduct violates Section 2 of the Sherman Antitrust Act based on additional grounds, as well as a judgment of tortious interference with contract. On February 22, 2021, Novartis filed, and Vetter moved to join, a motion to dismiss the amended complaint. On September 21, 2021, the court granted Novartis and Vetter's motion to transfer this lawsuit to the Northern District of New York. As a result, this lawsuit was transferred to the same judge that had been assigned to the patent infringement lawsuit discussed above.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Related to "Most Favored Nation" Interim Final Rule</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2020, the Company filed a lawsuit in the United States District Court for the Southern District of New York against the U.S. Department of Health and Human Services, the Secretary of HHS, the Centers for Medicare &amp; Medicaid Services ("CMS"), and the Administrator of CMS seeking declaratory and injunctive relief related to the interim final rule with comment period entitled "Most Favored Nation (MFN) Model" issued on November 20, 2020 by HHS, acting through CMS. On the same day, the Company filed a motion for a preliminary injunction and temporary restraining order, seeking to prevent implementation of the MFN Rule. On December 22, 2020, the court heard oral argument on the Company's motion for a preliminary injunction and temporary restraining order. On December 31, 2020, the court granted the Company's motion and issued a preliminary injunction. On February 2, 2021, the government stated to the court that the Solicitor General had determined not to appeal the preliminary injunction. On February 10, 2021, the court entered a 90-day stay of the litigation and subsequently extended the stay, with the most recent 30-day extension granted on October 11, 2021. On August 6, 2021, CMS issued a Notice of Proposed Rulemaking that proposes to rescind the MFN Rule.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to fasinumab</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 21, 2020, the Company and Teva Pharmaceutical Industries Limited ("Teva") filed a lawsuit against Rinat Neurosciences Corp. ("Rinat"), a wholly owned subsidiary of Pfizer Inc., in the English High Court of Justice in London, seeking invalidation and revocation of Rinat's European Patent No. 2,270,048 (the "'048 Patent"), European Patent No. 1,871,416 (the "'416 Patent"), and European Patent No. 2,305,711 (the "'711 Patent"), each of which pertains to the use of NGF monoclonal antibodies to treat certain symptoms in patients suffering from osteoarthritis. On July 21, 2020, Rinat filed its defense and counterclaim seeking a declaration of infringement of the '048 Patent by fasinumab. The counterclaim also seeks a permanent injunction, damages, an accounting of profits, and costs and interest. On December 15, 2020, Rinat filed an amended defense and counterclaim seeking a declaration of infringement of the '711 Patent by fasinumab. On May 5, 2021, the court stayed this litigation on terms mutually agreed by the parties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The '048 Patent is subject to opposition proceedings in the EPO, which were initiated by the Company on August 10, 2016 and two other opponents on August 11, 2016. On January 3, 2018, the Opposition Division of the EPO issued a preliminary, non-binding opinion regarding the validity of the '048 Patent, indicating that it considered the granted patent to be invalid. An oral </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hearing on the oppositions against the '048 Patent was held on November 29&#8211;30, 2018, at which the Opposition Division upheld the validity of the '048 Patent's claims in amended form. The Company filed a notice of appeal to the TBA of the EPO on March 7, 2019. On October 21, 2020, Teva filed a notice of intervention with the TBA to take part in the appeal proceedings as an intervener. An oral hearing before the TBA has been scheduled for April 5&#8211;6, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The '711 Patent is also subject to opposition proceedings in the EPO, which were initiated by the Company on May 1, 2018. On January 31, 2019, the Opposition Division of the EPO issued a preliminary, non-binding opinion regarding the validity of the '711 Patent, indicating that it considered the granted patent to be invalid. An oral hearing on the opposition against the '711 Patent was held on December 3, 2019, at which the Opposition Division upheld the validity of the '711 Patent's claims in amended form. The Company filed a notice of appeal to the TBA on December 20, 2019. On January 29, 2021, Teva filed a notice of intervention with the TBA to take part in the appeal proceedings as an intervener. An oral hearing before the TBA was held on July 29, 2021, at which the '711 Patent was revoked in its entirety. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to REGEN-COV (casirivimab and imdevimab)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2020, Allele Biotechnology and Pharmaceuticals, Inc. ("Allele") filed a lawsuit (as amended on April 8, 2021) against the Company in the United States District Court for the Southern District of New York, asserting infringement of U.S. Patent No. 10,221,221 (the "'221 Patent").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allele seeks a judgment of patent infringement of the '221 Patent, an award of monetary damages (together with interest), an order of willful infringement of the '221 Patent (which would allow the court in its discretion to award damages up to three times the amount assessed), costs and expenses of the lawsuit, and attorneys' fees. On July 16, 2021, the Company filed a motion to dismiss the complaint.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating to its support of 501(c)(3) organizations that provide financial assistance to patients; documents concerning its provision of financial assistance to patients with respect to products sold or developed by Regeneron (including EYLEA, Praluent, ARCALYST, and ZALTRAP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); and certain other related documents and communications. On June 24, 2020, the U.S. Attorney's Office for the District of Massachusetts filed a civil complaint in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. On August 24, 2020, the Company filed a motion to dismiss the complaint in its entirety. On December 4, 2020, the court denied the motion to dismiss.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company and Regeneron Healthcare Solutions, Inc., a wholly-owned subsidiary of the Company, each received a civil investigative demand ("CID") from the U.S. Department of Justice pursuant to the federal False Claims Act relating to remuneration paid to physicians in the form of consulting fees, advisory boards, speaker fees, and payment or reimbursement for travel and entertainment allegedly in violation of the federal Anti-Kickback Statute. The CIDs relate to EYLEA, Praluent, Dupixent, ZALTRAP, ARCALYST, and Kevzara and cover the period from January 2015 to the present. On June 3, 2021, the United States District Court for the Central District of California unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint filed against the Company, Regeneron Healthcare Solutions, Inc., and Sanofi-Aventis U.S. LLC by two </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plaintiffs (known as relators) purportedly on behalf the United States and various states (the "State Plaintiffs"), asserting causes of action under the federal False Claims Act and state law. Also on June 3, 2021, the United States and the State Plaintiffs notified the court of their decision to decline to intervene in the case. On October 29, 2021, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plaintiffs filed an amended complaint in this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company received a CID from the U.S. Department of Justice pursuant to the federal False Claims Act. The CID states that the investigation concerns allegations that the Company (i) violated the False Claims Act by paying kickbacks to distributors and ophthalmology practices to induce purchase of EYLEA, including through discounts, rebates, credit card fees, free units of EYLEA, and inventory management systems; and (ii) inflated reimbursement rates for EYLEA by excluding applicable discounts, rebates, and benefits from the average sales price reported to CMS. The CID covers the period from January 2011 through June 2021. The Company is cooperating with this investigation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Initiated by UnitedHealthcare</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2020, UnitedHealthcare Insurance Company and United Healthcare Services, Inc. (collectively, "UHC") filed a lawsuit against the Company in the United States District Court for the Southern District of New York alleging UHC has been damaged by the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. UHC alleges causes of action under state law and the federal Racketeer Influenced and Corrupt Organizations Act (the "RICO Act") and seeks monetary damages and equitable relief. On March 1, 2021, the Company filed a motion to dismiss the complaint in its entirety. On March 25, 2021, UHC filed an amended complaint; and, on April 22, 2021, the Company filed a motion to dismiss this amended complaint in its entirety. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Proceedings Initiated by Humana</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 22, 2021, Humana Inc. ("Humana") filed a lawsuit against the Company in the United States District Court for the Southern District of New York alleging Humana has been damaged by the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. Humana alleges causes of action under state law and the RICO Act and seeks monetary damages and equitable relief. On September 27, 2021, the Company filed a motion to dismiss the complaint in its entirety.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Demand</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or about September 30, 2020, the Company's board of directors received a demand letter from a purported shareholder of the Company. The demand alleges that Regeneron and its shareholders have been damaged by the conduct alleged in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The demand letter requests that the Company's board of directors investigate alleged breaches of fiduciary duty by its officers and directors and other alleged violations of law and corporate governance practices and procedures; bring legal action against the persons responsible for causing the alleged damages; and implement and maintain an effective system of internal controls, compliance mechanisms, and corporate governance practices and procedures. The Company's board of directors, working with outside counsel, investigated and evaluated the allegations in the demand letter and has concluded that pursuing the claims alleged in the demand would not be in the Company's best interests at this time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proceedings Relating to Shareholder Derivative Complaint</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, an alleged shareholder filed a shareholder derivative complaint in the New York Supreme Court, naming the current and certain former members of the Company's board of directors and certain current and former executive officers of the Company as defendants and Regeneron as a nominal defendant. The complaint asserts that the individual defendants breached their fiduciary duties in relation to the allegations in the civil complaint filed by the U.S. Attorney's Office for the District of Massachusetts discussed under "Department of Justice Matters" above. The complaint seeks an award of damages allegedly sustained by the Company; an order requiring Regeneron to take all necessary actions to reform and improve its corporate governance and internal procedures; disgorgement from the individual defendants of all profits and benefits obtained by them resulting from their sales of Regeneron stock; and costs and disbursements of the action, including attorneys' fees. On July 28, 2021, the defendants filed a notice of removal, removing the case from the New York Supreme Court to the U.S. District Court for the Southern District of New York. On September 24, 2021, the individual defendants moved to dismiss the complaint in its entirety. Also on September 24, 2021, the plaintiff filed a motion to remand the case to the New York Supreme Court.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237220715848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Financial Statements (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron," "Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all normal recurring adjustments and accruals necessary for a fair statement of the Company's condensed consolidated financial statements for such periods. The results of operations for any interim period are not necessarily indicative of the results for the full year. The December&#160;31, 2020 Condensed Consolidated Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Matters</a></td>
<td class="text">Costs associated with the Company's involvement in legal proceedings are expensed as incurred.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218781176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of product sales</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.309%"><tr><td style="width:1.0%"/><td style="width:46.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Net Product Sales in the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,473.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,530.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,142.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Previously, Sanofi recorded net product sales of Praluent in the United States. See Note 3 for further details.</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.118%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestone earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of losses in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi commercial expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our Bayer EYLEA collaboration are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.286%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's net profit in connection with commercialization of EYLEA outside the United States</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="padding-left:15.75pt;text-indent:-9pt"><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Bayer research and development expenses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our collaboration with Teva are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.286%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front and development milestone payments received</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts recognized in our Statements of Operations in connection with the Roche Collaboration Agreement are as follows:</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.411%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit true-up payment owed from Roche in connection with sales of casirivimab and imdevimab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of sales to customers as percentage of total gross product revenue</a></td>
<td class="text">Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"/><td style="width:45.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Besse Medical, a subsidiary of AmerisourceBergen Corporation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government (see Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Sales to the U.S. Government represented less than 10% of total gross product revenue during the period.</span></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218168104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of collaborative revenue</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.309%"><tr><td style="width:1.0%"/><td style="width:46.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Net Product Sales in the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EYLEA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,473.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,604.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praluent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REGEN-COV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,530.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evkeeza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARCALYST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,142.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Previously, Sanofi recorded net product sales of Praluent in the United States. See Note 3 for further details.</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.118%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antibody:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of profits in connection with commercialization of antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based milestone earned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immuno-oncology:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's share of losses in connection with commercialization of Libtayo outside the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of commercialization-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Sanofi commercial expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our Bayer EYLEA collaboration are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.286%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's net profit in connection with commercialization of EYLEA outside the United States</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement for manufacturing of commercial supplies</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="padding-left:15.75pt;text-indent:-9pt"><span><br/></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regeneron's obligation for its share of Bayer research and development expenses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in our Statements of Operations in connection with our collaboration with Teva are as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.286%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized in connection with up-front and development milestone payments received</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts recognized in our Statements of Operations in connection with the Roche Collaboration Agreement are as follows:</span></div><div style="margin-bottom:3pt;margin-top:13pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.411%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global gross profit true-up payment owed from Roche in connection with sales of casirivimab and imdevimab</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement of research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of accounts receivable and deferred revenue information</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's Antibody Collaboration with Sanofi:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.502%"><tr><td style="width:1.0%"/><td style="width:49.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.489%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Company's IO Collaboration with Sanofi:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.941%"><tr><td style="width:1.0%"/><td style="width:49.631%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.314%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.317%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with our Bayer EYLEA collaboration:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"><tr><td style="width:1.0%"/><td style="width:49.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Teva Collaboration Agreement:</span></div><div style="margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"><tr><td style="width:1.0%"/><td style="width:49.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes contract balances in connection with the Roche Collaboration Agreement:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.795%"><tr><td style="width:1.0%"/><td style="width:49.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237219142648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text">The calculations of basic and diluted net income per share are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"/><td style="width:48.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.799%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income - basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,846.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been antidilutive include the following: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.181%"><tr><td style="width:1.0%"/><td style="width:36.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.257%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Shares in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218338760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale Debt Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's investments in available-for-sale debt securities: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:46.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,911.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,924.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,600.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,614.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,649.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,689.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Marketable Securities, Based on Contractual Maturity Dates</a></td>
<td class="text">The fair values of available-for-sale debt securities by contractual maturity consist of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.473%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,355.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,259.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,295.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,614.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,689.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Fair Value and Unrealized Losses of Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the fair value of the Company's available-for-sale debt securities&#160;that have unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous loss position.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.590%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,932.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,932.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218378072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of assets measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's assets which are measured at fair value on a recurring basis. The following fair value hierarchy is used to classify assets, based on inputs to valuation techniques utilized to measure fair value:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Significant other observable inputs, such as quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-based valuations in which significant inputs used are observable</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Significant other unobservable inputs</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:48.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of September 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,924.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,924.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,614.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,090.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and government agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (unrestricted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities (restricted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,528.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,689.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237315926360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.555%"><tr><td style="width:1.0%"/><td style="width:47.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218355688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Issued Senior Unsecured Notes</a></td>
<td class="text">Long-term debt in connection with our senior unsecured notes (collectively, the "Notes"), net of underwriting discounts and offering expenses, consists of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.485%"><tr><td style="width:1.0%"/><td style="width:61.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.013%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.750% Senior Notes due September 2030</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.800% Senior Notes due September 2050</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218332040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Schedule of Shares Repurchased</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the shares of our Common Stock we repurchased under the programs during the three and nine months ended September&#160;30, 2021 and 2020 and the cost of the shares received, which were recorded as Treasury Stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.046%"><tr><td style="width:1.0%"/><td style="width:44.440%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of shares received </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23309-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237222207400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Cash Flows (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"/><td style="width:58.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.172%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,432.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,586.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"/><td style="width:58.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.172%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,432.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other noncurrent assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,586.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Summary of Non-Cash Investing and Financing Activities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts were included in accounts payable, accrued expenses, and other liabilities:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:26.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237225109320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales - Schedule of Net Product Sales (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,452.8<span></span>
</td>
<td class="nump">$ 2,294.0<span></span>
</td>
<td class="nump">$ 11,120.0<span></span>
</td>
<td class="nump">$ 6,074.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,279.9<span></span>
</td>
<td class="nump">1,482.2<span></span>
</td>
<td class="nump">8,142.0<span></span>
</td>
<td class="nump">3,945.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | EYLEA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,473.4<span></span>
</td>
<td class="nump">1,318.3<span></span>
</td>
<td class="nump">4,245.1<span></span>
</td>
<td class="nump">3,604.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Libtayo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">78.4<span></span>
</td>
<td class="nump">71.6<span></span>
</td>
<td class="nump">225.5<span></span>
</td>
<td class="nump">196.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Praluent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">44.8<span></span>
</td>
<td class="nump">48.5<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="nump">95.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | REGEN-COV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">676.7<span></span>
</td>
<td class="nump">40.2<span></span>
</td>
<td class="nump">3,530.1<span></span>
</td>
<td class="nump">40.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Evkeeza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | ARCALYST</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_EyleaNetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_EyleaNetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_LIBTAYONetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_LIBTAYONetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_PraluentNetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_PraluentNetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_REGENCOVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_REGENCOVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_EvkeezaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_EvkeezaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ArcalystNetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ArcalystNetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237219131000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details) - Gross product revenue - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossProductRevenueMember', window );">Besse Medical, a subsidiary of AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossProductRevenueMember', window );">McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossProductRevenueMember', window );">U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=regn_GrossProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=regn_BesseMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=regn_BesseMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=regn_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=regn_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=regn_USGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=regn_USGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237216654968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Product Sales - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,452.0<span></span>
</td>
<td class="nump">$ 4,114.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember', window );">Trade accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 4,086.0<span></span>
</td>
<td class="nump">$ 3,112.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237307072216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,452.8<span></span>
</td>
<td class="nump">$ 2,294.0<span></span>
</td>
<td class="nump">$ 11,120.0<span></span>
</td>
<td class="nump">$ 6,074.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Collaboration revenue | Regeneron's share of profits (losses) in connection with commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">387.0<span></span>
</td>
<td class="nump">212.8<span></span>
</td>
<td class="nump">975.2<span></span>
</td>
<td class="nump">555.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Collaboration revenue | Sales-based milestone earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Collaboration revenue | Reimbursement for manufacturing of commercial supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">144.7<span></span>
</td>
<td class="nump">94.3<span></span>
</td>
<td class="nump">361.2<span></span>
</td>
<td class="nump">275.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Research and development expense | Reimbursement of research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">45.2<span></span>
</td>
<td class="nump">45.5<span></span>
</td>
<td class="nump">122.3<span></span>
</td>
<td class="nump">174.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Research and development expense | Regeneron's obligation for its share of Sanofi research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(10.3)<span></span>
</td>
<td class="num">(17.5)<span></span>
</td>
<td class="num">(32.8)<span></span>
</td>
<td class="num">(59.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Selling, general and administrative expense | Reimbursement of commercialization-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">79.0<span></span>
</td>
<td class="nump">83.2<span></span>
</td>
<td class="nump">216.9<span></span>
</td>
<td class="nump">260.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Collaboration revenue | Regeneron's share of profits (losses) in connection with commercialization | Outside United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
<td class="num">(12.6)<span></span>
</td>
<td class="num">(17.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Collaboration revenue | Reimbursement for manufacturing of commercial supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Research and development expense | Reimbursement of research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">21.8<span></span>
</td>
<td class="nump">49.8<span></span>
</td>
<td class="nump">66.2<span></span>
</td>
<td class="nump">136.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Selling, general and administrative expense | Reimbursement of commercialization-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">22.8<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
<td class="nump">39.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Selling, general and administrative expense | Regeneron's obligation for its share of Sanofi commercial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(9.4)<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
<td class="num">(28.0)<span></span>
</td>
<td class="num">(15.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Cost of goods sold | Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(34.6)<span></span>
</td>
<td class="num">(31.5)<span></span>
</td>
<td class="num">(99.4)<span></span>
</td>
<td class="num">(86.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology | Other operating income | Amounts recognized in connection with up-front payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">$ (47.7)<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="num">$ (4.1)<span></span>
</td>
<td class="nump">$ 57.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ShareOfProfitLossesInConnectionWithCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ShareOfProfitLossesInConnectionWithCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_SalesBasedMilestoneEarnedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_SalesBasedMilestoneEarnedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfCommercializationRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfCommercializationRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_RegeneronsShareOfCommercialExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_RegeneronsShareOfCommercialExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=regn_CostOfGoodsSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=regn_CostOfGoodsSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_SanofisShareofLibtayoU.S.GrossProfitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_SanofisShareofLibtayoU.S.GrossProfitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237306968680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,452.8<span></span>
</td>
<td class="nump">$ 2,294.0<span></span>
</td>
<td class="nump">$ 11,120.0<span></span>
</td>
<td class="nump">$ 6,074.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived', window );">Levels of twelve-month sales at which sales milestone payments would be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis', window );">Period for achieving sales target for milestone payment, rolling basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels', window );">Remaining amount of sales milestone payments if total sales achieve specific levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | First Sales Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Second Sales Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty', window );">Percentage of trial costs required to be funded by collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty', window );">Percentage of trial costs required to be funded by collaborating party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_PraluentCrossLicenseAndCommercializationAgreementMember', window );">Praluent Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates', window );">Royalty percentage to be received on net product sales outside of the United States</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_LossContingencyPercentageOfDamagesResponsibleFor', window );">Percentage of damages company is responsible for</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_PraluentCrossLicenseAndCommercializationAgreementMember', window );">Praluent Agreement | Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_PercentageOfRoyaltyPaymentThatCanBeOffset', window );">Percentage of royalty payment that can be used to offset litigation proceedings (up to)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Levels Of Twelve Month Sales At Which Sales Milestone Payments Would Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_LossContingencyPercentageOfDamagesResponsibleFor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Percentage Of Damages Responsible For</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_LossContingencyPercentageOfDamagesResponsibleFor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PercentageOfRoyaltyPaymentThatCanBeOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Royalty Payment That Can Be Offset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PercentageOfRoyaltyPaymentThatCanBeOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Trial Costs Required To Be Funded By Collaborating Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for Achieving Sales Target for Milestone Payment, Rolling Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining Amount Of Sales Milestone Payments If Total Sales Achieve Specific Levels</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Percentage To Be Received On Net Product Sales Outside Of United States</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_SalesMilestonesAxis=regn_SalesMilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_SalesMilestonesAxis=regn_SalesMilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_SalesMilestonesAxis=regn_SalesMilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_SalesMilestonesAxis=regn_SalesMilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_PraluentCrossLicenseAndCommercializationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_PraluentCrossLicenseAndCommercializationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=regn_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=regn_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237220816360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,452.0<span></span>
</td>
<td class="nump">$ 4,114.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember', window );">Sanofi Collaboration Agreement, Antibody</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">536.0<span></span>
</td>
<td class="nump">407.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 431.7<span></span>
</td>
<td class="nump">$ 347.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237306574408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Contract Balances, IO Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,452.0<span></span>
</td>
<td class="nump">$ 4,114.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember', window );">Sanofi Collaboration Agreement, Immuno-oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">$ 286.0<span></span>
</td>
<td class="nump">$ 280.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237221102168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details) - Sanofi Collaboration Agreement, Immuno-oncology<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract', window );">Cumulative catch-up adjustment to revenue, change in estimate of transaction price</a></td>
<td class="nump">$ 66.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 591.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218209944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Bayer Narrative (Details) - Bayer<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan', window );">Revenue based on percentage of annual sales in Japan</a></td>
<td class="nump">33.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan', window );">Revenue based on percentage of annual sales in Japan</a></td>
<td class="nump">40.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_RevenueBasedOnPercentageOfAnnualSalesInJapan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage on annual sales in Japan that the Company is entitled to receive, subject to certain potential adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_RevenueBasedOnPercentageOfAnnualSalesInJapan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237224869816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Amounts Recognized in Statement of Operations with Bayer (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,452.8<span></span>
</td>
<td class="nump">$ 2,294.0<span></span>
</td>
<td class="nump">$ 11,120.0<span></span>
</td>
<td class="nump">$ 6,074.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer | Outside United States | Collaboration revenue | Regeneron's net profit in connection with commercialization of EYLEA outside the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">351.0<span></span>
</td>
<td class="nump">287.9<span></span>
</td>
<td class="nump">995.3<span></span>
</td>
<td class="nump">772.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer | Outside United States | Collaboration revenue | Reimbursement for manufacturing of commercial supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">14.0<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
<td class="nump">52.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer | Outside United States | Research and development expense | Reimbursement of research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">14.5<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="nump">34.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer | Outside United States | Research and development expense | Regeneron's obligation for its share of Bayer research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">$ (8.0)<span></span>
</td>
<td class="num">$ (12.9)<span></span>
</td>
<td class="num">$ (31.4)<span></span>
</td>
<td class="num">$ (26.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_NetProfitInConnectionWithCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_NetProfitInConnectionWithCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237224972328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,452.0<span></span>
</td>
<td class="nump">$ 4,114.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember', window );">Bayer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">374.8<span></span>
</td>
<td class="nump">336.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 115.2<span></span>
</td>
<td class="nump">$ 99.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BayerCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237222423288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details) - Teva - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember', window );">Reimbursement of research and development expenses | Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ReimbursementOfResearchAndDevelopmentExpense', window );">Reduction of Research and development expense</a></td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="nump">$ 25.9<span></span>
</td>
<td class="nump">$ 36.6<span></span>
</td>
<td class="nump">$ 82.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember', window );">Amounts recognized in connection with up-front and development milestone payments received | Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 17.2<span></span>
</td>
<td class="nump">$ 22.6<span></span>
</td>
<td class="nump">$ 54.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ReimbursementOfResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Of Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ReimbursementOfResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237225167800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,452.0<span></span>
</td>
<td class="nump">$ 4,114.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember', window );">Teva</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">$ 43.3<span></span>
</td>
<td class="nump">$ 66.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237219139720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Teva Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember', window );">Teva</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 96.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_TevaPharmaceuticalsCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237306603144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - U.S. Government Narrative (Details) - REGEN-COV - U.S. Government - Other Transaction Agreement<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>dose</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>dose</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase', window );">Number of doses | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_REGENCOVMember', window );">Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_MaximumTransactionAgreementPayments', window );">Maximum agreement payments | $</a></td>
<td class="nump">$ 2,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Doses Counterparty To Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MaximumTransactionAgreementPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Transaction Agreement Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MaximumTransactionAgreementPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_REGENCOVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_REGENCOVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=regn_USGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=regn_USGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BARDAOtherTransactionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_BARDAOtherTransactionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237219033928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,452.8<span></span>
</td>
<td class="nump">$ 2,294.0<span></span>
</td>
<td class="nump">$ 11,120.0<span></span>
</td>
<td class="nump">$ 6,074.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_CasirivimabAndImdevimabMember', window );">Casirivimab and imdevimab | Roche Collaboration Agreement | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">127.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">361.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=regn_CasirivimabAndImdevimabMember', window );">Casirivimab and imdevimab | Roche Collaboration Agreement | Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ReimbursementOfResearchAndDevelopmentExpense', window );">Reduction of Research and development expense</a></td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="nump">$ 138.3<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ReimbursementOfResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Of Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ReimbursementOfResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_CasirivimabAndImdevimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_CasirivimabAndImdevimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=regn_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237216821336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Roche Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 5,452.0<span></span>
</td>
<td class="nump">$ 4,114.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember', window );">Roche Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 305.5<span></span>
</td>
<td class="nump">$ 77.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_RocheCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237225239048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License, and Other Agreements - Intellia Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ResearchCollaborationAndLicensingArrangementsLineItems', window );"><strong>Research Collaboration and Licensing Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 665.4<span></span>
</td>
<td class="nump">$ 684.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,122.5<span></span>
</td>
<td class="nump">$ 1,990.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_IntelliaMember', window );">Intellia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ResearchCollaborationAndLicensingArrangementsLineItems', window );"><strong>Research Collaboration and Licensing Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_CollaborativeArrangementUpfrontPaymentMade', window );">Upfront payment made for collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_IntelliaMember', window );">Intellia | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_ResearchCollaborationAndLicensingArrangementsLineItems', window );"><strong>Research Collaboration and Licensing Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Shares purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_CollaborativeArrangementUpfrontPaymentMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment made under a collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_CollaborativeArrangementUpfrontPaymentMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ResearchCollaborationAndLicensingArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ResearchCollaborationAndLicensingArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_IntelliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_IntelliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237225267096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income - basic and diluted</a></td>
<td class="nump">$ 1,632.2<span></span>
</td>
<td class="nump">$ 3,098.9<span></span>
</td>
<td class="nump">$ 1,115.2<span></span>
</td>
<td class="nump">$ 842.1<span></span>
</td>
<td class="nump">$ 897.3<span></span>
</td>
<td class="nump">$ 624.6<span></span>
</td>
<td class="nump">$ 5,846.3<span></span>
</td>
<td class="nump">$ 2,364.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares - basic (in shares)</a></td>
<td class="nump">106.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.5<span></span>
</td>
<td class="nump">108.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares - diluted (in shares)</a></td>
<td class="nump">113.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111.8<span></span>
</td>
<td class="nump">116.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 15.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.42<span></span>
</td>
<td class="nump">$ 21.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 14.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.29<span></span>
</td>
<td class="nump">$ 20.36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237221289608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive weighted average number of shares (in shares)</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237221222472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">$ 6,600.9<span></span>
</td>
<td class="nump">$ 3,649.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">21.0<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">6,614.9<span></span>
</td>
<td class="nump">3,689.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">5,911.8<span></span>
</td>
<td class="nump">3,053.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">19.9<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(6.9)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">5,924.8<span></span>
</td>
<td class="nump">3,090.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">101.2<span></span>
</td>
<td class="nump">127.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">101.7<span></span>
</td>
<td class="nump">128.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember', window );">Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">64.6<span></span>
</td>
<td class="nump">65.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">65.1<span></span>
</td>
<td class="nump">66.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">272.6<span></span>
</td>
<td class="nump">276.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">272.6<span></span>
</td>
<td class="nump">276.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">231.7<span></span>
</td>
<td class="nump">127.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">231.7<span></span>
</td>
<td class="nump">$ 127.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218327544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturities within one year</a></td>
<td class="nump">$ 2,355.2<span></span>
</td>
<td class="nump">$ 1,393.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturities after one year through five years</a></td>
<td class="nump">4,259.7<span></span>
</td>
<td class="nump">2,295.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 6,614.9<span></span>
</td>
<td class="nump">$ 3,689.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237222443016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">$ 2,932.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">2,932.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">2,905.9<span></span>
</td>
<td class="nump">$ 364.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(6.9)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">2,905.9<span></span>
</td>
<td class="nump">364.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">(6.9)<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair Value - Less than 12 Months</a></td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Loss - Less than 12 months</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Value - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized Loss - 12 Months or Greater</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value - Total</a></td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss - Total</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218636936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Marketable securities, realized gain (loss)</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_MarketableSecuritiesRealizedGain', window );">Marketable securities, realized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_MarketableSecuritiesRealizedLoss', window );">Marketable securities, realized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MarketableSecuritiesRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Realized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MarketableSecuritiesRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_MarketableSecuritiesRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Realized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_MarketableSecuritiesRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237220472232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 6,614.9<span></span>
</td>
<td class="nump">$ 3,689.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">5,924.8<span></span>
</td>
<td class="nump">3,090.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">101.7<span></span>
</td>
<td class="nump">128.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember', window );">Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">65.1<span></span>
</td>
<td class="nump">66.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">272.6<span></span>
</td>
<td class="nump">276.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">231.7<span></span>
</td>
<td class="nump">127.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
<td class="nump">7,986.5<span></span>
</td>
<td class="nump">4,528.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">35.7<span></span>
</td>
<td class="nump">48.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Restricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,335.9<span></span>
</td>
<td class="nump">791.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">5,924.8<span></span>
</td>
<td class="nump">3,090.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">101.7<span></span>
</td>
<td class="nump">128.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">65.1<span></span>
</td>
<td class="nump">66.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">272.6<span></span>
</td>
<td class="nump">276.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">231.7<span></span>
</td>
<td class="nump">127.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
<td class="nump">1,371.6<span></span>
</td>
<td class="nump">839.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">35.7<span></span>
</td>
<td class="nump">48.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Restricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,335.9<span></span>
</td>
<td class="nump">791.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Total marketable securities</a></td>
<td class="nump">6,614.9<span></span>
</td>
<td class="nump">3,689.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Unrestricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Restricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">5,924.8<span></span>
</td>
<td class="nump">3,090.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | U.S. government and government agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">101.7<span></span>
</td>
<td class="nump">128.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Sovereign bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">65.1<span></span>
</td>
<td class="nump">66.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">272.6<span></span>
</td>
<td class="nump">276.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">231.7<span></span>
</td>
<td class="nump">$ 127.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measured on a recurring basis | Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ClassificationOfInvestmentAxis=regn_UnrestrictedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ClassificationOfInvestmentAxis=regn_UnrestrictedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_ClassificationOfInvestmentAxis=regn_RestrictedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_ClassificationOfInvestmentAxis=regn_RestrictedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237314037896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain (loss) on securities</a></td>
<td class="num">$ (29.1)<span></span>
</td>
<td class="num">$ (37.5)<span></span>
</td>
<td class="nump">$ 523.8<span></span>
</td>
<td class="nump">$ 133.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Securities owned not readily marketable</a></td>
<td class="nump">40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt fair value</a></td>
<td class="nump">$ 1,891.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,891.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,958.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237216831784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Schedule of Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 646.3<span></span>
</td>
<td class="nump">$ 459.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">843.7<span></span>
</td>
<td class="nump">904.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">60.1<span></span>
</td>
<td class="nump">121.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryNetOfReserves', window );">Deferred costs</a></td>
<td class="nump">503.7<span></span>
</td>
<td class="nump">430.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Inventories</a></td>
<td class="nump">$ 2,053.8<span></span>
</td>
<td class="nump">$ 1,916.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after of valuation reserves and allowances, of inventory, classified as other, expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237225085528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-offs and reserves</a></td>
<td class="nump">$ 38.7<span></span>
</td>
<td class="nump">$ 11.8<span></span>
</td>
<td class="nump">$ 188.0<span></span>
</td>
<td class="nump">$ 23.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218936568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="nump">$ 33,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=regn_BridgeFacilityMember', window );">Bridge Facility | Bridge Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2030Member', window );">1.750% Senior Notes due September 2030 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2050Member', window );">2.800% Senior Notes due September 2050 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=regn_BridgeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=regn_BridgeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237221857688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of Issued Senior Unsecured Notes (Details) - Senior Unsecured Notes - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,979.6<span></span>
</td>
<td class="nump">$ 1,978.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">1.750% Senior Notes due September 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,239.6<span></span>
</td>
<td class="nump">1,238.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2.800% Senior Notes due September 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 740.0<span></span>
</td>
<td class="nump">$ 739.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=regn_SeniorUnsecuredNotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218010760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">10.20%<span></span>
</td>
<td class="nump">15.60%<span></span>
</td>
<td class="nump">14.30%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237220944120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of treasury stock received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,500,000<span></span>
</td>
<td class="nump">$ 100,400,000<span></span>
</td>
<td class="nump">$ 802,700,000<span></span>
</td>
<td class="nump">$ 373,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Number of shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=regn_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of treasury stock received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Number of shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,806,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,014,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=regn_SanofiMember', window );">Sanofi | Libtayo development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of treasury stock received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Number of shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=regn_SanofiMember', window );">Sanofi | Dupilumab/REGN3500 Eligible Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of treasury stock received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Number of shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgram2019Member', window );">2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of treasury stock received</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramJanuary2021Member', window );">January 2021 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=regn_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=regn_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_LibtayoDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_LibtayoDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_DupilumabREGN3500EligibleInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_DupilumabREGN3500EligibleInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgram2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgram2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramJanuary2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=regn_ShareRepurchaseProgramJanuary2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218295256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Repurchased Shares (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Number of shares repurchased (in shares)</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Total cost of shares received</a></td>
<td class="nump">$ 190.5<span></span>
</td>
<td class="nump">$ 100.4<span></span>
</td>
<td class="nump">$ 802.7<span></span>
</td>
<td class="nump">$ 373.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218366408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,432.4<span></span>
</td>
<td class="nump">$ 2,193.7<span></span>
</td>
<td class="nump">$ 1,573.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash included in Other noncurrent assets</a></td>
<td class="nump">12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows</a></td>
<td class="nump">$ 3,444.9<span></span>
</td>
<td class="nump">$ 2,207.3<span></span>
</td>
<td class="nump">$ 1,586.6<span></span>
</td>
<td class="nump">$ 1,630.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237218010760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Cash Flows - Summary of Non-cash Investing and Financing Activities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued capital expenditures</a></td>
<td class="nump">$ 70.1<span></span>
</td>
<td class="nump">$ 100.4<span></span>
</td>
<td class="nump">$ 83.6<span></span>
</td>
<td class="nump">$ 133.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140237306695272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Legal Matters (Details)<br></strong></div></th>
<th class="th">
<div>Jul. 16, 2020 </div>
<div>claim</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>claim</div>
</th>
<th class="th">
<div>Feb. 11, 2020 </div>
<div>request</div>
</th>
<th class="th">
<div>Feb. 25, 2019 </div>
<div>claim</div>
</th>
<th class="th">
<div>Feb. 14, 2019 </div>
<div>claim</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A165PatentMember', window );">'165 Patent | Amgen v.s. Regeneron | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Pending claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_LossContingencyClaimsInvalidNumber', window );">Invalid claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A741PatentMember', window );">'741 Patent | Amgen v.s. Regeneron | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Pending claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A487PatentMember', window );">'487 Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_GainContingencyInterPartesReviewFiledNumber', window );">Number of IPR filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_GainContingencyClaimsInvalidatedNumber', window );">Number of claims invalidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A631PatentMember', window );">'631 Patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_GainContingencyInterPartesReviewFiledNumber', window );">Number of IPR filed</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A226PatentAnd992PatentMember', window );">'226 and '992 Patents | EYLEA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_regn_LossContingencyExParteReexaminationFiledNumber', window );">Number of ex parte reexamination requests | request</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_GainContingencyClaimsInvalidatedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Claims Invalidated, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_GainContingencyClaimsInvalidatedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_GainContingencyInterPartesReviewFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Inter Partes Review Filed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_GainContingencyInterPartesReviewFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_LossContingencyClaimsInvalidNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Invalid, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_LossContingencyClaimsInvalidNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_regn_LossContingencyExParteReexaminationFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Ex Parte Reexamination, Filed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">regn_LossContingencyExParteReexaminationFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>regn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A165PatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A165PatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=regn_Amgenv.s.RegeneronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=regn_Amgenv.s.RegeneronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A741PatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A741PatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A487PatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A487PatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A631PatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A631PatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A226PatentAnd992PatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=regn_A226PatentAnd992PatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=regn_EYLEAAfliberceptInjectionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=regn_EYLEAAfliberceptInjectionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( '0Z9%,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !T.F13+9- *>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2@,Q$(9?17+?G<VV"(9M+A5/"H(%Q5M(IFUPLPG)R&[?WFQLMX@^@,?,_/GF
M&YA.!Z%]Q.?H T:RF&XFUP])Z+!A1Z(@ )(^HE.ISHDA-_<^.D7Y&0\0E/Y0
M!X2V:6[!(2FC2,$,K,)"9+(S6NB(BGP\XXU>\.$S]@5F-&"/#@=*P&L.3,X3
MPVGJ.[@"9AAA=.F[@&8AENJ?V-(!=DY.R2ZI<1SK<55R>0<.;T^/+V7=R@Z)
MU* Q_TI6T"G@AETFOZZV][L')MNFY17G5;/><2[XG6C7[[/K#[^KL//&[NT_
M-KX(R@Y^W87\ E!+ P04    " !T.F13F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M '0Z9%/RUKZED04  (87   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM5C?<^(V$'Z^_A4:I@_M3 B6##'<))DA'+ECFA .<NU<.WU0; &>LRTJRR'\
M]UW98)&<6;N=N1?PK_WT:;7Z=K676ZF^I6LA-'F)HR2]:JVUWKSO=%)_+6*>
MGLN-2.#-4JJ8:[A5JTZZ48('N5$<=9CC7'1B'B:MZ\O\V4Q=7\I,1V$B9HJD
M61QSM;L1D=Q>M6CK\& >KM;:/.A<7V[X2BR$_K*9*;CKE"A!&(LD#65"E%A>
MM8;T_<CUC$'^Q>^AV*9'U\1,Y4G*;^9F$ERU',-(1,+7!H+#W[,8B2@R2,#C
MGSUHJQS3&!Y?']!O\\G#9)YX*D8R^B,,]/JJU6^10"QY%NFYW'X2^PGU#)XO
MHS3_)=OBVVZW1?PLU3+>&P.#.$R*?_ZR=\2Q 3UAP/8&[(T!/36"NS=P\XD6
MS/)I?>":7U\JN27*? UHYB+W36X-LPD3LXP+K>!M"';Z>B2?A2)MDJZY$NEE
M1P.F>=/Q]_8WA3T[83\@]S+1ZY2,DT $K^T[P*4DQ Z$;A@*N!";<^(Z9X0Y
MC%;P&>'F#[X^)XQ5F;^BXY;^<7,\]P3>.-&AWI%)4NP8$WE_W<$W9*)%G/Z-
MC- M1^CF(W1/C/!!^AGL"TT>=QM1M0"X.77:GQ$6O9)%KQF+SQE76JAH1^9B
M(Y6N8H1#:94)A-%%R>BB&:.94*$,3( 1"/%*%^%(AY#ZZ=V[FJCP2FY>PS53
M'!0M#XO3[L*QECQ*,7_U2TY]%&<?J;=A),@TBY^$JN*"8SAM.G#<+L)F4+(9
M-&$S%ZLPU> D3:8\KEP['&<^_CB>CN</4S+[-)S?#T?C+X^3T?!N<48FT]$Y
MPI0Z5@*=)EPGB2\5K&&^R\_(0D.P$:G(2&:)5COX#RHG4(,^_8J1/-)IVH3D
M(W\ADP!"+UR&?J%'IQ>[!I*Z;;?;[5XX'L:068:L"<-A$$ F2<\.%R27RX>D
MVG<XI.=YY"$*R()OR7T8160>FG0UEQQ+-=2*.W7_$^61N8,E?Y3;I)(N#O?(
ME=KI[VQ?D[-Y@>+*_I9<&9 S)9_#Q*]V*(Z)!Z--%A27^+?49C+5/")_AIO3
MNP1'I$YO0-L7'AZ+-G=07/+SA1Q"77N:#PXPH)@*4ILH**[N=]('Q\S6,L%4
MN0:DW_7:GN,X&".;)BBN\8^AA@PAEX2R7YY^)0OA9PJ\54D+1QK). ;]66CI
M?X,2<L,5>>91)LC/YXY#R09V:EY68K1M/J%X(H!,&X3)BBQV\9.,*MG69I(I
M5I_:=,%P03]XC(Q?_#5/5N)D:JL!F@X7'X98\<9L=F"-LL,H4\J4)44MDKL+
M1".KK.MK$+^^/0V\9F:S FN4%28)%)7%F<U4<?Q M9(9CEC#S(H_:R3^IF""
M) _:NI*J<AO4X-QQ!3$P]'TXFT+Q((("$N-H<P!KE ,6,8?D=Y.E\#JM7DT<
MIZ[(9%;Z62/I'\="K4R ?00$O0:9C3<\J78?#EA+S8H^PS7[X*RU &=AA'"8
M6D)6_!FNVX=="7&N( M,X(C\0GX3U:1P*%!_I^^Q7G^ ,;-)@-5(]UXH;L/4
MY*>O K0;.V#5P+7;E+5=[&3%K- S7*?+L]4QMUMX6!WW.%A=%\"*OHMK]5M6
M^T/I25XU<)]=C)65?1<7Z2%0"@I:$5]5\L !ZF+=M3KOXJH\BCC4^L.B&L 0
MCSHO/ZKUXEI]=1OIZW$E X5VW@LC#YF&JC8Q54=5'VJ/W,N13;?T^9KVF<OZ
ML+3/5:2LQ+JX(AZSP69IA=&]^%&>M%KG-M.Z_^-)[WM/.CV/#CRW]\:7G:-.
MI\E >0,X);XYHA=-S_)IV60>YJW5COV\Z%#?<Y/ 4A*))9@ZYQZ,KXJF;W&C
MY2;OFSY)K66<7ZX%#X0R'\#[I93Z<&,&*%OOU_\"4$L#!!0    ( '0Z9%->
M"MI_408  "8:   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULK9G;;MLX
M$(9?A3 *; LXMDA*HM0F 5PGBQ;H(:C3W6O&9F(ADNA25 [[]#LZ1))-BDZ!
M7K21[.'HYV@X'X<^?93JOM@*H=%3EN;%V62K]>[]?%ZLMR+CQ4SN1 [?W$J5
M<0VWZFY>[)3@FWI0ELZ)YX7SC"?YY/RT_NQ*G9_*4J=)+JX4*LHLX^KYHTCE
MX]D$3UX^^)'<;77UP?S\=,?OQ$KHG[LK!7?SSLLFR41>)#)'2MR>31;X_9)&
MU8#:XI]$/!:#:U1-Y4;*^^KF\^9LXE6*1"K6NG+!X<^#6(HTK3R!CE^MTTGW
MS&K@\/K%^]_UY&$R-[P02YG^FVST]FP23=!&W/(RU3_DXR?13BBH_*UE6M3_
MH\?6UIN@=5EHF;6#04&6Y,U?_M0&8C  ^R,#2#N O'8 ;0?0>J*-LGI:%USS
M\U,E'Y&JK,%;=5''IAX-LTGRZC6NM()O$QBGSY??OUU<?EM=7B"X6GW_\OEB
M<0TW'Q=?%M^6EVCUZ?+R>H7>_LQYN4FTV+Q#)^CGZ@*]??,.O4%)CKXF:0KO
MHSB=:Y!3.9VOVT=_;!Y-1AZ]$KL9HMX4$8]@R_"E>_B%6,-P7 _W]H?/(0A=
M)$@7"5+[HV.1*)42N4:\*(0NWCL\TLXCK3WZ8QYYL44\WZ!U=2%^E<D#3^$1
MUE@UKL+:5;7V'LZI3\G,/YT_#&-BFA$<TQGKS/:4^IU2WZGT*U?W0O.;5*!"
MK$N5Z$18539NV/#Q- AFY$"E:88IJ*1VE4&G,G"J7*S7LH3P0?E8"X@ER)VB
M7&B;T,93,% 0^,&AS,"0Z6/LCP4S[&2&3IF?\P=XR5*-A# T0^@%=!8=:#/-
M<(S#66C7QCIMS*GM2HD=3S9(/ $'"E'4Z2GU5B@H-L/\MREG1DS]Z#"DS)0=
M>H/)[:F..M614_6UU#Q]A<#(DG:,!<8B,NUBQN(9MJN,.Y7QGUE$L?'X(*1X
ML#H:E:89Q308RP#L]17?.Y(#L E0^GF*=BG/];3.@:HZ[0#/>G1%M5[W]- X
M&*R6MFI;[ C!H[H'I,).W1?B5D &;)#F3XXD:+T,G\\(-4J4Q2P*HED\HK*G
M""9.E=_KQ93+_'BZMI[V\M4/!A):I1:S,!K+5MS3";OQU*PJASQJ*?8AP[/@
M4*!IB!D.1^L][K&$_5<Q.4WX39+6"\H%9MR3!+\2)3O^7*U8Z_Q-AOC$R'8+
M0Z#B!",S[QF"W1 !@:H4SD(]"(I5?FC()UZ(#_5;.!/Z_F"Y[$^@!PUVD^;O
M).?Y6J!4P";[J%83+0P;Z\ T\D94]F#!;K)T-44)@'9ISP,3%X''#&#;S!@;
MVTS@GBK8C95]^!T+I 4:#+8TAEC3CH0Q&Y!R?P_=PX6XX?)%YG<G6J@,>JD;
M*T>(R0<< WW# XEVNVAL:9&>(\3-D=_*S-:7/>E:H1;@8#:V@LB@'W&3Y#6Y
M24PV!*%1H&U6;&Q31GJ $#= #-0=BZ7)B3 DYHNWF$5LC'>DAPEQ-SG-0CJF
MT6Q=0A]3,Z2^D1<AIF,A[;E$ B?P5EJN[[<RW0A5_%5ORO2SBWBD!PIQ P5V
M_FTZU<^8HC<S#P/^%(*FM!0?JD[<\^I_J-AR52&GU%MH8_X3FP\H*8H*1S6%
M2EUHN$CR.W12O7Y[9IKX,1:.RV1_FCUVB!L[B\TFJ<Z'X$U7C<Y)DD/WO4O@
MS5M%FNT*BW%L;,4M=K 1"D?7>,\?XN;/#V@8X"/@/%<Y!-2>DY:^)F34(C,R
M HJ]*![9AI$>0<2-(-B,E%F9<BVZ/8C,=DILJ^.\!X&2'.[M66!R)C;7D@5&
M\=CFD?8HHFX472LH\*5Z?DEXKD%VH3\@S*8Q9#N-NTR'+*D.H>KTQN'4IW@:
MD(-O/>NIC0FI$^9CSV@W;(8A5(S1:?8XHVZ<-66ML!0.JV"39YB1X'!_0$VF
M8>R18%1N3S7JIII1A>N@OUJ^23)[3V(Q=/8D='"H=^14+X66"2V:K'*=$O9@
MHNXNYW>+/NUQ0MUMSE)FF<R;Z%K#:;8XAT7::;(OJV<1=;.HE74T@GW5I^S/
M1K OT-1=H(]&,#(.9+W989-UQ*B1-A\<XE>_H'SEZB[)"]BFWL(H;\;@%:CF
M1XGF1LM=?:Y_([6667VY%1Q"4!G ][=2ZI>;ZJ>"[J>A\_\!4$L#!!0    (
M '0Z9%-;G'?_C ,  ' .   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
MO5=M;]HP$/XK5C1IK;21. D0*D"BP+1)6X=*NWV8]L$00ZPZ<68[L.[7ST[2
MD!1(H)W&!V([]_(\%]^=KK]E_$$$&$OP.Z21&!B!E/&5:8IE@$,D6BS&D7JS
M8CQ$4FWYVA0QQ\A/E4)JVI;5,4-$(F/83\]F?-AGB:0DPC,.1!*&B#]>8\JV
M P,:3P>W9!U(?6 .^S%:XSF6]_&,JYU96/%)B"-!6 0X7@V,$;P:0T\KI!+?
M"-Z*TAIH*@O&'O3FDS\P+(T(4[R4V@12CPT>8TJU)87C5V[4*'QJQ?+ZR?J'
ME+PBLT "CQG]3GP9# S/ #Y>H83*6[;]B'-";6UOR:A(_\$VD^WV#+!,A&1A
MKJP0A"3*GNAW'HB2 G2/*-BY@GVJ@I,K."G1#%E*:X(D&O8YVP*NI94UO4AC
MDVHK-B32GW$NN7I+E)X<CK_>3*8W\^D$J-7\Z^=/D]&=VER//H]NQE,P_SB=
MWLW!Q7V$$I]([%^"BQGB.)(!EF2)Z"5X#]X $XA G8J^*14F;=E<YOZO,__V
M$?]S'+> 8[T#MF7# ^KC>O4)7BIUF*I;57531:((AUV$PT[M.<?@2+9\"!CU
M,1=OP?170N0C&$G)R2*1:$$QD QD 0 _1@LAN;J'/VL<.X5C)W7L'G$\4[<7
M<XY]D$)X!V+$P0;1!(,+$@&?48JX #'F6:@O#X4Z<^&E+G3^;H96RU)1W90#
MVB!40>\6Z-WST&?7 :!$!HR3/^J%9I&='H2>V6^74#E6]GL&_P3!"H5V0:']
M(@I$B*09?GL/U7/<=1(5P)T"<.=%@%6M%A)%/HG63:@[C:CK)"JHNP7J;BWJ
M.]5K1,(?,]!- +M[[F&WYUA.[SG. X(=UX%M^PA<KX#KU<(=4R0$&&5H:]*\
M5]CK_=_Z JU=H;?JJ; P5'WS%>4E=]"KEHZ] M,H5B50ZE3P# )G5YC<>OF.
MN(=+S"F250Z[]@+M\SF<5F)RRY4[[KE>K[L'OUFPBG[7HV!]DSJ(_HQZDYL_
M@4*S8)7"KE'!^DY5IE"75KNV =O_.:-W#0#6=X!_D-&=TS*Z2:Q*8-<+8'TS
M>&U&[U=]QSZ2TJ>(5EGL6@1LZ!&OR&EO_Y[;;L?R;'?O&QP2A6W'4>+/&)BE
M<4#/8E\07Y-( (I72M=J=941GHTWV4:R.)T0%DRJ>2-=!FHDQ%P+J/<KQN33
M1@\=Q9 Y_ M02P,$%     @ =#ID4]3.BAO)!P  %B,  !@   !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6RM6MMNXS80_17"Z,,ND+7%BVY!$B!KJVB YH(X
MVSXK%FT+E457HI-MO[[4Q99$CABWVY=$D@^'/,/AS"&EJW=1_%%N.9?H^R[+
MR^O)5LK]Y6Q6KK9\%Y=3L>>Y^F4MBETLU6VQF97[@L=)W6B7S8CC>+-=G.:3
MFZOZV5-Q<R4.,DMS_E2@\K#;Q<5?7WDFWJ\G>')\\)QNMK)Z,+NYVL<;ON3R
MV_ZI4'>SDY4DW?&\3$6."KZ^GMSBRXC5#6K$;RE_+WO7J*+R*L0?U<U=<CUQ
MJA'QC*]D92)6_][XG&=994F-X\_6Z.349]6P?WVT_G--7I%YC4L^%]GO:2*W
MUY-@@A*^C@^9?!;OO_"6D%O96XFLK/^B]Q;K3-#J4$JQ:QNK$>S2O/D??V\=
MT6N@[, -2-N Z W82 /:-J#G]L#:!NS<'MRV04U]UG"O';>(97QS58AW5%1H
M9:VZJ+U?MU;^2O,J4):R4+^FJIV\F3\^+**'9;1 ZFKY^.O=XO9%W2Q?U+_[
MZ.%EB1Y_1H]/T?/MRYT"H-N'"GG_]!S]HIK=_1:ANP=U'Z%/W_+XD*22)Y_1
M%_1MN4"??OJ,RFU<\!*E.;I/LTQ%1GF!?NK?7LVD8E&-9;9J1_RU&3$9&3%%
M]R*7VQ)%><(3H/W"WCZTM)\I[YU<2(XN_$JL!I=\/T74N4#$(1@8S_S\Y@Y$
MY\=ZC_YS[P-GT%,\T=H>';'WS-]X?N#EI<46.]EBM2WV@2TH1IJ67MVR2H9O
M-Y2Y9!I<S=[ZKF]@V.GA" G9$+4 4!CCRA]]6&3VZ3D^FY(3;,#2/;%TK1Z+
MOJND7]H]YIUL>1]XK.1QL=JB.$]4NGQ3=6"OLKJ$/-A8\OML/'>JN68.H (V
M]30'FBB""9FZF@--& Y#IP<;D/9/I'TKZ:6J,FF^N4 ;GO,BSBYJ]G&BLF5:
MRB*N*A'D@,:JVQL-8]J(Y[XQ8DJ\::C1-U&8*%]2C3X <Q@9HQ^<Z =6^H]R
MRPNDE$/%--\@WL03^I3F*['CGR]0SL$ "$S^1*,?&"/^PLS9!U DU)=B!* P
M=<=63WAB'UK9ST4IRWK"6]ZJP$@AXPQB')H3X#FNSF<.P ASC%DW82S 1(=%
M)HQZ7M^) ][8Z0JW8V5^5T\O6A=B=YS]L7KJF(0"YD_UV89PCDNG6",.X#SJ
M^#HN G#*C^$H]9YFP=:4V81\$]_H4SOQGVT)%)/.-CEC.9V,MKV,+J+6VC"L
M/2.-0C 2Z ER <!<UX!% (S@H)=OAMR[VHWI!R$EN9)K\KB60,(4(,S,6 )@
M*G-2G3  8U2W%H$PT@NX(>%.8&"[PGBI,@428#B!Y)DY#NH8"02"N4S/B L
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M:K.>7.M).@>&MMR JF?KH7&$:FI8A/IAQ*,1.L0,^$&/<V$/'H-AKB'65-:
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M7',&)*D%X/]+*=7N16]0?P:Z^ ]02P,$%     @ =#ID4S-QFI=&!   /0H
M !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6RM5FV/&C<0_BNCK=07B;#
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MT-A8RT+?F;:U)&:& H6?X2+R03([B0]B=P[NM(M6L2DJ39P4&H2Y "..H>U
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M6RZL^D5G&K'_(X"U)-*+E7NF74U):=(5,'VD]EYWHP3IR.7W%H*20.FNS58
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MCL*3R0"TOY?Y@565NPLME,6;E7O,L8Q<DP%^7RJ4LAE0@.YR?/$/4$L#!!0
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M!GW["L%A9G0.7UMA/5HP!:M$PQN$IK591:;,P57"HN-!TUJX,G5-GE][DSU
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M/+T;PF=%#S6T/('&"T-Z] U>8/?T6_T+4$L#!!0    ( '0Z9%/)BAVGP@,
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MG.E1?A&=QV?X.^V@A5$<M:YO)H4@C>-+%&H0KW:1OYLNCTY[;PBM,7O,43O
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MJ;;6,E&S\.5G.IFV&E;7>@>>:422UBHK1"-SX,1FT1E=5+>JO)6(3YRXOYH
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M,EM4-/U+!;ZHCS8,UJY?GH$'8=1E%\V?0"]E-E)^??EIM(V:OPA4DDV<)E(
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M8E+^QB!*8TY=7VC4N1MD^#J%"":,JQ$=V!K10,ELE_R1:@V.K7:N@8_<C>_
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MU4MR>/2@'D(OS!<9"VJ;PL)*;2R&M0*V[4?Q/7+F/'SWS/- HU3H5X:D"<]
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MQ JGZ6TC*KXT,Z=&,3W__%V1W4SQ:@S4=6UCCAT$71&B-9)EC@#QO9SA/&]
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M2;T [Y="5.V#9M!]V#O_+U!+ P04    " !T.F13W" X/8H#  !L"   &0
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M"K6;!TEPV'C@FZUU&]%BUK -/J+]T=QK\J(>I>0U2L.5!(W5/+A*ILO<Q?N
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MC3.\2.1Z0%MOM,CL!#(3&L< NUSB4 O2',#O<R'T9F,$RC&Y]P=02P,$%
M  @ =#ID4V=V-S-9 @  $08  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&ULQ55=;]HP%/TK5M2'5F+DD[2J0J065*U26R%8MX=I#R:Y@%7'SFP#W;_?
MM1,BV@+;PZ2]8%_GGG/NN5<VV5:J%[T",.2UXD(/O94Q];7OZV(%%=5]68/
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MOMF@; )^7TAL7QO89Z'[%\A_ U!+ P04    " !T.F13PKD#HZP&  !_(@
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M96G<^.62OB"HG0.=SY6R;X:;.?4WJ?\'4$L#!!0    ( '0Z9%,P&!@?2P,
M ,L*   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;+566V_3,!3^*U:T
M!R:-YMK;U%;:FB(F,3&U AX0#VYRFEA+XF"[[4#\>(Z=++TL*P.TE\27\WWG
M:ON,MES<RQ1 D8<\*^382I4J+VU;1BGD5'9X"07NK+C(J<*I2&Q9"J"Q >69
M[3E.S\XI*ZS)R*S=B<F(KU7&"K@31*[SG(H?UY#Q[=ARK<>%.4M2I1?LR:BD
M"2Q ?2KO!,[LAB5F.122\8((6(VM*_=RYCH:8"0^,]C*O3'1KBPYO]>3FWAL
M.=HBR"!2FH+B;P-3R#+-A'9\KTFM1J<&[H\?V=\9Y]&9)94PY=D7%JMT; TL
M$L.*KC,UY]OW4#O4U7P1SZ3YDFTMZU@D6DO%\QJ,%N2LJ/[TH0[$'@!YV@%>
M#?". <$S +\&^"_5$-2 X*4:NC7 N&Y7OIO A531R4CP+1%:&MGTP$3?H#%>
MK-"%LE "=QGBU 0#G-$E%U2G[8)\8!$6 5P06L3DHTI!D*M$ &!I*$G>DJN<
MK_5H#A%/"O838L(*LE!4&1'"5^1C"16;1%=42N8<BYN\"4%1ELES)/FT",F;
MLW-RIK&W+,NT\,A6Z(XVRHYJTZ\KT[UG3/?)+2]4*LFLB"%NP8>G\<,3>!O#
MV,32>XSEM7>2< %EA_C.!?$<SVVQ9_IRN-/FSO]IG_VS]H-@^$UA^8;/?X8O
M9)(F6#J)J05=&'/80+$&\O4#BI(;K!CY[82BH%$4&$7!,XIJVM8"JI ]@]17
MYF;B!UVO,QC9F_V\5&)XV^WD/&\8'$J%+5*NZ^I@[8O-GNKL.?V@XS5B!UYV
M&R^[)[V<4LD$V["<+LW99'D,U>Q7?<(.3O+NU.+^X8ZHXG4B\KW&IM[KIKC?
M*.K_<XHK9'\_*5Z_XQYEN)+J[DD=I2U\RN/WW.-*F9WB.7!MT+@V>+6\SD$"
M%5%J@ C#5[\T6_!0ZEO\1.2'C7G#UTVQZ^P>(N</28[7T4[+W[A6OQ;.DY/G
M.IWN426T2 V/A<(V*G_0\8^JX0]<52#LO<<Y!Y&8KDB22#^DU77:K#:=UY7I
M-X[6K]W+J=NR'NI.S30#._JJS;NE(F'X#F>P0E5.IX^%*ZK.J9HH7IK68,D5
M-AIFF&*W"4(+X/Z*<_4XT0J:_G7R&U!+ P04    " !T.F13"(UT)WD"   ]
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6RU54UO&C$0_2NC50Z)
M1-EO:*,%*0%5C92H$2CMH>K!+ -8\=I;VT#Z[SOV;E;D ]1#RX&UU_/>O'EC
M>XN]TH]F@VCAJ1+2C(*-M?5E&)IR@Q4S?56CI)65TA6S--7KT-0:V=*#*A$F
M430(*\9E,"[\NWL]+M36"B[Q7H/95A73OZ]1J/THB(/G%S.^WECW(AP7-5OC
M'.U#?:]I%G8L2UZA-%Q)T+@:!5?QY63@XGW -XY[<S &5\E"J4<WN5F.@L@)
M0H&E=0R,'CN<H!".B&3\:CF#+J4#'HZ?V3_[VJF6!3,X4>([7]K-*/@8P!)7
M;"OL3.V_8%M/[OA*)8S_AWT;&P50;HU550LF!167S9,]M3X< .+L""!I <G?
M M(6D/I"&V6^K"FS;%QHM0?MHHG-#;PW'DW5<.FZ.+>:5CGA[)C*%VRA-'.F
M]N"6E]0A[ &32_AJ-ZCA:JT1J6_6P >8TRY:;@6"6L%$2:NI#7#-!),EFA[,
M%*W#"TXXGZ)E7)@+@C_,IW!^=@%GP"7<<2$HP!2AI4*<G+!L15\WHI,CHN=8
M]R&->I!$2?P.?'(:/L62X+&'1R_A(=G7>9AT'B:>+SW&QPU;DTOKIF"R9H8[
ME%N$'[<4"C<6*_/S1**T2Y3Z1-F11%=EJ;:N$1I+Y#NV$-0IB?8]!QNF./)4
M[BSOQGF6)T6X.S2JB1H<!&5QG/6'7=@+G5FG,SNI\[UMT&VC$S[D'7_^?PT?
M=(D&_\SPP1LKTRCOYZ\,?QLU'/:C3X>_5]Z'!X?;7:QW3*^Y-"!P11Q1?TA>
MZ>:R:B96U?Z\+Y2EV\,/-W2_HW8!M+Y2RCY/W!72?3'&?P!02P,$%     @
M=#ID4]A$M>Y( P    L  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL
MQ59=;^)&%/TK5]8^[$HI_@(#$2 E@6Q3;=HH*.U#U8>)?<%6[!EW9H"-U!_?
M.V/CA<2X2%MI7\ SON?<<S\\<R<[(5]4BJCA:Y%S-752K<M+UU5QB@53/5$B
MIS<K(0NF:2G7KBHELL2"BMP-/"]R"Y9Q9S:Q>P]R-A$;G6<<'R2H35$P^7J-
MN=A-'=_9;SQFZU2;#7<V*=D:EZB?R@=)*[=A2;("N<H$!XFKJ7/E7W[V+<!:
M_)[A3AT\@PGE68@7L[A+IHYG%&&.L384C/ZV>(-Y;IA(Q]\UJ=/X-,##YSW[
MK0V>@GEF"F]$_D>6Z'3JC!Q(<,4VN7X4NY^Q#FA@^&*1*_L+N]K6<R#>*"V*
M&DP*BHQ7_^QKG8@# /&T X(:$+P%]$\ PAH0G@OHUX#^N9(&-6!PKH>H!D1O
M >$)P+ &#&VQJNS:TLR99K.)%#N0QIK8S(.MKT5313)N6G&I);W-"*=G5,*<
M/0O)3&-<P)<LIC;#"V \@=]TBA*NUA*1FD\K^ GNN*:NR1C\RJ3!;!$^SE&S
M+%>?Z/73<@X?/WR"#Y!QN,_(4G U<34)->[<N!9U78D*3H@*X5YPG2I8\ 23
M%ORB&S_NP+N4H"9+P3Y+UT$GX1++'H3>!01>X+?HN3D?[K7 Y]WP7S:\$[[X
M/O&WWR?^<S?\GKU"Z+>ACRH1-OT:6KKP!-TC*F0R3N&H<6V[5KV;\35<46_R
M==VT?WXA"KC36*B_.@3T&P%]*Z#_7P*,RP2W=)B7QE%;EU=,D64R=\)V%D6#
M7G_B;@][I\5JU.]%QU:+]U:!'P2]P;'9[7LS?SSV#LR.@AXT00\Z@]Y_]AWY
MBQJJZ,<4<-@(&';&\E2N))T.4+)7PT^':8) =SK$QX+VQU[;]UIY\+V#- ^]
M]A2/&EFC_ZNOYJ/W[OT3%1XW[L=G51C^H<(4!25@J47\TI%OW_MVQ7@_IN3^
MP2WG=X:W3)E$!>6&9-#@ J4DQVV'6<USE-OP;6G=@_NV0+FVHY2B!MIP71UE
MS6XSKEW9(>7-_K5_.?=;]A?^Y6TUC'VCKV;#>R;7&5>0XXI<>;TA?;BR&K>J
MA1:EO>V?A:;9P3ZF-**B- ;T?B6$WB^,@V;HG?T+4$L#!!0    ( '0Z9%,!
MY$ />@0  +(1   9    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;,U876_B
M.!3]*Q;J0RMU\IT0*D":%EH8;5=5V<X\C/;!30Q836+6=LK,OU_;"2$D)A-U
M7N8%8ON<F^OC>^WKC/>$OK$M0AS\2).,309;SG<WILFB+4HA,\@.96)D36@*
MN6C2C<EV%,%8D=+$="PK,%.(L\%TK/J>Z'1,<I[@##U1P/(TA?3G+4K(?C*P
M!X>.9[S9<MEA3L<[N$$KQ%]V3U2TS,I*C%.4,4PR0-%Z,OALWRQM3Q(4XBM&
M>U9[!G(JKX2\R<8RG@PLZ1%*4,2E"2C^WM$=2A)I2?CQ7VET4+U3$NO/!^OW
M:O)B,J^0H3N2?,,QWTX&X0#$: WSA#^3_0*5$_*EO8@D3/V"?8FU!B#*&2=I
M218>I#@K_N&/4H@:0=C1$YR2X#0)WAF"6Q+<O@2O)'A]"7Y)\/L2@I(0]"4,
M2\*PKTIA20C[OF%4$D8J'(KU4XL_@QQ.QY3L 95H84T^J A2;+'F.)/!ON)4
MC&+!X]._13XMLXBD"#PA"E9;2!'X!%8BJ>(\08"LP2UD. (PB\$,)SE',="2
M+F>(0YRP*T%_6<W Y<45N  F8'*4 9R!EPQS=EWK>,1)(B)>]%W4FV.3BYE)
M_\RHG,5M,0OGS"Q<\$@ROF5@GL4HUO 7W?Q1!]\4BE:R.@=9;YU.@RNT,X!K
M70/'<FR-/W?=]"]YUDF?==,?(15T^RQ]WM]Y2T._[^^\CO[0WWD=??%[RB\_
M//>30'"K_'*5/?>,O3FD&<XV[)@HUX<TN@:O/\$=25.QY]\ED(DT$$F5Y+'
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MHA(@QM>$\$-#OJ#Z3#/]'U!+ P04    " !T.F13.\Q&U+0"  !W!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6RE55UOVC 4_2M6GEII(R&$MJL
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MOFMA&_W%5^M98*.K^'VZ%MC63=AR? Z-<(:7=R.*$!V66&@T,7R')D,1H\O
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M83&Y/,!YGFEG ,]W2MGGA3LQ9O\A6/P+4$L#!!0    ( '0Z9%-<$*]$F (
M *X'   9    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;*55WT_;,!#^5ZR(
M!Y!8DZ9MQE ;B?Z8QD,G1,7V,.W!3:Z-A6,'VVEA?_W.3IH%% H:+XU]ON_[
M[L[NW7@OU;W.  QYS+G0$R\SIKCT?9UDD%/=DP4(/-E(E5.#6[7U=:& I@Z4
M<S\,@LC/*1->/':V&Q6/96DX$W"CB"[SG*JG*7"YGWA][V"X9=O,6(,?CPNZ
MA168N^)&X<YO6%*6@]!,"J)@,_&N^I>+R/H[AQ\,]KJU)C:3M93W=G.=3KS
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ME@:;J5MF.%!!60<\WTAI#ALKT(SH^"]02P,$%     @ =#ID4[7C&N1/!P
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M6IUVLCS-#P^)+:3;6> O/TW/VV@;+8,<R,I=FCH'AG(7IEXGM8Z)+:2[50!
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M^426+Y%<Y[]D6_A>>PY),FUD6H+Q!"D3Q9.^E#KL 9"G'A"4@. 8T'P'$):
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MY0JK 91UP/<+*<UN8P-4?U[Z_P!02P,$%     @ =#ID4YG+]9^8 @  ZP8
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MKUXCX-I S1>,R?>.OO#Z]RW]"U!+ P04    " !T.F13<0PL%7$"  "<!@
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M4FC3.MRP,K\/D!9@UDLA]'9B#88?4OH'4$L#!!0    ( '0Z9%/" $.- P,
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M#9V^@Q)8D")5=WSS$:J$(L,7\U3:7[0I;;NA@^)"*IY58!U!1EGY3QXK(78
MFJ<9X%< _Z6 H ($+P6$%2!\*2"J #9UM\S="C<EBHP&@F^0,-::S0RL^A:M
M]:+,7)29$GJ7:IP:36&NT =T0X0@YLC0T104H:D\UJOWLRDZ>G<\<)7V9.S=
MN&(=EZS^ =8 77.F5A)=L 22!ORD'7_:@G=UAG6:_G.:8[^5< 9Y!P7>"?(]
M'S?%\W_P:3O\O%AJ.+9PKP%^T0Z_)D\'T'M:!/61!Y8N/)@,HUR@>R8A+@0D
MZ(8KD"W$84T<6N+@ /$G/4=\@2::E"IT26*:4O6$OMJ-*P69_-;B)JK=1*WQ
M7S$% J1"\*C+I82FZUDR8,]2F&*Y'F&,/?,,W/7NP3=8!D&P;[D79K<.L]L:
MYEC09 E;%7Z@7U9:I.C5/GIOJ7B_=M-O3<44B1.4"\IBFI,4D8P73#5=Y'Z#
M[I%7/<UZGM9!G+8&@3N]R'N/JMMK[RQ*"M +N<YS#D*_'X&G9?[K^XV];;'T
MWE)OO%.5\>LH/JV(]B7WHU;)L;^-PV^-P^_TO3^)'OV;Z-MRA8,W%7U;OG#X
M6J*'OXO>.Z"YN_-QSD L;5<D46RXR^]TO5IW7N>VWW"WYF7;=DW$DC*)4EAH
MJ*=?" >)LA,J)XKG]E,_YTHW#G:XTMTC"&.@]Q=<GTHU,0[J?G3T$U!+ P04
M    " !T.F1369,^%+4"  !V"   &0   'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6RU5EU/VS 4_2M6!!)(H_EJFQ:ED4:K:95@0E1L#],>W.2VM4CLS'8H
M_/M=.R$K(X1)B)?Z(_<<'Y_CQHGW0MZI'8 F#T7.U<S9:5V>NZY*=U!0-1 E
M<'RR$;*@&H=RZZI2 LTLJ,C=P//&;D$9=Y+8SEW+)!:5SAF':TE45114/EY
M+O8SQW>>)F[8=J?-A)O$)=W""O1M>2UQY+8L&2N *R8XD;"9.9_]\[EO ;;B
M.X.].N@3LY6U$'=FL,QFCF<400ZI-A04FWN80YX;)M3QNR%UVC4-\+#_Q/[%
M;AXWLZ8*YB+_P3*]FSD3AV2PH56N;\3^*S0;&AF^5.3*_I)]4^LY)*V4%D4#
M1@4%XW5+'QHC#@#^\!5 T ""_P6$#2"T&ZV5V6TMJ*9)+,6>2%.-;*9CO;%H
MW WC)L:5EOB4(4XG"UAK<D96=8I$;,A2J0HRL@+.A"2W7$%:29SX)C0H<K(
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M.K:[PP\#D*8 GV\$'H-F8*Z>]E,C^0-02P,$%     @ =#ID4S@LIDI* @
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M)936P9POA=#;C0W0?^;2OU!+ P04    " !T.F13;+8&E#(#   ##   &0
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M5#(N)./Z#G9#_'\[V"V4NR?J8*]0Z/UC!WMORHF/E[-?2/;KRQGVNGDY:Q+
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M<',O87!P+GAM;%!+ 0(4 Q0    ( '0Z9%,MDT I[@   "L"   1
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M965T,BYX;6Q02P$"% ,4    " !T.F136YQW_XP#  !P#@  &
M    @(%;%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M=#ID4]3.BAO)!P  %B,  !@              ("!'1@  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( '0Z9%,I44X@D T  '=?   8
M          " @1P@  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " !T.F13WL)_2;@&   2&@  &               @('B+0  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ =#ID4S-QFI=&!   /0H
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( '0Z9%.,RKULSP4  "@/   9
M      " @;Y<  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ =#ID4Q[M]6,C P  % <  !D              ("!Q&(  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !T.F138$K3/W8$   &"@
M&0              @($>9@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( '0Z9%/)BAVGP@,  (0*   9              " @<MJ  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ =#ID4S<.W[1_
M!P  ?10  !D              ("!Q&X  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " !T.F13_N]@6GP#   L"   &0
M@(%Z=@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( '0Z
M9%,_4,T%-B(  &%W   9              " @2UZ  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ =#ID4Y[Y+)-A!   D H  !D
M         ("!FIP  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " !T.F134&KDGJ$'  #L&   &0              @($RH0  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( '0Z9%,:S3RNT@<  .0;
M   9              " @0JI  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ =#ID4]P@.#V* P  ; @  !D              ("!$[$
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !T.F13+=T!
M]?L$   G#0  &0              @('4M   >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( '0Z9%/.UI^6>P0  .P*   9
M  " @0:Z  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M=#ID4VHB&DR. @  0P4  !D              ("!N+X  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " !T.F13-'1=T+L"  #$!0  &0
M            @(%]P0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( '0Z9%,@%J@US0(  /\%   9              " @6_$  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ =#ID4Z8KH,2! P
M]0H  !D              ("!<\<  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " !T.F13@8IH23X$  !Q$@  &0              @($K
MRP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( '0Z9%.O
M!,0N$@,  #(+   9              " @:#/  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ =#ID4V=V-S-9 @  $08  !D
M     ("!Z=(  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '0Z9%-<U*)#G (  *,%   9              "
M@2SG  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ =#ID
M4[DQ=$!E @  708  !D              ("!_^D  'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " !T.F13P?/<L1L$   ?#P  &0
M        @(&;[   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( '0Z9%-2XB\YE (  +<&   9              " @>WP  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ =#ID4\UHP,A! P  M D
M !D              ("!N/,  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " !T.F137NSJK9$"  "R!@  &0              @($P]P
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( '0Z9%.6@PKL
M'@(  %$$   9              " @?CY  !X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ =#ID4Q&)@7>C @  GP8  !D
M ("!3?P  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !T
M.F13,!@8'TL#  #+"@  &0              @($G_P  >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( '0Z9%,(C70G>0(  #T&   9
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M970T.2YX;6Q02P$"% ,4    " !T.F13<K ';(P"   9!@  &0
M    @('5%0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M '0Z9%,=>?:MLP,  "T0   9              " @9@8 0!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ =#ID4UP0KT28 @  K@<  !D
M             ("!@AP! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    " !T.F13M>,:Y$\'  "K-P  &0              @(%1'P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( '0Z9%,UINAS^0(
M ,@(   9              " @=<F 0!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ =#ID4YG+]9^8 @  ZP8  !D              ("!
M!RH! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !T.F13
M<0PL%7$"  "<!@  &0              @('6+ $ >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    ( '0Z9%/" $.- P,  )L*   9
M      " @7XO 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%
M  @ =#ID4UF3/A2U @  =@@  !D              ("!N#(! 'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " !T.F13."RF2DH"  "]!@
M&0              @(&D-0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+
M 0(4 Q0    ( '0Z9%-Z=/Y"6P0  'T3   9              " @24X 0!X
M;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ =#ID4X\N( >]
M @  NP<  !D              ("!MSP! 'AL+W=O<FMS:&5E=',O<VAE970V
M,2YX;6Q02P$"% ,4    " !T.F13;R-YU]H"  #5!P  &0
M@(&K/P$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( '0Z
M9%,S;@%YJ0(  /(&   9              " @;Q" 0!X;"]W;W)K<VAE971S
M+W-H965T-C,N>&UL4$L! A0#%     @ =#ID4VRV!I0R P   PP  !D
M         ("!G$4! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4
M    " !T.F13WM;C.!\#  !H$@  #0              @ $%20$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( '0Z9%.7BKL<P    !,"   +
M  "  4], 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( '0Z9%.P7[5RR@0  %$J
M   /              "  3A- 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !T.F13TDF\;1$"   7)@  &@              @ $O4@$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !T.F13P(AM=.D!  !^)0
M$P              @ %X5 $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..2 !( *\3  "25@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>368</ContextCount>
  <ElementCount>282</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>88</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Interim Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InterimFinancialStatements</Role>
      <ShortName>Interim Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Product Sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSales</Role>
      <ShortName>Product Sales</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Collaboration, License, and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements</Role>
      <ShortName>Collaboration, License, and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2125104 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2129105 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2135106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2139107 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2143108 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2147109 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2149110 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2153111 - Disclosure - Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StatementofCashFlows</Role>
      <ShortName>Statement of Cash Flows</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2157112 - Disclosure - Legal Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LegalMatters</Role>
      <ShortName>Legal Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Interim Financial Statements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InterimFinancialStatementsPolicies</Role>
      <ShortName>Interim Financial Statements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Product Sales (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesTables</Role>
      <ShortName>Product Sales (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/ProductSales</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Collaboration, License, and Other Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables</Role>
      <ShortName>Collaboration, License, and Other Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2326303 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/NetIncomePerShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2330304 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/MarketableSecurities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2336305 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2340306 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/Inventories</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2344307 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/Debt</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2350308 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2354309 - Disclosure - Statement of Cash Flows (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StatementofCashFlowsTables</Role>
      <ShortName>Statement of Cash Flows (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/StatementofCashFlows</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Product Sales - Schedule of Net Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails</Role>
      <ShortName>Product Sales - Schedule of Net Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails</Role>
      <ShortName>Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Product Sales - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/ProductSalesNarrativeDetails</Role>
      <ShortName>Product Sales - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, IO Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Contract Balances, IO Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Collaboration, License, and Other Agreements - Bayer Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Bayer Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Collaboration Agreements - Amounts Recognized in Statement of Operations with Bayer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails</Role>
      <ShortName>Collaboration Agreements - Amounts Recognized in Statement of Operations with Bayer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2417411 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2418412 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2419413 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2420414 - Disclosure - Collaboration, License, and Other Agreements - Teva Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Teva Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2421415 - Disclosure - Collaboration, License, and Other Agreements - U.S. Government Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - U.S. Government Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2422416 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2423417 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Roche Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Schedule of Contract Balances, Roche Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2424418 - Disclosure - Collaboration, License, and Other Agreements - Intellia Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails</Role>
      <ShortName>Collaboration, License, and Other Agreements - Intellia Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2427419 - Disclosure - Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2428420 - Disclosure - Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails</Role>
      <ShortName>Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2431421 - Disclosure - Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2432422 - Disclosure - Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2433423 - Disclosure - Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2434424 - Disclosure - Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2437425 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2438426 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2441427 - Disclosure - Inventories - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2442428 - Disclosure - Inventories - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2445429 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2446430 - Disclosure - Debt - Summary of Issued Senior Unsecured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails</Role>
      <ShortName>Debt - Summary of Issued Senior Unsecured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2448431 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/IncomeTaxes</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2451432 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2452433 - Disclosure - Stockholders' Equity - Schedule of Repurchased Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Repurchased Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2455434 - Disclosure - Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2456435 - Disclosure - Statement of Cash Flows - Summary of Non-cash Investing and Financing Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails</Role>
      <ShortName>Statement of Cash Flows - Summary of Non-cash Investing and Financing Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="regn-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2458436 - Disclosure - Legal Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.regeneron.com/role/LegalMattersDetails</Role>
      <ShortName>Legal Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.regeneron.com/role/LegalMatters</ParentRole>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="regn-20210930.htm">regn-20210930.htm</File>
    <File>regen-ex_101x9302021x10q.htm</File>
    <File>regen-ex_102x9302021x10q.htm</File>
    <File>regn-20210930.xsd</File>
    <File>regn-20210930_cal.xml</File>
    <File>regn-20210930_def.xml</File>
    <File>regn-20210930_lab.xml</File>
    <File>regn-20210930_pre.xml</File>
    <File>regn-ex_311x09302021x10q.htm</File>
    <File>regn-ex_312x09302021x10q.htm</File>
    <File>regn-ex_32x09302021x10q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>84
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "regn-20210930.htm": {
   "axisCustom": 2,
   "axisStandard": 27,
   "contextCount": 368,
   "dts": {
    "calculationLink": {
     "local": [
      "regn-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "regn-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "regn-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "regn-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "regn-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "regn-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 418,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 20,
   "keyStandard": 262,
   "memberCustom": 51,
   "memberStandard": 32,
   "nsprefix": "regn",
   "nsuri": "http://www.regeneron.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.regeneron.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125104 - Disclosure - Net Income Per Share",
     "role": "http://www.regeneron.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129105 - Disclosure - Marketable Securities",
     "role": "http://www.regeneron.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135106 - Disclosure - Fair Value Measurements",
     "role": "http://www.regeneron.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139107 - Disclosure - Inventories",
     "role": "http://www.regeneron.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143108 - Disclosure - Debt",
     "role": "http://www.regeneron.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147109 - Disclosure - Income Taxes",
     "role": "http://www.regeneron.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149110 - Disclosure - Stockholders' Equity",
     "role": "http://www.regeneron.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153111 - Disclosure - Statement of Cash Flows",
     "role": "http://www.regeneron.com/role/StatementofCashFlows",
     "shortName": "Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157112 - Disclosure - Legal Matters",
     "role": "http://www.regeneron.com/role/LegalMatters",
     "shortName": "Legal Matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Interim Financial Statements (Policies)",
     "role": "http://www.regeneron.com/role/InterimFinancialStatementsPolicies",
     "shortName": "Interim Financial Statements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "role": "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Product Sales (Tables)",
     "role": "http://www.regeneron.com/role/ProductSalesTables",
     "shortName": "Product Sales (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Collaboration, License, and Other Agreements (Tables)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables",
     "shortName": "Collaboration, License, and Other Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326303 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.regeneron.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330304 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336305 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.regeneron.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340306 - Disclosure - Inventories (Tables)",
     "role": "http://www.regeneron.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344307 - Disclosure - Debt (Tables)",
     "role": "http://www.regeneron.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350308 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.regeneron.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2354309 - Disclosure - Statement of Cash Flows (Tables)",
     "role": "http://www.regeneron.com/role/StatementofCashFlowsTables",
     "shortName": "Statement of Cash Flows (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Product Sales - Schedule of Net Product Sales (Details)",
     "role": "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails",
     "shortName": "Product Sales - Schedule of Net Product Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "ia3f29614787e4465a5554d3f160fa259_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "role": "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "id1b54518517447e2976804aef2938a70_D20210701-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)",
     "role": "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails",
     "shortName": "Product Sales - Schedule of Concentration of Risk, by Risk Factor (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "id1b54518517447e2976804aef2938a70_D20210701-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Product Sales - Narrative (Details)",
     "role": "http://www.regeneron.com/role/ProductSalesNarrativeDetails",
     "shortName": "Product Sales - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "id628995c65e443418912b4df46bdf6a1_I20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
     "shortName": "Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "ifded74cc07f44048a2c104e76b70e48e_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i44705b78f91d457fb2bee63fb813ff55_D20210101-20210930",
      "decimals": "-8",
      "lang": "en-US",
      "name": "regn:LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Contract Balances, Antibody Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "if9483a9e8f5b474ea373471543f0536b_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, IO Collaboration (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Contract Balances, IO Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "ie9bfe175438f49a9be01e98bcc545764_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i89ca366da43e409298cf61eea017813d_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i89ca366da43e409298cf61eea017813d_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i509963cbbe784be8973a31df2b9a8963_D20210101-20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "regn:RevenueBasedOnPercentageOfAnnualSalesInJapan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Collaboration, License, and Other Agreements - Bayer Narrative (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Bayer Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i509963cbbe784be8973a31df2b9a8963_D20210101-20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "regn:RevenueBasedOnPercentageOfAnnualSalesInJapan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Collaboration Agreements - Amounts Recognized in Statement of Operations with Bayer (Details)",
     "role": "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
     "shortName": "Collaboration Agreements - Amounts Recognized in Statement of Operations with Bayer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "ic1ba982dde844a9c82475e880a5f75f0_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417411 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Contract Balances, Bayer Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i2d7420067c744c329c85c868130a6ded_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)",
     "role": "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "ie6533a61e5ab4ad3a159b912aa4b022e_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:ReimbursementOfResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418412 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
     "shortName": "Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Teva (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "ie6533a61e5ab4ad3a159b912aa4b022e_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "regn:ReimbursementOfResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419413 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Contract Balances, Teva Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "ic802850933a14320a118ce1085b1dbcc_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "ic802850933a14320a118ce1085b1dbcc_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420414 - Disclosure - Collaboration, License, and Other Agreements - Teva Narrative (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Teva Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "ic802850933a14320a118ce1085b1dbcc_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i7f04700578124cab99fe2de9a5db10bc_D20210901-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "regn:CollaborativeArrangementNumberOfDosesCounterpartyToPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "dose",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421415 - Disclosure - Collaboration, License, and Other Agreements - U.S. Government Narrative (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - U.S. Government Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i7f04700578124cab99fe2de9a5db10bc_D20210901-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "regn:CollaborativeArrangementNumberOfDosesCounterpartyToPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "dose",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422416 - Disclosure - Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
     "shortName": "Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i27c9ab022abc478d8f79666d02a78330_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423417 - Disclosure - Collaboration, License, and Other Agreements - Schedule of Contract Balances, Roche Collaboration (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails",
     "shortName": "Collaboration, License, and Other Agreements - Schedule of Contract Balances, Roche Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i8a7ab84ea29f4779b5a42b782dc5859e_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424418 - Disclosure - Collaboration, License, and Other Agreements - Intellia Narrative (Details)",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails",
     "shortName": "Collaboration, License, and Other Agreements - Intellia Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "ibe25403ae1ba406b8be348b085927476_D20200401-20200630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "regn:CollaborativeArrangementUpfrontPaymentMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427419 - Disclosure - Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)",
     "role": "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i767fc2b3c91d49368bb428e956e1c15f_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i305115a444d14bd096edfc2b3a5fe574_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428420 - Disclosure - Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)",
     "role": "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails",
     "shortName": "Net Income Per Share - Schedule of Antidilutive Securities Excluded From Computation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i305115a444d14bd096edfc2b3a5fe574_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431421 - Disclosure - Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails",
     "shortName": "Marketable Securities - Schedule of Investments in Available For Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "ie0bf589234254d1fa1a8439438ed348f_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "role": "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "ib3a84e5477f34a4fa157fc0ff96532f9_D20200101-20200331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432422 - Disclosure - Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails",
     "shortName": "Marketable Securities - Schedule of Debt Securities Based on Contractual Maturity Dates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433423 - Disclosure - Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
     "shortName": "Marketable Securities - Schedule of Fair Value and Unrealized Losses of Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:MarketableSecuritiesRealizedGainLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434424 - Disclosure - Marketable Securities - Narrative (Details)",
     "role": "http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails",
     "shortName": "Marketable Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:MarketableSecuritiesRealizedGainLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437425 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Assets Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i928f7d720b6248cd934975804e4ee21a_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438426 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441427 - Disclosure - Inventories - Schedule of Inventories (Details)",
     "role": "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories - Schedule of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442428 - Disclosure - Inventories - Narrative (Details)",
     "role": "http://www.regeneron.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i07fe2aef96e54e809240ec9fba24d72c_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445429 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.regeneron.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i07fe2aef96e54e809240ec9fba24d72c_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "id1490f50984443fa9fc09db8661cd762_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446430 - Disclosure - Debt - Summary of Issued Senior Unsecured Notes (Details)",
     "role": "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails",
     "shortName": "Debt - Summary of Issued Senior Unsecured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "id1490f50984443fa9fc09db8661cd762_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448431 - Disclosure - Income Taxes (Details)",
     "role": "http://www.regeneron.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "role": "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockValueAcquiredCostMethod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451432 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "iec719ff1e7724d85bfffb28a5eac401e_D20200501-20200531",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockValueAcquiredCostMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i1050c845dfc44cdb9a0f967ecdce2c9a_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452433 - Disclosure - Stockholders' Equity - Schedule of Repurchased Shares (Details)",
     "role": "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails",
     "shortName": "Stockholders' Equity - Schedule of Repurchased Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i67bb2d31f4c14f1993cd54b0a2406e75_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455434 - Disclosure - Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Statement of Cash Flows - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i09b0b1c1c2a94afb988a7c59c235eee7_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456435 - Disclosure - Statement of Cash Flows - Summary of Non-cash Investing and Financing Activities (Details)",
     "role": "http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails",
     "shortName": "Statement of Cash Flows - Summary of Non-cash Investing and Financing Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i2e4f524ab89b4891b4ccfbd3555e3a26_I20190225",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458436 - Disclosure - Legal Matters (Details)",
     "role": "http://www.regeneron.com/role/LegalMattersDetails",
     "shortName": "Legal Matters (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i2e4f524ab89b4891b4ccfbd3555e3a26_I20190225",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Interim Financial Statements",
     "role": "http://www.regeneron.com/role/InterimFinancialStatements",
     "shortName": "Interim Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Product Sales",
     "role": "http://www.regeneron.com/role/ProductSales",
     "shortName": "Product Sales",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Collaboration, License, and Other Agreements",
     "role": "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements",
     "shortName": "Collaboration, License, and Other Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "regn-20210930.htm",
      "contextRef": "i252bf0019ce741548a01b718a72d854a_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 88,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "regn_A165PatentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "'165 Patent [Member]",
        "label": "'165 Patent [Member]",
        "terseLabel": "'165 Patent"
       }
      }
     },
     "localname": "A165PatentMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_A226PatentAnd992PatentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "'226 Patent And '992 Patent",
        "label": "'226 Patent And '992 Patent [Member]",
        "terseLabel": "'226 and '992 Patents"
       }
      }
     },
     "localname": "A226PatentAnd992PatentMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_A487PatentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "'487 Patent [Member]",
        "label": "'487 Patent [Member]",
        "terseLabel": "'487 Patent"
       }
      }
     },
     "localname": "A487PatentMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_A631PatentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "'631 Patent",
        "label": "'631 Patent [Member]",
        "terseLabel": "'631 Patent"
       }
      }
     },
     "localname": "A631PatentMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_A741PatentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "'741 Patent [Member]",
        "label": "'741 Patent [Member]",
        "terseLabel": "'741 Patent"
       }
      }
     },
     "localname": "A741PatentMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_Amgenv.s.RegeneronMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen v.s. Regeneron [Member]",
        "label": "Amgen v.s. Regeneron [Member]",
        "terseLabel": "Amgen v.s. Regeneron"
       }
      }
     },
     "localname": "Amgenv.s.RegeneronMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Recognized In Connection With Up-Front Payments [Member]",
        "label": "Amounts Recognized In Connection With Up-Front Payments [Member]",
        "terseLabel": "Amounts recognized in connection with up-front payments received",
        "verboseLabel": "Amounts recognized in connection with up-front and development milestone payments received"
       }
      }
     },
     "localname": "AmountsRecognizedInConnectionWithUpFrontPaymentsMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ArcalystNetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue during the period derived from a specified product line (ARCALYST), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions.",
        "label": "Arcalyst Net Product Sales [Member]",
        "terseLabel": "ARCALYST"
       }
      }
     },
     "localname": "ArcalystNetProductSalesMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_BARDAOtherTransactionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BARDA, Other Transaction Agreement",
        "label": "BARDA, Other Transaction Agreement [Member]",
        "terseLabel": "Other Transaction Agreement"
       }
      }
     },
     "localname": "BARDAOtherTransactionAgreementMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_BayerCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer Collaboration Agreement [Member]",
        "label": "Bayer Collaboration Agreement [Member]",
        "terseLabel": "Bayer"
       }
      }
     },
     "localname": "BayerCollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_BesseMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Besse Medical [Member]",
        "label": "Besse Medical [Member]",
        "terseLabel": "Besse Medical, a subsidiary of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "BesseMedicalMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_BridgeFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bridge Facility",
        "label": "Bridge Facility [Member]",
        "terseLabel": "Bridge Facility"
       }
      }
     },
     "localname": "BridgeFacilityMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_CasirivimabAndImdevimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Casirivimab and imdevimab",
        "label": "Casirivimab and imdevimab [Member]",
        "terseLabel": "Casirivimab and imdevimab"
       }
      }
     },
     "localname": "CasirivimabAndImdevimabMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ClassificationOfInvestmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the general categories of investments, which may be classified as Unrestricted or Restricted.",
        "label": "Classification of Investment [Axis]",
        "terseLabel": "Classification of Investment [Axis]"
       }
      }
     },
     "localname": "ClassificationOfInvestmentAxis",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "regn_ClassificationOfInvestmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides general categories of investments for which information is required or determined to be disclosed.",
        "label": "Classification of Investment [Domain]",
        "terseLabel": "Classification of Investment [Domain]"
       }
      }
     },
     "localname": "ClassificationOfInvestmentDomain",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Revenue",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_CollaborationandContractManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and Contract Manufacturing [Member]",
        "label": "Collaboration and Contract Manufacturing [Member]",
        "terseLabel": "Cost of collaboration and contract manufacturing"
       }
      }
     },
     "localname": "CollaborationandContractManufacturingMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_CollaborativeArrangementNumberOfDosesCounterpartyToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Doses Counterparty To Purchase",
        "label": "Collaborative Arrangement, Number Of Doses Counterparty To Purchase",
        "terseLabel": "Number of doses"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfDosesCounterpartyToPurchase",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "regn_CollaborativeArrangementUpfrontPaymentMade": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment made under a collaboration agreement",
        "label": "Collaborative Arrangement, Upfront Payment Made",
        "terseLabel": "Upfront payment made for collaboration agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontPaymentMade",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_CostOfGoodsSoldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Goods Sold",
        "label": "Cost Of Goods Sold [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsSoldMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_DupilumabREGN3500EligibleInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dupilumab/REGN3500 Eligible Investments [Member]",
        "label": "Dupilumab/REGN3500 Eligible Investments [Member]",
        "terseLabel": "Dupilumab/REGN3500 Eligible Investments"
       }
      }
     },
     "localname": "DupilumabREGN3500EligibleInvestmentsMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_EYLEAAfliberceptInjectionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EYLEA Aflibercept Injection",
        "label": "EYLEA Aflibercept Injection [Member]",
        "terseLabel": "EYLEA"
       }
      }
     },
     "localname": "EYLEAAfliberceptInjectionMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_EvkeezaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evkeeza",
        "label": "Evkeeza [Member]",
        "terseLabel": "Evkeeza"
       }
      }
     },
     "localname": "EvkeezaMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_EyleaNetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue during the period derived from a specified product line (EYLEA), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions.",
        "label": "EYLEA Net Product Sales [Member]",
        "terseLabel": "EYLEA"
       }
      }
     },
     "localname": "EyleaNetProductSalesMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_GainContingencyClaimsInvalidatedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Claims Invalidated, Number",
        "label": "Gain Contingency, Claims Invalidated, Number",
        "terseLabel": "Number of claims invalidated"
       }
      }
     },
     "localname": "GainContingencyClaimsInvalidatedNumber",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "regn_GainContingencyInterPartesReviewFiledNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Inter Partes Review Filed, Number",
        "label": "Gain Contingency, Inter Partes Review Filed, Number",
        "terseLabel": "Number of IPR filed"
       }
      }
     },
     "localname": "GainContingencyInterPartesReviewFiledNumber",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "regn_GrossProductRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Sales Revenue [Member]",
        "label": "Gross Product Revenue [Member]",
        "terseLabel": "Gross product revenue"
       }
      }
     },
     "localname": "GrossProductRevenueMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_IntelliaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intellia",
        "label": "Intellia [Member]",
        "terseLabel": "Intellia"
       }
      }
     },
     "localname": "IntelliaMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_LIBTAYONetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LIBTAYO Net Product Sales [Member]",
        "label": "LIBTAYO Net Product Sales [Member]",
        "terseLabel": "Libtayo"
       }
      }
     },
     "localname": "LIBTAYONetProductSalesMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Levels Of Twelve Month Sales At Which Sales Milestone Payments Would Be Received",
        "label": "Levels Of Twelve Month Sales At Which Sales Milestone Payments Would Be Received",
        "terseLabel": "Levels of twelve-month sales at which sales milestone payments would be received"
       }
      }
     },
     "localname": "LevelsOfTwelveMonthSalesAtWhichSalesMilestonePaymentsWouldBeReceived",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_LibtayoDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Libtayo Development [Member]",
        "label": "Libtayo Development [Member]",
        "terseLabel": "Libtayo development"
       }
      }
     },
     "localname": "LibtayoDevelopmentMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_LossContingencyClaimsInvalidNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims Invalid, Number",
        "label": "Loss Contingency, Claims Invalid, Number",
        "terseLabel": "Invalid claims"
       }
      }
     },
     "localname": "LossContingencyClaimsInvalidNumber",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "regn_LossContingencyExParteReexaminationFiledNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Ex Parte Reexamination, Filed, Number",
        "label": "Loss Contingency, Ex Parte Reexamination, Filed, Number",
        "terseLabel": "Number of ex parte reexamination requests"
       }
      }
     },
     "localname": "LossContingencyExParteReexaminationFiledNumber",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "regn_LossContingencyPercentageOfDamagesResponsibleFor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Percentage Of Damages Responsible For",
        "label": "Loss Contingency, Percentage Of Damages Responsible For",
        "terseLabel": "Percentage of damages company is responsible for"
       }
      }
     },
     "localname": "LossContingencyPercentageOfDamagesResponsibleFor",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_MarketableSecuritiesRealizedGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Realized Gain",
        "label": "Marketable Securities, Realized Gain",
        "terseLabel": "Marketable securities, realized gain"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGain",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_MarketableSecuritiesRealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Realized Loss",
        "label": "Marketable Securities, Realized Loss",
        "terseLabel": "Marketable securities, realized loss"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedLoss",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_MaximumTransactionAgreementPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Transaction Agreement Payments",
        "label": "Maximum Transaction Agreement Payments",
        "terseLabel": "Maximum agreement payments"
       }
      }
     },
     "localname": "MaximumTransactionAgreementPayments",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corporation [Member]",
        "label": "McKesson Corporation [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_NetProfitInConnectionWithCommercializationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Profit In Connection With Commercialization [Member]",
        "label": "Net Profit In Connection With Commercialization [Member]",
        "terseLabel": "Regeneron's net profit in connection with commercialization of EYLEA outside the United States"
       }
      }
     },
     "localname": "NetProfitInConnectionWithCommercializationMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_PercentageOfRoyaltyPaymentThatCanBeOffset": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Royalty Payment That Can Be Offset",
        "label": "Percentage Of Royalty Payment That Can Be Offset",
        "terseLabel": "Percentage of royalty payment that can be used to offset litigation proceedings (up to)"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentThatCanBeOffset",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Trial Costs Required To Be Funded By Collaborating Party",
        "label": "Percentage of Trial Costs Required To Be Funded By Collaborating Party",
        "terseLabel": "Percentage of trial costs required to be funded by collaborating party"
       }
      }
     },
     "localname": "PercentageOfTrialCostsRequiredToBeFundedByCollaboratingParty",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for Achieving Sales Target for Milestone Payment, Rolling Basis",
        "label": "Period for Achieving Sales Target for Milestone Payment, Rolling Basis",
        "terseLabel": "Period for achieving sales target for milestone payment, rolling basis"
       }
      }
     },
     "localname": "PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "regn_PraluentCrossLicenseAndCommercializationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Praluent Cross License And Commercialization Agreement [Member]",
        "label": "Praluent Cross License And Commercialization Agreement [Member]",
        "terseLabel": "Praluent Agreement"
       }
      }
     },
     "localname": "PraluentCrossLicenseAndCommercializationAgreementMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_PraluentNetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Praluent Net Product Sales",
        "label": "Praluent Net Product Sales [Member]",
        "terseLabel": "Praluent"
       }
      }
     },
     "localname": "PraluentNetProductSalesMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_REGENCOVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "REGEN-COV",
        "label": "REGEN-COV [Member]",
        "terseLabel": "REGEN-COV"
       }
      }
     },
     "localname": "REGENCOVMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RegeneronsShareOfCommercialExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron's Share Of Commercial Expenses",
        "label": "Regeneron's Share Of Commercial Expenses [Member]",
        "terseLabel": "Regeneron's obligation for its share of Sanofi commercial expenses"
       }
      }
     },
     "localname": "RegeneronsShareOfCommercialExpensesMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron's Share Of Research And Development Expenses [Member]",
        "label": "Regeneron's Share Of Research And Development Expenses [Member]",
        "terseLabel": "Regeneron's obligation for its share of Sanofi research and development expenses",
        "verboseLabel": "Regeneron's obligation for its share of Bayer research and development expenses"
       }
      }
     },
     "localname": "RegeneronsShareOfResearchAndDevelopmentExpensesMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementForManufacturingOfCommercialSuppliesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement For Manufacturing Of Commercial Supplies [Member]",
        "label": "Reimbursement For Manufacturing Of Commercial Supplies [Member]",
        "terseLabel": "Reimbursement for manufacturing of commercial supplies"
       }
      }
     },
     "localname": "ReimbursementForManufacturingOfCommercialSuppliesMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementOfCommercializationRelatedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement Of Commercialization-Related Expenses",
        "label": "Reimbursement Of Commercialization-Related Expenses [Member]",
        "terseLabel": "Reimbursement of commercialization-related expenses"
       }
      }
     },
     "localname": "ReimbursementOfCommercializationRelatedExpensesMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ReimbursementOfResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement Of Research And Development Expense",
        "label": "Reimbursement Of Research And Development Expense",
        "terseLabel": "Reduction of Research and development expense"
       }
      }
     },
     "localname": "ReimbursementOfResearchAndDevelopmentExpense",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_ReimbursementOfResearchAndDevelopmentExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement Of Research And Development Expenses [Member]",
        "label": "Reimbursement Of Research And Development Expenses [Member]",
        "terseLabel": "Reimbursement of research and development expenses",
        "verboseLabel": "Reimbursement of research and development expenses"
       }
      }
     },
     "localname": "ReimbursementOfResearchAndDevelopmentExpensesMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining Amount Of Sales Milestone Payments If Total Sales Achieve Specific Levels",
        "label": "Remaining Amount Of Sales Milestone Payments If Total Sales Achieve Specific Levels",
        "terseLabel": "Remaining amount of sales milestone payments if total sales achieve specific levels"
       }
      }
     },
     "localname": "RemainingAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_ResearchCollaborationAndLicensingArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research Collaboration and Licensing Arrangements [Line Items]",
        "terseLabel": "Research Collaboration and Licensing Arrangements [Line Items]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicensingArrangementsLineItems",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "regn_ResearchCollaborationAndLicensingArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Research Collaboration and Licensing Arrangements [Table]",
        "terseLabel": "Research Collaboration and Licensing Arrangements [Table]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicensingArrangementsTable",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "regn_RestrictedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted [Member]",
        "label": "Restricted [Member]",
        "terseLabel": "Restricted"
       }
      }
     },
     "localname": "RestrictedMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RevenueBasedOnPercentageOfAnnualSalesInJapan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage on annual sales in Japan that the Company is entitled to receive, subject to certain potential adjustments.",
        "label": "Revenue Based On Percentage Of Annual Sales In Japan",
        "terseLabel": "Revenue based on percentage of annual sales in Japan"
       }
      }
     },
     "localname": "RevenueBasedOnPercentageOfAnnualSalesInJapan",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_RocheCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche Collaboration Agreement",
        "label": "Roche Collaboration Agreement [Member]",
        "terseLabel": "Roche Collaboration Agreement"
       }
      }
     },
     "localname": "RocheCollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Percentage To Be Received On Net Product Sales Outside Of United States",
        "label": "Royalty Percentage To Be Received On Net Product Sales Outside Of United States",
        "terseLabel": "Royalty percentage to be received on net product sales outside of the United States"
       }
      }
     },
     "localname": "RoyaltyPercentageToBeReceivedOnNetProductSalesOutsideOfUnitedStates",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "regn_SalesBasedMilestoneEarnedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Milestone Earned",
        "label": "Sales-Based Milestone Earned [Member]",
        "terseLabel": "Sales-based milestone earned"
       }
      }
     },
     "localname": "SalesBasedMilestoneEarnedMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesMilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestone One",
        "label": "Sales Milestone One [Member]",
        "terseLabel": "First Sales Milestone"
       }
      }
     },
     "localname": "SalesMilestoneOneMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesMilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestone Two",
        "label": "Sales Milestone Two [Member]",
        "terseLabel": "Second Sales Milestone"
       }
      }
     },
     "localname": "SalesMilestoneTwoMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SalesMilestonesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestones",
        "label": "Sales Milestones [Axis]",
        "terseLabel": "Sales Milestones [Axis]"
       }
      }
     },
     "localname": "SalesMilestonesAxis",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "regn_SalesMilestonesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Milestones [Domain]",
        "label": "Sales Milestones [Domain]",
        "terseLabel": "Sales Milestones [Domain]"
       }
      }
     },
     "localname": "SalesMilestonesDomain",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofiCollaborationAgreementAntibodyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Collaboration Agreement, Antibody [Member]",
        "label": "Sanofi Collaboration Agreement, Antibody [Member]",
        "terseLabel": "Sanofi Collaboration Agreement, Antibody"
       }
      }
     },
     "localname": "SanofiCollaborationAgreementAntibodyMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofiCollaborationAgreementImmunooncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Collaboration Agreement, Immuno-oncology [Member]",
        "label": "Sanofi Collaboration Agreement, Immuno-oncology [Member]",
        "netLabel": "Sanofi Collaboration Agreement, Immuno-oncology",
        "terseLabel": "Sanofi Collaboration Agreement, Immuno-oncology",
        "verboseLabel": "Sanofi Collaboration Agreement, Immuno-oncology"
       }
      }
     },
     "localname": "SanofiCollaborationAgreementImmunooncologyMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi [Member]",
        "label": "Sanofi [Member]",
        "terseLabel": "Sanofi"
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SanofisShareofLibtayoU.S.GrossProfitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi's Share of Libtayo U.S. Gross Profits [Member]",
        "label": "Sanofi's Share of Libtayo U.S. Gross Profits [Member]",
        "terseLabel": "Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits"
       }
      }
     },
     "localname": "SanofisShareofLibtayoU.S.GrossProfitsMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SeniorUnsecuredNotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due 2030",
        "label": "Senior Unsecured Notes Due 2030 [Member]",
        "terseLabel": "1.750% Senior Notes due September 2030"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDue2030Member",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_SeniorUnsecuredNotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due 2050",
        "label": "Senior Unsecured Notes Due 2050 [Member]",
        "terseLabel": "2.800% Senior Notes due September 2050"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDue2050Member",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ShareOfProfitLossesInConnectionWithCommercializationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Of Profit (Losses) In Connection With Commercialization [Member]",
        "label": "Share Of Profit (Losses) In Connection With Commercialization [Member]",
        "terseLabel": "Regeneron's share of profits (losses) in connection with commercialization"
       }
      }
     },
     "localname": "ShareOfProfitLossesInConnectionWithCommercializationMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ShareRepurchaseProgram2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program, 2019",
        "label": "Share Repurchase Program, 2019 [Member]",
        "terseLabel": "2019 Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgram2019Member",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_ShareRepurchaseProgramJanuary2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program, January 2021",
        "label": "Share Repurchase Program, January 2021 [Member]",
        "terseLabel": "January 2021 Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgramJanuary2021Member",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued/Distributed During Period, Shares, Employee Benefit Plan",
        "label": "Stock Issued/Distributed During Period, Shares, Employee Benefit Plan",
        "terseLabel": "Issuance/distribution of Common Stock for 401(k) Savings Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDistributedDuringPeriodSharesEmployeeBenefitPlan",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "regn_StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued/Distributed During Period, Value, Employee Benefit Plan",
        "label": "Stock Issued/Distributed During Period, Value, Employee Benefit Plan",
        "terseLabel": "Issuance/distribution of Common Stock for 401(k) Savings Plan"
       }
      }
     },
     "localname": "StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "regn_TevaPharmaceuticalsCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Teva Pharmaceuticals Collaboration Agreement [Member]",
        "label": "Teva Pharmaceuticals Collaboration Agreement [Member]",
        "terseLabel": "Teva"
       }
      }
     },
     "localname": "TevaPharmaceuticalsCollaborationAgreementMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_USGovernmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Government",
        "label": "US Government [Member]",
        "terseLabel": "U.S. Government"
       }
      }
     },
     "localname": "USGovernmentMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "regn_UnrestrictedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments whose use is not restricted in whole or in part, by contractual agreements or regulatory requirements.",
        "label": "Unrestricted [Member]",
        "terseLabel": "Unrestricted"
       }
      }
     },
     "localname": "UnrestrictedMember",
     "nsuri": "http://www.regeneron.com/20210930",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r54",
      "r56",
      "r109",
      "r110",
      "r247",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r172",
      "r323",
      "r328",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r246",
      "r283",
      "r343",
      "r345",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r456",
      "r506",
      "r510",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r246",
      "r283",
      "r343",
      "r345",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r456",
      "r506",
      "r510",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r172",
      "r323",
      "r328",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r169",
      "r323",
      "r326",
      "r459",
      "r505",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/LegalMattersDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r169",
      "r323",
      "r326",
      "r459",
      "r505",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/LegalMattersDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r246",
      "r283",
      "r334",
      "r343",
      "r345",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r456",
      "r506",
      "r510",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r246",
      "r283",
      "r334",
      "r343",
      "r345",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r456",
      "r506",
      "r510",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r55",
      "r56",
      "r109",
      "r110",
      "r247",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r120",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario, Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r120",
      "r125",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r323",
      "r327",
      "r508",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r323",
      "r327",
      "r508",
      "r536",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r120",
      "r125",
      "r219",
      "r344",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r472",
      "r497"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r19",
      "r173",
      "r174"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r60",
      "r61",
      "r62",
      "r493",
      "r515",
      "r516"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r59",
      "r62",
      "r69",
      "r70",
      "r71",
      "r112",
      "r113",
      "r114",
      "r386",
      "r511",
      "r512",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r20",
      "r358",
      "r424"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r355",
      "r356",
      "r357",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r346",
      "r348",
      "r359",
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation charges"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive weighted average number of shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r185",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r106",
      "r158",
      "r161",
      "r167",
      "r196",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r384",
      "r387",
      "r406",
      "r422",
      "r424",
      "r467",
      "r490"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r53",
      "r106",
      "r196",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r384",
      "r387",
      "r406",
      "r422",
      "r424"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r178",
      "r203"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Available-for-sale debt securities:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r182",
      "r184",
      "r484"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Maturities after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r182",
      "r183",
      "r483"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturities within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r176",
      "r179",
      "r203",
      "r471"
     ],
     "calculation": {
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale debt securities",
        "totalLabel": "Total",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofDebtSecuritiesBasedonContractualMaturityDatesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r350",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BridgeLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place.",
        "label": "Bridge Loan [Member]",
        "terseLabel": "Bridge Facility"
       }
      }
     },
     "localname": "BridgeLoanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsSummaryofNoncashInvestingandFinancingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r34",
      "r96"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r91",
      "r96",
      "r100"
     ],
     "calculation": {
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r91",
      "r407"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "verboseLabel": "Statement of Cash Flows"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlows"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r103",
      "r106",
      "r128",
      "r132",
      "r133",
      "r135",
      "r137",
      "r145",
      "r146",
      "r147",
      "r196",
      "r232",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r281",
      "r282",
      "r286",
      "r290",
      "r406",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration, License, and Other Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r112",
      "r113",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "netLabel": "Common Stock",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails",
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common Stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r424"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r65",
      "r67",
      "r68",
      "r77",
      "r478",
      "r500"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Statements of Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r150",
      "r151",
      "r172",
      "r403",
      "r404",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r172",
      "r403",
      "r404",
      "r518",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r172",
      "r403",
      "r404",
      "r518",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r150",
      "r151",
      "r172",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r148",
      "r150",
      "r151",
      "r152",
      "r403",
      "r405",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r150",
      "r151",
      "r172",
      "r403",
      "r404",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of accounts receivable and deferred revenue information"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract",
        "terseLabel": "Cumulative catch-up adjustment to revenue, change in estimate of transaction price"
       }
      }
     },
     "localname": "ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r310",
      "r311",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r310",
      "r311",
      "r324"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r310",
      "r311",
      "r324"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "netLabel": "Corporate bonds",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r81",
      "r459"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods, collaboration and contract manufacturing"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Costs and expenses, total"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r149",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesScheduleofConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r102",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r260",
      "r267",
      "r268",
      "r270",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r105",
      "r111",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r273",
      "r274",
      "r275",
      "r276",
      "r419",
      "r468",
      "r469",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r243",
      "r273",
      "r274",
      "r417",
      "r419",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt, principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r43",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44",
      "r105",
      "r111",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r273",
      "r274",
      "r275",
      "r276",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r105",
      "r111",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r273",
      "r274",
      "r275",
      "r276",
      "r298",
      "r301",
      "r302",
      "r303",
      "r416",
      "r417",
      "r419",
      "r420",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r190",
      "r207",
      "r210"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Fair Value - 12 Months or Greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r190",
      "r207"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "Unrealized Loss - 12 Months or Greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r190",
      "r207",
      "r210"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Fair Value - Less than 12 Months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r190",
      "r207"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Unrealized Loss - Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Available-for-sale Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r188",
      "r204",
      "r210"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "totalLabel": "Fair Value - Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r189",
      "r205"
     ],
     "calculation": {
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Unrealized Loss - Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r187",
      "r206",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Fair Value and Unrealized Losses of Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r94",
      "r156"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r323",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of collaborative revenue",
        "verboseLabel": "Schedule of product sales"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTables",
      "http://www.regeneron.com/role/ProductSalesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r78",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r126",
      "r128",
      "r135",
      "r136",
      "r137",
      "r141",
      "r142",
      "r392",
      "r393",
      "r479",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r78",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r128",
      "r135",
      "r136",
      "r137",
      "r141",
      "r142",
      "r392",
      "r393",
      "r479",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r69",
      "r70",
      "r71",
      "r112",
      "r113",
      "r114",
      "r116",
      "r122",
      "r124",
      "r144",
      "r197",
      "r297",
      "r304",
      "r355",
      "r356",
      "r357",
      "r369",
      "r370",
      "r391",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r511",
      "r512",
      "r513",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r195",
      "r502"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized gain (loss) on securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Securities owned not readily marketable"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r394",
      "r395",
      "r396",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r258",
      "r273",
      "r274",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r395",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r394",
      "r395",
      "r397",
      "r398",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r258",
      "r335",
      "r336",
      "r341",
      "r342",
      "r395",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r258",
      "r273",
      "r274",
      "r335",
      "r336",
      "r341",
      "r342",
      "r395",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r258",
      "r273",
      "r274",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r399",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Measured on a recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r192",
      "r193",
      "r194",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r206",
      "r208",
      "r209",
      "r210",
      "r269",
      "r295",
      "r390",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r74",
      "r158",
      "r160",
      "r163",
      "r166",
      "r168",
      "r464",
      "r475",
      "r481",
      "r503"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r107",
      "r366",
      "r367",
      "r368",
      "r371",
      "r373",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r108",
      "r123",
      "r124",
      "r157",
      "r364",
      "r372",
      "r374",
      "r504"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase in accounts payable, accrued expenses, and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r93",
      "r457"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "(Decrease) increase in deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "(Increase) decrease in prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "verboseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r137"
     ],
     "calculation": {
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r73",
      "r155",
      "r415",
      "r418",
      "r480"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r84",
      "r264",
      "r272",
      "r275",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r213"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r51",
      "r424"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r213"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r27",
      "r213"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-offs and reserves"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "auth_ref": [
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of the investment.",
        "label": "Investment Owned, at Cost",
        "terseLabel": "Shares purchase price"
       }
      }
     },
     "localname": "InvestmentOwnedAtCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Marketable Securities, Based on Contractual Maturity Dates"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r191",
      "r465",
      "r485",
      "r535",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "terseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40",
      "r106",
      "r162",
      "r196",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r385",
      "r387",
      "r388",
      "r406",
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r106",
      "r196",
      "r406",
      "r424",
      "r470",
      "r495"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r106",
      "r196",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r385",
      "r387",
      "r388",
      "r406",
      "r422",
      "r423",
      "r424"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r38",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r15",
      "r257",
      "r271",
      "r273",
      "r274",
      "r469",
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long-term debt fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r44",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Pending claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "totalLabel": "Total marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r6",
      "r41"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Gain (Loss)",
        "negatedTerseLabel": "Gains on marketable and other securities, net"
       }
      }
     },
     "localname": "MarketableSecuritiesGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Marketable securities, realized gain (loss)"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r91",
      "r92",
      "r95"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r63",
      "r66",
      "r71",
      "r75",
      "r95",
      "r106",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r123",
      "r124",
      "r134",
      "r158",
      "r160",
      "r163",
      "r166",
      "r168",
      "r196",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r393",
      "r406",
      "r476",
      "r498"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income - basic and diluted"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Outside United States"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r158",
      "r160",
      "r163",
      "r166",
      "r168"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Interim Financial Statements"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InterimFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r57",
      "r60"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Unrealized gain (loss) on cash flow hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r64",
      "r67",
      "r69",
      "r70",
      "r72",
      "r76",
      "r297",
      "r408",
      "r413",
      "r414",
      "r477",
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r58",
      "r60"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (loss) gain on debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryNetOfReserves": {
     "auth_ref": [
      "r52",
      "r212"
     ],
     "calculation": {
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after of valuation reserves and allowances, of inventory, classified as other, expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory, Net of Reserves",
        "terseLabel": "Deferred costs"
       }
      }
     },
     "localname": "OtherInventoryNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncome": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Operating Income",
        "terseLabel": "Other operating income"
       }
      }
     },
     "localname": "OtherOperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other operating income (expense).",
        "label": "Other Operating Income (Expense) [Member]",
        "terseLabel": "Other operating income"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTerseLabel": "Other operating expense (income), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of Common Stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Payments in connection with Common Stock tendered for employee tax obligations"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable and other securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r86",
      "r378",
      "r379",
      "r380"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/LegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred Stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred Stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred Stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred Stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17",
      "r424"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r32",
      "r33"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "verboseLabel": "Sales or maturities of marketable and other securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from bridge loan facility"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsBayerNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesAntibodyCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesBayerCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesIOCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesRocheCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsScheduleofContractBalancesTevaCollaborationDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsUSGovernmentNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r215",
      "r424",
      "r486",
      "r496"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedTerseLabel": "Repayment of bridge loan facility"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r361",
      "r458",
      "r549"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsIntelliaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithTevaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r100",
      "r466",
      "r492"
     ],
     "calculation": {
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash included in Other noncurrent assets"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards and restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r304",
      "r358",
      "r424",
      "r494",
      "r514",
      "r516"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r112",
      "r113",
      "r114",
      "r116",
      "r122",
      "r124",
      "r197",
      "r355",
      "r356",
      "r357",
      "r369",
      "r370",
      "r391",
      "r511",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r153",
      "r154",
      "r159",
      "r164",
      "r165",
      "r169",
      "r170",
      "r172",
      "r322",
      "r323",
      "r459"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CollaborationAgreementsAmountsRecognizedinStatementofOperationswithBayerDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedinStatementofOperationswithRocheDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiAntibodyNarrativeDetails",
      "http://www.regeneron.com/role/ProductSalesScheduleofNetProductSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r325",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Product Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSales"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsSanofiImmunoOncologyNarrativeDetails",
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsTevaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Summary of Non-Cash Investing and Financing Activities"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of Issued Senior Unsecured Notes"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "auth_ref": [
      "r128",
      "r132",
      "r135",
      "r137",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r10",
      "r100",
      "r466",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StatementofCashFlowsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r46",
      "r103",
      "r145",
      "r146",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r290",
      "r295",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table Text Block]",
        "terseLabel": "Schedule of Shares Repurchased"
       }
      }
     },
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r148",
      "r150",
      "r151",
      "r152",
      "r403",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules of sales to customers as percentage of total gross product revenue"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CollaborationLicenseandOtherAgreementsAmountsRecognizedInStatementofOperationswithSanofiDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Unsecured Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails",
      "http://www.regeneron.com/role/DebtSummaryofIssuedSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r347",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SovereignDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by foreign government (not within the country of domicile of the entity).",
        "label": "Sovereign Debt Securities [Member]",
        "terseLabel": "Sovereign bonds",
        "verboseLabel": "Sovereign bonds"
       }
      }
     },
     "localname": "SovereignDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r103",
      "r106",
      "r128",
      "r132",
      "r133",
      "r135",
      "r137",
      "r145",
      "r146",
      "r147",
      "r196",
      "r232",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r281",
      "r282",
      "r286",
      "r290",
      "r297",
      "r406",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.regeneron.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r48",
      "r69",
      "r70",
      "r71",
      "r112",
      "r113",
      "r114",
      "r116",
      "r122",
      "r124",
      "r144",
      "r197",
      "r297",
      "r304",
      "r355",
      "r356",
      "r357",
      "r369",
      "r370",
      "r391",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r511",
      "r512",
      "r513",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r144",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r297",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r304",
      "r349",
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of Common Stock for equity awards granted under long-term incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Share repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r17",
      "r18",
      "r297",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Repurchases of Common Stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r17",
      "r18",
      "r297",
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Repurchases of Common Stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r23",
      "r24",
      "r106",
      "r175",
      "r196",
      "r406",
      "r424"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:",
        "verboseLabel": "Stockholders' Equity Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r282",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r304",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services  that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Trade accounts receivable"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/ProductSalesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r185",
      "r186",
      "r192",
      "r193",
      "r194",
      "r269",
      "r295",
      "r390",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r47",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r47",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "verboseLabel": "Treasury Stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r18",
      "r297",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "verboseLabel": "Number of shares repurchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r47",
      "r305",
      "r308"
     ],
     "calculation": {
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury Stock, at cost; 17,930,390 shares in 2021 and 16,431,520 shares in 2020"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r297",
      "r304",
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "terseLabel": "Cost of treasury stock received",
        "verboseLabel": "Total cost of shares received"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/StockholdersEquityNarrativeDetails",
      "http://www.regeneron.com/role/StockholdersEquityScheduleofRepurchasedSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r335",
      "r482",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "netLabel": "U.S. government and government agency obligations",
        "terseLabel": "U.S. government and government agency obligations",
        "verboseLabel": "U.S. government and government agency obligations"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/FairValueMeasurementsScheduleofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofFairValueandUnrealizedLossesofDebtSecuritiesDetails",
      "http://www.regeneron.com/role/MarketableSecuritiesScheduleofInvestmentsinAvailableForSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r127",
      "r137"
     ],
     "calculation": {
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding - diluted (in shares)",
        "totalLabel": "Weighted average shares - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r126",
      "r137"
     ],
     "calculation": {
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding - basic (in shares)",
        "verboseLabel": "Weighted average shares - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.regeneron.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUnaudited",
      "http://www.regeneron.com/role/NetIncomePerShareScheduleofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "http://asc.fasb.org/topic&trid=2134446"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6806780-109447"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(1),(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r550": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r551": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r552": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r553": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r554": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r555": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r556": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r557": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r558": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r559": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r560": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r561": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r562": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r563": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>85
<FILENAME>0001804220-21-000033-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001804220-21-000033-xbrl.zip
M4$L#!!0    ( '0Z9%."VNDL+BL  (.G 0 <    <F5G96XM97A?,3 Q>#DS
M,#(P,C%X,3!Q+FAT;>U]Z7?B2++O]_=7Y*U^K\?N RK$9KNJI\^10;;I9FO
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MC;5;K576B.8;_/B5>7:IBZUBN:,@->\$&)IHC_T=</,$]'&BY87L;$<I@*?
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M'$Y00DI*8G!\C/G) :C+0W*W&!)^H/3#.N(RE>G@B+!.B/U;,05/KJ\]EQ1
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M.JG QI1'L1+'D]CN^%'$-5(R,).R<X/A]T\CGF<$SVOTJ.6:](*0NY9X8*;
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MR12-)P/\'BV*_T2>,.RA'GSK6#+,SJ+<M_["19!K[DQ"GRU4C%!.Q_WNX'8
MQ+F7_@3"3!_N9F@PA)]^ZW>=<E%"<D(I!@T>L9;ZIAG65@WAGE=]BV"?-8-L
M[^)97C_A1 Z;@^2EH<K*ZXZ3:O CYC7ZN97\BN;X'T7%#W%Y"/B)<E8-%*W^
M3<.JDO!H\!/PY:] G.-,YI\WU3V:2>7B&XSOT^CZ1L4J*4JSQSS3.-XYT[35
M$]#"^OL[;24_J?_B9.;?FR>XJQB+P$L^=P^[^7X*(D*+AR^&X7_X^95G.G&L
M=)'A"[N^\)'7%VFQP,E#>)=(SM$&. 7VD&YX3[9DDFIKX$HNL*.O8XMU!U/8
M<\_CF$;@GN=(^CE"G6;%ABVY'V')M_0BUY5N[OK1BX['IGR03?E<V'1_3[C
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MX<%Z/N_<-)=2DG3,91"PHDIA(@E4]_A#]'FG6/N*K&Z<(BO<;W<T08X!1'K
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ME!05[PCUBT;%2XG\^</B'=,Y26'QRDK9TJ+>'=F *-2[-&M8?H2QBK-2*_#
MO0R@H-%=5N1 81\Y, S)K$(.3(D/R@L;*&0%&Y@E.<N*""A$( *6]>0HZUCG
MGF@5LN)!HOR(R(J7C9M85D$NZU@%F\P5_F2)\2>]4>"$^N3MH4N654#+.M:Y
MBB-)PGF*%G3\#@N%9^LDPMU\(RNJX#4K>,U+@]<4 W[H"E[S,N U R :Y8?7
M+*NY4-:QXM4N)H!Q.L\X$4\Q3HJ)T,.XXA$&#" \IH()51RAB[&9/O>'/; A
M[J6A]+'?0X,AO# ;3?Y$5Y_O!]<I:+G"ZW ZS8B*/5A@4AT71U3C:Y.W.MH;
M$"8V)'3!%A^Z("+'I<EU;V O+J$M_45MB(COLOLEI>2UHC?C8!YQ(0E[&.*P
MPWWX"<%_\)-P#*OPTGBE?.GDI66#"VL^T'SG?*EJ/E U'TASV*KY0-5\(*Y?
MY4*;#S2KY@,99+]5S0>JY@-5\X'$9*B:#[!5\X&=*Z!J/N!+):F:#U3-!\*O
M@2V&;W&G-1_@,@!=;S%<JY'!J&P&5\LFTXF)#Y\,SU]H9]%[0&RDOUM-AFVE
M/]<.T^JD?[7.AE_AOIY!3P?0!IP8CV&KU@/'\R;?=NN!DJ."EZOQ@,W J5OI
MF?8*R!L_O5%N^OA0_?-WNY6=-'L0_'DS3[O<%(I&W]\/8CGVMI]VAOX241@8
MXQ0YW=M>!G3YT( K5WCND^W?B 5>78*))@5-]U,[D$\+KP6S@)Q7BTYUB(&B
MG@WF,\]PA62+:S9&N+S9+''.N*6CS^I:T0UT+Z_E)Z#"8/T-=D(W7FGR(;*>
M99RZ+9/<<AI3(GG;>Z'X+,"RRY.+?1/,Q3X;Z>8HCV#$Z$Z^&.!-\70P[3PG
M^>[7N(CD^1/1R50)>ME*-\E!$5D\AQ@L,2"Y/[>J)$?]VX$H;_$,'W(ZVZ\6
M?3IG!&9^EH5\U*IUTYPS,+*KR5_LY)--+?Q&R#?#+H1)4Q/2@?SC8A9-<DTG
M;I2;9N'$HH!YN</F5=F!>?.D5*DQ=,.8F_,VF\J/CPM"T3W"R6\$17>O($/(
M>?\N PO71T2:9%4B*B9&OCUN3)2#TBVF$6*YTQ>+108\#0DWW*3II&C17!2"
M:X)DT,(^FKHH'?;TMX)G<C9M[U.1D7#TS(A03[L\AGT8G<,,>SN!L42:)P0W
M\FP,V$B0M-A4+HM#)0&^Y%ER386M].0(A9[,Z8RZ>,C$,Y&3\UUSRB"1&0A/
M$52)JL0]<(BUN("@<(U25&J_$9B8!&"!4<'Y$R.3N2\U)11!KNVIXJQ@!"L8
MP40P@JD4(<50]$'7_N4 &'3>.5\J+8"!X'A@<JY<:3,MFB-_ H!!BQ6S2-IG
M6YW4A^7!FF4SP$5@F4[GM-J-P^\UN?3K=^ <:K)"!8OP8\(BQ'>5)=H+GB1]
ME& K#D LM,Z$6-AUKTB]Y]+;QUC@F)*ZLLL(LI#@L14>0PYX#.U.ZDZNXN 8
M(K 64B\T*0AKH3!1.ZT":A\X(:^C(@Z4PKM?CX,DQ'?!IU'2X^/9TK8V/ )S
MD"IN2(H&W1M_6JAX!DN]\JCD$BAK[F6;A'0#YN&.DG/DD2?W^"G-^49=5$>]
M_K0[&8QI#C@^2\?][N 6&!:_0DN-OXPFOZ/I3)KU[_O#V?%Z!CM)J10+MIVT
M[N1'MP@O)VZ.T/%=2] D.E!RUBB&&F/:R (7+X!V=UMCH-FS:L@;=0N,CK0U
MFFXW&]VP\&>&Q'<O+U%_11IE+%[A:^9&7YLJ+LSJZO!U^9MF;$W$LUP'775'
MGP>].M?)M!2I(/)UF26:+O2-2H,;N+%)3\6M3<CM'=_DX6J/*7/5TWO7I#[$
M__XG55Y:S^2-3ULXI=%4-;YI"SBXKWJ?/DVO:YCZYH[ZN.')VMD!U=T!P[,#
M^"/>7>AIIBK#6WN[48,O_6>K&;B>#O=CB6 $R\,("WWQU9*U)8)S;<BQG7:+
M3-S^31#0U4(V-4/[IJWD.7E+6RDJ^:V&R%E8A\=?(UPI X.M8/H+#=:A6>H*
MS>&K9@UM-W@-?*W98&NP:TC1315>AM<VAHJ+_( @CW:Y#1@AEJ'*%EJIJ[EJ
MF Z!@-;DZ?AGL@YXQD;?;)<RK=)YDK6U:9&WI])DBF!2=1Y]QM0*5@2&,VDZ
MC>$;3$BF3V&LS#$<NI$77Y\,?;M6/!P-C.B44>I;<_F*X"D:V'TFY4#LHG(V
M!?A-L?G-T,RO9!M@XX#E:=TF953%X5/KF>P?+EO4OZG+@^/I6XNXWTTL$OC+
M#S )54%32[94DZ'3U$SG$7@4> J(E/-%_!C\IF;(I%34&7@A;TT89_X*7$FG
ML?"(#RDE?9%-]*@9P#2*:L'$X.,PB>ZSMI9I_Z"79VWQC)[A8VO]!9FP9!E>
MU(VE\J(I*I;BQ7*KT)6%31[3F3X/CS''?8K68'(KA$'K71TSJ,/2SKPUBTX]
M\)UHZ9?G0(EO&NE'Y&J"F#P?%P3\!)[O%!)<&ZW1;_)Z*P,K"&P-*,3#WYC
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MN_WA5+"9@ 5\7W-X=_<]5Q<S4Z*!04WNGHY9U&,4X;5]TTC+.JK+8?7^#\M
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MP=UH[CSPI\@V8#B5706_W5M%L]25B^[@8*+06,"N#8)G!-)H3=U#27$[(OC
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MK6>F*L+KQLMVQY-I@Q>[49C3>P;64,.F$+YVP:W&M2QA.M.-2I2ZX]#RE=_
M*6)?Y9#(U.""LW:;Y/2_DP9!8]<J?]:(U;>"4X7T-*#=9N*IK: KHEQ)6)VH
M0\+#9-$)2.$)60EZ-="<Q'8<617;+<]!FB"S\.A8^='[TZ<IHK5$,:?.$SUV
MPIJS_&+"_649X;2,4*[!B"%9H<[+'L<P;?:6^W;^]--/J#_LH=$M&DJ3B30;
M?.ZC+CQMB>"MDB=ZX:$UY>_OM):BM)N-QB/_R/)B2^FT!;[)*\W67!4%16WS
M_^+Y=^=GAS7$-++##O1V$8IH[M+I@+@T3DFM$ABQ*:2? L4Q G=:KM+!EC&,
M**2?6 47HV;Z&5 -AFVEGUO&L8PHIK]?<&7AFO%Z\21B X;C,\@MXY@.'X^T
M=K1U7^/9(NI/$C/T%_HS?UZ2$ASIEY*YPYU'BB8]Q$N;\G!^[EP@^'Q^[IPO
M<Z:HL'V"A#>.C<YXVY.[3D#L$N08-8^52Z7.:E5N6+JY80GRIDZ=;*H)6US[
MA\U;RX2HY_;E$X.%#&(@XRSI%2R=#>DT(S+HCG7=.Y4UV;)FPH[QR DR[6*D
MYZ2BVTYE_E#U%SCVXY[J)XN W8>22^@I3BM)CQ-BM*,\GL1W8I-*GLN-WAY_
M$1?F#VPQ?$ )U=DBHJ"']N-(8F"";3B<[.:G3;L QT>CT7:('^'Y\"D&_PV]
MX7PUZ@IZXIL=GFF<^MV#;PH"X?D,9MS):&"!S6C@%I_5P,V,N*+-QQ\X[OVI
M$W4I*J-I,.UWB<_A(ZHC[(282-T9DGKW@^%@.IM0?T1/FDG9%!*5ZZ/A&^SX
MCE/M<ITP3-+ Z<A[IUXSY-2#HS#GO.4&KB>]&PS[;M0JST<?.F\'L_[]J8VV
MSS%1&KY]L:-5P<P?LGWYWP3 _B#W(23=3U&7WHW0_6 \(3_%C ,V<$!Z?T$Y
MQTR/6+\?;_LW4^157%FQP%FB3&G7P>WM<Y?:T<W=Q]))[70FS=["EO%"WDD"
M9,]^&Z'AB IMV79.ZF++83H=?!P6NH&),Q *R L\3,?AI/0$])T'S1#YH$[
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M5+DV&J7FKG(D3+V?Z\HK_/-LK9:__G]02P,$%     @ =#ID4\L7Y-(;; ,
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MM"DLV9* ;0TFD08!(>GL5%%,%1RD^*MID;;U*-VJ=/B&?,]^ NBW#/PP('E
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MVHA!M4#!?NSE,RSRC3$V76/V^Y/7/US\&OM'YY/IZ+1I@_'%SM^: ?W.6?S
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M9Y=WU2Z7T\X(O2F@JH,B_Z)&4IA9L;/9(#C;99>=7=YQNUQ*?FDH@)B;#R4
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M/N8,)G(SI5L7[6J+RHB;;W%,O\9D^_1L,+I@GJ&R=W:#-9E;6?L*Z$PRBH-
M!U[KA,X6SKJPC095FY:'61D@EU.P2=7EY'-Q8($AQ&1RQ83-1T';VJ*"S<H
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MIJ@=@(%J#68V,<IK4>W-L^(U .AY@PGWCX9;G*>MLR#@7 H29 4,3OQ=L,2
MI3AG6,7U<'&GISQN]O@1Y<ZT!)A,.KAFPFFI%;35&4S2)7",GK0FM0[ -$_3
M:[](])GLU2T^&TWZ;7%LMAGIX*MDDD8!5(^DG=%@;4%C4?LU@&=S,N'I#UA>
M<_N$@=(U*O:F1$T@R5T,U<@?*J(1<J@MZ JVDLIM?B/%=-1:E9HJ1P=%DN^B
MK3?L$JELC;)K - RE-O\ '(UV&QMRM9;0(O9YLC*25[<C ;@%@S47$GE-C^
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M#";Z9'S,Y*%F2_6ZTJ37#M!_X? <QQ?-U=VVE-1S2OS%ZJK72M2*!VLH9D.
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MH"I$*PW 4ZM24'O.B:4EH?2IMQC&3S,K##01 ]VJ"<828TR;W&,KE_1GX)6
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M:YH'6(FE0=@DIIVQWOJTLLX9J]5*/&U^PJ,>IWJ:TNV+0A<$"^PU%R%YSGT
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M\/S<:O'LQS:\^'&U\3%V8L^V5ZOX@ VGK4ZK/^A5?4-+:9Z%"A%<B?354*#
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MB@1,E*11K*SS54UH 7\!_].?Y"_@GQ+\(\$!\-.(=C2BI))'W)B(K$@!$<;
M;=->ZVSVLU4I9U":=U[@+]UCRB"?W2"?0_>885BXD7K=T^N<F&ZG7PZV+$](
M[YL=@-?=?EG>)UO>_6A4+X;@B3$:Q:@=X@&6=TVQ09H'1:S!7"B3'7O-U<R:
MPRVH^;[<*)YO;*Z@>'H4-T=W\$Q,*I?3(D$CC@48Z=0$Y(B@AJ1$$I=582W!
MUDA!\?*B>+Y!MH+B&:!XI&F5",)YYE$2SN7Z4@GP3 F2&#-,.#81B]RHE6%5
M4+S,*)YOM*R@>'H4CP3,/*&18#"F63 *+&IK,XH#XHHHP[VR5/G<^P;P/+.
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M/K[5JQ+HUOC$" I8$01"HLA:K1"6AA$=B+6)5;TJV=1\?#<G/F77K4) 2TY
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M2#0& XLNLB'F%A!$(^VX@+58B"B22-A4%G6]NK4L8]6O<HT%NL9RA:W4G8O
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M"HWKYW\&6:GC/W^]&;^V!PCOX/\2CGX0I]]J^&F(\D(KAY3T!'%E"'*4,41
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MV;TY0J8"SO:/0YAACSAF"FGP/)'#@ME(I,-.K*S+547DS*I3%F(KQ%:#IYZ
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MG Q3/X&:GIU0'1X=C#^4TGL.#\:QK<N<CM<YA'K8G=6Y 3[#Q##=4;[K^L^
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MI(P):+'X4!PED:HO*N:8+K$W?GWBR27WS)-4%]XTU[%IGK5X4RJ;C 8! U9
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MNV6B*%1=2C)JC$F33P6;?Y5)V.YN7<Z]XFK8&P^E?.H;^>BWD&MI@$2(NE3
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M^FU])0'3[T[HMQ"BIP:=#DE HF  M=- O6) N]!;YYI*HI>7+FOS?N/\XXJ
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MK",9BBG&IPT4?#S/YR)ISX7;9Z5'U7MT_:C]K+PODS2<SJ/RT_GSXZ,.X'1
MHSQX5Z:S=CW]R4E[.!FF'I:?GH7M#X\.QA]*Z<TG!^/8UF5.N\M'YKFY+O=
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MC::)DV%^4YJ<:1^D4IJ/+>.HR[U3,Z_>CB<S-G57,G7//A,Q6J*6A0A2,WJ
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M@0]Q#0OZ.L;VJ4TM\%EB_[ T7O_'-<W^.[SA7!.>R?/7&T_O^4O.R;:97:B
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M&1LL<U8%DTH,+F;KA1%)L!2]5B'Z*[+^*\C<)<C,T#Z@DZ>$ B*8L 2T$\1
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MXKSDTD,RVEGJ$;X25\DQG. EGL:O,Q_NGU"/]7=[^,58R"#[AX,Q"V0CI06
MM]!::J9O6-['N>FE<3RD<)@UGP^S<C\<OSY9C\*!-"8NQ<O[U.T?/6]=:B_<
MC/CH?@F,T#Q8I6,3X;H,1@)6F;@+!B,I%N.8N<Y@N5@53#Z2P9I5QFYVU3K6
MKXU5KUIU,U:DAYE7<QVJI7,.&X?["\X,^D?G ^>/BV?C1$.<4Q ONFXX[&0<
MYH+I^$^6BZF25=T16=6Y;<L6B:DN27K$I5;M_#C8#Z]ZK?TQW>QPD0R)2M=5
M>94J75<5JT<U<P]+U_40!X7KO5'']^/Q\X<^9[TU@:R#K(-\L$'>4JUSDV3
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M*B;=%_68=M9SK4 S#4(XPZ2B)D2=F/&,RQK\7#Y,F@U^4A&$E=80I90L1S)
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M06UIBCIJ0H0CW'IK';$DB)@")M89>F?/6P'U4X-ZZH[S/M$DB$$6"!EQSQ6
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MYLJZBZ?U84>55YT#G^H8T3@S^+4XR$)X=R"\G=F#1$93857P2,4$I@E-$KD
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MI4%O<2,L+=3Q%:A3S;Q0U*. 1T<I%=+4!R1XB-$ !Y @RS9E0?NSH;TX$QZ
M=GH%[4**1+%QR)*<9-(I"DM\H"C0X"@G42M?T%[0?G_-O+@4%@-<?@6XT09,
M<1!(<NX0]RP@DSQ!#GN.$TY$L.73R!\:F3!/G: GRRG[HA/*KFDV6:F<HX&1
MQ#WAB1C#?!#<84LYEE&)4BQE!:AR&OX00M ^2)'=%J#=1$F1QD8B%GAP#//
MA-W8E*\DQH]?.6"9ME(*Z1726P#I%??-LY/=3!2(LH9+ZY#')"">W;-6.8NP
M4YYZ@Q-G?F.3DH=KA(7I"M,M3Z_ODICSN:FN^*X6X+L"JC.1>I8(8E02Q'64
MV4=M$&;4<<)L2A&H3MW =(LKC5)(KI#<FJESI2+*LW/<-'(H6.H]EQI1SVU6
MYSQRA >4A'%&\8@Y)Y7M2OB*V*YC[]^D%1/Y%A65+=JA_T3/F!DQ!L,2>B>
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MC)281')I=*04EQ%W5$693%*DW8BUB1.=Q'(9,UI7-2\KM'$IRQ[-:$9LJ@A
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M\%;S=PIAK=YHT#"$2RV;J[URD2B^X]MG^UH8:F--(D+ 1> DSB/)LSQR1%.
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MS)F=LGJWPX_]AH8ST=BW&A,Y9R5LUUM959F+,_!3X4O3>*QY0<.>X*ONZ/$
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M$9K*![")X6OZN&QQNAZ7N2SU*Q4GYIBY'.+RS7EJ-[.NT26 8=:(JJPD1,$
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M=L$^\TS\\XO\GT:QN5K80J+, ,?&"NK$>A[7.G<L[+VTKBE#C'U!ZG8'-D:
MA_VIW&U\P[W!\+A@],!-;C8%I)8P7\E5>/"P*R+Z[N,9@S_ 7D#',[JH-TC1
M <0K9>'D5'[#S$-G'0%\_NCZK3<:=[I1UXUK)U(VIN?58R12WJ4CR$X!V8H>
M904_BKZ()K:FOVUD4(ZFSM=:,#0P*6HF.:J01M3MYL4SF9"8+@N@U+MI/NFE
M2+OT3@R*2+N56^P[5^1>UD>)TRQE_@5\2D(X"*RRR$K):8.CZ,J7PQ=Y-D8%
M%C,T79CI*M<([MVH8"SGN4R(B8US"><L5W%F4F.SE*=YEF5QT0T^I4E4_K"J
MLWS ([ZCK1]XQ"<D0!4FTXAE-HZXL2[*$YY%L;5.)8GD++F(8?8:Q977"9@W
MS!S:@S,TQ*?X%3N%,"I6;]%4T/ X?$A +X/IR)<?8IWE6D:AS:2!7WP72Y3^
M*CNJ2+><!RES^=;C*N5^*C^CRA J@4M_O?6^JE$K;<>4$;P*'\T9N$'%6%@X
MM]/;8)D&!19A:FBW7)DI%B>?=5;.G@>,/@D"_P37=>NF).@:S[C;/OFJ:=!G
M7FR:ZS*97^NJ&+;FHRI6O'2CIQ?]61GD=)%!KG*$,%-Z/$3P-EO<5P,=V+S_
MMIZ&K(B/3X>G/YSDAZU7:^&2BP@%+D"!GP>32U#@8L&[R-V K;@/]]76NV\A
M_E/ALNI+4QSW@[Z9P#._=P>]4$=J"Z08&J:R4JP_'WH\V=JH9JL,J&<2<UEJ
M,%SPQ"^ZOBSG;G9)+C%DR*>O2#&'@133G],.+;Y.@<IF<GKY'(+W"]MNKEGE
M3F%:>_O"<H[*.VI[TP+X:X2AX@:.*P-1ER)W'SINEKC4M32#6DD7N![7&'A!
MU'_%^!=6VD]M!VQJ.YA7B6(IZSLNJ"/U\M2PRA>)TE4R5!/TU04[Q9B]7)7=
M Z==C#%V$L334^\C^%?5X9C% RC<;F>:!; Y-_O6DC(W/[.)YO-PN,+S"XS*
M])96RQWV7[B!X/D.@R7!4WOZ^QC_+>\\+&(+Y9Z$TUJT9#Y4)FS!X-U@3+NZ
M\#)/>'8O6HKSS[N>_8977]L&UZ[U'AM$X-)YZ[L6C'_WI/7>)RI_FO2> Y?H
M3H-]CRYJC'T10=D]['+-;(80,4$L.RYU_=_@A8)>H\+\VU<O?;;#[UUM0]\3
MM#/#$$; :__]N1BU#Q8'5+7M>4,!;/VO.CG]K?BU:ZK[8!;Q]N>2+AB_O6$
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M[GLC6E&<?/0"38%W/U4=-PS-S8KYFSY8"6YH\?52P'VXH8[W>@<=SX[KNXQ
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M=M._OFF>^G\TN^S."4%4!YA)%0&CUT'&AM'',)'L=X%[!8$#Y(\HPH=@AY%
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M5,G?8,1;PHC]QG[7T B#$7GEN==N/U"-Q&#$6\*(@Z/N VE!!A_>$CYT&\>
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M5F_DHTM44C9SAF=3-AT>W'2.5=MD;@#X\BP0*4WPFV%0''B@BHI:#'2:"PV
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M@E7(! R7U]%QW^H8X;3TNNMB\7SHXF5]\6P9@21O8B%NH'@-UY+4Y,V* )P
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M#L3Q5)!05@>R)%$C%79Z?7%S=?WK*8].2!5N"B2W2.2$-?9D:"G>HLITG2<
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M\%-;_'2=;J-MO /U1I+3[VUL4!G?P#:^@1&?A++WQ0SG'WQ_F=2?UZQ\.O;
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M^FMSXGX.W>DZDZ.,(59B^:V^*1^K.Y(.F1!GT&3NTBDAJ=TS0:O:(\DPO*-
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M0#SF,\^UPL#ZO?&E(<\*G^$)QFFDUA''*ISF?U(XGSQ#\P*VQZ($]A9.)C%
M$=0/0)^"#QZ"MGE)$@*>AA4 R'#=XH9U H13+9H!. 1N1&^PL$;<1<2"O.,
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MXD=_N_K\X<J*<I5GDDK9.+%<'H$4#@I9E QOJD<2%Z]<IB!)V>U)T6S3;;)
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MFSC5V$_QNWD4 I6-8U2LW# (.,TS%N.,)T"+N&J88D.(T/UF17R>1NZ4Q5P
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M2I4$/GLH!'2+\0D77BS"]A'.A1)1+165L&6YJF0=PCJ;<_B5R?+? Q.A(FW
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M=%=]3Z0Y,F5_L&B,.=(J,F@D\8OB^EI.%P"-OE+@"3>=PI*FPP-( <+1XK$
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MR30G(_?BJB*W1?YT91#VD9Y)PN4L!DM6O (%_(:O65DO4&B%L4:QKI97R48
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M@6@E+T.G"QK$)]-6X6 L&BL5+12*1G4#JW)0]*</5^J*47_>6&3%RH=E?HP
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M>]OF-HZC7?BOH'C7B<6J)2/)CA.7JIXJ6I8=)5;$(]K.<\ZW!3 @-@)VD5V
M-/SKS_35W3,]L[L@Z<BQ2-%?3)' OLST].O55P\=J9R1\H(1]1^=*._:0=W\
M&92S+'#0A!3%U9=,@)@B1A+"LP@8&4DTI\=AD)VL-^J6R7N!=3;MX/0(<Q:-
MCN1EE(L0,</- X'O4B9*Z8.K) >Z*OWQ75*[WI!*H!D=,D5>)HNF37? /'X$
M9:)[XI?=,0*X.(PH[76.0O\Q069$K\8)CQGPFSM*^_AN$!MB=&0G+7[+[*ND
MP!Z=ZU^S9</P=KN/P-IZ#^K2(;-;?+A]3:!V$7.?ST6O:IUU(\PW8;(G.Q"N
M%E_WLJPE?*<-Y^H76=?:+4!?I/-_8/;\9\G//#K_^DU'IIKNE"8K>9Z/.J*#
MK07>DMVXO+G??^/B!OZB5,0='8&J6X<T?9@WQ#ZR(<9\ &)+UC6PRANBDJ3#
M/S3@#G26@:TD$%OZYZE=9/7M2Z/R_95S;Y[]MT!BLF@9115V0I)%W79\QXDH
M4M#'B."8),DI&[3<1DD\0R],OP]FB-"K?SOV ' M# DW?38K,N&,[!^[29'%
MG\J,V#3B9L.$HTO70JK](C<\UG[-!R= 52/3MF)6L6;K4_+KAKIWA(*]J8E5
MT:UX[\!Y76B?BK_2@@*Y[*\R:9KYL7D2DU R*\<FCV[QWQ7"37Y7OBW/1,)X
M ^I5H->,V_9#_S&#BZQLEQM,14IGJ"V:-E]?_(:_H6XA.,&DY52"THA(G[H%
MSV0BSA+,<XJ$Q7C7&QB,*0)R[0FPR[)48"\VY/%P^(=*?VLCV$-E0)K85/GS
M?UG-_/I/Z?FD=K+F7 2J;SS5IY,!X'YC:O/1MM2A"L4C%C%B$?_RB$5\Q")^
M@KR8D/YN[9WVDW6SHEEE3A5ZT">&&$I($^%P9I@$J=6YLITMBY1)/XZ=,=.F
M8G,&A9>4NO ODV?\=9P4U)F.3V([KNSGMA]%9LQ/GD@*AYP388V<DK$I9ZZ=
M<L;R%K1+Q\6ME/:(HHYLE=D,I48)%+3_F0PUVD3M6#:>=U\'/L9TWOUC6)62
M)I&7WU*&>,%4FXAE8MB2AA:$F6&?XLG!V&(P-#MFPNU;NZ-,4[0C:RRYUG&Z
M#$J;^S-1=<H J$69?RAYYS>4?'K9S)DK>TTNR#[)OE,PI8<+<Y1T\F!<C!A[
M:3K\)>P(9XO"2ORA7&]>Q+6X4&)[<(\<O7QS<72L0X1Y(JID?+=")G\=Q]$H
M39",Z8)7:89XF?QLDIKK.7.V_!$*&W$=U,O.NGGBM!0T,LI&*<N4F58QBJ6.
MYS'&,WHNM5,N/9</X8!]EW;E&XJ6U#$WFT+2=PSMIU-#%-H#=[BC7_M(FU&7
M)LF0]?=@-A+17,HTCE!=$!IA@=#A;P5/VTLBK!!W]7@--"C:X%A('!.& FE1
M#'@Y&4)W(F-SVX"MVY_X"YT(4%FR(JS(+?099V//]42*6G@<#^OF#T0^8/,W
M4\(W4_2'M];*7C]"XDO:<;$V*]-6D.ZX)(2X!CBPW.PG3SZN]']U&EF'?X_S
M41AI,?UJ&,<ML?O:Q52\Q)5AX&_V9UMX%E R2[37LA<$Z^MB9A "I6VU=/L5
M&8V5F4W.Q2NEH3 'L)_EX,)1[U!$EHE@ D+&BYXA.:4R88L>Q51+6LG%[-GI
M<Z'",@UUU+B"0]&\5)/Y,>3N6!M9:F1%\F?'!UAO#]^VU=%BN"URB#SN6CTV
M6L ^V8:N,?@\4.IDQS.@QGHL:XMFQIA%,\C0>JNM0ZM#( E)1SGR/M(UF7K>
M7B4,-Y(^Y9&]/5#_><$XS&WKA,_3LD39ROXM_.2'8.P"^SR0T(:J!1U4$!^*
MMADLZH/ 2_+9>3.J&C(<TZ,\)6U<@M2SVS2K"I+SI(HRPI$6]GOE#]@<-!SL
M9!P3'M<O%<JTPUXD\CR2]_&VR*]DBZE1A#%4>AI84XFW!"+".FA9;?P[;Z_I
MM8-)JY/9LVVT4J$2@.H?>\+>:)XTBY--,Z.X4?WB,?4B\M_/^?<2[WY!YDA[
M"<649-7._84K5+J^IO_AHLJ6LP;O,>PA";I.73>.-5QW\0*3;>7=ES(J*/7\
M201'<DKS$\GPM">XC'M\Y<(><_</%!R3XM)T;'K@&950DYDWHO&.7OWL0W%<
MY"W"&O_(YVVS;J!B7QJZ$-$99VO_<#X G;QB?KLCK\^Z'2==\U6JZC#5Z-DI
MX/M-AT')%0WW\:]J)<42% D'I0HV>UD"[<ZHCMC^$+#YYVA]D F7(4&<8^B-
M&S3#F4(@<D[L(5]'GP0-'\>372>/Q],!<11)-'1F%_+.SKIGL8##PZY9_-/Y
M3;6[;)ACIV]89-.3*"FAN%GM1[UDR=*[EH;+;64\8[L-4%=>#Q3J\G(51B4.
ME A%)N6Q",)NK"4VI\B,%J6/:10Z+YRQW^4EZS.(O7_BKLN]"CCF2MUAT$+P
M78Q:"CY'UOM&W]?4-?>L(&<2]%%.^A&K 9DR,*:OX.;Z'7[,W6H5-+U3.6.7
M60C&9LIDK? 8*"M#*P(-856H"CC&H'7DD1'U$6-2.R/_7%V,"^*_["TPA29V
MRP=W&HNT6[V?;':M%U7:!+^M*;RB5_B%^CA0]\T'W@0O[C )^4;U NU-14>"
M!I3)&,R8W+,](LQ-+N"7F^-E"*L6;P,%$'DKVH22^2RGHMW\X=:4&:JU$/CI
M;G[IMJ9,) ^@M5S.GSV(RFR2^:*0VR^@%P#=EI 1D7&%T3X#YM-Q(&QB#Y[C
M2 6*.<UM"_NOE!A!)=L+7_'_- HIIU2JA%#7CAX*54HNLB6 -W#>Q6X@*'5[
M76:!*F?+RE%5L+QJ6F2&8IJ']EL&X9JQ-)(?12!FHMMXR".!^J!#C%+Q.*B&
M(H;PW)3O!A5F*%9/ZAW&+/BKFY<IXM_3@PGM'"^L[0Q"GZ8) :3LW'P@,9 3
MGG0<OH"%!!7/<O+>[0/;X6+7N61R93\ODEZL3JN>EF"1YO$VETZ=Y:J[]7F7
M,:HW<.>E"/ L/2A/^! "CM?11"DYI9GC&NRBR6F.)[8&?>P<NY_DO\5*\U6O
MQ]#_$A=&GG=)X,:'"L\I<,+LN6H9P1S  ?$\\S1K0!9UFB1']L-P^YN)Y4>0
M51DP1VWWP)I'JV=J,X"GRXQ62N)/399&,CI5F&>Y*J]U/!<_"VO6)*G-VY $
M$AIGI8MW14MR[4^K*E9^5#DD^+$0]>9_5[YW,E-[AC]R=*,T20G!;P$C(!D>
MSNH;(C3E>Z.97]?\(0P?CD@/]HP$+I'/3*7;OOI1%8W?S$T$HA)].(=EFLR"
M=9+V2H2BE#ZEIX!U K%@9+<,:1VV9,'IEY1*+'!H%7!8VPFAYD!N;/R^RYT_
M[Y1U(G?,O@*[&RP0Y&P0"^("_HEM(>U=%41X+#;4VDJ<4>7<+Q5= @^/D,#+
MC'RTEI_EH3MUGU(LEECN1U1'0'5\]8CJ>$1U?*JH#J[S>B]P5<ZT1C&@B;3)
M@2S6*9J8!@>(0ED1MM&903XWS841SSMW+GO&5Z8#'<!BCC<R#%XONL/("5%C
MQ;V9"7/'CH ??GM2XGNR<+]2>=W329PW,54S+L/V&\WZ>>-IU6S=;%E38FXO
M0.(D;^==CUW'9PI.:/*%(ONT-HI044CN!Z")8(\5>2&/0>J"QP4GDRLOR;5T
MK<&2^=@F>+*X@?XCM+UF[9PIT=:LW+"'Q!%YI.8)P*@BY@&EBQ'^GG\"_[PS
MC@W\O[W.FS>L(H&8<^F[A,R3JY?P0T-C521D%Q>*E!WZG<L9(Y.5*/2**RP4
MI'$&0*=",]['*%L4& S>@,':COH8 ,=#2T./@HPH,9(M-WL49<9H@9))?I(T
MMU8H<S)W5\Z6!_(K#R'UQFE*(NSO1AG<*VM1R?BZ+$;BB_!7N.Q+.3/:OH83
M5!0H#;9_8V<Y._K3J^^^]7];5M,JG]WUC^:*<C>L\[_S,5]-&_['=XT_F9]U
MD^]WY&%6OTV/WI=$W'(+MI=>^$%;??(YONT/ :15=IP .*RI__ _S_[\Q>](
M4G/T_TV>^!/GE_P7KR"FQT58ZL\F7[OF:O>XI+]F2:<^I-W-PIH.2^W%KKNJ
MULWC"O^'0CMI.*=+Q3RON5*RNHMRW>V\!OFZ:MS&*Y"7S6DQ^7X[YR$Z_K>7
MKIZ\KF>G?D.\'8E]<EQJ)>6CVL7;R<W2F\W5&D6_;FN@2URZ;1:+$V_,J$QI
MZZ6MVY2S]R6A!$$?TC"HK2\104-"%98T(;FA$G\QF;JK4N2I"$F8V.%CRM!:
M>?JLLWHVID7IB:^E;* M0QI7B=?!V3L?*?';5C.M &AIUP+:D8#\YLTKIB;\
MZ:T: T%TB450CK^VO*KHL5>Z6QTWDY&D-9UWDIIJ[A=:AJSC&O%I34DB(GZO
MFQ8]6\U C_EB*#X(;:54]Y!)SGCU4 K?)A,5DE7.S-K@2N<( $X5^X>8[B?3
M53/#X\H.RU83%&>SS:"G#%)$@Y\MON+1L_T'9H (2#1K+45[\IBV!A1^5E\^
M/\:.]:;SAF56>%!<8B,6YHA848XS[OG&09#)!S[!*\;\JETA_OC(5?7@"57*
M0&]%RZVN6^=#3(JRAX;[^&/+,%>#:1B<2U35B?0H#"1)FQ),#^6"];2JS;#A
ML !Q\8=?/6M,V>Y;PM"ZB1>*$M>.[H_73"X*@27\<7MW,F]C750$3V18/DE[
M&+ZMOC #=U$;)X(QH1*VE,5!64W^[]GW/[P[.^=$A6HVK #R[.7*#6LB[_8[
MPA%H]M8_;3&A?ELZ#[O+9;@PS?ADW**K+21K/A$:6[R;@$=EY5,=4O^+1RP8
ME:%B/%N5U3J.=]/WZQ]/04/7D\UNNJJZI3/AF-<8)9 U3F#??KGTZ:5"TI4+
M] @+&@N%94&W^!>__WD&3L=(VHLV0FEI/^N2CH->+)6P6'4B>1:B8PXAJR3_
MYC09WH%@SY][A2ZB["=:"9^AL,\+@M"=M "L^I]<E2H?5@^)*O@A7)"Y:5":
M\#?]V]G?S=EC9'Z-(XSQXDK8^?K[DV>?IZ#FWE/'<ZJPXO01$N4[;-,8<&-L
M,1X#?[$/\JY\5DS>_O]?/"WHWY\_>Q>*EO3G<N4C9;Y=MUVNRR()[;V(AD'F
MJND&[D-B["_VIPE1?$&KQ%^IT>(92.M=W=!$VIT7H,FK%ZPC(GEKEUZ>&J5O
MVBVNL!DI8D-J_ KMYM9_IG!C*&;SDI.7[RZN_W%NA4"EJOE5%@+/8^_?NZ.N
MO'%(#YV39*K=T&;L25:[;>L/]6JRVJ\WRV;35)3FF3PY^N'B^_.CXPEO_^>?
MFRW3G3J-#X=EY*@_27I01LP?A'*5):3Y36X\Z0]!WWU?3;?EOK%+-)9%'A"E
MY) I2,!P5O$!/7RZS[\Y>::?//_&GV7OP<E1TOG1MK="*4.U?\R>&607+;(@
M%/GE-8_36:?M[+U7[']W^VV[FY>/L>FOB4TW;DT)@!#^?^U]K6VS.GFS)YMP
M\>]=-9T2*_/&'X_'\/]7+7%=$9TQ+Z]&SS^@GZ&M_GU?E_1WG9,Y>>)=[5^,
MU)+F."-@\O_U<<BL] O\>KVHZE^J^[J\O^_JSG<4H&-M'X*1#*45]J-_97TE
M8QX/)1;]TW75N9[Y A.ZAMJ]<CWG"M+? ^1YV3H!K"FYP[J/]!HPYNR2W]64
MAY?34-]D89 #X)S-@CMPWOWC+'ZPX'&"_G?4>:PNP<N+OW]53,[^\=WY#]]_
MCM7U7MZ7QN'_\ET8E!7H'9[0W//%,*-CZLP6 MVR#G2U"#[&<>KCQH$DKZ[>
M._=+R>KB[^[JE[(M"R4/ H[Y_DO[H5)[GTWW-@"MW^UM,/&#RKT?3>,SGN@G
M+X:SUQ1#NM_DP?Y\^I=?]61C]N:+T^<?K;W!@DXLI"'F(Y',H+RB*,7PJ9!@
M-,E4),I++^>NS=.K1HU@U'LOA&1ZM\&&J:%2O=1/M-,Q?:Q>3#SZ"GD&NO2.
M861;] JU$CA'A>9"7(_J/R&3\<-D1F'ZDY=G[T[XY^/D!IG!R%/G8LYN_]JE
MZ,B)JR]1'PJA'"-%\MXD+MKP(@B-0X1#:99 DO[!8L%"(TLK?Q%  ^WM_B3?
M];ZE.-!A],GA;[]\^HB_?<3??EC\[4?C%PQ676V%."L&-JWQAMFIC=YN+$*&
MZM=(PI2[J(:46N:NJGE(,Z9I.3IA#Y_F8RPBY;<VTMC<)?7+Q<$-G8OO8)-Z
M95TW- R BFBQ@2?:1AHW09[T5;.Z$K9->;3P^E.7Y)=Y%>I\-GA&A([.[K9D
M(S# ^N_CHK(W^VDO[3X#Z6QI/T\Z7X=HVH;IH,STO<#7EM4V$$E4;;>-"T#-
M,27WNVA)"9UY7*>$Q201+$')C@[0$ATD0^G7*U#T B2AC ]7@&BO +:D5% I
MW+(6#GXV\V=\C@I48<@B"+2Y<<K\IUG68A 27M#.A-[4X1TKA%APZ]*^)1GO
MC@*3[IR0'XD+=E"D>YPZ23B*HJP2$EH(];]WI9(%)\M!ZTR$M;-M;'57KI<I
ML_]RAW>V\#R8BLH)@4<QS,?@.8T9E6(*(<@\I)183KA^F>17!"@VZ@T(/DMX
MZ(H7-XCYA4/#)_L^OY[^;%#>[T=D>_>)7)BO+0N09%$D=_)UN7?<^7I1ULVB
MRD;.5K_ ($C%8A@[>S^6[O"(J67E;?VU4.NXC@#.C!] Q_^U#([(6!DLI3S6
MC:$C@YSYVF)X>(12$9ZA;OB6"?H[[DLAH&RO@Z8[W-\"R<W#-+LMM<#WG^C4
M_W/N!/.!/EC98"]:-#E3RDV#>3<K.L)F2G1-Q!_"W37>@(E@\>FE83R3W0;L
M]3_# EZ[U17QC=7;);58D_:?H=_<W[T0 GR#!9M5[6RW)B ^6>O+"N:XI90B
MZ2R^,3WC,590A5Z>D#5Q/?F;7R)OS+R@DSG:[-J.="DZ^KV3=R(<-M*7_XU=
MW+.!-_^LXPNB'KY8^*7WRXKZ<.!$DMD&]/+TF/[_QSQ6J[>S" [M'0,2JTHZ
MD49W\Z-.5?6)(7;#LG>F68&7J>!) _CKM^D?"NT.%]TU:T[2UNM8(_<?TF+P
MT/D$";JRC$09 M],"PO"M_";?J,F&#W_[(DFG [I\^O8MED#OX9:>.FUTRL-
MW=\1XS[!9K25FCRB0%\R-*U0G5<S%D5G(YSJXR!Z4#)4'18=O0C*#!/!1M Z
M=H*TA4X,K':2>Y';$2<LS;U7\\_/;W%*(^-(P#U0^F\J/U(T;\(":I\,M! !
M\?I/I[S]K#*,%;S=*1T3L=L<VDFP.^YG$MI.#8[TI<=3<N!@ ,23'0P6HEL>
M!H4;6R*- T_-/4ADHW!YX@E3JHWDA@92:080Q$GH2L%K'=7_Z-!!OM.7D/6A
M<A7-&8!9+3MMQ1]C LZX'&J61KKZX"N*4$;GF_3]HBW7B#J!<UH]!"<IJJNQ
MSEH30^,$8&/EV/6I4_K=LK;9DY?;.JR%-.*R5?<_RUE5\Z\];;%B->CQ[H3/
M^C]D*1<6N52%$E,%D=M"K^",:*.OB> 23^WP,;N.[#5$DJAA:HNOH?U/C(J]
MID"9"!E46-](0;R\?B.N77' #H<0NJ=NA-$5S9%)5R>-?$. '.E!><*RA)HV
MZS(T9'F88J?+IIP<T+!D:,S-[=#GUEV6+3N9MPR.O$UU;F H(57A_#]EJ&K-
M V) #4A;_+%-)GR]&*BIF_<UD4P7#Q=3-_$GC,1/D06BI!Y5(\SX6*A=&+ /
M<MR*H'@2.J9H.O1PQ/Z%5./<$ ZI%H?R5E5>1 5>#)YW2GZX^4<P3Q O_$ $
M<\37&=4])+EB"G*!_8WD3F2ML)T.Q8#,F4:N6]$=W&L1O"<NSH<=:<DQBX4R
M#8Z@EVUCLD-\F,.HSI)GC4W]EDA->#6]%<S)5>_'PM\XSR_$J^'-KS/$V'C\
M-T#;U[_<MC_$'<G.+$X2+_%.\+,#3Y;1J&J^3#C-Z+V7H8=S+Z19R%&O&BHD
MZ'Q,-^H@F9R"B1@#A'STX9$6VT97L1ECUSE6$53YK<8<,U+ +-G(:P:V\/CZ
M>!LCO1K089P)B!N)V9?9BKVWO])_/*&R &$LO"%[7U-&EAHPRI8:NE8\.([+
MF,3,$YALCT_)V,7/$&C;;T"#%XKM<0E&L5QM90F;MKK,B=$Z I6 );E% QP^
M77/5B0B<:Z+.5)C*FO(Y//I'NVW ".VVQTR*%ZM>@=B47G!>+="SO$6!25G/
M9:%\K%4!8H.EY/)-9Y U+/<RM5EJ0\&<&>@B0(N8\;QU80$!'.EH-'GY\Z3E
MZE=CZ.S, &J<+"9W_C&<%$/Z85S*0,4XPIUTHV_6*90F)IR0TL+53R<7W'%*
M2:]X: ^D3 [Y$#<]ZS:EGTWPK /:9&X<X4/!7NM&7I&?BJC00U/S*-74< ;G
M$?(3(#_/'B$_CY"?3Y5R;UCKA)[I53/#)&08#"=<YJ'K+&!"D<U))@BRM1JC
M@062I'?KPLXK2#$$_%@,"T6 @Y&U3'*EQ&"PJ:2C:\DVT)Z5=3GGML8W[N=J
MU@08Q5WGF]_:VPG7"QBD_I,->$2])%6.M9'6A<!R#R@,.4*:.N4KP@1G:\<L
MYP>R'"-/$,M#<DOT)8:A"AI-YS.WZ66!7Z';WK#6>1@4?;,3=3_4Q9->%/&+
M#?9#O-I9P*J\^K&0H G>?1R-$R8;S'5NB;:X&V 5LO1$.X*<*563]QM^!8W/
M2!:H.+--6/W556.FF''92HC*E6^R5=)[7J\LA!Q&*4$H"!:633+7[.6@WWY/
M L.[@UH"]?=XP6$L7AH=D\Y4( GL91S 1VEMVYH[ZI45MO-&(4N<QK&55V3(
MTYWM)Z\BF;)DJ^XGANDPA1UQBQ#9:@:RF[LUCU81$!Y1=6QYX1+Z<%/N'MD]
MAI@%+FQA. F5U$CX/H U9=/$\#4=B##,;GKX&>XB05R=9$ ,(#3#L[6X]$5S
M9#8 R9 VT8GU_* \4X/K++LZ2-' S$RD+6X[$B$IEB;Y4'Z5K&KNQ%!:+9G1
M@ X@'7GN1L!E*8\F!<[;R&%/!M9K='^GW6PK$SWF_@D;VW@"ZLF3;E:"P3)6
M@TQ3AU*TXU@F7TB*_SZ,9]/Q2I\KSB1CS$0(QP^C")*"(/@T?M[0-&F9TD7Y
MX!,:9;);8^:.GI%K=P@6G<W-."Q^1>3\E*D?X_,,YK%T+^!.K9N3);N2W(G%
M^1)1:,><0@IO6Y=S2Z>"A4J2GBIX'ZQ*BSY0%Q+F#T%9_G [<N5 _3IU/2O#
M;L?ECB8YT#H+Q0B '7.MY#79-%R:6X"A87%L'9R49)B8C(51;1,:;V60$_8>
M#$+^$61BIGWJT\D%R</A)Q,_(+(]D4 V-94E]^E($9V#67B!$L84LJAA3")!
MG-U6IIM(FM',GKULF]V&@Q8,[U[XV&9NZ?@$&T6!NA=U%SBJ'H*8O1W6(LQL
M!,X]_[Y" 819WD3KY6IN[UCL.BG>A3\)XQ<E4W?3V<YK?L>?508P]9/2.!"C
M:T&]0SU^B#J,C>/X$,3$<+&]3NV(E2VP HJMTS"DYVZ-V_+<8(FFE*<8@+'?
MDTV_N]_-6TZ>"!T*X'E+Z18RW%?^N9NU3FQ/.SXHIC*.N(211?"^J.2!/[;)
MUY(9<QPU<?A'I85PN^OAC?T5X=''</2TC0L%AV'/, Z= 5Z5PDAR2C( Y6"*
M@QPW(48(KHBZ?O"-O;X/7;]*31XS('I"X^G$8YK<N R(X0S1D/DP0\O#729/
MDKL<,WP';CD1*S):?,)TGQ?>T<6LFS_\S[,OG[[X_&F!F:%X __#4\Y7>,7=
MY8C2'A269.FZ,9(D8XHX+U8*123IF[*K>-G_]/G_PIW^\N7_4F'>-F1HTAL&
M ;<L"BSN(T_V[M5WK_YQ\O+M3YK@R"<DQF?#\4KF-W_^E_ T@\_!LD#P5R^.
M#=)6/&?UGPHXX#\G35JR*N13@90'A^>_@S?H*2)NB/\]N_$MZDC+050^[9SC
M28 (RIF'WT1)TN7N=.NOXXYG%5P3[A4*A2TTYR2S-/T%^?S13M_J_'*WF?CI
M.GHJS/_+,<W9(XV<X-/)V4IH0*\IZ;;"4,1KQMIZ7SQ!_=FG1+01 NW"FH+)
MG,<BH!3.0LHTI.V.I\>Q]991+T*$O*;]H1!OUZ9SR+NA1L;$9O"D<ZFY"0OJ
M09-%^A659#V(G3@"W/=2KM"APJ/5U)K1RR"*##<NLIL,&#CTS[W7/.>ZP%5F
M=/55+, BV]R9U"?BJ@AS;?&M11QP2?/N>U5,#<IHQO8F<)ZNQSRE3RS?*+#G
M9'10S$3<'==K.'RP]!0TZ-2WFZ IHU?],)!F11KU@L1[LK.'>_P^"")[WB#(
MC&U\TGO*B9*D<S#O#MSJ2.$;>TH&$M0'>D@T&>.$5?P_E$W2&)0>4M^!!LMX
M@S)W_Z&(9DT_BX:&G&NN7OM?5,UR!\S-#3 '^USNWML2^R^G[G)7Q[7D(=S#
MRYEW*/7[4)1<5,Z70,*2ED;_O>#*?X"=M!G/J9N5E&$YL)%)G2I@N>H0ZZWV
M+_I*D$U\S6'OI@6.Z!%K$K FSQ^Q)H]8DT\5:V+K12^TIJW3>Y-JDN@D'A]
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MG/0KXRGBDL5BP\(IMDZOQ95)^B:-;+1A&HUX;YUE-,I936WHF(M(Y[;,':S
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ME6ZD\)%R3H8[V74/[(; C16!3G)5UK*84\I;<Z(Y([*JD,59IF;R:%-M'.?
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MG3VK+\B43:>3E])U(A'"CZ<7IXG%14ZL9_=42(G4$ Q63!&-J2"-3##%</+
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M8(?YQ&P]E%#;;! _\6_!Z:>4*]B-0OHE?)BVV6TE9E.<)\,L>6/[%7*#&7@
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MQX3#!3T+F"Z' 0]HRT,. =<H8P]OT.&ZOQ2*Z"@&Z68LK\O6S,.+O@%#;9@
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MJ7G]!-<.ECH_6**(4/P!4_W^22F5Y#8%1OZ78<& "AM$>&>N$?"^_<8BI$R
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M;UH#QP1U/IJ-<@Z6-(UZ,SQJ1>ZZCPE[7Y>_@P.NK#?,L*:5RH5X'B]2@9?
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MX_>I?J9PM0D=/#ZG[O&3%XB>,P=/D63TATDQG$V(;;Y4,XBV5Q,J=DV<FAD
MT2([P&TF@D-D__W;[$R7F::9@3."N\8\M<1=B$_\N;9QQF[!L/5O?*O!:N]7
M*/J!\1A^INX;CQFZC+$"=NFNJ?KWJ"_0+I+PL[;,60U>60Z-UP7_X,7_#,&?
MO]GF)">'ZV/EY*#;"GUOW^AR.C=TQ5'AV<HU@:)OA$)''%Z_;I$2.LZ ,S%@
MX*BH(8+)<$H'BN/6DG5"@X.%W-&! $@W$"XZ91])0-OD98M^$KS)X:=_'+_=
M[._;1VPT5-C!+8A!]A3Z]3K\"IY.;2F14H/_TFQ#I_N$P1UM03A_WN_@ZR3R
MU//E2#IL/M=8N2?=W==_R0R$"U;6ZZE5U0 %.G77J?46Y% = F8B+[($%>N)
ME-(N$/IS+:S_ZH\.4:S)F)$3=A_X?M_>ZN\%Z_#AM</#$[SB(:-UB&H -U0F
MA1)Z0I<>?XF"$T%T2%1MMGQ0VB: IG&"-YDQO7QY0?D.+*.;F4&P&,\BV,2R
M;5;8'_#G1GPF8IIY&&C&]HTVR4,W)"[\<E\;%V_P.M-E$;-N+5O7I/"GTFT/
MITD %.+1)!>9A0"E%4K43)A-1R)V#F=_*(VE3$7() ;,SR)Z 9Q5LQE-.!3&
M!P Z;PC_+82[DI%X_<F80<U-;(JVA$Q\"_\/DJXS%3C(_L8X&*US9[:C$W A
MXPM)$L4]U<;^TTY7A7D%O#+ABHB%3-8F=6D$^NMJY$)>^\X9\SS2=&-H4E(E
M@,GVB2HB=EH>'2=3D0R<Y^1<LU ;7WY9' G%S7,(Y<!$-Z][9YX[;G>_/0FF
MVUZUG!TL0<YQ-F%%@.#<.!A3Z?ZWR20K1$AJ)G+*.& R816D.<AO-?<&&BX+
M.OKRM^!-D@^ 'I,](F'YW4!6 )+4]4CCZ0DKE(I%J>RM4"HKE,H/C%+1AK^>
M&CGZ8F+%=Z2R%+P%PZ'H=D^=$ RYBN_>GIR*JPC_C?'G$)/9P I;$-\RD10I
M]AEUN[950T:^I]?@S(6GH4T3-Y?<N19Y%!H4D6KH4HBKFKDP'EGA\DP-4^'5
M'3D)W,+P=&/7C2E_\6>TW*FQR.!59$")"*5,9&<>"YD81)SX&/>]0,T,GL5_
M_6EO9_?%Z^VMP*QUZDI6<+.C&I)YM;C8V/!J(.+TP-N%UHD^^A)\(/CHF78"
MB( :B[8F\AS03WBY$XHL:W0RBEU$N!.N8J_!EEFJN*-8D0.40A M.*02[C);
M?J^@M[[ @HAL.!#%31=A1L?V>ZR[I%.?[-=[FYJE-.:6\.32Q"CP#PTBJ-->
M6SD8XL>J6%) >J^U)(_;(_7C ZW&\ F=,NK:;,#(CTI4\);D%4N?=TF2@$Z)
MF&)\TMUJ[GQ\$1-7F=E/H^%7"N!I8@>1"4#M3L1S-29.Z]:P'IEG/!"N;?YC
M_YS5TORXRJ6784LZ#6469JRI+C:(L0-2-A31N*Q[K/AMM;R/V?>6/@F=,F)8
M$^DCQ@E+C0J63W)X5+.G'A3F,'+=*GG&]!^^)I3F=%C(1,!KB:P^:!%5Y89X
MNA8D,Y;G/F&HP03+Y>R2:KE)6V5J3PJ%G2$)_V&:#QWO /T<28[86:YBHKW"
M( 9A#=,I F8X"]=$^W&OMR?LY6_06C3F"6]R.,;I&,Q58OS,U.QE/%$()Y7-
M^EGFQG4EM1W 7O#!3&2.:7PO%S: DWEU 06DQ:4C_AI;J&_[EK"ND.!TZZC\
MD!0C NW$E+:$#$Q,:!HO"0CG%Z)^F"W"&U@0EQ*TGV'5<I((EUV[T*=D>VPA
MH5;<1GR73U4_\"7>D9-^Y'-F1=.DXI,N-"TBBH(:3Y3_YG:!NG2,0J<UKAQ;
M<L.=A\B,!%$>7)SNY+'XP/RQE4L34"L.!7F4=<6A0MI<O0O$$0Z**^T[E4!C
MO"=K=F-SZ< ;1/RSR)B4(HOGHJ6)$VF5?H1LA'<$O3>D8.FB09"2N"!R<C%C
MJ47\)C' 0Y)RLEC4RB:.3'P+EZN>9T<?35MTWI4[<9=-J^#"C=3Q/ E%7XO0
MDJ^TFW !&/E:<B23RX:F63':".VT D;QW'$WP>?Y4F$)&@#G!+]QVLKEP</:
M8I:RFDP\E8*S!8V=/ZN/X+X9Q#'SM\06(6?NC6%LELK\U414D1EZQKK((]^6
M^7E4K&JB?8\53(H/ON?K RR2ZV6PG%"I&B,ZAO2/0D<=1?H2I-$Z0KJF3=IN
MZ&F!B,DX9F1Z?34;$^BCHFJ49L\AG74\YEL!#(!_*X /63\934)TWDXAW;9A
M!Y>PW^RK-:Q4O4%%?4VI*KT2RF5J&_G/?H. 8R"*?3XSMP-@:4-A[<9W4%ZX
MIKX5UYZT2FP!!GN5F9</AF.+4HY>ET\&4C!S+X$W-!*:K"[06&04=O$Y6&AC
M9$H DLE)P;AE'Y,=(WB:C,4$7P"5U0&'NN+<=#NQX0&F_!$-2?=,AV[ DIR,
M6P*JCJW2DNC6(0HCQ5Z_B"<+Q:$+F"RSP@J?R%:..).U%\#H*>$QP4AELCP:
M:]?V(0C,WY:@J?:O1*MFE9DCU-CVYK/*\[0D*,PDCB@Q T=FEDD4P*Z35_*!
MIE/Z)_3XE\:'BP7*+-I*DH*P28':,NJO.)\95R;%S(T-YINV$*-/R5]@'1.C
M>3Q#E=-4]+['0[RYV6&[0".(V7OWS)8& H'W3$R"Q-T,VE)X*YH3:O5JT2JI
MP2I;W,+7Z(8"#U>H'? JT;!4A%="3NFV-X,."W X;6$(<4YJYA TK?^"R&8?
MIJ[9O]%.?:RB*GZYC;@H\5*+?VIWIX6W=%D:009CBBPG;"YU?!N34\2T@R1,
M:-%C$3@G^T2L9PC\'8+X:<__-*2RZV4R C; +XQ1RB>Q$,N26HMM/:!\@%5*
MF1+3?,']])5$M.[P:%GE%HL,B\*],.U"RBBB;$)+\SNA0<Y'D/+L_; [\D '
MFN@5=6C:6%>#B[ZUFO,=6Q.5:]9(E#7:+[0.XW)=FHO(3A7A-92<S3^Y )(!
M.JT8!2>49%F.%[ZMIT4KVT$+RL?^^%/MYWBWG$59/D[@$J:&!9C$\#[VI.M8
M5-$%UR^T!A;;$#_ND$)+G5*Y6R0!\]C0?RQTE6B6S85J7)N0-6'\-C*B3%ZN
M$]#I-A9PX@'<RO4>#+%F4^20PF07K_.#K4$O^&=+_W9K/#?,-WD,MFK$HZ/B
MQH*MO*[@W]#I11EI,T+ANPV#O\67_XD*UKHVWNPT_FJNJL%&*%\"4U369&)A
MGOA2UOS;5GH3VZ.Y9[<-YZG_R-X#\O(UI_'*K99;%'1")C."@7H066\\Y)2'
M#'9D[["@OU8>.R>H/5BP3A%P5[W5F8@Z*,_M,UUE\+IML *_6/#+_@K\L@*_
MW"_XY2E<.8AK_6(M==VML'864VQD;"^B="R&[4[VM=4: N])8BS=//<XR,UD
M4 ?_YFP*TG#J+P:ST7E<47D+1M=AA[OM8#<//%A('@WET7,QTK/6.KQY1>-;
M176:9-5HR$_#AI*FZ1:?!_C$GH$+8SQ8601Q0ZE>VNW3PF\;/BVDTZ,D;4PY
M5$1%:5 CCLGCT#J3M2:3^XC.%GB?L!7MK[T*:X(9!RFT>NEU[(SV4L^9K2+!
MAX;)5#:1^(!>(XW"@_MNA:ZP2?:;MF\9QU\U/<S8XHH@9P4+B5FK@17/23'T
M&D>79BHQ?V^6M=0N.>I[V.D8SLP?(Z"&L2 :?.TVQRB/65<F+E"E'M95KV<;
MB5!;P,#-TPU'=,9+?H>8Q?./])<)&LR73&F202C^*"CAQ_H+H+SNB%:ND:-P
MB0<W?(H"*]HS/%;OF<B*Y:1KU)N-KO?+NT),QS*RTJ5J*R1".#3+I,!E^W7N
ML/#>\ET1+IVNH5I%KZCKC,3=3[T?\\?=:\T-_ZC<\:0* (A:OG 45](M+YTK
M#3W3Y<&,%8^4X22%%+9,QM*!%S">I3>0?>*QV46N]TW7;RY'!93.%Z!DEL-Y
MN%M";-C,=[V)YHP7/OK7^Z.#1N*KX$^HN\F6(NN7365U*!\N8Z:QP/ZII?%W
M6X0?(^=U$4>7"7GQM'!M'D#K8;IF_GK\/*2UPK9?0J4OI)QL\=0765>%#204
M&#XS30D=$3K(1-W?<+D]"WRG"W+!ZQQGRB2$_';016!?S\&M0!$;QG+='IMA
M=1]YRQ#/@6@+HG9*H&75;(R08CI'"R0)/W,_!=-94<X@ 8=PEL-\T]S7D]RQ
M!P%:.!E0U_V!\"^'W'#-)11JV(+4+ZO-A>JDF^@)1X%R7,*U@!XEO7]MJ#PL
M9F<6)Y/A^^KD8ULX*]L178*7;FZ<X5N=VQN[BVX)"1 /7CC,@=@S7!C?!CH2
M:W9W<<R I($)Q("Y!'HQLZO,SKP$%J:LN@"(T.@2ZRF$GF]A>/!X':#8BN>!
MRZV5NV/5Y%_%17SK 8?2$ \K1$[NA8Z&8/=^-5-8$I@?]7V[(<C7QSR9<&/K
M4=T][%%0=<0A>+1AQ-8G9_HN5DMZ*KD8K9T1Y838;@M 0:(^<5 0CV))^.#'
M#4564<,J:EC"J(&,6J?YNH<@X4Y^S'(X>[=T\#^UMI*43 +KFBQ00I:!N7*=
M1R-CYEE4(>/+717/Q+6J):NOR?]XH!Y4\:YI"@N!'NYWHI*U!<+E6*+K_'&F
M_D0G0HMBU]JZ7!N?% K,'^'9"3L643K_#T\_H7'AG6[[D?C9B0>B2K)+^, Y
M_,;<LA4!#MVHU&K"J(QKF/XRAOZT"TTTIZN<TVCX-3J7UAWSM7&*G_%2_<+1
MZI[.SXCMR' W=!0TVDG.7<6"YCBT3:;VWQGU?]KBL]]9U%56Z=K +4+I')IV
M*&:#$4MJ5VK[@Y*Q:S*A&"DFD18;[*"'J%+R\3>N\]>ZL(J6K>)@PX6N)(!?
MV71]@?VF+:'LK4E18_#G[W2E _7@9EB@.YL1FLN^&;2L(0)/A0DRA!%%^^Y2
MM/A#$_'&E]AL!=TY!02>Y08A31=U5+W[<&*VZ;OW)T0R]^[P!)H0LE%4C'1W
M =0:S"&")]1]Q= *;5/?F*\[5=_P>5';UB&/407.$AT/YE[0K(A/QWG!K05R
M_XE:,N]8X8.Y#0IAJ0RJY5[U]KT4+;4Q:QZ$^D6F(^F%AYR.(IP^V7)$,>!(
MLVYC3,@8-;[)QYJW-5F:B+/ ]I:)8Y@R#R,)HX9]DWBP><6C,:$_:4Y2:YQO
M#[A[2.C:5=HG#FTQ])C'Q0H!8[?PWM8* ;-"P#Q_^I=N7++.7!P)TG\Y+J?;
MLV>#1T?^*-[ZA&S_:EP]*SI)F$S,89C+&DRO<8N+65()$1X %0&" \:9F3L%
MM1!V!6-MZ?%<,=37\A$VO_JL:B$P]T!@ UT;>@EJ(-[X6SR<$:,D:DDA&3G>
M\[!.$^2TL==<&6<).0,BT%+%T<15J0XOHJ0PO\4K5O492V**UW.=6EP#[5-$
M)5!,"/6 O7'S\4;@]>S3SJFO(-SV?-G6JQI7-@SEM+1Z=G#2,[,]#_YA7L=\
M=QA\Z+WMD;JAO(IMS,R-;XQH8&2WR$'*]GUL_&'ST[-><#:\2.-D#!$K/>/D
M O\'_O3$DH7"/!U>)/$X.++33IJ[!:FOOHO-/HV#M[W@7\9OSZ?&"W?#NN:1
M9TAF@TK;_$S+VH"!8MMF@#=%)[]*A.]3S0ZM37/195? N127^RZ'LH:E$VKC
MA%@HLY)T($P$B)_BL&*0 %/)169.TCFD:T;FH!54HW*BMB7-A3 (T=BIA\I:
M'G[>M0-?E-J!M [%XN)O#G1WLBO4LA"OMFKPY2TRO H'6'\&%UP:1#<FODWB
MRYBE5*!_^1Q4CA ,8+;8D@4_7:W#KE'NLUM_K 8LQ^O=\OK48F$F5BMF4TNN
MYDF@N+DHD4A?,T(T>Z5O0IZT7-NEFV34*1J6?KNT?Q]"<@&)%YAGC/M$P.5W
M'UP\Y3J%23ID<<6*2/83*ORV W.TNZKN+^W87C.VWU1MB6YER:V1E[<A@AWN
M5IX 20'PN6">10714NMTY"3G!2D>)QDKSZ/%@?R3Z#<)YV^=Q]PZ 35".R#2
M-E^]"47YS0O(2&*OL@ ,:UTW2LG"]L$2Q2&L?@L='*4))M,92%7(='!CM:?!
M<#E+@=N!;?/Q9_XP'I6OH_R*Z!#;IGX")Q9EIH#4=U9:8([]WLO$_%A*K6;7
MYI.K".X-Q:1/M$LV<4S_*Z@&<+6:F\+E>'%];('49UF*4Q&D&+/T7.M.-3\N
M(G,YS%P&6O%RX:*J](D>>@0JV)AIP4MH2()IQ#0S)A6!6B.S<'CAV'$M\&;B
MQ?$70E(P./7.R!7T.S9:UIPQK[]MHJ<L(K-EP[HQU<E@SM))7DY(LJ;/PL(U
M: >T+>C>^/YM8"=V$R0DT-TS4^<(#.R,X0=D1V G>ZQD)?"A !/(E"P(>^H]
M8C)M?B7=1'^\U]YA&XP=BJ"Y!.P*'4/WQ[ [\>$#8&F<1 D!SO77W[1/7R7P
MF\H:^I,;]]#2?X:5KJHR@Z:E-8\$?M)-=Z,1CWI)+!+3"RB-#-U!A+^9P'R:
MA45*[)+O-R6.0839J#)J"80 ='4)T O-$8O.-HP;<K5YAEP $$-6U"VYP8:3
M PI]+0(;)87@ !T16BX:4!BL79CW@W0R5!;6 JZBEY5#:,A\')#& 3!Z"XM(
MYM_N3 @[!<<>64+KAT/!9,<%*=3(#)O-2KXV-N1$%6\#OY#&G^U@*X'R#WZ
MJ3 !#(B5H8H(C>C2@[I*CO$D%(>ZF%[!=%+5TO+M(R4H0YP4::/X>;2T;3=
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M2;W/JT]@(U\L!XJJT'9UM>J >#SZ/IQECAL E)O.Z2XS<YKE *O1K_8/U"/
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MX[*4N06SKC?S)#87\ZBL0>+]5($=KB=&:D> X'YP#4(BG<?CIM/\!=E&8JU
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M2.9FK9VK#?*0&X3M.3?B48TEM+ 0_BTUAA-:L+V5 WNVB=IID5E8K>5#KJ4
MVMHIGNAH5?8DH@?.>?006URIY^8;,.=9P8)AY8@:*%'! G!1%J7S<F6_'W9)
MI08A76**=QE+&6\/ M+X0/17AYP;42$DA:)6@%)<4F*&6%*RI<K@F1T4MCH!
M/ZL?6ZSNSZ%*#5IMZL)V/%/R#0:^7FYPM:A%K'W<O!#626.O[79J&*'51OR>
M&[&<#29)64J5(].KO&B)FY0;'3OJY@V-JYWP77<"=E-BO5Z$*8D_"/&D4#RH
M46@(UUQSD5=K_%376&+^<8<$18-MUD&=V.C;F//TZ-W1QTWSB-6*?4_[;#-!
MK,B<&0-LJ8A:SIV-^]4!7:W80ZX844 C0Q@I/U@B&\UDX=81"X9C**/'[,Y!
MO39;F<('7J8+$]7&"*)02T7T$+P DI$].OG$7;8$(CH[^?QIM3@/ZHN0DL@P
M!\!.IE Y932.B:+($N-CE3[W\F'-[%:[<;P-D\9JP1_6^4R&'%V:D'<RF!5E
M;-F2D;%N% ^3DK5'"\QK3\P'1I&-FQ51OPJ2P86!OKN"_HYP-9Z6:; ND/"+
M.$JK"])NB(7R2'\2C,#)FP\F>"4<B<!0AI@%/X]#?_#XC3."RUVW.]O\Y]6>
M>] ]U\K?I&#H0K00E<@*1V@9124$2,;5"CWD"GF 2"M>G-)IO$BFI7"7JDP6
M'":0@[-R4*LE^IY+5'4KS*+4G#;3G$KB7!-9WR'J_KFPTQCRDINF&?L+EC)G
M#MWU!YZ.3L1#^QHE/8=G>(P] GC8*4#K21%*T'( "RXFT1#Q^?"O>6EN6T+.
M-7#=H#'!0HF:,R@DS2T0F79T0^5L"@I!-EOH?9%9IP$UVTR2;S%=OX@!A'UR
M#M!"45V,4 88U[:(B4!E$HM+%E118F;/89R)!YA&ZD381 AN8W7<'_*X$Z+;
M QYHE(CP8C=%T9WSI;3\K!0XR7$H<(HFZ$.Y\UK=2EPJ1X2X6OB'#I>EI[&*
MOA$&/43)K5 T1(LI"'/+ZL"GX->K97G0]& !\F8I*\>!1DPERH/@!%E1]-?!
M:AD><!D8Q">X"D<YN]K]WS."<WT^C8N)G!:\,BZ(?MU^EFE$6Z([1UN]6L>'
M7$?0*^9V>F!KG5/*7&J/5A*MB =1RGU@4*K&A<7D'5U,Y.XVECZQ:%52:""R
M,_,#\EL1&B/_:'%I\.N%^Q*^:F5+'_90D]RTX(Q=:R %*N; K@&>/OB-/K&&
MA(.K)7G0\WF!^MP )813PB EU=\&R=A9QN(!=8)ME?X4Y1;2,.0U?B8M (%8
ML4X,O6T18(4C;#O3>M4#( )SO &H)SY.9T R0@EH9/!&W1 1V2YCU=+/$^KG
M3X1('JZRR@1?D'D6:OF(6W19%J)MS%Y7 O(8CY)R."M+.I'G&+$7T/8'RL1T
MS:X]K;3,;S7H0E?4VAF 8AJ?.5>@T;]L[>0 <$72(+:GM#+1Q2<9UIM$CVF,
MS=/E8V:,UD!.*[\*[4[ 8TX,GJV[H031&^HGB()R M#_;(:L!A:++EHC/LG^
M@:-_X1Y,JO%A*VWK=ZV2>[7D'FDK>6S"OGF)4UP8GED+Z\6FC7P*]+\VB];Z
MA_!$G9/AW(T@_=L6=D.D&<PN$E6JUM5% \5[3*J[W,E$6?Q!D4<C)"K&W\(V
M*R#)[]$D5C>RLZ@^P'8SKG']V[YA,HW\>0++PQ:],B\6U[N=B)@I&@(I"\L\
M7#:D1*X?ES W";&D(]>?UZP&T5'!=\UKK>3FRTYCC#>A>YZ8);"[V7S03"3P
MA568!H9!P,^0O LFMC3?6=(;S7O!&YAN>7/ODK',\&WD6C=H%#MV5"VA;HL?
MIA&K@("63R)"ZG@KYN,JSJA]+C%^!.D0"I.GVRCC/$U)C 5XK'+* S=6(O%L
M,ZPE,#/,ISA>]<5U"3;-VLVBB)!5,0M55"*'$9%<RL\EWJ:990A9M7K;5N\7
MJU;O5:OW\V_U;M_]5IM.^_AH37VQ@$GT-?9E BPE1<Z6>A[\/AN=6S8@^'E<
M56FL3)CFY8+26PV].RUR; QYCAQLMVQ&?^(QP)),^F*2T]9XP)O$@?%;0$$+
M&PI!/=.7RN@.0QL".G4*52)I!%4!<#'+VN)-4[-V;XM><#:\2.-D''/'X^%%
M$H^#(UNM_$0>;]@8*'@CGC[@SJO>[I]M#X2B$L+O+<F^N?&#"U[.)DC05BNX
M+QP'\X:!'R8P">/+'*(G=6 C=+/%&GXF%4R!Z9[K^MBDS9QJ[.]?)!/%J,.?
M1O,,'KD9Y^Y6,#+7ZX*91PK.ZP[.%=#1 DE=8ZW;SV+BQ1#"QTJI6Q$05/DH
MS!8K23PXI/EP../YN\YC92,]1G7*,S$0MS(.:. G<!;(L"<5Q1E 8PA=]43.
M1)9?&P/@*3,3 _N&24]SX5O=%&HWGUA*<7"AGX^N/X=G0R<)"O*=M&/-SX%U
M:SGLR^UI20NDVH, -,OQC!6L3ZJD456MQYW.QB[ [;7PKR*M)$C\'$LRKPOM
MMHG7_AIE,Y"M<+9TD$<%<OC9?("@:O^#TJR=532_#C>;P@]^ZO=>DMGPY,Q:
M&$8ZEI,SR-*#5/MNM#&= Y)A6R6VEAJ@U6R +E<S:/"LC(&".I.?6+7J2E2)
MXO9KIQK((W1*Q>CS,>$@ZQQB40LFP$D_=;ABH:CW=A@ND? ].'M[\/?@79J;
M41E#G4*L_D&Q6/LE%=GEY,O$P(^8QB#;(\25PG/ZAX]4RX$ASCN2 EZ.LW,'
MUB,K2.Q=$J)ARG20<-U6WI689.,4Z4&)LVX"&8:BY$U4>YQKOL4%OHR+6H9B
M269WH67ZBRL@>2X/A#TY^BR./0FS>7JZX2.R24=>6@@KNC/P1L?8KHP)MH2B
M,$X^LE\>DF-DEL?$790[C;/@DH2O8S8Z&(2E1.$NH_5.0>T1T"H-CW!/N-:[
MO>B8"/+D^B]Z>W^6\AK#+D?P%9@HP[PL.X#MSBEN(?^Y(*6CW5I)B.H9IJ,L
M F/GR%$1,IGB@$3M TE?D=*MW>K(=B6;'3U5L%GJ8E"W#ONR.&.0M&.Y3B<I
M@&RB0J# R $*M2?1[[E(FB-6U?Y MZY[LX9)RIK*IU*Z(TMJM=/HS^1FP3RC
M3V()[U)%7Q-/G-P;*TM:UPT%L%G:S"VQ3]ODY@#B&TN/*4EEE:-=D)Q=N-%6
MU%T/C582>M 6@"SEFF7;MP2@KWJO[A1QU@)(VD/W%4)BV$4PP_*/QI),'K[?
MV[K>FMUL$IJ634W+]WZ]YZ&,^=1/V"H)]"A)H,QVS@D+'"Y$<P$6O"D-R9_B
M%R]Z^T_&&BP:^Q^=PE4!T1807ZX*B*L"XC,N(-X^RXE"#ILFD(@QTB?N@Y*I
MU:@!SV9@3,!;5'A]S3>I/P<#ES$.\%]Y\55%(N;W'J,KWS0HSX--=>[IGJ@!
M\@2.5.,MPB"LM@;]D@.UEA%"KWM6TE^!:#7+V"AM#DK)HY8 \U&%Q.& G,;(
M2^8TQUUOV1JKI)HOPM?(TS7X[UFIB[%MJ);NB.D9I%$@)06K@:6+*B;*1]D$
M>&-CQE=O%TPKRGYY(^'NH?N;X'U$2DZ14NY12XVQK=*UQNN5Q3?&M*+,]\!K
M2A*YO'ZD3 /KI]9DBB#B>IZ+JS_U^-G&SBX!B?)XXM$9+Q"$\JSVCAHZ[[VD
M-/\!K [PNV_XQ"H64-""*H\W%,CS83JVEM" /Z<MVT@+2*JE,2(L,I'XN]NR
M^/:.P)-J4 /*TG+#]#2:URI'=IBM:=N6 7#_Q"H_\*"]?+I0 0N'(H?!VB %
M(;CA13S\NJ;DB$K)A(+?F93UW_ )I&(*]56/G*3E2$#\+74>\%E!0HIDM=IR
MSB$A-@MXH3(HX\SJ;^5E>Z6BX7FO&JH>="N9043GYZ@<V%SA,"AS-APB?H,&
M"87<(.4Q-,8>R62S;.;C?9%/&.6%E H;ADJUO.UJ?1]V?55E47+>$TEHNZ.,
M2(@LQ;H3W;YF0X#U)Q%'= SAUU#Q)$$M<Y.A\->E9-RQ6I?&45D%.*JYM @$
MZWM;?]Z0T+PE^M8U#WP6?+':A,KO;'D?N.PO(V._AG.I<[;8*JZIC<UM%_.[
ML&$SSS*N"0QGM2>_TYZT#H.YE(SI@181LX@,^.8%1NU,J,0 -_6(*QM@?1#,
M#I]G"X,=GBWE4_JLW%&1?#RDQ4_&H9.#)%ZO(;FXRDAYCT55QHQ[4IR':J_5
MRB$WZYZFO)H^9>Y5@M$LG5/>#E)6/,[5'OS.=M&V?/.:E7$L*J(#+*K;8AZ7
M@R&VI'NO<R?.4 N=,!( P$JQ7L<1).I (H-<Q1+K5P#?@O FHVU@XR41XG4@
MD56-X*&WB&,ONC:^Q2R]I+5)ZYA2&E!W+42@UB&P@2H=\;YKK07B-8C36%I1
MA[28^\B"-:GH@@?OMENX!F7T-,*\/Y6BB2\P*_,T&46Z:BY/Q TZB-E?9V?_
M*M\T6[.@GAFIJ)<VU7V#^QO1EWEF0N>8 GH0MF9841 -S#<!\ D&9/[HB?6
MWA:6HX6R'@26\RC=GL\@F?7;K""@R5F4Y>,D#-Y$<_@GS/?G^#+"$HR3K1@
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M*)K>Z !=@'#+R>>&J#K%/T9]6T77#07UR_G^V#TL+H/V$']6?^^[M@_L#]$
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M-@P736<SS^$A(![!<=BX;RKY#1><X0L</8_L73=,CRL$4229DI%8H(9(5Q*
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M]0)5(ED,.6LP]$<@_9,,AR#XUH<?"='["_86PO>*2*T4\#V>GJ[A&"$QYIC
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M3@9[0ET'9TKN=?/T\(=?_MI',W8N?^U#18.#;ALRU#(D25N\XK0IYYS!,\]
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M]?M ZICVR0+90YCW7<=T8PDW9A G%8+)T@,IN:<WVB)X24NRTCMR\)2QC5K
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M>A.A) 5&!RAE(..CD/'!@P)1.)/<F1P:C=+: NIH3OVA"1AP$/P=T-83SCN
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M$*T'8W<!-7@@:2.<PP>2]F?J)NT#B;G-:W\+.!=L#J6(V@8H$;@HP%ORJ7E
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M^#$T#WKM"NAP@:]!1'8M^"68]LZ([ P&Y6G;<8GTIQ19.$>G=<?@UZ[0&@?
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M<@"Q'ZZCR7+?=-)RLHT]!*OJL"V4!-(+LJ.MUC(5LIS;#+I[;,V1]@EY#47
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M+FS6Y*U#8@7J'B<XLJ!K:G%)WO+(R5OL-%?N66S'J"MNPH[')>5-U=#ZJ-F
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M@$(NS&E48QFHC6E-"$?;9M*'%W<2M!:VFXF6A.1MA/O)ZWN,V]BKK6[(UN:
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M'_6JNJU)>GSOSM\GP&Y1,-J 3MCX#[*FXG[7NQ)L]+:\:@\6U$U4_T[.13-
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MM582/!@MW>L7[@.I2$*3!"'("0D@RB(,64PP#'@D A&2.'/-*3H;RFERB,8
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M'-M&]@-OQ[/^X!R9/O>0;'4%:V4]]I*T L5O2\E^D=-VEK0R?Z_!I-U= RN
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M-*K<;'A0'NUOYMBEPG%([#RW$8$>F7 W,7;J4^:QP<0P\/RVDG#48=JF$<,
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M4<9FK.['PXZ19\_DFY'M;JT<?OL1.S#?C,%QH^;;;Q>6'G^RK97:1=GE0[,
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M:LL%)"@D)BHWOV)^.OW])J?&,L="C//69[ORMC!>-YJ,LDN3,11Z-^Z)"^C
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M$< X+B7DNJ2$^R501_>?&F>U[_G:QV3KI&]J=(R@:RH4C,LXJ8\C) %)SL7
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MW+ ^TFD)""89T 5/4RE2D1(O*;QN<U-C_;VW2;5SUR\9[L'7+>>-A]K -'X
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M\3R1QN'@.@[G 7![*0X!Z\#O2>O8457'.<01FQ5XXA.W$8&K\7&;#'A"<M9
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M88:Y5M7F_TJR\H[FZ5U.TVUEK.$Q^]6L3PEDQ1W*LSL,3WZ;^K':A0%Q8Z]
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ME?:J=XO5WY[3G-M&W3&[&&LLATY$Z@&LD7Y[.(![WYM?V@$]_;>#"R(F+C&
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M:QN<W6^Z,DS)-L"F^=E!B/:B;9![O;111(/B#\8@FD(1W?PEDD/Q8;ZF2#2
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M2?5Y56W8XO^;/[U>234K&,$%)PH(R$J !** ___E7=^/W"80?N]?P5M;::G
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M;I;U0%[@! 9;>8,N='@C[F=$A\1Q9#-Y"X3A9:,]<1FVB'17I].6E/:$X*3
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M57O!WX+V2;(U6BP"O% M8V/9& I7(25I5>8HK=@NK,A#-&R'F,>2'^U8YN-
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M.\D9%BZ'Z/=.J!PB[!$@YADN/SR9E?:?%_]U/OV$I\S,\LGJ&2X67Z:SD__
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M:'%-1I.B2 B7/%!J@QZD4Q "2:A)F2AKBJ8\5/&[/VBV(&Z8#I+]8:EK?8P
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MG]! 4(:WH1%9*IFJ4_T<?7L2_#AJ,79!VWU-=?K4Y A.T6V9>_KE"J.7F?>
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MP -DHV2L.B,JLR6\]EA^C!-@#P!8WPH8'F+7MM MY_ MG>**R@T.?=7>YA3
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MKQ0I-"1\[B>F>(BJ47IA>^I_WI,R1@"LNR*N5U-,T]/IZLL$JR1!SH!%R:Y
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MC-(/W!-M6R0,CZGZ$:!_P\S7UB5O:%'GB[-6#O<ZG4XOQ#ZIV=?H^:Q0[+V
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M'2B<?4831IE]%+4OIPRT)/H 7B0'100=K?5&LC8=_Z8:&3G3++]#X-5*+AU
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M#F%H!]KG63>0JVRXT(XL$J.J&QC!>4F[AZ&P3@AO&K5[?<%MQ\><B),*I .
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M7?'-LI?ICU-<WAH);F)F(KK:UD)'4"P;"$)7PR,K)./;E%C::+T&JYD7S"/
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MHU"N7_+Z?%VWV;UFCBQYU$R2K152J2'A4*>@9.!%&>&5*%ZUB73N2V''2F<
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MWP\F!4MDCJ@3@)911G[/41W%9J5<Y@D8)X@TZ#-5QN@32%H):1THE,12!8!
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M>%\S,3)X,#DS,#(P,C%X,3!Q+FAT;>U::U,;.1;]OK]"8VH2J/+[P<,0JC+
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MD*D!'S^<]?;$W(Y8DNJ)G<'6R!MEG2'AP>EEL!M6UI?09V?&K%C[8@'8WSH
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M,C%X,3!Q+FAT;5!+ 0(4 Q0    ( '0Z9%.<(&!$PDH  )R) P <
M      "  6@K  !R96=E;BUE>%\Q,#)X.3,P,C R,7@Q,'$N:'1M4$L! A0#
M%     @ =#ID4\L7Y-(;; , L;<G !$              ( !9'8  ')E9VXM
M,C R,3 Y,S N:'1M4$L! A0#%     @ =3ID4^RZM]9A$@  M,@  !$
M         ( !KN(# ')E9VXM,C R,3 Y,S N>'-D4$L! A0#%     @ =3ID
M4U)K5YA#&0  Q?   !4              ( !/O4# ')E9VXM,C R,3 Y,S!?
M8V%L+GAM;%!+ 0(4 Q0    ( '4Z9%-CQ.X*MF\  -[F!  5
M  "  ;0.! !R96=N+3(P,C$P.3,P7V1E9BYX;6Q02P$"% ,4    " !U.F13
M_AF'?)K"  !QWP< %0              @ &=?@0 <F5G;BTR,#(Q,#DS,%]L
M86(N>&UL4$L! A0#%     @ =3ID4W(-\:A%AP  ?",& !4
M ( !:D$% ')E9VXM,C R,3 Y,S!?<')E+GAM;%!+ 0(4 Q0    ( '4Z9%,C
MUCM ?P@  *4N   <              "  >+(!0!R96=N+65X7S,Q,7@P.3,P
M,C R,7@Q,'$N:'1M4$L! A0#%     @ =3ID4WID45-Y"   O2X  !P
M         ( !F]$% ')E9VXM97A?,S$R># Y,S R,#(Q>#$P<2YH=&U02P$"
M% ,4    " !U.F139Q^V[0@%  !D&@  &P              @ %.V@4 <F5G
M;BUE>%\S,G@P.3,P,C R,7@Q,'$N:'1M4$L%!@     +  L ^P(  (_?!0
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
